10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 FORM 10-K

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2019

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-34950

 SABRA HEALTH CARE REIT, INC.

(Exact Name of Registrant as Specified in Its Charter)

Maryland	27-2560479
(State of Incorporation)	(I.R.S. Employer Identification No.)

18500 Von Karman Avenue, Suite 550

Irvine, CA 92612

(888) 393-8248

(Address, zip code and telephone number of Registrant)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, $0.01 par value	SBRA	The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes ☒    No  ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐   No  ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: $3.7 billion

As of February 17, 2020, there were 205,274,476 shares of the registrant’s $0.01 par value Common Stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Proxy Statement for the registrant’s 2020 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2019, are incorporated by reference in Part III herein.

SABRA HEALTH CARE REIT, INC. AND SUBSIDIARIES

Index

PART I	4
ITEM 1. BUSINESS	4
ITEM 1A. RISK FACTORS	13
ITEM 1B. UNRESOLVED STAFF COMMENTS	25
ITEM 2. PROPERTIES	25
ITEM 3. LEGAL PROCEEDINGS	26
ITEM 4. MINE SAFETY DISCLOSURES	26
PART II	27
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	27
ITEM 6. SELECTED FINANCIAL DATA	29
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	31
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	50
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	51
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	51
ITEM 9A. CONTROLS AND PROCEDURES	51
ITEM 9B. OTHER INFORMATION	52
PART III	52
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE	52
ITEM 11. EXECUTIVE COMPENSATION	52
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	52
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE	52
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES	52
PART IV	53
ITEM 15. EXHIBITS, FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES	53
ITEM 16. FORM 10-K SUMMARY	55
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS	F-1

1

References throughout this document to “Sabra,” “we,” “our,” “ours” and “us” refer to Sabra Health Care REIT, Inc. and its direct and indirect consolidated subsidiaries and not any other person.

STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this Annual Report on Form 10-K (this “10-K”) contain “forward-looking” information as that term is defined by the Private Securities Litigation Reform Act of 1995. Any statements that do not relate to historical or current facts or matters are forward-looking statements. Examples of forward-looking statements include all statements regarding our expected future financial position, results of operations, cash flows, liquidity, financing plans, business strategy, tenants, the expected amounts and timing of dividends and other distributions, projected expenses and capital expenditures, competitive position, growth opportunities, potential investments, potential dispositions, plans and objectives for future operations, and compliance with and changes in governmental regulations. You can identify some of the forward-looking statements by the use of forward-looking words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “should,” “may” and other similar expressions, although not all forward-looking statements contain these identifying words.

Our actual results may differ materially from those projected or contemplated by our forward-looking statements as a result of various factors, including, among others, the following:

• our dependence on the operating success of our tenants;

• the potential variability of our reported rental and related revenues following the adoption of Topic 842 (as defined below) on January 1, 2019;

• operational risks with respect to our Senior Housing - Managed communities (as defined below);

• the effect of our tenants declaring bankruptcy or becoming insolvent;

• our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties;

• the impact of litigation and rising insurance costs on the business of our tenants;

• the possibility that Sabra may not acquire the remaining majority interest in the Enlivant Joint Venture (as defined below);

• risks associated with our investments in joint ventures;

• changes in healthcare regulation and political or economic conditions;

• the impact of required regulatory approvals of transfers of healthcare properties;

• competitive conditions in our industry;

• our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries;

• the significant amount of and our ability to service our indebtedness;

• covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms;

• increases in market interest rates;

• the potential phasing out of the London Interbank Offered Rate (“LIBOR”) benchmark after 2021;

• our ability to raise capital through equity and debt financings;

• changes in foreign currency exchange rates;

• the relatively illiquid nature of real estate investments;

• the loss of key management personnel;

• uninsured or underinsured losses affecting our properties and the possibility of environmental compliance costs and liabilities;

• the impact of a failure or security breach of information technology in our operations;

• our ability to maintain our status as a real estate investment trust (“REIT”) under the federal tax laws;

• changes in tax laws and regulations affecting REITs (including the potential effects of the Tax Cuts and Jobs Act);

• compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT; and

• the ownership limits and takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities.

We urge you to carefully consider these risks and review the additional disclosures we make concerning risks and other factors that may materially affect the outcome of our forward-looking statements and our future business and operating results, including those made in Part I, Item 1A, “Risk Factors” in this 10-K, as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission (“SEC”), including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. We caution you that any forward-looking statements made in this 10-K are not guarantees of future performance, events or results, and you should not place undue reliance on these forward-looking statements, which speak only as of the date of this report. We do not intend, and we

2

undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this 10-K or to reflect the occurrence of unanticipated events, unless required by law to do so.

TENANT AND BORROWER INFORMATION

This 10-K includes information regarding certain of our tenants that lease properties from us and our borrowers, most of which are not subject to SEC reporting requirements. The information related to our tenants and borrowers that is provided in this 10-K has been provided by, or derived from information provided by, such tenants and borrowers. We have not independently verified this information. We have no reason to believe that such information is inaccurate in any material respect. We are providing this data for informational purposes only.

3

PART I

ITEM 1. BUSINESS

Overview

We operate as a self-administered, self-managed REIT that, through our subsidiaries, owns and invests in real estate serving the healthcare industry. Our primary business consists of acquiring, financing and owning real estate property to be leased to third party tenants in the healthcare sector. We primarily generate revenues by leasing properties to tenants and owning properties operated by third-party property managers throughout the United States (“U.S.”) and Canada.

As of December 31, 2019, our investment portfolio consisted of 429 real estate properties held for investment (consisting of (i) 296 skilled nursing/transitional care facilities, (ii) 62 senior housing communities (“Senior Housing - Leased”), (iii) 46 senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”) and (iv) 25 specialty hospitals and other facilities), one investment in a direct financing lease, 18 investments in loans receivable (consisting of (i) one mortgage loan, (ii) one construction loan and (iii) 16 other loans), nine preferred equity investments and one investment in an unconsolidated joint venture. As of December 31, 2019, our real estate properties held for investment included 43,112 beds/units, spread across the U.S. and Canada. As of December 31, 2019, the substantial majority of our real estate properties (excluding 46 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 15 years.

We expect to continue to grow our investment portfolio while diversifying our portfolio by tenant, facility type and geography within the healthcare sector. We plan to achieve these objectives primarily through making investments directly or indirectly in healthcare real estate, including the development of purpose-built healthcare facilities with select developers. We also intend to achieve our objective of diversifying our portfolio by tenant and facility type through select asset sales and other arrangements with our tenants. During the year ended December 31, 2019, we completed the following transactions related to facilities previously operated by Senior Care Centers: (i) the sale of 29 facilities (27 skilled nursing/transitional care facilities and two senior housing communities) and (ii) the transition of eight facilities to a current operator in the Sabra portfolio.

We employ a disciplined, opportunistic approach in our healthcare real estate investment strategy by investing in assets that provide attractive opportunities for dividend growth and appreciation of asset values, while maintaining balance sheet strength and liquidity, thereby creating long-term stockholder value.

We were incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following our separation from Sun. We elected to be treated as a REIT with the filing of our U.S. federal income tax return for the taxable year beginning January 1, 2011. We believe that we have been organized and have operated, and we intend to continue to operate, in a manner to qualify as a REIT.

Our principal executive offices are located at 18500 Von Karman Avenue, Suite 550, Irvine, CA 92612, and our telephone number is (888) 393-8248. We maintain a website at www.sabrahealth.com. Sabra Health Care REIT, Inc. files reports with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We make such filings available free of charge on our website as soon as reasonably practicable after such information has been filed or furnished with the SEC.

Our Industry

We operate as a REIT that holds investments in income-producing healthcare facilities located in the U.S. and Canada. We invest primarily in the U.S. nursing home industry, including skilled nursing and transitional care facilities, the U.S. and Canadian senior housing industry, which includes independent living, assisted living, memory care and continuing care retirement communities and select behavioral, acute care and other hospitals. The primary growth drivers of these industries – an aging population and longer life expectancies – present attractive investment opportunities for us. According to the 2017 National Population Projections published by the U.S. Census Bureau, the number of Americans age 75 and older is projected to grow at a compounded annual growth rate of 3.1% between 2016 and 2020 and 3.7% between 2016 and 2025. According to the 2014 National Population Projections published by the U.S. Census Bureau, life expectancy is expected to increase to 81.7 years in 2030 from 79.4 years in 2015. Furthermore, the National Investment Center for Seniors Housing and Care, a leading industry data provider, estimates that as of the fourth quarter of 2017, only 12.8% of nursing home and senior housing properties were owned by publicly traded REITs. The highly-fragmented nature of the skilled nursing and senior housing industries presents additional investment opportunities.

4

Demand for senior housing is expected to increase as a result of an aging population and an increase in acuity across the post-acute landscape. Cost containment measures adopted by the federal government have encouraged patient treatment in more cost-effective settings, such as skilled nursing facilities. As a result, high acuity patients that previously would have been treated in long-term acute care hospitals and inpatient rehabilitation facilities are increasingly being treated in skilled nursing facilities. According to the National Health Expenditure Projections for 2018-2027 published by the Centers for Medicare & Medicaid Services (“CMS”), nursing home expenditures are projected to grow from approximately $171 billion in 2018 to approximately $271 billion in 2027, representing a compounded annual growth rate of 5.3%. This focus on high acuity patients in skilled nursing facilities has resulted in the typical senior housing resident requiring more assistance with activities for daily living, such as assistance with bathing, grooming, dressing, eating, and medication management; however, many older senior housing communities were not built to accommodate a resident who has more needs as well as increased mobility and cognitive issues than in the past. We believe that these trends will create an emphasis on operators who can effectively adapt their operating model to accommodate the changing nursing home patient and senior housing resident and will result in increased demand for purpose-built properties that are complementary to this new system of healthcare delivery.

The hospital industry is broadly defined to include acute care, long-term acute care, rehabilitation and behavioral hospitals. Hospital services comprise one of the largest categories of healthcare expenditures. According to the CMS National Health Expenditure Projections for 2018-2027, hospital care expenditures are projected to grow from approximately $1.2 trillion in 2018 to approximately $2.0 trillion in 2027, representing a compounded annual growth rate of 5.7%. Hospitals offer a wide range of services, both inpatient and outpatient, in a variety of settings. We believe that demand will increase for innovative means of delivering those services and present additional investment opportunities.

Portfolio of Healthcare Investments

We have a geographically diverse portfolio of healthcare investments across the U.S. and Canada that offer a range of services including skilled nursing/transitional care, assisted and independent living, mental health and acute care. As of December 31, 2019, our investment portfolio consisted of 429 real estate properties held for investment, one investment in a direct financing lease, 18 investments in loans receivable, nine preferred equity investments and one investment in an unconsolidated joint venture. Of our 429 properties held for investment as of December 31, 2019, we owned fee title to 423 properties and title under ground leases for six properties.

Our portfolio consisted of the following types of healthcare facilities as of December 31, 2019:

• Skilled Nursing/Transitional Care Facilities

Skilled nursing facilities. Skilled nursing facilities provide services that include daily nursing, therapeutic rehabilitation, social services, activities, housekeeping, nutrition, medication management and administrative services for individuals requiring certain assistance for activities in daily living. A typical skilled nursing facility includes mostly one and two bed units, each equipped with a private or shared bathroom and community dining facilities.

Mental health facilities. Mental health facilities provide a range of inpatient and outpatient behavioral health services for adults and children through specialized treatment programs.

Transitional care facilities/units. Transitional care facilities/units are licensed nursing facilities or distinct units within a licensed nursing facility that provide short term, intensive, high acuity nursing and medical services. These facilities tend to focus on delivering specialized treatment to patients with cardiac, neurological, pulmonary, orthopedic, and renal conditions. Length of service is typically 30 days or less with the majority of patients returning to prior living arrangements and functional abilities. Generally, transitional care facilities/units provide services to Medicare, managed care and commercial insurance patients.

• Senior Housing Communities

Independent living communities. Independent living communities are age-restricted multi-family properties with central dining facilities that provide services that include security, housekeeping, activities, nutrition and limited laundry services. Our independent living communities are designed specifically for independent seniors who are able to live on their own, but desire the security and conveniences of community living. Independent living communities typically offer several services covered under a regular monthly fee.

Assisted living communities. Assisted living communities provide services that include assistance for activities in daily living and permit residents to maintain some of their privacy and independence as they do not require constant supervision and assistance. Services bundled within one regular monthly fee usually include three meals per day in a central dining room, daily housekeeping, laundry, medical reminders and 24-hour availability of

5

assistance with the activities of daily living, such as eating, dressing and bathing. Professional nursing and healthcare services are usually available at the community on call or at regularly scheduled times. Assisted living communities typically are comprised of studios and one and two bedroom suites equipped with private bathrooms and efficiency kitchens.

Memory care communities. Memory care communities offer specialized options, services and clinical programs for individuals with Alzheimer’s disease and other forms of dementia. Purpose-built, free-standing memory care communities offer a more residential environment than offered in a secured unit of a nursing facility. These communities offer dedicated care and specialized programming from specially trained staff for various conditions relating to memory loss in a secured environment that is typically smaller in scale and more residential in nature than traditional assisted living communities. Residents require a higher level of care, a secure environment, customized therapeutic recreation programs and more assistance with activities of daily living than in assisted living communities. Therefore, these communities have staff available 24 hours a day to respond to the unique needs of their residents.

Continuing care retirement communities. Continuing care retirement communities, or CCRCs, provide, as a continuum of care, the services described above for independent living communities, assisted living communities, memory care communities and skilled nursing facilities in an integrated campus.

• Specialty Hospitals and Other Facilities

Acute care hospitals. Acute care hospitals provide emergency room, inpatient and outpatient medical care and other related services for surgery, acute medical conditions or injuries (usually for a short-term illness or condition).

Long-term acute care hospitals. Long-term acute care hospitals provide care for patients with complex medical conditions that require longer stays and more intensive care, monitoring or emergency back-up than that available in most skilled nursing facilities.

Rehabilitation hospitals. Rehabilitation hospitals provide inpatient and outpatient care for patients who have sustained traumatic injuries or illnesses, such as spinal cord injuries, strokes, head injuries, orthopedic problems, work-related disabilities and neurological diseases.

Behavioral hospitals. Behavioral hospitals provide inpatient and outpatient care for patients with mental health conditions, chemical dependence or substance addictions.

Addiction treatment centers. Addiction treatment centers provide treatment services for chemical dependence and substance addictions, which may include inpatient care, outpatient care, medical detoxification, therapy and counseling.

Residential services facilities. Residential services facilities provide services in home and community-based settings, which may include assistance with activities of daily living.

Other facilities. Other facilities include facilities other than those described above that are not classified as skilled nursing/transitional care or senior housing.

6

Geographic and Property Type Diversification

The following tables display the geographic concentration by property type and by investment and the distribution of beds/units for our real estate held for investment as of December 31, 2019 (dollars in thousands):

Geographic Concentration — Property Type
Location	Skilled Nursing / Transitional Care		Senior Housing - Leased		Senior Housing - Managed		Specialty Hospitals and Other		Consolidated Total		% of Consolidated Total		Unconsolidated JV Senior Housing - Managed		Total		% of Total
Texas	40		9		5		14		68		15.8	%	29		97		16.2	%
Indiana	14		1		—		1		16		3.7		21		37		6.2
Washington	15		1		1		—		17		4.0		17		34		5.7
California	24		1		1		4		30		7.0		—		30		5.0
Oregon	15		4		—		—		19		4.4		11		30		5.0
Kentucky	24		—		—		2		26		6.1		1		27		4.5
Ohio	6		1		—		—		7		1.6		15		22		3.7
Wisconsin	5		3		3		—		11		2.6		10		21		3.5
Pennsylvania	3		—		5		1		9		2.1		11		20		3.3
Massachusetts	18		—		—		—		18		4.2		—		18		3.0
Other (34 states & Canada)	132		42		31		3		208		48.5		55		263		43.9
Total	296		62		46		25		429		100.0	%	170		599		100.0	%
% of Consolidated Total	69.0	%	14.5	%	10.7	%	5.8	%	100.0	%
% of Total	49.4	%	10.3	%	7.7	%	4.2	%	71.6	%			28.4	%	100.0	%

Distribution of Beds/Units
		Property Type
Location	Total Number of Properties	Skilled Nursing / Transitional Care		Senior Housing - Leased		Senior Housing - Managed		Specialty Hospitals and Other		Consolidated Total		% of Consolidated Total		Unconsolidated JV Senior Housing - Managed		Total		% of Total
Texas	97	4,816		577		743		366		6,502		15.1	%	1,122		7,624		15.1	%
Kentucky	27	2,598		—		—		100		2,698		6.3		55		2,753		5.4
Indiana	37	1,547		140		—		48		1,735		4.0		963		2,698		5.3
California	30	2,058		58		102		340		2,558		5.9		—		2,558		5.1
Washington	34	1,591		52		113		—		1,756		4.1		725		2,481		4.9
Oregon	30	1,520		377		—		—		1,897		4.4		399		2,296		4.5
Massachusetts	18	2,209		—		—		—		2,209		5.1		—		2,209		4.4
North Carolina	15	1,454		—		237		—		1,691		3.9		—		1,691		3.3
New York	10	1,566		—		105		—		1,671		3.9		—		1,671		3.3
Missouri	15	1,392		—		184		—		1,576		3.7		—		1,576		3.1
Other (34 states & Canada)	286	12,539		2,616		3,325		339		18,819		43.6		4,274		23,093		45.6
Total	599	33,290		3,820		4,809		1,193		43,112		100.0	%	7,538		50,650		100.0	%
% of Consolidated Total		77.2	%	8.9	%	11.1	%	2.8	%	100.0	%
% of Total		65.7	%	7.5	%	9.5	%	2.4	%	85.1	%			14.9	%	100.0	%

7

Geographic Concentration — Investment (1)
		Property Type
Location	Total Number of Properties	Skilled Nursing / Transitional Care			Senior Housing - Leased			Senior Housing - Managed			Specialty Hospitals and Other			Total			% of Total
Texas	68	$	384,682		$	81,305		$	156,225		$	196,098		$	818,310		13.9	%
California	30	435,612			18,160			36,340			224,761			714,873			12.2
Oregon	19	261,316			86,860			—			—			348,176			5.9
Maryland	9	322,390			6,681			—			—			329,071			5.6
New York	10	297,326			—			19,945			—			317,271			5.4
Kentucky	26	228,773			—			—			39,696			268,469			4.6
Washington	17	188,548			10,686			27,636			—			226,870			3.8
Indiana	16	174,427			26,161			—			5,310			205,898			3.5
Arizona	8	31,977			10,348			37,969			121,757			202,051			3.4
North Carolina	15	123,462			—			68,251			—			191,713			3.3
Other (31 states & Canada) (2)	211	1,253,153			390,487			561,405			52,099			2,257,144			38.4
Total	429	$	3,701,666		$	630,688		$	907,771		$	639,721		$	5,879,846		100.0	%
% of Total		63.0		%	10.7		%	15.4		%	10.9		%	100.0		%

⁽¹⁾  Represents the undepreciated book value of our real estate held for investment as of December 31, 2019. Excludes unconsolidated joint venture.

⁽²⁾  Investment balance in Canada is based on the exchange rate as of December 31, 2019 of $0.7682 per CAD $1.00.

Loans Receivable and Other Investments

As of December 31, 2019 and 2018, our loans receivable and other investments consisted of the following (dollars in thousands):

											December 31, 2019
Investment	Quantity as of December 31, 2019	Property Type	Principal Balance as of December 31, 2019 (1)		Book Value as of December 31, 2019			Book Value as of December 31, 2018			Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of December 31, 2019
Loans Receivable:
Mortgage	1	Specialty Hospital	$	19,000	$	19,000		$	18,577		10.0	%	10.0	%	01/31/27
Construction	1	Senior Housing	2,468		2,487			4,629			8.0	%	7.8	%	09/30/22
Mezzanine	—	Skilled Nursing	—		—			2,188			N/A		N/A		N/A
Other	16	Multiple	46,059		42,147			45,324			6.8	%	7.0	%	09/23/19- 08/31/28
	18		67,527		63,634			70,718			7.8	%	7.9	%
Loan loss reserve			—		(564		)	(1,258		)
			67,527		63,070			69,460
Other Investments:
Preferred Equity	9	Skilled Nursing / Senior Housing	43,893		44,304			44,262			12.0	%	12.0	%	N/A
Total	27		$	111,420	$	107,374		$	113,722		9.4	%	9.6	%

⁽¹⁾  Principal balance includes amounts funded and accrued unpaid interest / preferred return and excludes capitalizable fees.

Significant Credit Concentrations

For the year ended December 31, 2019, no tenant relationship represented 10% or more of our total revenues.

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Concentration of Credit Risk” in Part II, Item 7 for additional information, including risks and uncertainties, regarding tenant concentration.

8

Investment Financing Strategy

We intend to invest in additional healthcare properties as suitable opportunities arise and adequate sources of financing are available. We expect that future investments in properties, including any improvements or renovations of current or newly-acquired properties, will depend on and will be financed, in whole or in part, by our existing cash, borrowings available to us under our Revolving Credit Facility (as defined below), future borrowings or the proceeds from issuances of common stock, preferred stock, debt or other securities. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae and the U.S. Department of Housing and Urban Development (“HUD”), in appropriate circumstances in connection with acquisitions. We also use derivative instruments in the normal course of business to mitigate interest rate and foreign currency risk.

Competitive Strengths

We believe the following competitive strengths contribute significantly to our success:

Diverse Property Portfolio

Our portfolio of 429 properties held for investment as of December 31, 2019 is broadly diversified by location across the U.S. and Canada. Our properties in any one state or province did not account for more than 16% of our total beds/units as of December 31, 2019. Our geographic diversification will limit the effect of a decline in any one regional market on our overall performance. The annual occupancy percentages of our stabilized properties over the last three fiscal years ranged between 82.1% and 84.0% for our skilled nursing/transitional care facilities, between 86.7% and 87.8% for our Senior Housing - Leased communities, between 87.7% and 91.5% for our Senior Housing - Managed communities and between 71.0% and 79.2% for our specialty hospitals and other facilities. We have also been able to diversify, through acquisitions and dispositions, the extent to which our revenues are dependent on our tenants’, borrowers’ and equity investees’ revenues from federal, state and local government reimbursement programs. Based on the information provided to us by our tenants and borrowers, which information is provided quarterly in arrears, on an annualized basis as of December 31, 2019, 57.7% of our tenants’, borrowers’ and equity investees’ revenue was from federal, state and local government reimbursement programs.

Long-Term, Triple-Net Lease Structure

As of December 31, 2019, the substantial majority of our real estate properties held for investment (excluding 46 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 15 years, pursuant to which the tenants are responsible for all facility maintenance, insurance required in connection with the leased properties and the business conducted on the leased properties, taxes levied on or with respect to the leased properties and all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties. As of December 31, 2019, the leases had a weighted-average remaining term of eight years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. We retain substantially all of the risks and benefits of ownership of the real estate assets leased to tenants. We may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee or other parties related to the lessee. In addition, certain of our tenants have deposited amounts with us for future real estate taxes, insurance expenditures and tenant improvements related to our properties and their operations.

Senior Housing - Managed Structure

As of December 31, 2019, our real estate properties held for investment included 46 Senior Housing - Managed communities operated by six third-party property managers pursuant to property management agreements. In addition, as of December 31, 2019, the Enlivant Joint Venture owned 170 Senior Housing - Managed communities managed by Enlivant. The Senior Housing - Managed structure gives us direct exposure to the risks and benefits of the operations of the communities. We generally utilize the Senior Housing - Managed structure when properties present growth opportunities that may be achievable through capital investment and/or property managers providing scale, operating efficiencies and/or ancillary services. The third-party property managers manage our communities in exchange for the receipt of a management fee, and as such, we are not directly exposed to the credit risk of the property managers in the same manner or to the same extent as we are to our triple-net tenants. However, we rely on the property managers’ personnel, expertise, technical resources and information systems, proprietary information, good faith and judgment to manage our communities efficiently and effectively. We also rely on the property managers to set appropriate resident fees and otherwise operate our communities in compliance with the terms of our management agreements and all applicable laws and regulations.

Strong Relationships with Operators

The members of our management team have developed an extensive network of relationships with qualified local,

9

regional and national operators of skilled nursing/transitional care facilities and senior housing communities across the U.S. and Canada. This extensive network has been built by our management team through more than 100 years of combined operating experience, involvement in industry trade organizations and the development of banking relationships and investor relations within the skilled nursing and senior housing industries. We believe these strong relationships with operators help us to source investment opportunities.

Our relationships with operators include pipeline agreements that we have entered into with certain operators that provide for the acquisition of, and interim capital commitments for, various healthcare facilities. These pipeline agreements, together with repeat transactions with other operators, help support our future growth potential by providing additional investment opportunities with lower acquisition costs than would be required for investments with new operators.

Ability to Identify Talented Operators

As a result of our management team’s operating experience, network of relationships and industry insight, we have been able and expect to continue to be able to identify qualified local, regional and national operators. We seek operators who possess local market knowledge, demonstrate hands-on management, have proven track records and emphasize patient care. These operators are often located in secondary markets, which generally have lower costs to build and favorable demographics as demonstrated by the fact that the percentage of the population over the age of 65 is greater in the markets where we have invested than in the U.S. as a whole. We believe our management team’s experience gives us a key competitive advantage in objectively evaluating an operator’s financial position, emphasis on care and operating efficiency.

Significant Experience in Proactive Asset Management

The members of our management team have significant experience developing systems to collect and evaluate data relating to the underlying operational and financial success of healthcare companies and healthcare-related real estate assets. We are able to utilize this experience and expertise to provide our operators, when requested, with assistance in the areas of marketing, development, facility expansion and strategic planning. We have also developed a proprietary information technology system that allows us to efficiently and effectively collect tenant, financial, asset management and acquisitions information. Leveraging this system allows us to be lean in our operations and proactive in sharing information with our tenants and operators where we can be helpful to them. We actively monitor the operating results of our tenants, and, when requested, we offer support to our operators to identify and capitalize on opportunities to improve the operations of our facilities and the overall financial and operating strength of our operators.

Experienced Management Team

Our management team has extensive healthcare and real estate experience. Richard K. Matros, Chairman, President and Chief Executive Officer of Sabra, has more than 30 years of experience in the acquisition, development and disposition of healthcare assets, including nine years at Sun Healthcare Group, Inc. Harold W. Andrews, Jr., Executive Vice President, Chief Financial Officer and Secretary of Sabra, is a finance professional with more than 20 years of experience in both the provision of healthcare services and healthcare real estate. Talya Nevo-Hacohen, Executive Vice President, Chief Investment Officer and Treasurer of Sabra, is a real estate finance executive with more than 25 years of experience in real estate finance, acquisition and development, including three years of experience managing and implementing the capital markets strategy of an S&P 500 healthcare REIT. Through years of public company experience, our management team also has extensive experience accessing both debt and equity capital markets to fund growth and maintain a flexible capital structure.

Business Strategies

We pursue business strategies focused on opportunistic acquisitions and property diversification where such acquisitions meet our investing and financing strategy. We also intend to further develop our relationships with tenants and healthcare providers with a goal to progressively expand the mixture of tenants managing and operating our properties.

The key components of our business strategies include:

Diversify Asset Portfolio

We expect to continue to grow our portfolio primarily through the acquisition of assisted living, independent living and memory care communities in the U.S. and Canada and through the acquisition of skilled nursing/transitional care and behavioral health facilities in the U.S. We have and expect to continue to opportunistically acquire other types of healthcare real estate, originate financing secured directly or indirectly by healthcare facilities and invest in the development of senior housing communities and skilled nursing/transitional care facilities. We also expect to expand our portfolio through the development of purpose-built healthcare facilities through pipeline agreements and other arrangements with select developers. We further expect to work with existing operators to identify strategic development opportunities. These opportunities may involve

10

replacing, renovating or expanding facilities in our portfolio that may have become less competitive and new development opportunities that present attractive risk-adjusted returns. In addition to pursuing acquisitions with triple-net leases, we expect to continue to pursue other forms of investment, including investments in Senior Housing - Managed communities, mezzanine and secured debt investments, and joint ventures for senior housing communities and skilled nursing/transitional care facilities. We also expect to continue to enhance the strength of our investment portfolio by selectively disposing of underperforming facilities or working with new or existing operators to transfer underperforming but promising properties to new operators.

With respect to our debt and preferred equity investments, in general, we originate loans and make preferred equity investments when an attractive investment opportunity is presented and (a) the property is in or near the development phase, (b) the development of the property is completed but the operations of the facility are not yet stabilized or (c) the loan investment will provide capital to existing relationships. A key component of our development strategy related to loan originations and preferred equity investments is having the option to purchase the underlying real estate that is owned by our borrowers (and that directly or indirectly secures our loan investments) or by the entity in which we have an investment. These options become exercisable upon the occurrence of various criteria, such as the passage of time or the achievement of certain operating goals, and the method to determine the purchase price upon exercise of the option is set in advance based on the same valuation methods we use to value our investments in healthcare real estate. This proprietary development pipeline strategy allows us to diversify our revenue streams and build relationships with operators and developers, and provides us with the option to add new properties to our existing real estate portfolio if we determine that those properties enhance our investment portfolio and stockholder value at the time the options are exercisable.

Maintain Balance Sheet Strength and Liquidity

We seek to maintain a capital structure that provides the resources and flexibility to support the growth of our business. As of December 31, 2019, we had over $1.0 billion in liquidity, consisting of unrestricted cash and cash equivalents of $39.1 million and available borrowings under our Revolving Credit Facility of $1.0 billion. The Credit Agreement (as defined below) also contains an accordion feature that can increase the total available borrowings to $2.75 billion (up from U.S. $2.1 billion plus CAD $125.0 million), subject to terms and conditions.

We have filed a shelf registration statement with the SEC that expires in December 2022, which allows us to offer and sell shares of common stock, preferred stock, warrants, rights, units, and certain of our subsidiaries to offer and sell debt securities, through underwriters, dealers or agents or directly to purchasers, on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering, subject to market conditions.

We intend to maintain a mix of Revolving Credit Facility debt, term loan debt, secured debt and unsecured term debt, which, together with our anticipated ability to complete future equity financings (including through our New ATM Program, as defined below), we expect will fund the growth of our operations. Further, we may opportunistically seek access to U.S. government agency financing, including through Fannie Mae, Freddie Mac and HUD, in appropriate circumstances in connection with acquisitions.

Develop New Investment Relationships

We seek to cultivate our relationships with tenants and healthcare providers in order to expand the mix of tenants operating our properties and, in doing so, to reduce our dependence on any single tenant or operator. We have grown our investment relationships from one in 2010 to 69 as of December 31, 2019. We expect to continue to develop new investment relationships as part of our overall strategy to acquire new properties and further diversify our overall portfolio of healthcare properties.

Capital Source to Underserved Operators

We believe that there is a significant opportunity to be a capital source to healthcare operators through the acquisition of healthcare properties that are consistent with our investment and financing strategy, but that, due to size and other considerations, are not a focus for other healthcare REITs. We utilize our management team’s operating experience, network of relationships and industry insight to identify financially strong and growing operators in need of capital funding for future growth. In appropriate circumstances, we may negotiate with operators to acquire individual healthcare properties from those operators and then lease those properties back to the operators pursuant to long-term triple-net leases or refinance new projects.

Strategic Capital Improvements

We intend to continue to support operators by providing capital to them for a variety of purposes, including for capital expenditures and facility modernization. We expect to structure the majority of these investments as either lease amendments that produce additional rents or as loans that are repaid by operators during the applicable lease term.

11

Pursue Strategic Development Opportunities

We expect to work with existing operators to identify strategic development opportunities. These opportunities may involve replacing, renovating or expanding facilities in our portfolio that may have become less competitive and new development opportunities that present attractive risk-adjusted returns. In addition to pursuing acquisitions with triple-net leases, we expect to continue to pursue other forms of investment, including investments in Senior Housing - Managed communities, mezzanine and secured debt investments, and joint ventures for senior housing and skilled nursing/transitional care facilities.

 Our Employees

As of December 31, 2019, we employed 34 full-time employees, including our executive officers, none of whom is subject to a collective bargaining agreement.

Competition

We compete for real property investments with other REITs, investment companies, private equity and hedge fund investors, sovereign funds, healthcare operators, lenders and other investors. Some of our competitors are significantly larger and have greater financial resources and lower costs of capital than we do. Increased competition makes it more challenging to identify and successfully capitalize on acquisition opportunities that meet our investment objectives. Our ability to compete is also impacted by national and local economic trends, availability of investment alternatives, availability and cost of capital, construction and renovation costs, existing laws and regulations, new legislation and population trends.

In addition, revenues from our properties are dependent on the ability of our tenants and operators to compete with other healthcare operators. These operators compete on a local and regional basis for residents and patients, and the operators’ ability to successfully attract and retain residents and patients depends on key factors such as the number of facilities in the local market, the types of services available, the quality of care, reputation, age and appearance of each facility, and the cost of care in each locality. Private, federal and state payment programs and the effect of other laws and regulations may also have a significant impact on the ability of our tenants and operators to compete successfully for residents and patients at the properties.

Government Regulation

Our tenants are subject to extensive and complex federal, state and local healthcare laws and regulations, including anti-kickback, anti-fraud and abuse provisions codified under the Social Security Act. These provisions prohibit certain business practices and relationships that might affect the provision and cost of healthcare services reimbursable under Medicare and Medicaid. Sanctions for violating these anti-kickback, anti-fraud and abuse provisions include criminal penalties, civil sanctions, fines and possible exclusion from government programs such as Medicare and Medicaid. If a facility is decertified as a Medicare or Medicaid provider by CMS or a state, the facility will not thereafter be reimbursed for caring for residents that are covered by Medicare and Medicaid, and the facility would be forced to care for such residents without being reimbursed or to transfer such residents.

Most of our tenants’ skilled nursing/transitional care, assisted living and mental health facilities are licensed under applicable state law. Most of our skilled nursing/transitional care facilities and mental health facilities are certified or approved as providers under the Medicare and Medicaid programs. Some of our assisted living facilities are certified or approved as providers under various state Medicaid and/or Medicaid waiver programs. Similarly, the operators of our specialty hospitals must meet the applicable conditions of participation established by the U.S. Department of Health and Human Services and comply with state and local laws and regulations in order to receive Medicare and Medicaid reimbursement. State and local agencies survey all skilled nursing/transitional care facilities and some assisted living facilities on a regular basis to determine whether such facilities are in compliance with governmental operating and health standards and conditions for participation in government sponsored third party payor programs. Under certain circumstances, the federal and state agencies have the authority to take adverse actions against a facility or service provider, including the imposition of a monitor, the imposition of monetary penalties and the decertification of a facility or provider from participation in the Medicare and/or Medicaid/Medicaid waiver programs or licensure revocation. Challenging and appealing notices or allegations of noncompliance can require significant legal expenses and management attention.

Various states in which our tenants operate our facilities have established minimum staffing requirements or may establish minimum staffing requirements in the future. Failure to comply with such minimum staffing requirements may result in the imposition of fines or other sanctions. Most states in which our tenants operate have statutes requiring that prior to the addition or construction of new nursing home beds, to the addition of new services or to certain capital expenditures in excess of defined levels, the tenant first must obtain a certificate of need, which certifies that the state has made a determination that a need exists for such new or additional beds, new services or capital expenditures. The certification process is intended to

12

promote quality healthcare at the lowest possible cost and to avoid the unnecessary duplication of services, equipment and centers. This certification process can restrict or prohibit the undertaking of a project or lengthen the period of time required to enlarge or renovate a facility or replace a tenant.

In addition to the above, those of our tenants who provide services that are paid for by Medicare and Medicaid are subject to federal and state budgetary cuts and constraints that limit the reimbursement levels available from these government programs. Changes to reimbursement or methods of payment from Medicare and Medicaid could result in a substantial reduction in our tenants’ revenues. On January 20, 2017, the President issued an executive order aimed at seeking the prompt repeal of the Patient Protection and Affordable Care Act of 2010 (the “Affordable Care Act”), and on December 22, 2017, the President signed into law the Tax Cuts and Jobs Act (the “2017 Tax Act”), which amends certain provisions of the Affordable Care Act.  Amendments to or repeal of the Affordable Care Act and regulatory changes could impose further limitations on government payments to our tenants. On July 31, 2018, CMS issued a final rule, CMS-1696-F, which includes changes to the case-mix classification system used under the Prospective Payment System. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Skilled Nursing Facility Reimbursement Rates” in Part II, Item 7 for additional information.

As of December 31, 2019, our subsidiaries owned 13 healthcare facilities (seven skilled nursing/transitional care facilities and six senior housing communities) with mortgage loans that are guaranteed by HUD. Those facilities are subject to the rules and regulations of HUD, including periodic inspections by HUD, although the tenants of those facilities have the primary responsibility for maintaining the facilities in compliance with HUD’s rules and regulations. The regulatory agreements entered into by each owner and each operator of the property restrict, among other things, any sale or other transfer of the property, modification of the lease between the owner and the operator, use of surplus cash from the property except upon certain conditions and renovations of the property, all without prior HUD approval.

In addition, as an owner of real property, we are subject to various federal, state and local environmental and health and safety laws and regulations. These laws and regulations address various matters, including asbestos, fuel oil management, wastewater discharges, air emissions, medical wastes and hazardous wastes. The costs of complying with these laws and regulations and the penalties for non-compliance can be substantial. For example, although we do not generally operate or actively manage our properties, we may be held primarily or jointly and severally liable for costs relating to the investigation and clean up of any property from which there has been a release or threatened release of a regulated material as well as other affected properties, regardless of whether we knew of or caused the release. In addition to these costs, which are typically not limited by law or regulation and could exceed the property’s value, we could be liable for certain other costs, including governmental fines and injuries to persons, property or natural resources. See “Risk Factors—Risks Relating to Our Business—Environmental compliance costs and liabilities associated with real estate properties owned by us may materially impair the value of those investments.” in Part I, Item 1A.

ITEM 1A. RISK FACTORS

The following describes the risks and uncertainties that could cause our actual results to differ materially from those presented in our forward-looking statements. The risks and uncertainties described below are not the only ones we face but do represent those risks and uncertainties that we believe are material to us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also harm our business.

Risks Relating to Our Business

We are dependent on the operating success of our tenants.

Our tenants’ revenues are primarily driven by occupancy, Medicare and Medicaid reimbursement and private pay rates. Revenues from government reimbursement have been, and may continue to be, subject to rate cuts and further pressure from federal and state budgetary cuts and constraints. A weakening of economic conditions in the U.S. may adversely affect occupancy rates of healthcare facilities that rely on private pay residents. Our tenants’ expenses are driven by the costs of labor, food, utilities, taxes, insurance and rent or debt service. In addition, any failure by a tenant to effectively conduct its operations or to maintain and improve our properties could adversely affect its business reputation and its ability to attract and retain residents in our properties. To the extent any decrease in revenues and/or any increase in operating expenses results in our tenants’ not generating enough cash to make scheduled lease payments to us, our business, financial position or results of operations could be materially adversely affected.

13

Our reported rental and related revenues may be subject to increased variability as a result of the adoption of Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”).

In February 2016, the Financial Accounting Standards Board issued Topic 842, which supersedes guidance related to accounting for leases and provides for the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous accounting guidance. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. We elected to adopt Topic 842 on January 1, 2019 using the modified retrospective transition method. Among other things, under Topic 842, if at any time we cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received and all receivables associated with the lease will be written off, irrespective of amounts expected to be collectible. Recoveries of these amounts will be recorded in future periods upon receipt of payment. Under Topic 842, future write-offs of receivables and any recoveries of previously written-off receivables will be recorded as adjustments to rental revenue. As a result, the adoption of this new accounting standard could cause increased variability related to our reported rental and related revenues, which could increase the volatility in the market price of our common stock.

We are exposed to operational risks with respect to our Senior Housing - Managed communities.

We are exposed to various operational risks with respect to our Senior Housing - Managed communities that may increase our costs or adversely affect our ability to generate revenues. These risks are similar to the ones described above with respect to our tenants and include fluctuations in occupancy and private pay rates; economic conditions; competition; federal, state, local, and industry-regulated licensure, certification and inspection laws, regulations, and standards; the availability and increases in cost of general and professional liability insurance coverage; state regulation and rights of residents related to entrance fees; and the availability and increases in the cost of labor (as a result of unionization or otherwise). Any one or a combination of these factors may adversely affect our business, financial position or results of operations.

Our tenants and operators may be adversely affected by increasing healthcare regulation and enforcement.

Over the last several years, the regulatory environment of the long-term healthcare industry has intensified both in the amount and type of regulations and in the efforts to enforce those regulations. This is particularly true for large for-profit, multi-facility providers. The extensive federal, state and local laws and regulations affecting the healthcare industry include those relating to, among other things, licensure, conduct of operations, ownership of facilities, addition of facilities and equipment, allowable costs, services, prices for services, qualified beneficiaries, quality of care, patient rights, fraudulent or abusive behavior, and financial and other arrangements that may be entered into by healthcare providers. Changes in enforcement policies by federal and state governments have resulted in a significant increase in the number of inspections, citations of regulatory deficiencies and other regulatory sanctions, including terminations from the Medicare and Medicaid programs, bars on Medicare and Medicaid payments for new admissions, civil monetary penalties and even criminal penalties.

If our tenants or operators fail to comply with the extensive laws, regulations and other requirements applicable to their businesses and the operation of our properties, they could become ineligible to receive reimbursement from governmental and private third-party payor programs, face bans on admissions of new patients or residents, suffer civil or criminal penalties or be required to make significant changes to their operations. Our tenants and operators also could be forced to expend considerable resources responding to an investigation, lawsuit or other enforcement action under applicable laws or regulations. In such event, the results of operations and financial condition of our tenants and operators and the results of operations of our properties operated by those entities could be adversely affected, which, in turn, could have a material adverse effect on us. We are unable to predict future federal, state and local regulations and legislation, including the Medicare and Medicaid statutes and regulations, or the intensity of enforcement efforts with respect to such regulations and legislation, and any changes in the regulatory framework could have a material adverse effect on our tenants, which, in turn, could have a material adverse effect on us.

Our tenants and operators depend on reimbursement from governmental and other third-party payor programs, and reimbursement rates from such payors may be reduced.

Many of our tenants and operators depend on third-party payors, including Medicare, Medicaid or private third-party payors, for the majority of their revenue. The reduction in reimbursement rates from third-party payors, including insurance companies and the Medicare and Medicaid programs, or other measures reducing reimbursements for services provided by our tenants and operators, may result in a reduction in our tenants’ and operators’ revenues and operating margins. In addition, reimbursement from private third-party payors may be reduced as a result of retroactive adjustment during claims settlement processes or as a result of post-payment audits. Furthermore, new laws and regulations could impose additional limitations on government and private payments to healthcare providers. For example, our tenants and operators may be affected by health reform initiatives that modify certain payment systems to encourage more cost-effective care and a reduction of inefficiencies

14

and waste (e.g., the implementation of a voluntary bundled payment program and the creation of accountable care organizations). We cannot assure you that adequate reimbursement levels will continue to be available for the services provided by our tenants and operators. Although moderate reimbursement rate reductions may not affect our tenants’ ability to meet their financial obligations to us, significant limits on reimbursement rates or on the services reimbursed could have a material adverse effect on their business, financial position or results of operations, which could materially adversely affect their ability to meet their financial obligations to us.

While reimbursement rates have generally increased over the past few years, President Trump and members of the U.S. Congress may approve or propose various spending cuts and tax reform initiatives that could result in changes (including substantial reductions in funding) to Medicare, Medicaid or Medicare Advantage Plans. In addition, a number of states are currently managing budget deficits, which may put pressure on states to decrease reimbursement rates for our tenants and operators with a goal of decreasing state expenditures under their state Medicaid programs. Any such existing or future federal or state legislation relating to deficit reduction that reduces reimbursement payments to healthcare providers could have a material adverse effect on our tenants’ and operators’ business, financial position or results of operations, which could materially adversely affect their ability to meet their financial obligations to us and could have a material adverse effect on us.

We face potential adverse consequences of bankruptcy or insolvency by our tenants, operators, borrowers, managers and other obligors.

We are exposed to the risk that our tenants could become bankrupt or insolvent. Although our lease agreements provide us with the right to exercise certain remedies in the event of default on the obligations owing to us or upon the occurrence of certain insolvency events, the bankruptcy and insolvency laws afford certain rights to a party that has filed for bankruptcy or reorganization. For example, a lessee may reject its lease with us in a bankruptcy proceeding. In such a case, our claim against the lessee for unpaid and future rents would be limited by the statutory cap of the U.S. Bankruptcy Code. This statutory cap could be substantially less than the remaining rent actually owed under the lease, and any claim we have for unpaid rent might not be paid in full. In addition, a lessee may assert in a bankruptcy proceeding that its lease should be re-characterized as a financing agreement. If such a claim is successful, our rights and remedies as a lender, compared to a landlord, are generally more limited.

We may be unable to find a replacement tenant for one or more of our leased properties.

We may need to find a replacement tenant for one or more of our leased properties for a variety of reasons, including upon the expiration of the lease term or the occurrence of a tenant default. During any period in which we are attempting to locate one or more replacement tenants, there could be a decrease or cessation of rental payments on the applicable property or properties. We cannot be sure that any of our current or future tenants will elect to renew their respective leases upon expiration of the terms thereof. Similarly, we cannot be sure that we will be able to locate a suitable replacement tenant or, if we are successful in locating a replacement tenant, that the rental payments from the new tenant would not be significantly less than the existing rental payments. Our ability to locate a suitable replacement tenant may be significantly delayed or limited by various state licensing, receivership, certificate of need or other laws, as well as by Medicare and Medicaid change-of-ownership rules. We also may incur substantial additional expenses in connection with any such licensing, receivership or change-of-ownership proceedings. Any such delays, limitations and expenses could delay or impact our ability to collect rent, obtain possession of leased properties or otherwise exercise remedies for default, which could materially adversely affect our business, financial condition and results of operations.

Potential litigation and rising insurance costs may affect our tenants’ and operators’ ability to obtain and maintain adequate liability and other insurance and their ability to make lease payments and fulfill their insurance and indemnification obligations to us.

Our tenants and operators may be subject to lawsuits filed by advocacy groups that monitor the quality of care at healthcare facilities or by patients, facility residents or their families. Significant damage awards are possible in cases where neglect has been found. This litigation has increased our tenants’ and operators’ costs of monitoring and reporting quality of care and has resulted in increases in the cost of liability and medical malpractice insurance. These increased costs may materially adversely affect our tenants’ and operators’ ability to obtain and maintain adequate liability and other insurance; manage related risk exposures; fulfill their insurance, indemnification and other obligations to us under their leases or property management agreements, as applicable; or make lease payments to us, as applicable. In addition, from time to time, we may be subject to claims brought against us in lawsuits and other legal proceedings arising out of our alleged actions or the alleged actions of our tenants and operators for which such tenants or operators may have agreed to indemnify, defend and hold us harmless. An unfavorable resolution of any such pending or future litigation could materially adversely affect our liquidity, financial condition and results of operations and have a material adverse effect on us in the event that we are not ultimately indemnified by our tenants or operators.

15

We are subject to risks and liabilities in connection with our investments in joint ventures.

As of December 31, 2019, our investment portfolio included 170 properties owned through an unconsolidated joint venture. This joint venture involves risks not present with respect to our wholly owned properties, including the following:

• We may be unable to take specific major actions, or such actions may be delayed, if our joint venture partner disagrees with such action, due to arrangements that require us to share decision-making authority over major decisions affecting the ownership or operation of the joint venture and any property owned by the joint venture, such as the sale or financing of the property or the making of additional capital contributions for the benefit of the property;

• For the joint venture in which we have a non-controlling interest, our joint venture partner may take actions with which we disagree;

• Under our joint venture agreement, as of January 2, 2020, our partner in the joint venture has the right to transfer its 51% equity interest in the joint venture, subject to our right of first offer, and also has the right to require us to sell our interest in the joint venture in the same transaction pursuant to a drag-along obligation; in the event that our partner wishes to transfer its interest, we would need to decide between acquiring the 51% equity interest at that time or potentially being required to sell some or all of our own 49% equity interest in a sale to a third party;

• Our ability to sell or transfer our interest in the joint venture on advantageous terms when we so desire may be limited or restricted under the terms of our agreements with our partner;

• We may be required to contribute additional capital if our joint venture partner fails to fund its share of required capital contributions;

• Upon bankruptcy of a joint venture entity, we may become liable for the obligations of the joint venture;

• Our joint venture partner might have economic or other business interests or goals that are inconsistent with our business interests or goals, including with respect to the timing, terms and strategies for investment, which could increase the likelihood of disputes regarding the ownership, management or disposition of the properties owned by the joint venture;

• Disagreements with our joint venture partner could result in litigation or arbitration that increases our expenses, distracts our officers and directors, and disrupts the day-to-day operations of the properties owned by the joint venture, including by delaying important decisions until the dispute is resolved; and

• We may suffer losses as a result of actions taken by our joint venture partner with respect to our joint venture investment.

Required regulatory approvals can delay or prohibit transfers of our healthcare properties, which could result in periods in which we are unable to receive rent for such properties.

Our tenants are operators of skilled nursing and other healthcare facilities, which operators must be licensed under applicable state law and, depending upon the type of facility, certified or approved as providers under the Medicare and/or Medicaid programs. Prior to the transfer of the operations of such healthcare properties to successor operators, the new operator generally must become licensed under state law and, in certain states, receive change-of-ownership approvals under certificate of need laws (which laws provide for a certification that the state has made a determination that a need exists for the beds located on the applicable property). If applicable, Medicare and Medicaid provider approvals may be needed as well. In the event that an existing lease is terminated or expires and a new tenant is found, then any delays in the new tenant receiving regulatory approvals from the applicable federal, state or local government agencies, or the inability of such tenant to receive such approvals, may prolong the period during which we are unable to collect the applicable rent. We could also incur substantial additional expenses in connection with any licensing, receivership or change-of-ownership proceedings.

Real estate is a competitive business and this competition may make it difficult for us to identify and purchase suitable healthcare properties, to finance acquisitions on favorable terms, or to retain or attract tenants.

We operate in a highly competitive industry and face competition from other REITs, investment companies, private equity and hedge fund investors, sovereign funds, healthcare operators, lenders and other investors, some of whom are significantly larger than us and have greater resources and lower costs of capital than we do. This competition makes it more challenging to identify and successfully capitalize on acquisition opportunities that meet our investment objectives. Similarly, our properties face competition for patients and residents from other properties in the same market, which may affect our ability to attract and retain tenants or may reduce the rents we are able to charge. If we cannot identify and purchase a sufficient quantity of healthcare properties at favorable prices, finance acquisitions on commercially favorable terms, or attract and retain profitable tenants, our business, financial position or results of operations could be materially adversely affected.

16

We depend on investments in the healthcare property sector, making our profitability more vulnerable to a downturn or slowdown in that specific sector than if we were investing in multiple industries.

We concentrate our investments in the healthcare property sector. As a result, we are subject to risks inherent to investments in a single industry, in real estate, and specifically in healthcare properties. A downturn or slowdown in the healthcare property sector would have a greater adverse impact on our business than if we had investments in multiple industries. Specifically, a downturn in the healthcare property sector could negatively impact the ability of our tenants, operators and borrowers to meet their obligations to us, as well as the ability to maintain rental and occupancy rates. This could adversely affect our business, financial condition and results of operations. In addition, a downturn in the healthcare property sector could adversely affect the value of our properties and our ability to sell properties at prices or on terms acceptable to us.

We have substantial indebtedness and have the ability to incur significant additional indebtedness and other liabilities.

As of December 31, 2019, we had outstanding indebtedness of $2.4 billion, which consisted of $1.3 billion of Senior Notes (as defined below), $1.1 billion in Term Loans (as defined below) and aggregate secured indebtedness to third parties of $114.8 million on certain of our properties, and we had $1.0 billion available for borrowing under our Revolving Credit Facility. Our high level of indebtedness may have the following important consequences to us:

• It may increase our cost of borrowing;

• It may limit our ability to obtain additional financing to fund future acquisitions, working capital, capital expenditures or other general corporate requirements;

• It may expose us to the risk of increased interest rates under debt instruments subject to variable rates of interest, such as our Revolving Credit Facility;

• It may adversely impact our credit ratings;

• It may limit our ability to adjust rapidly to changing market conditions and we may be vulnerable in the event of a downturn in general economic conditions or in the real estate and/or healthcare sectors;

• It may place us at a competitive disadvantage against less leveraged competitors;

• It may restrict the way in which we conduct our business because of financial and operating covenants in the agreements governing our existing and future indebtedness;

• It may become more difficult for us to satisfy our obligations (including ongoing interest payments and, where applicable, scheduled amortization payments) with respect to the Senior Notes and our other debt; and

• It may require us to sell assets and properties at an inopportune time.

In addition, the Senior Notes Indentures (as defined below) permit us to incur substantial additional debt, including secured debt (to which the Senior Notes will be effectively subordinated). If we incur additional debt, the related risks described above could intensify. Furthermore, the Senior Notes Indentures do not impose any limitation on our ability to incur liabilities that are not considered indebtedness under the Senior Notes Indentures.

The impact of any of these potential adverse consequences could have a material adverse effect on our results of operations, financial condition, and liquidity.

We may be unable to service our indebtedness.

Our ability to make scheduled payments on and to refinance our indebtedness depends on and is subject to our future financial and operating performance, which in turn is affected by general and regional economic, financial, competitive, business and other factors beyond our control, including the availability of financing in the international banking and capital markets. Our business may fail to generate sufficient cash flow from operations or future borrowings may be unavailable to us under our Revolving Credit Facility or from other sources in an amount sufficient to enable us to service our debt, to refinance our debt or to fund our other liquidity needs. If we are unable to meet our debt obligations or to fund our other liquidity needs, we will need to restructure or refinance all or a portion of our debt. We may be unable to refinance any of our debt, including our Term Loans and any amounts outstanding under our Revolving Credit Facility, on commercially reasonable terms or at all. In particular, our Term Loans and our Revolving Credit Facility will mature prior to the maturity of the majority of the Senior Notes. If we were unable to make payments or refinance our debt or obtain new financing under these circumstances, we would have to consider other options, such as asset sales, equity issuances and/or negotiations with our lenders to restructure the applicable debt. Our Credit Agreement and the Senior Notes Indentures restrict, and market or business conditions may limit, our ability to take some or all of these actions. Any restructuring or refinancing of our indebtedness could be at higher interest rates and may require us to comply with more onerous covenants that could further restrict our business operations.

17

Covenants in our debt agreements restrict our and our subsidiaries’ activities and could adversely affect our business.

Our debt agreements, including the agreement governing our 2027 Notes (as defined below) and the Credit Agreement, contain various covenants that limit our ability and the ability of our subsidiaries to engage in various transactions including:

• Incurring additional secured and unsecured debt;

• Paying dividends or making other distributions on, redeeming or repurchasing capital stock;

• Entering into transactions with affiliates;

• Issuing stock of or interests in subsidiaries;

• Engaging in non-healthcare related business activities;

• Creating restrictions on the ability of certain of our subsidiaries to pay dividends or other amounts to us;

• Selling assets; or

• Effecting a consolidation or merger or selling substantially all of our assets.

The agreement governing our 2027 Notes also restricts us from making certain investments. The indentures governing our 2024 Notes, our 2026 Notes and our 2029 Notes (each as defined below) contain certain of the above restrictions as well. These covenants limit our operational flexibility and could prevent us from taking advantage of business opportunities as they arise, growing our business or competing effectively. In addition, the Credit Agreement requires us to comply with specified financial covenants, which include a maximum leverage ratio, a minimum fixed charge coverage ratio and a minimum tangible net worth ratio, as well as satisfy other financial condition tests. The indentures governing the 2024 Notes and 2029 Notes require us to comply with an unencumbered asset ratio, and the agreement governing our 2027 Notes requires us to comply with specified financial covenants, which include a maximum leverage ratio, a maximum secured debt leverage ratio, a maximum unsecured debt leverage ratio, a minimum fixed charge coverage ratio, a minimum net worth, a minimum unsecured interest coverage ratio and a minimum unencumbered debt yield ratio. Our ability to meet these requirements may be affected by events beyond our control, and we may not meet these requirements.

A breach of any of the covenants or other provisions in our debt agreements could result in an event of default, which, if not cured or waived, could result in such debt becoming immediately due and payable. Further, certain change in control events could result in an event of default under the agreement governing our 2027 Notes. Any of these events of default, in turn, could cause our other debt to become due and payable as a result of cross-acceleration provisions contained in the agreements governing such other debt. We may be unable to maintain compliance with these covenants and, if we fail to do so, we may be unable to obtain waivers from the lenders and holders and/or amend the covenants. In the event that some or all of our debt is accelerated and becomes immediately due and payable, we may not have the funds to repay, or the ability to refinance, such debt.

 An increase in market interest rates could increase our interest costs on borrowings on our Revolving Credit Facility and future debt and could adversely affect our stock price.

If interest rates increase, so could our interest costs for borrowings on our Revolving Credit Facility and any new debt. This increased cost could make the financing of any acquisition more costly. Rising interest rates could limit our ability to refinance existing debt when it matures or cause us to pay higher interest rates upon refinancing. In addition, an increase in interest rates could decrease the access third parties have to credit, thereby decreasing the amount they are willing to pay for our assets, and consequently limit our ability to reposition our portfolio promptly in response to changes in economic or other conditions.

In addition, increased inflation may have a pronounced negative impact on the interest expense we pay in connection with our outstanding indebtedness and our general and administrative expenses, as these costs could increase at a rate higher than our rents.

Changes in the method pursuant to which the LIBOR rates are determined and potential phasing out of LIBOR after 2021 may affect our financial results.

Our Credit Agreement uses LIBOR as a reference rate for our U.S. dollar Term Loans and Revolving Credit Facility, such that the interest rate applicable to such loans may, at our option, be calculated based on LIBOR. In July 2017, the U.K.’s Financial Conduct Authority, which regulates LIBOR, announced that it intends to phase out LIBOR by the end of 2021. The U.S. Federal Reserve has begun publishing a Secured Overnight Funding Rate, which is intended to replace U.S. dollar LIBOR. Plans for alternative reference rates for other currencies have also been announced. At this time, we cannot predict how markets will respond to these proposed alternative rates or the effect of any changes to LIBOR or the discontinuation of LIBOR. If LIBOR is no longer available or if our lenders have increased costs due to changes in LIBOR, we may experience potential increases in interest rates on our variable rate debt, which could adversely impact our interest expense, results of

18

operations and cash flows. In addition, although not expected, replacing LIBOR with an alternative reference rate for any of our debt (or other changes to our debt in connection with such replacement) could be a taxable event.

Our ability to raise capital through equity financings is dependent, in part, on the market price of our common stock, which depends on market conditions and other factors affecting REITs generally.

Our ability to raise capital through equity financings depends, in part, on the market price of our common stock, which in turn depends on fluctuating market conditions and other factors including the following:

• The reputation of REITs and attractiveness of their equity securities in comparison with other equity securities, including securities issued by other real estate companies;

• Our financial performance and that of our tenants;

• Concentrations in our investment portfolio by tenant and property type;

• Concerns about our tenants’ financial condition, including as a result of uncertainty regarding reimbursement from governmental and other third-party payor programs;

• Our ability to meet or exceed investor expectations of prospective investment and earnings targets;

• The contents of analyst reports about us and the REIT industry;

• Changes in interest rates on fixed-income securities, which may lead prospective investors to demand a higher annual yield from investments in our common stock;

• Maintaining or increasing our dividend, which is determined by our board of directors and depends on our financial position, results of operations, cash flows, capital requirements, debt covenants (which include limits on distributions by us), applicable law, and other factors as our board of directors deems relevant; and

• Regulatory action and changes in REIT tax laws.

The market value of a REIT’s equity securities is generally based upon the market’s perception of the REIT’s growth potential and its current and potential future earnings and cash distributions. If we fail to meet the market’s expectation with regard to future earnings and cash distributions, the market price of our common stock could decline, and our ability to raise capital through equity financings could be materially adversely affected.

We may be adversely affected by fluctuations in foreign currency exchange rates.

Our ownership of properties in Canada subjects us to fluctuations in the exchange rate between U.S. dollars and Canadian dollars. Although we have pursued hedging alternatives, by borrowing in Canadian dollar denominated debt and entering into cross currency swaps, to protect against foreign currency fluctuations, no amount of hedging activity can fully insulate us from the risks associated with changes in foreign currency exchange rates, and the failure to hedge effectively against foreign currency exchange rate risk could materially adversely affect our business, financial position or results of operations. In addition, any income derived from such hedging transactions may not qualify under the 75% gross income test or the 95% gross income test that we must satisfy annually in order to qualify and maintain our status as a REIT.

We may not be able to sell properties when we desire because real estate investments are relatively illiquid, which could have a material adverse effect on our business, financial position or results of operations.

Real estate investments generally cannot be sold quickly. In addition, some and potentially substantially all of our properties serve as collateral for our current and future secured debt obligations and cannot readily be sold unless the underlying secured indebtedness is concurrently repaid. We may not be able to vary our portfolio promptly in response to changes in the real estate market. A downturn in the real estate market could materially adversely affect the value of our properties and our ability to sell such properties for acceptable prices or on other acceptable terms. We also cannot predict the length of time needed to find a willing purchaser and to close the sale of a property or portfolio of properties. These factors and any others that would impede our ability to respond to adverse changes in the performance of our properties could have a material adverse effect on our business, financial position or results of operations.

If we lose our key management personnel, we may not be able to successfully manage our business and achieve our objectives.

Our success depends in large part upon the leadership and performance of our executive management team, particularly Mr. Matros, our President and Chief Executive Officer. If we lose the services of Mr. Matros, we may not be able to successfully manage our business or achieve our business objectives.

19

We may experience uninsured or underinsured losses, which could result in a significant loss of the capital we have invested in a property, decrease anticipated future revenues or cause us to incur unanticipated expenses.

While our lease agreements and property management agreements require that comprehensive insurance and hazard insurance be maintained by the tenants or operators, as applicable, there are certain types of losses, generally of a catastrophic nature, such as earthquakes, hurricanes and floods, that may be uninsurable or not economically insurable. Insurance coverage may not be sufficient to pay the full current market value or current replacement cost of a loss. Inflation, changes in building codes and ordinances, environmental considerations, and other factors also might make it infeasible to use insurance proceeds to replace properties after they have been damaged or destroyed. Under such circumstances, the insurance proceeds received might not be adequate to restore the economic position with respect to a damaged property.

Environmental compliance costs and liabilities associated with real estate properties owned by us may materially impair the value of those investments.

As an owner of real property, we or our subsidiaries are subject to various federal, state and local environmental and health and safety laws and regulations. Although we do not currently operate or manage the substantial majority of our properties, we or our subsidiaries may be held primarily or jointly and severally liable for costs relating to the investigation and clean-up of any property where there has been a release or threatened release of a hazardous regulated material as well as other affected properties, regardless of whether we knew of or caused the release. In addition to these costs, which are typically not limited by law or regulation and could exceed an affected property’s value, we could be liable for certain other costs, including governmental fines and injuries to persons, property or natural resources. Further, some environmental laws provide for the creation of a lien on a contaminated site in favor of the government as security for damages and any costs the government incurs in connection with such contamination and associated clean-up.

Although we require our operators and tenants to undertake to indemnify us for environmental liabilities they cause, the amount of such liabilities could exceed the financial ability of the tenant or operator to indemnify us. The presence of contamination or the failure to remediate contamination may adversely affect our ability to sell or lease the real estate or to borrow using the real estate as collateral.

We rely on information technology in our operations, and any material failure, inadequacy, interruption or security failure of that technology could harm our business.

We rely on information technology networks and systems, including the Internet, to process, transmit and store electronic information, and to manage or support a variety of business processes, including financial transactions and records, personal identifying information, tenant and lease data. We purchase some of our information technology from vendors, on whom our systems depend. We rely on commercially available systems, software, tools and monitoring to provide security for processing, transmission and storage of confidential tenant, borrower and operator information, some of which may include individually identifiable information, including information relating to financial accounts. Although we have taken steps to protect the security of our information systems and the data maintained in those systems, it is possible that our safety and security measures will not be able to prevent the systems’ improper functioning or damage, or the improper access or disclosure of personally identifiable information such as in the event of cyber-attacks. Security breaches (including physical or electronic break-ins, computer viruses, phishing attacks, computer denial-of-service attacks, worms, covert introduction of malware to computers and networks, impersonation of authorized users, and efforts to discover and exploit any design flaws, bugs, security vulnerabilities or security weaknesses, as well as intentional or unintentional acts by employees or other insiders with access privileges, intentional acts of vandalism by third parties and sabotage) can create system disruptions, shutdowns or unauthorized disclosure of confidential information. Any failure to maintain proper function, security and availability of our information systems could interrupt our operations, damage our reputation, subject us to liability claims or regulatory penalties and could have a material adverse effect on our business, financial condition and results of operations.

The tax imposed on REITs engaging in “prohibited transactions” may limit our ability to engage in transactions which would be treated as sales for federal income tax purposes.

A REIT’s net income from prohibited transactions is subject to a 100% penalty tax. In general, prohibited transactions are sales or other dispositions of property, other than foreclosure property, held primarily for sale to customers in the ordinary course of business. Although we do not intend to hold any properties that would be characterized as held for sale to customers in the ordinary course of our business, unless a sale or disposition qualifies under certain statutory safe harbors, such characterization is a factual determination and no guarantee can be given that the Internal Revenue Service (“IRS”) would agree with our characterization of our properties or that we will always be able to make use of the available safe harbors.

20

An ownership limit and certain takeover defenses could inhibit a change of control of Sabra or reduce the value of our stock.

Certain provisions of Maryland law and of our charter and bylaws may have an anti-takeover effect. The following provisions of Maryland law and these governing documents could have the effect of making it more difficult for a third party to acquire control of Sabra, including certain acquisitions that our stockholders may deem to be in their best interests:

• Our charter contains transfer and ownership restrictions on the percentage by number and value of outstanding shares of our stock that may be owned or acquired by any stockholder;

• Our charter permits the issuance of one or more classes or series of preferred stock with rights and preferences to be determined by the board of directors and permits our board of directors, without stockholder action, to amend the charter to increase or decrease the aggregate number of authorized shares or the number of shares of any class or series that we have authority to issue;

• Our bylaws require advance notice of stockholder proposals and director nominations;

• “Business combination” provisions of Maryland law, subject to certain limitations, impose a moratorium on business combinations with “interested stockholders” or affiliates thereof for five years and thereafter impose additional requirements on such business combinations; and

• “Control share” provisions of Maryland law that provide that holders of “control shares” of a corporation (defined as voting shares of stock that, if aggregated with all other shares of stock owned or controlled by the acquirer, would entitle the acquirer to exercise one of three increasing ranges of voting power in electing directors) acquired in a “control share acquisition” (defined as the direct or indirect acquisition of issued and outstanding “control shares”) have no voting rights except to the extent approved by the stockholders by the affirmative vote of at least two-thirds of all of the votes entitled to be cast on the matter, excluding all interested shares.

Sabra is subject to the Maryland business combination statute. Our bylaws contain a provision exempting us from the control share provisions of the Maryland General Corporation Law (the “MGCL”). There can be no assurance that this bylaw provision exempting us from the control share provisions will not be amended or eliminated at any time in the future.

Additionally, Title 3, Subtitle 8 of the MGCL permits our Board of Directors, without stockholder approval and regardless of what currently is provided in our charter or bylaws, to implement certain takeover defenses, such as a classified board, some of which we do not have.

Our bylaws provide that the Circuit Court for Baltimore City, Maryland or the United States District Court for the District of Maryland, Baltimore Division will be the sole and exclusive forum for substantially all disputes between our company and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with our company or our directors, officers or other employees.

Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Circuit Court for Baltimore City, Maryland, or, if that court does not have jurisdiction, the United States District Court for the District of Maryland, Baltimore Division, will be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of our company, (ii) any action asserting a claim of breach of any duty owed by any director or officer or other employee of our company to our company or to the stockholders of our company, (iii) any action asserting a claim against our company or any director or officer or other employee of our company arising pursuant to any provision of Maryland law, our charter or our bylaws, or (iv) any action asserting a claim against our company or any director or officer or other employee of our company that is governed by the internal affairs doctrine. This exclusive forum provision is intended to apply to claims arising under Maryland state law and would not apply to claims brought pursuant to the Exchange Act or the Securities Act of 1933, or any other claim for which the federal courts have exclusive jurisdiction. This exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.

21

This exclusive forum provision may limit a stockholder’s ability to bring a claim in a judicial forum of its choosing for disputes with our company or our directors, officers or other employees, which may discourage lawsuits against our company and our directors, officers and other employees. In addition, stockholders who do bring a claim in the Circuit Court for Baltimore City, Maryland could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Maryland. The Circuit Court for Baltimore City, Maryland may also reach different judgments or results than would other courts, including courts where a stockholder would otherwise choose to bring the action, and such judgments or results may be more favorable to our company than to our stockholders. However, the enforceability of similar exclusive forum provisions in other companies’ charters and bylaws has been challenged in legal proceedings, and it is possible that a court could find this type of provision to be inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings. If a court were to find the exclusive forum provision contained in our bylaws to be inapplicable or unenforceable in an action, we might incur additional costs associated with resolving such action in other jurisdictions.

Risks Associated with Our Status as a REIT

Our failure to maintain our qualification as a REIT would subject us to U.S. federal income tax, which could adversely affect the value of the shares of our common stock and would substantially reduce the cash available for distribution to our stockholders.

Our qualification and taxation as a REIT will depend upon our ability to meet on a continuing basis, through actual annual operating results, certain qualification tests set forth in the U.S. federal tax laws. Accordingly, given the complex nature of the rules governing REITs, the ongoing importance of factual determinations, including the potential tax treatment of investments we make, and the possibility of future changes in our circumstances, no assurance can be given that our actual results of operations for any particular taxable year will satisfy such requirements.

If we fail to qualify as a REIT in any calendar year, we would be required to pay U.S. federal income tax (and any applicable state and local tax) on our taxable income at regular corporate rates, and dividends paid to our stockholders would not be deductible by us in computing our taxable income (although such dividends received by certain non-corporate U.S. taxpayers generally would currently be subject to a preferential rate of taxation). Further, if we fail to qualify as a REIT, we might need to borrow money or sell assets in order to pay any resulting tax. Our payment of income tax would decrease the amount of our income available for distribution to our stockholders. Furthermore, if we fail to maintain our qualification as a REIT, we no longer would be required under U.S. federal tax laws to distribute substantially all of our REIT taxable income to our stockholders. Unless our failure to qualify as a REIT was subject to relief under U.S. federal tax laws, we could not re-elect to qualify as a REIT until the fifth calendar year following the year in which we failed to qualify.

The 90% distribution requirement will decrease our liquidity and may limit our ability to engage in otherwise beneficial transactions.

To comply with the 90% taxable income distribution requirement applicable to REITs and to avoid the nondeductible excise tax, we must make distributions to our stockholders. The Senior Notes Indentures permit us to declare or pay any dividend or make any distribution that is necessary to maintain our REIT status if the aggregate principal amount of all outstanding Indebtedness of the Parent and its Restricted Subsidiaries on a consolidated basis at such time is less than 60% of Adjusted Total Assets (as each term is defined in the Senior Notes Indentures) and to make additional distributions if we pass certain other financial tests.

We are required under the Internal Revenue Code of 1986, as amended (the “Code”) to distribute at least 90% of our taxable income, determined without regard to the dividends-paid deduction and excluding any net capital gain, and the Operating Partnership (as defined below) is required to make distributions to us to allow us to satisfy these REIT distribution requirements. However, distributions may limit our ability to rely upon rental payments from our properties or subsequently acquired properties to finance investments, acquisitions or new developments.

Although we anticipate that we generally will have sufficient cash or liquid assets to enable us to satisfy the REIT distribution requirement, it is possible that, from time to time, we may not have sufficient cash or other liquid assets to meet the 90% distribution requirement. This may be due to the timing differences between the actual receipt of income and actual payment of deductible expenses, on the one hand, and the inclusion of that income and deduction of those expenses in arriving at our taxable income, on the other hand. Moreover, the 2017 Tax Act amends the Code such that income must be accrued for U.S. federal income tax purposes no later than when such income is taken into account as revenue in our financial statements, subject to certain exceptions, which could also create timing differences between net taxable income and the receipt of cash attributable to such income. In addition, non-deductible expenses such as principal amortization or repayments or capital expenditures in excess of non-cash deductions also may cause us to fail to have sufficient cash or liquid assets to enable us to satisfy the 90% distribution requirement.

22

In the event that such an insufficiency occurs, in order to meet the 90% distribution requirement and maintain our status as a REIT, we may have to sell assets at unfavorable prices, borrow at unfavorable terms, make taxable stock dividends, or pursue other strategies. This may require us to raise additional capital to meet our obligations. The terms of our Credit Agreement and the terms of the Senior Notes Indentures may restrict our ability to engage in some of these transactions.

We could fail to qualify as a REIT if income we receive is not treated as qualifying income, including as a result of one or more of the lease agreements we have entered into or assumed not being characterized as true leases for U.S. federal income tax purposes, which would subject us to U.S. federal income tax at corporate tax rates.

Under applicable provisions of the Code, we will not be treated as a REIT unless we satisfy various requirements, including requirements relating to the sources of our gross income. Rents received or accrued by us will not be treated as qualifying rent for purposes of these requirements if the lease agreements we have entered into or assumed (as well as any other leases we enter into or assume) are not respected as true leases for U.S. federal income tax purposes and are instead treated as service contracts, joint ventures, loans or some other type of arrangement. In the event that the lease agreements entered into with lessees are not characterized as true leases for U.S. federal income tax purposes, we may fail to qualify as a REIT. In addition, rents received by us from a lessee will not be treated as qualifying rent for purposes of these requirements if we are treated, either directly or under the applicable attribution rules, as owning 10% or more of the lessee’s stock, capital or profits. We will be treated as owning, under the applicable attribution rules, 10% or more of a lessee’s stock, capital or profits at any time that a stockholder owns, directly or under the applicable attribution rules, (a) 10% or more of our common stock and (b) 10% or more of the lessee’s stock, capital or profits. The provisions of our charter restrict the transfer and ownership of our common stock that would cause the rents received or accrued by us from a tenant of ours to be treated as non-qualifying rent for purposes of the REIT gross income requirements. Nevertheless, there can be no assurance that such restrictions will be effective in ensuring that we will not be treated as related to a tenant of ours. If we fail to qualify as a REIT, we would be subject to U.S. federal income tax (including any applicable minimum tax) on our taxable income at corporate tax rates, which would decrease the amount of cash available for distribution to holders of our common stock.

Complying with REIT requirements may cause us to forego otherwise attractive acquisition opportunities or liquidate otherwise attractive investments, which could materially hinder our performance.

To qualify as a REIT for U.S. federal income tax purposes, we must continually satisfy certain tests, including tests concerning the sources of our income, the nature and diversification of our assets, the amounts we distribute to our stockholders and the ownership of our stock. In order to meet these tests, we may be required to forego investments or acquisitions we might otherwise make. Thus, compliance with the REIT requirements may materially hinder our performance.

If we have significant amounts of non-cash taxable income, we may have to declare taxable stock dividends or make other non-cash distributions, which could cause our stockholders to incur tax liabilities in excess of cash received.

We currently intend to pay dividends in cash only, and not in-kind. However, if for any taxable year, we have significant amounts of taxable income in excess of available cash flow, we may have to declare dividends in-kind in order to satisfy the REIT annual distribution requirements. We may distribute a portion of our dividends in the form of our stock or our debt instruments. In either event, a holder of our common stock will be required to report dividend income as a result of such distributions even though we distributed no cash or only nominal amounts of cash to such stockholder.

The IRS issued a Revenue Procedure treating certain distributions that are paid by an SEC-registered REIT partly in cash and partly in shares as dividends that would satisfy the REIT annual distribution requirement and qualify for the dividends paid deduction for U.S. federal income tax purposes so long as at least 20% of the total dividend is available in cash. However, if we make such a distribution, U.S. holders would be required to include the full amount of the dividend (i.e., the cash and stock portion) as ordinary income to the extent of our current and accumulated earnings and profits for U.S. federal income tax purposes. As a result, a U.S. holder may be required to pay income taxes with respect to such dividends in excess of the cash received. If a U.S. holder sells our stock that it receives as a dividend in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the dividend, depending on the market price of the stock at the time of the sale. Furthermore, with respect to non-U.S. holders, we may be required to withhold U.S. tax with respect to such dividends, including in respect of all or a portion of such dividend that is payable in stock. In addition, if a significant number of our stockholders determine to sell shares of our stock in order to pay taxes owed on dividends, these sales may put downward pressure on the trading price of our stock. No assurance can be given that the IRS will not impose additional requirements in the future with respect to taxable dividends payable in cash and/or stock, including on a retroactive basis, or assert that the requirements for such taxable dividends have not been met.

23

Our charter restricts the transfer and ownership of our stock, which may restrict change of control or business combination opportunities in which our stockholders might receive a premium for their shares.

In order for us to maintain our qualification as a REIT, no more than 50% of the value of our outstanding stock may be owned, directly or constructively, by five or fewer individuals, as defined in the Code. For the purpose of preserving our REIT qualification, our charter prohibits, subject to certain exceptions, beneficial and constructive ownership of more than 9.9% in value or in number of shares, whichever is more restrictive, of our outstanding common stock or more than 9.9% in value of all classes or series of our outstanding stock. The constructive ownership rules are complex and may cause shares of stock owned directly or constructively by a group of related individuals to be constructively owned by one individual or entity. The ownership limits may have the effect of discouraging an acquisition of control of us without the approval of our board of directors.

We may be subject to adverse legislative or regulatory tax changes that could reduce the market price of our common stock.

The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Department of the Treasury. Changes to the tax law could materially adversely affect our stockholders. In particular, the 2017 Tax Act significantly reforms the Code with respect to the taxation of both individuals and corporate entities (although certain changes will expire at the end of 2025) and the tax consequences of such changes as they apply to us and our stockholders may differ, in some cases materially, from the consequences under the laws in effect prior to January 1, 2018. We cannot predict with certainty whether, when, in what forms, or with what effective dates, the tax laws applicable to us or our stockholders may be changed.

Dividends payable by REITs do not qualify for the reduced tax rates available for some dividends.

The maximum income tax rate applicable to “qualified dividends” payable by non-REIT corporations to domestic stockholders taxed at individual rates is currently 20%. Dividends payable by REITs, however, generally are not eligible for the reduced rates. For taxable years after December 31, 2017 and continuing through 2025, the 2017 Tax Act temporarily reduces the maximum individual federal income tax rate from 39.6% to 37% and the effective tax rate on ordinary REIT dividends (i.e., dividends other than capital gain dividends and dividends attributable to certain qualified dividend income received by us) for U.S. holders of our common shares that are individuals, estates or trusts by permitting such holders to claim a deduction in determining their taxable income equal to 20% of any such dividends they receive. Although not adversely affecting the taxation of REITs or dividends payable by REITs, the more favorable rates applicable to regular corporate qualified dividends could cause investors who are taxed at individual rates to perceive investments in REITs to be relatively less attractive than investments in the stocks of non-REIT corporations that pay dividends treated as qualified dividend income, which could adversely affect the value of the stock of REITs, including our common stock.

Our ownership of and relationship with any taxable REIT subsidiaries that we have formed or will form will be limited and a failure to comply with the limits would jeopardize our REIT status and may result in the application of a 100% excise tax.

A REIT may own up to 100% of the stock of one or more taxable REIT subsidiaries (“TRSs”). A TRS may earn income that would not be qualifying income if earned directly by the parent REIT. Both the subsidiary and the REIT must jointly elect to treat the subsidiary as a TRS. A corporation (other than a REIT) of which a TRS directly or indirectly owns securities possessing more than 35% of the total voting power or total value of the outstanding securities of such corporation will automatically be treated as a TRS. Overall, no more than 25% of the value of a REIT’s total assets may consist of stock or securities of one or more TRSs. Under the 2017 Tax Act, such overall limitation on the value of a REIT’s total assets consisting of stock or securities of one or more TRSs was reduced to 20%. A domestic TRS will pay U.S. federal, state and local income tax at regular corporate rates on any income that it earns, but as a result of the enactment of the 2017 Tax Act, net operating loss (“NOL”) carryforwards of TRS losses arising in taxable years beginning after December 31, 2017 may be deducted only to the extent of 80% of TRS taxable income in the carryforward year (computed without regard to the NOL deduction). In contrast to prior law, which permitted unused NOL carryforwards to be carried back two years and forward 20 years, the 2017 Tax Act provides that losses arising in taxable years ending after December 31, 2017 can no longer be carried back but can be carried forward indefinitely. In addition, for taxable years beginning after December 31, 2017, taxpayers, including TRSs, may be subject to a limitation on their ability to deduct net business interest generally equal to 30% of adjusted taxable income, subject to certain exceptions. This provision may limit the ability of our TRSs to deduct interest, which could increase their taxable income. The rules also impose a 100% excise tax on certain transactions between a TRS and its parent REIT that are not conducted on an arm’s length basis. Any domestic TRS that we have formed or may form will pay U.S. federal, state and local income tax on its taxable income, and its after-tax net income will be available for distribution to us but is not required to be distributed to us unless necessary to maintain our REIT qualification.

24

ITEM 1B. UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 2. PROPERTIES    

As of December 31, 2019, our investment portfolio consisted of 429 real estate properties held for investment (consisting of (i) 296 skilled nursing/transitional care facilities, (ii) 62 Senior Housing - Leased communities, (iii) 46 Senior Housing - Managed communities and (iv) 25 specialty hospitals and other facilities), one investment in a direct financing lease, 18 investments in loans receivable (consisting of (i) one mortgage loan, (ii) one construction loan and (iii) 16 other loans), nine preferred equity investments and one investment in an unconsolidated joint venture. As of December 31, 2019, our real estate properties held for investment included 43,112 beds/units, spread across the U.S. and Canada. As of December 31, 2019, the substantial majority of our real estate properties (excluding 46 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 15 years.

The following table displays the expiration of annualized contractual rental revenues under our lease agreements as of December 31, 2019, net of repositioning reserves, if applicable, by year and property type (dollars in thousands) and, in each case, without giving effect to any renewal options:

	Skilled Nursing/Transitional Care (1)		Senior Housing - Leased (1)		Specialty Hospitals and Other		Total Annualized Revenues		% of Revenue
2020 (2)	$	11,641	$	—	$	1,241	$	12,882	3.0	%
2021	4,557		1,165		—		5,722		1.3	%
2022	24,121		4,990		3,965		33,076		7.8	%
2023	8,851		—		—		8,851		2.1	%
2024	32,417		4,485		—		36,902		8.7	%
2025	9,702		8,111		—		17,813		4.2	%
2026	24,710		603		—		25,313		6.0	%
2027	38,427		2,463		32,727		73,617		17.3	%
2028	14,729		7,694		3,919		26,342		6.2	%
2029	52,825		3,511		5,628		61,964		14.6	%
Thereafter	99,529		18,257		4,253		122,039		28.8	%
Total Annualized Revenues	$	321,509	$	51,279	$	51,733	$	424,521	100.0	%

⁽¹⁾  Excludes (i) Senior Housing - Managed communities and (ii) two non-operational skilled nursing/transitional care facilities.

⁽²⁾  2020 lease expirations include (i) for skilled nursing/transitional care leases, $4.9 million in the second quarter, $1.0 million in the third quarter and $5.7 million in the fourth quarter (on December 31, 2020) and (ii) for specialty hospitals and other leases, $1.2 million in the fourth quarter.

We believe that all of our properties are adequately covered by insurance and are suitable for their intended uses as described in “Business—Portfolio of Healthcare Properties” in Part I, Item 1.

Occupancy Trends

The following table sets forth the occupancy percentages for our properties for the periods indicated:

	Occupancy Percentage (1)
	2019		2018		2017
Skilled Nursing/Transitional Care	82.1	%	82.8	%	84.0	%
Senior Housing - Leased	87.0	%	86.7	%	87.8	%
Specialty Hospitals and Other	71.0	%	76.7	%	79.2	%
Senior Housing - Managed	87.7	%	91.5	%	90.6	%
Unconsolidated Joint Venture Senior Housing - Managed	82.2	%	81.7	%	N/A

⁽¹⁾  Occupancy percentage represents the facilities’ average operating occupancy for the period indicated and is calculated by dividing the actual census from the period presented by the available beds/units for the same period. Occupancy percentage includes only facilities owned by Sabra as of the end of the respective period for the duration that such facilities were classified as stabilized facilities and excludes facilities for which data is not available or meaningful. Occupancy is only included in periods subsequent to our acquisition, except for the facilities previously owned by Care Capital Properties, Inc. (“CCP”) which are presented as if these real estate investments were owned by Sabra during the entirety of the periods presented, and is presented for the trailing twelve month period and one quarter in arrears, except for Senior Housing - Managed, which is presented for the current period on a trailing three

25

month basis. All facility financial performance information was provided by, or derived solely from information provided by, operators/tenants without independent verification by us.

You should not rely upon occupancy percentages, either individually or in the aggregate, to determine the performance of a facility. Other factors that may impact the performance of a facility include the sources of payment, terms of reimbursement and the acuity level of the patients (i.e., the condition of patients that determines the level of skilled nursing and rehabilitation therapy services required).

See “Business—Portfolio of Healthcare Properties” in Part I, Item 1 for further discussion regarding the ownership of our properties and the types of healthcare facilities that comprise our properties.

Secured Indebtedness

Of our 429 properties held for investment, 16 are subject to secured indebtedness to third parties that, as of December 31, 2019, totaled approximately $114.8 million. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Secured Indebtedness” in Part II, Item 7 for further discussion regarding our secured indebtedness. As of December 31, 2019 and 2018, our secured debt consisted of the following (dollars in thousands):

	Principal Balance as of December 31, (1)				Weighted Average Interest Rate at December 31, (2)
Interest Rate Type	2019		2018		2019		2018		Maturity Date
Fixed Rate	$	114,777	$	117,464	3.67	%	3.66	%	December 2021 -  August 2051

⁽¹⁾  Principal balance does not include deferred financing costs, net of $1.7 million and $1.8 million as of December 31, 2019 and 2018, respectively.

⁽²⁾  Weighted average interest rate includes private mortgage insurance.

Corporate Office

We are headquartered and have our corporate office in Irvine, California. We lease our corporate office from an unaffiliated third party.

ITEM 3. LEGAL PROCEEDINGS

For a description of our legal proceedings, see Note 16, “Commitments and Contingencies—Legal Matters” in the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K, which is incorporated by reference in response to this item.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

26

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Stockholder Information

Our common stock is listed on The Nasdaq Stock Market LLC and trades on the Nasdaq Global Select Market under the symbol “SBRA.”

At February 17, 2020, we had approximately 5,170 stockholders of record.

We did not repurchase any shares of our common stock during the quarter ended December 31, 2019.

To maintain REIT status, we are required each year to distribute to stockholders at least 90% of our annual REIT taxable income after certain adjustments. All distributions will be made by us at the discretion of our board of directors and will depend on our financial position, results of operations, cash flows, capital requirements, debt covenants (which include limits on distributions by us), applicable law, and other factors as our board of directors deems relevant. For example, while the Senior Notes Indentures and the Credit Agreement permit us to declare and pay any dividend or make any distribution that is necessary to maintain our REIT status, those distributions are subject to certain financial tests under the Senior Notes Indentures, and therefore, the amount of cash distributions we can make to our stockholders may be limited.

Distributions with respect to our common stock and preferred stock can be characterized for federal income tax purposes as taxable ordinary dividends, which may be non-qualified, long-term capital gain, or qualified, non-dividend distributions (return of capital) or a combination thereof. Following is the characterization of our annual cash dividends on common stock and preferred stock per share:

	Year Ended December 31,
Common Stock	2019		2018		2017
Non-qualified ordinary dividends	$	0.9098	$	1.0905	$	1.2288
Qualified ordinary dividends	0.0367		0.0112		—
Long-term capital gains	—		0.2132		—
Unrecaptured Section 1250	—		0.4851		—
Non-dividend distributions	0.8535		—		0.5012
	$	1.8000	$	1.8000	$	1.7300

	Year Ended December 31,
Preferred Stock (1)	2018		2017
Non-qualified ordinary dividends	$	0.4496	$	1.7813
Qualified ordinary dividends	0.0047		—
Long-term capital gains	0.0879		—
Unrecaptured Section 1250	0.2000		—
	$	0.7422	$	1.7813

⁽¹⁾ We redeemed all outstanding shares of our Series A Preferred Stock on June 1, 2018. See Note 11, “Equity,” in the Notes to Consolidated Financial Statements for additional information.

27

Stock Price Performance Graph

The following graph compares the cumulative total stockholder return of our common stock for the five-year period ending December 31, 2019. The graph assumes that $100 was invested at the close of market on December 31, 2014 in (i) our common stock, (ii) the Nasdaq Composite Index and (iii) the SNL US Healthcare REIT Index and assumes the reinvestment of all dividends. Stock price performances shown in the graph are not necessarily indicative of future price performances.

The above performance graph shall not be deemed to be soliciting material or to be filed with the SEC under the Securities Act of 1933 or the Securities Exchange Act of 1934 or incorporated by reference in any document as filed.

28

ITEM 6. SELECTED FINANCIAL DATA

The following table sets forth our selected financial data and other data for our company on a historical basis. The following data should be read in conjunction with our audited consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere herein. Our historical operating results may not be comparable to our future operating results. The comparability of our selected financial data is significantly affected by our merger with CCP and our other acquisitions and new investments from 2015 through 2019. See Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

	As of December 31,
	2019			2018			2017			2016			2015
	(Dollars in thousands, except per share data)
Balance sheet data:
Total real estate investments, net	$	5,341,370		$	5,853,545		$	5,994,432		$	2,009,939		$	2,039,616
Loans receivable and other investments, net	$	107,374		$	113,722		$	114,390		$	96,036		$	300,177
Investment in unconsolidated joint venture	$	319,460		$	340,120		$	—		$	—		$	—
Cash and cash equivalents	$	39,097		$	50,230		$	518,632		$	25,663		$	7,434
Total assets	$	6,069,299		$	6,665,303		$	7,032,277		$	2,265,919		$	2,468,837
Secured debt, net	$	113,070		$	115,679		$	256,430		$	160,752		$	174,846
Revolving credit facility	$	—		$	624,000		$	641,000		$	26,000		$	255,000
Term loans, net	$	1,040,258		$	1,184,930		$	1,190,774		$	335,673		$	264,229
Senior unsecured notes, net	$	1,248,773		$	1,307,394		$	1,306,286		$	688,246		$	685,704
Total liabilities	$	2,580,839		$	3,410,556		$	3,595,028		$	1,250,310		$	1,414,961
Total Sabra Health Care REIT, Inc. stockholders’ equity	$	3,488,460		$	3,250,414		$	3,432,807		$	1,015,574		$	1,053,770
Operating data:
Total revenues	$	661,736		$	623,409		$	408,281		$	268,250		$	238,864
Net income attributable to common stockholders	$	68,996		$	269,314		$	148,141		$	60,034		$	69,171
Net income attributable to common stockholders per share, basic	$	0.37		$	1.51		$	1.40		$	0.92		$	1.11
Net income attributable to common stockholders per share, diluted	$	0.37		$	1.51		$	1.40		$	0.92		$	1.11
Other data:
Cash flows provided by operations	$	372,475		$	360,586		$	135,789		$	175,928		$	121,101
Cash flows provided by (used in) investing activities	$	262,844		$	(258,494	)	$	(182,560	)	$	142,363		$	(489,226	)
Cash flows (used in) provided by financing activities	$	(646,180	)	$	(629,344	)	$	598,817		$	(300,898	)	$	314,078
Dividends declared and paid per common share	$	1.80		$	1.80		$	1.73		$	1.67		$	1.60
Weighted-average number of common shares outstanding, basic	187,172,210			178,305,738			105,621,242			65,284,251			62,235,014
Weighted-average number of common shares outstanding, diluted—net income and FFO attributable to common stockholders	188,127,092			178,721,744			105,842,434			65,520,672			62,460,239
Weighted-average number of common shares outstanding, diluted—AFFO attributable to common stockholders	188,775,872			179,338,881			106,074,862			65,904,435			62,659,935
FFO attributable to common stockholders (1)	$	393,310		$	355,002		$	211,267		$	164,439		$	132,411
Diluted FFO attributable to common stockholders per common share (1)	$	2.09		$	1.99		$	2.00		$	2.51		$	2.12
AFFO attributable to common stockholders (1)	$	392,775		$	379,037		$	242,278		$	161,465		$	133,913
Diluted AFFO attributable to common stockholders per common share (1)	$	2.08		$	2.11		$	2.28		$	2.45		$	2.14

⁽¹⁾  We believe that net income attributable to common stockholders as defined by U.S. generally accepted accounting principles (“GAAP”) is the most appropriate earnings measure. We also believe that funds from operations attributable to common stockholders (“FFO”), as defined in accordance with the definition used by the National Association of Real Estate Investment Trusts (“NAREIT”), and adjusted funds from operations attributable to common stockholders (“AFFO”) (and related per share amounts) are important non-GAAP supplemental measures of our operating performance. We consider FFO and AFFO to be useful measures for reviewing comparative operating and financial performance because, by excluding gains or losses from real estate dispositions and our share of gains or losses from real estate dispositions related to our unconsolidated joint venture, real estate depreciation and amortization, net of amounts related to noncontrolling interests, plus our share of depreciation and amortization related to our unconsolidated joint venture, and real estate impairment charges, and for AFFO, by excluding merger and acquisition costs, stock-based compensation expense, non-cash rental and

29

related revenues, non-cash interest income, non-cash interest expense, change in fair value of contingent consideration, non-cash portion of loss on extinguishment of debt, provision for doubtful straight-line rental income, loan losses and other reserves, non-cash lease termination income and deferred income taxes, as well as other non-cash revenue and expense items (including ineffectiveness gain/loss on derivative instruments, and non-cash revenue and expense amounts related to noncontrolling interests) and our share of non-cash adjustments related to our unconsolidated joint venture, FFO and AFFO can help investors compare our operating performance between periods or as compared to other companies. See further discussion of FFO and AFFO in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Funds from Operations and Adjusted Funds from Operations” in Part II, Item 7.

30

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The discussion below contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those which are discussed in Part I, Item 1A, “Risk Factors.” Also see “Statement Regarding Forward-Looking Statements” preceding Part I.

The following discussion and analysis should be read in conjunction with Part II, Item 6, “Selected Financial Data” above and our accompanying consolidated financial statements and the notes thereto.

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is organized as follows:

• Overview

• Critical Accounting Policies

• Recently Issued Accounting Standards Update

• Results of Operations

• Liquidity and Capital Resources

• Concentration of Credit Risk

• Skilled Nursing Facility Reimbursement Rates

• Obligations and Commitments

• Impact of Inflation

• Off-Balance Sheet Arrangements

• Quarterly Financial Data

Overview

In 2017 and 2018, we completed a series of transactions—including our merger with CCP (“CCP Merger”), sales of 67 facilities leased to Genesis Healthcare, Inc., investment in an unconsolidated joint venture with Enlivant and TPG Real Estate (“Enlivant Joint Venture”) and entry into a new credit agreement (which was further amended and restated on September 9, 2019, the Credit Agreement as defined below)—that have significantly enhanced our scale and increased our diversification. Additionally, Sabra has substantially completed the repositioning of the CCP portfolio, which included a combination of lease modifications, working capital advances, transitioning facilities to other Sabra tenants and strategic sales or closures of underperforming facilities (including the sales of Senior Care Centers facilities described below under “—Dispositions”). In 2019, we completed multiple transactions in the equity and debt markets, as described below under “—At-The-Market Common Stock Offering Program” and “—Senior Unsecured Notes”, respectively, that resulted in an improvement in our leverage.

Following these transactions, we expect to continue to grow our investment portfolio while diversifying our portfolio by tenant, facility type and geography within the healthcare sector. We plan to achieve these objectives primarily through making investments directly or indirectly in healthcare real estate, including the development of purpose-built healthcare facilities with select developers. We also intend to achieve our objective of diversifying our portfolio by tenant and facility type through select asset sales and other arrangements with our tenants.

Acquisitions

During the year ended December 31, 2019, we acquired two senior housing communities, two specialty hospitals/other facilities and one Senior Housing - Managed community for an aggregate $51.1 million. See Note 3, “Recent Real Estate Acquisitions,” in the Notes to Consolidated Financial Statements for additional information regarding these acquisitions.

Dispositions

During the year ended December 31, 2019, we completed the sale of 39 skilled nursing/transitional care facilities and seven senior housing communities for aggregate consideration, net of closing costs, of $323.6 million. The net carrying value of the assets and liabilities of these facilities was $321.3 million, which resulted in an aggregate $2.3 million net gain on sale.

On February 15, 2019, we entered into a settlement agreement with Senior Care Centers in connection with the notices of default and lease termination we issued to Senior Care Centers during the third quarter of 2018. In accordance with the order entered by the bankruptcy court in March 2019, the settlement agreement provided for the discharge of our claims against Senior Care Centers in exchange for $9.5 million of settlement payments, a portion of which was applied to pay post-petition

31

rent. We recorded $6.2 million of such post-petition rent during the year ended December 31, 2019. On April 1, 2019, we completed the sale of 28 facilities (26 skilled nursing/transitional care facilities and two senior housing communities) previously operated by Senior Care Centers and received gross sales proceeds of $282.5 million. In connection with the sale, we entered into an agreement to indemnify the buyer from certain costs, expenses and liabilities related to the historical operations of the facilities by Senior Care Centers. In May 2019, we transitioned eight facilities previously operated by Senior Care Centers to a current operator in the Sabra portfolio, and we subsequently sold the remaining two facilities previously operated by Senior Care Centers (one during the fourth quarter of 2019 and one in January 2020). During the year ended December 31, 2019, we recorded an impairment charge of $95.2 million related to the Senior Care Centers facilities, which includes $10.2 million related to our estimated contractual indemnification obligations. As of December 31, 2019, we adjusted our contractual indemnification obligations estimate down to $8.8 million.

Holiday

On December 19, 2018, we entered into a letter of intent to terminate our triple-net master lease with Holiday Retirement (“Holiday”) with respect to all 21 senior housing communities subject to the master lease (the “Holiday Communities”) and concurrently enter into management agreements pursuant to which Holiday would manage the Holiday Communities. On April 1, 2019, we completed the conversion of the Holiday Communities to our Senior Housing - Managed portfolio and recognized lease termination income of $66.9 million, which includes a $57.2 million lease termination payment received in exchange for terminating the Holiday master lease and a $9.7 million gain related to the assumption of fixed assets and liabilities.

Credit Agreement

Effective on September 9, 2019, we and certain of our subsidiaries entered into the Credit Agreement. See “—Liquidity and Capital Resources—Loan Agreements—Credit Agreement.”

At-The-Market Common Stock Offering Program

On February 25, 2019, we established an at-the-market equity offering program (the “Prior ATM Program”) to sell shares of our common stock from time to time through a consortium of banks acting as sales agents (the “Prior Sales Agents”). During the year ended December 31, 2019, we sold 23.9 million shares under the Prior ATM Program at an average price of $20.92 per share, generating gross proceeds of $500.0 million, before $7.5 million of commissions. On December 5, 2019, the Prior ATM Program automatically terminated in accordance with its terms upon the issuance and sale of the maximum aggregate amount of the shares subject to the Prior ATM Program.

On December 11, 2019, we established a new ATM program (the “New ATM Program”) pursuant to which shares of our common stock having an aggregate gross sales price of up to $400.0 million may be sold from time to time (i) by us through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. During December 2019, we sold 2.9 million shares under the New ATM Program at an average price of $20.86 per share, generating gross proceeds of $60.0 million, before $0.2 million of commissions.

Senior Unsecured Notes

On May 29, 2019, we completed an underwritten public offering of $300.0 million aggregate principal amount of 4.80% senior unsecured notes due 2024, resulting in net proceeds of $295.3 million after deducting underwriting discounts and other offering expenses.

On June 29, 2019, we redeemed all $500.0 million aggregate principal amount outstanding of the 5.5% senior unsecured notes due 2021 at a premium of 101.375%, plus accrued and unpaid interest. The redemption resulted in $10.1 million of redemption related costs and write-offs, consisting of $6.9 million in payments made to noteholders and legal fees for early redemption and $3.2 million of write-offs associated with unamortized deferred financing and premium costs.

On October 7, 2019, we completed an underwritten public offering of $350.0 million aggregate principal amount of 3.90% senior unsecured notes due 2029, resulting in net proceeds of $340.5 million after deducting underwriting discounts and other offering expenses.

On October 27, 2019, we redeemed all $200.0 million aggregate principal amount outstanding of the 5.375% senior unsecured notes due 2023 at a premium of 101.792%, plus accrued and unpaid interest. The redemption resulted in $5.6 million of redemption related costs and write-offs, consisting of $3.6 million in payments made to noteholders and legal fees for early redemption and $2.0 million of write-offs associated with unamortized deferred financing costs.

32

Critical Accounting Policies

Below is a discussion of the accounting policies that management considers critical in that they involve significant management judgments and assumptions, require estimates about matters that are inherently uncertain and because they are important for understanding and evaluating our reported financial results. These judgments affect the reported amounts of assets and liabilities and our disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. With different estimates or assumptions, materially different amounts could be reported in our financial statements. Additionally, other companies may utilize different estimates that may impact the comparability of our results of operations to those of companies in similar businesses.

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include the accounts of Sabra and our wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements are prepared in accordance with GAAP.

GAAP requires us to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If we were determined to be the primary beneficiary of the VIE, we would consolidate investments in the VIE. We may change our original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

We identify the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. We perform this analysis on an ongoing basis. As of December 31, 2019, we determined that we were not the primary beneficiary of any VIEs.

As it relates to investments in loans, in addition to our assessment of VIEs and whether we are the primary beneficiary of those VIEs, we evaluate the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if we participate in the majority of the borrower’s expected residual profit, we would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At December 31, 2019, none of our investments in loans were accounted for as real estate joint ventures.

As it relates to investments in joint ventures, we assess any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. We also apply this guidance to managing member interests in limited liability companies. We reassess our determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of December 31, 2019, our determination of which entity controls our investments in joint ventures has not changed as a result of any reassessment.

Real Estate Investments and Rental Revenue Recognition

Real Estate Acquisition Valuation

All assets acquired and liabilities assumed in an acquisition of real estate accounted for as a business combination are measured at their acquisition date fair values. For acquisitions of real estate accounted for as an asset acquisition, the fair value of consideration transferred by us (including transaction costs) is allocated to all assets acquired and liabilities assumed on a relative fair value basis. The acquisition value of land, building and improvements are included in real estate investments on the consolidated balance sheets. The acquisition value of above market lease, tenant origination and absorption costs and tenant relationship intangible assets is included in lease intangible assets, net on the consolidated balance sheets. The acquisition value of below market lease intangible liabilities is included in lease intangible liabilities, net on the consolidated balance sheets.

33

Acquisition costs associated with real estate acquisitions deemed asset acquisitions are capitalized, and costs associated with real estate acquisitions deemed business combinations are expensed as incurred.

Estimates of the fair values of the tangible assets, identifiable intangibles and assumed liabilities require us to make significant assumptions to estimate market lease rates, property operating expenses, carrying costs during lease-up periods, discount rates, market absorption periods, and the number of years the property will be held for investment. We make our best estimate based on our evaluation of the specific characteristics of each tenant’s lease. The use of inappropriate assumptions would result in an incorrect valuation of our acquired tangible assets, identifiable intangibles and assumed liabilities, which would impact the amount of our net income.

Impairment of Real Estate Investments

We continually monitor events and changes in circumstances that could indicate that the carrying amounts of our real estate investments may not be recoverable or realized. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, we assess the recoverability by estimating whether we will recover the carrying value of our real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. In some instances, there may be various potential outcomes for an investment and its potential future cash flows. In these instances, the undiscounted future cash flows used to assess recoverability are based on several assumptions and are probability-weighted based on our best estimates as of the date of evaluation. These assumptions include, among others, cash flow projections, discount rates, market capitalization rates and recent sales data for comparable properties. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If, based on this analysis, we do not believe that we will be able to recover the carrying value of our real estate investments, we would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of our real estate investments.

Revenue Recognition

We recognize rental revenue from tenants, including rental abatements, lease incentives and contractual fixed increases attributable to operating leases, on a straight-line basis over the term of the related leases when it is probable that substantially all rents over the life of a lease are collectible. Certain of our leases provide for contingent rents equal to a percentage of the facility’s revenue in excess of specified base amounts or other thresholds. Such revenue is recognized when actual results reported by the tenant, or estimates of tenant results, exceed the applicable base amount or other threshold.

We assess the collectability of rents on a lease-by-lease basis, and in doing so, consider such things as historical bad debts, tenant creditworthiness, current economic trends, facility operating performance, lease structure, credit enhancements (including guarantees), current developments relevant to a tenant’s business specifically and to its business category generally, and changes in tenants’ payment patterns. Our assessment includes an estimation of a tenant’s ability to fulfill all of its rental obligations over the remaining lease term. In addition, with respect to tenants in bankruptcy, management makes estimates of the expected recovery of pre-petition and post-petition claims in assessing the estimated collectability of the related receivable. If at any time we cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received, and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Write-offs of receivables and any recoveries of previously written-off receivables are recorded as adjustments to rental revenue.

Revenue from resident fees and services is recorded monthly as services are provided and includes resident room and care charges, ancillary services charges and other resident charges.

Loans Receivable and Interest Income

Loans Receivable

Loans receivable are reflected at amortized cost on our consolidated balance sheets. The amortized cost of a loan receivable is the outstanding unpaid principal balance, net of unamortized discounts, costs and fees directly associated with the origination of the loan.

Loans acquired in connection with a business combination are recorded at their acquisition date fair value. We determine the fair value of loans receivable based on estimates of expected discounted cash flows, collateral, credit risk and other factors. A valuation allowance is not established at the acquisition date, as the amount of estimated future cash flows reflects our judgment regarding their uncertainty. The difference between the acquisition date fair value and the total expected cash flows is

34

recognized as interest income using the effective interest method over the life of the applicable loan. Any unamortized balances are immediately recognized in income if the loan is repaid before its contractual maturity.

On a quarterly basis, we evaluate the collectability of our loan portfolio, including related interest income receivable, and establish a reserve for loan losses. Our evaluation includes reviewing credit quality indicators such as payment status, changes affecting the underlying real estate collateral (for collateral dependent loans), changes affecting the operations of the facilities securing the loans, and national and regional economic factors. The reserve for loan losses is a valuation allowance that reflects management’s estimate of loan losses inherent in the loan portfolio as of the balance sheet date. The reserve is adjusted through provision for doubtful accounts, straight-line rental income and loan losses on our consolidated statements of income and is decreased by charge-offs to specific loans when losses are confirmed. The reserve for loan losses includes an asset-specific component and a portfolio-based component.

An asset-specific reserve relates to reserves for losses on loans considered impaired and interest income receivable that is deemed uncollectible. We consider a loan to be impaired when, based upon current information and events, we believe that it is probable that we will be unable to collect all amounts due under the contractual terms of the loan agreement resulting from the borrower’s failure to repay contractual amounts due, the granting of a concession by us or our expectation that we will receive assets with fair values less than the carrying value of the loan in satisfaction of the loan. If a loan is considered to be impaired, a reserve is established when the carrying value of that loan is greater than the present value of payments expected to be received, the observable market prices for similar instruments, the estimated fair value of the collateral (for loans that are dependent on the collateral for repayment) or other amounts expected to be received in satisfaction of the loan.

As of December 31, 2019, we had no asset-specific loan loss reserve, and we had a $0.7 million asset-specific loan loss reserve as of December 31, 2018. During the years ended December 31, 2019, 2018 and 2017, we recorded a provision for asset-specific loan losses of $1.2 million, $0.7 million and $4.8 million, respectively. As of December 31, 2019, we did not consider any loans receivable investments to be impaired. As of December 31, 2018, we considered one loan receivable investment to be impaired, which had a principal balance of $1.3 million and $1.4 million as of December 31, 2018 and 2017, respectively.

A portfolio-based reserve covers the pool of loans that do not have asset-specific reserves. A provision for loan losses is recorded when available information as of each balance sheet date indicates that it is probable that a loss occurred in the pool of loans and the amount of the loss can be reasonably estimated, but we do not know which specific loans within the pool will ultimately result in losses. The required reserve balances for this pool of loans is derived based on estimated probabilities of default and estimated loss severities assuming a default occurs.

As of each of December 31, 2019 and 2018, our portfolio-based loan loss reserve totaled $0.6 million. During the years ended December 31, 2019 and 2018, we increased our portfolio-based loan loss reserve by $4,000 and $0.5 million, respectively, and during the year ended December 31, 2017, we decreased our portfolio-based loan loss reserve by $0.3 million.

Interest Income

Interest income on our loans receivable is recognized on an accrual basis over the life of the investment using the interest method. Direct loan origination costs are amortized over the term of the loan as an adjustment to interest income. When concerns exist as to the ultimate collection of principal or interest due under a loan, the loan is placed on nonaccrual status, and we will not recognize interest income until the cash is received, or the loan returns to accrual status. If we determine that the collection of interest according to the contractual terms of the loan or through the receipts of assets in satisfaction of contractual amounts due is probable, we will resume the accrual of interest. In instances where borrowers are in default under the terms of their loans, we may continue recognizing interest income provided that all amounts owed under the contractual terms of the loan, including accrued and unpaid interest, do not exceed the estimated fair value of the collateral, less costs to sell. As of December 31, 2019, two loans receivable with no book value were on nonaccrual status.

Preferred Equity Investments and Preferred Return

Preferred equity investments are accounted for at unreturned capital contributions, plus accrued and unpaid preferred returns. We recognize preferred return income on a monthly basis based on the outstanding investment including any previously accrued and unpaid return. As a preferred member of the preferred equity joint ventures in which we participate, we are not entitled to share in the joint venture’s earnings or losses. Rather, we are entitled to receive a preferred return, which is deferred if the cash flow of the joint venture is insufficient to currently pay the accrued preferred return. As of December 31, 2019, we did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

35

Income Taxes

We elected to be treated as a REIT with the filing of our U.S. federal income tax return for the taxable year beginning January 1, 2011. We believe that we have been organized and have operated, and we intend to continue to operate, in a manner to qualify as a REIT. To qualify as a REIT, we must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of our annual REIT taxable income to stockholders (which is computed without regard to the dividends-paid deduction or net capital gains and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, we generally will not be subject to federal income tax on income that we distribute as dividends to our stockholders. If we fail to qualify as a REIT in any taxable year, we will be subject to U.S. federal income tax on our taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost, unless the IRS grants us relief under certain statutory provisions. Such an event could materially and adversely affect our net income and net cash available for distribution to stockholders. However, we believe that we are organized and operate in such a manner as to qualify for treatment as a REIT.

As a result of certain investments, we now record income tax expense or benefit with respect to certain of our entities that are taxed as taxable REIT subsidiaries under provisions similar to those applicable to regular corporations and not under the REIT provisions.

We account for deferred income taxes using the asset and liability method and recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our financial statements or tax returns. Under this method, we determine deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in the deferred tax liability that results from a change in circumstances, and that causes a change in our judgment about expected future tax consequences of events, is included in the tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss and tax credit carryforwards. A valuation allowance is provided if we believe it is more likely than not that all or some portion of the deferred tax asset will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, and that causes a change in our judgment about the realizability of the related deferred tax asset, is included in the tax provision when such changes occur.

We evaluate our tax positions using a two-step approach: step one (recognition) occurs when we conclude that a tax position, based solely on its technical merits, is more likely than not to be sustained upon examination, and step two (measurement) is only addressed if step one has been satisfied (i.e., the position is more likely than not to be sustained). Under step two, the tax benefit is measured as the largest amount of benefit (determined on a cumulative probability basis) that is more likely than not to be realized upon ultimate settlement. We will recognize tax penalties relating to unrecognized tax benefits as additional tax expense.

Fair Value Measurements

Under GAAP, we are required to measure certain financial instruments at fair value on a recurring basis. In addition, we are required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:

• Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;

• Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and

• Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.

When available, we utilize quoted market prices from an independent third-party source to determine fair value and classify such items in Level 1 or Level 2. In instances where the market for a financial instrument is not active, regardless of the availability of a nonbinding quoted market price, observable inputs might not be relevant and could require us to make a significant adjustment to derive a fair value measurement. Additionally, in an inactive market, a market price quoted from an independent third party may rely more on models with inputs based on information available only to that independent third party. When we determine the market for a financial instrument owned by us to be illiquid or when market transactions for similar instruments do not appear orderly, we may use several valuation sources (including internal valuations, discounted cash

36

flow analysis and quoted market prices) to establish a fair value. If more than one valuation source is used, we will assign weights to the various valuation sources. Additionally, when determining the fair value of liabilities in circumstances in which a quoted price in an active market for an identical liability is not available, we measure fair value using (i) a valuation technique that uses the quoted price of the identical liability when traded as an asset or quoted prices for similar liabilities or similar liabilities when traded as assets or (ii) another valuation technique that is consistent with the principles of fair value measurement, such as the income approach or the market approach.

Changes in assumptions or estimation methodologies can have a material effect on these estimated fair values. In this regard, the derived fair value estimates cannot be substantiated by comparison to independent markets and, in many cases, may not be realized in an immediate settlement of the instrument.

We consider the following factors to be indicators of an inactive market: (i) there are few recent transactions, (ii) price quotations are not based on current information, (iii) price quotations vary substantially either over time or among market makers (for example, some brokered markets), (iv) indexes that previously were highly correlated with the fair values of the asset or liability are demonstrably uncorrelated with recent indications of fair value for that asset or liability, (v) there is a significant increase in implied liquidity risk premiums, yields, or performance indicators (such as delinquency rates or loss severities) for observed transactions or quoted prices when compared with our estimate of expected cash flows, considering all available market data about credit and other nonperformance risk for the asset or liability, (vi) there is a wide bid-ask spread or significant increase in the bid-ask spread, (vii) there is a significant decline or absence of a market for new issuances (that is, a primary market) for the asset or liability or similar assets or liabilities, and (viii) little information is released publicly (for example, a principal-to-principal market).

We consider the following factors to be indicators of non-orderly transactions: (i) there was not adequate exposure to the market for a period before the measurement date to allow for marketing activities that are usual and customary for transactions involving such assets or liabilities under current market conditions, (ii) there was a usual and customary marketing period, but the seller marketed the asset or liability to a single market participant, (iii) the seller is in or near bankruptcy or receivership (that is, distressed), or the seller was required to sell to meet regulatory or legal requirements (that is, forced), and (iv) the transaction price is an outlier when compared with other recent transactions for the same or similar assets or liabilities.

Recently Issued Accounting Standards Update

See Note 2, “Summary of Significant Accounting Policies,” in the Notes to Consolidated Financial Statements for information concerning recently issued accounting standards updates.

Results of Operations

As of December 31, 2019, our investment portfolio consisted of 429 real estate properties held for investment, one investment in a direct financing lease, 18 investments in loans receivable, nine preferred equity investments and one investment in an unconsolidated joint venture. As of December 31, 2018, our investment portfolio consisted of 470 real estate properties held for investment, one investment in a direct financing lease, 22 investments in loans receivable, nine preferred equity investments and one investment in an unconsolidated joint venture. In general, we expect that income and expenses related to our portfolio will fluctuate in future periods in comparison to the corresponding prior periods as a result of investment and disposition activity and anticipated future changes in our portfolio. The results of operations presented are not directly comparable due to ongoing acquisition and disposition activity.

A discussion of our results of operations for the year ended December 31, 2017 is included in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Comparison of results of operations for the years ended December 31, 2018 and 2017” section in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2018.

37

Comparison of results of operations for the years ended December 31, 2019 and 2018 (dollars in thousands):

	For the Year Ended December 31,						Increase / (Decrease)			Percentage Difference		Variance due to Acquisitions, Originations and Dispositions (1)			Remaining Variance (2)
	2019			2018
Revenues:
Rental and related revenues	$	452,138		$	536,605		$	(84,467	)	(16	)%	$	(48,785	)	$	(35,682	)
Interest and other income	81,540			16,667			64,873			389	%	(3,438		)	68,311
Resident fees and services	128,058			70,137			57,921			83	%	(923		)	58,844
Expenses:
Depreciation and amortization	181,549			191,379			(9,830		)	(5	)%	(13,635		)	3,805
Interest	126,610			147,106			(20,496		)	(14	)%	—			(20,496		)
Triple-net portfolio operating expenses	22,215			—			22,215			NM		—			22,215
Senior housing - managed portfolio operating expenses	86,257			49,546			36,711			74	%	(549		)	37,260
General and administrative	30,462			36,458			(5,996		)	(16	)%	(2,035		)	(3,961		)
Merger and acquisition costs	424			636			(212		)	(33	)%	(212		)	—
Provision for doubtful accounts, straight-line rental income and loan losses	1,238			39,075			(37,837		)	(97	)%	—			(37,837		)
Impairment of real estate	121,819			1,413			120,406			8,521	%	88,902			31,504
Other (expense) income:
Loss on extinguishment of debt	(16,340		)	(2,917		)	(13,423		)	460	%	—			(13,423		)
Other income	2,094			4,480			(2,386		)	(53	)%	—			(2,386		)
Net gain on sales of real estate	2,300			128,198			(125,898		)	(98	)%	(125,898		)	—
Loss from unconsolidated joint venture	(6,796		)	(5,431		)	(1,365		)	25	%	(1,690		)	325
Income tax expense	(3,402		)	(3,011		)	(391		)	13	%	—			(391		)

⁽¹⁾  Represents the dollar amount increase (decrease) for the year ended December 31, 2019 compared to the year ended December 31, 2018 as a result of investments/dispositions made after January 1, 2018.

⁽²⁾  Represents the dollar amount increase (decrease) for the year ended December 31, 2019 compared to the year ended December 31, 2018 that is not a direct result of investments/dispositions made after January 1, 2018.

Rental and Related Revenues

During the year ended December 31, 2019, we recognized $452.1 million of rental income compared to $536.6 million for the year ended December 31, 2018. The $84.5 million net decrease in rental income is primarily due to (i) a $53.4 million decrease from properties disposed of after January 1, 2018, (ii) a $29.6 million decrease from the 21 Holiday Communities that were transitioned to Senior Housing - Managed communities in April 2019, (iii) a $24.4 million decrease primarily related to lease restructurings and leases that we concluded should no longer be accounted for on an accrual basis as a result of adopting Topic 842 in 2019, consisting of a $15.5 million net decrease in earned cash rents and a $12.6 million net decrease in straight-line rental income, partially offset by a $3.7 million net increase in above/below market lease intangible amortization and (iv) a $6.1 million decrease related to the nine remaining Senior Care Centers facilities, eight of which were transitioned to a new operator.

These amounts were partially offset by (i) a $17.6 million increase primarily related to property tax recoveries due to the adoption of Topic 842, which now requires lessor costs that are paid by the lessor and reimbursed by the lessee to be included in the measurement of variable lease revenue and the associated expense, (ii) a $4.8 million increase primarily related to facilities that were transitioned to new operators in 2018 and (iii) an increase of $4.6 million from properties acquired after January 1, 2018.

Our reported rental and related revenues may be subject to increased variability in the future as a result of adopting Topic 842. However, there can be no assurances regarding the timing and amount of these collections. Amounts due under the terms of all of our lease agreements are subject to contractual increases, and contingent rental income may be derived from certain lease agreements. No material contingent rental income was derived during the year ended December 31, 2019 and 2018.

38

Interest and Other Income

Interest and other income primarily consists of income earned on our loans receivable investments, preferred returns earned on our preferred equity investments and income on the direct financing lease. During the year ended December 31, 2019, we recognized $81.5 million of interest and other income compared to $16.7 million for the year ended December 31, 2018. The net increase of $64.9 million is primarily due to (i) $66.9 million of income related to the transition of the Holiday Communities to our Senior Housing - Managed portfolio, consisting of a $57.2 million lease termination payment and a $9.7 million gain related to the assumption of fixed assets net of liabilities, (ii) a $1.9 million increase in income from investments made after January 1, 2018 and (iii) a $0.9 million increase in income related to the transition of one Senior Housing - Leased community to our Senior Housing - Managed portfolio, related to the assumption of fixed assets net of liabilities, partially offset by (i) a $5.4 million decrease in income from investments that were repaid after January 1, 2018 and (ii) a $0.4 million decrease in interest income primarily related to funds previously held by exchange accommodation titleholders. The remaining increase is due to income on additional fundings for loans receivable investments made before January 1, 2018.

Resident Fees and Services

During the year ended December 31, 2019, we recognized $128.1 million of resident fees and services compared to $70.1 million for the year ended December 31, 2018. The $57.9 million net increase is primarily due to (i) a $57.4 million increase from the 21 Holiday Communities and one Senior Housing - Leased community that were transitioned to Senior Housing - Managed communities in April 2019 and December 2019, respectively, and (ii) a $0.6 million increase from one Senior Housing - Managed community acquired after January 1, 2018, partially offset by a $1.5 million decrease from one Senior Housing - Managed community disposed of after January 1, 2018.

Depreciation and Amortization

During the year ended December 31, 2019, we incurred $181.5 million of depreciation and amortization expense compared to $191.4 million for the year ended December 31, 2018. The $9.8 million net decrease is primarily due to a decrease of $15.7 million from properties disposed of after January 1, 2018, partially offset by (i) a $5.7 million increase due to the acceleration of lease intangible amortization related to the transition of the 21 Holiday Communities to Senior Housing - Managed communities in April 2019 and (ii) an increase of $2.0 million from properties acquired after January 1, 2018. The remaining decrease is primarily related to assets that were fully amortized or written-off in a prior period.

Interest Expense

We incur interest expense comprised of costs of borrowings plus the amortization of deferred financing costs related to our indebtedness. During the year ended December 31, 2019, we incurred $126.6 million of interest expense compared to $147.1 million for the year ended December 31, 2018. The $20.5 million net decrease is primarily related to (i) an aggregate $16.9 million decrease in interest expense related to the redemptions of the 2021 Notes in June 2019 and the 2023 Notes in October 2019, which includes an aggregate $1.6 million of incremental interest expense related to the redemptions of the 2021 Notes and 2023 Notes occurring after the issuances of the 2024 Notes and 2029 Notes, respectively, (ii) a $11.0 million decrease in interest expense related to the borrowings outstanding on the Revolving Credit Facility and (iii) a $5.1 million decrease in interest expense related to our secured borrowings primarily due to the repayment of five mortgage notes during 2018, which were partially offset by an aggregate $12.5 million increase in interest expense related to the issuances of the 2024 Notes and 2029 Notes.

Triple-Net Portfolio Operating Expenses

During the year ended December 31, 2019, we recognized $22.2 million of triple-net portfolio operating expenses, of which $17.6 million is due to the adoption of Topic 842 in 2019, which now requires lessor costs that are paid by the lessor and reimbursed by the lessee to be included in the measurement of variable lease revenue and the associated expense, and the remaining $4.6 million is primarily due to property taxes paid on behalf of cash basis tenants that have not yet been reimbursed and property taxes that are not expected to be reimbursed by our tenants.

Senior Housing - Managed Portfolio Operating Expenses

During the year ended December 31, 2019, we recognized $86.3 million of operating expenses compared to $49.5 million for the year ended December 31, 2018. The $36.7 million increase is primarily due to a (i) a $36.1 million increase from the 21 Holiday Communities and one Senior Housing - Leased community that were transitioned to Senior Housing - Managed communities in April 2019 and December 2019, respectively, and (ii) a $0.6 million increase from one Senior Housing - Managed community acquired after January 1, 2018, partially offset by a $1.2 million decrease from one Senior Housing - Managed community disposed of after January 1, 2018.

39

General and Administrative Expenses

General and administrative expenses include compensation-related expenses as well as professional services, office costs and other costs associated with asset management. During the year ended December 31, 2019, general and administrative expenses were $30.5 million compared to $36.5 million during the year ended December 31, 2018. The $6.0 million net decrease is primarily related to (i) a $4.7 million decrease in non-Senior Housing - Managed operating expenses primarily due to property taxes recorded during the year ended December 31, 2018 for the Senior Care Centers facilities following our termination of these leases, (ii) a $2.5 million decrease in legal expenses primarily due to expenses incurred during the year ended December 31, 2018 related to the recovery of previously reserved cash rental income, the previously anticipated refinancing of certain Senior Notes and the repositioning of the CCP portfolio, (iii) a $1.3 million decrease in transition expenses related to the CCP Merger and (iv) a $0.8 million decrease in expenses incurred by our specialty valuation firm that we sold in March 2018, partially offset by (i) a $2.2 million increase in stock-based compensation expense and (ii) a $1.4 million increase in employee compensation primarily due to increased staffing. The increase in stock-based compensation expense, from $7.6 million during the year ended December 31, 2018 to $9.8 million during the year ended December 31, 2019, is primarily due to a change in performance-based vesting assumptions on management’s equity compensation. We expect stock-based compensation expense to fluctuate from period to period depending upon changes in our stock price and estimates associated with performance-based compensation.

Merger and Acquisition Costs

During the year ended December 31, 2019, we incurred $0.4 million of merger and acquisition costs compared to $0.6 million for the year ended December 31, 2018. The costs incurred during the years ended December 31, 2019 and 2018 were primarily related to the CCP Merger. We expect expensed merger and acquisition costs to fluctuate from period to period depending on acquisition activity and whether these acquisitions are considered business combinations.

Provision for Doubtful Accounts, Straight-Line Rental Income and Loan Losses

During the year ended December 31, 2019, we recognized a $1.2 million provision for doubtful accounts, straight-line rental income and loan losses, all of which was associated with loan loss reserves. During the year ended December 31, 2018, we recognized a $39.1 million provision for doubtful accounts, straight-line rental income and loan losses, which was comprised of (i) a $39.7 million provision for straight-line rental income primarily related to the termination of the master leases for the Senior Care Centers facilities and the transfer of four skilled nursing/transitional care facilities and one senior housing community to a new operator and the then-pending transition of the Holiday portfolio to a Senior Housing - Managed communities structure and (ii) a $1.2 million increase in loan loss reserves, partially offset by a $1.8 million net recovery of previously reserved cash rental income.

Impairment of Real Estate

During the year ended December 31, 2019, we recognized $121.8 million of impairment of real estate, consisting of (i) $95.2 million related to the Senior Care Centers portfolio, including the 28 facilities sold on April 1, 2019, which included a $10.2 million estimate of our contractual indemnification obligations, and (ii) $26.6 million related to six skilled nursing/transitional care facilities and four senior housing communities. During the year ended December 31, 2018, we recognized $1.4 million of impairment of real estate related to one senior housing community and one skilled nursing/transitional care facility. The senior housing community was sold during the year ended December 31, 2018.

Loss on Extinguishment of Debt

During the year ended December 31, 2019, we recognized a $16.3 million loss on extinguishment of debt, consisting of (i) $10.1 million in connection with the redemption of the 2021 Notes, including $6.9 million in payments made to noteholders and legal fees for early redemption and $3.2 million of write-offs associated with unamortized deferred financing and premium costs, (ii) $5.6 million in connection with the redemption of the 2023 Notes, including $3.6 million in payments made to noteholders and legal fees for early redemption and $2.0 million of write-offs associated with unamortized deferred financing and premium costs and (iii) $0.6 million related to the write-off of unamortized deferred financing costs in connection with entering into the Credit Agreement. During the year ended December 31, 2018, we recognized a $2.9 million loss on extinguishment of debt, which was comprised of a $2.0 million prepayment penalty fee associated with the early repayment of a $98.5 million variable rate secured term loan and $0.9 million related to write-offs of deferred financing costs in connection with the repayment of four secured mortgage notes.

40

Other Income

During the year ended December 31, 2019, we recognized $2.1 million of other income primarily related to settlement payments received related to a legacy CCP investment. During the year ended December 31, 2018, we recognized $4.5 million of other income, which was primarily comprised of (i) a $2.0 million contingency fee related to a legacy CCP investment, (ii) $1.3 million of insurance proceeds received related to a legacy CCP investment, (iii) $0.6 million related to cash payments received from two facilities not subject to a lease and (iv) $0.2 million related to the sale of our specialty valuation firm.

Net Gain on Sales of Real Estate

During the year ended December 31, 2019, we recognized an aggregate net gain on the sales of real estate of $2.3 million related to the disposition of 39 skilled nursing/transitional care facilities and seven senior housing communities. During the year ended December 31, 2018, we recognized an aggregate net gain on the sales of real estate of $128.2 million related to the disposition of 51 skilled nursing/transitional care facilities, six senior housing communities and one Senior Housing - Managed community.

Loss from Unconsolidated Joint Venture

During the year ended December 31, 2019, we recognized $6.8 million of loss from the Enlivant Joint Venture compared to $5.4 million of loss for the year ended December 31, 2018. The $1.4 million net increase is primarily related to (i) a $1.7 million net loss on the sale of two senior housing communities, (ii) a $1.0 million increase in interest expense primarily due to an increase in interest rates, (iii) a $0.8 million increase in income tax expense and (iv) a $0.6 million change in the mark-to-market adjustments related to interest cap agreements, from gains recognized during the year ended December 31, 2018 to losses recognized during the year ended December 31, 2019, partially offset by a $2.6 million increase in revenues net of operating expenses primarily due to increased rates and improved margin.

Income Tax Expense

During the year ended December 31, 2019, we recognized $3.4 million of income tax expense compared to $3.0 million for the year ended December 31, 2018. The increase is primarily due to the increase in Senior Housing - Managed communities.

Funds from Operations and Adjusted Funds from Operations

We believe that net income attributable to common stockholders as defined by GAAP is the most appropriate earnings measure. We also believe that FFO, as defined in accordance with the definition used by NAREIT, and AFFO (and related per share amounts) are important non-GAAP supplemental measures of our operating performance. Because the historical cost accounting convention used for real estate assets requires straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. However, since real estate values have historically risen or fallen with market and other conditions, presentations of operating results for a REIT that uses historical cost accounting for depreciation could be less informative. Thus, NAREIT created FFO as a supplemental measure of operating performance for REITs that excludes historical cost depreciation and amortization, among other items, from net income attributable to common stockholders, as defined by GAAP. FFO is defined as net income attributable to common stockholders, computed in accordance with GAAP, excluding gains or losses from real estate dispositions and our share of gains or losses from real estate dispositions related to our unconsolidated joint venture, plus real estate depreciation and amortization, net of amounts related to noncontrolling interests, plus our share of depreciation and amortization related to our unconsolidated joint venture, and real estate impairment charges. AFFO is defined as FFO excluding merger and acquisition costs, stock-based compensation expense, non-cash rental and related revenues, non-cash interest income, non-cash interest expense, change in fair value of contingent consideration, non-cash portion of loss on extinguishment of debt, provision for doubtful straight-line rental income, loan losses and other reserves, non-cash lease termination income and deferred income taxes, as well as other non-cash revenue and expense items (including ineffectiveness gain/loss on derivative instruments, and non-cash revenue and expense amounts related to noncontrolling interests) and our share of non-cash adjustments related to our unconsolidated joint venture. We believe that the use of FFO and AFFO (and the related per share amounts), combined with the required GAAP presentations, improves the understanding of our operating results among investors and makes comparisons of operating results among REITs more meaningful. We consider FFO and AFFO to be useful measures for reviewing comparative operating and financial performance because, by excluding the applicable items listed above, FFO and AFFO can help investors compare our operating performance between periods or as compared to other companies. While FFO and AFFO are relevant and widely used measures of operating performance of REITs, they do not represent cash flows from operations or net income attributable to common stockholders as defined by GAAP and should not be considered an alternative to those measures in evaluating our liquidity or operating performance. FFO and AFFO also do not consider the costs associated with capital expenditures related

41

to our real estate assets nor do they purport to be indicative of cash available to fund our future cash requirements. Further, our computation of FFO and AFFO may not be comparable to FFO and AFFO reported by other REITs that do not define FFO in accordance with the current NAREIT definition or that interpret the current NAREIT definition or define AFFO differently than we do.

The following table reconciles our calculations of FFO and AFFO for the years ended December 31, 2019, 2018 and 2017, to net income attributable to common stockholders, the most directly comparable GAAP financial measure, for the same periods (in thousands, except share and per share amounts):

	Year Ended December 31,
	2019			2018			2017
Net income attributable to common stockholders	$	68,996		$	269,314		$	148,141
Depreciation and amortization of real estate assets	181,549			191,379			113,882
Depreciation and amortization of real estate assets related to noncontrolling interests	(93		)	(159		)	(53		)
Depreciation and amortization of real estate assets related to unconsolidated joint venture	21,649			21,253			—
Net gain on sales of real estate	(2,300		)	(128,198		)	(52,029		)
Net loss on sales of real estate related to unconsolidated joint venture	1,690			—			—
Impairment of real estate	121,819			1,413			1,326
FFO attributable to common stockholders	393,310			355,002			211,267
Merger and acquisition costs (1)	424			636			30,255
Stock-based compensation expense	9,819			7,648			7,017
Non-cash rental and related revenues	(19,449		)	(36,443		)	(30,352		)
Non-cash interest income	(2,212		)	(2,300		)	(769		)
Non-cash interest expense	10,080			10,137			7,776
Non-cash portion of loss on extinguishment of debt	5,838			874			553
Provision for doubtful straight-line rental income, loan losses and other reserves	1,238			40,806			16,854
Non-cash lease termination income	(10,579		)	—			—
Other non-cash adjustments related to unconsolidated joint venture	4,135			2,652			—
Other non-cash adjustments	171			25			(323		)
AFFO attributable to common stockholders	$	392,775		$	379,037		$	242,278
FFO attributable to common stockholders per diluted common share	$	2.09		$	1.99		$	2.00
AFFO attributable to common stockholders per diluted common share	$	2.08		$	2.11		$	2.28
Weighted average number of common shares outstanding, diluted:
FFO attributable to common stockholders	188,127,092			178,721,744			105,842,434
AFFO attributable to common stockholders	188,775,872			179,338,881			106,074,862

⁽¹⁾  Merger and acquisition costs primarily relate to the CCP Merger. In addition, costs incurred during the year ended December 31, 2017 include $1.4 million of stock-based compensation expense related to former CCP employees.

42

The following table sets forth additional information related to certain other items included in net income attributable to common stockholders above, and the portions of each that are included in FFO and AFFO attributable to common stockholders, which may be helpful in assessing our operating results. Please refer to “—Results of Operations” above for additional information regarding these items (in millions):

	Year Ended December 31,
	2019		2018		2017		2019		2018		2017		2019		2018			2017
	Net Income						FFO						AFFO
Rental and related revenues:
Reduction of revenues related to straight-line rental income receivable write-offs	$	1.5	$	—	$	—	$	1.5	$	—	$	—	$	—	$	—		$	—
Reduction of revenues related to above/below market lease intangible write-offs	5.9		11.5		—		5.9		11.5		—		—		—			—
Interest and other income:
Lease termination income	67.8		—		—		67.8		—		—		57.2		—			—
Income on repayment of loan	—		0.9		—		—		0.9		—		—		0.9			—
Interest expense:
Incremental interest expense related to the redemption of the 2021 and 2023 Notes	1.6		—		—		1.6		—		—		1.6		—			—
General and administrative expense:
Previously anticipated Senior Notes refinancing expenses	—		0.6		—		—		0.6		—		—		0.6			—
CCP transition expenses	0.2		1.5		5.5		0.2		1.5		5.5		0.2		1.5			5.5
Legal fees related to the recovery of previously reserved cash rental income	—		0.9		—		—		0.9		—		—		0.9			—
Merger and acquisition costs	0.4		0.6		30.3		0.4		0.6		30.3		—		—			—
Provision for (recovery of) doubtful accounts	1.2		39.1		17.1		1.2		39.1		17.1		—		(1.7		)	0.3
Loss on extinguishment of debt	16.3		2.9		0.6		16.3		2.9		0.6		10.5		2.0			—
Other income	2.1		4.5		0.5		2.1		4.5		0.5		2.1		4.4			2.8
Loss from unconsolidated joint venture:
Deferred income tax expense	2.3		1.7		—		2.3		1.7		—		—		—			—
Preferred stock dividends:
Preferred stock redemption charge	—		5.5		—		—		5.5		—		—		5.5			—

Liquidity and Capital Resources

As of December 31, 2019, we had over $1.0 billion in liquidity, consisting of unrestricted cash and cash equivalents of $39.1 million and available borrowings under our Revolving Credit Facility of $1.0 billion. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion (from U.S. $2.1 billion plus CAD $125.0 million), subject to terms and conditions.

We have filed a shelf registration statement with the SEC that expires in December 2022, which allows us to offer and sell shares of common stock, preferred stock, warrants, rights, units, and certain of our subsidiaries to offer and sell debt securities, through underwriters, dealers or agents or directly to purchasers, on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering, subject to market conditions.

On February 25, 2019, we established the Prior ATM Program to sell shares of our common stock having an aggregate gross sales price of up to $500.0 million from time to time through the Prior Sales Agents. During the year ended December 31, 2019, we sold 23.9 million shares under the Prior ATM Program at an average price of $20.92 per share, generating gross proceeds of $500.0 million, before $7.5 million of commissions. On December 5, 2019, the Prior ATM Program automatically terminated in accordance with its terms upon the issuance and sale of the maximum aggregate amount of the shares subject to the Prior ATM Program.

On December 11, 2019, we established the New ATM Program, pursuant to which shares of our common stock having an aggregate gross sales price of up to $400.0 million may be sold from time to time (i) by us through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. During December 2019, we sold 2.9 million shares

43

under the New ATM Program at an average price of $20.86 per share, generating gross proceeds of $60.0 million, before $0.2 million of commissions. As of December 31, 2019, we had $340.0 million available under the New ATM Program. Subject to market conditions, we expect to use proceeds from our New ATM Program to reduce our outstanding indebtedness and to finance future investments in properties.

We believe that our available cash, operating cash flows and borrowings available to us under our Revolving Credit Facility provide sufficient funds for our operations, scheduled debt service payments and dividend requirements for the next twelve months. In addition, we do not believe that the restrictions under our Senior Notes Indentures or Credit Agreement significantly limit our ability to use our available liquidity for these purposes.

We intend to invest in additional healthcare properties as suitable opportunities arise and adequate sources of financing are available. We expect that future investments in properties, including any improvements or renovations of current or newly-acquired properties, will depend on and will be financed, in whole or in part, by our existing cash, borrowings available to us under our Revolving Credit Facility, future borrowings or the proceeds from issuances of common stock (including through our New ATM Program), preferred stock, debt or other securities. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae, Freddie Mac and HUD, in appropriate circumstances in connection with acquisitions. We also use derivative instruments in the normal course of business to mitigate interest rate and foreign currency risk.

Cash Flows from Operating Activities

Net cash provided by operating activities was $372.5 million for the year ended December 31, 2019. Operating cash inflows were derived primarily from the rental payments received under our lease agreements, resident fees and services net of the corresponding operating expenses and interest payments from borrowers under our loan investments. In addition, net cash provided by operating activities for the year ended December 31, 2019 includes a $57.2 million lease termination payment in connection with the transition of the Holiday Communities to our Senior Housing - Managed portfolio. Operating cash outflows consisted primarily of interest payments on borrowings and payment of general and administrative expenses, including corporate overhead. We expect our annualized cash flows provided by operating activities to fluctuate as a result of completed investment and disposition activity and anticipated future changes in our portfolio.

Cash Flows from Investing Activities

During the year ended December 31, 2019, net cash provided by investing activities was $262.8 million and included $329.1 million in sales proceeds related to the disposition of 46 real estate facilities, $18.4 million in repayments of loans receivable and $5.1 million in repayments of preferred equity investments, partially offset by an aggregate $51.1 million used in the acquisition of two senior housing communities, two specialty hospitals/other facilities and one Senior Housing - Managed community, $25.5 million used for tenant improvements and $13.1 million used to provide additional funding for existing loans receivable.

We expect to continue using available liquidity and proceeds from sales of our common stock under the New ATM Program to fund anticipated future real estate investments, loan originations, preferred equity investments and capital expenditures.

Cash Flows from Financing Activities

During the year ended December 31, 2019, net cash used in financing activities was $646.2 million and included the redemption of $500.0 million aggregate principal amount of outstanding 2021 Notes, $335.4 million of dividends paid to stockholders, the redemption of $200.0 million aggregate principal amount of outstanding 2023 Notes, $15.6 million of payments of deferred financing costs, $10.5 million of payments related to extinguishment of debt and $3.4 million of principal repayments of secured debt, partially offset by $549.3 million of aggregate net proceeds from shares sold through our Prior ATM Program and New ATM Program, net of payroll tax payments related to the issuance of common stock pursuant to equity compensation arrangements as well as expenses with respect to establishing the Prior ATM Program and the New ATM Program, $341.8 million of gross proceeds from the issuance of the 2029 Notes and $297.0 million of gross proceeds from the issuance of the 2024 Notes. In addition, during the year ended December 31, 2019, we repaid a net amount of $624.0 million on our Revolving Credit Facility and repaid $145.0 million of our Term Loans.

Please see the accompanying consolidated statements of cash flows for details of our operating, investing and financing cash activities.

Loan Agreements

2021 Notes. On January 23, 2014, the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of Sabra (the “Issuers”), issued $350.0 million aggregate principal amount of 5.5% senior unsecured notes due 2021 (the

44

“Original 2021 Notes”), providing net proceeds of approximately $340.8 million after deducting underwriting discounts and other offering expenses. On October 10, 2014, the Issuers issued an additional $150.0 million aggregate principal amount of 5.5% senior unsecured notes due 2021 (together with the Original 2021 Notes, the “2021 Notes”), providing net proceeds of approximately $145.6 million (not including pre-issuance accrued interest), after deducting underwriting discounts and other offering expenses. On June 29, 2019, we redeemed the 2021 Notes at a premium of 101.375%, plus accrued and unpaid interest. The redemption resulted in $10.1 million of redemption related costs and write-offs.

2023 Notes. On May 23, 2013, the Issuers issued $200.0 million aggregate principal amount of 5.375% senior notes due 2023 (the “2023 Notes”), providing net proceeds of approximately $194.6 million after deducting underwriting discounts and other offering expenses. On October 27, 2019, we redeemed the 2023 Notes at a premium of 101.792%, plus accrued and unpaid interest. The redemption resulted in $5.6 million of redemption related costs and write-offs.

2024 Notes. On May 29, 2019, the Issuers issued $300.0 million aggregate principal amount of 4.80% senior notes due 2024 (the “2024 Notes”), providing net proceeds of $295.3 million after deducting underwriting discounts and other offering expenses. Upon redemption of the 2023 Notes, Sabra Capital Corporation’s obligations as a co-issuer under the 2024 Notes were automatically released and discharged.

2026 and 2027 Notes. In connection with the CCP Merger, on August 17, 2017, Sabra assumed $500 million aggregate principal amount of 5.125% senior notes due 2026 (the “2026 Notes”) and $100 million aggregate principal amount of 5.38% senior notes due 2027 (the “2027 Notes”).

2029 Notes. On October 7, 2019, the Issuers issued $350.0 million aggregate principal amount of 3.90% senior notes due 2029 (the “2029 Notes” and, together with the 2024 Notes, the 2026 Notes and the 2027 Notes, the “Senior Notes”), providing net proceeds of $340.5 million after deducting underwriting discounts and other offering expenses. Upon redemption of the 2023 Notes, Sabra Capital Corporation’s obligations as a co-issuer under the 2029 Notes were automatically released and discharged.

See Note 8, “Debt,” in the Notes to Consolidated Financial Statements for additional information concerning the Senior Notes, including information regarding the indentures and agreements governing the Senior Notes (the “Senior Notes Indentures”). As of December 31, 2019, we were in compliance with all applicable covenants under the Senior Notes Indentures.

Credit Agreement. Effective on September 9, 2019, Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”) and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Credit Agreement”).

The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), $1.1 billion in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $175.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of September 9, 2023, and includes two six-month extension options. $250.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2022, $350.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2023, and the other Term Loans have a maturity date of September 9, 2024.

The obligations of the Borrowers under the Credit Agreement are guaranteed by us and one of our non-operating subsidiaries, subject to release under certain customary circumstances.

See Note 8, “Debt,” in the Notes to Consolidated Financial Statements for additional information concerning the Credit Agreement, including information regarding covenants contained in the Credit Agreement. As of December 31, 2019, we were in compliance with all applicable covenants under the Credit Agreement.

45

Secured Indebtedness

Of our 429 properties held for investment, 16 are subject to secured indebtedness to third parties that, as of December 31, 2019, totaled approximately $114.8 million. As of December 31, 2019 and December 31, 2018, our secured debt consisted of the following (dollars in thousands): 

Interest Rate Type	Principal Balance as of December 31, 2019 (1)		Principal Balance as of December 31, 2018 (1)		Weighted Average Interest Rate at December 31, 2019 (2)		Maturity Date
Fixed Rate	$	114,777	$	117,464	3.67	%	December 2021 -  August 2051

⁽¹⁾  Principal balance does not include deferred financing costs, net of $1.7 million and $1.8 million as of December 31, 2019 and 2018, respectively.

⁽²⁾  Weighted average interest rate includes private mortgage insurance.

Capital Expenditures

For the years ended December 31, 2019, 2018 and 2017, our aggregate capital expenditures were $25.5 million, $27.7 million, and $7.0 million, respectively. There are no present plans for the improvement or development of any unimproved or undeveloped property; however, from time to time we may agree to fund improvements our tenants make at our facilities. Accordingly, we anticipate that our aggregate capital expenditure requirements for the next 12 months will principally be for improvements to our facilities and will not exceed $78.0 million, of which $58.0 million will directly result in incremental rental income.

Dividends

We paid dividends of $335.4 million on our common stock during the year ended December 31, 2019. On February 4, 2020, our board of directors declared a quarterly cash dividend of $0.45 per share of common stock. The dividend will be paid on February 28, 2020 to stockholders of record as of February 14, 2020.

Concentration of Credit Risk

Concentrations of credit risk arise when a number of operators, tenants or obligors related to our investments are engaged in similar business activities, or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to us, to be similarly affected by changes in economic conditions. We regularly monitor our portfolio to assess potential concentrations of risks.

Management believes our current portfolio is reasonably diversified across healthcare related real estate and geographical location and does not contain any other significant concentration of credit risks. Our portfolio of 429 real estate properties held for investment as of December 31, 2019 is diversified by location across the U.S. and Canada.

For the year ended December 31, 2019, no tenant relationship represented 10% or more of our total revenues.

Skilled Nursing Facility Reimbursement Rates

For the year ended December 31, 2019 (excluding the one-time lease termination income of $66.9 million), 56.2% of our revenues was derived directly or indirectly from skilled nursing/transitional care facilities. Medicare reimburses skilled nursing facilities for Medicare Part A services under the Prospective Payment System (“PPS”), as implemented pursuant to the Balanced Budget Act of 1997 and modified pursuant to subsequent laws, most recently the Patient Protection and Affordable Care Act of 2010. PPS regulations predetermine a payment amount per patient, per day, based on a market basket index calculated for all covered costs.

Prior to October 1, 2019, the amount to be paid was determined by classifying each patient into one of 66 Resource Utilization Group (“RUG”) categories that represented the level of services required to treat different conditions and levels of acuity. The system of 66 RUG categories, or Resource Utilization Group version IV (“RUG IV”), became effective as of October 1, 2010. RUG IV resulted from research performed by CMS and was part of CMS’s continuing effort to increase the correlation of the cost of services to the condition of individual patients.

On July 31, 2018, CMS issued a final rule, CMS-1696-F, which includes changes to the case-mix classification system used under the PPS and fiscal year 2019 Medicare payment updates.

CMS-1696-F includes a new case-mix classification system called the skilled nursing facility Patient-Driven Payment Model (“PDPM”) that became effective on October 1, 2019. PDPM reflects significant changes to the Resident Classification

46

System, Version I (“RCS-I”) that was being considered to replace RUG IV as outlined in an Advanced Notice of Proposed Rulemaking released by CMS in May 2017.

PDPM focuses on clinically relevant factors, rather than volume-based service, for determining Medicare payment. PDPM adjusts Medicare payments based on each aspect of a resident’s care, most notably for non-therapy ancillaries, which are items and services not related to the provision of therapy such as drugs and medical supplies, thereby more accurately addressing costs associated with medically complex patients. It further adjusts the skilled nursing facility per diem payments to reflect varying costs throughout the stay and incorporates safeguards against potential financial incentives to ensure that beneficiaries receive care consistent with their unique needs and goals.

Based on changes contained within CMS-1696-F, CMS estimated that the fiscal year 2019 aggregate impact would be an increase of $820 million in Medicare payments to skilled nursing facilities, resulting from the fiscal year 2019 market basket update required to be 2.4% by the Bipartisan Budget Act of 2018. Absent the application of this statutory requirement, the fiscal year 2019 market basket update factor would have been 2.0% (comprised of a market basket index of 2.8% less the productivity adjustment of 0.8%). This 2.0% update would have resulted in an estimated aggregate increase of $670 million in Medicare payments to skilled nursing facilities. The new payment rates became effective on October 1, 2018.

On July 30, 2019, CMS released final fiscal year 2020 Medicare rates for skilled nursing facilities providing an estimated net increase of 2.4% over fiscal year 2019 payments (comprised of a market basket increase of 2.8% less the productivity adjustment of 0.4%). The new payment rates became effective on October 1, 2019.

Obligations and Commitments

The following table summarizes our contractual obligations and commitments in future years, including our secured indebtedness to third parties on certain of our properties, our Revolving Credit Facility, our Term Loans, our Senior Notes and our operating leases. The following table is presented as of December 31, 2019 (in thousands): 

			Payments Due During the Years Ending December 31,
	Total		2020		2021		2022		2023		2024		After 2024
Secured indebtedness (1)	$	161,092	$	7,277	$	22,446	$	6,121	$	6,121	$	6,121	$	113,006
Revolving Credit Facility (2)	9,362		2,542		2,535		2,535		1,750		—		—
Term Loans (3)	1,176,205		27,280		30,797		134,970		374,766		608,392		—
Senior Notes (4)	1,678,566		59,396		59,055		59,055		59,055		359,055		1,082,950
Operating leases	2,878		426		445		467		507		529		504
Total	$	3,028,103	$	96,921	$	115,278	$	203,148	$	442,199	$	974,097	$	1,196,460

⁽¹⁾  Secured indebtedness includes principal payments and interest payments through the applicable maturity dates. Total interest on secured indebtedness, based on contractual rates, is $46.3 million which is attributable to fixed rate debt.

⁽²⁾  Revolving Credit Facility consists of payments related to the facility fee due to the lenders based on the amount of commitments under the Revolving Credit Facility through the maturity date (assuming no exercise of our two six-month extension options) totaling $9.4 million.

⁽³⁾  Term Loans includes interest payments through the applicable maturity dates totaling $125.2 million, which reflects the impact of interest rate swaps.

⁽⁴⁾  Senior Notes includes interest payments through the applicable maturity dates totaling $428.6 million.

In addition to the above, as of December 31, 2019, we have committed to provide up to $2.9 million of future funding related to four loans receivable investments with maturity dates ranging from March 2020 to December 2022.

Impact of Inflation

Our rental income in future years will be impacted by changes in inflation. Several of our lease agreements provide for an annual rent escalator based on the percentage change in the Consumer Price Index (but not less than zero), subject to minimum or maximum fixed percentages that range from 1.0% to 5.0%.

Off-Balance Sheet Arrangements

We have a 49% interest in an unconsolidated joint venture. See Note 2, “Summary of Significant Accounting Policies,” in the Notes to Consolidated Financial Statements for additional information. We have no other off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources.

47

Quarterly Financial Data

The following table presents our quarterly financial data. This information has been prepared on a basis consistent with that of our audited consolidated financial statements. Our quarterly results of operations for the periods presented are not necessarily indicative of future results of operations. This unaudited quarterly data should be read together with the accompanying consolidated financial statements and related notes thereto (in thousands, except share and per share amounts).

	For the Year Ended December 31, 2019
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Operating data
Total revenues	$	136,773		$	219,366		$	149,834		$	155,763
Net (loss) income attributable to common stockholders	(77,704		)	83,677			23,282			39,741
Net (loss) income per common share, basic	(0.44		)	0.46			0.12			0.20
Net (loss) income per common share, diluted	(0.44		)	0.46			0.12			0.20
Other data
Cash flows provided by operations	$	53,959		$	137,919		$	85,103		$	95,494
Cash flows provided by (used in) investing activities	6,347			311,535			(19,337		)	(35,701		)
Cash flows used in financing activities	(87,474		)	(424,770		)	(83,489		)	(50,447		)
Weighted-average number of common shares outstanding, basic	178,385,984			181,567,464			190,650,400			197,840,180
Weighted-average number of common shares outstanding, diluted:
Net income (loss)	178,385,984			182,254,100			191,952,389			199,048,481
FFO	178,936,854			182,254,100			191,952,389			199,048,481
AFFO	179,709,444			183,007,434			192,590,320			199,496,049
FFO attributable to common stockholders (1)	$	77,175		$	139,398		$	85,784		$	90,953
FFO attributable to common stockholders per diluted common share (1)	0.43			0.76			0.45			0.46
AFFO attributable to common stockholders (1)	83,165			132,374			87,656			89,580
AFFO attributable to common stockholder per diluted common share (1)	0.46			0.72			0.46			0.45
Reconciliation of FFO and AFFO
Net (loss) income attributable to common stockholders	$	(77,704	)	$	83,677		$	23,282		$	39,741
Depreciation and amortization of real estate assets	44,949			49,476			43,092			44,032
Depreciation and amortization of real estate assets related to noncontrolling interests	(40		)	(39		)	(14		)	—
Depreciation and amortization of real estate assets related to unconsolidated joint venture	5,316			5,347			5,439			5,547
Net loss (gain) on sales of real estate	1,520			(2,755		)	19			(1,084		)
Net loss on sales of real estate related to unconsolidated joint venture	—			1,690			—			—
Impairment of real estate	103,134			2,002			13,966			2,717
FFO attributable to common stockholders	77,175			139,398			85,784			90,953
Merger and acquisition costs	6			56			130			232
Stock-based compensation expense	2,775			2,795			3,259			990
Non-cash rental and related revenues	(1,164		)	(6,843		)	(4,958		)	(6,484		)
Non-cash interest income	(562		)	(563		)	(555		)	(532		)
Non-cash interest expense	2,561			2,762			2,523			2,234
Non-cash portion of loss on extinguishment of debt	—			3,224			642			1,972
Provision for doubtful straight-line rental income, loan losses and other reserves	1,207			193			57			(219		)
Non-cash lease termination income	—			(9,725		)	—			(854		)
Other non-cash adjustments related to unconsolidated joint venture	1,115			1,031			777			1,212
Other non-cash adjustments	52			46			(3		)	76
AFFO attributable to common stockholders	$	83,165		$	132,374		$	87,656		$	89,580

48

	For the Year Ended December 31, 2018
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Operating data
Total revenues	$	166,086		$	166,312		$	151,802		$	139,209
Net income (loss) attributable to common stockholders	59,910			193,580			35,218			(19,394		)
Net income (loss) per common share, basic	0.34			1.09			0.20			(0.11		)
Net income (loss) per common share, diluted	0.34			1.08			0.20			(0.11		)
Other data
Cash flows provided by operations	$	101,647		$	109,906		$	71,471		$	77,562
Cash flows (used in) provided by investing activities	(516,379		)	219,480			(19,354		)	57,759
Cash flows used in financing activities	(114,392		)	(161,805		)	(138,351		)	(214,796		)
Weighted-average number of common shares outstanding, basic	178,294,605			178,314,750			178,317,769			178,314,638
Weighted-average number of common shares outstanding, diluted:
Net income (loss)	178,516,388			178,684,024			178,941,213			178,314,638
FFO	178,516,388			178,684,024			178,941,213			178,932,966
AFFO	179,266,983			179,226,155			179,469,883			179,394,677
FFO attributable to common stockholders (1)	$	113,431		$	104,509		$	88,847		$	48,215
FFO attributable to common stockholders per diluted common share (1)	0.64			0.58			0.50			0.27
AFFO attributable to common stockholders (1)	106,420			98,040			97,290			77,287
AFFO attributable to common stockholder per diluted common share (1)	0.59			0.55			0.54			0.43
Reconciliation of FFO and AFFO
Net income (loss) attributable to common stockholders	$	59,910		$	193,580		$	35,218		$	(19,394	)
Depreciation and amortization of real estate assets	48,005			46,828			48,468			48,078
Depreciation and amortization of real estate assets related to noncontrolling interests	(40		)	(40		)	(39		)	(40		)
Depreciation and amortization of real estate assets related to unconsolidated joint venture	4,552			6,163			5,214			5,324
Net loss (gain) on sales of real estate	472			(142,903		)	(14		)	14,247
Impairment of real estate	532			881			—			—
FFO attributable to common stockholders	113,431			104,509			88,847			48,215
Merger and acquisition costs	330			112			151			43
Stock-based compensation expense	1,135			2,704			2,436			1,373
Non-cash rental and related revenues	(12,247		)	(12,873		)	(5,091		)	(6,232		)
Non-cash interest income	(570		)	(604		)	(548		)	(578		)
Non-cash interest expense	2,481			2,516			2,551			2,589
Non-cash portion of loss on extinguishment of debt	—			—			—			874
Provision for doubtful straight-line rental income, loan losses and other reserves	2,181			311			8,801			29,513
Other non-cash adjustments related to unconsolidated joint venture	(336		)	1,350			118			1,520
Other non-cash adjustments	15			15			25			(30		)
AFFO attributable to common stockholders	$	106,420		$	98,040		$	97,290		$	77,287

⁽¹⁾  We believe that net income attributable to common stockholders as defined by GAAP is the most appropriate earnings measure. We also believe that FFO, as defined in accordance with the definition used by NAREIT, and AFFO (and related per share amounts) are important non-GAAP supplemental measures of our operating performance. We consider FFO and AFFO to be useful measures for reviewing comparative operating and financial performance because, by excluding gains or losses from real estate dispositions and our share of gains or losses from real estate dispositions related to our unconsolidated joint venture, real estate depreciation and amortization, net of amounts related to noncontrolling interests, plus our share of depreciation and amortization related to our unconsolidated joint venture, and real estate impairment charges, and for AFFO, by excluding merger and acquisition costs, stock-based compensation expense, non-cash rental and related revenues, non-cash interest income, non-cash interest expense, change in fair value of contingent consideration, non-cash portion of loss on extinguishment of debt, provision for doubtful straight-line rental income, loan losses and other reserves, non-cash lease termination income and deferred income taxes, as well as other non-cash revenue and expense items (including ineffectiveness gain/loss on derivative instruments, and

49

non-cash revenue and expense amounts related to noncontrolling interests) and our share of non-cash adjustments related to our unconsolidated joint venture, FFO and AFFO can help investors compare our operating performance between periods or as compared to other companies. See “—Results of Operations—Funds from Operations and Adjusted Funds from Operations” for further discussion of FFO and AFFO.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to various market risks, primarily related to adverse changes in interest rates and the exchange rate for Canadian dollars. We use derivative instruments in the normal course of business to mitigate interest rate and foreign currency risk. We do not use derivative financial instruments for speculative or trading purposes. See Note 9, “Derivative and Hedging Instruments,” in the Notes to Consolidated Financial Statements for further discussion of our derivative instruments.

Interest rate risk. As of December 31, 2019, our indebtedness included $1.3 billion aggregate principal amount of Senior Notes outstanding, $1.1 billion in Term Loans and $114.8 million of secured indebtedness to third parties on certain of the properties that our subsidiaries own. As of December 31, 2019, we had $1.1 billion of outstanding variable rate indebtedness and $1.0 billion available for borrowing under our Revolving Credit Facility. Additionally, as of December 31, 2019, our share of unconsolidated joint venture debt was $378.7 million, all of which was variable rate indebtedness.

We expect to manage our exposure to interest rate risk by maintaining a mix of fixed and variable rates for our indebtedness. We also may manage, or hedge, interest rate risks related to our borrowings through interest rate swap agreements. As of December 31, 2019, we had interest rate swaps that fix the LIBOR portion of the interest rate for $845.0 million of LIBOR-based borrowings under the U.S. dollar Term Loans at a weighted average rate of 1.19% and two interest rate swaps that fix the Canadian Dollar Offered Rate (“CDOR”) portion of the interest rate for CAD $90.0 million and CAD $35.0 million of CDOR-based borrowings at 1.59% and 0.93%, respectively. As of December 31, 2019, our share of unconsolidated joint venture debt included $368.4 million of LIBOR-based borrowings subject to interest rate cap agreements that cap the LIBOR portion of the interest rate at a weighted average rate of 2.89%.

From time to time, we may borrow under the Revolving Credit Facility to finance future investments in properties, including any improvements or renovations of current or newly acquired properties, or for other purposes. Because borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at our option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0%, the interest rate we will be required to pay on any such borrowings will depend on then applicable rates and may vary. An increase in interest rates could make the financing of any investment by us more costly. Rising interest rates could also limit our ability to refinance our debt when it matures or cause us to pay higher interest rates upon refinancing and increase interest expense on refinanced indebtedness.

Assuming a 100 basis point increase or decrease in the interest rate related to our variable rate debt, including our share of unconsolidated joint venture debt, and after giving effect to the impact of interest rate derivative instruments, income would decrease by $4.7 million or increase by $4.9 million, respectively, for the twelve months following December 31, 2019.

Foreign currency risk. We are exposed to changes in foreign exchange rates as a result of our investments in Canadian real estate. Our foreign currency exposure is partially mitigated through the use of Canadian dollar denominated debt totaling CAD $146.2 million and cross currency swap instruments. Based on our operating results for the three months ended December 31, 2019, if the value of the Canadian dollar relative to the U.S. dollar were to increase or decrease by 10% compared to the average exchange rate during the three months ended December 31, 2019, our cash flows would have decreased or increased, as applicable, by $0.1 million.

50

The table below summarizes the book values and the weighted-average interest rates of our indebtedness by type as of December 31, 2019, based on the maturity dates (dollars in thousands):

	Maturity
	2020			2021			2022			2023			2024			Thereafter			Total Book Value (1)			Total Fair Value
Secured indebtedness
Fixed rate	$	3,568		$	18,853		$	3,198		$	3,296		$	3,396		$	82,466		$	114,777		$	105,510
Weighted average effective interest rate	3.63		%	3.63		%	3.63		%	3.64		%	3.65		%	3.85		%	3.67		%
Term Loans	$	—		$	—		$	105,000		$	350,000		$	596,025		$	—		$	1,051,025		$	1,051,025
Weighted average effective interest rate (2)	—			—			2.49		%	2.61		%	2.47		%	—			2.52		%
Senior Notes	$	—		$	—		$	—		$	—		$	300,000		$	950,000		$	1,250,000		$	1,328,714
Weighted average effective interest rate	—			—			—			—			4.80		%	4.70		%	4.72		%

⁽¹⁾  Total book value for secured indebtedness and Term Loans does not include deferred financing costs, net of $1.7 million and $10.8 million, respectively, as of December 31, 2019. Total book value for Senior Notes does not include premium, net of $7.6 million and deferred financing costs, net of $8.8 million as of December 31, 2019.

⁽²⁾  Term loans include $845.0 million subject to swap agreements that fix LIBOR at a weighted average rate of 1.19%, and $69.1 million (CAD $90.0 million) and $26.9 million (CAD $35.0 million) subject to swap agreements that fix CDOR at 1.59% and 0.93%, respectively. Excluding these amounts, variable rate debt was 17.5% of total debt as of December 31, 2019.

For a discussion of the interest rate risks related to the current capital and credit markets, see Part I, Item 1A, “Risk Factors.”

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

See the Index to Financial Statements at page F-1 of this 10-K. See also “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Quarterly Financial Data” in Part II, Item 7.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As of the end of the period covered by this report, management, including our chief executive officer and chief financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures. Based upon, and as of the date of, the evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2019 to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

Management’s Annual Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a–15(f) and 15d–15(f). Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria described in the 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on our evaluation using the criteria described in Internal Control—Integrated Framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2019.

51

The effectiveness of our internal control over financial reporting as of December 31, 2019 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included herein.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

Except as provided below, the information required under Item 10 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2019 in connection with our 2020 Annual Meeting of Stockholders.

Code of Conduct and Ethics

We have adopted a Code of Conduct and Ethics that applies to all of our directors and employees, including our principal executive officer and principal financial officer. Our Code of Conduct and Ethics can be found in the Investors—Corporate Governance section of our website at www.sabrahealth.com. Waivers from, and amendments to, our Code of Conduct and Ethics that apply to our directors, executive officers or persons performing similar functions will be timely posted in the Investors—Corporate Governance section of our website at www.sabrahealth.com to the extent required by applicable rules of the Securities and Exchange Commission or the Nasdaq Stock Market LLC.

ITEM 11. EXECUTIVE COMPENSATION

The information required under Item 11 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2019 in connection with our 2020 Annual Meeting of Stockholders.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required under Item 12 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2019 in connection with our 2020 Annual Meeting of Stockholders.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

The information required under Item 13 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2019 in connection with our 2020 Annual Meeting of Stockholders.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required under Item 14 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2019 in connection with our 2020 Annual Meeting of Stockholders.

52

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES

(a) Documents filed as part of this 10-K:

(1) Financial Statements

See the Index to Consolidated Financial Statements at page F-1 of this report.

(2) Financial Statement Schedules

        The following financial statement schedules are included herein at pages F-51 through F-69 of this report:

Schedule II - Valuation and Qualifying Accounts for the years ended December 31, 2019, 2018 and 2017

Schedule III - Real Estate Assets and Accumulated Depreciation as of December 31, 2019

Schedule IV - Mortgage Loans on Real Estate as of December 31, 2019

(3) Exhibits

The following exhibits are filed herewith or are incorporated by reference, as specified below, to exhibits previously filed with the SEC.

EXHIBIT LIST

Ex.	Description
2.1	Agreement and Plan of Merger, dated as of May 7, 2017, by and among Sabra Health Care REIT, Inc., PR Sub, LLC, Sabra Health Care Limited Partnership, Care Capital Properties, Inc. and Care Capital Properties, LP. (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on May 8, 2017). †
3.1	Articles of Amendment and Restatement of Sabra Health Care REIT, Inc., dated October 20, 2010, filed with the State Department of Assessments and Taxation of the State of Maryland on October 21, 2010 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on October 26, 2010).
3.1.1	Articles of Amendment of Sabra Health Care REIT, Inc., dated as of July 31, 2017 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on July 31, 2017).
3.2	Amended and Restated Bylaws of Sabra Health Care REIT, Inc. (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on March 15, 2019).
4.1*	Description of Sabra Health Care REIT, Inc.’s Capital Stock
4.2	Indenture, dated as of May 23, 2013, among Sabra Health Care Limited Partnership, Sabra Capital Corporation, Sabra Health Care REIT, Inc., and Wells Fargo Bank, National Association, as Trustee (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on May 23, 2013).
4.2.1	Eighth Supplemental Indenture, dated May 29, 2019, among Sabra Health Care Limited Partnership, Sabra Capital Corporation, Sabra Health Care REIT, Inc., the other guarantors named therein, and Wells Fargo Bank, National Association, as Trustee (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on May 29, 2019).
4.2.2	Ninth Supplemental Indenture, dated October 7, 2019, among Sabra Health Care Limited Partnership, Sabra Capital Corporation, Sabra Health Care REIT, Inc. and Wells Fargo Bank, National Association, as Trustee (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on October 7, 2019).
4.3	Form of 4.80% senior note due 2024 (included in Exhibit 4.2.1).
4.4	Form of 3.90% senior note due 2029 (included in Exhibit 4.2.2).
4.5	Indenture, dated as of July 14, 2016, by and among Care Capital Properties, LP, Care Capital Properties, Inc., Care Capital Properties GP, LLC and Regions Bank, as trustee (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on August 23, 2017).

53

Ex.	Description
4.5.1	First Supplemental Indenture, dated as of August 17, 2017, by and among Care Capital Properties, LP, PR Sub, LLC, Care Capital Properties GP, LLC and Regions Bank, as trustee (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on August 23, 2017).
4.5.2	Second Supplemental Indenture, dated as of August 17, 2017, by and among Sabra Health Care Limited Partnership as successor to Care Capital Properties, LP, Sabra Health Care REIT, Inc., Care Capital Properties GP, LLC and Regions Bank, as trustee (incorporated by reference to Exhibit 4.3 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on August 23, 2017).
4.5.3	Third Supplemental Indenture, dated as of August 17, 2017, by and among Sabra Health Care Limited Partnership, Sabra Health Care REIT, Inc., Care Capital Properties GP, LLC and Regions Bank, as trustee (incorporated by reference to Exhibit 4.4 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on August 23, 2017).
4.5.4	Fourth Supplemental Indenture, dated as of August 18, 2017, by and among Sabra Health Care Limited Partnership, Sabra Health Care REIT, Inc. and Regions Bank, as trustee (incorporated by reference to Exhibit 4.5 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on August 23, 2017).
4.6	Form of 5.125% senior note due 2026 (included in Exhibit 4.5.1).
4.7	Form of Indenture for Senior Debt Securities (incorporated by reference to Exhibit 4.7 of the Registration Statement on Form S-3 filed by Sabra Health Care REIT, Inc. and Sabra Health Care Limited Partnership on December 11, 2019).
10.1	Limited Partnership Agreement of Sabra Health Care Limited Partnership, dated as of November 15, 2010 (incorporated by reference to Exhibit 3.4 of the Registration Statement on Form S-4 (File No. 333-171820) filed by the issuers and guarantors on January 21, 2011).
10.1.1	First Amendment to the Limited Partnership Agreement by Sabra Health Care REIT, Inc. and Sabra Health Care, LLC, dated March 21, 2013 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on March 21, 2013).
10.2	Fifth Amended and Restated Credit Agreement, dated September 9, 2019, among Sabra Health Care Limited Partnership and Sabra Canadian Holdings, LLC, as Borrowers; Sabra Health Care REIT, Inc., as a guarantor; the other guarantors party thereto; the lenders party thereto; Bank of America, N.A., as Administrative Agent and L/C Issuer; Citizens Bank, National Association, Crédit Agricole Corporate and Investment Bank and Wells Fargo Bank, National Association, as Co-Syndication Agents and L/C Issuers; BMO Harris Bank, N.A., The Bank of Nova Scotia, MUFG Bank, Ltd., Barclays Bank PLC, Citibank, N.A., BBVA USA, Fifth Third Bank, JPMorgan Chase Bank, N.A., Morgan Stanley Senior Funding, Inc., Sumitomo Mitsui Banking Corporation and Suntrust Bank, as Co-Documentation Agents; BofA Securities, Inc., as Joint Lead Arranger and Sole Bookrunner; and Citizens Bank, National Association, Crédit Agricole Corporate and Investment Bank and Wells Fargo Securities, LLC, as Joint Lead Arrangers (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on September 11, 2019).
10.3	Form of Indemnification Agreement entered into with each of the directors and officers of Sabra Health Care REIT, Inc. (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on November 5, 2010).
10.4+	Employment Agreement, dated December 24, 2019, between Sabra Health Care REIT, Inc. and Richard K. Matros (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on December 27, 2019).
10.5+	Employment Agreement, dated December 24, 2019, between Sabra Health Care REIT, Inc. and Harold W. Andrews, Jr. (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on December 27, 2019).
10.6+	Employment Agreement, dated December 24, 2019, between Sabra Health Care REIT, Inc. and Talya Nevo-Hacohen (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on December 27, 2019).
10.7+	Sabra Health Care REIT, Inc. 2009 Performance Incentive Plan, effective April 21, 2017 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on June 21, 2017).
10.8.1+*	Form of Notice and Terms and Conditions of Stock Unit Award (Time-Based Stock Units) (for Executive Officers).
10.8.2+*	Form of Notice and Terms and Conditions of Stock Unit Award (FFO Units) (for Executive Officers).

54

Ex.	Description
10.8.3+*	Form of Notice and Terms and Conditions of Stock Unit Award (TSR Units) (for Executive Officers).
10.8.4+	Form of Notice and Terms and Conditions of Stock Unit Award (for Non-Employee Directors) (incorporated by reference to Exhibit 10.3 of the Quarterly Report on Form 10-Q filed by Sabra Health Care REIT, Inc. on November 1, 2017).
10.8.5+	Non-Employee Directors Stock-for-Fees Program (incorporated by reference to Exhibit 10.10.5 of the Registration Statement on Form S-4 (File No. 333-171820-26) filed by Sabra Health Care REIT, Inc. on January 21, 2011).
10.9+	Sabra Health Care REIT, Inc. Directors’ Compensation Policy, effective January 1, 2019 (incorporated by reference to Exhibit 10.9 of the Annual Report on Form 10-K filed by Sabra Health Care REIT, Inc. on February 25, 2019).
21.1*	List of Subsidiaries of Sabra Health Care REIT, Inc.
23.1*	Consent of PricewaterhouseCoopers LLP.
31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	XBRL Instance Document.
101.SCH*	XBRL Taxonomy Extension Schema Document.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.

 

*	Filed herewith.
**	Furnished herewith.
+	Designates a management compensation plan, contract or arrangement.

† Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrants hereby agree to furnish supplementally copies of any of the omitted schedules and exhibits upon request by the Securities and Exchange Commission.

ITEM 16. FORM 10-K SUMMARY

None.

55

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Consolidated Financial Statements
Report of Independent Registered Public Accounting Firm	F-2
Consolidated Balance Sheets	F-5
Consolidated Statements of Income	F-6
Consolidated Statements of Comprehensive Income	F-7
Consolidated Statements of Equity	F-8
Consolidated Statements of Cash Flows	F-9
Notes to Consolidated Financial Statements	F-11
Financial Statement Schedules
Schedule II—Valuation and Qualifying Accounts for the years ended December 31, 2019, 2018 and 2017	F-51
Schedule III—Real Estate Assets and Accumulated Depreciation as of December 31, 2019	F-52
Schedule IV—Mortgage Loans on Real Estate as of December 31, 2019	F-69
All other schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To The Board of Directors and Stockholders

Sabra Health Care REIT, Inc.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Sabra Health Care REIT, Inc. and its subsidiaries (the “Company”) as of December 31, 2019 and 2018, and the related consolidated statements of income, of comprehensive income, of equity, and of cash flows for each of the three years in the period ended December 31, 2019, including the related notes and financial statement schedules listed in the index appearing under Item 15(a)(2) (collectively referred to as the “consolidated financial statements”). We also have audited the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

Basis for Opinions

The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the

F-2

company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Impairment Assessment of Real Estate

As described in Note 2 and Note 4 to the consolidated financial statements, the Company’s consolidated real estate net carrying value was $5,341,370 thousand as of December 31, 2019. Management continually monitors events and changes in circumstances that could indicate that the carrying amounts of its real estate investments may not be recoverable or realized. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, management assesses the recoverability by estimating whether the Company will recover the carrying value of its real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. In some instances, there may be various potential outcomes for an investment and its potential future cash flows. In these instances, the undiscounted future cash flows used to assess recoverability are based on several assumptions and are probability-weighted based on management’s best estimates as of the date of evaluation. These assumptions include, among others, cash flow projections, discount rates, market capitalization rates, and recent sales data for comparable properties. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties.

The principal considerations for our determination that performing procedures relating to impairment assessment of real estate is a critical audit matter are (i) there was a high degree of auditor judgment and subjectivity involved in applying procedures relating to the fair value of its real estate investments used in the impairment assessment of real estate due to the significant amount of judgment by management when developing these estimates; (ii) significant audit effort was necessary to perform procedures and evaluate the audit evidence relating to the significant assumptions used in the fair value of its real estate investments, including the cash flow projections, probability weightings, discount rates, market capitalization rates and recent sales data for comparable properties; (iii) in certain circumstances, the audit effort involved the use of professionals with specialized skill and knowledge to assist in performing these procedures and evaluating the audit evidence obtained from these procedures.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s impairment assessment of real estate, including controls over the development of assumptions used in the fair value of its real estate investments. These procedures also included, among others, testing the completeness and accuracy of underlying data used in management’s model, evaluating the appropriateness of the methods and the reasonableness of significant assumptions used by management in developing the fair value of its real estate investments including the cash flow projections, probability weightings, discount rates, market capitalization rates and recent sales data for comparable properties. Evaluating the reasonableness of the cash flow projections assumption involved considering (i) the past performance of the real estate; (ii) evidence such as the underlying internal or market data related to management’s assumptions and (iii) whether the assumption was consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in the evaluation of certain significant assumptions, including but not limited to, cash flow projections, probability weightings, discount rates, market capitalization rates and recent sales data for comparable properties.

/s/ PricewaterhouseCoopers LLP

Irvine, California

February 24, 2020

F-3

We have served as the Company’s auditor since 2010.

F-4

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

	December 31,
	2019			2018
Assets
Real estate investments, net of accumulated depreciation of $539,213 and $402,338 as of December 31, 2019 and 2018, respectively	$	5,341,370		$	5,853,545
Loans receivable and other investments, net	107,374			113,722
Investment in unconsolidated joint venture	319,460			340,120
Cash and cash equivalents	39,097			50,230
Restricted cash	10,046			9,428
Lease intangible assets, net	101,509			131,097
Accounts receivable, prepaid expenses and other assets, net	150,443			167,161
Total assets	$	6,069,299		$	6,665,303
Liabilities
Secured debt, net	$	113,070		$	115,679
Revolving credit facility	—			624,000
Term loans, net	1,040,258			1,184,930
Senior unsecured notes, net	1,248,773			1,307,394
Accounts payable and accrued liabilities	108,792			94,827
Lease intangible liabilities, net	69,946			83,726
Total liabilities	2,580,839			3,410,556
Commitments and contingencies (Note 16)
Equity
Preferred stock, $.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of December 31, 2019 and 2018	—			—
Common stock, $.01 par value; 250,000,000 shares authorized, 205,208,018 and 178,306,528 shares issued and outstanding as of December 31, 2019 and 2018, respectively	2,052			1,783
Additional paid-in capital	4,072,079			3,507,925
Cumulative distributions in excess of net income	(573,283		)	(271,595		)
Accumulated other comprehensive (loss) income	(12,388		)	12,301
Total Sabra Health Care REIT, Inc. stockholders’ equity	3,488,460			3,250,414
Noncontrolling interests	—			4,333
Total equity	3,488,460			3,254,747
Total liabilities and equity	$	6,069,299		$	6,665,303

See accompanying notes to consolidated financial statements.

F-5

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except share and per share amounts)

	Year Ended December 31,
	2019			2018			2017
Revenues:
Rental and related revenues	$	452,138		$	536,605		$	364,191
Interest and other income	81,540			16,667			17,660
Resident fees and services	128,058			70,137			26,430
Total revenues	661,736			623,409			408,281
Expenses:
Depreciation and amortization	181,549			191,379			113,882
Interest	126,610			147,106			88,440
Triple-net portfolio operating expenses	22,215			—			—
Senior housing - managed portfolio operating expenses	86,257			49,546			17,860
General and administrative	30,462			36,458			32,401
Merger and acquisition costs	424			636			30,255
Provision for doubtful accounts, straight-line rental income and loan losses	1,238			39,075			17,113
Impairment of real estate	121,819			1,413			1,326
Total expenses	570,574			465,613			301,277
Other (expense) income:
Loss on extinguishment of debt	(16,340		)	(2,917		)	(553		)
Other income	2,094			4,480			536
Net gain on sales of real estate	2,300			128,198			52,029
Total other (expense) income	(11,946		)	129,761			52,012
Income before loss from unconsolidated joint venture and income tax expense	79,216			287,557			159,016
Loss from unconsolidated joint venture	(6,796		)	(5,431		)	—
Income tax expense	(3,402		)	(3,011		)	(651		)
Net income	69,018			279,115			158,365
Net (income) loss attributable to noncontrolling interests	(22		)	(33		)	18
Net income attributable to Sabra Health Care REIT, Inc.	68,996			279,082			158,383
Preferred stock dividends	—			(9,768		)	(10,242		)
Net income attributable to common stockholders	$	68,996		$	269,314		$	148,141
Net income attributable to common stockholders, per:
Basic common share	$	0.37		$	1.51		$	1.40
Diluted common share	$	0.37		$	1.51		$	1.40
Weighted-average number of common shares outstanding, basic	187,172,210			178,305,738			105,621,242
Weighted-average number of common shares outstanding, diluted	188,127,092			178,721,744			105,842,434

See accompanying notes to consolidated financial statements.

F-6

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

	Year Ended December 31,
	2019			2018			2017
Net income	$	69,018		$	279,115		$	158,365
Other comprehensive (loss) income:
Unrealized gain (loss), net of tax:
Foreign currency translation gain	679			720			154
Unrealized (loss) gain on cash flow hedges (1)	(25,368		)	292			12,933
Total other comprehensive (loss) income	(24,689		)	1,012			13,087
Comprehensive income	44,329			280,127			171,452
Comprehensive (income) loss attributable to noncontrolling interest	(22		)	(33		)	18
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	44,307		$	280,094		$	171,470

⁽¹⁾  Amounts are net of income tax benefit of $49,000 and $48,000 for the years ended December 31, 2019 and 2018, respectively, and income tax expense of $0.1 million for the year ended December 31, 2017.

See accompanying notes to consolidated financial statements.

F-7

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF EQUITY

(in thousands, except share and per share amounts)

	Preferred Stock					Common Stock			Additional Paid-in Capital			Cumulative Distributions in Excess of Net Income			Accumulated Other Comprehensive (Loss) Income			Total Stockholders’ Equity			Noncontrolling Interests			Total Equity
	Shares		Amounts			Shares	Amounts
Balance, December 31, 2016	5,750,000		$	58		65,285,614	$	653	$	1,208,862		$	(192,201	)	$	(1,798	)	$	1,015,574		$	35		$	1,015,609
Net income (loss)	—		—			—	—		—			158,383			—			158,383			(18		)	158,365
Other comprehensive income	—		—			—	—		—			—			13,087			13,087			—			13,087
Change in noncontrolling interests	—		—			—	—		—			—			—			—			4,455			4,455
Distributions to noncontrolling interests	—		—			—	—		—			—			—			—			(30		)	(30		)
Amortization of stock-based compensation	—		—			—	—		9,244			—			—			9,244			—			9,244
Common stock issuance, net	—		—			112,970,229	1,130		2,418,807			—			—			2,419,937			—			2,419,937
Preferred dividends	—		—			—	—		—			(10,242		)	—			(10,242		)	—			(10,242		)
Common dividends ($1.73 per share)	—		—			—	—		—			(173,176		)	—			(173,176		)	—			(173,176		)
Balance, December 31, 2017	5,750,000		58			178,255,843	1,783		3,636,913			(217,236		)	11,289			3,432,807			4,442			3,437,249
Cumulative effect of ASU 2017-12 adoption	—		—			—	—		—			(795		)	795			—			—			—
Net income	—		—			—	—		—			279,082			—			279,082			33			279,115
Other comprehensive income	—		—			—	—		—			—			217			217			—			217
Distributions to noncontrolling interests	—		—			—	—		—			—			—			—			(142		)	(142		)
Amortization of stock-based compensation	—		—			—	—		9,574			—			—			9,574			—			9,574
Preferred stock redemption	(5,750,000	)	(58		)	—	—		(138,191		)	(5,501		)	—			(143,750		)	—			(143,750		)
Common stock issuance, net	—		—			50,685	—		(371		)	—			—			(371		)	—			(371		)
Preferred dividends	—		—			—	—		—			(4,267		)	—			(4,267		)	—			(4,267		)
Common dividends ($1.80 per share)	—		—			—	—		—			(322,878		)	—			(322,878		)	—			(322,878		)
Balance, December 31, 2018	—		—			178,306,528	1,783		3,507,925			(271,595		)	12,301			3,250,414			4,333			3,254,747
Cumulative effect of Topic 842 adoption	—		—			—	—		—			(32,502		)	—			(32,502		)	—			(32,502		)
Net income	—		—			—	—		—			68,996			—			68,996			22			69,018
Other comprehensive loss	—		—			—	—		—			—			(24,689		)	(24,689		)	—			(24,689		)
Buyout of noncontrolling interests	—		—			—	—		4,039			—			—			4,039			(4,039		)	—
Distributions to noncontrolling interests	—		—			—	—		—			—			—			—			(316		)	(316		)
Amortization of stock-based compensation	—		—			—	—		12,567			—			—			12,567			—			12,567
Common stock issuance, net	—		—			26,901,490	269		547,548			—			—			547,817			—			547,817
Common dividends ($1.80 per share)	—		—			—	—		—			(338,182		)	—			(338,182		)	—			(338,182		)
Balance, December 31, 2019	—		$	—		205,208,018	$	2,052	$	4,072,079		$	(573,283	)	$	(12,388	)	$	3,488,460		$	—		$	3,488,460

See accompanying notes to consolidated financial statements.

F-8

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	Year Ended December 31,
	2019			2018			2017
Cash flows from operating activities:
Net income	$	69,018		$	279,115		$	158,365
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	181,549			191,379			113,882
Non-cash rental and related revenues	(19,449		)	(36,443		)	(30,352		)
Non-cash interest income	(2,212		)	(2,300		)	(769		)
Non-cash interest expense	10,080			10,137			7,776
Stock-based compensation expense	9,819			7,648			8,359
Non-cash lease termination income	(10,579		)	—			—
Loss on extinguishment of debt	16,340			2,917			553
Provision for doubtful accounts, straight-line rental income and loan losses	1,238			39,075			17,113
Change in fair value of contingent consideration	—			—			(426		)
Net gain on sales of real estate	(2,300		)	(128,198		)	(52,029		)
Impairment of real estate	121,819			1,413			1,326
Loss from unconsolidated joint venture	6,796			5,431			—
Distributions of earnings from unconsolidated joint venture	13,865			8,910			—
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net	(9,639		)	(6,753		)	(16,811		)
Accounts payable and accrued liabilities	(13,870		)	(11,745		)	(71,198		)
Net cash provided by operating activities	372,475			360,586			135,789
Cash flows from investing activities:
Acquisition of real estate	(51,136		)	(261,511		)	(419,905		)
Cash received in CCP Merger	—			—			77,859
Origination and fundings of loans receivable	(13,065		)	(50,731		)	(17,239		)
Origination and fundings of preferred equity investments	—			(5,313		)	(2,749		)
Additions to real estate	(25,451		)	(27,697		)	(6,954		)
Repayments of loans receivable	18,367			51,789			32,430
Repayments of preferred equity investments	5,079			6,870			3,755
Investment in unconsolidated joint venture	—			(354,461		)	—
Net proceeds from sales of real estate	329,050			382,560			150,243
Net cash provided by (used in) investing activities	262,844			(258,494		)	(182,560		)
Cash flows from financing activities:
Net (repayments of) proceeds from revolving credit facility	(624,000		)	(17,000		)	253,000
Proceeds from issuance of senior unsecured notes	638,779			—			—
Principal payments on senior unsecured notes	(700,000		)	—			—
Proceeds from term loans	—			—			181,000
Principal payments on term loans	(145,000		)	—			—
Principal payments on secured debt	(3,436		)	(140,338		)	(4,145		)
Payments of deferred financing costs	(15,598		)	(352		)	(15,337		)
Payments related to extinguishment of debt	(10,502		)	(2,043		)	—
Payment of contingent consideration	—			—			(382		)
Distributions to noncontrolling interests	(316		)	(142		)	(30		)
Preferred stock redemption	—			(143,750		)	—
Issuance of common stock, net	549,328			(499		)	366,800
Dividends paid on common and preferred stock	(335,435		)	(325,220		)	(182,089		)
Net cash (used in) provided by financing activities	(646,180		)	(629,344		)	598,817
Net (decrease) increase in cash, cash equivalents and restricted cash	(10,861		)	(527,252		)	552,046
Effect of foreign currency translation on cash, cash equivalents and restricted cash	346			(539		)	738
Cash, cash equivalents and restricted cash, beginning of period	59,658			587,449			34,665
Cash, cash equivalents and restricted cash, end of period	$	49,143		$	59,658		$	587,449

See accompanying notes to consolidated financial statements.

F-9

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(in thousands)

	Year Ended December 31,
	2019		2018		2017
Supplemental disclosure of cash flow information:
Interest paid	$	123,854	$	137,668	$	69,686
Income taxes paid	$	3,911	$	1,800	$	714
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of business in CCP Merger	$	—	$	—	$	3,726,092
Assumption of indebtedness in CCP Merger	$	—	$	—	$	(1,751,373	)
Stock exchanged in CCP Merger	$	—	$	—	$	(2,052,578	)
Real estate acquired through loan receivable foreclosure	$	—	$	—	$	19,096
Decrease in loans receivable and other investments due to acquisition of real estate	$	—	$	—	$	(6,913	)

See accompanying notes to consolidated financial statements.

F-10

SABRA HEALTH CARE REIT, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.BUSINESS

Overview

Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun (the “Separation Date”). Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants and operators throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in loans receivable; preferred equity investments; and an investment in an unconsolidated joint venture.

On August 17, 2017, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) entered into by the Company, the Operating Partnership, PR Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Merger Sub”), Care Capital Properties, Inc., a Delaware corporation (“CCP”), and Care Capital Properties, L.P. (“CCPLP”), a Delaware limited partnership and wholly owned subsidiary of CCP, CCP merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation (the “CCP Merger”), following which Merger Sub merged with and into the Company, with the Company continuing as the surviving entity (the “Subsequent Merger”), and, simultaneous with the Subsequent Merger, CCPLP merged with and into the Operating Partnership, with the Operating Partnership continuing as the surviving entity.

Pursuant to the Merger Agreement, as of the effective time of the CCP Merger, each share of CCP common stock, par value $0.01 per share, issued and outstanding immediately prior to the effective time of the CCP Merger (other than shares of CCP common stock owned directly by CCP, the Company or their respective subsidiaries, in each case not held on behalf of third parties) was converted into the right to receive 1.123 newly issued shares of Company common stock, par value $0.01 per share, plus cash in lieu of any fractional shares.

The acquisition of CCP has been reflected in the Company’s consolidated financial statements since the effective date of the CCP Merger.

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of December 31, 2019 and 2018 and for the years ended December 31, 2019, 2018 and 2017. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements

F-11

that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of December 31, 2019, the Company determined that it was not the primary beneficiary of any VIEs.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At December 31, 2019 and 2018, none of the Company’s investments in loans were accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of December 31, 2019, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications

Certain amounts in the Company’s consolidated statements of income and consolidated statements of cash flows for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations.

Real Estate Investments and Rental Revenue Recognition

Real Estate Acquisition Valuation

All assets acquired and liabilities assumed in an acquisition of real estate accounted for as a business combination are measured at their acquisition date fair values. For acquisitions of real estate accounted for as an asset acquisition, the fair value of consideration transferred by the Company (including transaction costs) is allocated to all assets acquired and liabilities assumed on a relative fair value basis. The acquisition value of land, building and improvements are included in real estate investments on the accompanying consolidated balance sheets. The acquisition value of above market lease, tenant origination and absorption costs and tenant relationship intangible assets is included in lease intangible assets, net on the accompanying consolidated balance sheets. The acquisition value of below market lease intangible liabilities is included in lease intangible liabilities, net on the accompanying consolidated balance sheets. Acquisition costs associated with real estate acquisitions deemed asset acquisitions are capitalized, and costs associated with real estate acquisitions deemed business combinations are expensed as incurred. The Company capitalized $0.6 million and $0.7 million of acquisition costs during the years ended December 31, 2019 and 2018, respectively. Restructuring costs that do not meet the definition of a liability at the acquisition date are expensed in periods subsequent to the acquisition date. During the years ended December 31, 2019, 2018 and 2017, the Company expensed $0.4 million, $0.6 million and $30.3 million, respectively, of merger and acquisition costs.

Estimates of the fair values of the tangible assets, identifiable intangibles and assumed liabilities require the Company to make significant assumptions to estimate market lease rates, property operating expenses, carrying costs during lease-up periods, discount rates, market absorption periods, and the number of years the property will be held for investment. The Company makes its best estimate based on the Company’s evaluation of the specific characteristics of each tenant’s lease. The use of inappropriate assumptions would result in an incorrect valuation of the Company’s acquired tangible assets, identifiable intangibles and assumed liabilities, which would impact the amount of the Company’s net income.

F-12

Depreciation and Amortization

Real estate costs related to the acquisition and improvement of properties are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term of any property subject to a ground lease. Tenant improvements are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term. Depreciation is discontinued when a property is identified as held for sale. Repair and maintenance costs are charged to expense as incurred and significant replacements and betterments are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate asset. The Company considers the period of future benefit of an asset to determine its appropriate useful life. Depreciation of real estate assets and amortization of tenant origination and absorption costs and tenant relationship lease intangibles are included in depreciation and amortization on the accompanying consolidated statements of income. Amortization of above and below market lease intangibles is included in rental income on the accompanying consolidated statements of income. The Company anticipates the estimated useful lives of its assets by class to be generally as follows: land improvements, five to 20 years; buildings and building improvements, five to 40 years; and furniture and equipment, three to 20 years. Intangibles are generally amortized over the remaining noncancellable lease terms, with tenant relationship intangible amortization periods including extension periods of up to 10 years.

Impairment of Real Estate Investments

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its real estate investments may not be recoverable or realized. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, the Company assesses the recoverability by estimating whether the Company will recover the carrying value of its real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. In some instances, there may be various potential outcomes for an investment and its potential future cash flows. In these instances, the undiscounted future cash flows used to assess recoverability are based on several assumptions and are probability-weighted based on the Company’s best estimates as of the date of evaluation. These assumptions include, among others, cash flow projections, discount rates, market capitalization rates and recent sales data for comparable properties. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its real estate investments, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its real estate investments.

Revenue Recognition

The Company recognizes rental revenue from tenants, including rental abatements, lease incentives and contractual fixed increases attributable to operating leases, on a straight-line basis over the term of the related leases when it is probable that substantially all rents over the life of a lease are collectible. Certain of the Company’s leases provide for contingent rents equal to a percentage of the facility’s revenue in excess of specified base amounts or other thresholds. Such revenue is recognized when actual results reported by the tenant, or estimates of tenant results, exceed the applicable base amount or other threshold.

The Company assesses the collectability of rents on a lease-by-lease basis, and in doing so, considers such things as historical bad debts, tenant creditworthiness, current economic trends, facility operating performance, lease structure, credit enhancements (including guarantees), current developments relevant to a tenant’s business specifically and to its business category generally, and changes in tenants’ payment patterns. The Company’s assessment includes an estimation of a tenant’s ability to fulfill all of its rental obligations over the remaining lease term. In addition, with respect to tenants in bankruptcy, management makes estimates of the expected recovery of pre-petition and post-petition claims in assessing the estimated collectability of the related receivable. If at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received, and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Write-offs of receivables and any recoveries of previously written-off receivables are recorded as adjustments to rental revenue.

Revenue from resident fees and services is recorded monthly as services are provided and includes resident room and care charges, ancillary services charges and other resident charges.

Assets Held for Sale, Dispositions and Discontinued Operations

The Company generally considers real estate to be “held for sale” when the following criteria are met: (i) management commits to a plan to sell the property, (ii) the property is available for sale immediately, (iii) the property is actively being marketed for sale at a price that is reasonable in relation to its current fair value, (iv) the sale of the property within one year is considered probable and (v) significant changes to the plan to sell are not expected. Real estate that is held for sale and its related assets are classified as assets held for sale and are included in accounts receivable, prepaid expenses and other assets,

F-13

net on the accompanying consolidated balance sheets. Secured indebtedness and other liabilities related to real estate held for sale are classified as liabilities related to assets held for sale and are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets. Real estate classified as held for sale is no longer depreciated and is reported at the lower of its carrying value or its estimated fair value less estimated costs to sell. As of December 31, 2019 and 2018, the Company did not have any assets held for sale.

For sales of real estate where the Company has collected the consideration to which it is entitled in exchange for transferring the real estate, the related assets and liabilities are removed from the balance sheet and the resultant gain or loss is recorded in the period in which the transaction closes. Any post-sale involvement is accounted for as separate performance obligations, and when the separate performance obligations are satisfied, the portion of the sales price allocated to each such obligation is recognized.

Additionally, the Company records the operating results related to real estate that has been disposed of or classified as held for sale as discontinued operations for all periods presented if it represents a strategic shift that has or will have a major effect on the Company’s operations and financial results.

Investment in Unconsolidated Joint Venture

The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in the Company’s consolidated statements of income. The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company’s cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings of the joint venture.

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its equity method investments may not be recoverable or realized. When indicators of potential impairment are identified, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period and any estimated debt premiums or discounts. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its equity method investment.

On January 2, 2018, the Company completed its transaction with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, and contributed $352.7 million, before closing costs, to acquire a 49% equity interest in an entity that owned 172 senior housing communities managed by Enlivant (the “Enlivant Joint Venture”). At closing, the Enlivant Joint Venture had outstanding indebtedness of $791.3 million and net working capital of $22.9 million. The joint venture agreement includes an option for the Company to acquire the remainder of the outstanding equity interests in the Enlivant Joint Venture by January 2, 2021 and grants the Company the right of first offer if the Company’s partner in the Enlivant Joint Venture desires to transfer its equity interest (which it may do commencing on January 2, 2020). Sabra also has the right to designate three directors on the seven member board of directors of the Enlivant Joint Venture and has other customary minority rights. During 2019, the Enlivant Joint Venture sold two senior housing communities for gross proceeds of $6.3 million, and the Company recorded an aggregate net loss on sale of real estate related to unconsolidated joint venture of $1.7 million. As of December 31, 2019, the book value of the Company’s investment in the Enlivant Joint Venture was $319.5 million.

Net Investment in Direct Financing Lease

As of December 31, 2019, the Company had a $23.9 million net investment in one skilled nursing/transitional care facility leased to an operator under a direct financing lease, as the tenant is obligated to purchase the property at the end of the lease term. The net investment in direct financing lease is recorded in accounts receivable, prepaid expenses and other assets, net on the accompanying consolidated balance sheets and represents the present value of total rental payments of $4.0 million, plus the estimated unguaranteed residual value of $24.7 million, less the unearned lease income of $4.8 million as of December 31, 2019. Unearned lease income represents the excess of the minimum lease payments and residual value over the cost of the investment. Unearned lease income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured. Income from the Company’s net investment in direct financing lease was $2.7 million, $2.6 million and $1.0 million for the years ended December 31, 2019, 2018 and 2017, respectively, and is reflected in interest and other income on the accompanying consolidated statements of income. Future minimum lease payments contractually due under the direct financing lease at December 31, 2019, were as follows: $2.3 million for 2020 and $2.1 million for 2021.

F-14

Loans Receivable and Interest Income

Loans Receivable

The Company’s loans receivable are reflected at amortized cost on the accompanying consolidated balance sheets. The amortized cost of a loan receivable is the outstanding unpaid principal balance, net of unamortized discounts, costs and fees directly associated with the origination of the loan.

Loans acquired in connection with a business combination are recorded at their acquisition date fair value. The Company determines the fair value of loans receivable based on estimates of expected discounted cash flows, collateral, credit risk and other factors. The Company does not establish a valuation allowance at the acquisition date, as the amount of estimated future cash flows reflects its judgment regarding their uncertainty. The Company recognizes the difference between the acquisition date fair value and the total expected cash flows as interest income using the effective interest method over the life of the applicable loan. The Company immediately recognizes in income any unamortized balances if the loan is repaid before its contractual maturity.

On a quarterly basis, the Company evaluates the collectability of its loan portfolio, including related interest income receivable, and establishes a reserve for loan losses. The Company’s evaluation includes reviewing credit quality indicators such as payment status, changes affecting the underlying real estate collateral (for collateral dependent loans), changes affecting the operations of the facilities securing the loans, and national and regional economic factors. The reserve for loan losses is a valuation allowance that reflects management’s estimate of loan losses inherent in the loan portfolio as of the balance sheet date. The reserve is adjusted through provision for doubtful accounts, straight-line rental income and loan losses on the Company’s consolidated statements of income and is decreased by charge-offs to specific loans when losses are confirmed. The reserve for loan losses includes an asset-specific component and a portfolio-based component.

An asset-specific reserve relates to reserves for losses on loans considered impaired and interest income receivable that is deemed uncollectible. The Company considers a loan to be impaired when, based upon current information and events, management believes that it is probable that the Company will be unable to collect all amounts due under the contractual terms of the loan agreement resulting from the borrower’s failure to repay contractual amounts due, the granting of a concession by the Company or the expectation that the Company will receive assets with fair values less than the carrying value of the loan in satisfaction of the loan. If a loan is considered to be impaired, a reserve is established when the carrying value of that loan is greater than the present value of payments expected to be received, the observable market prices for similar instruments, the estimated fair value of the collateral (for loans that are dependent on the collateral for repayment) or other amounts expected to be received in satisfaction of the loan.

A portfolio-based reserve covers the pool of loans that do not have asset-specific reserves. A provision for loan losses is recorded when available information as of each balance sheet date indicates that it is probable that a loss occurred in the pool of loans and the amount of the loss can be reasonably estimated, but the Company does not know which specific loans within the pool will ultimately result in losses. The required reserve balances for this pool of loans is derived based on estimated probabilities of default and estimated loss severities assuming a default occurs.

Interest Income

Interest income on the Company’s loans receivable is recognized on an accrual basis over the life of the investment using the interest method. Direct loan origination costs are amortized over the term of the loan as an adjustment to interest income. When concerns exist as to the ultimate collection of principal or interest due under a loan, the loan is placed on nonaccrual status, and the Company will not recognize interest income until the cash is received, or the loan returns to accrual status. If the Company determines that the collection of interest according to the contractual terms of the loan or through the receipts of assets in satisfaction of contractual amounts due is probable, the Company will resume the accrual of interest. In instances where borrowers are in default under the terms of their loans, the Company may continue recognizing interest income provided that all amounts owed under the contractual terms of the loan, including accrued and unpaid interest, do not exceed the estimated fair value of the collateral, less costs to sell.

Preferred Equity Investments and Preferred Return

Preferred equity investments are accounted for at unreturned capital contributions, plus accrued and unpaid preferred returns. The Company recognizes preferred return income on a monthly basis based on the outstanding investment including any previously accrued and unpaid return. As a preferred member of the preferred equity joint ventures in which the Company participates, the Company is not entitled to share in the joint venture’s earnings or losses. Rather, the Company is entitled to receive a preferred return, which is deferred if the cash flow of the joint venture is insufficient to currently pay the accrued preferred return.

F-15

Cash and Cash Equivalents

The Company considers all short-term (with an original maturity of three months or less), highly-liquid investments utilized as part of the Company’s cash-management activities to be cash equivalents. Cash equivalents may include cash and short-term investments. Short-term investments are stated at cost, which approximates fair value.

The Company’s cash and cash equivalents balance exceeded federally insurable limits as of December 31, 2019. To date, the Company has experienced no loss or lack of access to cash in its operating accounts. The Company has a corporate banking relationship with Bank of America, N.A. in which it deposits the majority of its cash.

Restricted Cash

Restricted cash primarily consists of amounts held by an exchange accommodation titleholder or by secured debt lenders to provide for future real estate tax expenditures, tenant improvements and capital expenditures. Pursuant to the terms of the Company’s leases with certain tenants, the Company has assigned its interests in certain of these restricted cash accounts with secured debt lenders to the tenants, and this amount is included in accounts payable and accrued liabilities on the Company’s consolidated balance sheets. As of December 31, 2019 and 2018, restricted cash totaled $10.0 million and $9.4 million, respectively, and restricted cash obligations totaled $5.6 million and $5.5 million, respectively.

Stock-Based Compensation

Stock-based compensation expense for stock-based awards granted to Sabra’s employees and its non-employee directors is recognized in the statements of income based on the estimated grant date fair value, as adjusted. Compensation expense for awards with graded vesting schedules is generally recognized ratably over the period from the grant date to the date when the award is no longer contingent on the employee providing additional services. Compensation expense for awards with performance-based vesting conditions is recognized based on the Company’s estimate of the ultimate value of such award after considering the Company’s expectations of future performance. Forfeitures of stock-based awards are recognized as they occur.

Deferred Financing Costs

Deferred financing costs representing fees paid to third parties are amortized over the terms of the respective financing agreements using the interest method. Deferred financing costs related to secured debt, term loans and senior unsecured notes are recorded as a reduction of the related debt liability, and deferred financing costs related to the revolving credit facility are recorded in accounts receivable, prepaid expenses and other assets, net. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financings that do not close are expensed in the period in which it is determined that the financing will not close.

Income Taxes

The Company elected to be treated as a REIT with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. The Company believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. To qualify as a REIT, the Company must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of the Company’s annual REIT taxable income to stockholders (which is computed without regard to the dividends-paid deduction or net capital gains and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, the Company generally will not be subject to federal income tax on income that it distributes as dividends to its stockholders. If the Company fails to qualify as a REIT in any taxable year, it will be subject to U.S. federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost, unless the Internal Revenue Service grants the Company relief under certain statutory provisions. Such an event could materially and adversely affect the Company’s net income and net cash available for distribution to stockholders. However, the Company believes that it is organized and operates in such a manner as to qualify for treatment as a REIT.

 As a result of certain investments, the Company now records income tax expense or benefit with respect to certain of its entities that are taxed as taxable REIT subsidiaries under provisions similar to those applicable to regular corporations and not under the REIT provisions.

     The Company accounts for deferred income taxes using the asset and liability method and recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company’s financial statements or tax returns. Under this method, the Company determines deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in the deferred tax liability that results from a change in

F-16

circumstances, and that causes a change in the Company’s judgment about expected future tax consequences of events, is included in the tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss and tax credit carryforwards. A valuation allowance is provided if the Company believes it is more likely than not that all or some portion of the deferred tax asset will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, and that causes a change in the Company’s judgment about the realizability of the related deferred tax asset, is included in the tax provision when such changes occur. 

The Company evaluates its tax positions using a two step approach: step one (recognition) occurs when the Company concludes that a tax position, based solely on its technical merits, is more likely than not to be sustained upon examination, and step two (measurement) is only addressed if step one has been satisfied (i.e., the position is more likely than not to be sustained). Under step two, the tax benefit is measured as the largest amount of benefit (determined on a cumulative probability basis) that is more likely than not to be realized upon ultimate settlement. The Company will recognize tax penalties relating to unrecognized tax benefits as additional tax expense.

Foreign Currency

Certain of the Company’s subsidiaries’ functional currencies are the local currencies of their respective foreign jurisdictions. The Company translates the results of operations of its foreign subsidiaries into U.S. dollars using average rates of exchange in effect during the period presented, and it translates balance sheet accounts using exchange rates in effect at the end of the period presented. The Company records resulting currency translation adjustments in accumulated other comprehensive income (loss), a component of stockholders’ equity, on its consolidated balance sheets, and it records foreign currency transaction gains and losses as a component of interest and other income on its consolidated statements of income.

Derivative Instruments

The Company uses certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at inception, the Company must make an assessment that the transaction that the Company intends to hedge is probable of occurring, and this assessment must be updated each reporting period.

The Company recognizes all derivative instruments as assets or liabilities on the consolidated balance sheets at their fair value. For derivatives designated and qualified as a hedge, the change in fair value of the effective portion of the derivatives is recognized in accumulated other comprehensive income (loss). Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria for hedge accounting would be recognized in earnings.

The Company formally documents all relationships between hedging instruments and hedged items, as well as its risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific transactions, as well as recognizing obligations or assets on the consolidated balance sheets. The Company also assesses and documents, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying transaction will not occur, the Company would discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the then-current fair value of the derivative.

Fair Value Measurements

Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:

• Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;

• Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and

• Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.

F-17

When available, the Company utilizes quoted market prices from an independent third-party source to determine fair value and classifies such items as Level 1 or Level 2. In instances where the market for a financial instrument is not active, regardless of the availability of a nonbinding quoted market price, observable inputs might not be relevant and could require the Company to make a significant adjustment to derive a fair value measurement. Additionally, in an inactive market, a market price quoted from an independent third party may rely more on models with inputs based on information available only to that independent third party. When the Company determines the market for a financial instrument owned by the Company to be illiquid or when market transactions for similar instruments do not appear orderly, the Company may use several valuation sources (including internal valuations, discounted cash flow analysis and quoted market prices) to establish a fair value. If more than one valuation source is used, the Company will assign weights to the various valuation sources. Additionally, when determining the fair value of liabilities in circumstances in which a quoted price in an active market for an identical liability is not available, the Company measures fair value using (i) a valuation technique that uses the quoted price of the identical liability when traded as an asset or quoted prices for similar liabilities or similar liabilities when traded as assets or (ii) another valuation technique that is consistent with the principles of fair value measurement, such as the income approach or the market approach.

Changes in assumptions or estimation methodologies can have a material effect on these estimated fair values. In this regard, the derived fair value estimates cannot be substantiated by comparison to independent markets and, in many cases, may not be realized in an immediate settlement of the instrument.

The Company considers the following factors to be indicators of an inactive market: (i) there are few recent transactions, (ii) price quotations are not based on current information, (iii) price quotations vary substantially either over time or among market makers (for example, some brokered markets), (iv) indexes that previously were highly correlated with the fair values of the asset or liability are demonstrably uncorrelated with recent indications of fair value for that asset or liability, (v) there is a significant increase in implied liquidity risk premiums, yields, or performance indicators (such as delinquency rates or loss severities) for observed transactions or quoted prices when compared with the Company’s estimate of expected cash flows, considering all available market data about credit and other nonperformance risk for the asset or liability, (vi) there is a wide bid-ask spread or significant increase in the bid-ask spread, (vii) there is a significant decline or absence of a market for new issuances (that is, a primary market) for the asset or liability or similar assets or liabilities, and (viii) little information is released publicly (for example, a principal-to-principal market).

The Company considers the following factors to be indicators of non-orderly transactions: (i) there was not adequate exposure to the market for a period before the measurement date to allow for marketing activities that are usual and customary for transactions involving such assets or liabilities under current market conditions, (ii) there was a usual and customary marketing period, but the seller marketed the asset or liability to a single market participant, (iii) the seller is in or near bankruptcy or receivership (that is, distressed), or the seller was required to sell to meet regulatory or legal requirements (that is, forced), and (iv) the transaction price is an outlier when compared with other recent transactions for the same or similar assets or liabilities.

Per Share Data

Basic earnings per common share is computed by dividing net income applicable to common stockholders by the weighted average number of shares of common stock and common equivalents outstanding during the period. Diluted earnings per common share is calculated by including the effect of dilutive securities. See Note 14, “Earnings Per Common Share.”

Industry Segments

The Company has one reportable segment consisting of investments in healthcare-related real estate properties.

Beds, Units and Other Measures

The number of beds, units and other measures used to describe the Company’s real estate investments included in the Notes to Consolidated Financial Statements are presented on an unaudited basis.

Recently Issued Accounting Standards Update

Adopted

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”). Topic 842 supersedes guidance related to accounting for leases and provides for the recognition of lease assets and lease liabilities by lessees for those leases previously classified as operating leases under GAAP. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a

F-18

lease. Topic 842 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. Topic 842 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company elected to adopt Topic 842 on January 1, 2019 using the modified retrospective transition method, which permits application of the new standard on the adoption date as opposed to the earliest comparative period presented in the financial statements. In addition, the Company elected to use the available practical expedient package, and therefore did not reassess classification of its existing leases.

Additionally, the Company has elected a practical expedient not to separate lease and nonlease components (such as services rendered), which can only be applied to leasing arrangements for which (i) the timing and pattern of transfer are the same for the lease and nonlease components and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Under this practical expedient, contracts that are predominantly lease-based would be accounted for under Topic 842, and contracts that are predominantly service-based would be accounted for under Topic 606, Revenue from Contracts with Customers. As a result of electing this practical expedient, the Company, beginning January 1, 2019, recognizes revenue from its leased skilled nursing/transitional care facilities, senior housing communities, and specialty hospitals and other facilities under Topic 842 and recognizes revenue from its Senior Housing - Managed communities under the Revenue ASUs (codified under Topic 606). Upon adoption of Topic 842, the Company recognized its operating leases for which it is the lessee, mainly its corporate office lease and ground leases, on its consolidated balance sheets, as a lease liability of $10.0 million, included in accounts payable and accrued liabilities on the condensed consolidated balance sheets, and a corresponding right-of-use asset, included in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. As of December 31, 2019, the balances of the lease liability and the corresponding right-of-use asset were $9.8 million and $9.3 million, respectively.

The Company assesses the collectability of rental revenues on a lease-by-lease basis. Prior to the adoption of Topic 842, the Company recorded rental revenue and receivables to the extent those amounts were expected to be collected, irrespective of the Company’s determination of the collectability of substantially all rents over the life of a lease. Upon adoption of Topic 842, if at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Upon adoption of Topic 842 and as of the adoption date, the Company recorded a $32.5 million reduction in equity and accounts receivable due to the cumulative effect of this change. This reduction consisted of $17.5 million of straight-line rental income receivables and $15.0 million of cash rent receivables, although management believes the $15.0 million of cash rent receivables are collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Under Topic 842, future write-offs of receivables and any recoveries of previously written-off receivables will be recorded as adjustments to rental revenue.

Furthermore, Topic 842 requires lessors to exclude from variable payments lessor costs paid by lessees directly to third parties. In contrast, lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized $17.6 million of variable lease revenue and the associated expense during the year ended December 31, 2019.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold under current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which amends ASU 2016-13 to clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, and instead, impairment of such receivables should be accounted for in accordance with Topic 842, Leases. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2019-11”), which amends ASU 2016-13 to clarify or address stakeholders’ specific issues about certain aspects of ASU 2016-13. ASU 2016-13, ASU 2018-19 and ASU 2019-11 are effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in these updates through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company adopted ASU 2016-13, ASU 2018-19 and ASU 2019-11 on January 1, 2020. The adoption of these standards did not have a material impact on the Company’s consolidated financial statements.

F-19

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 updates the fair value measurement disclosure requirements by (i) eliminating certain requirements, including disclosure of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements, (ii) modifying certain requirements, including clarifying that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date and (iii) adding certain requirements, including disclosure of the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted for any eliminated or modified disclosures. The Company adopted ASU 2018-13 on January 1, 2020. The Company does not expect the adoption of ASU 2018-13 to have a material impact on its consolidated financial statements.

3. RECENT REAL ESTATE ACQUISITIONS

During the year ended December 31, 2019, the Company acquired two senior housing communities, two specialty hospitals/other facilities and one Senior Housing - Managed community. During the year ended December 31, 2018, the Company acquired 11 Senior Housing - Managed communities, eight senior housing communities and two skilled nursing/transitional care facilities. The consideration was allocated as follows (in thousands):

	Year Ended December 31,
	2019		2018
Land	$	10,049	$	29,712
Building and improvements	39,434		232,893
Tenant origination and absorption costs intangible assets	1,438		2,046
Tenant relationship intangible assets	215		677
Total consideration	$	51,136	$	265,328

The tenant origination and absorption costs intangible assets and tenant relationship intangible assets acquired in connection with these acquisitions had weighted-average amortization periods as of the respective dates of acquisition of 6 years and 21 years, respectively, for acquisitions completed during the year ended December 31, 2019, and 13 years and 22 years, respectively, for acquisitions completed during the year ended December 31, 2018.

For the year ended December 31, 2019, the Company recognized $0.8 million and $0.4 million of total revenues and net income attributable to common stockholders, respectively, from the properties acquired during the year ended December 31, 2019. For the year ended December 31, 2018, the Company recognized $44.0 million and $14.0 million of total revenues and net income attributable to common stockholders, respectively, from the properties acquired during the year ended December 31, 2018.

4. REAL ESTATE PROPERTIES HELD FOR INVESTMENT

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of December 31, 2019  

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	296	33,290	$	3,701,666	$	(306,565	)	$	3,395,101
Senior Housing - Leased (1)	62	3,820	630,688		(72,278		)	558,410
Senior Housing - Managed (1)	46	4,809	907,771		(112,893		)	794,878
Specialty Hospitals and Other	25	1,193	639,721		(47,124		)	592,597
	429	43,112	5,879,846		(538,860		)	5,340,986
Corporate Level			737		(353		)	384
			$	5,880,583	$	(539,213	)	$	5,341,370

F-20

As of December 31, 2018

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	335	37,628	$	4,094,484	$	(224,942	)	$	3,869,542
Senior Housing - Leased (1)	90	7,332	1,237,790		(125,902		)	1,111,888
Senior Housing - Managed (1)	23	1,603	301,739		(19,537		)	282,202
Specialty Hospitals and Other	22	1,085	621,236		(31,640		)	589,596
	470	47,648	6,255,249		(402,021		)	5,853,228
Corporate Level			634		(317		)	317
			$	6,255,883	$	(402,338	)	$	5,853,545

⁽¹⁾ During the year ended December 31, 2019, the Company transitioned 21 senior housing communities to its Senior Housing - Managed portfolio.

	December 31, 2019			December 31, 2018
Building and improvements	$	5,042,435		$	5,388,102
Furniture and equipment	239,229			237,145
Land improvements	1,534			1,254
Land	597,385			629,382
	5,880,583			6,255,883
Accumulated depreciation	(539,213		)	(402,338		)
	$	5,341,370		$	5,853,545

Operating Leases

As of December 31, 2019, the substantial majority of the Company’s real estate properties (excluding 46 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 15 years. As of December 31, 2019, the leases had a weighted-average remaining term of eight years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee or other parties related to the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets and totaled $10.5 million and $12.4 million as of December 31, 2019 and 2018, respectively, and letters of credit deposited with the Company totaled approximately $83 million and $98 million as of December 31, 2019 and 2018, respectively. In addition, the Company’s tenants have deposited with the Company $14.3 million and $17.5 million as of December 31, 2019 and 2018, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations.

As of December 31, 2018, the Company had a $1.3 million reserve for unpaid cash rental income and a $35.8 million reserve associated with accumulated straight-line rental income. Upon adoption of Topic 842 on January 1, 2019, if at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received, and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. As such, the Company no longer records reserves for unpaid cash rental income or accumulated straight-line rental income.

On February 15, 2019, the Company entered into a settlement agreement with Senior Care Centers in connection with the notices of default and lease termination issued by the Company to Senior Care Centers during the third quarter of 2018. In accordance with the order entered by the bankruptcy court in March 2019, the settlement agreement provided for the discharge by the Company of its claims against Senior Care Centers in exchange for $9.5 million of settlement payments, a portion of which was applied to pay post-petition rent. The Company recorded $6.2 million of such post-petition rent during the year ended December 31, 2019. On April 1, 2019, the Company completed the sale of 28 facilities (26 skilled nursing/transitional care facilities and two senior housing communities) previously operated by Senior Care Centers and received gross sales proceeds of $282.5 million. In connection with the sale, the Company entered into an agreement to indemnify the buyer from certain costs, expenses and liabilities related to the historical operations of the facilities by Senior Care Centers. In May 2019, the Company transitioned eight facilities previously operated by Senior Care Centers to a current operator in the Sabra portfolio, and the Company subsequently sold the remaining two facilities previously operated by Senior Care Centers (one

F-21

during the fourth quarter of 2019 and one in January 2020). During the year ended December 31, 2019, the Company recorded an impairment charge of $95.2 million related to the Senior Care Centers facilities, which includes $10.2 million related to the Company’s estimated contractual indemnification obligations. As of December 31, 2019, the Company adjusted its contractual indemnification obligations estimate down to $8.8 million.

On December 19, 2018, the Company entered into a letter of intent to terminate its triple-net master lease with Holiday Retirement (“Holiday”) with respect to all 21 senior housing communities subject to the master lease (the “Holiday Communities”) and concurrently enter into management agreements pursuant to which Holiday would manage the Holiday Communities. On April 1, 2019, the Company completed the conversion of the Holiday Communities to its Senior Housing - Managed portfolio and recognized lease termination income of $66.9 million, which includes a $57.2 million lease termination payment received in exchange for terminating the Holiday master lease and a $9.7 million gain related to the assumption of fixed assets and liabilities.

The Company monitors the creditworthiness of its tenants by reviewing credit ratings (if available) and evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including the evaluation of any parent guarantees (or the guarantees of other related parties) of tenant lease obligations. As formal credit ratings may not be available for most of the Company’s tenants, the primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio or the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.

For the year ended December 31, 2019, no tenant relationship represented 10% or more of the Company’s total revenues.

The future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):

As of December 31, 2019

2020	$	428,101
2021	427,791
2022	404,568
2023	389,810
2024	380,944
Thereafter	1,672,008
	$	3,703,222

As of December 31, 2018

2019	$	465,766
2020	456,207
2021	452,346
2022	454,216
2023	437,277
Thereafter	2,407,064
	$	4,672,876

Senior Housing - Managed Communities

The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The

F-22

Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services includes ancillary service revenue of $0.8 million, $0.5 million and $0.3 million for the years ended December 31, 2019, 2018 and 2017, respectively.

5. IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

2019

Impairment of Real Estate

During the year ended December 31, 2019, the Company recognized a $121.8 million real estate impairment, of which amount $95.2 million related to the 28 Senior Care Centers facilities sold on April 1, 2019 and three additional Senior Care Centers facilities, two of which were subsequently sold, and the remaining $26.6 million related to six skilled nursing/transitional care facilities, five of which were subsequently sold, and four senior housing communities.

Dispositions

During the year ended December 31, 2019, the Company completed the sale of 39 skilled nursing/transitional care facilities and seven senior housing communities for aggregate consideration, net of closing costs, of $323.6 million. The net carrying value of the assets and liabilities of these facilities was $321.3 million, which resulted in an aggregate $2.3 million net gain on sale.

Excluding the net gain on sale and real estate impairment, the Company recognized $2.2 million, $19.1 million and $13.0 million of net income during the years ended December 31, 2019, 2018 and 2017, respectively, from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

2018

Impairment of Real Estate

During the year ended December 31, 2018, the Company recognized a $1.4 million real estate impairment, of which $0.9 million related to one skilled nursing/transitional care facility and $0.5 million related to one senior housing community sold during the year.

Dispositions

During the year ended December 31, 2018, the Company completed the sale of 51 skilled nursing/transitional care facilities, six senior housing communities and one Senior Housing - Managed community for aggregate consideration, net of closing costs, of $382.6 million. The net carrying value of the assets and liabilities of these facilities was $254.4 million, resulting in an aggregate $128.2 million net gain on sale.

Excluding the net gain on sale and real estate impairment to one senior housing community sold during the year, the Company recognized $23.6 million and $47.1 million of net income during the years ended December 31, 2018 and 2017, respectively, from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

2017

Impairment of Real Estate

During the year ended December 31, 2017, the Company recognized a $1.3 million real estate impairment related to one skilled nursing/transitional care facility.

Dispositions

During the year ended December 31, 2017, the Company completed the sale of 31 skilled nursing/transitional care facilities and one senior housing community for aggregate consideration, net of closing costs, of $150.2 million. The net carrying value of the assets and liabilities of these facilities was $98.2 million, resulting in an aggregate $52.0 million net gain on sale.

F-23

Excluding the net gain on sale, the Company recognized $12.6 million of net income during the year ended December 31, 2017 from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

6. INTANGIBLE ASSETS AND LIABILITIES

The following table summarizes the Company’s intangible assets and liabilities as of December 31, 2019 and 2018 (in thousands):

	December 31,
	2019			2018
Lease Intangible Assets:
Above market leases	$	51,040		$	61,572
Tenant origination and absorption costs	65,234			73,323
Tenant relationship	23,150			26,936
Gross lease intangible assets	139,424			161,831
Accumulated amortization	(37,915		)	(30,734		)
Lease intangible assets, net	$	101,509		$	131,097
Lease Intangible Liabilities:
Below market leases	$	99,133		$	102,098
Accumulated amortization	(29,187		)	(18,372		)
Lease intangible liabilities, net	$	69,946		$	83,726

The following is a summary of real estate intangible amortization income (expense) for the years ended December 31, 2019, 2018 and 2017 (in thousands): 

	Year Ended December 31,
	2019			2018			2017
Increase (decrease) to rental income related to above/below market leases, net	$	508		$	(7,701	)	$	912
Depreciation and amortization related to tenant origination and absorption costs and tenant relationship	(17,674		)	(16,118		)	(11,822		)

The remaining unamortized balance for these outstanding intangible assets and liabilities as of December 31, 2019 will be amortized for the years ending December 31 as follows (dollars in thousands):

	Lease Intangible Assets		Lease Intangible Liabilities
2020	$	14,140	$	12,221
2021	11,782		8,012
2022	11,441		7,269
2023	9,702		7,269
2024	9,061		7,168
Thereafter	45,383		28,007
	$	101,509	$	69,946
Weighted-average remaining amortization period	10.5 years		8.9 years

F-24

7. LOANS RECEIVABLE AND OTHER INVESTMENTS

As of December 31, 2019 and 2018, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

											December 31, 2019
Investment	Quantity as of December 31, 2019	Property Type	Principal Balance as of December 31, 2019 (1)		Book Value as of December 31, 2019			Book Value as of December 31, 2018			Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of December 31, 2019
Loans Receivable:
Mortgage	1	Specialty Hospital	$	19,000	$	19,000		$	18,577		10.0	%	10.0	%	01/31/27
Construction	1	Senior Housing	2,468		2,487			4,629			8.0	%	7.8	%	09/30/22
Mezzanine	—	Skilled Nursing	—		—			2,188			N/A		N/A		N/A
Other	16	Multiple	46,059		42,147			45,324			6.8	%	7.0	%	09/23/19- 08/31/28
	18		67,527		63,634			70,718			7.8	%	7.9	%
Loan loss reserve			—		(564		)	(1,258		)
			$	67,527	$	63,070		$	69,460
Other Investments:
Preferred Equity	9	Skilled Nursing / Senior Housing	43,893		44,304			44,262			12.0	%	12.0	%	N/A
Total	27		$	111,420	$	107,374		$	113,722		9.4	%	9.6	%

⁽¹⁾  Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

As of December 31, 2019 and 2018, the Company had four and seven loans receivable investments, respectively, with an aggregate principal balance of $2.3 million and $27.7 million, respectively, that were considered to have deteriorated credit quality. As of December 31, 2019 and 2018, the book value of the outstanding loans with deteriorated credit quality was $0.8 million and $4.2 million, respectively. During the year ended December 31, 2019, three loans with deteriorated credit quality were repaid.

The following table presents changes in the accretable yield for the years ended December 31, 2019 and 2018 (in thousands):

	Year Ended December 31,
	2019			2018
Accretable yield, beginning of period	$	449		$	2,483
Accretion recognized in earnings	(377		)	(2,761		)
Reduction due to payoff	(33		)	—
Net reclassification from nonaccretable difference	—			727
Accretable yield, end of period	$	39		$	449

During the year ended December 31, 2019, the Company recorded a $1.2 million provision for specific loan losses and increased its portfolio-based loan loss reserve by $4,000.

As of December 31, 2019, the Company had no asset-specific loan loss reserve and a $0.6 million portfolio-based loan loss reserve. As of December 31, 2019, the Company did not consider any loans receivable investments to be impaired. As of December 31, 2019, two loans receivable investments with no book value were on nonaccrual status. As of December 31, 2019, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

During the year ended December 31, 2018, the Company recorded a $0.7 million provision for asset-specific loan losses and increased its portfolio-based loan loss reserve by $0.5 million.

F-25

As of December 31, 2018, the Company had a $0.7 million asset-specific loan loss reserve, and the portfolio-based loan loss reserve was $0.6 million. As of December 31, 2018, the Company considered one loan receivable investment to be impaired, which had a principal balance of $1.3 million and $1.4 million as of December 31, 2018 and 2017, respectively. As of December 31, 2018, two loans receivable investments with an aggregate book value of $1.3 million were on nonaccrual status. Additionally, as of December 31, 2018, the Company recognized interest income related to one loan receivable investment, with a book value of $4.3 million, that was more than 90 days past due. As of December 31, 2018, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

8. DEBT

Secured Indebtedness

The Company’s secured debt consists of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of December 31, 2019 (1)		Principal Balance as of December 31, 2018 (1)		Weighted Average Interest Rate at December 31, 2019 (2)		Maturity Date
Fixed Rate	$	114,777	$	117,464	3.67	%	December 2021 -  August 2051

⁽¹⁾  Principal balance does not include deferred financing costs, net of $1.7 million and $1.8 million as of December 31, 2019 and 2018, respectively.

⁽²⁾  Weighted average interest rate includes private mortgage insurance.

During the year ended December 31, 2018, the Company (i) prepaid a $98.5 million variable rate secured term loan and recognized a $2.0 million loss on extinguishment of debt related to prepayment penalty fees associated with the early repayment of the loan and (ii) repaid $37.6 million of fixed rate debt secured by facilities sold during the year ended December 31, 2018 and recognized a $0.9 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with this repayment.

Senior Unsecured Notes

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of December 31,
Title	Maturity Date	2019 (1)		2018 (1)
5.5% senior unsecured notes due 2021 (“2021 Notes”)	February 1, 2021	$	—	$	500,000
5.375% senior unsecured notes due 2023 (“2023 Notes”)	June 1, 2023	—		200,000
4.80% senior unsecured notes due 2024 (“2024 Notes”)	June 1, 2024	300,000		—
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	500,000		500,000
5.38% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
3.90% senior unsecured notes due 2029 (“2029 Notes”)	October 15, 2029	350,000		—
		$	1,250,000	$	1,300,000

⁽¹⁾  Principal balance does not include premium, net of $7.6 million and deferred financing costs, net of $8.8 million as of December 31, 2019 and does not include premium, net of $14.5 million and deferred financing costs, net of $7.1 million as of December 31, 2018.

 5.5% Notes Due 2021. On January 23, 2014, the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company (the “Issuers”), issued $350.0 million aggregate principal amount of 5.5% senior unsecured notes due 2021 (the “Original 2021 Notes”), and on October 10, 2014, they issued $150.0 million aggregate principal amount of 5.5% senior unsecured notes due 2021, which were treated as a single class with, and had the same terms as, the Original 2021 Notes (the additional notes and the Original 2021 Notes, together, the “2021 Notes”). The 2021 Notes accrued interest at a rate of 5.5% per annum payable semiannually on February 1 and August 1 of each year.

On June 29, 2019, the Issuers redeemed all $500.0 million aggregate principal amount outstanding of the 2021 Notes at a cash redemption price of 101.375% of the principal amount being redeemed, plus accrued and unpaid interest. The redemption resulted in $10.1 million of redemption related costs and write-offs for the year ended December 31, 2019, consisting of $6.9 million in payments made to noteholders and legal fees for early redemption and $3.2 million of write-offs associated with unamortized deferred financing and premium costs. These amounts are included in loss on extinguishment of debt on the accompanying consolidated statements of income.

F-26

5.375% Notes Due 2023. On May 23, 2013, the Issuers issued $200.0 million aggregate principal amount of 5.375% senior unsecured notes due 2023 (the “2023 Notes”). The 2023 Notes accrued interest at a rate of 5.375% per annum payable semiannually on June 1 and December 1 of each year.

On October 27, 2019, the Issuers redeemed all $200.0 million aggregate principal amount outstanding of the 2023 Notes at a cash redemption price of 101.792% of the principal amount being redeemed, plus accrued and unpaid interest. The redemption resulted in $5.6 million of redemption related costs and write-offs for the year ended December 31, 2019, consisting of $3.6 million in payments made to noteholders and legal fees for early redemption and $2.0 million of write-offs associated with unamortized deferred financing costs. These amounts are included in loss on extinguishment of debt on the accompanying consolidated statements of income.

4.80% Notes Due 2024. On May 29, 2019, the Issuers completed an underwritten public offering of $300.0 million aggregate principal amount of 4.80% senior unsecured notes due 2024 (the “2024 Notes”). The net proceeds were $295.3 million after deducting underwriting discounts and other offering expenses. The net proceeds, together with borrowings under the Revolving Credit Facility, were used to redeem the 2021 Notes as discussed above. The 2024 Notes accrue interest at a rate of 4.80% per annum payable semiannually on June 1 and December 1 of each year. Upon redemption of the 2023 Notes as discussed above, Sabra Capital Corporation’s obligations as a co-issuer under the 2024 Notes were automatically released and discharged.

The 2024 Notes are redeemable at the option of the Operating Partnership, in whole or in part at any time and from time to time, prior to May 1, 2024, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date, plus a make-whole premium. The Operating Partnership may also redeem the 2024 Notes on or after May 1, 2024, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date. Assuming the 2024 Notes are not redeemed, the 2024 Notes mature on June 1, 2024.

5.125% Notes Due 2026. In connection with the CCP Merger, on August 17, 2017, the Operating Partnership assumed $500.0 million aggregate principal amount of 5.125% senior unsecured notes due 2026 (the “2026 Notes”) issued by Care Capital Properties, LP in July 2016. The 2026 Notes accrue interest at a rate of 5.125% per annum payable semiannually on February 15 and August 15 of each year.

The Operating Partnership may, at its option, redeem the 2026 Notes at any time in whole or from time to time in part prior to their stated maturity. The redemption price for 2026 Notes that are redeemed will be equal to (i) 100% of their principal amount, together with accrued and unpaid interest thereon, if any, to (but excluding) the date of redemption, plus, (ii) if redeemed prior to May 15, 2026, a make-whole premium. Assuming the 2026 Notes are not redeemed, the 2026 Notes mature on August 15, 2026.

5.38% Notes Due 2027. In connection with the CCP Merger, on August 17, 2017, the Operating Partnership assumed $100.0 million aggregate principal amount of unregistered 5.38% senior unsecured notes due 2027 (the “2027 Notes”) issued by Care Capital Properties, LP in May 2016. The 2027 Notes accrue interest at a rate of 5.38% per annum payable semiannually on May 17 and November 17 of each year.

The Operating Partnership may prepay the 2027 Notes, in whole at any time or in part from time to time, at 100% of the principal amount to be prepaid plus a make-whole premium. Assuming the 2027 Notes are not redeemed, the 2027 Notes mature on May 17, 2027.

3.90% Notes Due 2029. On October 7, 2019, the Issuers completed an underwritten public offering of $350.0 million aggregate principal amount of 3.90% senior unsecured notes due 2029 (the “2029 Notes”). The net proceeds were $340.5 million after deducting underwriting discounts and other offering expenses. A portion of the net proceeds was used to redeem all of the 2023 Notes as discussed above, and the remaining net proceeds were used to repay borrowings outstanding on the Revolving Credit Facility. The 2029 Notes accrue interest at a rate of 3.90% per annum payable semiannually on April 15 and October 15 of each year. Upon redemption of the 2023 Notes as discussed above, Sabra Capital Corporation’s obligations as a co-issuer under the 2029 Notes were automatically released and discharged.

The 2029 Notes are redeemable at the option of the Operating Partnership, in whole or in part at any time and from time to time, prior to July 15, 2029, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date, plus a make-whole premium. The Operating Partnership may also redeem the 2029 Notes on or after July 15, 2029, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date. Assuming the 2029 Notes are not redeemed, the 2029 Notes mature on October 15, 2029.

F-27

The obligations under the 2024 Notes and 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes and 2029 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances.  See Note 15, “Summarized Consolidating Information,” for additional information concerning the circumstances pursuant to which the guarantors will be automatically and unconditionally released from their obligations under the guarantees.

The indenture governing the 2024 Notes contains restrictive covenants that, among other things, restrict the ability of Sabra, the Issuers and their restricted subsidiary to: (i) incur or guarantee additional indebtedness; (ii) incur or guarantee secured indebtedness; and (iii) merge or consolidate or sell all or substantially all of their assets. The indenture governing the 2024 Notes also provides for customary events of default, including, but not limited to, the failure to make payments of interest or premium, if any, on, or principal of, the 2024 Notes, the failure to comply with certain covenants and agreements specified in the indenture for a period of time after notice has been provided, the acceleration of other indebtedness resulting from the failure to pay principal on such other indebtedness prior to its maturity, and certain events of insolvency. If any event of default occurs, the principal of, premium, if any, and accrued interest on all the then-outstanding 2024 Notes may become due and payable immediately. The indenture governing the 2024 Notes requires Sabra, the Issuers and their restricted subsidiary to maintain Total Unencumbered Assets (as defined in the indentures) of at least 150% of the Company’s unsecured indebtedness.

The indenture governing the 2026 Notes contains certain covenants that, among other things, limits the ability of Sabra, the Issuers and their subsidiaries to: (i) consummate a merger, consolidate or sell all or substantially all of our consolidated assets and (ii) incur secured or unsecured indebtedness. In addition, Sabra, the Operating Partnership and their subsidiaries are required to maintain at all times consolidated unencumbered total asset value in an amount not less than 150% of the aggregate outstanding principal amount of the Company’s consolidated unsecured debt.

The agreement governing the 2027 Notes provides for customary events of default, including, but not limited to, the failure to make payments of interest or premium, if any, on, or principal of, the 2027 Notes, the failure to comply with certain covenants and agreements specified in the agreement governing the 2027 Notes for a period of time after notice has been provided, the acceleration of other indebtedness resulting from the failure to pay principal on such other indebtedness prior to its maturity, and certain events of insolvency. In addition, certain change of control events constitute an event of default under the agreement governing the 2027 Notes. If any event of default occurs, the principal of, premium, if any, and accrued interest on all the then-outstanding 2027 Notes may become due and payable immediately.

The indenture governing the 2029 Notes contains restrictive covenants that, among other things, restrict the ability of Sabra, the Issuers and their subsidiaries to: (i) incur or guarantee additional indebtedness; (ii) incur or guarantee secured indebtedness; and (iii) merge or consolidate or sell all or substantially all of their assets. The indenture governing the 2029 Notes also provides for customary events of default, including, but not limited to, the failure to make payments of interest or premium, if any, on, or principal of, the 2029 Notes, the failure to comply with certain covenants and agreements specified in the indenture for a period of time after notice has been provided, the acceleration of other indebtedness resulting from the failure to pay principal on such other indebtedness prior to its maturity, and certain events of insolvency. If any event of default occurs, the principal of, premium, if any, and accrued interest on all the then-outstanding 2029 Notes may become due and payable immediately. The indenture governing the 2029 Notes requires Sabra, the Issuers and their subsidiaries to maintain Total Unencumbered Assets (as defined in the indentures) of at least 150% of the Company’s unsecured indebtedness.

The Company was in compliance with all applicable financial covenants under the indentures and agreements (the “Senior Notes Indentures”) governing the 2024 Notes, 2026 Notes, 2027 Notes and 2029 Notes (collectively, the “Senior Notes”) outstanding as of December 31, 2019.

Credit Agreement

Effective on August 17, 2017, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fourth amended and restated unsecured credit agreement (the “Prior Credit Agreement”). The Prior Credit Agreement amended and restated the previous credit agreement entered into by the Borrowers in January 2016 (the “2016 Credit Agreement”). The Company recognized a $0.6 million loss on extinguishment of debt during the year ended December 31, 2017 related to write-offs of deferred financing costs in connection with amending and restating the 2016 Credit Agreement.

The Prior Credit Agreement included a $1.0 billion revolving credit facility (the “Prior Revolving Credit Facility”), $1.1 billion in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Prior Term Loans”). Further, up to $175.0 million of the Prior Revolving Credit Facility could be used for borrowings in certain foreign currencies. The Prior Credit Agreement also contained an accordion feature that allowed for an increase in the total available borrowings to $2.5 billion, subject to terms and conditions.

F-28

The Prior Revolving Credit Facility had a maturity date of August 17, 2021, and included two six-month extension options. $200.0 million of the U.S. dollar Prior Term Loans had a maturity date of August 17, 2020, and the other Prior Term Loans had a maturity date of August 17, 2022.

Borrowings under the Prior Revolving Credit Facility bore interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Base Rate”). On August 17, 2017, Sabra’s ratings met the Investment Grade Ratings Criteria (as defined in the Prior Credit Agreement), and Sabra elected to use the ratings-based applicable interest margin for borrowings which varied based on the Debt Ratings, as defined in the Prior Credit Agreement, and ranged from 0.875% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Base Rate. In addition, the Operating Partnership paid a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Prior Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Prior Term Loans bore interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings, as defined in the Prior Credit Agreement, and ranged from 0.90% to 1.90% per annum for LIBOR based borrowings and 0.00% to 0.90% per annum for borrowings at the Base Rate. The Canadian dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to the Canadian Dollar Offered Rate (“CDOR”) plus an interest margin that ranged from 0.90% to 1.90% depending on the Debt Ratings.

On September 9, 2019, the Borrowers, Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Credit Agreement”). The Credit Agreement amends and restates the Prior Credit Agreement. The Company recognized a $0.6 million loss on extinguishment of debt related to write-offs of unamortized deferred financing costs in connection with amending and restating the Prior Credit Agreement during the year ended December 31, 2019.

The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), $1.1 billion in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $175.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of September 9, 2023, and includes two six-month extension options. $250.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2022, $350.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2023, and the other Term Loans have a maturity date of September 9, 2024.

As of December 31, 2019, there were no amounts outstanding under the Revolving Credit Facility and $1.0 billion available for borrowing. As of December 31, 2019, $955.0 million in U.S. dollar term loans and the CAD $125.0 million Canadian dollar term loan were outstanding.

Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.45% per annum for LIBOR based borrowings and 0.00% to 0.45% per annum for borrowings at the Base Rate. As of December 31, 2019, the interest rate on the Revolving Credit Facility was 2.91%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Term Loans bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Base Rate. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal to CDOR plus an interest margin that ranges from 0.85% to 1.65% depending on the Debt Ratings.

On June 10, 2015, the Company entered into an interest rate swap agreement to fix the CDOR portion of the interest rate for CAD $90.0 million of its Canadian dollar Term Loan at 1.59%. In addition, CAD $90.0 million of the Canadian dollar Term Loan was designated as a net investment hedge. On August 10, 2016, the Company entered into two interest rate swap agreements to fix the LIBOR portion of the interest rate for $245.0 million of its U.S. dollar Term Loans at 0.90% and one interest rate swap agreement to fix the CDOR portion on CAD $35.0 million of its Canadian dollar Term Loan at 0.93%. See Note 9, “Derivative and Hedging Instruments,” for further information.

F-29

As a result of the CCP Merger, the Company assumed eight interest rate swap agreements that fix the LIBOR portion of the interest rate for $600 million of the Company’s U.S. dollar Term Loans at a weighted average rate of 1.31%. See Note 9, “Derivative and Hedging Instruments,” for further information.

The obligations of the Borrowers under the Credit Agreement are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances.

The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a minimum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of December 31, 2019, the Company was in compliance with all applicable financial covenants under the Credit Agreement.

Interest Expense

During the years ended December 31, 2019, 2018 and 2017, the Company incurred interest expense of $126.6 million, $147.1 million and $88.4 million, respectively. Interest expense includes non-cash interest expense of $10.1 million, $10.1 million and $7.8 million for the years ended December 31, 2019, 2018 and 2017, respectively. As of December 31, 2019 and 2018, the Company had $16.7 million and $24.0 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.

Maturities

The following is a schedule of maturities for the Company’s outstanding debt as of December 31, 2019 (in thousands):

	Secured Indebtedness			Term Loans			Senior Notes			Total
2020	$	3,568		$	—		$	—		$	3,568
2021	18,853			—			—			18,853
2022	3,198			105,000			—			108,198
2023	3,296			350,000			—			353,296
2024	3,396			596,025			300,000			899,421
Thereafter	82,466			—			950,000			1,032,466
Total Debt	114,777			1,051,025			1,250,000			2,415,802
Premium, net	—			—			7,612			7,612
Deferred financing costs, net	(1,707		)	(10,767		)	(8,839		)	(21,313		)
Total Debt, Net	$	113,070		$	1,040,258		$	1,248,773		$	2,402,101

9. DERIVATIVE AND HEDGING INSTRUMENTS

The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.

Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.

F-30

Cash Flow Hedges

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and collars as part of its interest rate risk management strategy. In May 2019, the Company terminated three forward starting interest rate swaps, resulting in a payment to counterparties totaling $12.6 million. The balance of the loss in other comprehensive income will be reclassified to earnings through 2029. As of December 31, 2019, approximately $1.2 million of gains, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months.

Net Investment Hedges

The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.

The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):  

	December 31, 2019		December 31, 2018
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)	$	1,490,000	$	1,045,000
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	54,489	$	55,401
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars	$	1,811	$	899

⁽¹⁾ Balance includes four forward starting interest rate swaps and one forward starting interest rate collar with an effective date of August 2020 and two forward starting interest rate swaps and one forward starting interest rate collar with an effective date of January 2021 that had been entered into as of December 31, 2019. The forward starting interest rate swaps and forward starting interest rate collars have an aggregate initial notional amount of $645.0 million accreting to $845.0 million in January 2023.

Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at December 31, 2019 and 2018 (dollars in thousands):    

		Count as of December 31, 2019	Fair Value				Maturity Dates
			December 31,
Type	Designation		2019		2018			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	10	$	4,239	$	25,184	2020 - 2023	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	3,238		4,160		2025	Accounts receivable, prepaid expenses and other assets, net
			$	7,477	$	29,344
Liabilities:
Forward starting interest rate swaps	Cash flow	6	$	494	$	4,529	2024	Accounts payable and accrued liabilities
Forward starting interest rate collars	Cash flow	2	132		—		2024	Accounts payable and accrued liabilities
CAD term loan	Net investment	1	96,025		91,700		2024	Term loans, net
			$	96,651	$	96,229

F-31

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of income and the consolidated statements of equity for the years ended December 31, 2019, 2018 and 2017:

	Gain (Loss) Recognized in Other Comprehensive Income								Gain (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income							Income Statement Location
	For the year ended December 31,
	2019			2018		2017			2019		2018		2017
Cash Flow Hedges:
Interest rate products	$	(19,932	)	$	2,707	$	10,807		$	5,545	$	3,099	$	(2,174	)	Interest expense
Net Investment Hedges:
Foreign currency products	(772		)	3,554		(2,378		)	—		—		—			N/A
CAD term loan	(4,325		)	7,888		(6,588		)	—		—		—			N/A
	$	(25,029	)	$	14,149	$	1,841		$	5,545	$	3,099	$	(2,174	)

The gain (loss) in the table above related to interest rate products was reclassified from accumulated other comprehensive income into interest expense. Interest expense totaled $126.6 million, $147.1 million and $88.4 million for the years ended December 31, 2019, 2018 and 2017, respectively.

During the years ended December 31, 2019 and 2018, no cash flow hedges were determined to be ineffective. During the year ended December 31, 2017, the Company determined that a portion of a cash flow hedge was ineffective and recognized $22,000 of unrealized gains related to its interest rate swaps to other income on the consolidated statements of income.

Derivatives Not Designated as Hedging Instruments

As of December 31, 2019, the Company had one outstanding cross currency interest rate swap, of which a portion was not designated as a hedging instrument, in an asset position with a fair value of $105,000 and included this amount in accounts receivable, prepaid expenses and other assets, net on the consolidated balance sheets. During the years ended December 31, 2019, 2018 and 2017, the Company recorded $5,000 and $34,000 of other income and $8,000 of other expense, respectively, related to the portion of derivatives not designated as hedging instruments.

Offsetting Derivatives

The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2019 and 2018 (in thousands):

	As of December 31, 2019
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Financial Instruments			Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	7,477	$	—	$	7,477	$	(544	)	$	—	$	6,933
Offsetting Liabilities:
Derivatives	$	626	$	—	$	626	$	(544	)	$	—	$	82

	As of December 31, 2018
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Financial Instruments			Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	29,344	$	—	$	29,344	$	(2,069	)	$	—	$	27,275
Offsetting Liabilities:
Derivatives	$	4,529	$	—	$	4,529	$	(2,069	)	$	—	$	2,460

F-32

Credit-risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of December 31, 2019, the fair value of derivatives in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, related to these agreements was $0.1 million. As of December 31, 2019, the Company has not posted any collateral related to these agreements. If the Company had breached any of these provisions at December 31, 2019, it could have been required to settle its obligations under the agreements at their termination value of $0.1 million.

10.FAIR VALUE DISCLOSURES

Financial Instruments

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. As such, the Company classifies these instruments as Level 3.

F-33

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of December 31, 2019 and 2018 whose carrying amounts do not approximate their fair value (in thousands):

	December 31, 2019						December 31, 2018
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	67,527	$	63,070	$	59,832	$	96,492	$	69,460	$	65,797
Preferred equity investments	43,893		44,304		44,493		43,851		44,262		43,825
Financial liabilities:
Senior Notes	1,250,000		1,248,773		1,328,714		1,300,000		1,307,394		1,270,877
Secured indebtedness	114,777		113,070		105,510		117,464		115,679		101,820

⁽¹⁾  Face value represents amounts contractually due under the terms of the respective agreements.

⁽²⁾  Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

The Company determined the fair value of financial instruments as of December 31, 2019 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets:
Loans receivable	$	59,832	$	—	$	—	$	59,832
Preferred equity investments	44,493		—		—		44,493
Financial liabilities:
Senior Notes	1,328,714		—		1,328,714		—
Secured indebtedness	105,510		—		—		105,510

Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Despite increased capital market and credit market activity, transaction volume for certain financial instruments remains relatively low. This has made the estimation of fair values difficult and, therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.

Items Measured at Fair Value on a Recurring Basis

During the year ended December 31, 2019, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps	$	4,239	$	—	$	4,239	$	—
Cross currency swaps	3,238		—		3,238		—
Financial liabilities:
Forward starting interest rate swaps	494		—		494		—
Forward starting interest rate collars	132		—		132		—

11. EQUITY

Preferred Stock

The Company redeemed all 5,750,000 shares of its 7.125% Series A Cumulative Redeemable Preferred Stock (the “Series A Preferred Stock”) on June 1, 2018 (the “Redemption Date”) for $25.00 per share, plus accrued and unpaid dividends to, but

F-34

not including, the Redemption Date, without interest, in the amount of $0.4453125 per share of Series A Preferred Stock, for a total redemption price per share of Series A Preferred Stock equal to $25.4453125. As a result of the redemption, the Company incurred a charge of $5.5 million related to the original issuance costs of the Series A Preferred Stock. The charge is presented as an additional preferred stock dividend in the Company’s consolidated statements of income for the year ended December 31, 2018.

Common Stock

On February 25, 2019, the Company established an at-the-market equity offering program (the “Prior ATM Program”) to sell shares of its common stock having an aggregate gross sales price of up to $500.0 million from time to time through a consortium of banks acting as sales agents. On December 5, 2019, the Prior ATM Program automatically terminated in accordance with its terms upon the issuance and sale of the maximum aggregate amount of the shares subject to the Prior ATM Program.

During the year ended December 31, 2019, the Company sold 23.9 million shares under the Prior ATM Program at an average price of $20.92 per share, generating gross proceeds of $500.0 million, before $7.5 million of commissions.

On December 11, 2019, the Company established a new ATM program (the “New ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $400.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement.

During December 2019, the Company sold 2.9 million shares under the New ATM Program at an average price of $20.86 per share, generating gross proceeds of $60.0 million, before $0.2 million of commissions. As of December 31, 2019, the Company had $340.0 million available under the New ATM Program.

Other Common Stock Issuances

During each of the years ended December 31, 2019 and 2018, the Company issued 0.1 million shares of common stock as a result of restricted stock unit vestings.

Upon any payment of shares to employees as a result of restricted stock unit vestings, the employees’ related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the years ended December 31, 2019, 2018 and 2017, the Company incurred $1.5 million, $0.4 million and $3.1 million, respectively, in tax withholding obligations on behalf of its employees that were satisfied through a reduction in the number of shares delivered to those participants.

Accumulated Other Comprehensive (Loss) Income

The following is a summary of the Company’s accumulated other comprehensive (loss) income (in thousands):

	Year Ended December 31,
	2019			2018
Foreign currency translation gain (loss)	$	(1,516	)	$	(2,193	)
Unrealized (loss) gain on cash flow hedges	(10,872		)	14,494
Total accumulated other comprehensive (loss) income	$	(12,388	)	$	12,301

12. STOCK-BASED COMPENSATION

All stock-based awards are subject to the terms of the 2009 Performance Incentive Plan, which was assumed by the Company effective as of November 15, 2010 in connection with the Company’s separation from Sun and was most recently amended and restated in April 2017. The 2009 Performance Incentive Plan provides for the granting of stock-based compensation, including stock options, time-based stock units, funds from operations-based stock units (“FFO Units”), relative total stockholder return-based stock units (“TSR Units”) and performance-based restricted stock units to officers, employees and directors in connection with their employment with or services provided to the Company.

F-35

Stock Options

In connection with the CCP Merger, the Company assumed stock options outstanding as of the effective time of the CCP Merger.

During the year ended December 31, 2019, no stock options were exercised and 1.2 million stock options expired. As of December 31, 2019, no stock options were outstanding.

As of December 31, 2018, 1.2 million stock options with a weighted average exercise price per share of $28.04 were outstanding.

Restricted Stock Units and Performance-Based Restricted Stock Units

Under the 2009 Performance Incentive Plan, restricted stock units and performance-based restricted stock units generally have a contractual life or vest over a three- to five-year period. The vesting of certain restricted stock units may accelerate, as defined in the grant, upon retirement, a change in control and other events. When vested (and subject to any applicable deferral or holdback period), each performance-based restricted stock unit is convertible into one share of common stock, subject to any deferrals in issuance pursuant to the grant. The restricted stock units are valued on the grant date based on the market price of the Company’s common stock on that date. Generally, the Company recognizes the fair value of the awards over the applicable vesting period as compensation expense. In addition, since the shares to be issued may vary based on the performance of the Company, the Company must make assumptions regarding the projected performance criteria and the shares that will ultimately be issued. The amount of FFO Units that will ultimately vest is dependent on the amount by which the Company’s funds from operations as adjusted (“FFO”) differs from a target FFO amount for a period specified in each grant and will range from 0% to 200% of the FFO Units initially granted. Similarly, the amount of TSR Units that will ultimately vest is dependent on the amount by which the total shareholder return (“TSR”) of the Company’s common stock differs from a predefined peer group for a period specified in each grant and will range from 0% to 200% of the TSR Units initially granted. Upon any payment of shares as a result of restricted stock unit vestings, the related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. The value of the shares withheld is dependent on the closing price of the Company’s common stock on the date the relevant transaction occurs.

The following table summarizes additional information concerning restricted stock units at December 31, 2019:

	Restricted Stock Units		Weighted Average Grant Date Fair Value Per Unit
Unvested as of December 31, 2018	1,477,318		$	17.88
Granted	603,131		20.59
Vested	(433,181	)	18.34
Dividends reinvested	152,329		18.60
Cancelled/forfeited	(61,735	)	18.29
Unvested as of December 31, 2019	1,737,862		$	18.90

As of December 31, 2019, the weighted average remaining vesting period of restricted stock units was 2.5 years. The weighted average fair value per share at the date of grant for restricted stock units for the years ended December 31, 2019, 2018 and 2017 was $20.59, $16.02 and $19.38, respectively. The total fair value of units vested during the years ended December 31, 2019, 2018 and 2017 was $7.9 million, $3.6 million and $8.4 million, respectively.

The fair value of the TSR Units is estimated on the date of grant using a Monte Carlo valuation model that uses the assumptions noted in the table below. The risk-free rate is based on the U.S. Treasury yield curve in effect at the grant date for the expected performance period. Expected volatility is based on historical volatility for the most recent 3-year period ending on the grant date for the Company and the selected peer companies, and is calculated on a daily basis. The following are the key assumptions used in this valuation:

	2019		2018		2017
Risk free interest rate	1.57% - 2.54%		2.36% - 2.59%		1.42% - 1.99%
Expected stock price volatility	23.80% - 28.57%		28.57% - 30.02%		28.86% - 30.97%
Expected service period	2.4 - 3.0 years		2.5 - 3.0 years		2.2 - 3.0 years
Expected dividend yield (assuming full reinvestment)	—	%	—	%	—	%

F-36

During the years ended December 31, 2019, 2018 and 2017, the Company recognized $9.8 million, $7.6 million and $7.0 million, respectively, of stock-based compensation expense included in general and administrative expense in the consolidated statements of income. During the year ended December 31, 2017, the Company recognized $1.4 million of stock-based compensation expense related to former CCP employees included in merger and acquisition costs in the consolidated statements of income. As of December 31, 2019, there was $20.1 million of total unrecognized stock-based compensation expense related to unvested awards, which is expected to be recognized over a weighted average period of 2.5 years.

Employee Benefit Plan

The Company maintains a 401(k) plan that allows for eligible participants to defer compensation, subject to certain limitations imposed by the Internal Revenue Code of 1986, as amended (the “Code”). The Company provides a discretionary matching contribution of up to 3% of each participant’s eligible compensation. During the years ended December 31, 2019, 2018 and 2017, the Company’s matching contributions were approximately $211,000, $171,000 and $143,000, respectively.

13. INCOME TAXES

The Company elected to be treated as a REIT with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. To qualify as a REIT, the Company must meet a number of organizational and operational requirements, including a requirement to distribute at least 90% of its taxable ordinary income. In addition, the Company is required to meet certain asset and income tests. As a REIT, the Company generally will not be subject to corporate level federal income tax on taxable income that it distributes to its stockholders. The Company also elected to treat certain of its consolidated subsidiaries as taxable REIT subsidiaries, which are subject to federal, state and foreign income taxes.

As a result of acquisitions in Canada during 2015, the Company is subject to income taxes under the laws of Canada. The Company recorded a $0.5 million, $0.6 million and $1.3 million income tax benefit during the years ended December 31, 2019, 2018 and 2017, respectively, with respect to its Canadian operations. Due to uncertainty over the Company’s ability to utilize this income tax benefit in future periods, the Company recorded a valuation allowance of $0.5 million, $0.7 million and $1.2 million against the deferred tax benefit during the years ended December 31, 2019, 2018 and 2017, respectively.

The Company classifies interest and penalties from significant uncertain tax positions as interest expense and operating expenses, respectively, in its consolidated financial statements. During the years ended December 31, 2019, 2018 and 2017, the Company did not incur any such interest or penalties. With certain exceptions, the tax years 2016 and thereafter remain open to examination by the major taxing jurisdictions with which the Company files tax returns.

14. EARNINGS PER COMMON SHARE

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except share and per share amounts):

	Year Ended December 31,
	2019		2018		2017
Numerator
Net income attributable to common stockholders	$	68,996	$	269,314	$	148,141
Denominator
Basic weighted average common shares and common equivalents	187,172,210		178,305,738		105,621,242
Dilutive stock options and restricted stock units	954,882		416,006		221,192
Diluted weighted average common shares	188,127,092		178,721,744		105,842,434
Net income attributable to common stockholders, per:
Basic common share	$	0.37	$	1.51	$	1.40
Diluted common share	$	0.37	$	1.51	$	1.40

During the years ended December 31, 2019, 2018 and 2017, approximately 1,000, 121,000 and 132,000 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. No stock options were outstanding as of December 31, 2019, and no stock options were considered anti-dilutive during the years ended December 31, 2018 and 2017.

F-37

15. SUMMARIZED CONSOLIDATING INFORMATION

The 2024 Notes are issued by the Operating Partnership and fully and unconditionally guaranteed, jointly and severally, by the Company and one of the Company’s non-operating subsidiaries, subject to release under certain customary circumstances as described below. In connection with the Operating Partnership’s assumption of the 2026 Notes as a result of the CCP Merger, the Company has fully and unconditionally guaranteed the 2026 Notes, subject to release under certain circumstances as described below. The 2029 Notes are issued by the Operating Partnership and guaranteed, fully and unconditionally, by the Company.

These guarantees are subordinated to all existing and future senior debt and senior guarantees of the applicable guarantors and are unsecured. The Company conducts all of its business through and derives virtually all of its income from its subsidiaries. Therefore, the Company’s ability to make required payments with respect to its indebtedness (including the Senior Notes) and other obligations depends on the financial results and condition of its subsidiaries and its ability to receive funds from its subsidiaries.

A guarantor will be automatically and unconditionally released from its obligations under the guarantee with respect to the 2024 Notes in the event of:

• Any sale of the subsidiary guarantor or of all or substantially all of its assets;

• A merger or consolidation of the subsidiary guarantor with the Operating Partnership or the Company, provided that the surviving entity remains a guarantor;

• The requirements for legal defeasance or covenant defeasance or to discharge the indenture governing the 2024 Notes have been satisfied;

• A liquidation or dissolution, to the extent permitted under the indenture governing the 2024 Notes, of the subsidiary guarantor;

• The release or discharge of the guaranty that resulted in the creation of the subsidiary guaranty, except a discharge or release by or as a result of payment under such guaranty; or

• If the subsidiary guarantor is not a guarantor or is not otherwise liable in respect of any obligations under any credit facility (as defined in the indenture governing the 2024 Notes) of the Company or any of its subsidiaries.

The Company will be automatically and unconditionally released from its obligations under the guarantee with respect to the 2026 Notes in the event of:

• A liquidation or dissolution, to the extent permitted under the indenture governing the 2026 Notes;

• A merger or consolidation, provided that the surviving entity remains a guarantor; or

• The requirements for legal defeasance or covenant defeasance or to discharge the indenture governing the 2026 Notes have been satisfied.

Pursuant to Rule 3-10 of Regulation S-X, the following summarized consolidating information is provided for the Company (the “Parent Company”), the Operating Partnership, Sabra Health Care, L.L.C. (the guarantor subsidiary of the 2024 Notes) and the Company’s non-guarantor subsidiaries with respect to the 2024 Notes. This summarized financial information has been prepared from the books and records maintained by the Company, the Operating Partnership, Sabra Health Care, L.L.C. and the non-guarantor subsidiaries. The summarized financial information may not necessarily be indicative of the results of operations or financial position had the Operating Partnership, Sabra Health Care, L.L.C. or non-guarantor subsidiaries operated as independent entities. Sabra’s investments in its consolidated subsidiaries are presented based upon Sabra’s proportionate share of each subsidiary’s net assets. Intercompany activities between subsidiaries and the Parent Company are presented within operating activities on the consolidating statement of cash flows.

Consolidating financial statements for the Company and its subsidiaries, including the Parent Company only, the Operating Partnership only, Sabra Health Care, L.L.C. only and the combined non-guarantor subsidiaries, are as follows:

F-38

CONSOLIDATING BALANCE SHEET

December 31, 2019

(in thousands, except share and per share amounts)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)		Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	384		$	—	$	—	$	5,340,986	$	—		$	5,341,370
Loans receivable and other investments, net	(564		)	—		—		107,938		—			107,374
Investment in unconsolidated joint venture	—			—		—		319,460		—			319,460
Cash and cash equivalents	29,369			—		—		9,728		—			39,097
Restricted cash	—			—		—		10,046		—			10,046
Lease intangible assets, net	—			—		—		101,509		—			101,509
Accounts receivable, prepaid expenses and other assets, net	4,753			18,655		—		137,247		(10,212		)	150,443
Intercompany	2,126,198			1,728,096		—		—		(3,854,294		)	—
Investment in subsidiaries	1,359,702			1,823,897		—		35,150		(3,218,749		)	—
Total assets	$	3,519,842		$	3,570,648	$	—	$	6,062,064	$	(7,083,255	)	$	6,069,299
Liabilities
Secured debt, net	$	—		$	—	$	—	$	113,070	$	—		$	113,070
Revolving credit facility	—			—		—		—		—			—
Term loans, net	—			945,393		—		94,865		—			1,040,258
Senior unsecured notes, net	—			1,248,773		—		—		—			1,248,773
Accounts payable and accrued liabilities	31,382			16,780		—		70,842		(10,212		)	108,792
Lease intangible liabilities, net	—			—		—		69,946		—			69,946
Intercompany	—			—		—		3,854,294		(3,854,294		)	—
Total liabilities	31,382			2,210,946		—		4,203,017		(3,864,506		)	2,580,839
Total equity	3,488,460			1,359,702		—		1,859,047		(3,218,749		)	3,488,460
Total liabilities and equity	$	3,519,842		$	3,570,648	$	—	$	6,062,064	$	(7,083,255	)	$	6,069,299

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

F-39

CONSOLIDATING BALANCE SHEET

December 31, 2018

(in thousands, except share and per share amounts)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)		Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	317		$	—	$	—	$	5,853,228	$	—		$	5,853,545
Loans receivable and other investments, net	(560		)	—		—		114,282		—			113,722
Investment in unconsolidated joint venture	—			—		—		340,120		—			340,120
Cash and cash equivalents	40,835			—		—		9,395		—			50,230
Restricted cash	—			—		—		9,428		—			9,428
Lease intangible assets, net	—			—		—		131,097		—			131,097
Accounts receivable, prepaid expenses and other assets, net	798			37,075		—		140,307		(11,019		)	167,161
Intercompany	1,972,059			2,646,669		—		—		(4,618,728		)	—
Investment in subsidiaries	1,258,715			1,629,795		—		33,083		(2,921,593		)	—
Total assets	$	3,272,164		$	4,313,539	$	—	$	6,630,940	$	(7,551,340	)	$	6,665,303
Liabilities
Secured debt, net	$	—		$	—	$	—	$	115,679	$	—		$	115,679
Revolving credit facility	—			624,000		—		—		—			624,000
Term loans, net	—			1,094,177		—		90,753		—			1,184,930
Senior unsecured notes, net	—			1,307,394		—		—		—			1,307,394
Accounts payable and accrued liabilities	21,750			29,253		—		54,843		(11,019		)	94,827
Lease intangible liabilities, net	—			—		—		83,726		—			83,726
Intercompany	—			—		—		4,618,728		(4,618,728		)	—
Total liabilities	21,750			3,054,824		—		4,963,729		(4,629,747		)	3,410,556
Total Sabra Health Care REIT, Inc. stockholders’ equity	3,250,414			1,258,715		—		1,662,878		(2,921,593		)	3,250,414
Noncontrolling interests	—			—		—		4,333		—			4,333
Total equity	3,250,414			1,258,715		—		1,667,211		(2,921,593		)	3,254,747
Total liabilities and equity	$	3,272,164		$	4,313,539	$	—	$	6,630,940	$	(7,551,340	)	$	6,665,303

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

F-40

CONSOLIDATING STATEMENT OF INCOME

For the Year Ended December 31, 2019

(in thousands, except share and per share amounts)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Revenues:
Rental and related revenues	$	—		$	—		$	—	$	485,138		$	(33,000	)	$	452,138
Interest and other income	255			5,655			—		81,285			(5,655		)	81,540
Resident fees and services	—			—			—		128,058			—			128,058
Total revenues	255			5,655			—		694,481			(38,655		)	661,736
Expenses:
Depreciation and amortization	50			—			—		181,499			—			181,549
Interest	—			118,656			—		13,609			(5,655		)	126,610
Triple-net portfolio operating expenses	—			—			—		22,215			—			22,215
Senior housing - managed portfolio operating expenses	—			—			—		119,257			(33,000		)	86,257
General and administrative	28,486			175			—		1,801			—			30,462
Merger and acquisition costs	423			—			—		1			—			424
Provision for doubtful accounts, straight-line rental income and loan losses	4			—			—		1,234			—			1,238
Impairment of real estate	—			—			—		121,819			—			121,819
Total expenses	28,963			118,831			—		461,435			(38,655		)	570,574
Other income (expense):
Loss on extinguishment of debt	—			(16,296		)	—		(44		)	—			(16,340		)
Other (expense) income	—			(321		)	—		2,415			—			2,094
Net gain on sales of real estate	—			—			—		2,300			—			2,300
Total other (expense) income	—			(16,617		)	—		4,671			—			(11,946		)
Income in subsidiary	98,665			228,459			—		6,846			(333,970		)	—
Income before loss from unconsolidated joint venture and income tax expense	69,957			98,666			—		244,563			(333,970		)	79,216
Loss from unconsolidated joint venture	—			—			—		(6,796		)	—			(6,796		)
Income tax expense	(961		)	(1		)	—		(2,440		)	—			(3,402		)
Net income	68,996			98,665			—		235,327			(333,970		)	69,018
Net income attributable to noncontrolling interests	—			—			—		(22		)	—			(22		)
Net income attributable to common stockholders	$	68,996		$	98,665		$	—	$	235,305		$	(333,970	)	$	68,996
Net income attributable to common stockholders, per:
Basic common share															$	0.37
Diluted common share															$	0.37
Weighted-average number of common shares outstanding, basic															187,172,210
Weighted-average number of common shares outstanding, diluted															188,127,092

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

F-41

CONSOLIDATING STATEMENT OF INCOME

For the Year Ended December 31, 2018

(in thousands, except share and per share amounts)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Revenues:
Rental and related revenues	$	—		$	—		$	—	$	554,030		$	(17,425	)	$	536,605
Interest and other income	110			399			—		16,557			(399		)	16,667
Resident fees and services	—			—			—		70,137			—			70,137
Total revenues	110			399			—		640,724			(17,824		)	623,409
Expenses:
Depreciation and amortization	887			—			—		190,492			—			191,379
Interest	—			134,096			—		13,409			(399		)	147,106
Senior housing - managed portfolio operating expenses	—			—			—		66,971			(17,425		)	49,546
General and administrative	26,801			71			—		9,586			—			36,458
Merger and acquisition costs	642			—			—		(6		)	—			636
Provision for doubtful accounts, straight-line rental income and loan losses	822			—			—		38,253			—			39,075
Impairment of real estate	—			—			—		1,413			—			1,413
Total expenses	29,152			134,167			—		320,118			(17,824		)	465,613
Other income (expense):
Loss on extinguishment of debt	—			—			—		(2,917		)	—			(2,917		)
Other income (expense)	1,977			(55		)	—		2,558			—			4,480
Net gain on sales of real estate	—			—			—		128,198			—			128,198
Total other income (expense)	1,977			(55		)	—		127,839			—			129,761
Income in subsidiary	307,736			441,560			—		24,316			(773,612		)	—
Income before loss from unconsolidated joint venture and income tax expense	280,671			307,737			—		472,761			(773,612		)	287,557
Loss from unconsolidated joint venture	—			—			—		(5,431		)	—			(5,431		)
Income tax expense	(1,589		)	(1		)	—		(1,421		)	—			(3,011		)
Net income	279,082			307,736			—		465,909			(773,612		)	279,115
Net loss attributable to noncontrolling interests	—			—			—		(33		)	—			(33		)
Net income attributable to Sabra Health Care REIT, Inc.	279,082			307,736			—		465,876			(773,612		)	279,082
Preferred stock dividends	(9,768		)	—			—		—			—			(9,768		)
Net income attributable to common stockholders	$	269,314		$	307,736		$	—	$	465,876		$	(773,612	)	$	269,314
Net income attributable to common stockholders, per:
Basic common share															$	1.51
Diluted common share															$	1.51
Weighted-average number of common shares outstanding, basic															178,305,738
Weighted-average number of common shares outstanding, diluted															178,721,744

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

F-42

CONSOLIDATING STATEMENT OF INCOME

For the Year Ended December 31, 2017

(in thousands, except share and per share amounts)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Revenues:
Rental and related revenues	$	—		$	—		$	—	$	371,704		$	(7,513	)	$	364,191
Interest and other income	2,673			143			—		15,005			(161		)	17,660
Resident fee and services	—			—			—		26,430			—			26,430
Total revenues	2,673			143			—		413,139			(7,674		)	408,281
Expenses:
Depreciation and amortization	867			—			—		113,015			—			113,882
Interest	—			77,767			—		10,816			(143		)	88,440
Senior housing - managed portfolio operating expenses	—			—			—		25,391			(7,531		)	17,860
General and administrative	24,810			65			—		7,526			—			32,401
Merger and acquisition costs	30,208			—			—		47			—			30,255
Provision for doubtful accounts, straight-line rental income and loan losses	227			—			—		16,886			—			17,113
Impairment of real estate	—			—			—		1,326			—			1,326
Total expenses	56,112			77,832			—		175,007			(7,674		)	301,277
Other income (expense):
Loss on extinguishment of debt	—			(422		)	—		(131		)	—			(553		)
Other income (expense)	—			1,130			—		(594		)	—			536
Net gain on sales of real estate	—			—			—		52,029			—			52,029
Total other income	—			708			—		51,304			—			52,012
Income in subsidiary	212,432			289,414			—		7,199			(509,045		)	—
Income before income tax expense	158,993			212,433			—		296,635			(509,045		)	159,016
Income tax expense	(610		)	(1		)	—		(40		)	—			(651		)
Net income	158,383			212,432			—		296,595			(509,045		)	158,365
Net loss attributable to noncontrolling interests	—			—			—		18			—			18
Net income attributable to Sabra Health Care REIT, Inc.	158,383			212,432			—		296,613			(509,045		)	158,383
Preferred stock dividends	(10,242		)	—			—		—			—			(10,242		)
Net income attributable to common stockholders	$	148,141		$	212,432		$	—	$	296,613		$	(509,045	)	$	148,141
Net income attributable to common stockholders, per:
Basic common share															$	1.40
Diluted common share															$	1.40
Weighted-average number of common shares outstanding, basic															105,621,242
Weighted-average number of common shares outstanding, diluted															105,842,434

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

F-43

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Year Ended December 31, 2019

(in thousands)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)		Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net income	$	68,996	$	98,665		$	—	$	235,327		$	(333,970	)	$	69,018
Other comprehensive (loss) income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(1,276		)	—		1,955			—			679
Unrealized (loss) gain on cash flow hedge	—		(25,416		)	—		48			—			(25,368		)
Total other comprehensive (loss) income	—		(26,692		)	—		2,003			—			(24,689		)
Comprehensive income	68,996		71,973			—		237,330			(333,970		)	44,329
Comprehensive income attributable to noncontrolling interests	—		—			—		(22		)	—			(22		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	68,996	$	71,973		$	—	$	237,308		$	(333,970	)	$	44,307

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

F-44

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Year Ended December 31, 2018

(in thousands)

					Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)		Operating Partnership(2)		Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net income	$	279,082	$	307,736	$	—	$	465,909		$	(773,612	)	$	279,115
Other comprehensive income (loss):
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	—		4,329		—		(3,609		)	—			720
Unrealized gain on cash flow hedge	—		244		—		48			—			292
Total other comprehensive income (loss)	—		4,573		—		(3,561		)	—			1,012
Comprehensive income	279,082		312,309		—		462,348			(773,612		)	280,127
Comprehensive income attributable to noncontrolling interests	—		—		—		(33		)	—			(33		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	279,082	$	312,309	$	—	$	462,315		$	(773,612	)	$	280,094

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

F-45

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Year Ended December 31, 2017

(in thousands)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)		Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net income	$	158,383	$	212,432		$	—	$	296,595		$	(509,045	)	$	158,365
Other comprehensive income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(2,821		)	—		2,975			—			154
Unrealized gain (loss) on cash flow hedges	—		13,078			—		(145		)	—			12,933
Total other comprehensive income	—		10,257			—		2,830			—			13,087
Comprehensive income	158,383		222,689			—		299,425			(509,045		)	171,452
Comprehensive loss attributable to noncontrolling interests	—		—			—		18			—			18
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	158,383	$	222,689		$	—	$	299,443		$	(509,045	)	$	171,470

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

F-46

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Year Ended December 31, 2019

(in thousands)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net cash provided by operating activities	$	359,681		$	—		$	—	$	12,794		$	—		$	372,475
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(51,136		)	—			(51,136		)
Origination and fundings of loans receivable	—			—			—		(13,065		)	—			(13,065		)
Additions to real estate	(115		)	—			—		(25,336		)	—			(25,451		)
Repayment of loans receivable	—			—			—		18,367			—			18,367
Repayment of preferred equity investments	—			—			—		5,079			—			5,079
Net proceeds from sales of real estate	—			—			—		329,050			—			329,050
Distribution from subsidiaries	5,248			5,248			—		—			(10,496		)	—
Intercompany financing	(590,173		)	266,148			—		—			324,025			—
Net cash (used in) provided by investing activities	(585,040		)	271,396			—		262,959			313,529			262,844
Cash flows from financing activities:
Net repayments of revolving credit facility	—			(624,000		)	—		—			—			(624,000		)
Proceeds from issuance of senior unsecured notes	—			638,779			—		—			—			638,779
Principal payments on senior unsecured notes	—			(700,000		)	—		—			—			(700,000		)
Principal payments on term loans	—			(145,000		)	—		—			—			(145,000		)
Principal payments on secured debt	—			—			—		(3,436		)	—			(3,436		)
Payments of deferred financing costs	—			(15,598		)	—		—			—			(15,598		)
Payments related to extinguishment of debt	—			(10,502		)	—		—			—			(10,502		)
Distributions to noncontrolling interests	—			—			—		(316		)	—			(316		)
Issuance of common stock, net	549,328			—			—		—			—			549,328
Dividends paid on common stock	(335,435		)	—			—		—			—			(335,435		)
Distribution to parent	—			(5,248		)	—		(5,248		)	10,496			—
Intercompany financing	—			590,173			—		(266,148		)	(324,025		)	—
Net cash provided by (used in) financing activities	213,893			(271,396		)	—		(275,148		)	(313,529		)	(646,180		)
Net (decrease) increase in cash, cash equivalents and restricted cash	(11,466		)	—			—		605			—			(10,861		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		346			—			346
Cash, cash equivalents and restricted cash, beginning of period	40,835			—			—		18,823			—			59,658
Cash, cash equivalents and restricted cash, end of period	$	29,369		$	—		$	—	$	19,774		$	—		$	49,143

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

F-47

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Year Ended December 31, 2018

(in thousands)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net cash provided by operating activities	$	312,485		$	—		$	—	$	48,101		$	—		$	360,586
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(261,511		)	—			(261,511		)
Origination and fundings of loans receivable	—			—			—		(50,731		)	—			(50,731		)
Origination and fundings of preferred equity investments	—			—			—		(5,313		)	—			(5,313		)
Additions to real estate	(40		)	—			—		(27,657		)	—			(27,697		)
Repayment of loans receivable	—			—			—		51,789			—			51,789
Repayment of preferred equity investments	—			—			—		6,870			—			6,870
Investment in unconsolidated JV	—			—			—		(354,461		)	—			(354,461		)
Net proceeds from sales of real estate	—			—			—		382,560			—			382,560
Distribution from subsidiaries	5,457			5,457			—		—			(10,914		)	—
Intercompany financing	(319,268		)	(299,873		)	—		—			619,141			—
Net cash used in investing activities	(313,851		)	(294,416		)	—		(258,454		)	608,227			(258,494		)
Cash flows from financing activities:
Net repayments of revolving credit facility	—			(17,000		)	—		—			—			(17,000		)
Principal payments on secured debt	—			—			—		(140,338		)	—			(140,338		)
Payments of deferred financing costs	—			(352		)	—		—			—			(352		)
Payments related to extinguishment of debt	—			(2,043		)	—		—			—			(2,043		)
Distributions to noncontrolling interests	—			—			—		(142		)	—			(142		)
Preferred stock redemption	(143,750		)	—			—		—			—			(143,750		)
Issuance of common stock, net	(499		)	—			—		—			—			(499		)
Dividends paid on common and preferred stock	(325,220		)	—			—		—			—			(325,220		)
Distribution to parent	—			(5,457		)	—		(5,457		)	10,914			—
Intercompany financing	—			319,268			—		299,873			(619,141		)	—
Net cash (used in) provided by financing activities	(469,469		)	294,416			—		153,936			(608,227		)	(629,344		)
Net decrease in cash, cash equivalents and restricted cash	(470,835		)	—			—		(56,417		)	—			(527,252		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		(539		)	—			(539		)
Cash, cash equivalents and restricted cash, beginning of period	511,670			—			—		75,779			—			587,449
Cash, cash equivalents and restricted cash, end of period	$	40,835		$	—		$	—	$	18,823		$	—		$	59,658

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

F-48

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Year Ended December 31, 2017

(in thousands)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net cash provided by operating activities	$	59,640		$	—		$	—	$	76,149		$	—		$	135,789
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(419,905		)	—			(419,905		)
Cash received in CCP Merger	77,859			—			—		—			—			77,859
Origination and fundings of loans receivable	—			—			—		(17,239		)	—			(17,239		)
Origination and fundings of preferred equity investments	—			—			—		(2,749		)	—			(2,749		)
Additions to real estate	(181		)	—			—		(6,773		)	—			(6,954		)
Repayment of loans receivable	—			—			—		32,430			—			32,430
Repayment of preferred equity investments	—			—			—		3,755			—			3,755
Net proceeds from the sales of real estate	—			—			—		150,243			—			150,243
Distribution from subsidiaries	2,474			2,474			—		—			(4,948		)	—
Intercompany financing	168,999			(249,664		)	—		—			80,665			—
Net cash provided by (used in) investing activities	249,151			(247,190		)	—		(260,238		)	75,717			(182,560		)
Cash flows from financing activities:
Net borrowings from revolving credit facility	—			253,000			—		—			—			253,000
Proceeds from term loans	—			181,000			—		—			—			181,000
Principal payments on secured debt	—			—			—		(4,145		)	—			(4,145		)
Payments of deferred financing costs	—			(15,337		)	—		—			—			(15,337		)
Payment of contingent consideration	—			—			—		(382		)	—			(382		)
Distributions to noncontrolling interests	—			—			—		(30		)	—			(30		)
Issuance of common stock, net	366,800			—			—		—			—			366,800
Dividends paid on common and preferred stock	(182,089		)	—			—		—			—			(182,089		)
Distribution to parent	—			(2,474		)	—		(2,474		)	4,948			—
Intercompany financing	—			(168,999		)	—		249,664			(80,665		)	—
Net cash provided by financing activities	184,711			247,190			—		242,633			(75,717		)	598,817
Net increase in cash, cash equivalents and restricted cash	493,502			—			—		58,544			—			552,046
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		738			—			738
Cash, cash equivalents and restricted cash, beginning of period	18,168			—			—		16,497			—			34,665
Cash, cash equivalents and restricted cash, end of period	$	511,670		$	—		$	—	$	75,779		$	—		$	587,449

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

F-49

16.COMMITMENTS AND CONTINGENCIES

Environmental

As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of December 31, 2019, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.

Legal Matters

From time to time, the Company is party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.

17. SUBSEQUENT EVENTS

The Company evaluates subsequent events up until the date the consolidated financial statements are issued.

Dividend Declaration

On February 4, 2020, the Company announced that its board of directors declared a quarterly cash dividend of $0.45 per share of common stock. The dividend will be paid on February 28, 2020 to stockholders of record as of the close of business on February 14, 2020.

F-50

SCHEDULE II

VALUATION AND QUALIFYING ACCOUNTS

For the Years Ended December 31, 2019, 2018 and 2017

(dollars in thousands)

	Balance at Beginning of Year		Charged to Earnings		Recoveries			Uncollectible Accounts Written-off			Balance at End of Year
Year ended December 31, 2019
Allowance for doubtful accounts (1)	$	3,706	$	—	$	—		$	(3,706	)	$	—
Straight-line rent receivable allowance (1)	35,778		—		—			(35,778		)	—
Loan loss reserves	1,258		1,238		—			(1,932		)	564
	$	40,742	$	1,238	$	—		$	(41,416	)	$	564
Year ended December 31, 2018
Allowance for doubtful accounts	$	5,520	$	986	$	(2,718	)	$	(82	)	$	3,706
Straight-line rent receivable allowance	12,355		39,646		—			(16,223		)	35,778
Loan loss reserves	97		1,161		—			—			1,258
	$	17,972	$	41,793	$	(2,718	)	$	(16,305	)	$	40,742
Year ended December 31, 2017
Allowance for doubtful accounts	$	3,693	$	2,485	$	(385	)	$	(273	)	$	5,520
Straight-line rent receivable allowance	3,668		10,487		—			(1,800		)	12,355
Loan loss reserves	2,750		4,526		—			(7,179		)	97
	$	10,111	$	17,498	$	(385	)	$	(9,252	)	$	17,972

⁽¹⁾ Balances written-off in connection with the adoption of Topic 842 on January 1, 2019.

F-51

SCHEDULE III

REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION

As of December 31, 2019

(dollars in thousands)

				Initial Cost to Company						Cost Capitalized Subsequent to Acquisition		Gross Amount at which Carried at Close of Period											Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land		Building and Improve- ments(2)(3)		Total				Land		Building and Improve- ments(2)(3)		Total		Accumulated Depreciation and Amortization			Original Date of Construction/ Renovation	Date Acquired
Skilled Nursing/Transitional Care Facilities
Forest Hills (SNF)	Broken Arrow, OK	100%	(4)	$	1,653	$	11,259	$	12,912	$	—	$	1,653	$	9,565	$	11,218	$	(3,655	)	1994/2008, 2009/2010, 2015	11/15/10	40
Seminole Estates	Seminole, OK	100%	—	655		3,527		4,182		—		655		3,167		3,822		(1,126		)	1987	11/15/10	32
Bedford Hills	Bedford, NH	100%	5,782	1,911		12,245		14,156		—		1,911		10,867		12,778		(4,272		)	1992/2010, 2019	11/15/10	36
The Elms Care	Milford, NH	100%	—	312		1,679		1,991		—		312		1,334		1,646		(895		)	1890/2005	11/15/10	20
Missouri River	Great Falls, MT	100%	10,366	2,023		16,967		18,990		—		2,023		15,531		17,554		(7,673		)	1960/1990, 2010	11/15/10	30
Deer Lodge	Deer Lodge, MT	100%	3,940	190		3,032		3,222		2		190		2,619		2,809		(1,232		)	1973	11/15/10	30
Arden House	Hamden, CT	100%	17,879	2,250		23,816		26,066		—		2,250		22,119		24,369		(9,913		)	1973/2008, 2010	11/15/10	28
Lake Drive	Henryetta, OK	100%	—	160		549		709		—		160		51		211		(42		)	1968	11/15/10	10
Mineral Springs	North Conway, NH	100%	11,593	417		5,352		5,769		—		417		4,642		5,059		(1,832		)	1988/2009	11/15/10	43
Wolfeboro	Wolfeboro, NH	100%	9,765	454		4,531		4,985		—		454		3,827		4,281		(1,383		)	1984/1986, 1987, 2009	11/15/10	41
Broadmeadow Healthcare	Middletown, DE	100%	—	1,650		21,730		23,380		—		1,650		21,730		23,380		(5,275		)	2005	08/01/11	40
Capitol Healthcare	Dover, DE	100%	—	4,940		15,500		20,440		—		4,940		15,500		20,440		(3,935		)	1996/2016	08/01/11	40
Pike Creek Healthcare	Wilmington, DE	100%	—	2,460		25,240		27,700		—		2,460		25,240		27,700		(6,195		)	2009	08/01/11	40
Renaissance Healthcare	Millsboro, DE	100%	—	1,640		22,620		24,260		—		1,640		22,620		24,260		(5,660		)	2008	08/01/11	40
Clara Burke	Plymouth Meeting, PA	100%	—	2,527		12,453		14,980		179		2,527		12,632		15,159		(3,065		)	1927/1990, 2007/2016	03/30/12	40
Warrington	Warrington, PA	100%	—	2,617		11,662		14,279		106		2,617		11,768		14,385		(2,614		)	1958/2009/2016	03/30/12	40
Ridgecrest	Duffield, VA	100%	—	509		5,018		5,527		1,333		509		6,351		6,860		(1,687		)	1981/2013	05/10/12	40
Arbrook Plaza	Arlington, TX	100%	—	3,783		14,219		18,002		—		3,783		14,219		18,002		(2,895		)	2002/2012	11/30/12	40
Northgate Plaza	Irving, TX	100%	—	4,901		10,299		15,200		—		4,901		10,299		15,200		(2,160		)	2003/2012, 2015	11/30/12	40
Gulf Pointe Plaza	Rockport, TX	100%	—	1,005		6,628		7,633		—		1,005		6,628		7,633		(1,461		)	2002/2012, 2018	11/30/12	40
Gateway Senior Living	Lincoln, NE	100%	—	6,368		29,919		36,287		—		6,368		29,919		36,287		(4,982		)	1962/1996/2013	02/14/14	40
Legacy	Fremont, NE	100%	—	615		16,176		16,791		—		615		16,176		16,791		(2,955		)	2008	02/14/14	40
Pointe	Fremont, NE	100%	—	615		2,943		3,558		—		615		2,943		3,558		(638		)	1970/1979/1983/1994	02/14/14	40
Regency	South Sioux City, NE	100%	—	246		6,206		6,452		—		246		6,206		6,452		(1,380		)	1962/1968/1975/2000/2004	02/14/14	40

F-52

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Parkmoor Village	Colorado Springs, CO	100%	—	430	13,703	14,133	—	430	13,703	14,133	(2,637	)	1985/2017, 2018	03/05/14	40
Adams PARC	Barlesville, OK	100%	—	1,332	6,904	8,236	—	1,332	6,904	8,236	(1,121	)	1989/2019	10/29/14	40
PARCway	Oklahoma City, OK	100%	—	2,189	23,567	25,756	890	2,189	24,457	26,646	(3,627	)	1963/1984, 2018, 2019	10/29/14	40
Brookhaven Extensive Care	Norman, OK	100%	—	869	5,236	6,105	—	869	5,237	6,106	(950	)	2001/2013, 2019	10/29/14	40
Cadia Healthcare of Hyattsville	Hyattsville, MD	100%	—	6,343	65,573	71,916	14	6,343	65,587	71,930	(8,890	)	1950/1976, 2008	06/30/15	40
Cadia Healthcare of Annapolis	Annapolis, MD	100%	—	1,548	40,773	42,321	103	1,548	40,876	42,424	(5,155	)	1964/1993, 2012	06/30/15	40
Cadia Healthcare of Wheaton	Wheaton, MD	100%	—	676	56,897	57,573	22	676	56,919	57,595	(7,050	)	1966/1991, 2012	06/30/15	40
Cadia Healthcare of Hagerstown	Hagerstown, MD	100%	—	1,475	56,237	57,712	1,236	1,475	57,473	58,948	(6,536	)	1953/1975, 2014, 2019	11/25/15	40
Cadia Healthcare of Spring Brook	Silver Spring, MD	100%	—	963	48,085	49,048	7	963	48,092	49,055	(4,599	)	1965/2015	07/26/16	40
Andrew Residence	Minneapolis, MN	100%	—	2,931	6,943	9,874	192	2,931	7,135	10,066	(596	)	1941/2014, 2019	08/17/17	40
Avamere Riverpark of Eugene	Eugene, OR	100%	—	2,205	28,700	30,905	2,252	2,205	30,952	33,157	(2,167	)	1988/2016	08/17/17	40
Avamere Rehab of Lebanon	Lebanon, OR	100%	—	958	14,176	15,134	—	958	14,176	15,134	(894	)	1974	08/17/17	40
Avamere Crestview of Portland	Portland, OR	100%	—	1,791	12,833	14,624	2,761	1,791	15,594	17,385	(1,277	)	1964/2016	08/17/17	40
Avamere Rehabilitation of King City	Tigard, OR	100%	—	2,011	11,667	13,678	—	2,011	11,667	13,678	(761	)	1975	08/17/17	40
Avamere Rehabilitation of Hillsboro	Hillsboro, OR	100%	—	1,387	14,028	15,415	—	1,387	14,028	15,415	(884	)	1973	08/17/17	40
Avamere Rehab of Junction City	Junction City, OR	100%	—	584	7,901	8,485	—	584	7,901	8,485	(517	)	1966/2015	08/17/17	40
Avamere Rehab of Eugene	Eugene, OR	100%	—	1,380	14,921	16,301	1,791	1,380	16,712	18,092	(1,260	)	1966/2016	08/17/17	40
Avamere Rehab of Coos Bay	Coos Bay, OR	100%	—	829	8,518	9,347	—	829	8,518	9,347	(578	)	1968	08/17/17	40
Avamere Rehab of Clackamas	Gladstone, OR	100%	—	792	5,000	5,792	—	792	5,000	5,792	(334	)	1961	08/17/17	40
Avamere Rehab of Newport	Newport, OR	100%	—	406	5,001	5,407	—	406	5,001	5,407	(319	)	1973/2014	08/17/17	40
Avamere Rehab of Oregon City	Oregon City, OR	100%	—	1,496	12,142	13,638	—	1,496	12,142	13,638	(765	)	1974	08/17/17	40
Avamere Transitional Care of Puget Sound	Tacoma, WA	100%	—	1,771	11,595	13,366	15	1,771	11,610	13,381	(852	)	2017	08/17/17	40
Richmond Beach Rehab	Shoreline, WA	100%	—	4,703	14,444	19,147	—	4,703	14,444	19,147	(943	)	1993/2014	08/17/17	40
St. Francis of Bellingham	Bellingham, WA	100%	—	—	15,330	15,330	—	—	15,330	15,330	(1,010	)	1984/2015	08/17/17	40
Avamere Olympic Rehabilitation of Sequim	Sequim, WA	100%	—	427	4,450	4,877	—	427	4,450	4,877	(352	)	1974	08/17/17	40
Avamere Heritage Rehabilitation of Tacoma	Tacoma, WA	100%	—	1,705	4,952	6,657	—	1,705	4,952	6,657	(341	)	1968	08/17/17	40
Avamere at Pacific Ridge	Tacoma, WA	100%	—	2,195	1,956	4,151	—	2,195	1,956	4,151	(178	)	1972/2014	08/17/17	40

F-53

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Avamere Rehabilitation of Cascade Park	Vancouver, WA	100%	—	1,782	15,116	16,898	—	1,782	15,116	16,898	(1,031	)	1991	08/17/17	40
The Pearl at Kruse Way	Lake Oswego, OR	100%	—	5,947	13,401	19,348	—	5,947	13,401	19,348	(882	)	2005/2016	08/17/17	40
Avamere at Medford	Medford, OR	100%	—	2,043	38,485	40,528	2,960	2,043	41,445	43,488	(2,864	)	1974/2016	08/17/17	40
Avamere Bellingham Healthcare and Rehab Services	Bellingham, WA	100%	—	2,908	2,058	4,966	—	2,908	2,058	4,966	(182	)	1972/2015	08/17/17	40
Queen Anne Healthcare	Seattle, WA	100%	—	2,508	6,401	8,909	—	2,508	6,401	8,909	(427	)	1970	08/17/17	40
Avamere Transitional Care and Rehab - Boise	Boise, ID	100%	—	681	9,348	10,029	—	681	9,348	10,029	(623	)	1979	08/17/17	40
Avamere Transitional Care at Sunnyside	Salem, OR	100%	—	2,114	15,651	17,765	—	2,114	15,651	17,765	(1,016	)	1981	08/17/17	40
Avamere Health Services of Rogue Valley	Medford, OR	100%	—	1,375	23,808	25,183	—	1,375	23,808	25,183	(1,559	)	1961/2016	08/17/17	40
Avamere Transitional Care and Rehab - Malley	Northglenn, CO	100%	—	1,662	26,014	27,676	3,258	1,662	29,272	30,934	(2,179	)	1972/2016	08/17/17	40
Avamere Transitional Care and Rehab - Brighton	Brighton, CO	100%	—	1,933	11,624	13,557	—	1,933	11,624	13,557	(779	)	1971	08/17/17	40
Phoenix Rehabilitation Services	Phoenix, AZ	100%	—	1,270	11,502	12,772	—	1,270	11,502	12,772	(726	)	2008	08/17/17	40
Tustin Subacute Care Facility	Santa Ana, CA	100%	—	1,889	11,682	13,571	—	1,889	11,682	13,571	(717	)	2008	08/17/17	40
La Mesa Inpatient Rehabilitation Facility	La Mesa, CA	100%	—	1,276	8,177	9,453	—	1,276	8,177	9,453	(522	)	2012	08/17/17	40
Golden Living Center - Westminster	Westminster, MD	100%	—	2,128	6,614	8,742	487	2,128	7,101	9,229	(630	)	1973/2010, 2019	08/17/17	40
Maple Wood Care Center	Kansas City, MO	100%	—	1,142	3,226	4,368	653	1,142	3,879	5,021	(539	)	1983	08/17/17	40
Garden Valley Nursing & Rehab	Kansas City, MO	100%	—	1,985	2,714	4,699	303	1,985	3,017	5,002	(490	)	1983	08/17/17	40
Worthington Nursing & Rehab	Parkersburg, WV	100%	—	697	10,688	11,385	285	697	10,973	11,670	(892	)	1974/1999, 2019	08/17/17	40
Burlington House Rehabilitative and Alzheimer’s Care Center	Cincinnati, OH	100%	—	2,686	10,062	12,748	—	2,686	10,062	12,748	(758	)	1989/2015	08/17/17	40
Golden Living Center - Charlottesville	Charlottesville, VA	100%	—	2,840	8,450	11,290	1,157	2,840	9,607	12,447	(769	)	1964/2009, 2019	08/17/17	40
Golden Living Center - Sleepy Hollow	Annandale, VA	100%	—	7,241	17,727	24,968	1,806	7,241	19,533	26,774	(1,405	)	1963/2013, 2019	08/17/17	40
Golden Living Center - Petersburg	Petersburg, VA	100%	—	988	8,416	9,404	146	988	8,562	9,550	(641	)	1970/2009	08/17/17	40
Golden Living Center - Battlefield Park	Petersburg, VA	100%	—	1,174	8,858	10,032	151	1,174	9,009	10,183	(664	)	1976/2010	08/17/17	40
Golden Living Center - Hagerstown	Hagerstown, MD	100%	—	1,393	13,438	14,831	150	1,393	13,588	14,981	(959	)	1971/2010	08/17/17	40
Golden Living Center - Cumberland	Cumberland, MD	100%	—	800	16,973	17,773	457	800	17,430	18,230	(1,219	)	1968	08/17/17	40
Gilroy Healthcare and Rehabilitation Center	Gilroy, CA	100%	—	662	23,775	24,437	—	662	23,775	24,437	(1,482	)	1968	08/17/17	40

F-54

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
North Cascades Health and Rehabilitation Center	Bellingham, WA	100%	—	1,437	14,196	15,633	—	1,437	14,196	15,633	(926	)	1999	08/17/17	40
Granite Rehabilitation & Wellness	Cheyenne, WY	100%	—	387	13,613	14,000	2,246	387	15,859	16,246	(1,170	)	1967/2017	08/17/17	40
Rawlins Rehabilitation & Wellness	Rawlins, WY	100%	—	281	6,007	6,288	—	281	6,007	6,288	(389	)	1967	08/17/17	40
Wind River Rehabilitation & Wellness	Riverton, WY	100%	—	199	11,398	11,597	—	199	11,398	11,597	(720	)	1967	08/17/17	40
Sage View Care Center	Rock Springs, WY	100%	—	420	8,665	9,085	—	420	8,665	9,085	(571	)	1964/2017	08/17/17	40
Shelton Health and Rehabilitation Center	Shelton, WA	100%	—	415	8,965	9,380	—	415	8,965	9,380	(629	)	1998	08/17/17	40
Dundee Nursing Home	Bennettsville, SC	100%	—	1,437	4,631	6,068	—	1,437	4,631	6,068	(334	)	1958	08/17/17	40
Mt. Pleasant Nursing Center	Mount Pleasant, SC	100%	—	2,689	3,942	6,631	—	2,689	3,942	6,631	(302	)	1977/2015	08/17/17	40
Tri-State Comp Care Center	Harrogate, TN	100%	—	1,811	4,963	6,774	—	1,811	4,963	6,774	(388	)	1990/2005	08/17/17	40
Epic-Conway	Conway, SC	100%	—	1,408	10,784	12,192	—	1,408	10,784	12,192	(758	)	1975	08/17/17	40
Epic- Bayview	Beaufort, SC	100%	—	1,842	11,389	13,231	—	1,842	11,389	13,231	(777	)	1970	08/17/17	40
Focused Care at Baytown	Baytown, TX	100%	—	479	6,351	6,830	209	479	6,456	6,935	(451	)	1970/2019	08/17/17	40
Focused Care at Allenbrook	Baytown, TX	100%	—	426	3,236	3,662	173	426	3,371	3,797	(297	)	1975/2019	08/17/17	40
Focused Care at Huntsville	Huntsville, TX	100%	—	302	3,153	3,455	75	302	3,200	3,502	(250	)	1968/2019	08/17/17	40
Focused Care at Center	Center, TX	100%	—	231	1,335	1,566	312	231	1,555	1,786	(174	)	1972/2019	08/17/17	40
Focused Care at Humble	Humble, TX	100%	—	2,114	1,643	3,757	596	2,114	2,099	4,213	(268	)	1972/2019	08/17/17	40
Focused Care at Beechnut	Houston, TX	100%	—	1,019	5,734	6,753	318	1,019	5,876	6,895	(436	)	1982/2019	08/17/17	40
Focused Care at Linden	Linden, TX	100%	—	112	256	368	133	112	331	443	(57	)	1968/2019	08/17/17	40
Focused Care at Sherman	Sherman, TX	100%	—	469	6,310	6,779	255	469	6,400	6,869	(463	)	1971/2019	08/17/17	40
Focused Care at Mount Pleasant	Mount Pleasant, TX	100%	—	250	6,913	7,163	345	250	7,249	7,499	(532	)	1970/2019	08/17/17	40
Focused Care at Waxahachie	Waxahachie, TX	100%	—	416	7,259	7,675	205	416	7,412	7,828	(539	)	1976/2019	08/17/17	40
Focused Care at Gilmer	Gilmer, TX	100%	—	707	4,552	5,259	93	707	4,605	5,312	(352	)	1990/2019	08/17/17	40
Hearthstone of Northern Nevada	Sparks, NV	100%	—	1,986	9,004	10,990	—	1,986	9,004	10,990	(631	)	1988	08/17/17	40
Sunset Hills Healthcare and Rehabilitation Center	St. Louis, MO	100%	—	1,595	5,822	7,417	—	966	3,157	4,123	—		1954/2016	08/17/17	40
Mountainview Specialty Care Center	Greensburg, PA	100%	—	549	9,926	10,475	—	549	9,926	10,475	(824	)	1971/2016	08/17/17	40
Golden Living Center - Richmond	Richmond, IN	100%	—	259	9,819	10,078	—	259	9,819	10,078	(655	)	1975	08/17/17	40
Golden Living Center - Petersburg	Petersburg, IN	100%	—	581	5,367	5,948	—	581	5,367	5,948	(383	)	1970/2009	08/17/17	40
Beverly Health - Ft. Pierce	Fort Pierce, FL	100%	—	787	16,648	17,435	—	787	16,648	17,435	(1,067	)	1960/2011	08/17/17	40

F-55

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Maryville	Maryville, MO	100%	—	114	5,955	6,069	—	150	5,955	6,105	(437	)	1972	08/17/17	40
Ashland Healthcare	Ashland, MO	100%	—	765	2,669	3,434	—	765	2,669	3,434	(210	)	1993	08/17/17	40
Bellefontaine Gardens	St. Louis, MO	100%	—	2,071	5,739	7,810	—	2,071	5,739	7,810	(451	)	1988/1991	08/17/17	40
Current River Nursing Center	Doniphan, MO	100%	—	657	8,251	8,908	—	657	8,251	8,908	(571	)	1991	08/17/17	40
Dixon Nursing & Rehab	Dixon, MO	100%	—	521	3,358	3,879	—	521	3,358	3,879	(252	)	1989/2011	08/17/17	40
Forsyth Nursing & Rehab	Forsyth, MO	100%	—	594	8,549	9,143	—	594	8,549	9,143	(601	)	1993/2007	08/17/17	40
Glenwood Healthcare	Seymour, MO	100%	—	658	901	1,559	—	658	901	1,559	(88	)	1990	08/17/17	40
Silex Community Care	Silex, MO	100%	—	807	4,990	5,797	—	807	4,990	5,797	(356	)	1991	08/17/17	40
South Hampton Place	Columbia, MO	100%	—	2,322	6,547	8,869	—	2,322	6,547	8,869	(474	)	1994	08/17/17	40
Strafford Care Center	Strafford, MO	100%	—	1,634	6,518	8,152	—	1,634	6,518	8,152	(462	)	1995	08/17/17	40
Windsor Healthcare & Rehab	Windsor, MO	100%	—	471	6,819	7,290	—	471	6,819	7,290	(438	)	1996	08/17/17	40
Park Manor of Conroe	Conroe, TX	100%	—	1,222	19,099	20,321	—	1,222	19,099	20,321	(1,198	)	2001	08/17/17	40
Park Manor of Cypress Station	Houston, TX	100%	—	1,334	11,615	12,949	—	1,334	11,615	12,949	(759	)	2003/2013	08/17/17	40
Park Manor of Humble	Humble, TX	100%	—	1,541	12,332	13,873	645	1,541	12,977	14,518	(870	)	2003/2019	08/17/17	40
Park Manor of Quail Valley	Missouri City, TX	100%	—	1,825	9,681	11,506	—	1,825	9,681	11,506	(657	)	2005	08/17/17	40
Park Manor of Westchase	Houston, TX	100%	—	2,676	7,396	10,072	—	2,676	7,396	10,072	(514	)	2005	08/17/17	40
Park Manor of CyFair	Houston, TX	100%	—	1,732	12,921	14,653	—	1,732	12,921	14,653	(838	)	1999	08/17/17	40
Park Manor of McKinney	McKinney, TX	100%	—	1,441	9,017	10,458	—	1,441	9,017	10,458	(638	)	1993/2012	08/17/17	40
Tanglewood Health and Rehabilitation	Topeka, KS	100%	—	176	2,340	2,516	—	176	2,340	2,516	(175	)	1973/2013	08/17/17	40
Smoky Hill Health and Rehabilitation	Salina, KS	100%	—	301	4,201	4,502	—	301	4,201	4,502	(300	)	1981	08/17/17	40
Belleville Health Center	Belleville, KS	100%	—	600	1,664	2,264	—	600	1,664	2,264	(149	)	1977	08/17/17	40
Westridge Healthcare Center	Terre Haute, IN	100%	—	1,067	7,061	8,128	—	1,067	7,061	8,128	(474	)	1965/1984	08/17/17	40
Willow Bend Living Center	Muncie, IN	100%	—	1,168	9,562	10,730	—	1,168	9,562	10,730	(612	)	1976/1986	08/17/17	40
Twin City Healthcare	Gas City, IN	100%	—	345	8,852	9,197	—	345	8,852	9,197	(566	)	1974	08/17/17	40
Pine Knoll Rehabilitation Center	Winchester, IN	100%	—	711	5,554	6,265	—	711	5,554	6,265	(374	)	1986/1998	08/17/17	40
Willow Crossing Health & Rehab Center	Columbus, IN	100%	—	1,290	10,714	12,004	—	1,290	10,714	12,004	(688	)	1988/2004	08/17/17	40
Persimmon Ridge Center	Portland, IN	100%	—	315	9,848	10,163	—	315	9,848	10,163	(642	)	1964	08/17/17	40
Vermillion Convalescent Center	Clinton, IN	100%	—	884	9,839	10,723	—	884	9,839	10,723	(674	)	1971	08/17/17	40
Las Vegas Post Acute & Rehabilitation	Las Vegas, NV	100%	—	509	18,216	18,725	—	509	18,216	18,725	(1,118	)	1964	08/17/17	40
Torey Pines Rehabilitation Hospital	Las Vegas, NV	100%	—	3,169	7,863	11,032	—	3,169	7,863	11,032	(544	)	1972/1997	08/17/17	40

F-56

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Villa Campana Rehabilitation Hospital	Tucson, AZ	100%	—	1,800	4,387	6,187	—	1,800	4,387	6,187	(352	)	1983/2011	08/17/17	40
Kachina Point Rehabilitation Hospital	Sedona, AZ	100%	—	2,035	10,981	13,016	—	2,035	10,981	13,016	(770	)	1984/2011	08/17/17	40
Bay View Rehabilitation Hospital	Alameda, CA	100%	—	3,078	22,328	25,406	—	3,078	22,328	25,406	(1,402	)	1967	08/17/17	40
Dover Center for Health & Rehabilitation	Dover, NH	100%	—	522	5,839	6,361	—	522	5,839	6,361	(510	)	1969/1992, 2017	08/17/17	40
Augusta Center for Health & Rehabilitation	Augusta, ME	100%	—	135	6,470	6,605	—	135	6,470	6,605	(444	)	1967	08/17/17	40
Eastside Center for Health & Rehabilitation	Bangor, ME	100%	—	302	1,811	2,113	632	302	2,443	2,745	(147	)	1967/1993, 2019	08/17/17	40
Winship Green Center for Health & Rehabilitation	Bath, ME	100%	—	250	1,934	2,184	—	250	1,934	2,184	(148	)	1974	08/17/17	40
Brewer Center for Health & Rehabilitation	Brewer, ME	100%	—	177	14,497	14,674	944	177	15,441	15,618	(967	)	1974/1990, 2019	08/17/17	40
Kennebunk Center for Health & Rehabilitation	Kennebunk, ME	100%	—	198	6,822	7,020	—	198	6,822	7,020	(461	)	1977	08/17/17	40
Norway Center for Health & Rehabilitation	Norway, ME	100%	—	791	3,680	4,471	—	791	3,680	4,471	(269	)	1976	08/17/17	40
Brentwood Center for Health & Rehabilitation	Yarmouth, ME	100%	—	134	2,072	2,206	—	134	2,072	2,206	(163	)	1952	08/17/17	40
Country Center for Health & Rehabilitation	Newburyport, MA	100%	—	269	4,436	4,705	12	269	4,448	4,717	(403	)	1968/2009	08/17/17	40
Sachem Center for Health & Rehabilitation	E. Bridgewater, MA	100%	—	447	1,357	1,804	—	447	1,357	1,804	(151	)	1968	08/17/17	40
Eliot Center for Health & Rehabilitation	Natick, MA	100%	—	475	1,491	1,966	—	475	1,491	1,966	(143	)	1964	08/17/17	40
The Reservoir Center for Health & Rehabilitation	Marlborough, MA	100%	—	942	1,541	2,483	8,697	942	10,238	11,180	(547	)	1973/2018	08/17/17	40
Newton Wellesley Center for Alzheimer’s Care	Wellesley, MA	100%	—	1,186	13,917	15,103	—	1,186	13,917	15,103	(894	)	1971	08/17/17	40
Colony Center for Health & Rehabilitation	Abington, MA	100%	—	1,727	2,103	3,830	19	1,727	2,122	3,849	(188	)	1965	08/17/17	40
Westgate Center for Rehab & Alzheimer’s Care	Bangor, ME	100%	—	229	7,171	7,400	10	229	7,181	7,410	(501	)	1969/1993	08/17/17	40
New Orange Hills	Orange, CA	100%	—	4,163	14,755	18,918	—	4,163	14,755	18,918	(973	)	1987	08/17/17	40
Millbrook Healthcare & Rehabilitation Center	Lancaster, TX	100%	—	548	5,794	6,342	—	548	5,794	6,342	(420	)	2008	08/17/17	40
Pleasant Valley Health & Rehab	Garland, TX	100%	—	1,118	7,490	8,608	—	1,118	7,490	8,608	(517	)	2008	08/17/17	40
Focused Care at Clarksville	Clarksville, TX	100%	—	279	4,269	4,548	100	279	4,369	4,648	(338	)	1989/2019	08/17/17	40
McKinney Healthcare & Rehab	McKinney, TX	100%	—	1,272	6,047	7,319	—	1,272	6,047	7,319	(448	)	2006	08/17/17	40
Golden Living Center - Hopkins	Hopkins, MN	100%	—	807	4,668	5,475	530	807	5,198	6,005	(423	)	1961/2008, 2019	08/17/17	40
Golden Living Center - Village Gardens	Green Bay, WI	100%	—	1,299	1,247	2,546	—	1,299	1,247	2,546	(142	)	1965/2012	08/17/17	40

F-57

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Golden Living Center - Florence	Florence, WI	100%	—	291	3,778	4,069	—	291	3,778	4,069	(293	)	1970	08/17/17	40
Golden Living Center - South Shore	St. Francis, WI	100%	—	166	1,887	2,053	—	166	1,887	2,053	(152	)	1960/1997	08/17/17	40
Golden Living Center - Rochester East	Rochester, MN	100%	—	645	7,067	7,712	178	645	7,245	7,890	(489	)	1967/2011, 2019	08/17/17	40
Golden Living Center - Wisconsin Dells	Wisconsin Dells, WI	100%	—	1,640	1,599	3,239	—	1,640	1,599	3,239	(167	)	1972/2006	08/17/17	40
Golden Living Center - Sheboygan	Sheboygan, WI	100%	—	1,038	2,839	3,877	—	1,038	2,839	3,877	(251	)	1967/2012	08/17/17	40
Golden Living Center - Hendersonville	Hendersonville, NC	100%	—	1,611	3,503	5,114	—	1,611	3,503	5,114	(285	)	1979	08/17/17	40
Focused Care at Corpus	Corpus Christi, TX	100%	—	366	6,961	7,327	91	51	1,025	1,076	(152	)	1973/2010	08/17/17	40
Focused Care at Burnet Bay	Baytown, TX	100%	—	579	22,317	22,896	28	579	22,345	22,924	(1,409	)	2000/2013	08/17/17	40
Focused Care at Cedar Bayou	Baytown, TX	100%	—	589	20,475	21,064	35	589	20,510	21,099	(1,336	)	2008	08/17/17	40
Focused Care at Westwood	Houston, TX	100%	—	1,300	13,353	14,653	—	1,300	13,353	14,653	(906	)	2006	08/17/17	40
Focused Care at Pasadena	Pasadena, TX	100%	—	1,148	23,579	24,727	—	1,148	23,579	24,727	(1,515	)	2004	08/17/17	40
Focused Care at Webster	Webster, TX	100%	—	904	10,315	11,219	—	904	10,315	11,219	(716	)	2000/2009	08/17/17	40
Focused Care at Summer Place	Beaumont, TX	100%	—	945	20,424	21,369	18	945	20,442	21,387	(1,296	)	2009	08/17/17	40
Focused Care at Orange	Orange, TX	100%	—	711	10,737	11,448	16	711	10,753	11,464	(711	)	2006	08/17/17	40
Cypress Glen	Port Arthur, TX	100%	—	1,209	13,444	14,653	—	90	814	904	—		2000/2008	08/17/17	40
Signature Healthcare of Whitesburg Gardens	Huntsville, AL	100%	—	634	28,071	28,705	—	634	28,071	28,705	(1,735	)	1968/2012	08/17/17	40
Signature Healthcare of Terre Haute	Terre Haute, IN	100%	—	644	37,451	38,095	—	644	37,451	38,095	(2,601	)	1996/2013	08/17/17	40
Signature Healthcare at Larkin Springs	Madison, TN	100%	—	902	3,850	4,752	—	902	3,850	4,752	(325	)	1969/2016	08/17/17	40
Signature Healthcare of Savannah	Savannah, GA	100%	—	1,235	3,765	5,000	—	1,235	3,765	5,000	(334	)	1970/2015	08/17/17	40
Signature Healthcare of Bluffton	Bluffton, IN	100%	—	254	5,105	5,359	—	254	5,105	5,359	(384	)	1970	08/17/17	40
Signature Healthcare of Bowling Green	Bowling Green, KY	100%	—	280	13,975	14,255	—	280	13,975	14,255	(955	)	1970/2015	08/17/17	40
Oakview Nursing and Rehabilitation Center	Calvert City, KY	100%	—	1,176	7,012	8,188	—	1,176	7,012	8,188	(509	)	1962/2015	08/17/17	40
Fountain Circle Care and Rehabilitation Center	Winchester, KY	100%	—	554	13,207	13,761	—	554	13,207	13,761	(921	)	1967/2015	08/17/17	40
Riverside Care & Rehabilitation Center	Calhoun, KY	100%	—	613	7,643	8,256	—	613	7,643	8,256	(570	)	1963/2015	08/17/17	40
Signature Healthcare of Bremen	Bremen, IN	100%	—	173	7,393	7,566	—	173	7,393	7,566	(504	)	1982/2015	08/17/17	40
Signature Healthcare of Muncie	Muncie, IN	100%	—	374	27,429	27,803	—	374	27,429	27,803	(1,733	)	1980/2013	08/17/17	40
Signature Healthcare at Parkwood	Lebanon, IN	100%	—	612	11,755	12,367	—	612	11,755	12,367	(787	)	1977/2012	08/17/17	40

F-58

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Signature Healthcare at Tower Road	Marietta, GA	100%	—	364	16,116	16,480	—	364	16,116	16,480	(1,106	)	1969/2015	08/17/17	40
Danville Centre for Health and Rehabilitation	Danville, KY	100%	—	790	9,356	10,146	—	790	9,356	10,146	(753	)	1962/2015	08/17/17	40
Signature Healthcare at Hillcrest	Owensboro, KY	100%	—	1,048	22,587	23,635	—	1,048	22,587	23,635	(1,483	)	1963/2011	08/17/17	40
Signature Healthcare of Elizabethtown	Elizabethtown, KY	100%	—	239	4,853	5,092	—	239	4,853	5,092	(357	)	1969	08/17/17	40
Signature Healthcare of Primacy	Memphis, TN	100%	—	1,633	9,371	11,004	—	1,633	9,371	11,004	(674	)	1981/2015	08/17/17	40
Signature Healthcare of Harbour Pointe	Norfolk, VA	100%	—	705	16,451	17,156	—	705	16,451	17,156	(1,222	)	1969/2015	08/17/17	40
Harrodsburg Health & Rehabilitation Center	Harrodsburg, KY	100%	—	1,049	9,851	10,900	—	1,049	9,851	10,900	(754	)	1975/2016	08/17/17	40
Signature Healthcare of Putnam County	Cookeville, TN	100%	—	1,034	15,555	16,589	—	1,034	15,555	16,589	(1,045	)	1979/2016	08/17/17	40
Signature Healthcare of Fayette County	Washington Court House, OH	100%	—	405	4,839	5,244	—	405	4,839	5,244	(385	)	1984/2015	08/17/17	40
Signature Healthcare of Warren	Warren, OH	100%	—	955	5,260	6,215	—	955	5,260	6,215	(489	)	1967/2015	08/17/17	40
Signature Healthcare of Galion	Galion, OH	100%	—	836	668	1,504	—	836	668	1,504	(86	)	1967/1985	08/17/17	40
Signature Healthcare of Roanoke Rapids	Roanoke Rapids, NC	100%	—	373	10,308	10,681	—	373	10,308	10,681	(761	)	1967/2015	08/17/17	40
Signature Healthcare of Kinston	Kinston, NC	100%	—	954	7,987	8,941	—	954	7,987	8,941	(662	)	1960/2015	08/17/17	40
Signature Healthcare of Chapel Hill	Chapel Hill, NC	100%	—	809	2,703	3,512	302	809	3,005	3,814	(321	)	1984/2015	08/17/17	40
Signature Healthcare of Chillicothe	Chillicothe, OH	100%	—	260	8,924	9,184	—	260	8,924	9,184	(681	)	1974/2015	08/17/17	40
Signature Healthcare of Coshocton	Coshocton, OH	100%	—	374	2,530	2,904	—	374	2,530	2,904	(261	)	1974/2015	08/17/17	40
McCreary Health & Rehabilitation Center	Pine Knot, KY	100%	—	208	7,665	7,873	—	208	7,665	7,873	(532	)	1990	08/17/17	40
Colonial Health & Rehabilitation Center	Bardstown, KY	100%	—	634	4,094	4,728	—	634	4,094	4,728	(332	)	1968/2010	08/17/17	40
Glasgow Health & Rehabilitation Center	Glasgow, KY	100%	—	83	2,057	2,140	—	83	2,057	2,140	(202	)	1968	08/17/17	40
Green Valley Health & Rehabilitation Center	Carrollton, KY	100%	—	124	1,693	1,817	—	124	1,693	1,817	(174	)	1978/2016	08/17/17	40
Hart County Health & Rehabilitation	Horse Cave, KY	100%	—	208	7,070	7,278	—	208	7,070	7,278	(536	)	1993	08/17/17	40
Heritage Hall Health & Rehabilitation Center	Lawrenceburg, KY	100%	—	635	9,861	10,496	—	635	9,861	10,496	(694	)	1973	08/17/17	40
Jackson Manor	Annville, KY	100%	—	479	6,078	6,557	—	479	6,078	6,557	(419	)	1989	08/17/17	40
Jefferson Manor	Louisville, KY	100%	—	3,528	4,653	8,181	—	3,528	4,653	8,181	(402	)	1982/2012	08/17/17	40
Jefferson Place	Louisville, KY	100%	—	2,207	20,733	22,940	—	2,207	20,733	22,940	(1,349	)	1991/2010	08/17/17	40

F-59

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Monroe Health & Rehabilitation Center	Tompkinsville, KY	100%	—	333	9,556	9,889	—	333	9,556	9,889	(665	)	1969	08/17/17	40
North Hardin Health & Rehabilitation Center	Radcliff, KY	100%	—	1,815	7,470	9,285	—	1,815	7,470	9,285	(659	)	1986	08/17/17	40
Professional Care Health & Rehabilitation Center	Hartford, KY	100%	—	312	8,189	8,501	—	312	8,189	8,501	(582	)	1967	08/17/17	40
Rockford Health & Rehabilitation Center	Louisville, KY	100%	—	427	6,003	6,430	—	427	6,003	6,430	(455	)	1975/2005	08/17/17	40
Summerfield Health & Rehabilitation Center	Louisville, KY	100%	—	1,134	9,166	10,300	—	1,134	9,166	10,300	(712	)	1979/2013	08/17/17	40
Tanbark Senior Living	Lexington, KY	100%	—	2,558	4,311	6,869	—	2,558	4,311	6,869	(365	)	1989	08/17/17	40
Summit Manor Health & Rehabilitation Center	Columbia, KY	100%	—	114	11,141	11,255	—	114	11,141	11,255	(759	)	1965	08/17/17	40
Belle View Estates Rehabilitation and Care Center	Monticello, AR	100%	—	206	3,179	3,385	—	206	3,179	3,385	(259	)	1995	08/17/17	40
River Chase Rehabilitation and Care Center	Morrilton, AR	100%	—	508	—	508	—	508	—	508	—		1988/2019	08/17/17	40
Heartland Rehabilitation and Care Center	Benton, AR	100%	—	1,336	7,386	8,722	—	1,336	7,386	8,722	(550	)	1992	08/17/17	40
River Ridge Rehabilitation and Care Center	Wynne, AR	100%	—	227	4,007	4,234	—	227	4,007	4,234	(301	)	1990	08/17/17	40
Brookridge Cove Rehabilitation and Care Center	Morrilton, AR	100%	—	412	2,642	3,054	—	412	2,642	3,054	(244	)	1996	08/17/17	40
Southern Trace Rehabilitation and Care Center	Bryant, AR	100%	—	819	8,938	9,757	—	819	8,938	9,757	(593	)	1989/2015	08/17/17	40
Lake Village Rehabilitation and Care Center	Lake Village, AR	100%	—	507	4,838	5,345	—	507	4,838	5,345	(369	)	1998	08/17/17	40
Savannah Specialty Care Center	Savannah, GA	100%	—	2,194	11,711	13,905	—	2,194	11,711	13,905	(766	)	1972	08/17/17	40
Pettigrew Rehabilitation Center	Durham, NC	100%	—	470	9,633	10,103	—	470	9,633	10,103	(624	)	1968/2006	08/17/17	40
Sunnybrook Rehabilitation Center	Raleigh, NC	100%	—	1,155	11,749	12,904	—	1,155	11,749	12,904	(780	)	1971	08/17/17	40
Raleigh Rehabilitation Center	Raleigh, NC	100%	—	926	17,649	18,575	—	926	17,649	18,575	(1,151	)	1967/2007	08/17/17	40
Cypress Pointe Rehabilitation Center	Wilmington, NC	100%	—	611	5,051	5,662	—	611	5,051	5,662	(374	)	1966/2013	08/17/17	40
Silas Creek Rehabilitation Center	Winston-Salem, NC	100%	—	879	3,283	4,162	—	879	3,283	4,162	(277	)	1965	08/17/17	40
Lincolnton Rehabilitation Center	Lincolnton, NC	100%	—	—	9,967	9,967	—	—	9,967	9,967	(664	)	1976	08/17/17	40
Rehabilitation and Nursing Center of Monroe	Monroe, NC	100%	—	166	5,906	6,072	—	166	5,906	6,072	(438	)	1963/2005	08/17/17	40
Guardian Care of Zebulon	Zebulon, NC	100%	—	594	8,559	9,153	—	594	8,559	9,153	(548	)	1973/2010	08/17/17	40

F-60

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Guardian Care of Rocky Mount	Rocky Mount, NC	100%	—	—	18,314	18,314	—	—	18,314	18,314	(1,151	)	1975	08/17/17	40
San Pedro Manor	San Antonio, TX	100%	—	671	2,504	3,175	—	671	2,504	3,175	(211	)	1986	08/17/17	40
Park Manor Health Care & Rehabilitation	DeSoto, TX	100%	—	942	6,033	6,975	—	942	6,033	6,975	(440	)	1987	08/17/17	40
Avalon Place - Trinity	Trinity, TX	100%	—	363	3,852	4,215	—	363	3,852	4,215	(303	)	1985/2019	08/17/17	40
Avalon Place - Kirbyville	Kirbyville, TX	100%	—	208	5,809	6,017	—	208	5,809	6,017	(437	)	1987	08/17/17	40
Heritage House of Marshall	Marshall, TX	100%	—	732	4,288	5,020	—	732	4,288	5,020	(332	)	2008	08/17/17	40
Autumn Woods Residential Health Care Facility	Warren, MI	100%	—	2,052	25,539	27,591	—	2,052	25,539	27,591	(1,845	)	1961/2001	08/17/17	40
Autumn View Health Care Facility	Hamburg, NY	100%	—	1,026	54,086	55,112	—	1,026	54,086	55,112	(3,416	)	1983/2014	08/17/17	40
Brookhaven Health Care Facility	East Patchogue, NY	100%	—	2,181	30,373	32,554	—	2,181	30,373	32,554	(2,018	)	1988/2011	08/17/17	40
Harris Hill Nursing Facility	Williamsville, NY	100%	—	1,122	46,413	47,535	—	1,122	46,413	47,535	(2,879	)	1992/2007	08/17/17	40
Garden Gate Health Care Facility	Cheektowaga, NY	100%	—	1,164	29,905	31,069	—	1,164	29,905	31,069	(1,966	)	1979/2006	08/17/17	40
Northgate Health Care Facility	North Tonawanda, NY	100%	—	830	29,488	30,318	—	830	29,488	30,318	(1,937	)	1982/2007	08/17/17	40
Seneca Health Care Center	West Seneca, NY	100%	—	1,325	26,839	28,164	—	1,325	26,839	28,164	(1,731	)	1974/2008	08/17/17	40
Blueberry Hill Rehab and Healthcare Center	Beverly, MA	100%	—	2,410	13,588	15,998	—	2,410	13,588	15,998	(1,179	)	1965/2015	08/17/17	40
River Terrace Rehabilitation and Healthcare Center	Lancaster, MA	100%	—	343	7,733	8,076	—	343	7,733	8,076	(518	)	1970/2005	08/17/17	40
The Crossings West Campus	New London, CT	100%	—	356	152	508	—	356	152	508	(23	)	1967/2016	08/17/17	40
The Crossings East Campus	New London, CT	100%	—	505	2,248	2,753	—	505	2,248	2,753	(257	)	1967/2016	08/17/17	40
Parkway Pavilion Healthcare	Enfield, CT	100%	—	437	16,461	16,898	—	437	16,461	16,898	(1,127	)	1968/2015	08/17/17	40
Quincy Health & Rehabilitation Center	Quincy, MA	100%	—	894	904	1,798	—	894	904	1,798	(111	)	1965/2003	08/17/17	40
Den-Mar Health & Rehabilitation Center	Rockport, MA	100%	—	—	1,765	1,765	—	—	1,765	1,765	(155	)	1963/1993	08/17/17	40
Firesteel Healthcare Community	Mitchell, SD	100%	—	621	14,059	14,680	8,716	621	22,775	23,396	(2,280	)	1966/2017	08/17/17	40
Fountain Springs Healthcare Community	Rapid City, SD	100%	—	1,134	13,109	14,243	169	1,134	13,278	14,412	(857	)	1989/2016, 2019	08/17/17	40
Palisade Healthcare Community	Garretson, SD	100%	—	362	2,548	2,910	230	362	2,778	3,140	(216	)	1971/1982, 2019	08/17/17	40
Shepherd of the Valley Healthcare Community	Casper, WY	100%	—	803	19,210	20,013	573	803	19,783	20,586	(1,305	)	1961/1990, 2019	08/17/17	40
Wheatcrest Hills Healthcare Community	Britton, SD	100%	—	679	3,216	3,895	269	679	3,485	4,164	(261	)	1969/2019	08/17/17	40

F-61

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Riverview Healthcare Community & Independent Living	Flandreau, SD	100%	—	240	6,327	6,567	—	240	6,327	6,567	(442	)	1965/1989	08/17/17	40
Prairie View Healthcare Center	Woonsocket, SD	100%	—	383	2,041	2,424	—	383	2,041	2,424	(167	)	1968/2012	08/17/17	40
Wingate at Dutchess (Fishkill)	Fishkill, NY	100%	—	964	30,107	31,071	261	964	30,368	31,332	(2,001	)	1995	08/17/17	40
Wingate at Ulster (Highland)	Highland, NY	100%	—	4,371	11,473	15,844	—	4,371	11,473	15,844	(813	)	1998	08/17/17	40
Wingate at Beacon	Beacon, NY	100%	—	—	25,400	25,400	—	—	25,400	25,400	(1,760	)	2002	08/17/17	40
Wingate at Springfield	Springfield, MA	100%	—	817	11,357	12,174	—	817	11,357	12,174	(763	)	1987	08/17/17	40
Wingate at Andover	Andover, MA	100%	—	2,123	5,383	7,506	—	2,123	5,383	7,506	(414	)	1992	08/17/17	40
Wingate at Reading	Reading, MA	100%	—	1,534	5,221	6,755	—	1,534	5,221	6,755	(412	)	1988	08/17/17	40
Wingate at Sudbury	Sudbury, MA	100%	—	2,017	3,458	5,475	—	2,017	3,458	5,475	(315	)	1997	08/17/17	40
Wingate at Belvidere (Lowell)	Lowell, MA	100%	—	1,335	9,019	10,354	—	1,335	9,019	10,354	(654	)	1966/2007	08/17/17	40
Wingate at Worcester	Worcester, MA	100%	—	945	8,770	9,715	—	945	8,770	9,715	(624	)	1970/1988	08/17/17	40
Wingate at West Springfield	W. Springfield, MA	100%	—	2,022	7,345	9,367	—	2,022	7,345	9,367	(573	)	1960/1985	08/17/17	40
Wingate at East Longmeadow	East Longmeadow, MA	100%	—	2,968	8,957	11,925	—	2,968	8,957	11,925	(704	)	1985/2005	08/17/17	40
Broadway by the Sea	Long Beach, CA	100%	—	2,939	11,782	14,721	—	2,939	11,690	14,629	(809	)	1968/2011	09/19/17	40
Coventry Court Health Center	Anaheim, CA	100%	—	2,044	14,167	16,211	—	2,044	14,167	16,211	(952	)	1968/2011	09/19/17	40
Fairfield Post-Acute Rehab	Fairfield, CA	100%	—	586	23,582	24,168	—	586	23,582	24,168	(1,474	)	1966/2006	09/19/17	40
Garden View Post-Acute Rehab	Baldwin Park, CA	100%	—	2,270	17,063	19,333	—	2,270	17,063	19,333	(1,125	)	1970/2015	09/19/17	40
Grand Terrace Health Care Center	Grand Terrace, CA	100%	—	432	9,382	9,814	—	432	9,382	9,814	(624	)	1945/2017	09/19/17	40
Pacifica Nursing & Rehab Center	Pacifica, CA	100%	—	1,510	27,397	28,907	—	1,510	27,397	28,907	(1,689	)	1975	09/19/17	40
Burien Nursing & Rehab Center	Burien, WA	100%	—	823	17,431	18,254	—	823	17,431	18,254	(1,132	)	1965/2014	09/19/17	40
Park West Care Center	Seattle, WA	100%	—	4,802	7,927	12,729	—	4,802	7,927	12,729	(577	)	1963/2016	09/19/17	40
Beachside Nursing Center	Huntington Beach, CA	100%	—	2,312	9,885	12,197	—	2,312	9,885	12,197	(654	)	1965/2010	09/19/17	40
Chatsworth Park Health Care	Chatsworth, CA	100%	—	7,841	16,916	24,757	—	7,841	16,916	24,757	(1,166	)	1976	09/19/17	40
Cottonwood Post-Acute Rehab	Woodland, CA	100%	—	504	7,369	7,873	—	504	7,369	7,873	(513	)	1975/2010	09/19/17	40
Danville Post-Acute Rehab	Danville, CA	100%	—	1,491	17,157	18,648	—	1,491	17,157	18,648	(1,107	)	1965	09/19/17	40
Lake Balboa Care Center	Van Nuys, CA	100%	—	2,456	16,462	18,918	—	2,456	16,462	18,918	(1,023	)	1958/2015	09/19/17	40
Lomita Post-Acute Care Center	Lomita, CA	100%	—	2,743	14,734	17,477	—	2,743	14,734	17,477	(995	)	1969	09/19/17	40
University Post-Acute Rehab	Sacramento, CA	100%	—	2,846	17,962	20,808	—	2,846	17,962	20,808	(1,144	)	1972	09/19/17	40

F-62

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Issaquah Nursing & Rehab Center	Issaquah, WA	100%	—	10,125	7,771	17,896	—	10,125	7,771	17,896	(595	)	1975/2012	09/19/17	40
Alamitos-Belmont Rehab Hospital	Long Beach, CA	100%	—	3,157	22,067	25,224	—	3,157	22,067	25,224	(1,440	)	1966/2014	09/19/17	40
Edgewater Skilled Nursing Center	Long Beach, CA	100%	—	2,857	5,878	8,735	—	2,857	5,878	8,735	(414	)	1952/2013	09/19/17	40
Fairmont Rehabilitation Hospital	Lodi, CA	100%	—	812	21,059	21,871	—	812	21,059	21,871	(1,279	)	1965	09/19/17	40
Palm Terrace Care Center	Riverside, CA	100%	—	1,717	13,806	15,523	—	1,717	13,806	15,523	(981	)	1966	09/19/17	40
Woodland Nursing & Rehab	Woodland, CA	100%	—	278	16,729	17,007	—	278	16,729	17,007	(1,076	)	1930/2007	09/19/17	40
Park Manor at Bee Cave	Bee Cave, TX	100%	—	2,107	10,413	12,520	—	2,107	10,413	12,520	(773	)	2014	12/15/17	40
Ramona	El Monte, CA	100%	—	2,058	19,671	21,729	—	2,058	19,671	21,729	(1,138	)	1965	01/10/18	40
Park Ridge	Shoreline, WA	100%	—	8,861	11,478	20,339	—	8,861	11,478	20,339	(770	)	1964/2012	01/19/18	40
			59,325	386,812	3,298,282	3,685,094	50,151	384,785	3,316,881	3,701,666	(306,565	)
Senior Housing - Leased
Forest Hills (ALF)	Broken Arrow, OK	100%	(4)	1,803	3,927	5,730	—	1,803	3,323	5,126	(1,571	)	2000/2018	11/15/10	30
Langdon Place of Exeter	Exeter, NH	100%	2,759	571	7,183	7,754	—	571	6,129	6,700	(2,408	)	1987	11/15/10	43
Langdon Place of Nashua	Nashua, NH	100%	4,999	—	5,654	5,654	—	—	4,635	4,635	(1,549	)	1989	11/15/10	40
Langdon Place of Keene	Keene, NH	100%	4,126	304	3,992	4,296	—	304	3,449	3,753	(1,520	)	1995	11/15/10	46
Langdon Place of Dover	Dover, NH	100%	3,426	801	10,036	10,837	—	801	8,934	9,735	(3,462	)	1987/2009, 2019	11/15/10	42
Age-Well Senior Living	Green Bay, WI	100%	—	256	2,262	2,518	1,032	256	3,294	3,550	(1,569	)	2004/2011	11/22/11	40
New Dawn Aurora	Aurora, CO	100%	—	2,874	12,829	15,703	6	2,874	12,835	15,709	(2,521	)	2009/2018	09/20/12	40
Gulf Pointe Village	Rockport, TX	100%	—	789	607	1,396	—	789	607	1,396	(210	)	1996/2018	11/30/12	40
Aspen Ridge Retirement Village	Gaylord, MI	100%	—	2,024	5,467	7,491	—	2,024	5,467	7,491	(1,375	)	2002	12/14/12	40
Green Acres of Cadillac	Cadillac, MI	100%	—	217	3,000	3,217	—	217	3,000	3,217	(638	)	2001/2006	12/14/12	40
Green Acres of Greenville	Greenville, MI	100%	—	684	5,832	6,516	249	684	6,081	6,765	(1,281	)	1999/2001, 2012, 2013, 2018	12/14/12	40
Green Acres of Manistee	Manistee, MI	100%	—	952	2,578	3,530	2,547	952	5,125	6,077	(963	)	2002/2017	12/14/12	40
Green Acres of Mason	Mason, MI	100%	—	198	4,131	4,329	—	198	4,131	4,329	(916	)	2009/2012	12/14/12	40
Nottingham Place	Midland, MI	100%	—	744	1,745	2,489	400	744	2,145	2,889	(491	)	1995/2015	12/14/12	40
Royal View	Mecosta, MI	100%	—	307	2,477	2,784	—	307	2,477	2,784	(601	)	2001	12/14/12	40
Tawas Village	East Tawas, MI	100%	—	258	3,713	3,971	45	258	3,758	4,016	(1,074	)	2005	12/14/12	40
Turning Brook	Alpena, MI	100%	—	546	13,139	13,685	—	546	13,139	13,685	(2,503	)	2006/2008, 2010	12/14/12	40
Greenfield of Woodstock	Woodstock, VA	100%	—	597	5,465	6,062	—	597	5,465	6,062	(1,034	)	1996/2015	06/28/13	40
Nye Square	Fremont, NE	100%	—	504	17,670	18,174	—	504	17,670	18,174	(2,995	)	1989/2002	02/14/14	40
The Meadows	Norfolk, NE	100%	—	217	9,906	10,123	1,000	217	10,906	11,123	(1,812	)	1989/1991, 1994, 2018, 2019	02/14/14	40

F-63

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Park Place	Fort Wayne, IN	100%	13,131	2,300	21,115	23,415	2,747	2,300	23,861	26,161	(4,441	)	2011/2016, 2018	04/30/14	40
Avalon MC - Boat Club	Fort Worth, TX	100%	—	359	8,126	8,485	—	359	8,126	8,485	(1,224	)	1996/2015	09/29/14	40
Avalon MC - 7200	Arlington, TX	100%	—	123	4,914	5,037	—	123	4,914	5,037	(742	)	1988/2014	09/29/14	40
Avalon MC - 7204	Arlington, TX	100%	—	215	4,821	5,036	—	215	4,822	5,037	(732	)	1988/2014	09/29/14	40
Avalon MC - 7140	Arlington, TX	100%	—	143	6,653	6,796	—	143	6,653	6,796	(980	)	2011	09/29/14	40
Delaney Creek Lodge	Brandon, FL	100%	—	1,283	8,424	9,707	483	1,283	8,907	10,190	(1,459	)	1999/2016	10/01/14	40
Nature Coast Lodge	Lecanto, FL	100%	—	1,031	5,577	6,608	452	1,031	6,030	7,061	(1,134	)	1997/2016	10/01/14	40
West Winds	Zephyrhills, FL	100%	—	1,688	9,098	10,786	360	1,688	9,459	11,147	(1,683	)	2008/2016	10/01/14	40
Tudor Heights	Baltimore, MD	100%	—	561	4,865	5,426	1,255	561	6,121	6,682	(1,178	)	1920/1997, 2015	10/14/14	40
Life’s Journey of Mattoon	Mattoon, IL	100%	—	812	6,796	7,608	63	264	1,921	2,185	(59	)	2006/2008	09/01/15	40
Life’s Journey of Pana	Pana, IL	100%	—	154	2,098	2,252	—	46	524	570	(20	)	1998/2012	09/01/15	40
Life’s Journey of Taylorville	Taylorville, IL	100%	—	267	5,201	5,468	50	106	1,794	1,900	(45	)	2012/2014	09/01/15	40
Life’s Journey of Paris	Paris, IL	100%	—	132	3,090	3,222	—	49	996	1,045	(23	)	1998/2013	09/01/15	40
Ashley Pointe	Lake Stevens, WA	100%	—	1,559	9,059	10,618	68	1,559	9,127	10,686	(1,186	)	1998/2012	09/17/15	40
Farmington Square Eugene	Eugene, OR	100%	—	1,428	16,138	17,566	101	1,428	16,239	17,667	(1,870	)	1996/1997, 2011, 2019	09/17/15	40
Farmington Square Tualatin	Tualatin, OR	100%	—	527	14,659	15,186	101	527	14,760	15,287	(1,709	)	1995/1997, 2019	09/17/15	40
Farmington Square of Salem	Salem, OR	100%	—	1,074	19,421	20,495	408	1,074	19,829	20,903	(2,345	)	1989/1995, 2018	09/17/15	40
Colorado Springs	Colorado Springs, CO	100%	—	1,210	9,490	10,700	—	1,210	9,490	10,700	(1,175	)	2013/2019	11/16/15	40
Sun City West	Sun City West, AZ	100%	—	930	9,170	10,100	248	930	9,418	10,348	(1,005	)	2012	07/01/16	40
Poet’s Walk at Fredericksburg	Fredericksburg, VA	100%	—	1,379	21,209	22,588	—	1,379	21,209	22,588	(2,167	)	2016	07/14/16	40
Poet’s Walk at Chandler Oaks	Round Rock, TX	100%	—	679	13,642	14,321	—	679	13,642	14,321	(1,398	)	2016	08/01/16	40
The Montecito Santa Fe	Santa Fe, NM	100%	—	2,536	19,441	21,977	1,892	2,807	23,468	26,275	(1,996	)	2006	09/23/16	40
The Golden Crest	Franklin, NH	100%	—	292	6,889	7,181	97	292	6,996	7,288	(736	)	1988	11/30/16	40
Poet’s Walk at Henderson	Henderson, NV	100%	—	1,430	21,850	23,280	—	1,430	21,862	23,292	(1,920	)	2016	12/01/16	40
Kruse Village	Brenham, TX	100%	—	476	11,912	12,388	—	476	11,922	12,398	(1,198	)	1991	12/02/16	40
Poet’s Walk of Cedar Parks	Cedar Park, TX	100%	—	1,035	13,127	14,162	—	1,035	13,127	14,162	(999	)	2017	06/01/17	40
Avamere Court at Keizer	Keizer, OR	100%	—	1,220	31,783	33,003	—	1,220	31,783	33,003	(2,002	)	1970	08/17/17	40
Arbor Court Retirement Community at Alvamar	Lawrence, KS	100%	—	584	4,431	5,015	—	584	4,431	5,015	(313	)	1995/2014	08/17/17	40
Arbor Court Retirement Community at Salina	Salina, KS	100%	—	584	3,020	3,604	—	584	3,020	3,604	(212	)	1989/2014	08/17/17	40
Arbor Court Retirement Community at Topeka	Topeka, KS	100%	—	313	5,492	5,805	—	313	5,492	5,805	(356	)	1986/2014	08/17/17	40
Aspen Grove Assisted Living	Sturgis, SD	100%	—	555	6,487	7,042	—	555	6,487	7,042	(464	)	2013	08/17/17	40

F-64

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Maurice Griffith Manor Living Center	Casper, WY	100%	—	294	72	366	—	294	72	366	(9	)	1984/1985	08/17/17	40
The Peaks at Old Laramie Trail (Lafayette)	Lafayette, CO	100%	—	1,085	19,243	20,328	—	1,883	19,196	21,079	(1,217	)	2016	12/15/17	40
Prairie View	Winnebago, IL	100%	—	263	3,743	4,006	—	263	3,743	4,006	(229	)	2007	01/31/18	40
Arbor View Assisted Living	Pewaukee, WI	100%	—	1,019	3,606	4,625	—	1,019	3,606	4,625	(187	)	2010	04/16/18	40
Legacy Assisted Living	Pewaukee, WI	100%	—	661	5,680	6,341	—	661	5,680	6,341	(272	)	2015	04/16/18	40
Greenfield of Strasburg	Strasburg, VA	100%	—	666	5,551	6,217	—	666	5,551	6,217	(273	)	2001	04/30/18	40
Poets Walk of Sarasota	Sarasota, FL	100%	—	1,440	22,541	23,981	—	1,440	22,541	23,981	(991	)	2018	05/18/18	40
The Pointe at Lifespring	Knoxville, TN	100%	—	1,603	9,219	10,822	—	1,603	9,219	10,822	(413	)	2017	08/31/18	40
Shavano Park Senior Living	Shavano Park, TX	100%	—	2,131	11,541	13,672	—	2,131	11,541	13,672	(472	)	2015	08/31/18	40
Traditions of Beavercreek	Beavercreek, OH	100%	—	1,622	24,215	25,837	5,686	1,622	29,901	31,523	(916	)	2016	11/01/18	40
Cadence at Poway Gardens	Poway, CA	100%	—	3,693	14,467	18,160	—	3,693	14,467	18,160	(35	)	1987/2011	11/22/19	40
			28,441	56,002	569,489	625,491	19,290	56,171	574,517	630,688	(72,278	)
Senior Housing - Managed
Winter Village	Frankenmuth, MI	100%	—	5,027	20,929	25,956	871	5,027	21,800	26,827	(4,475	)	1982/2008	09/21/12	40
Stoney River Marshfield	Marshfield, WI	100%	—	574	8,733	9,307	163	574	8,896	9,470	(1,806	)	2010	12/18/12	40
Kensington Court	Windsor, ON	100%	—	1,360	16,855	18,215	590	1,405	17,993	19,398	(2,458	)	1998	06/11/15	40
Masonville Manor	London, ON	100%	—	960	19,056	20,016	376	991	20,051	21,042	(2,662	)	1998/2015, 2019	06/11/15	40
Okanagan Chateau	Kelowna, BC	100%	—	2,321	8,308	10,629	1,065	2,396	9,643	12,039	(1,381	)	1990/2019	06/11/15	40
Court at Laurelwood	Waterloo, ON	100%	—	1,823	22,135	23,958	283	1,881	23,138	25,019	(3,035	)	2005/2015	06/11/15	40
Fairwinds Lodge	Sarnia, ON	100%	—	1,187	20,346	21,533	485	1,224	21,493	22,717	(2,811	)	2000/2019	06/11/15	40
The Shores	Kamloops, BC	100%	4,957	679	8,024	8,703	222	700	8,507	9,207	(1,163	)	1992/2014	06/11/15	40
Orchard Valley	Vernon, BC	100%	6,599	843	10,724	11,567	178	278	11,251	11,529	(1,456	)	1990/2008	06/11/15	40
Cherry Park	Penticton, BC	100%	4,752	763	6,771	7,534	592	787	7,584	8,371	(1,013	)	1990/1991, 2014, 2019	06/11/15	40
Maison Senior Living	Calgary, AB	100%	—	3,908	20,996	24,904	508	4,034	22,187	26,221	(2,631	)	2013	09/17/15	40
Ramsey	Ramsey, MN	100%	—	1,182	13,280	14,462	31	1,182	13,316	14,498	(909	)	2015	10/06/17	40
Marshfield II	Marshfield, WI	100%	—	500	4,134	4,634	9	500	4,148	4,648	(317	)	2014	10/06/17	40
Dover Place	Dover, DE	100%	—	2,797	23,054	25,851	99	2,797	23,153	25,950	(1,381	)	1999	01/02/18	40
Kanawha Place	Charleston, WV	100%	—	419	4,239	4,658	305	419	4,544	4,963	(368	)	1969	01/02/18	40
Leighton Place	Williamsport, PA	100%	—	296	9,191	9,487	174	296	9,365	9,661	(591	)	1990/2009	01/02/18	40
Maidencreek Place	Reading, PA	100%	—	684	12,950	13,634	34	684	12,984	13,668	(796	)	2004	01/02/18	40
Rolling Meadows Place	Scott Depot, WV	100%	—	230	6,271	6,501	238	230	6,510	6,740	(483	)	1996	01/02/18	40
Willowbrook Place	Clarks Summit, PA	100%	—	406	9,471	9,877	352	406	9,823	10,229	(667	)	1997	01/02/18	40
Wyncote Place	Wyncote, PA	100%	—	1,781	4,911	6,692	289	1,781	5,199	6,980	(419	)	1909	01/02/18	40
Amity Place	Douglassville, PA	100%	—	611	19,083	19,694	74	611	19,157	19,768	(1,111	)	2008	01/02/18	40
Milford Place	Milford, DE	100%	—	1,199	18,786	19,985	153	1,199	18,939	20,138	(1,131	)	1999	01/02/18	40

F-65

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Oak Hill Place	Oak Hill, WV	100%	—	609	2,636	3,245	128	609	2,765	3,374	(258	)	2001/2014	01/02/18	40
Seasons Place	Lewisburg, WV	100%	—	355	5,055	5,410	339	355	5,394	5,749	(443	)	1995	01/02/18	40
Parkview in Allen	Allen, TX	100%	—	2,190	45,767	47,957	—	2,190	46,425	48,615	(6,898	)	2004/2010	09/25/14	40
The Atrium At Gainesville	Gainesville, FL	100%	—	2,139	44,789	46,928	—	2,139	46,439	48,578	(7,164	)	1986/2013, 2015, 2019	09/25/14	40
The Chateau	McKinney, TX	100%	—	2,760	44,397	47,157	—	2,760	45,243	48,003	(6,787	)	2006/2010, 2019	09/25/14	40
Gardens At Wakefield Plantation	Raleigh, NC	100%	—	2,344	37,506	39,850	—	2,344	38,200	40,544	(5,572	)	2002/2014	09/25/14	40
Las Brisas	San Luis Obispo, CA	100%	—	4,992	30,909	35,901	—	4,992	31,349	36,341	(4,749	)	1987/2006, 2015	09/25/14	40
Creekside Terrace	Winston-Salem, NC	100%	—	2,995	24,428	27,423	—	2,995	24,713	27,708	(3,822	)	2001	09/25/14	40
Colonial Village	Longview, TX	100%	—	805	26,498	27,303	—	805	27,458	28,263	(4,157	)	1985/2010	09/25/14	40
Garden Village	Kansas City, MO	100%	—	1,325	20,510	21,835	—	1,325	21,381	22,706	(3,413	)	1983	09/25/14	40
Desert Rose	Yuma, AZ	100%	—	530	21,775	22,305	—	530	22,066	22,596	(3,395	)	1996/2014	09/25/14	40
Windland South	Nashville, TN	100%	—	1,996	19,368	21,364	—	1,996	20,281	22,277	(3,330	)	1986/2000	09/25/14	40
Cedar Woods	Branford, CT	100%	—	2,403	18,821	21,224	—	2,403	19,263	21,666	(2,962	)	1987	09/25/14	40
Virginian	Richmond, VA	100%	—	1,080	19,545	20,625	—	1,080	20,131	21,211	(3,141	)	1989/2007	09/25/14	40
Monarch Estates	Auburn, AL	100%	—	3,209	17,326	20,535	—	3,209	17,640	20,849	(2,821	)	2001	09/25/14	40
Village At The Falls	Menomonee Falls, WI	100%	—	1,477	18,778	20,255	—	1,477	19,044	20,521	(3,030	)	2005/2006, 2007/2011, 2019	09/25/14	40
Holiday At The Atrium	Glenville, NY	100%	—	978	18,257	19,235	—	978	18,967	19,945	(2,919	)	2001/2014	09/25/14	40
Lake Ridge Village	Eustis, FL	100%	—	1,152	17,523	18,675	—	1,152	18,330	19,482	(2,885	)	1984/1988, 2013	09/25/14	40
Heritage Village	McAllen, TX	100%	—	4,092	13,823	17,915	—	4,092	14,321	18,413	(2,339	)	1988	09/25/14	40
Madison Meadows	Phoenix, AZ	100%	—	2,567	12,029	14,596	—	2,567	12,807	15,374	(2,136	)	1986	09/25/14	40
South Wind Heights	Jonesboro, AR	100%	—	1,782	11,244	13,026	—	1,782	11,721	13,503	(1,939	)	1999	09/25/14	40
Harrison Regent	Ogden, UT	100%	—	794	10,873	11,667	—	794	11,607	12,401	(1,843	)	1985/2016	09/25/14	40
Capital Place	Olympia, WA	100%	—	2,477	23,767	26,244	—	2,477	25,160	27,637	(3,769	)	1986/2016	10/07/14	40
The Monarch at Richardson	Richardson, TX	100%	—	2,282	10,556	12,838	94	2,282	10,650	12,932	(57	)	1999	11/01/19	40
			16,308	76,883	804,427	881,310	7,652	76,735	831,036	907,771	(112,893	)
Specialty Hospitals and Other
Texas Regional Medical Center	Sunnyvale, TX	100%	—	4,020	57,620	61,640	—	4,020	57,620	61,640	(15,928	)	2009	05/03/11	40
Baylor Orthopedic Spine Hospital at Arlington	Arlington, TX	100%	—	—	44,217	44,217	—	—	44,217	44,217	(2,651	)	2009/2016	08/17/17	40
Touchstone Neurorecovery Center	Conroe, TX	100%	—	2,935	25,003	27,938	—	2,935	25,003	27,938	(1,695	)	1992	08/17/17	40
HealthBridge Children’s Hospital (Houston)	Houston, TX	100%	—	3,001	14,581	17,582	—	3,001	14,581	17,582	(890	)	1999/2009	08/17/17	40
Nexus Specialty Hospital - Woodlands Campus	Spring, TX	100%	—	1,319	15,153	16,472	—	1,319	15,153	16,472	(927	)	1995/1998	08/17/17	40
HealthBridge Children’s Hospital (Orange)	Orange, CA	100%	—	2,060	5,538	7,598	—	2,060	5,538	7,598	(353	)	2000	08/17/17	40

F-66

					Initial Cost to Company						Cost Capitalized Subsequent to Acquisition		Gross Amount at which Carried at Close of Period											Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)		Land		Building and Improve- ments(2)(3)		Total				Land		Building and Improve- ments(2)(3)		Total		Accumulated Depreciation and Amortization			Original Date of Construction/ Renovation	Date Acquired
ResCare Tangram - Texas Hill Country School	Maxwell, TX	100%	—		902		2,384		3,286		1		902		2,385		3,287		(170		)	1993	08/17/17	40
ResCare Tangram - Chaparral	Maxwell, TX	100%	—		901		1,198		2,099		—		901		1,198		2,099		(103		)	1994/2009	08/17/17	40
ResCare Tangram - Sierra Verde & Roca Vista	Maxwell, TX	100%	—		456		2,632		3,088		—		456		2,632		3,088		(176		)	1992	08/17/17	40
ResCare Tangram - 618 W. Hutchinson	San Marcos, TX	100%	—		51		359		410		62		51		421		472		(70		)	1869	08/17/17	40
ResCare Tangram - Ranch	Seguin, TX	100%	—		539		2,627		3,166		—		539		2,627		3,166		(223		)	1989	08/17/17	40
ResCare Tangram - Mesquite	Seguin, TX	100%	—		228		3,407		3,635		79		228		3,486		3,714		(247		)	1985/1991	08/17/17	40
ResCare Tangram - Hacienda	Kingsbury, TX	100%	—		104		2,788		2,892		27		104		2,814		2,918		(182		)	1990/2012	08/17/17	40
ResCare Tangram - Loma Linda	Seguin, TX	100%	—		52		805		857		—		52		805		857		(57		)	1970	08/17/17	40
Aurora Chicago Lakeshore Hospital	Chicago, IL	100%	—		8,574		39,732		48,306		—		8,574		39,732		48,306		(2,576		)	1992/2011	08/17/17	40
Aurora Arizona West	Glendale, AZ	100%	—		1,501		67,046		68,547		—		1,501		67,046		68,547		(4,104		)	1996/2013	08/17/17	40
Aurora Arizona East	Tempe, AZ	100%	—		3,137		50,073		53,210		—		3,137		50,073		53,210		(3,133		)	2001/2016	08/17/17	40
Aurora Charter Oak Hospital	Covina, CA	100%	—		23,472		71,542		95,014		—		23,472		71,542		95,014		(4,549		)	1974/2011	08/17/17	40
Aurora Vista del Mar Hospital	Ventura, CA	100%	—		8,089		43,645		51,734		—		8,089		43,645		51,734		(3,017		)	1984/2018	08/17/17	40
Aurora San Diego Hospital	San Diego, CA	100%	—		8,403		55,015		63,418		6,999		8,403		62,013		70,416		(3,855		)	1988/2017	08/17/17	40
Gateway Rehabilitation Hospital at Florence	Florence, KY	100%	—		3,866		26,447		30,313		—		3,866		26,447		30,313		(1,615		)	2000	08/17/17	40
Highlands Regional Rehabilitation Hospital	El Paso, TX	100%	—		2,009		6,639		8,648		—		2,009		6,639		8,648		(450		)	1999/2009	08/17/17	40
Landmark Carmel	Carmel, IN	100%	—		963		4,347		5,310		—		963		4,347		5,310		(64		)	1996/2019	07/24/19	40
Landmark Louisville	Louisville, KY	100%	—		1,078		8,305		9,383		—		1,078		8,305		9,383		(89		)	2002/2018	08/21/19	40
Recovery Centers of America at Monroeville	Monroeville, PA	100%	—		2,034		1,758		3,792		—		2,034		1,758		3,792		—			1987/2020	12/18/19	40
			—		79,694		552,861		632,555		7,168		79,694		560,027		639,721		(47,124		)
Multi-property Indebtedness			10,703		—		—		—		—		—		—		—		—
			114,777		599,391		5,225,059		5,824,450		84,261		597,385		5,282,461		5,879,846		(538,860		)
Corporate Assets			—		—		136		136		601		—		737		737		(353		)
			$	114,777	$	599,391	$	5,225,195	$	5,824,586	$	84,862	$	597,385	$	5,283,198	$	5,880,583	$	(539,213	)

⁽¹⁾  Encumbrances do not include deferred financing costs, net of $1.7 million as of December 31, 2019.

⁽²⁾  Building and building improvements include land improvements and furniture and equipment.

⁽³⁾  The aggregate cost of real estate for federal income tax purposes was $4.9 billion.

⁽⁴⁾  Property serves as collateral for secured debt totaling $10.7 million as of December 31, 2019.

F-67

SCHEDULE III

REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION

(dollars in thousands)

	Year Ended December 31,
	2019			2018			2017
Real estate:
Balance at the beginning of the year	$	6,255,883		$	6,334,855		$	2,292,751
Acquisitions	49,483			262,605			4,145,977
Real estate assumed	12,962			—			—
Real estate acquired through loans receivable foreclosure	—			—			19,096
Improvements	25,451			27,697			6,954
Impairment	(143,655		)	(1,576		)	(2,211		)
Sale of real estate	(322,910		)	(351,922		)	(133,897		)
Foreign currency translation	6,918			(12,639		)	10,556
Write-off of fully depreciated assets	(3,549		)	(3,137		)	(4,371		)
Balance at the end of the year	$	5,880,583		$	6,255,883		$	6,334,855
Accumulated depreciation:
Balance at the beginning of the year	$	(402,338	)	$	(340,423	)	$	(282,812	)
Depreciation expense	(163,863		)	(174,398		)	(101,198		)
Impairment	22,070			163			885
Sale of real estate	2,092			108,122			38,914
Foreign currency translation	(723		)	1,061			(583		)
Write-off of fully depreciated assets	3,549			3,137			4,371
Balance at the end of the year	$	(539,213	)	$	(402,338	)	$	(340,423	)

F-68

SCHEDULE IV

MORTGAGE LOANS ON REAL ESTATE

As of December 31, 2019

(dollars in thousands)

Description	Contractual Interest Rate		Maturity Date	Periodic Payment Terms	Prior Liens		Principal Balance		Book Value (1)		Principal Amount of Loans Subject to Delinquent Principal or Interest
Mortgages:
River Vista	10.0	%	2027	(2)	$	—	$	19,000	$	19,000	N/A
Construction Mortgages:
Arlington	8.0		2022	(3)	—		2,468		2,487		N/A
					$	—	$	21,468	$	21,487

⁽¹⁾  The aggregate cost for federal income tax purposes was $21.6 million as of December 31, 2019.

⁽²⁾  Interest is due monthly, and principal is due at the maturity date.

⁽³⁾  Interest and principal for the first 36 months is deferred and due at the maturity date. Interest after the first 36 months is due monthly.

Changes in mortgage loans are summarized as follows:

	Year Ended December 31,
	2019			2018			2017
Balance at the beginning of the year	$	23,146		$	16,033		$	39,026
Additions during period:
Draws	1,689			10,943			1,738
New mortgage loans	—			—			12,987
Interest income added to principal	194			1,528			539
Deductions during period:
Paydowns/repayments	(3,561		)	(5,358		)	(14,570		)
Conversion to real property	—			—			(19,085		)
Write-offs (1)	—			—			(4,602		)
Balance at the end of the year	$	21,468		$	23,146		$	16,033

⁽¹⁾  During the year ended December 31, 2017, the Company wrote off uncollectible amounts related to one mortgage loan that was repaid.

F-69

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on February 24, 2020.

SABRA HEALTH CARE REIT, INC.
By:	/S/    RICHARD K. MATROS
	Richard K. Matros Chairman, President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

Name	Title	Date
/S/    RICHARD K. MATROS	Chairman, President and Chief Executive Officer (Principal Executive Officer)	February 24, 2020
Richard K. Matros
/S/    HAROLD W. ANDREWS, JR.	Executive Vice President, Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)	February 24, 2020
Harold W. Andrews, Jr.
/S/    CRAIG A. BARBAROSH	Director	February 24, 2020
Craig A. Barbarosh
/S/    ROBERT A. ETTL	Director	February 24, 2020
Robert A. Ettl
/S/    MICHAEL J. FOSTER	Director	February 24, 2020
Michael J. Foster
/S/    RONALD G. GEARY	Director	February 24, 2020
Ronald G. Geary
/S/    LYNNE S. KATZMANN	Director	February 24, 2020
Lynne S. Katzmann
/S/    RAYMOND J. LEWIS	Director	February 24, 2020
Raymond J. Lewis
/S/    JEFFREY A. MALEHORN	Director	February 24, 2020
Jeffrey A. Malehorn
/S/    MILTON J. WALTERS	Director	February 24, 2020
Milton J. Walters

EX-4.1

DESCRIPTION OF CAPITAL STOCK OF

SABRA HEALTH CARE REIT, INC.

The following is a summary of the material terms of our capital stock as set forth in our Articles of Amendment and Restatement (our “charter) and our Amended and Restated Bylaws (our “bylaws”), which govern the rights of holders of our capital stock. The following summary does not purport to be complete and is subject to and qualified in its entirety by reference to applicable provisions of the Maryland General Corporation Law (the “MGCL”) and to our charter and bylaws. For a complete description, we refer to the MGCL, our charter and our bylaws. Copies of our charter and bylaws are included as exhibits to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part.

General

Our charter provides that we may issue up to 250,000,000 shares of common stock, $0.01 par value per share, and up to 10,000,000 shares of preferred stock, $0.01 par value per share. As of December 31, 2019, 205,208,018 shares of common stock were issued and outstanding, and no shares of preferred stock were issued and outstanding. Under Maryland law, stockholders are not generally liable for our or our subsidiaries’ debts or obligations solely as a result of their status as stockholders.

Common Stock

All issued and outstanding shares of common stock are fully paid and nonassessable. Subject to the preferential rights of any other class or series of stock and the provisions of our charter that restrict transfer and ownership of our stock, the holders of shares of our common stock generally are entitled to receive dividends on such stock out of assets legally available for distribution to our stockholders when, as and if authorized by our board of directors and declared by us. The holders of shares of common stock are also entitled to share ratably in our net assets legally available for distribution to our stockholders in the event of our liquidation, dissolution or winding up, after payment of, or adequate provision for, all of our known debts and liabilities.

Subject to the rights of any other class or series of ourstock and the provisions of our charter that restrict the transfer and ownership of our stock, each outstanding share of common stock entitles the holder to one vote on all matters submitted to a vote of the stockholders, including the election of directors, and the holders of shares of our common stock possess the exclusive voting power.

Holders of shares of our common stock generally have no preference, conversion, exchange, sinking fund, redemption or appraisal rights and have no preemptive rights to subscribe for any of our securities. Subject to the provisions of our charter that restrict transfer and ownership of our stock, all shares of common stock have equal dividend, liquidation and other rights.

Preferred Stock

Under our charter, our board of directors may from time to time establish and cause us to issue one or more classes or series of preferred stock. Prior to the issuance of shares of each class or series of preferred stock, our board of directors will be required by the MGCL and our charter to adopt resolutions and file articles supplementary with the State Department of Assessments and Taxation of Maryland. The articles supplementary will fix for each class or series the terms, preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications, and terms and conditions of redemption, including, but not limited to, the following:

1

• the title, designation and stated value of the preferred stock;

• the number of shares constituting each class or series;

• voting rights;

• rights and terms of redemption (including sinking fund provisions);

• dividend rights and rates;

• dissolution;

• terms concerning the distribution of assets;

• conversion or exchange terms;

• redemption prices; and

• liquidation preferences.

All shares of preferred stock will, when issued in exchange for the consideration therefor, be fully paid and nonassessable and, unless otherwise provided for in the terms of a particular class or series of preferred stock, will not have any preemptive or similar rights. Our board of directors, without stockholder approval, could authorize the issuance of shares of preferred stock with terms and conditions that could have the effect of delaying, deferring or preventing a takeover or other transaction that might involve a premium price for holders of the shares or which holders might believe to be in their best interests. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock and may adversely affect the voting and other rights of the holders of our common stock.

We will set forth in the applicable prospectus supplement relating to the class or series of preferred stock being offered the specific terms of each class or series of our preferred stock, including the price at which the preferred stock may be purchased, the number of shares of preferred stock offered, and the terms, if any, on which the preferred stock may be convertible into common stock or exchangeable for other securities.

Power to Reclassify Unissued Shares

Our board of directors has the power, without stockholder approval, to amend our charter to increase or decrease the aggregate number of authorized shares of capital stock or the number of authorized shares of capital stock of any class or series, to authorize us to issue additional authorized but unissued shares of common stock or preferred stock and to classify and reclassify any unissued shares of common stock or preferred stock into other classes or series of stock, including one or more classes or series of common stock or preferred stock that have priority with respect to voting rights, dividends or upon liquidation over shares of common stock. Prior to the issuance of shares of each new class or series, our board of directors will be required by the MGCL and our charter to set, subject to the provisions of our charter regarding restrictions on transfer and ownership of stock, the terms, preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications, and terms and conditions of redemption for each class or series of capital stock.

Restrictions on Transfer and Ownership of Stock

In order for us to qualify as a real estate investment trust (“REIT”) under the Internal Revenue Code of 1986, as amended (the “Code”), among other requirements, our stock must be beneficially owned by 100 or more persons during at least 335 days of a taxable year of 12 months (other than the first year for which an election to be a REIT has been made) or during a proportionate part of a shorter taxable year. Also, not more than 50% of the value of the outstanding shares of our stock may be owned, directly or

2

indirectly, by five or fewer individuals (as defined in the Code to include certain entities such as qualified pension plans) during the last half of a taxable year (other than the first year for which an election to be a REIT has been made). In addition, rent from related-party tenants (generally, a tenant of a REIT that is 10% or more owned, actually or constructively, by the REIT, or that is a 10% owner of the REIT) is not qualifying income for purposes of the gross income tests under the Code.

Our charter contains restrictions on the transfer and ownership of our stock. The relevant sections of our charter provide that, subject to the exceptions described below, no person or entity may beneficially own, or be deemed to own by virtue of the applicable constructive ownership provisions of the Code, more than 9.9% in value or number of shares, whichever is more restrictive, of our outstanding common stock or more than 9.9% in value of our outstanding stock. In addition, classes of shares other than common stock may be subject to ownership limitations set forth in the articles supplementary relating to such shares. These limits are collectively referred to as the “ownership limits.” The constructive ownership rules under the Code are complex and may cause stock owned actually or constructively by a group of related individuals and/or entities to be owned constructively by one individual or entity. As a result, the acquisition of less than 9.9% of our outstanding common stock or less than 9.9% of our outstanding stock, or the acquisition of an interest in an entity that owns, actually or constructively, our stock, could, nevertheless, cause the acquiror, or another individual or entity, to own constructively shares of our outstanding stock in excess of the ownership limits.

Our board of directors may, upon receipt of certain representations, covenants and undertakings and in its sole and absolute discretion, prospectively or retroactively, exempt a person from the ownership limits or establish a different limit on ownership, or an excepted holder limit, for a particular stockholder if the stockholder’s ownership in excess of the ownership limits would not result in our being “closely held” under Section 856(h) of the Code or otherwise failing to qualify as a REIT. As a condition of granting a waiver of the ownership limits or creating an excepted holder limit, our board of directors may, but is not required to, require an Internal Revenue Service ruling or opinion of counsel satisfactory to our board of directors (in its sole discretion) as it may deem necessary or advisable to determine or ensure our status as a REIT. Our board of directors may only reduce any excepted holder limit with the written consent of such excepted holder at any time or pursuant to the terms and conditions of the agreements entered into with the stockholder in connection with the establishment of the excepted holder limit.

Our board of directors may also, from time to time, increase or decrease the ownership limits unless, after giving effect to the increased or decreased ownership limits, five or fewer persons could beneficially own, in the aggregate, more than 49.9% in number or value of our outstanding stock or we would otherwise fail to qualify as a REIT. Decreased ownership limits do not apply to any person or entity whose ownership of stock is in excess of the decreased ownership limits until the person or entity’s ownership of stock equals or falls below the decreased ownership limits, but any further acquisition of stock would be in violation of the decreased ownership limits.

Our charter also prohibits:

• any person from beneficially or constructively owning shares of our stock to the extent such beneficial or constructive ownership would result in our being “closely held” under Section 856(h) of the Code (without regard to whether the ownership interest is held during the last half of a taxable year), or otherwise cause us to fail to qualify as a REIT;

• any transfer of shares of our stock if the transfer would result in shares of our stock being beneficially owned by fewer than 100 persons;

3

• any person from beneficially or constructively owning shares of our stock to the extent such beneficial or constructive ownership would result in our constructively owning 9.9% or more of the ownership interests in a tenant within the meaning of Section 856(d)(2)(B) of the Code; and

• any person from constructively owning shares of our stock to the extent such constructive ownership would cause any “eligible independent contractor” that operates a “qualified health care property” on behalf of a “taxable REIT subsidiary” of ours (as such terms are defined in Sections 856(d)(9)(A), 856(e)(6)(D)(i) and 856(l) of the Code, respectively) to fail to qualify as such.  

Any person who acquires or attempts or intends to acquire beneficial or constructive ownership of shares of our stock that will or may violate the ownership limits, or any of the other restrictions on transfer and ownership of stock, and any person who is the intended transferee of shares of stock that are transferred to the charitable trust described below, will be required to give us immediate written notice and, in the case of a proposed transaction, at least 15 days’ prior written notice and to provide us with such other information as we may request in order to determine the effect of the transfer on our status as a REIT. The provisions of our charter regarding restrictions on transfer and ownership of stock do not apply if our board of directors determines that it is no longer in our best interests to attempt to qualify, or to continue to qualify, as a REIT or that compliance is no longer required in order for us to qualify as a REIT.

Any attempted transfer of our stock which, if effective, would result in our stock being beneficially owned by fewer than 100 persons will be null and void and the intended transferee shall acquire no rights in such shares of stock. Any attempted transfer of our stock which, if effective, would violate any of the other restrictions described above will cause the number of shares causing the violation (rounded up to the nearest whole share) to be automatically transferred to a trust for the exclusive benefit of one or more charitable beneficiaries, and the proposed transferee will not acquire any rights in the shares. We will appoint the trustee of the trust, who will be unaffiliated with us and any proposed transferee of the shares. The automatic transfer will be deemed to be effective as of the close of business on the business day prior to the date of the violative transfer or other event that results in a transfer to the trust. Shares of our stock held in the trust will be issued and outstanding shares. If the transfer to the trust as described above is not automatically effective, for any reason, to prevent violation of the applicable restrictions on transfer and ownership of stock, then the transfer of the shares will be null and void.

The proposed transferee shall have no rights in the shares held by the trust. The proposed transferee will not benefit economically from ownership of any shares of stock held in the trust, will have no rights to dividends or other distributions and no rights to vote or other rights attributable to the shares of stock held in the trust. The trustee of the trust will exercise all voting rights and receive all dividends and other distributions with respect to shares held in the trust for the exclusive benefit of the charitable beneficiary of the trust. Any dividend or other distribution paid prior to our discovery that shares have been transferred to a trust as described above must be repaid by the recipient to the trustee upon demand and any dividend or other distribution authorized but unpaid shall be held in trust for the charitable beneficiary. Subject to Maryland law, effective as of the date that the shares have been transferred to the trust, the trustee will have the authority, at the trustee’s sole discretion, to rescind as void any vote cast by a proposed transferee prior to our discovery that the shares have been transferred to the trust and to recast the vote in accordance with the desires of the trustee acting for the benefit of the charitable beneficiary of the trust. However, if we have already taken irreversible corporate action, then the trustee may not rescind and recast the vote.

If our board of directors or a committee thereof or other designee if permitted by the MGCL determines in good faith that a proposed transfer or other event has taken place that violates the restrictions on transfer

4

and ownership of stock set forth in our charter or that a person intends to acquire or has attempted to acquire beneficial or constructive ownership in violation of our ownership limits, then our board of directors or such committee or other designee if permitted by the MGCL shall take such action as it deems advisable to refuse to give effect to or to prevent such transfer or other event, including, but not limited to, causing us to redeem shares of stock, refusing to give effect to the transfer on our books or instituting proceedings to enjoin the transfer; provided, however, that any transfer or attempted transfer or other event in violation of the above restrictions shall automatically result in the transfer to the trust described above, and, where applicable, such transfer or other event shall be null and void as provided above irrespective of any action or non-action by our board of directors or any committee or designee thereof.

Shares of stock transferred to the trustee will be deemed offered for sale to us, or our designee, at a price per share equal to the lesser of (i) the price paid per share in the transaction that resulted in such transfer to the charitable trust (or, in the case of a devise or gift, the market price of such stock at the time of such devise or gift) and (ii) the market price of such stock on the date we, or our designee, accepts such offer. We will have the right to accept such offer until the trustee has sold the shares held in the charitable trust. Upon a sale to us, the interest of the charitable beneficiary in the shares sold will terminate and the trustee will be required to distribute the net proceeds of the sale to the proposed transferee and any distributions held by the trustee with respect to such shares to the charitable beneficiary. We may reduce the amount payable to the proposed transferee by the amount of dividends and distributions that have been paid to the proposed transferee and are owed by the proposed transferee to the trustee. We may pay the amount of such reduction to the trustee for the benefit of the charitable beneficiary.

If we do not buy the shares, the trustee will be required, within 20 days of receiving notice from us of a transfer of shares to the trust, to sell the shares to a person or entity designated by the trustee who could own the shares without violating the ownership limits, or the other restrictions on transfer and ownership of stock. Upon such sale, the interest of the charitable beneficiary in the shares of stock sold shall terminate and the trustee shall distribute the net proceeds of the sale to the proposed transferee and to the charitable beneficiary. After selling the shares, the trustee will be required to distribute to the proposed transferee an amount equal to the lesser of (i) the price paid by the proposed transferee for the shares or, if the proposed transferee did not give value for the shares in connection with the event causing the shares to be held by the trust (e.g., in the case of a gift, devise or other such transaction), the market price of such stock on the day of the event causing the shares to be held by the trust and (ii) the price per share received by the trustee (net of any commissions and other expenses) from the sale or other disposition of the shares. The trustee may reduce the amount payable to the proposed transferee by the amount of dividends and distributions that have been paid to the proposed transferee and are owed by the proposed transferee to the trustee. Any net sales proceeds in excess of the amount payable to the proposed transferee will be paid immediately to the charitable beneficiary. If the proposed transferee sells such shares prior to the discovery that such shares have been transferred to the trustee, then (i) such shares shall be deemed to have been sold on behalf of the trust and (ii) to the extent that the proposed transferee received an amount for such shares that exceeds the amount that such proposed transferee would have received if such shares had been sold by the trustee, such excess shall be paid to the trustee upon demand.

Any certificates representing shares of our stock will bear a legend referring to the restrictions on transfer and ownership described above or state that we will furnish a full statement of the above restrictions on request and without charge.

Every owner of 5% or more (or such lower percentage as required by the Code or the regulations promulgated thereunder) of our stock, in number or in value, within 30 days after the end of each taxable

5

year, will be required to give us written notice stating the person’s name and address, the number of shares of each class and series of stock that the person beneficially owns, a description of the manner in which the shares are held and any additional information that we request in order to determine the effect, if any, of the person’s beneficial ownership on our status as a REIT and to ensure compliance with the ownership limits. In addition, any beneficial owner or constructive owner of shares of our stock and any person or entity (including the stockholder of record) who holds shares of our stock for a beneficial owner or constructive owner will be required to, on request, disclose to us in writing such information as we may request in order to determine the effect, if any, of the stockholder’s actual and constructive ownership of stock on our status as a REIT and to comply with the requirements of any governmental or taxing authority.

The restrictions on transfer and ownership described above could have the effect of delaying, deferring or preventing a change of control in which holders of shares of our stock might receive a premium for their shares over the then-prevailing price.

Certain Provisions of Maryland Law and of Our Charter and Bylaws

The following paragraphs summarize certain provisions of our charter and bylaws, as well as selected provisions of the MGCL.

Board of Directors

Our charter and bylaws provide that the number of directors of our company may be established by our board of directors, but may not be fewer than the minimum number required by the MGCL nor more than nine. Currently, we have nine directors. We have elected to be subject to certain provisions of the MGCL, as a result of which our board of directors has the exclusive power to fill vacancies on the board of directors.

Each of our directors is elected by our stockholders to serve until the next annual meeting of stockholders and until his or her successor is duly elected and qualifies. In order for any incumbent director to become a nominee of our board of directors for further service on our board of directors, such person must submit an irrevocable resignation, which will only become effective as described below. Under our charter, there is no cumulative voting in the election of our board of directors. Instead, our bylaws require that, in uncontested elections, each director be elected by the majority of votes cast with respect to such director. This means that the number of shares voted “for” a director nominee must exceed the number of shares affirmatively voted “against” that nominee in order for that nominee to be elected. If a nominee who is an incumbent director does not receive a majority of the votes cast in an uncontested election, the nominating and governance committee of our board of directors shall consider the facts and circumstances relating to the election and the resignation submitted by such nominee, and recommend to our board of directors, within sixty (60) days following certification of the election results, whether such resignation should be accepted or rejected or whether other action should be taken. The board of directors shall act on the resignation within ninety (90) days following certification of the election results, taking into account the committee’s recommendation, and publicly disclose (by a press release and filing an appropriate disclosure with the Securities and Exchange Commission) its decision regarding the resignation. The committee in making its recommendation and the board of directors in making its decision each may consider any factors and other information that they consider appropriate and relevant.

Removal of Directors

6

Our charter provides that, subject to the rights of holders of any class or series of stock separately entitled to elect or remove one or more directors, a director may be removed with or without cause, by the affirmative vote of at least a majority of the votes entitled to be cast generally in the election of directors.

Amendments to Our Charter and Bylaws and Approval of Extraordinary Actions

Under Maryland law, a Maryland corporation generally cannot amend its charter, merge, convert, consolidate, sell all or substantially all of its assets, engage in a statutory share exchange, dissolve or engage in similar transactions outside the ordinary course of business unless the action is advised by the board of directors and approved by the affirmative vote of stockholders entitled to cast at least two-thirds of the votes entitled to be cast on the matter. However, a Maryland corporation may provide in its charter for approval of these actions by a lesser percentage, but not less than a majority of all of the votes entitled to be cast on the matter. Our charter provides that the affirmative vote of at least a majority of the votes entitled to be cast on the matter will be required to approve all charter amendments or extraordinary actions. Also, Maryland law permits a Maryland corporation to transfer all or substantially all of its assets without the approval of the stockholders of the corporation to one or more persons if 90% or more of the equity interests of the person or persons are owned, directly or indirectly, by the corporation.

Our bylaws may be altered, amended or repealed, in whole or in part, and new bylaws may be adopted by (i) our board of directors or (ii) our stockholders with the affirmative vote of a majority of the votes entitled to be cast on the matter by stockholders entitled to vote generally in the election of directors.

Business Combinations

Under the MGCL, “business combinations” between a Maryland corporation and an interested stockholder or an affiliate of an interested stockholder are prohibited for five years after the most recent date on which the interested stockholder becomes an interested stockholder. These business combinations include a merger, consolidation, share exchange or, in circumstances specified in the statute, an asset transfer or issuance or reclassification of equity securities. An interested stockholder is defined as:

• any person who beneficially owns, directly or indirectly, 10 percent or more of the voting power of the corporation’s outstanding voting stock; or

• an affiliate or associate of the corporation who, at any time within the two-year period prior to the date in question, was the beneficial owner, directly or indirectly, of 10 percent or more of the voting power of the then outstanding voting stock of the corporation.

A person is not an interested stockholder under the statute if the board of directors approved in advance the transaction by which such person otherwise would have become an interested stockholder. However, in approving a transaction, a board of directors may provide that its approval is subject to compliance, at or after the time of approval, with any terms and conditions determined by the board of directors.

After the five-year prohibition, any business combination between the Maryland corporation and an interested stockholder generally must be recommended by the board of directors of the corporation and approved by the affirmative vote of at least:

• eighty percent of the votes entitled to be cast by holders of outstanding shares of voting stock of the corporation; and

• two-thirds of the votes entitled to be cast by holders of voting stock of the corporation other than shares held by the interested stockholder with whom or with whose affiliate the business combination is to be effected or held by an affiliate or associate of the interested stockholder, voting together as a single class.

7

These supermajority vote requirements do not apply if the corporation’s common stockholders receive a minimum price, as defined under the MGCL, for their shares in the form of cash or other consideration in the same form as previously paid by the interested stockholder for its shares. The statute provides various exemptions from its provisions, including for business combinations that are exempted by the board of directors before the time that the interested stockholder becomes an interested stockholder. Our board of directors has not opted out of the business combination provisions of the MGCL, and consequently, the five-year prohibition and the supermajority vote requirements will apply to business combinations between us and any interested stockholder.

We are subject to the business combination provisions described above. However, our board of directors may elect to opt out of the business combination provisions at any time.

Control Share Acquisitions

Maryland law provides that issued and outstanding control shares of a Maryland corporation acquired in a control share acquisition have no voting rights except to the extent approved by the stockholders by the affirmative vote of two-thirds of all the votes entitled to be cast on the matter. Shares owned by the acquiror, by officers or by employees who are directors of the corporation are excluded from shares entitled to vote on the matter. Control shares are voting shares of stock which, if aggregated with all other shares of stock owned by the acquiror or in respect of which the acquiror is able to exercise or direct the exercise of voting power (except solely by virtue of a revocable proxy), would entitle the acquiror to, directly or indirectly, exercise voting power in electing directors within one of the following ranges of voting power:

• one-tenth or more but less than one-third,

• one-third or more but less than a majority, or

• a majority or more of all voting power.

Control shares do not include shares the acquiror is then entitled to vote as a result of having previously obtained stockholder approval or shares acquired directly from the corporation. A control share acquisition means the acquisition of control shares, subject to certain exceptions.

A person who has made or proposes to make a control share acquisition may compel the board of directors of the corporation to call a special meeting of stockholders to be held within 50 days of demand to consider the voting rights of the shares. The right to compel the calling of a special meeting is subject to the satisfaction or waiver of certain conditions, including an undertaking to pay the expenses of the special meeting. If no request for a special meeting is made, the corporation may itself present the question at any stockholders meeting.

If voting rights are not approved at the special meeting or if the acquiror does not deliver an acquiring person statement as required by the statute, then the corporation may, subject to certain conditions and limitations, redeem for fair value any or all of the control shares, except those for which voting rights have previously been approved. Fair value is determined, without regard to the absence of voting rights for the control shares, as of the date of the last control share acquisition by the acquiror or of any meeting of stockholders at which the voting rights of such shares are considered and not approved. If voting rights for control shares are approved at a stockholders meeting and the acquiror becomes entitled to vote a majority of the shares entitled to vote, all other stockholders may exercise appraisal rights. The fair value of the shares as determined for purposes of appraisal rights may not be less than the highest price per share paid by the acquiror in the control share acquisition.

8

The control share acquisition statute does not apply (a) to shares acquired in a merger, consolidation or share exchange if the corporation is a party to the transaction or (b) to acquisitions approved or exempted by the charter or bylaws of the corporation.

Our bylaws contain a provision that exempts from the control share acquisition statute any and all acquisitions by any person of shares of our stock. This provision may be amended or eliminated at any time in the future.

Subtitle 8

Subtitle 8 of Title 3 of the MGCL permits a Maryland corporation with a class of equity securities registered under the the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and at least three independent directors to elect to be subject, by provision in its charter or bylaws or by a resolution of its board of directors and notwithstanding any contrary provision in the charter or bylaws, to any or all of the following five provisions:

• a classified board,

• a two-thirds vote requirement for removing a director,

• a requirement that the number of directors be fixed only by vote of the directors,

• a requirement that a vacancy on the board be filled only by the affirmative vote of a majority of the remaining directors in office and such director shall hold office for the remainder of the full term of the class of directors in which the vacancy occurred and until a successor is elected and qualifies, and

• a majority requirement for the calling of a stockholder-requested special meeting of stockholders.  

Pursuant to our charter, we have elected to be subject to the provision of Subtitle 8 that requires that vacancies on the board may be filled only by the remaining directors and for the remainder of the full term of the directorship in which the vacancy occurred. Through provisions in our bylaws unrelated to Subtitle 8, we already (1) vest in the board of directors the exclusive power to fix the number of directors and (2) require, unless called by our chairman, chief executive officer, president or the board of directors, the request of stockholders entitled to cast not less than a majority of the votes entitled to be cast at such meeting to call a special meeting of stockholders if certain procedural requirements are met.

Special Meetings of the Stockholders

Each of our chairman of the board, chief executive officer, president and board of directors has the power to call a special meeting of the stockholders. A special meeting of the stockholders to act on any matter that may properly be brought before a meeting of stockholders will also be called by our secretary upon the written request of the stockholders entitled to cast a majority of all the votes entitled to be cast on such matter at the meeting and containing the information required by our bylaws. The secretary will be required to inform the requesting stockholders of the reasonably estimated cost of preparing and mailing the notice of meeting (including our proxy materials), and the requesting stockholder will be required to pay such estimated cost to the secretary prior to the preparation and mailing of any notice for such special meeting.

Advance Notice of Director Nomination and New Business; Proxy Access

Our charter and bylaws provide that, at any annual meeting of stockholders, nominations of individuals for election to the board of directors and proposals of business to be considered by stockholders may be

9

made only (i) pursuant to our notice of the meeting, (ii) by or at the direction of the board of directors, or (iii) by a stockholder who was a stockholder of record at each of (A) the record date with respect to the annual meeting, (B) the time of giving of notice by the stockholder as provided in the advance notice provisions set forth in our bylaws, and (C) the time of the annual meeting (and any postponement or adjournment thereof), who is entitled to vote at the annual meeting in the election of directors or on such other proposed business and who has complied with the advance notice provisions set forth in our bylaws. The stockholder generally must provide notice to the secretary not less than 120 days nor more than 150 days prior to the first anniversary of the date of our proxy statement for the solicitation of proxies for election of directors at the preceding year’s annual meeting.

Only the business specified in our notice of meeting may be brought before any special meeting of stockholders. Our bylaws provide that nominations of individuals for election to our board of directors at a special meeting of stockholders may be made only (i) by or at the direction of our board of directors, (ii) by a stockholder that has requested that a special meeting be called for the purpose of electing directors and provides the information required to request such a meeting under our bylaws, or (iii) provided that the special meeting has been called for the purpose of electing directors, by any stockholder of record at each of (A) the record date with respect to the special meeting, (B) the time of giving of notice provided for in the advance notice provisions set forth in our bylaws and (C) the time of the special meeting (and any postponement or adjournment thereof), who is entitled to vote at the meeting in the election of each individual so nominated and who has complied with the advance notice provisions set forth in our bylaws. Such stockholder will be entitled to nominate one or more individuals, as the case may be, for election as a director if the stockholder’s notice, containing the information required by our bylaws, is delivered to the secretary at our principal executive office not earlier than the 120th day prior to such special meeting and not later than 5:00 p.m., Eastern Time, on the later of (i) the 90th day prior to such special meeting or (ii) the tenth day following the day on which public announcement is first made of the date of the special meeting and any of the nominees proposed by the board of directors to be elected at such meeting.

Our bylaws also include proxy access to allow eligible stockholders to include their own nominee or nominees for director in our proxy materials for an annual meeting of stockholders, along with the candidates nominated by the board of directors. A stockholder, or group of up to 20 stockholders, owning 3% or more of our outstanding common stock continuously for at least three years would be permitted to include director candidates constituting up to 25% of our board of directors (rounded down to the nearest whole number, but not less than two). Under the proxy access procedure, for the stockholders’ notice in respect of the annual meeting of our stockholders to be timely, such notice must be delivered to us not later than the close of business on the 120th day nor earlier than the 150th day prior to the first anniversary of the release date of the proxy materials for the preceding year’s annual meeting of stockholders. The foregoing proxy access right is subject to additional eligibility, procedural and disclosure requirements set forth in our bylaws.

The purpose of requiring stockholders to give advance notice of nominations and other proposals is to afford our board of directors the opportunity to consider the qualifications of the proposed nominees or the advisability of the other proposals and, to the extent considered necessary by our board of directors, to inform stockholders and make recommendations regarding the nominations or other proposals. The advance notice and proxy access procedures also permit a more orderly procedure for conducting stockholder meetings.

Exclusive Forum

10

Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Circuit Court for Baltimore City, Maryland, or, if that court does not have jurisdiction, the United States District Court for the District of Maryland, Baltimore Division, shall be the sole and exclusive forum for:

• any derivative action or proceeding brought on behalf of our company,

• any action asserting a claim of breach of any duty owed by any director or officer or other employee of our company to our company or to the stockholders of our company,

• any action asserting a claim against our company or any director or officer or other employee of our company arising pursuant to any provision of the MGCL, our charter or our bylaws, or

• any action asserting a claim against our company or any director or officer or other employee of our company that is governed by the internal affairs doctrine.

This exclusive forum provision is intended to apply to claims arising under Maryland state law and would not apply to claims brought pursuant to the Exchange Act or the Securities Act of 1933, or any other claim for which the federal courts have exclusive jurisdiction. This exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.

Anti-Takeover Effect of Certain Provisions of Maryland Law and of Our Charter and Bylaws

The restrictions on transfer and ownership of our stock will prohibit any person from acquiring more than 9.9% of outstanding common stock or more than 9.9% of outstanding stock without prior approval of our board of directors. The business combination statute may discourage others from trying to acquire more than 10% of our stock without the advance approval of our board of directors, and may substantially delay or increase the difficulty of consummating any transaction with or change in control of us. Because our board of directors can approve exceptions to the transfer and ownership limits and exempt transactions from the business combination statute, the transfer and ownership limits and the business combination statute will not interfere with a merger or other business combination approved by our board of directors. The power of our board of directors to classify and reclassify unissued common stock or preferred stock, and authorize us to issue classified or reclassified shares, also could have the effect of delaying, deferring or preventing a change in control or other transaction.

These provisions, along with other provisions of the MGCL and our charter and bylaws discussed above, including provisions relating to the removal of directors and the filling of vacancies, the advance notice provisions and the procedures that stockholders will be required to follow to request a special meeting, alone or in combination, could have the effect of delaying, deferring or preventing a proxy contest, tender offer, merger or other change in control that might involve a premium price for shares of our common stock or otherwise be in the best interest of our stockholders, and could increase the difficulty of consummating any offer.  

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC.

Listing

Shares of our common stock are listed on the Nasdaq Global Select Market under the symbol “SBRA.”

11

EX-10.8.1

NOTICE OF STOCK UNIT GRANT

SABRA HEALTH CARE REIT, INC.

2009 PERFORMANCE INCENTIVE PLAN

Name of Grantee:    [●]

Number of Stock Units:    [●]

Date of Grant:[●]

Vesting: Continued ServiceVesting Schedule. Subject to earlier termination as provided in the Terms and Conditions of Stock Unit Award, the units shall become vested as follows if you are employed by or providing services to the Corporation or its subsidiaries on the applicable vesting date: 25% of the units shall vest on each of the following anniversaries of December 31, 2019: 12 months, 24 months, 36 months and 48 months.

Certain Terminations of Employment or Services. Your units, to the extent then outstanding and unvested, shall become vested in full upon the date of (A) your death or Disability or (B) the termination of your employment or service with the Corporation or its subsidiaries either by the Corporation (or subsidiary) without Good Cause or by you for Good Reason, but only if such termination of your employment or services without Good Cause or for Good Reason occurs (i) in connection with a Change in Control and within thirty (30) days before the date of the Change in Control or (ii) on the date of the Change in Control or during the eighteen month period following the date of a Change in Control. (In order to effect the foregoing 30-day protection, if your employment or service with the Corporation or its subsidiaries terminates as a result of a termination by the Corporation (or subsidiary) without Good Cause or by you for Good Reason in connection with a Change in Control then, notwithstanding anything to the contrary in the Terms and Conditions of Stock Unit Award, your units shall not terminate until the 31st day after your termination of employment, at which time they shall automatically terminate if a Change in Control does not occur in such 30-day period.) For the avoidance of doubt, if the termination of your employment or services occurs other than in the circumstances and the periods set forth in this paragraph, you will not be entitled to any vesting pursuant to this paragraph. The terms Disability, Good Cause, Good Reason and Change in Control are used as defined in the Plan.

1

By signing your name below, you accept this stock unit award and acknowledge and agree that the units are granted under and governed by the terms and conditions of the Sabra Health Care REIT, Inc. 2009 Performance Incentive Plan (the “Plan”) and the Terms and Conditions of Stock Unit Award, both of which are hereby made a part of this document.

“GRANTEE” _________________________________ Signature SABRA HEALTH CARE REIT, INC., a Maryland corporation __________________________________ By: Harold W. Andrews, Jr. Its: Chief Financial Officer

2

TERMS AND CONDITIONS OF STOCK UNIT AWARD

SABRA HEALTH CARE REIT, INC.

2009 PERFORMANCE INCENTIVE PLAN

1.Grant of Stock Units.

(a)Award. These Terms and Conditions of Stock Unit Award (these “Terms”) apply to a particular stock unit award (the “Award”) if incorporated by reference in the Notice of Stock Unit Grant (the “Grant Notice”) corresponding to that particular grant. The recipient of the Award identified in the Grant Notice is referred to as the “Grantee.” The effective date of grant of the Award as set forth in the Grant Notice is referred to as the “Date of Grant.” The Award was granted under and subject to the Sabra Health Care REIT, Inc. 2009 Performance Incentive Plan (the “Plan”). The number of shares covered by the Award are subject to adjustment under Section 7.1 of the Plan. Capitalized terms are defined in the Plan if not defined herein. The Award has been granted to the Grantee in addition to, and not in lieu of, any other form of compensation otherwise payable or to be paid to the Grantee. The Grant Notice and these Terms are collectively referred to as the “Award Agreement” applicable to the Award.

(b)Stock Units. As used herein, a “Stock Unit” is a non-voting unit of measurement which is deemed for bookkeeping purposes to be equivalent in value to one outstanding share of Common Stock of the Corporation. The Stock Units shall be used solely as a device for the determination of any payment to eventually be made to the Grantee if and when such Stock Units vest and become earned pursuant to Section 2. The Stock Units create no fiduciary duty to the Grantee and shall create only a contractual obligation on the part of the Corporation to make payments, subject to vesting and the other terms and conditions hereof, as provided in Section 6 below. The Stock Units shall not be treated as property or as a trust fund of any kind. No assets have been secured or set aside by the Corporation with respect to the Award and, if amounts become payable to the Grantee pursuant to this Award Agreement, the Grantee’s rights with respect to such amounts shall be no greater than the rights of any general unsecured creditor of the Corporation.

2.Vesting. As set forth in the Grant Notice, this Award shall vest and become earned in percentage installments, subject to earlier termination or acceleration and subject to adjustment as provided herein and in the Plan. Except as expressly provided in the Grant Notice, no portion of the Award will be earned or vested (regardless of performance) unless the applicable time-based vesting requirement is satisfied. The Award may be subject to time and/or performance-based vesting conditions, as set forth in the Grant Notice. Continued employment will not entitle the Grantee to any proportionate vesting or avoid or mitigate a termination of rights or benefits in connection with the end of a performance period to the extent the related performance condition(s) are not satisfied.

3.Continuance of Employment/Service Required; No Employment/Service Commitment. The vesting schedule requires continued employment or service through each applicable vesting date as a condition to the vesting of the applicable installment of the Award and the rights and benefits under this Award Agreement. Employment or service for only a portion of the vesting period, even if a substantial portion, will not entitle the Grantee to any proportionate vesting or avoid or mitigate a termination of rights and benefits upon or following a termination of employment or services as provided in Section 7 below or under the Plan.

Nothing contained in this Award Agreement or the Plan constitutes a continued employment or service commitment by the Corporation or any of its Subsidiaries, affects the Grantee’s status, if he or she is an employee, as an employee at will who is subject to termination without cause, confers upon the Grantee any right to remain employed by or in service to the Corporation or any Subsidiary, interferes in any way with the

right of the Corporation or any Subsidiary at any time to terminate such employment or service, or affects the right of the Corporation or any Subsidiary to increase or decrease the Grantee’s other compensation. Nothing in this paragraph, however, is intended to adversely affect any independent contractual right of the Grantee under any written employment agreement with the Corporation.

4.Dividend and Voting Rights.

(a)Limitations on Rights Associated with Units. The Grantee shall have no rights as a stockholder of the Corporation, no dividend rights (except as expressly provided in Section 4(b) hereof) and no voting rights with respect to the Stock Units or any shares of Common Stock issuable in respect of such Stock Units, until shares of Common Stock are actually issued to and held of record by the Grantee. No adjustments will be made for dividends or other rights of a holder for which the record date is prior to the date of issuance of the stock certificate evidencing the shares.

(b)Dividend Equivalent Reinvestment. As of each date that the Corporation pays an ordinary cash dividend on its outstanding Common Stock for which the related record date occurs after the Date of Grant and prior to the date all Stock Units subject to the Award have either been paid or have terminated, the Corporation shall credit the Grantee with an additional number of Stock Units equal to (a) the amount of the ordinary cash dividend paid by the Corporation on a single share of Common Stock on that date, multiplied by (b) the number of Stock Units subject to the Award outstanding and unpaid as of such record date (including any Stock Units previously credited under this Section 4(b) and with such total number subject to adjustment pursuant to Section 7.1 of the Plan), divided by (c) the closing price of a share of Common Stock on that date. Any Stock Units credited pursuant to the foregoing provisions of this Section 4(b) will be subject to the same vesting, payment, termination and other terms, conditions and restrictions as the original Stock Units to which they relate. No crediting of Stock Units will be made pursuant to this Section 4(b) with respect to any Stock Units which, as of the related record date, have either been paid or have terminated.

5.Restrictions on Transfer. Prior to the time the Stock Units are vested and paid, neither the Stock Units comprising the Award nor any interest therein or amount payable in respect thereof may be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution.

6.Timing and Manner of Payment of Stock Units. The Stock Units subject to this Award Agreement shall be paid in an equivalent number of whole shares of Common Stock (with any fractional Stock Units credited in respect of the Stock Units that are paid initially rounded up to the nearest whole number of shares of Common Stock and subsequently rounded down to the nearest whole number of shares of Common Stock as necessary to arrive at the appropriate whole number of shares in the aggregate) pursuant to the terms of this Section 6. Any Stock Units subject to this Award Agreement that become earned and vested pursuant to the vesting schedule set forth in the Grant Notice shall be paid on the first to occur of (1) the fifth calendar year following the calendar year in which the Date of Grant occurs, (2) within thirty (30) days after the first anniversary of the date of the Grantee’s Separation from Service, (3) within thirty (30) days after the date of the Grantee’s Disability and (4) within thirty (30) days after the date of the Grantee’s death. In the event there is a Change in Control prior to the time that all Stock Units subject to this Award Agreement have been paid, the following rules shall apply (A) any Stock Units that have become earned and vested pursuant to the time- and performance-based vesting schedule set forth in the Grant Notice on or prior to the date of the Change in Control shall be paid within thirty (30) days after the Change in Control, and (B) any Stock Units that have not become earned and vested pursuant to the time- and performance-based vesting schedule set forth in the Grant Notice on or prior to the date of the Change in Control shall be paid as provided for in the preceding sentence, provided that if any Stock Units become payable as a result of the Grantee’s Separation from Service within the two year period following the date of the Change in Control, the Stock Units shall be paid within

2

thirty (30) days after the date of the Grantee’s Separation from Service instead. Except for any payment made on or following the date of a Change in Control or the Grantee’s death or Disability, in no event shall any Stock Units be paid earlier than the first anniversary of the applicable vesting date. For purposes of this Section 6, references to a Change in Control shall mean a change in the ownership or effective control of the Corporation, or in the ownership of a substantial portion of the assets of the Corporation, within the meaning of Section 409A of the Code. Each such payment of Stock Units shall be subject to the tax withholding provisions of Section 9 hereof and Section 8.5 of the Plan and subject to adjustment as provided in Section 7.1 of the Plan and shall be in complete satisfaction of such earned and vested Stock Units. The Grantee or any other person entitled under the Plan to receive a payment of shares of Common Stock shall deliver to the Corporation any representations or other documents or assurances required pursuant to Section 8.1 of the Plan. The Grantee shall have no rights to designate the calendar year in which the Stock Units are paid. Notwithstanding the foregoing provisions of this Section 6, the Administrator may provide for payment of any Stock Units in accordance with the requirements of Treasury Regulation 1.409A-3(j)(4)(ix)(A), (B) or (C) promulgated under Section 409A of the Code (or any similar successor provision), which regulation generally provides that a deferred compensation arrangement may be terminated in limited circumstances following a dissolution or change in control of the Corporation.

7.Effect of Termination of Employment or Services.Except as otherwise provided in the Grant Notice, the Grantee’s Stock Units shall terminate to the extent such units have not become earned and vested upon the first date the Grantee is no longer employed by or providing services to the Corporation or one of its Subsidiaries, regardless of the reason for the termination of such employment or services, whether with or without cause, voluntarily or involuntarily. If the Grantee is employed by a Subsidiary and that entity ceases to be a Subsidiary, such event shall be deemed to be a termination of employment of the Grantee for purposes of this Award Agreement, unless the Grantee otherwise continues to be employed by the Corporation or another of its Subsidiaries following such event. If the Grantee is not an employee or director of the Corporation or a Subsidiary, the Administrator shall be the sole judge for purposes of this Award Agreement whether the Grantee continues to render services to the Corporation or a Subsidiary and the date, if any, upon which such services shall be deemed to have terminated. The Corporation shall have no obligation as to any Stock Units that are terminated pursuant to the Grant Notice or this Section 7.

8.Adjustments Upon Specified Events. Upon the occurrence of certain events relating to the Corporation’s stock contemplated by Section 7.1 of the Plan, the Administrator will make adjustments if appropriate in the number of Stock Units contemplated hereby and the number and kind of securities that may be issued in respect of the Award.

9.Tax Withholding. The Corporation shall reasonably determine the amount of any federal, state, local or other income, employment, or other taxes which the Corporation or any of its affiliates may reasonably be obligated to withhold with respect to the grant, vesting, payment or other event with respect to the Stock Units. Except for any employment taxes becoming due as a result of the vesting of any Stock Units, the Corporation shall withhold a sufficient number of shares of Common Stock in connection with the vesting or payment of the Stock Units at the then fair market value of the Common Stock (determined either as of the date of such withholding or as of the immediately preceding trading day, as determined by the Corporation in its discretion) to satisfy any applicable withholding obligations that arise with respect to the vesting or payment of such Stock Units. Except for any employment taxes becoming due as a result of the vesting of any Stock Units, the Corporation may take such action(s) without notice to the Grantee and shall remit to the Grantee the balance of any proceeds from withholding such shares in excess of the amount reasonably determined to be necessary to satisfy such withholding obligations. The Grantee shall have no discretion as to the satisfaction of tax withholding obligations in such manner. Upon the vesting of any Stock Units or if any withholding event occurs with respect to the Stock Units other than the vesting or payment of such units, or if the Corporation for any reason does not satisfy the withholding obligations with respect to the vesting or payment of the Stock

3

Units as provided above in this Section 9, the Corporation shall be entitled to require a cash payment by or on behalf of the Grantee and/or to deduct from other compensation payable to the Grantee the amount of any such withholding obligations.

10.Notices. Any notice to be given under the terms of this Award Agreement shall be in writing and addressed to the Corporation at its principal office to the attention of the Secretary, and to the Grantee at the Grantee’s last address reflected on the Corporation’s records, or at such other address as either party may hereafter designate in writing to the other. Any such notice shall be given only when received, but if the Grantee is no longer an employee of the Corporation or one of its Subsidiaries, shall be deemed to have been duly given by the Corporation when enclosed in a properly sealed envelope addressed as aforesaid, registered or certified, and deposited (postage and registry or certification fee prepaid) in a post office or branch post office regularly maintained by the United States Government.

11.Plan. The Award and all rights of the Grantee under this Award Agreement are subject to, and the Grantee agrees to be bound by, all of the terms and conditions of the provisions of the Plan, incorporated herein by this reference. The Grantee agrees to be bound by the terms of the Plan and of this Award Agreement. The Grantee acknowledges reading and understanding the Plan, the Prospectus for the Plan, and this Award Agreement. Unless otherwise expressly provided in other sections of this Award Agreement, provisions of the Plan that confer discretionary authority on the Board or the Administrator do not (and shall not be deemed to) create any rights in the Grantee unless such rights are expressly set forth herein or are otherwise in the sole discretion of the Board or the Administrator so conferred by appropriate action of the Board or the Administrator under the Plan after the date hereof.

12.Entire Agreement. This Award Agreement and the Plan together constitute the entire agreement and supersede all prior understandings and agreements, written or oral, of the parties hereto with respect to the subject matter hereof. The Plan and this Award Agreement may be amended pursuant to Section 8.6 of the Plan. Such amendment to this Award Agreement must be in writing and signed by the Corporation. The Corporation may, however, unilaterally waive any provision hereof in writing to the extent such waiver does not adversely affect the interests of the Grantee hereunder, but no such waiver shall operate as or be construed to be a subsequent waiver of the same provision or a waiver of any other provision hereof.

13.Counterparts. This Award Agreement may be executed simultaneously in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

14.Section Headings. The section headings of this Award Agreement are for convenience of reference only and shall not be deemed to alter or affect any provision hereof.

15.Governing Law. This Award Agreement and the rights of the parties hereunder with respect to the Award shall be governed by and construed and enforced in accordance with the laws of the State of Maryland without regard to conflict of law principles thereunder.

16.Clawback Policy. The Stock Units are subject to the terms of the Corporation’s recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of the Stock Units or any shares of Common Stock or other cash or property received with respect to the Stock Units (including any value received from a disposition of the shares acquired upon payment of the Stock Units).

17.Six-Month Delay. Notwithstanding any provision of these Terms to the contrary, if the Grantee is a “specified employee” as defined in Section 409A of the Code, the Grantee shall not be entitled

4

to any payment with respect to the Award in connection with the Grantee’s Separation from Service until the date which is six (6) months after the Grantee’s Separation from Service. Any amounts otherwise payable to the Grantee following the Grantee’s Separation from Service that are not so paid by reason of this Section 17 shall be paid as soon as practicable for the Corporation (and in all events within thirty (30) days) after the date that is six (6) months after the Grantee’s Separation from Service. The provisions of this Section 17 shall only apply if, and to the extent, required to comply with Section 409A of the Code.

18.Construction. It is intended that the terms of the Award will not result in the imposition of any tax liability pursuant to Section 409A of the Code. This Award Agreement shall be construed and interpreted consistent with that intent.

5

EX-10.8.2

NOTICE OF STOCK UNIT GRANT

SABRA HEALTH CARE REIT, INC.

2009 PERFORMANCE INCENTIVE PLAN

Name of Grantee:    [●]

Target Number
of Stock Units:        [●]

Date of Grant:[●]

Vesting: In general, and with limited exceptions set forth below, your units are subject to two different vesting requirements. The first requirement is a funds from operations-based requirement. To the extent it is satisfied, your units are subject to time-based vesting. These requirements, and the limited exceptions, are set forth in more detail below.

FFO Vesting Condition. Subject to earlier termination as provided in the Terms and Conditions of Stock Unit Award, your target units are subject to a vesting requirement based on the Corporation’s Adjusted Normalized Funds From Operations Per Share results during the period beginning on January 1, 2020 and ending on December 31, 2022 (the “Performance Period”). The Corporation will establish the applicable Adjusted Normalized Funds From Operations Per Share target for the Performance Period (the “Adjusted Normalized FFO Target”) no later than the end of calendar 2019. The percentage of your target units that will be subject to the time-based vesting requirements described below will be determined with reference to the Corporation’s achievement of the Adjusted Normalized FFO Target, as set forth in the table below:

% of Adjusted Normalized FFO Target Achieved	% of Target # of Units Eligible to Become Earned and Vested
<90.96%	0%
90.96%	80%
93.97%	87%
96.99%	93%
100%	100%
103.01%	133%
106.03%	167%
109.04%	200%

Except as described below, all of your units will terminate at the end of the Performance Period if the Corporation achieves an Adjusted Normalized Funds From Operations Per Share amount for the Performance Period at or below the threshold

1

amount listed in the table above. If the Corporation achieves an Adjusted Normalized Funds From Operations Per Share amount for the Performance Period between the amounts listed in the table above, the percentage of your target units that will be subject to the time-based vesting requirements described below will be pro-rated on a straight-line basis between the closest two percentages listed in the table above. The maximum percentage of your target units that may become subject to the time-based vesting requirements described below is the maximum percentage listed in the table above. Any of your units that are not eligible for time-based vesting at the end of the Performance Period based on the Corporation’s Adjusted Normalized Funds From Operations Per Share for the Performance Period will automatically terminate at the end of the Performance Period.

“Adjusted Normalized Funds From Operations Per Share” shall mean the Corporation’s adjusted normalized funds from operations per share during the Performance Period, as defined by the Corporation’s Compensation Committee.

Change in Control. If a Change in Control (as defined in the Plan) occurs after the Date of Grant and prior to the end of the Performance Period while any of your target units are outstanding, on the date of the Change in Control, the target number of your units then outstanding and not previously terminated shall no longer be subject to the Adjusted Normalized Funds From Operations Per Share vesting requirement. Such units shall be subject to the time-based vesting requirements described below but no other performance-based conditions. Thereafter, the performance-based conditions set forth above shall not apply to the units.

Continued Service Vesting Condition. Except as provided below in connection with certain terminations of your employment or services, any of your units that become eligible for time-based vesting based on the Corporation’s Adjusted Normalized Funds From Operations Per Share performance or because of a Change in Control will become earned and vested if you are employed by or providing services to the Corporation or its subsidiaries on the last day of the Performance Period. If your employment or service terminates for any reason other than described below prior to the applicable vesting date provided for above, your units shall terminate in accordance with the Terms and Conditions of Stock Unit Award.

Certain Terminations of Employment or Services. If your employment or service with the Corporation or its subsidiaries terminates prior to the end of the Performance Period due to (A) your death or Disability or (B) the termination of your employment or service with the Corporation or its subsidiaries either by the Corporation (or subsidiary) without Good Cause or by you for Good Reason, but only if such termination of your employment or services without Good Cause or for Good Reason occurs (i) in connection with a Change in Control and within thirty (30) days before the date of the Change in Control or (ii) on the date of the Change in Control or during the eighteen month period following the date of a Change in Control, then the target number of your units then outstanding shall become earned and vested on the date of such termination, and shall be paid in accordance with the Terms and Conditions of Stock Unit Award. (In order to effect the foregoing 30-day protection, if your employment or service with the Corporation or its subsidiaries terminates as a result of a termination by the Corporation (or subsidiary) without Good Cause or by you for Good Reason in connection with a Change in Control then, notwithstanding

2

anything to the contrary in the Terms and Conditions of Stock Unit Award, your units shall not terminate until the 31^st day after your termination of employment, at which time they shall automatically terminate if a Change in Control does not occur in such 30-day period.)

For the avoidance of doubt, (i) if the termination of your employment or services occurs other than in the circumstances and the periods set forth in this paragraph, you will not be entitled to any vesting pursuant to this paragraph, and (ii) no additional portion of the award will become earned and vested based on performance after a termination of employment. The terms Disability, Good Cause and Good Reason are used as defined in the Plan.

By signing your name below, you accept this stock unit award and acknowledge and agree that the units are granted under and governed by the terms and conditions of the Sabra Health Care REIT, Inc. 2009 Performance Incentive Plan (the “Plan”) and the Terms and Conditions of Stock Unit Award, both of which are hereby made a part of this document.

“GRANTEE” _________________________________ Signature SABRA HEALTH CARE REIT, INC., a Maryland corporation __________________________________ By: Harold W. Andrews, Jr. Its: Chief Financial Officer

3

TERMS AND CONDITIONS OF STOCK UNIT AWARD

SABRA HEALTH CARE REIT, INC.

2009 PERFORMANCE INCENTIVE PLAN

1.Grant of Stock Units.

(a)Award. These Terms and Conditions of Stock Unit Award (these “Terms”) apply to a particular stock unit award (the “Award”) if incorporated by reference in the Notice of Stock Unit Grant (the “Grant Notice”) corresponding to that particular grant. The recipient of the Award identified in the Grant Notice is referred to as the “Grantee.” The effective date of grant of the Award as set forth in the Grant Notice is referred to as the “Date of Grant.” The Award was granted under and subject to the Sabra Health Care REIT, Inc. 2009 Performance Incentive Plan (the “Plan”). The number of shares covered by the Award are subject to adjustment under Section 7.1 of the Plan. Capitalized terms are defined in the Plan if not defined herein. The Award has been granted to the Grantee in addition to, and not in lieu of, any other form of compensation otherwise payable or to be paid to the Grantee. The Grant Notice and these Terms are collectively referred to as the “Award Agreement” applicable to the Award.

(b)Stock Units. As used herein, a “Stock Unit” is a non-voting unit of measurement which is deemed for bookkeeping purposes to be equivalent in value to one outstanding share of Common Stock of the Corporation. The Stock Units shall be used solely as a device for the determination of any payment to eventually be made to the Grantee if and when such Stock Units vest and become earned pursuant to Section 2. The Stock Units create no fiduciary duty to the Grantee and shall create only a contractual obligation on the part of the Corporation to make payments, subject to vesting and the other terms and conditions hereof, as provided in Section 6 below. The Stock Units shall not be treated as property or as a trust fund of any kind. No assets have been secured or set aside by the Corporation with respect to the Award and, if amounts become payable to the Grantee pursuant to this Award Agreement, the Grantee’s rights with respect to such amounts shall be no greater than the rights of any general unsecured creditor of the Corporation.

2.Vesting. As set forth in the Grant Notice, this Award shall vest and become earned in percentage installments, subject to earlier termination or acceleration and subject to adjustment as provided herein and in the Plan. Except as expressly provided in the Grant Notice, no portion of the Award will be earned or vested (regardless of performance) unless the applicable time-based vesting requirement is satisfied. The Award may be subject to time and/or performance-based vesting conditions, as set forth in the Grant Notice. Continued employment will not entitle the Grantee to any proportionate vesting or avoid or mitigate a termination of rights or benefits in connection with the end of a performance period to the extent the related performance condition(s) are not satisfied.

3.Continuance of Employment/Service Required; No Employment/Service Commitment. The vesting schedule requires continued employment or service through each applicable vesting date as a condition to the vesting of the applicable installment of the Award and the rights and benefits under this Award Agreement. Employment or service for only a portion of the vesting period, even if a substantial portion, will not entitle the Grantee to any proportionate vesting or avoid or mitigate a termination of rights and benefits upon or following a termination of employment or services as provided in Section 7 below or under the Plan.

Nothing contained in this Award Agreement or the Plan constitutes a continued employment or service commitment by the Corporation or any of its Subsidiaries, affects the Grantee’s status, if he or she is an employee, as an employee at will who is subject to termination without cause, confers upon the Grantee any right to remain employed by or in service to the Corporation or any Subsidiary, interferes in any way with the

right of the Corporation or any Subsidiary at any time to terminate such employment or service, or affects the right of the Corporation or any Subsidiary to increase or decrease the Grantee’s other compensation. Nothing in this paragraph, however, is intended to adversely affect any independent contractual right of the Grantee under any written employment agreement with the Corporation.

4.Dividend and Voting Rights.

(a)Limitations on Rights Associated with Units. The Grantee shall have no rights as a stockholder of the Corporation, no dividend rights (except as expressly provided in Section 4(b) hereof) and no voting rights with respect to the Stock Units or any shares of Common Stock issuable in respect of such Stock Units, until shares of Common Stock are actually issued to and held of record by the Grantee. No adjustments will be made for dividends or other rights of a holder for which the record date is prior to the date of issuance of the stock certificate evidencing the shares.

(b)Dividend Equivalent Reinvestment. As of each date that the Corporation pays an ordinary cash dividend on its outstanding Common Stock for which the related record date occurs after the Date of Grant and prior to the date all Stock Units subject to the Award have either been paid or have terminated, the Corporation shall credit the Grantee with an additional number of Stock Units equal to (a) the amount of the ordinary cash dividend paid by the Corporation on a single share of Common Stock on that date, multiplied by (b) the number of Stock Units subject to the Award outstanding and unpaid as of such record date (including any Stock Units previously credited under this Section 4(b) and with such total number subject to adjustment pursuant to Section 7.1 of the Plan), divided by (c) the closing price of a share of Common Stock on that date. Any Stock Units credited pursuant to the foregoing provisions of this Section 4(b) will be subject to the same vesting, payment, termination and other terms, conditions and restrictions as the original Stock Units to which they relate. No crediting of Stock Units will be made pursuant to this Section 4(b) with respect to any Stock Units which, as of the related record date, have either been paid or have terminated.

5.Restrictions on Transfer. Prior to the time the Stock Units are vested and paid, neither the Stock Units comprising the Award nor any interest therein or amount payable in respect thereof may be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution.

6.Timing and Manner of Payment of Stock Units. The Stock Units subject to this Award Agreement shall be paid in an equivalent number of whole shares of Common Stock (with any fractional Stock Units credited in respect of the Stock Units that are paid initially rounded up to the nearest whole number of shares of Common Stock and subsequently rounded down to the nearest whole number of shares of Common Stock as necessary to arrive at the appropriate whole number of shares in the aggregate) pursuant to the terms of this Section 6. Any Stock Units subject to this Award Agreement that become earned and vested pursuant to the vesting schedule set forth in the Grant Notice shall be paid on the first to occur of (1) the fifth calendar year following the calendar year in which the Date of Grant occurs, (2) within thirty (30) days after the first anniversary of the date of the Grantee’s Separation from Service, (3) within thirty (30) days after the date of the Grantee’s Disability and (4) within thirty (30) days after the date of the Grantee’s death. In the event there is a Change in Control prior to the time that all Stock Units subject to this Award Agreement have been paid, the following rules shall apply (A) if the Change in Control occurs on or after the last day of the Performance Period, any Stock Units that have become earned and vested pursuant to the time- and performance-based vesting schedule set forth in the Grant Notice shall be paid within thirty (30) days after the Change in Control, and (B) if the Change in Control occurs before the last day of the Performance Period, the Stock Units shall be paid as provided for in the preceding sentence, provided that if any Stock Units become payable as a result of the Grantee’s Separation from Service within the two year period following the date of the Change in Control, the Stock Units shall be paid within thirty (30) days after the date of the Grantee’s Separation from

2

Service instead. Except for any payment made on or following the date of a Change in Control or the Grantee’s death or Disability, in no event shall any Stock Units be paid earlier than the first anniversary of the applicable vesting date. For purposes of this Section 6, references to a Change in Control shall mean a change in the ownership or effective control of the Corporation, or in the ownership of a substantial portion of the assets of the Corporation, within the meaning of Section 409A of the Code. Each such payment of Stock Units shall be subject to the tax withholding provisions of Section 9 hereof and Section 8.5 of the Plan and subject to adjustment as provided in Section 7.1 of the Plan and shall be in complete satisfaction of such earned and vested Stock Units. The Grantee or any other person entitled under the Plan to receive a payment of shares of Common Stock shall deliver to the Corporation any representations or other documents or assurances required pursuant to Section 8.1 of the Plan. The Grantee shall have no rights to designate the calendar year in which the Stock Units are paid. Notwithstanding the foregoing provisions of this Section 6, the Administrator may provide for payment of any Stock Units in accordance with the requirements of Treasury Regulation 1.409A-3(j)(4)(ix)(A), (B) or (C) promulgated under Section 409A of the Code (or any similar successor provision), which regulation generally provides that a deferred compensation arrangement may be terminated in limited circumstances following a dissolution or change in control of the Corporation.

7.Effect of Termination of Employment or Services. Except as otherwise provided in the Grant Notice, the Grantee’s Stock Units shall terminate to the extent such units have not become earned and vested upon the first date the Grantee is no longer employed by or providing services to the Corporation or one of its Subsidiaries, regardless of the reason for the termination of such employment or services, whether with or without cause, voluntarily or involuntarily. If the Grantee is employed by a Subsidiary and that entity ceases to be a Subsidiary, such event shall be deemed to be a termination of employment of the Grantee for purposes of this Award Agreement, unless the Grantee otherwise continues to be employed by the Corporation or another of its Subsidiaries following such event. If the Grantee is not an employee or director of the Corporation or a Subsidiary, the Administrator shall be the sole judge for purposes of this Award Agreement whether the Grantee continues to render services to the Corporation or a Subsidiary and the date, if any, upon which such services shall be deemed to have terminated. The Corporation shall have no obligation as to any Stock Units that are terminated pursuant to the Grant Notice or this Section 7.

8.Adjustments Upon Specified Events. Upon the occurrence of certain events relating to the Corporation’s stock contemplated by Section 7.1 of the Plan, the Administrator will make adjustments if appropriate in the number of Stock Units contemplated hereby and the number and kind of securities that may be issued in respect of the Award.

9.Tax Withholding. The Corporation shall reasonably determine the amount of any federal, state, local or other income, employment, or other taxes which the Corporation or any of its affiliates may reasonably be obligated to withhold with respect to the grant, vesting, payment or other event with respect to the Stock Units. Except for any employment taxes becoming due as a result of the vesting of any Stock Units, the Corporation shall withhold a sufficient number of shares of Common Stock in connection with the vesting or payment of the Stock Units at the then fair market value of the Common Stock (determined either as of the date of such withholding or as of the immediately preceding trading day, as determined by the Corporation in its discretion) to satisfy any applicable withholding obligations that arise with respect to the vesting or payment of such Stock Units. Except for any employment taxes becoming due as a result of the vesting of any Stock Units, the Corporation may take such action(s) without notice to the Grantee and shall remit to the Grantee the balance of any proceeds from withholding such shares in excess of the amount reasonably determined to be necessary to satisfy such withholding obligations. The Grantee shall have no discretion as to the satisfaction of tax withholding obligations in such manner. Upon the vesting of any Stock Units or if any withholding event occurs with respect to the Stock Units other than the vesting or payment of such units, or if the Corporation for any reason does not satisfy the withholding obligations with respect to the vesting or payment of the Stock Units as provided above in this Section 9, the Corporation shall be entitled to require a cash payment by or

3

on behalf of the Grantee and/or to deduct from other compensation payable to the Grantee the amount of any such withholding obligations.

10.Notices. Any notice to be given under the terms of this Award Agreement shall be in writing and addressed to the Corporation at its principal office to the attention of the Secretary, and to the Grantee at the Grantee’s last address reflected on the Corporation’s records, or at such other address as either party may hereafter designate in writing to the other. Any such notice shall be given only when received, but if the Grantee is no longer an employee of the Corporation or one of its Subsidiaries, shall be deemed to have been duly given by the Corporation when enclosed in a properly sealed envelope addressed as aforesaid, registered or certified, and deposited (postage and registry or certification fee prepaid) in a post office or branch post office regularly maintained by the United States Government.

11.Plan. The Award and all rights of the Grantee under this Award Agreement are subject to, and the Grantee agrees to be bound by, all of the terms and conditions of the provisions of the Plan, incorporated herein by this reference. The Grantee agrees to be bound by the terms of the Plan and of this Award Agreement. The Grantee acknowledges reading and understanding the Plan, the Prospectus for the Plan, and this Award Agreement. Unless otherwise expressly provided in other sections of this Award Agreement, provisions of the Plan that confer discretionary authority on the Board or the Administrator do not (and shall not be deemed to) create any rights in the Grantee unless such rights are expressly set forth herein or are otherwise in the sole discretion of the Board or the Administrator so conferred by appropriate action of the Board or the Administrator under the Plan after the date hereof.

12.Entire Agreement. This Award Agreement and the Plan together constitute the entire agreement and supersede all prior understandings and agreements, written or oral, of the parties hereto with respect to the subject matter hereof. The Plan and this Award Agreement may be amended pursuant to Section 8.6 of the Plan. Such amendment to this Award Agreement must be in writing and signed by the Corporation. The Corporation may, however, unilaterally waive any provision hereof in writing to the extent such waiver does not adversely affect the interests of the Grantee hereunder, but no such waiver shall operate as or be construed to be a subsequent waiver of the same provision or a waiver of any other provision hereof.

13.Counterparts. This Award Agreement may be executed simultaneously in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

14.Section Headings. The section headings of this Award Agreement are for convenience of reference only and shall not be deemed to alter or affect any provision hereof.

15.Governing Law. This Award Agreement and the rights of the parties hereunder with respect to the Award shall be governed by and construed and enforced in accordance with the laws of the State of Maryland without regard to conflict of law principles thereunder.

16.Clawback Policy. The Stock Units are subject to the terms of the Corporation’s recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of the Stock Units or any shares of Common Stock or other cash or property received with respect to the Stock Units (including any value received from a disposition of the shares acquired upon payment of the Stock Units).

17.Six-Month Delay. Notwithstanding any provision of these Terms to the contrary, if the Grantee is a “specified employee” as defined in Section 409A of the Code, the Grantee shall not be entitled to any payment with respect to the Award in connection with the Grantee’s Separation from Service until the

4

date which is six (6) months after the Grantee’s Separation from Service. Any amounts otherwise payable to the Grantee following the Grantee’s Separation from Service that are not so paid by reason of this Section 17 shall be paid as soon as practicable for the Corporation (and in all events within thirty (30) days) after the date that is six (6) months after the Grantee’s Separation from Service. The provisions of this Section 17 shall only apply if, and to the extent, required to comply with Section 409A of the Code.

18.Construction. It is intended that the terms of the Award will not result in the imposition of any tax liability pursuant to Section 409A of the Code. This Award Agreement shall be construed and interpreted consistent with that intent.

5

EX-10.8.3

NOTICE OF STOCK UNIT GRANT

SABRA HEALTH CARE REIT, INC.

2009 PERFORMANCE INCENTIVE PLAN

Name of Grantee:    [●]

Target Number
of Stock Units:        [●]

Date of Grant:        [●]

Vesting: In general, and with limited exceptions set forth below, your units are subject to two different vesting requirements. The first requirement is a total shareholder return-based requirement. To the extent it is satisfied, your units are subject to time-based vesting. These requirements, and the limited exceptions, are set forth in more detail below.

Performance Vesting Condition. Subject to earlier termination as provided in the Terms and Conditions of Stock Unit Award, your target units are subject to a vesting requirement based on the percentile ranking of the Corporation’s Total Shareholder Return among the Total Shareholder Returns for the stocks comprising the Comparison Group during a performance period beginning on January 1, 2020 and ending on December 31, 2022 (the “Performance Period”), with performance determined with reference to the goals set forth in the table below:

Total Shareholder Return Percentile Rank	% of Target # of Units Becoming Earned and Vested
<30%	0%
30%	50%
35%	60%
40%	70%
45%	80%
50%	90%
55%	100%
60%	120%
65%	140%
70%	160%
75%	180%
80%	200%

Except as described below, all of your units will terminate at the end of the Performance Period if the Corporation achieves a Total Shareholder Return percentile ranking for the Performance Period below the threshold percentile listed in the table above. If the Corporation achieves a Total Shareholder Return percentile ranking for the Performance Period between the percentiles listed in the table above, the percentage of your target units that will be subject to the time-based vesting requirements described below will be pro-rated on a straight-line basis between the closest two percentages listed in the table above. The maximum percentage of your target units that may become subject to the time-based vesting requirements described below is the maximum percentage listed in the table above. In addition, and notwithstanding anything in the table listed above to the contrary, if the Corporation’s absolute Total Shareholder Return during the Performance Period is less than zero (0), the maximum percentage of your target units that may become subject to the time-based vesting requirements described below is equal to 100% of your target number of units. Any of your target units that are not eligible for time-based vesting at the end of the Performance Period based on the Corporation’s Total Shareholder Return percentile ranking for the Performance Period will automatically terminate at the end of the Performance Period.

“Total Shareholder Return” means a company’s total shareholder return over the entire Performance Period assuming that any dividends are reinvested in the company’s stock on the payment date, and shall be calculated using (i) the average stock price at the close of regular trading for the relevant stock on the principal exchange on which the relevant stock is listed or traded for the 20-trading-day period ending with the last day on which the applicable exchange is open for trading preceding the first day of the Performance Period, and (ii) the average stock price at the close of regular trading for the relevant stock on the principal exchange on which the relevant stock is listed or traded for the 20-trading-day period ending with the last trading day of the Performance Period.

The “Comparison Group” means each of the companies approved by the Corporation’s Compensation Committee as a comparison company that remains an independent publicly traded REIT for the entire Performance Period.

Change in Control. If a Change in Control (as defined in the Plan) occurs during the Performance Period while any of your target units are outstanding, the Performance Period will be deemed to end on the date of the Change in Control and performance will be measured based on the Corporation’s Total Shareholder Return percentile ranking through the date of the Change in Control.

Continued Service Vesting Condition. Except as provided below in connection with certain terminations of your employment or services, any of your units that become eligible for time-based vesting based on the Corporation’s Total Shareholder Return percentile ranking (including any units becoming eligible in connection with a Change in Control) will become earned and vested if you are employed by or providing services to the Corporation or its subsidiaries on the last day of the normal Performance Period (e.g., any deemed termination of the Performance Period on the date of a Change in Control is ignored for these purposes). If your employment or service terminates for any reason other than described below prior to the applicable vesting

2

date provided for above, your units shall terminate in accordance with the Terms and Conditions of Stock Unit Award.

Certain Terminations of Employment or Services. If your employment or service with the Corporation or its subsidiaries terminates prior to the end of the Performance Period due to your death or Disability, then the target number of your units then outstanding shall become earned and vested on the date of such termination, and shall be paid in accordance with the Terms and Conditions of Stock Unit Award. If your employment or service with the Corporation or its subsidiaries terminates prior to the end of the Performance Period due to the termination of your employment or service with the Corporation or its subsidiaries either by the Corporation (or subsidiary) without Good Cause or by you for Good Reason, but only if such termination of your employment or services without Good Cause or for Good Reason occurs (i) in connection with a Change in Control and within thirty (30) days before the date of the Change in Control or (ii) on the date of the Change in Control or during the eighteen month period following the date of a Change in Control, then any of your units eligible for time-based vesting in connection with the Change in Control shall become earned and vested on the date of such termination, and shall be paid in accordance with the Terms and Conditions of Stock Unit Award. (In order to effect the foregoing 30-day protection, if your employment or service with the Corporation or its subsidiaries terminates as a result of a termination by the Corporation (or subsidiary) without Good Cause or by you for Good Reason in connection with a Change in Control then, notwithstanding anything to the contrary in the Terms and Conditions of Stock Unit Award, your units shall not terminate until the 31^st day after your termination of employment, at which time they shall automatically terminate if a Change in Control does not occur in such 30-day period.) For the avoidance of doubt, (i) if the termination of your employment or services occurs other than in the circumstances and the periods set forth in this paragraph, you will not be entitled to any vesting pursuant to this paragraph, and (ii) your target number of units will become earned and vested upon your termination due to death or Disability prior to the end of the Performance Period regardless of whether the Corporation’s Total Shareholder Return percentile ranking (including any ranking determined in connection with a Change in Control) would result in a number of units becoming earned and vested that is greater than, less than or equal to your target number of units. The terms Disability, Good Cause and Good Reason are used as defined in the Plan.

By signing your name below, you accept this stock unit award and acknowledge and agree that the units are granted under and governed by the terms and conditions of the Sabra Health Care REIT, Inc. 2009 Performance Incentive Plan (the “Plan”) and the Terms and Conditions of Stock Unit Award, both of which are hereby made a part of this document.

“GRANTEE” _________________________________ Signature SABRA HEALTH CARE REIT, INC., a Maryland corporation __________________________________ By: Harold W. Andrews, Jr. Its: Chief Financial Officer

3

TERMS AND CONDITIONS OF STOCK UNIT AWARD

SABRA HEALTH CARE REIT, INC.

2009 PERFORMANCE INCENTIVE PLAN

1.Grant of Stock Units.

(a)Award. These Terms and Conditions of Stock Unit Award (these “Terms”) apply to a particular stock unit award (the “Award”) if incorporated by reference in the Notice of Stock Unit Grant (the “Grant Notice”) corresponding to that particular grant. The recipient of the Award identified in the Grant Notice is referred to as the “Grantee.” The effective date of grant of the Award as set forth in the Grant Notice is referred to as the “Date of Grant.” The Award was granted under and subject to the Sabra Health Care REIT, Inc. 2009 Performance Incentive Plan (the “Plan”). The number of shares covered by the Award are subject to adjustment under Section 7.1 of the Plan. Capitalized terms are defined in the Plan if not defined herein. The Award has been granted to the Grantee in addition to, and not in lieu of, any other form of compensation otherwise payable or to be paid to the Grantee. The Grant Notice and these Terms are collectively referred to as the “Award Agreement” applicable to the Award.

(b)Stock Units. As used herein, a “Stock Unit” is a non-voting unit of measurement which is deemed for bookkeeping purposes to be equivalent in value to one outstanding share of Common Stock of the Corporation. The Stock Units shall be used solely as a device for the determination of any payment to eventually be made to the Grantee if and when such Stock Units vest and become earned pursuant to Section 2. The Stock Units create no fiduciary duty to the Grantee and shall create only a contractual obligation on the part of the Corporation to make payments, subject to vesting and the other terms and conditions hereof, as provided in Section 6 below. The Stock Units shall not be treated as property or as a trust fund of any kind. No assets have been secured or set aside by the Corporation with respect to the Award and, if amounts become payable to the Grantee pursuant to this Award Agreement, the Grantee’s rights with respect to such amounts shall be no greater than the rights of any general unsecured creditor of the Corporation.

2.Vesting. As set forth in the Grant Notice, this Award shall vest and become earned in percentage installments, subject to earlier termination or acceleration and subject to adjustment as provided herein and in the Plan. Except as expressly provided in the Grant Notice, no portion of the Award will be earned or vested (regardless of performance) unless the applicable time-based vesting requirement is satisfied. The Award may be subject to time and/or performance-based vesting conditions, as set forth in the Grant Notice. Continued employment will not entitle the Grantee to any proportionate vesting or avoid or mitigate a termination of rights or benefits in connection with the end of a performance period to the extent the related performance condition(s) are not satisfied.

3.Continuance of Employment/Service Required; No Employment/Service Commitment. The vesting schedule requires continued employment or service through each applicable vesting date as a condition to the vesting of the applicable installment of the Award and the rights and benefits under this Award Agreement. Employment or service for only a portion of the vesting period, even if a substantial portion, will not entitle the Grantee to any proportionate vesting or avoid or mitigate a termination of rights and benefits upon or following a termination of employment or services as provided in Section 7 below or under the Plan.

Nothing contained in this Award Agreement or the Plan constitutes a continued employment or service commitment by the Corporation or any of its Subsidiaries, affects the Grantee’s status, if he or she is an employee, as an employee at will who is subject to termination without cause, confers upon the Grantee any right to remain employed by or in service to the Corporation or any Subsidiary, interferes in any way with the

right of the Corporation or any Subsidiary at any time to terminate such employment or service, or affects the right of the Corporation or any Subsidiary to increase or decrease the Grantee’s other compensation. Nothing in this paragraph, however, is intended to adversely affect any independent contractual right of the Grantee under any written employment agreement with the Corporation.

4.Dividend and Voting Rights.

(a)Limitations on Rights Associated with Units. The Grantee shall have no rights as a stockholder of the Corporation, no dividend rights (except as expressly provided in Section 4(b) hereof) and no voting rights with respect to the Stock Units or any shares of Common Stock issuable in respect of such Stock Units, until shares of Common Stock are actually issued to and held of record by the Grantee. No adjustments will be made for dividends or other rights of a holder for which the record date is prior to the date of issuance of the stock certificate evidencing the shares.

(b)Dividend Equivalent Reinvestment. As of each date that the Corporation pays an ordinary cash dividend on its outstanding Common Stock for which the related record date occurs after the Date of Grant and prior to the date all Stock Units subject to the Award have either been paid or have terminated, the Corporation shall credit the Grantee with an additional number of Stock Units equal to (a) the amount of the ordinary cash dividend paid by the Corporation on a single share of Common Stock on that date, multiplied by (b) the number of Stock Units subject to the Award outstanding and unpaid as of such record date (including any Stock Units previously credited under this Section 4(b) and with such total number subject to adjustment pursuant to Section 7.1 of the Plan), divided by (c) the closing price of a share of Common Stock on that date. Any Stock Units credited pursuant to the foregoing provisions of this Section 4(b) will be subject to the same vesting, payment, termination and other terms, conditions and restrictions as the original Stock Units to which they relate. No crediting of Stock Units will be made pursuant to this Section 4(b) with respect to any Stock Units which, as of the related record date, have either been paid or have terminated.

5.Restrictions on Transfer. Prior to the time the Stock Units are vested and paid, neither the Stock Units comprising the Award nor any interest therein or amount payable in respect thereof may be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution.

6.Timing and Manner of Payment of Stock Units. The Stock Units subject to this Award Agreement shall be paid in an equivalent number of whole shares of Common Stock (with any fractional Stock Units credited in respect of the Stock Units that are paid initially rounded up to the nearest whole number of shares of Common Stock and subsequently rounded down to the nearest whole number of shares of Common Stock as necessary to arrive at the appropriate whole number of shares in the aggregate) pursuant to the terms of this Section 6. Any Stock Units subject to this Award Agreement that become earned and vested pursuant to the vesting schedule set forth in the Grant Notice shall be paid on the first to occur of (1) the fifth calendar year following the calendar year in which the Date of Grant occurs, (2) within thirty (30) days after the first anniversary of the date of the Grantee’s Separation from Service, (3) within thirty (30) days after the date of the Grantee’s Disability and (4) within thirty (30) days after the date of the Grantee’s death. In the event there is a Change in Control prior to the time that all Stock Units subject to this Award Agreement have been paid, the following rules shall apply (A) if the Change in Control occurs on or after the last day of the Performance Period, any Stock Units that have become earned and vested pursuant to the time- and performance-based vesting schedule set forth in the Grant Notice shall be paid within thirty (30) days after the Change in Control, and (B) if the Change in Control occurs before the last day of the Performance Period, the Stock Units shall be paid as provided for in the preceding sentence, provided that if any Stock Units become payable as a result of the Grantee’s Separation from Service within the two year period following the date of the Change in Control, the Stock Units shall be paid within thirty (30) days after the date of the Grantee’s Separation from

2

Service instead. Except for any payment made on or following the date of a Change in Control or the Grantee’s death or Disability, in no event shall any Stock Units be paid earlier than the first anniversary of the applicable vesting date. For purposes of this Section 6, references to a Change in Control shall mean a change in the ownership or effective control of the Corporation, or in the ownership of a substantial portion of the assets of the Corporation, within the meaning of Section 409A of the Code. Each such payment of Stock Units shall be subject to the tax withholding provisions of Section 9 hereof and Section 8.5 of the Plan and subject to adjustment as provided in Section 7.1 of the Plan and shall be in complete satisfaction of such earned and vested Stock Units. The Grantee or any other person entitled under the Plan to receive a payment of shares of Common Stock shall deliver to the Corporation any representations or other documents or assurances required pursuant to Section 8.1 of the Plan. The Grantee shall have no rights to designate the calendar year in which the Stock Units are paid. Notwithstanding the foregoing provisions of this Section 6, the Administrator may provide for payment of any Stock Units in accordance with the requirements of Treasury Regulation 1.409A-3(j)(4)(ix)(A), (B) or (C) promulgated under Section 409A of the Code (or any similar successor provision), which regulation generally provides that a deferred compensation arrangement may be terminated in limited circumstances following a dissolution or change in control of the Corporation.

7.Effect of Termination of Employment or Services. Except as otherwise provided in the Grant Notice, the Grantee’s Stock Units shall terminate to the extent such units have not become earned and vested upon the first date the Grantee is no longer employed by or providing services to the Corporation or one of its Subsidiaries, regardless of the reason for the termination of such employment or services, whether with or without cause, voluntarily or involuntarily. If the Grantee is employed by a Subsidiary and that entity ceases to be a Subsidiary, such event shall be deemed to be a termination of employment of the Grantee for purposes of this Award Agreement, unless the Grantee otherwise continues to be employed by the Corporation or another of its Subsidiaries following such event. If the Grantee is not an employee or director of the Corporation or a Subsidiary, the Administrator shall be the sole judge for purposes of this Award Agreement whether the Grantee continues to render services to the Corporation or a Subsidiary and the date, if any, upon which such services shall be deemed to have terminated. The Corporation shall have no obligation as to any Stock Units that are terminated pursuant to the Grant Notice or this Section 7.

8.Adjustments Upon Specified Events. Upon the occurrence of certain events relating to the Corporation’s stock contemplated by Section 7.1 of the Plan, the Administrator will make adjustments if appropriate in the number of Stock Units contemplated hereby and the number and kind of securities that may be issued in respect of the Award.

9.Tax Withholding. The Corporation shall reasonably determine the amount of any federal, state, local or other income, employment, or other taxes which the Corporation or any of its affiliates may reasonably be obligated to withhold with respect to the grant, vesting, payment or other event with respect to the Stock Units. Except for any employment taxes becoming due as a result of the vesting of any Stock Units, the Corporation shall withhold a sufficient number of shares of Common Stock in connection with the vesting or payment of the Stock Units at the then fair market value of the Common Stock (determined either as of the date of such withholding or as of the immediately preceding trading day, as determined by the Corporation in its discretion) to satisfy any applicable withholding obligations that arise with respect to the vesting or payment of such Stock Units. Except for any employment taxes becoming due as a result of the vesting of any Stock Units, the Corporation may take such action(s) without notice to the Grantee and shall remit to the Grantee the balance of any proceeds from withholding such shares in excess of the amount reasonably determined to be necessary to satisfy such withholding obligations. The Grantee shall have no discretion as to the satisfaction of tax withholding obligations in such manner. Upon the vesting of any Stock Units or if any withholding event occurs with respect to the Stock Units other than the vesting or payment of such units, or if the Corporation for any reason does not satisfy the withholding obligations with respect to the vesting or payment of the Stock Units as provided above in this Section 9, the Corporation shall be entitled to require a cash payment by or

3

on behalf of the Grantee and/or to deduct from other compensation payable to the Grantee the amount of any such withholding obligations.

10.Notices. Any notice to be given under the terms of this Award Agreement shall be in writing and addressed to the Corporation at its principal office to the attention of the Secretary, and to the Grantee at the Grantee’s last address reflected on the Corporation’s records, or at such other address as either party may hereafter designate in writing to the other. Any such notice shall be given only when received, but if the Grantee is no longer an employee of the Corporation or one of its Subsidiaries, shall be deemed to have been duly given by the Corporation when enclosed in a properly sealed envelope addressed as aforesaid, registered or certified, and deposited (postage and registry or certification fee prepaid) in a post office or branch post office regularly maintained by the United States Government.

11.Plan. The Award and all rights of the Grantee under this Award Agreement are subject to, and the Grantee agrees to be bound by, all of the terms and conditions of the provisions of the Plan, incorporated herein by this reference. The Grantee agrees to be bound by the terms of the Plan and of this Award Agreement. The Grantee acknowledges reading and understanding the Plan, the Prospectus for the Plan, and this Award Agreement. Unless otherwise expressly provided in other sections of this Award Agreement, provisions of the Plan that confer discretionary authority on the Board or the Administrator do not (and shall not be deemed to) create any rights in the Grantee unless such rights are expressly set forth herein or are otherwise in the sole discretion of the Board or the Administrator so conferred by appropriate action of the Board or the Administrator under the Plan after the date hereof.

12.Entire Agreement. This Award Agreement and the Plan together constitute the entire agreement and supersede all prior understandings and agreements, written or oral, of the parties hereto with respect to the subject matter hereof. The Plan and this Award Agreement may be amended pursuant to Section 8.6 of the Plan. Such amendment to this Award Agreement must be in writing and signed by the Corporation. The Corporation may, however, unilaterally waive any provision hereof in writing to the extent such waiver does not adversely affect the interests of the Grantee hereunder, but no such waiver shall operate as or be construed to be a subsequent waiver of the same provision or a waiver of any other provision hereof.

13.Counterparts. This Award Agreement may be executed simultaneously in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

14.Section Headings. The section headings of this Award Agreement are for convenience of reference only and shall not be deemed to alter or affect any provision hereof.

15.Governing Law. This Award Agreement and the rights of the parties hereunder with respect to the Award shall be governed by and construed and enforced in accordance with the laws of the State of Maryland without regard to conflict of law principles thereunder.

16.Clawback Policy. The Stock Units are subject to the terms of the Corporation’s recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of the Stock Units or any shares of Common Stock or other cash or property received with respect to the Stock Units (including any value received from a disposition of the shares acquired upon payment of the Stock Units).

17.Six-Month Delay. Notwithstanding any provision of these Terms to the contrary, if the Grantee is a “specified employee” as defined in Section 409A of the Code, the Grantee shall not be entitled to any payment with respect to the Award in connection with the Grantee’s Separation from Service until the

4

date which is six (6) months after the Grantee’s Separation from Service. Any amounts otherwise payable to the Grantee following the Grantee’s Separation from Service that are not so paid by reason of this Section 17 shall be paid as soon as practicable for the Corporation (and in all events within thirty (30) days) after the date that is six (6) months after the Grantee’s Separation from Service. The provisions of this Section 17 shall only apply if, and to the extent, required to comply with Section 409A of the Code.

18.Construction. It is intended that the terms of the Award will not result in the imposition of any tax liability pursuant to Section 409A of the Code. This Award Agreement shall be construed and interpreted consistent with that intent.

5

EX-21.1

Exhibit 21.1

Sabra Subsidiaries

	Jurisdiction of Organization
1717 Senior Partners, LLC (Subsidiary of Joint Venture)	Indiana
2100 Benvoulin Court Holdings, Inc.	British Columbia
2829-34th Street Holdings, Inc.	British Columbia
317 Winnipeg St. Holdings Inc.	British Columbia
3211 Alexis Park Drive Holdings Inc.	British Columbia
870 Westminster Ave. Holdings, Inc.	British Columbia
Arden Real Estate Holdings, LLC	Delaware
Beaumont Senior Partners, LLC (Subsidiary of Joint Venture)	Indiana
Beavercreek Investors, LLC	Indiana
Beavercreek Senior Partners, LLC	Indiana
Bloomsburg Nominee LLC	Delaware
Bloomsburg Nominee LP	Delaware
C.H.W. Limited Liability Company	New Hampshire
CCP Alpine 7614 LLC	Delaware
CCP Arlington 1961 LLC	Delaware
CCP Ashland 7250 LLC	Delaware
CCP Aspen Grove 7382 LLC	Delaware
CCP Augusta 0544 LLC	Delaware
CCP Autumn View 7580 LLC	Delaware
CCP Autumn Woods 7586 LLC	Delaware
CCP Avalon 5010 LP	Delaware
CCP Avis Adams 7173 LLC	Delaware
CCP Azalea 0824 LLC	Delaware
CCP Bay View 0738 LP	Delaware
CCP Bayview 7176 LLC	Delaware
CCP Bear Creek 3764 LLC	Delaware
CCP Bellefontaine Gardens 7251 LLC	Delaware
CCP Belleville 7343 LLC	Delaware
CCP Bellingham 0158 LLC	Delaware
CCP Bellingham 1501 LLC	Delaware
CCP Blueberry Hill 0581 LLC	Delaware
CCP Boise 0216 LLC	Delaware
CCP Bolton Manor 0529 LLC	Delaware
CCP Booker T. Washington 7617 LLC	Delaware
CCP Bradford 7612 LLC	Delaware
CCP Bremen 0290 LLC	Delaware
CCP Brentwood 0555 LLC	Delaware
CCP Brewer 0547 LLC	Delaware
CCP Brighton 0873 LLC	Delaware
CCP Brookhaven 7581 LLC	Delaware

CCP Burlington House 2702 LP	Delaware
CCP Camelot 0563 LLC	Delaware
CCP Cascade Park 7360 LLC	Delaware
CCP Chapel Hill 0806 LP	Delaware
CCP Cherry Hills 1159 LLC	Delaware
CCP Cheyenne 0441 LLC	Delaware
CCP Chillicothe 0569 LP	Delaware
CCP Clackamas 1513 LLC	Delaware
CCP Colonial Manor 0766 LLC	Delaware
CCP Colonial Oaks 7615 LLC	Delaware
CCP Colony House 0582 LLC	Delaware
CCP Colony Oaks 0767 LLC	Delaware
CCP Conway 7175 LLC	Delaware
CCP Coos Bay 1510 LLC	Delaware
CCP Coshocton 0635 LP	Delaware
CCP Country Manor 0507 LLC	Delaware
CCP Covina 4003 LP	Delaware
CCP Crestview 1505 LLC	Delaware
CCP Crownpointe Carmel 7000 LLC	Delaware
CCP Current River 7252 LLC	Delaware
CCP Cypress Pointe 0188 LP	Delaware
CCP Danville Centre 0782 LLC	Delaware
CCP Den-Mar 0542 LLC	Delaware
CCP Dixon 7253 LLC	Delaware
CCP Dover 0591 LLC	Delaware
CCP Driftwood 7140 LP	Delaware
CCP Dundee 7170 LLC	Delaware
CCP Dutchess 1741 LLC	Delaware
CCP Eastside 0545 LLC	Delaware
CCP Eliot 0526 LLC	Delaware
CCP Elizabethtown 0787 LLC	Delaware
CCP Eugene 1509 LLC	Delaware
CCP Evergreen North Cascades 7201 LLC	Delaware
CCP Fayette County 7452 LP	Delaware
CCP Finance I LLC	Delaware
CCP Finance II LLC	Delaware
CCP Firesteel 7380 LLC	Delaware
CCP Florence Villa 3781 LLC	Delaware
CCP Forsyth 7254 LLC	Delaware
CCP Fountain Circle 0280 LLC	Delaware
CCP Fountain Springs 7381 LLC	Delaware
CCP Galion 7451 LP	Delaware
CCP Garden Gate 7583 LLC	Delaware
CCP Garden Valley 1155 LLC	Delaware

CCP Gastonia 0724 LP	Delaware
CCP Glendale 4001 LLC	Delaware
CCP Glenwood 7255 LLC	Delaware
CCP Golden/7470 LLC	Delaware
CCP Gravios 2227 LLC	Delaware
CCP Guardian Roanoke 0704 LP	Delaware
CCP Guardian Rocky Mount 0723 LP	Delaware
CCP Guardian Zebulon 0713 LP	Delaware
CCP Guest House 7613 LLC	Delaware
CCP Harbour Point 0826 LLC	Delaware
CCP Harris Hill 7582 LLC	Delaware
CCP Harrodsburg 0864 LLC	Delaware
CCP Healthbridge 7403 LP	Delaware
CCP Hillcrest 0785 LLC	Delaware
CCP Hillsboro 1507 LLC	Delaware
CCP Holdings GP1 LLC	Delaware
CCP Hopkins 3784 LLC	Delaware
CCP Junction City 1508 LLC	Delaware
CCP Kachina Point 0853 LLC	Delaware
CCP Kansas II LLC	Delaware
CCP Keizer 1526 LLC	Delaware
CCP Kennebunk 0549 LLC	Delaware
CCP Kennedy Park 0771 LLC	Delaware
CCP King City 1506 LLC	Delaware
CCP Kinston 0711 LP	Delaware
CCP La Mesa 1910 LLC	Delaware
CCP Lakeshore 4000 LLC	Delaware
CCP Lakeview Manor 1552 LLC	Delaware
CCP Las Vegas 0640 LLC	Delaware
CCP Lebanon Country 0868 LP	Delaware
CCP Lincoln 0307 LP	Delaware
CCP Madison 0132 LLC	Delaware
CCP Malley 0859 LLC	Delaware
CCP Marietta 0645 LLC	Delaware
CCP Maryville 3785 LLC	Delaware
CCP Masters 0884 LLC	Delaware
CCP McKinney 1677 LLC	Delaware
CCP Meadowvale 0269 LLC	Delaware
CCP Medford 0453 LLC	Delaware
CCP MG Manor 7387 LLC	Delaware
CCP Millbrook 1678 LLC	Delaware
CCP Minneapolis 7005 LLC	Delaware
CCP Monroe 0707 LP	Delaware
CCP Mountain View 1529 LLC	Delaware

CCP Mountain View 2228 LLC	Delaware
CCP Mt. Pleasant 7171 LLC	Delaware
CCP Muncie 0406 LLC	Delaware
CCP Mustang Holdings LLC	Delaware
CCP Newport 1528 LLC	Delaware
CCP Newton Wellesley 0539 LLC	Delaware
CCP Nicholas 1157 LLC	Delaware
CCP North Gate 7584 LLC	Delaware
CCP Northern Nevada 2226 LLC	Delaware
CCP Norway 0550 LLC	Delaware
CCP Nutmeg Pavilion 0567 LLC	Delaware
CCP Oakridge 3766 LLC	Delaware
CCP Oakview 0278 LLC	Delaware
CCP Oakwood 0517 LLC	Delaware
CCP Olympic 1503 LLC	Delaware
CCP Orange Hills 7390 LP	Delaware
CCP Palisade 7383 LLC	Delaware
CCP Park Place 7541 LLC	Delaware
CCP Parkway Pavilion 0568 LLC	Delaware
CCP Parkwood 0407 LLC	Delaware
CCP Pearl Kruse 1527 LLC	Delaware
CCP Petersburg 3767 LLC	Delaware
CCP Pettigrew 0116 LP	Delaware
CCP Phoenix 1930 LLC	Delaware
CCP Pilgrim Manor 7610 LLC	Delaware
CCP Pleasant Valley 1679 LLC	Delaware
CCP Prairie View 7385 LLC	Delaware
CCP Primacy 0822 LLC	Delaware
CCP Properties Business Trust	Massachusetts
CCP Queen Anne 0462 LLC	Delaware
CCP Quincy 0537 LLC	Delaware
CCP Raleigh 0143 LP	Delaware
CCP Rawlins 0481 LLC	Delaware
CCP Regency 1676 LLC	Delaware
CCP Regency Manor 2701 LP	Delaware
CCP Richmond Beach 1500 LLC	Delaware
CCP River Terrace 0587 LLC	Delaware
CCP Riverpark 1502 LLC	Delaware
CCP Riverside 0281 LLC	Delaware
CCP Riverview 7384 LLC	Delaware
CCP Rosewood 0277 LLC	Delaware
CCP Royal Oaks 0112 LLC	Delaware
CCP Sachem 0514 LLC	Delaware
CCP Sage View 0483 LLC	Delaware

CCP San Diego 4005 LP	Delaware
CCP San Diego GP LLC	Delaware
CCP Savannah Rehab 0155 LLC	Delaware
CCP Savannah Specialty 0660 LLC	Delaware
CCP SCC Holdings LLC	Delaware
CCP Seneca 7585 LLC	Delaware
CCP Senior Indiana LLC	Delaware
CCP Shepherd 7386 LLC	Delaware
CCP Shreveport Manor 7616 LLC	Delaware
CCP Silas Creek 0191 LP	Delaware
CCP Silex 7256 LLC	Delaware
CCP Smoky Hill 7350 LLC	Delaware
CCP South Hampton 7257 LLC	Delaware
CCP South Shore Manor 3782 LLC	Delaware
CCP Spring Lake 7611 LLC	Delaware
CCP Spring Lake VL 7611 LLC	Delaware
CCP Springfield Business Trust	Massachusetts
CCP St. Francis 1742 LLC	Delaware
CCP Strafford 7258 LLC	Delaware
CCP Summit West 1551 LLC	Delaware
CCP Sunnybrook 0137 LP	Delaware
CCP Sunnyside 0452 LLC	Delaware
CCP Tacoma 1512 LLC	Delaware
CCP Tacoma 1515 LLC	Delaware
CCP Tacoma Pearl 1532 LLC	Delaware
CCP Tempe 4002 LLC	Delaware
CCP Three Fountains 1525 LLC	Delaware
CCP Torrey Pines 0641 LLC	Delaware
CCP Torrington 7542 LLC	Delaware
CCP Tri-State 7172 LLC	Delaware
CCP Twin Oaks 1511 LLC	Delaware
CCP Ulster 1743 LLC	Delaware
CCP Vallhaven 0770 LLC	Delaware
CCP Ventura 4004 LP	Delaware
CCP Villa Campana 0851 LLC	Delaware
CCP Village 1931 LLC	Delaware
CCP Warren 7453 LP	Delaware
CCP Western Village 3780 LLC	Delaware
CCP Westgate Manor 0554 LLC	Delaware
CCP Westminster 3775 LLC	Delaware
CCP Westwood Manor 7348 LLC	Delaware
CCP WH Holdings LLC	Delaware
CCP Wheatcrest 7388 LLC	Delaware
CCP Whitesburg 0791 LLC	Delaware

CCP Wind River 0482 LLC	Delaware
CCP Windsor 7259 LLC	Delaware
CCP Winship Green 0546 LLC	Delaware
CCP Worthington 1160 LLC	Delaware
CCP Wyomissing 1237 LLC	Delaware
Charleston AID II OpCo LLC	Delaware
Charleston AID II PropCo LLC	Delaware
Chief1 Holdings, LLC (Joint Venture)	Delaware
Clarks Summit AID II OpCo LLC	Delaware
Clarks Summit AID II PropCo LLC	Delaware
Clarksville Investors, LLC	Indiana
Clarksville Senior Partners, LLC (Subsidiary of Joint Venture)	Indiana
Connecticut Holdings I, LLC	Delaware
Deerfield Senior Partners, LLC (Subsidiary of Joint Venture)	Indiana
Douglassville AID II OpCo LLC	Delaware
Douglassville AID II PropCo LLC	Delaware
Dover AID II OpCo LLC	Delaware
Dover AID II PropCo LLC	Delaware
Elms Haven-Thorton, LLC	Colorado
HEB Healthcare Partners, LLC (Joint Venture)	Texas
HEB SNF RE GenPar, LLC	Texas
HEB SNF RE, L.P.	Texas
HHC 1998-1 Trust	Massachusetts
Langdon Place of Dover, a general partnership	New Hampshire
Langdon Place of Keene Limited Partnership	New Hampshire
Lewisburg AID II OpCo LLC	Delaware
Lewisburg AID II PropCo LLC	Delaware
L.P.E.	New Hampshire
Madeira Senior Partners, LLC (Subsidiary of Joint Venture)	Indiana
Master Aid II PROPCO LLC	Delaware
Master Aid II-B PROPCO LLC	Delaware
Master Tenant (FNMA) AID II Opco LLC	Delaware
Master Tenant (UNEN) AID II Opco LLC	Delaware
McCordsville Senior Partners, LLC (Subsidiary of Joint Venture)	Indiana
Meridian Shavano Park AL/ALZ RE, L.P.	Texas
Milford AID II OpCo LLC	Delaware
Milford AID II PropCo LLC	Delaware
MLD Properties, LLC	Delaware
MLD Shelton Investors Partnership	California
MSP AL/ALZ RE GenPar, LLC	Texas
New Hampshire Holdings, LLC	Delaware
Oak Hill AID II OpCo LLC	Delaware
Oak Hill AID II PropCo LLC	Delaware
Parent AID II Opco TRS LLC	Delaware

Park Place AL, LLC	Indiana
Reading AID II OpCo LLC	Delaware
Reading AID II PropCo LLC	Delaware
Reservoir Real Estate Holdings, LLC	Delaware
Sabra 1717 Preferred Equity, LLC	Delaware
Sabra Alamitos, LP	Delaware
Sabra Beachside, LP	Delaware
Sabra Beaumont Preferred Equity, LLC	Delaware
Sabra Beavercreek Preferred Equity, LLC	Delaware
Sabra Bedford Hills, LLC	Delaware
Sabra Broadway, LP	Delaware
Sabra Burien, LLC	Delaware
Sabra CA Holdco, Inc.	British Columbia
Sabra CA Holdings, LP	Delaware
Sabra California GP, LLC	Delaware
Sabra California I, LLC	Delaware
Sabra California II, LLC	Delaware
Sabra Canadian GP I, Inc.	British Columbia
Sabra Canadian GP II, Inc.	British Columbia
Sabra Canadian GP III, Inc.	British Columbia
Sabra Canadian GP IV, Inc.	British Columbia
Sabra Canadian Holdings, LLC	Delaware
Sabra Canadian Properties I, Limited Partnership	British Columbia
Sabra Canadian Properties II, Limited Partnership	British Columbia
Sabra Canadian Properties III, Limited Partnership	British Columbia
Sabra Canadian Properties IV, Limited Partnership	British Columbia
Sabra Capital Corporation	Delaware
Sabra Chatsworth, LP	Delaware
Sabra Clarksville Preferred Equity, LLC	Delaware
Sabra Colorado, LLC	Nevada
Sabra Colorado II, LLC	Nevada
Sabra Connecticut II, LLC	Delaware
Sabra Cottonwood, LP	Delaware
Sabra Coventry, LP	Delaware
Sabra Danville, LP	Delaware
Sabra Deer Lodge, LLC	Delaware
Sabra Deerfield Preferred Equity, LLC	Delaware
Sabra Edgewater, LP	Delaware
Sabra Fairfield, LP	Delaware
Sabra Fairmont, LP	Delaware
Sabra FHAPT, LLC	Delaware
Sabra Forest Hills, LLC	Delaware
Sabra Garden View, LP	Delaware
Sabra Grand Terrace, LP	Delaware

Sabra Hagerstown, LLC	Delaware
Sabra Health Care AL, LLC	Delaware
Sabra Health Care Delaware, LLC	Delaware
Sabra Health Care Frankenmuth, LLC	Delaware
Sabra Health Care Holdings I, LLC	Delaware
Sabra Health Care Holdings II, LLC	Delaware
Sabra Health Care Holdings III, LLC	Delaware
Sabra Health Care Holdings IV, LLC	Delaware
Sabra Health Care Holdings V, LLC	Delaware
Sabra Health Care Holdings VI, LLC	Delaware
Sabra Health Care Investments, LP	Delaware
Sabra Health Care Limited Partnership	Delaware
Sabra Health Care Northeast, LLC	Delaware
Sabra Health Care Pennsylvania, LLC	Delaware
Sabra Health Care Virginia II, LLC	Delaware
Sabra Health Care Virginia, LLC	Delaware
Sabra Health Care, L.L.C.	Delaware
Sabra Idaho, LLC	Delaware
Sabra IL California GP, LLC	Delaware
Sabra IL California, L.P.	Delaware
Sabra IL Holdings, LLC	Delaware
Sabra IL Operations, LLC	Delaware
Sabra IL Texas GP, LLC	Texas
Sabra IL Texas, L.P.	Texas
Sabra Issaquah, LLC	Delaware
Sabra Lake Balboa, LP	Delaware
Sabra Lake Drive, LLC	Delaware
Sabra LBG 1717 JV, LLC (Joint Venture)	Delaware
Sabra LBG Beavercreek JV, LLC (Joint Venture)	Delaware
Sabra LBG Beavercreek JV II, LLC (Joint Venture)	Delaware
Sabra LBG Clarksville JV, LLC (Joint Venture)	Delaware
Sabra LBG Deerfield JV, LLC (Joint Venture)	Delaware
Sabra LBG JV, LLC (Joint Venture)	Delaware
Sabra LBG Madeira, LLC (Joint Venture)	Delaware
Sabra LBG McCordsville, LLC (Joint Venture)	Delaware
Sabra Lomita, LP	Delaware
Sabra Madiera Preferred Equity, LLC	Delaware
Sabra Marshfield II RP, LLC	Delaware
Sabra Marshfield II TRS, LLC	Delaware
Sabra McCordsville Preferred Equity, LLC	Delaware
Sabra McKinley, LLC	Delaware
Sabra Michigan, LLC	Delaware
Sabra Missouri River, LLC	Delaware
Sabra Montana, LLC	Delaware

Sabra Nashua, LLC	New Hampshire
Sabra New Braunfels Preferred Equity, LLC	Delaware
Sabra New Mexico II, LLC	Delaware
Sabra North Carolina GP, LLC	Delaware
Sabra North Carolina, L.P.	Delaware
Sabra North Conway, L.L.C.	New Hampshire
Sabra Opco AL, LLC	Delaware
Sabra Pacifica, LP	Delaware
Sabra Palm Terrace, LP	Delaware
Sabra Park Ridge, LLC	Delaware
Sabra Park West, LLC	Delaware
Sabra Phoenix Holding, LLC	Delaware
Sabra Phoenix Marshfield, LLC	Delaware
Sabra Phoenix TRS Venture II, LLC	Delaware
Sabra Phoenix TRS Venture, LLC	Delaware
Sabra Phoenix Wisconsin, LLC	Delaware
Sabra Propco AL, LLC	Delaware
Sabra Ramona, LP	Delaware
Sabra Ramsey, LLC	Delaware
Sabra Ramsey TRS, LLC	Delaware
Sabra San Juan, LLC	Delaware
Sabra Sundara Master Developer LLC (Joint Venture)	Delaware
Sabra Texas GP, LLC	Texas
Sabra Texas Holdings GP, LLC	Texas
Sabra Texas Holdings, L.P.	Texas
Sabra Texas Holdings II, L.P.	Texas
Sabra Texas Properties, L.P.	Texas
Sabra Texas Properties II, L.P.	Texas
Sabra Texas Properties III, L.P.	Texas
Sabra Texas Properties IV, L.P.	Texas
Sabra Texas Properties VI, L.P.	Texas
Sabra TRS Holdings, LLC	Delaware
Sabra University, LP	Delaware
Sabra Virginia III, LLC	Delaware
Sabra Wisconsin, LLC	Delaware
Sabra Wisconsin II, LLC	Delaware
Sabra Woodland, LP	Delaware
Sabra-Sundara Master Developer, LLC	Delaware
SbraREIT Assisted Living I, ULC	Nova Scotia
SbraREIT Canadian GP V Inc.	Nova Scotia
SbraREIT Canadian Properties V, Limited Partnership	Alberta
SbraREIT Independent Living I, ULC	British Columbia
SbraREIT Independent Living II, ULC	British Columbia
Scott Depot AID II OpCo LLC	Delaware

Scott Depot AID II PropCo LLC	Delaware
Sundara Prop-1, LLC (Subsidiary of Joint Venture)	Texas
TSL NB Prop Co., LLC (Joint Venture)	Delaware
United Rehab Realty Holding, LLC	Delaware
WHC Limited Partnership	Wisconsin
Williamsport AID II OpCo LLC	Delaware
Williamsport AID II PropCo LLC	Delaware
Wyncote AID II OpCo LLC	Delaware
Wyncote AID II PropCo LLC	Delaware

EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-215574) and Form S‑8 (Nos. 333-197216 and 333-220055) of Sabra Health Care REIT, Inc. of our report datedFebruary 24, 2020 relating to the financial statements, financial statement schedules, and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.

/s/ PricewaterhouseCoopers LLP

Irvine, California

February 24, 2020

EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Richard K. Matros, certify that:

1. I have reviewed this annual report on Form 10-K of Sabra Health Care REIT, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 24, 2020

/S/    RICHARD K. MATROS

Richard K. Matros

Chairman, President and

Chief Executive Officer

EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Harold W. Andrews, Jr., certify that:

1. I have reviewed this annual report on Form 10-K of Sabra Health Care REIT, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 24, 2020

/S/    HAROLD W. ANDREWS, JR.

Harold W. Andrews, Jr.

Executive Vice President,

Chief Financial Officer and Secretary

EX-32.1

Exhibit 32.1

Certification pursuant to 18 U.S.C. Section 1350,

as Adopted pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with the Annual Report on Form 10-K of Sabra Health Care REIT, Inc. (the “Registrant”) for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Richard K. Matros, as Chairman, President and Chief Executive Officer of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: February 24, 2020

/S/    RICHARD K. MATROS

Richard K. Matros

Chairman, President and

Chief Executive Officer

EX-32.2

Exhibit 32.2

Certification pursuant to 18 U.S.C. Section 1350,

as Adopted pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with the Annual Report on Form 10-K of Sabra Health Care REIT, Inc. (the “Registrant”) for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Harold W. Andrews, Jr., as Executive Vice President, Chief Financial Officer and Secretary of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: February 24, 2020

/S/    HAROLD W. ANDREWS, JR.

Harold W. Andrews, Jr.

Executive Vice President,

Chief Financial Officer and Secretary

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivatives and Financial Instruments Designated as Hedging Instruments on Income and Equity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain in other comprehensive (loss) income, cash flow hedges and net investment hedges	$ (25,029)	$ 14,149	$ 1,841
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income	5,545	3,099	(2,174)
Interest rate products
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain recognized in other comprehensive (loss) income, cash flow hedges	(19,932)	2,707	10,807
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income	5,545	3,099	(2,174)
Foreign currency products
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain recognized in other comprehensive (loss) income, net investment hedges	(772)	3,554	(2,378)
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income	0	0	0
CAD term loan
Derivative Instruments, Gain (Loss) [Line Items]
(Loss) gain recognized in other comprehensive (loss) income, net investment hedges	(4,325)	7,888	(6,588)
Gain (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income	$ 0	$ 0	$ 0

XML

FAIR VALUE DISCLOSURES - Amounts Measured at Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	$ 7,477	$ 29,344
Financial liabilities	626	$ 4,529
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cross Currency Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Forward Starting Interest Rate Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Forward Starting Interest Rate Collar
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring | Significant Other Observable Inputs (Level 2) | Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	4,239
Recurring | Significant Other Observable Inputs (Level 2) | Cross Currency Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	3,238
Recurring | Significant Other Observable Inputs (Level 2) | Forward Starting Interest Rate Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	494
Recurring | Significant Other Observable Inputs (Level 2) | Forward Starting Interest Rate Collar
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	132
Recurring | Significant Unobservable Inputs (Level 3) | Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Recurring | Significant Unobservable Inputs (Level 3) | Cross Currency Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Recurring | Significant Unobservable Inputs (Level 3) | Forward Starting Interest Rate Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring | Significant Unobservable Inputs (Level 3) | Forward Starting Interest Rate Collar
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring | Total | Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	4,239
Recurring | Total | Cross Currency Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	3,238
Recurring | Total | Forward Starting Interest Rate Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	494
Recurring | Total | Forward Starting Interest Rate Collar
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ 132

XML

RECENT REAL ESTATE ACQUISITIONS - Narrative (Details) - Recent Real Estate Acquisitions $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($) Property	Dec. 31, 2018 USD ($) Property
Business Acquisition [Line Items]
Revenues from the properties acquired | $	$ 0.8	$ 44.0
Net income attributable to common stockholders from the properties acquired | $	$ 0.4	$ 14.0
Tenant Origination and Absorption Costs
Business Acquisition [Line Items]
Finite-lived intangible assets, weighted average amortization period as of date of acquisition	6 years	13 years
Tenant Relationship
Business Acquisition [Line Items]
Finite-lived intangible assets, weighted average amortization period as of date of acquisition	21 years	22 years
Senior Housing Communities
Business Acquisition [Line Items]
Number of acquired properties	2	8
Specialty Hospitals and Other
Business Acquisition [Line Items]
Number of acquired properties	2
Senior Housing - Managed
Business Acquisition [Line Items]
Number of acquired properties	1	11
Skilled Nursing/Transitional Care
Business Acquisition [Line Items]
Number of acquired properties		2

XML

EARNINGS PER COMMON SHARE (Tables)

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except share and per share amounts):

	Year Ended December 31,
	2019		2018		2017
Numerator
Net income attributable to common stockholders	$	68,996	$	269,314	$	148,141
Denominator
Basic weighted average common shares and common equivalents	187,172,210		178,305,738		105,621,242
Dilutive stock options and restricted stock units	954,882		416,006		221,192
Diluted weighted average common shares	188,127,092		178,721,744		105,842,434
Net income attributable to common stockholders, per:
Basic common share	$	0.37	$	1.51	$	1.40
Diluted common share	$	0.37	$	1.51	$	1.40

XML

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Future Minimum Rental Payments from Non-Cancelable Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases:
2020	$ 428,101
2021	427,791
2022	404,568
2023	389,810
2024	380,944
Thereafter	1,672,008
Total	$ 3,703,222
Future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases:
2019		$ 465,766
2020		456,207
2021		452,346
2022		454,216
2023		437,277
Thereafter		2,407,064
Total		$ 4,672,876

XML

SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE

12 Months Ended

Dec. 31, 2019

SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Abstract]

SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE

SCHEDULE IV

MORTGAGE LOANS ON REAL ESTATE

As of December 31, 2019

(dollars in thousands)

Description	Contractual Interest Rate		Maturity Date	Periodic Payment Terms	Prior Liens		Principal Balance		Book Value (1)		Principal Amount of Loans Subject to Delinquent Principal or Interest
Mortgages:
River Vista	10.0	%	2027	(2)	$	—	$	19,000	$	19,000	N/A
Construction Mortgages:
Arlington	8.0		2022	(3)	—		2,468		2,487		N/A
					$	—	$	21,468	$	21,487

⁽¹⁾  The aggregate cost for federal income tax purposes was $21.6 million as of December 31, 2019.

⁽²⁾  Interest is due monthly, and principal is due at the maturity date.

⁽³⁾  Interest and principal for the first 36 months is deferred and due at the maturity date. Interest after the first 36 months is due monthly.

Changes in mortgage loans are summarized as follows:

	Year Ended December 31,
	2019			2018			2017
Balance at the beginning of the year	$	23,146		$	16,033		$	39,026
Additions during period:
Draws	1,689			10,943			1,738
New mortgage loans	—			—			12,987
Interest income added to principal	194			1,528			539
Deductions during period:
Paydowns/repayments	(3,561		)	(5,358		)	(14,570		)
Conversion to real property	—			—			(19,085		)
Write-offs (1)	—			—			(4,602		)
Balance at the end of the year	$	21,468		$	23,146		$	16,033

⁽¹⁾ 

During the year ended December 31, 2017, the Company wrote off uncollectible amounts related to one mortgage loan that was repaid.

XML

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION

All stock-based awards are subject to the terms of the 2009 Performance Incentive Plan, which was assumed by the Company effective as of November 15, 2010 in connection with the Company’s separation from Sun and was most recently amended and restated in April 2017. The 2009 Performance Incentive Plan provides for the granting of stock-based compensation, including stock options, time-based stock units, funds from operations-based stock units (“FFO Units”), relative total stockholder return-based stock units (“TSR Units”) and performance-based restricted stock units to officers, employees and directors in connection with their employment with or services provided to the Company.

Stock Options

In connection with the CCP Merger, the Company assumed stock options outstanding as of the effective time of the CCP Merger.

During the year ended December 31, 2019, no stock options were exercised and 1.2 million stock options expired. As of December 31, 2019, no stock options were outstanding.

As of December 31, 2018, 1.2 million stock options with a weighted average exercise price per share of $28.04 were outstanding.

Restricted Stock Units and Performance-Based Restricted Stock Units

Under the 2009 Performance Incentive Plan, restricted stock units and performance-based restricted stock units generally have a contractual life or vest over a three- to five-year period. The vesting of certain restricted stock units may accelerate, as defined in the grant, upon retirement, a change in control and other events. When vested (and subject to any applicable deferral or holdback period), each performance-based restricted stock unit is convertible into one share of common stock, subject to any deferrals in issuance pursuant to the grant. The restricted stock units are valued on the grant date based on the market price of the Company’s common stock on that date. Generally, the Company recognizes the fair value of the awards over the applicable vesting period as compensation expense. In addition, since the shares to be issued may vary based on the performance of the Company, the Company must make assumptions regarding the projected performance criteria and the shares that will ultimately be issued. The amount of FFO Units that will ultimately vest is dependent on the amount by which the Company’s funds from operations as adjusted (“FFO”) differs from a target FFO amount for a period specified in each grant and will range from 0% to 200% of the FFO Units initially granted. Similarly, the amount of TSR Units that will ultimately vest is dependent on the amount by which the total shareholder return (“TSR”) of the Company’s common stock differs from a predefined peer group for a period specified in each grant and will range from 0% to 200% of the TSR Units initially granted. Upon any payment of shares as a result of restricted stock unit vestings, the related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. The value of the shares withheld is dependent on the closing price of the Company’s common stock on the date the relevant transaction occurs.

The following table summarizes additional information concerning restricted stock units at December 31, 2019:

	Restricted Stock Units		Weighted Average Grant Date Fair Value Per Unit
Unvested as of December 31, 2018	1,477,318		$	17.88
Granted	603,131		20.59
Vested	(433,181	)	18.34
Dividends reinvested	152,329		18.60
Cancelled/forfeited	(61,735	)	18.29
Unvested as of December 31, 2019	1,737,862		$	18.90

As of December 31, 2019, the weighted average remaining vesting period of restricted stock units was 2.5 years. The weighted average fair value per share at the date of grant for restricted stock units for the years ended December 31, 2019, 2018 and 2017 was $20.59, $16.02 and $19.38, respectively. The total fair value of units vested during the years ended December 31, 2019, 2018 and 2017 was $7.9 million, $3.6 million and $8.4 million, respectively.

The fair value of the TSR Units is estimated on the date of grant using a Monte Carlo valuation model that uses the assumptions noted in the table below. The risk-free rate is based on the U.S. Treasury yield curve in effect at the grant date for the expected performance period. Expected volatility is based on historical volatility for the most recent 3-year period ending on the grant date for the Company and the selected peer companies, and is calculated on a daily basis. The following are the key assumptions used in this valuation:

	2019		2018		2017
Risk free interest rate	1.57% - 2.54%		2.36% - 2.59%		1.42% - 1.99%
Expected stock price volatility	23.80% - 28.57%		28.57% - 30.02%		28.86% - 30.97%
Expected service period	2.4 - 3.0 years		2.5 - 3.0 years		2.2 - 3.0 years
Expected dividend yield (assuming full reinvestment)	—	%	—	%	—	%

During the years ended December 31, 2019, 2018 and 2017, the Company recognized $9.8 million, $7.6 million and $7.0 million, respectively, of stock-based compensation expense included in general and administrative expense in the consolidated statements of income. During the year ended December 31, 2017, the Company recognized $1.4 million of stock-based compensation expense related to former CCP employees included in merger and acquisition costs in the consolidated statements of income. As of December 31, 2019, there was $20.1 million of total unrecognized stock-based compensation expense related to unvested awards, which is expected to be recognized over a weighted average period of 2.5 years.

Employee Benefit Plan

The Company maintains a 401(k) plan that allows for eligible participants to defer compensation, subject to certain limitations imposed by the Internal Revenue Code of 1986, as amended (the “Code”). The Company provides a discretionary matching contribution of up to 3% of each participant’s eligible compensation. During the years ended December 31, 2019, 2018 and 2017, the Company’s matching contributions were approximately $211,000, $171,000 and $143,000, respectively.

XML

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

Environmental

As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of December 31, 2019, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.

Legal Matters

From time to time, the Company is party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.

XML

CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Rental and related revenues	$ 452,138	$ 536,605	$ 364,191
Interest and other income	81,540	16,667	17,660
Resident fees and services	128,058	70,137	26,430
Total revenues	661,736	623,409	408,281
Expenses:
Depreciation and amortization	181,549	191,379	113,882
Interest	126,610	147,106	88,440
Operating expenses		49,546	17,860
General and administrative	30,462	36,458	32,401
Merger and acquisition costs	424	636	30,255
Provision for doubtful accounts, straight-line rental income and loan losses	1,238	39,075	17,113
Impairment of real estate	121,819	1,413	1,326
Total expenses	570,574	465,613	301,277
Other (expense) income:
Loss on extinguishment of debt	(16,340)	(2,917)	(553)
Other income	2,094	4,480	536
Net gain on sales of real estate	2,300	128,198	52,029
Total other (expense) income	(11,946)	129,761	52,012
Income before loss from unconsolidated joint venture and income tax expense	79,216	287,557	159,016
Loss from unconsolidated joint venture	(6,796)	(5,431)	0
Income tax expense	(3,402)	(3,011)	(651)
Net income	69,018	279,115	158,365
Net (income) loss attributable to noncontrolling interests	(22)	(33)	18
Net income attributable to Sabra Health Care REIT, Inc.	68,996	279,082	158,383
Preferred stock dividends	0	(9,768)	(10,242)
Net income attributable to common stockholders	$ 68,996	$ 269,314	$ 148,141
Net income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ 0.37	$ 1.51	$ 1.40
Diluted common share (in dollars per share)	$ 0.37	$ 1.51	$ 1.40
Weighted-average number of common shares outstanding, basic (in shares)	187,172,210	178,305,738	105,621,242
Weighted-average number of common shares outstanding, diluted (in shares)	188,127,092	178,721,744	105,842,434
Triple-Net Portfolio
Expenses:
Operating expenses	$ 22,215	$ 0	$ 0
Senior Housing - Managed
Expenses:
Operating expenses	$ 86,257	$ 49,546	$ 17,860

XML

CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Stockholders' Equity [Abstract]
Common dividends (in dollars per share)	$ 1.80	$ 1.80	$ 1.73

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)

12 Months Ended

Dec. 31, 2019

REAL ESTATE LOANS RECEIVABLE [Abstract]

Loans Receivable and Other Investments

As of December 31, 2019 and 2018, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

											December 31, 2019
Investment	Quantity as of December 31, 2019	Property Type	Principal Balance as of December 31, 2019 (1)		Book Value as of December 31, 2019			Book Value as of December 31, 2018			Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of December 31, 2019
Loans Receivable:
Mortgage	1	Specialty Hospital	$	19,000	$	19,000		$	18,577		10.0	%	10.0	%	01/31/27
Construction	1	Senior Housing	2,468		2,487			4,629			8.0	%	7.8	%	09/30/22
Mezzanine	—	Skilled Nursing	—		—			2,188			N/A		N/A		N/A
Other	16	Multiple	46,059		42,147			45,324			6.8	%	7.0	%	09/23/19- 08/31/28
	18		67,527		63,634			70,718			7.8	%	7.9	%
Loan loss reserve			—		(564		)	(1,258		)
			$	67,527	$	63,070		$	69,460
Other Investments:
Preferred Equity	9	Skilled Nursing / Senior Housing	43,893		44,304			44,262			12.0	%	12.0	%	N/A
Total	27		$	111,420	$	107,374		$	113,722		9.4	%	9.6	%

⁽¹⁾ 

Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

Changes in Accretable Yield

The following table presents changes in the accretable yield for the years ended December 31, 2019 and 2018 (in thousands):

	Year Ended December 31,
	2019			2018
Accretable yield, beginning of period	$	449		$	2,483
Accretion recognized in earnings	(377		)	(2,761		)
Reduction due to payoff	(33		)	—
Net reclassification from nonaccretable difference	—			727
Accretable yield, end of period	$	39		$	449

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Basis of Presentation

The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of December 31, 2019 and 2018 and for the years ended December 31, 2019, 2018 and 2017. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).

Variable Interest Entities

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements

that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of December 31, 2019, the Company determined that it was not the primary beneficiary of any VIEs.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At December 31, 2019 and 2018, none of the Company’s investments in loans were accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of December 31, 2019, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications

Certain amounts in the Company’s consolidated statements of income and consolidated statements of cash flows for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations.

Real Estate Investments

Real Estate Acquisition Valuation

All assets acquired and liabilities assumed in an acquisition of real estate accounted for as a business combination are measured at their acquisition date fair values. For acquisitions of real estate accounted for as an asset acquisition, the fair value of consideration transferred by the Company (including transaction costs) is allocated to all assets acquired and liabilities assumed on a relative fair value basis. The acquisition value of land, building and improvements are included in real estate investments on the accompanying consolidated balance sheets. The acquisition value of above market lease, tenant origination and absorption costs and tenant relationship intangible assets is included in lease intangible assets, net on the accompanying consolidated balance sheets. The acquisition value of below market lease intangible liabilities is included in lease intangible liabilities, net on the accompanying consolidated balance sheets. Acquisition costs associated with real estate acquisitions deemed asset acquisitions are capitalized, and costs associated with real estate acquisitions deemed business combinations are expensed as incurred. The Company capitalized $0.6 million and $0.7 million of acquisition costs during the years ended December 31, 2019 and 2018, respectively. Restructuring costs that do not meet the definition of a liability at the acquisition date are expensed in periods subsequent to the acquisition date. During the years ended December 31, 2019, 2018 and 2017, the Company expensed $0.4 million, $0.6 million and $30.3 million, respectively, of merger and acquisition costs.

Estimates of the fair values of the tangible assets, identifiable intangibles and assumed liabilities require the Company to make significant assumptions to estimate market lease rates, property operating expenses, carrying costs during lease-up periods, discount rates, market absorption periods, and the number of years the property will be held for investment. The Company makes its best estimate based on the Company’s evaluation of the specific characteristics of each tenant’s lease. The use of inappropriate assumptions would result in an incorrect valuation of the Company’s acquired tangible assets, identifiable intangibles and assumed liabilities, which would impact the amount of the Company’s net income.

Depreciation and Amortization

Real estate costs related to the acquisition and improvement of properties are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term of any property subject to a ground lease. Tenant improvements are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term. Depreciation is discontinued when a property is identified as held for sale. Repair and maintenance costs are charged to expense as incurred and significant replacements and betterments are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate asset. The Company considers the period of future benefit of an asset to determine its appropriate useful life. Depreciation of real estate assets and amortization of tenant origination and absorption costs and tenant relationship lease intangibles are included in depreciation and amortization on the accompanying consolidated statements of income. Amortization of above and below market lease intangibles is included in rental income on the accompanying consolidated statements of income. The Company anticipates the estimated useful lives of its assets by class to be generally as follows: land improvements, five to 20 years; buildings and building improvements, five to 40 years; and furniture and equipment, three to 20 years. Intangibles are generally amortized over the remaining noncancellable lease terms, with tenant relationship intangible amortization periods including extension periods of up to 10 years.

Impairment of Real Estate Investments

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its real estate investments may not be recoverable or realized. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, the Company assesses the recoverability by estimating whether the Company will recover the carrying value of its real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. In some instances, there may be various potential outcomes for an investment and its potential future cash flows. In these instances, the undiscounted future cash flows used to assess recoverability are based on several assumptions and are probability-weighted based on the Company’s best estimates as of the date of evaluation. These assumptions include, among others, cash flow projections, discount rates, market capitalization rates and recent sales data for comparable properties. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its real estate investments, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its real estate investments.

Real Estate Investments, Inventory

Real Estate Acquisition Valuation

All assets acquired and liabilities assumed in an acquisition of real estate accounted for as a business combination are measured at their acquisition date fair values. For acquisitions of real estate accounted for as an asset acquisition, the fair value of consideration transferred by the Company (including transaction costs) is allocated to all assets acquired and liabilities assumed on a relative fair value basis. The acquisition value of land, building and improvements are included in real estate investments on the accompanying consolidated balance sheets. The acquisition value of above market lease, tenant origination and absorption costs and tenant relationship intangible assets is included in lease intangible assets, net on the accompanying consolidated balance sheets. The acquisition value of below market lease intangible liabilities is included in lease intangible liabilities, net on the accompanying consolidated balance sheets. Acquisition costs associated with real estate acquisitions deemed asset acquisitions are capitalized, and costs associated with real estate acquisitions deemed business combinations are expensed as incurred. The Company capitalized $0.6 million and $0.7 million of acquisition costs during the years ended December 31, 2019 and 2018, respectively. Restructuring costs that do not meet the definition of a liability at the acquisition date are expensed in periods subsequent to the acquisition date. During the years ended December 31, 2019, 2018 and 2017, the Company expensed $0.4 million, $0.6 million and $30.3 million, respectively, of merger and acquisition costs.

Estimates of the fair values of the tangible assets, identifiable intangibles and assumed liabilities require the Company to make significant assumptions to estimate market lease rates, property operating expenses, carrying costs during lease-up periods, discount rates, market absorption periods, and the number of years the property will be held for investment. The Company makes its best estimate based on the Company’s evaluation of the specific characteristics of each tenant’s lease. The use of inappropriate assumptions would result in an incorrect valuation of the Company’s acquired tangible assets, identifiable intangibles and assumed liabilities, which would impact the amount of the Company’s net income.

Depreciation and Amortization

Real estate costs related to the acquisition and improvement of properties are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term of any property subject to a ground lease. Tenant improvements are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term. Depreciation is discontinued when a property is identified as held for sale. Repair and maintenance costs are charged to expense as incurred and significant replacements and betterments are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate asset. The Company considers the period of future benefit of an asset to determine its appropriate useful life. Depreciation of real estate assets and amortization of tenant origination and absorption costs and tenant relationship lease intangibles are included in depreciation and amortization on the accompanying consolidated statements of income. Amortization of above and below market lease intangibles is included in rental income on the accompanying consolidated statements of income. The Company anticipates the estimated useful lives of its assets by class to be generally as follows: land improvements, five to 20 years; buildings and building improvements, five to 40 years; and furniture and equipment, three to 20 years. Intangibles are generally amortized over the remaining noncancellable lease terms, with tenant relationship intangible amortization periods including extension periods of up to 10 years.

Impairment of Real Estate Investments

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its real estate investments may not be recoverable or realized. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, the Company assesses the recoverability by estimating whether the Company will recover the carrying value of its real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. In some instances, there may be various potential outcomes for an investment and its potential future cash flows. In these instances, the undiscounted future cash flows used to assess recoverability are based on several assumptions and are probability-weighted based on the Company’s best estimates as of the date of evaluation. These assumptions include, among others, cash flow projections, discount rates, market capitalization rates and recent sales data for comparable properties. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its real estate investments, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its real estate investments.

Revenue Recognition

Revenue Recognition

The Company recognizes rental revenue from tenants, including rental abatements, lease incentives and contractual fixed increases attributable to operating leases, on a straight-line basis over the term of the related leases when it is probable that substantially all rents over the life of a lease are collectible. Certain of the Company’s leases provide for contingent rents equal to a percentage of the facility’s revenue in excess of specified base amounts or other thresholds. Such revenue is recognized when actual results reported by the tenant, or estimates of tenant results, exceed the applicable base amount or other threshold.

The Company assesses the collectability of rents on a lease-by-lease basis, and in doing so, considers such things as historical bad debts, tenant creditworthiness, current economic trends, facility operating performance, lease structure, credit enhancements (including guarantees), current developments relevant to a tenant’s business specifically and to its business category generally, and changes in tenants’ payment patterns. The Company’s assessment includes an estimation of a tenant’s ability to fulfill all of its rental obligations over the remaining lease term. In addition, with respect to tenants in bankruptcy, management makes estimates of the expected recovery of pre-petition and post-petition claims in assessing the estimated collectability of the related receivable. If at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received, and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Write-offs of receivables and any recoveries of previously written-off receivables are recorded as adjustments to rental revenue.

Revenue from resident fees and services is recorded monthly as services are provided and includes resident room and care charges, ancillary services charges and other resident charges.

Assets Held for Sale, DIspositions and Discontinued Operations

The Company generally considers real estate to be “held for sale” when the following criteria are met: (i) management commits to a plan to sell the property, (ii) the property is available for sale immediately, (iii) the property is actively being marketed for sale at a price that is reasonable in relation to its current fair value, (iv) the sale of the property within one year is considered probable and (v) significant changes to the plan to sell are not expected. Real estate that is held for sale and its related assets are classified as assets held for sale and are included in accounts receivable, prepaid expenses and other assets,

net on the accompanying consolidated balance sheets. Secured indebtedness and other liabilities related to real estate held for sale are classified as liabilities related to assets held for sale and are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets. Real estate classified as held for sale is no longer depreciated and is reported at the lower of its carrying value or its estimated fair value less estimated costs to sell. As of December 31, 2019 and 2018, the Company did not have any assets held for sale.

For sales of real estate where the Company has collected the consideration to which it is entitled in exchange for transferring the real estate, the related assets and liabilities are removed from the balance sheet and the resultant gain or loss is recorded in the period in which the transaction closes. Any post-sale involvement is accounted for as separate performance obligations, and when the separate performance obligations are satisfied, the portion of the sales price allocated to each such obligation is recognized.

Additionally, the Company records the operating results related to real estate that has been disposed of or classified as held for sale as discontinued operations for all periods presented if it represents a strategic shift that has or will have a major effect on the Company’s operations and financial results.

Investment in Unconsolidated Joint Venture and Preferred Equity Investments and Preferred Return

Preferred equity investments are accounted for at unreturned capital contributions, plus accrued and unpaid preferred returns. The Company recognizes preferred return income on a monthly basis based on the outstanding investment including any previously accrued and unpaid return. As a preferred member of the preferred equity joint ventures in which the Company participates, the Company is not entitled to share in the joint venture’s earnings or losses. Rather, the Company is entitled to receive a preferred return, which is deferred if the cash flow of the joint venture is insufficient to currently pay the accrued preferred return.

The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in the Company’s consolidated statements of income. The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company’s cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings of the joint venture.

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its equity method investments may not be recoverable or realized. When indicators of potential impairment are identified, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period and any estimated debt premiums or discounts. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its equity method investment.

Net Investment in Direct Financing Lease

As of December 31, 2019, the Company had a $23.9 million net investment in one skilled nursing/transitional care facility leased to an operator under a direct financing lease, as the tenant is obligated to purchase the property at the end of the lease term. The net investment in direct financing lease is recorded in accounts receivable, prepaid expenses and other assets, net on the accompanying consolidated balance sheets and represents the present value of total rental payments of $4.0 million, plus the estimated unguaranteed residual value of $24.7 million, less the unearned lease income of $4.8 million as of December 31, 2019. Unearned lease income represents the excess of the minimum lease payments and residual value over the cost of the investment. Unearned lease income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured.

Loans Receivable and Interest Income

Loans Receivable

The Company’s loans receivable are reflected at amortized cost on the accompanying consolidated balance sheets. The amortized cost of a loan receivable is the outstanding unpaid principal balance, net of unamortized discounts, costs and fees directly associated with the origination of the loan.

Loans acquired in connection with a business combination are recorded at their acquisition date fair value. The Company determines the fair value of loans receivable based on estimates of expected discounted cash flows, collateral, credit risk and other factors. The Company does not establish a valuation allowance at the acquisition date, as the amount of estimated future cash flows reflects its judgment regarding their uncertainty. The Company recognizes the difference between the acquisition date fair value and the total expected cash flows as interest income using the effective interest method over the life of the applicable loan. The Company immediately recognizes in income any unamortized balances if the loan is repaid before its contractual maturity.

On a quarterly basis, the Company evaluates the collectability of its loan portfolio, including related interest income receivable, and establishes a reserve for loan losses. The Company’s evaluation includes reviewing credit quality indicators such as payment status, changes affecting the underlying real estate collateral (for collateral dependent loans), changes affecting the operations of the facilities securing the loans, and national and regional economic factors. The reserve for loan losses is a valuation allowance that reflects management’s estimate of loan losses inherent in the loan portfolio as of the balance sheet date. The reserve is adjusted through provision for doubtful accounts, straight-line rental income and loan losses on the Company’s consolidated statements of income and is decreased by charge-offs to specific loans when losses are confirmed. The reserve for loan losses includes an asset-specific component and a portfolio-based component.

An asset-specific reserve relates to reserves for losses on loans considered impaired and interest income receivable that is deemed uncollectible. The Company considers a loan to be impaired when, based upon current information and events, management believes that it is probable that the Company will be unable to collect all amounts due under the contractual terms of the loan agreement resulting from the borrower’s failure to repay contractual amounts due, the granting of a concession by the Company or the expectation that the Company will receive assets with fair values less than the carrying value of the loan in satisfaction of the loan. If a loan is considered to be impaired, a reserve is established when the carrying value of that loan is greater than the present value of payments expected to be received, the observable market prices for similar instruments, the estimated fair value of the collateral (for loans that are dependent on the collateral for repayment) or other amounts expected to be received in satisfaction of the loan.

A portfolio-based reserve covers the pool of loans that do not have asset-specific reserves. A provision for loan losses is recorded when available information as of each balance sheet date indicates that it is probable that a loss occurred in the pool of loans and the amount of the loss can be reasonably estimated, but the Company does not know which specific loans within the pool will ultimately result in losses. The required reserve balances for this pool of loans is derived based on estimated probabilities of default and estimated loss severities assuming a default occurs.

Interest Income

Interest income on the Company’s loans receivable is recognized on an accrual basis over the life of the investment using the interest method. Direct loan origination costs are amortized over the term of the loan as an adjustment to interest income. When concerns exist as to the ultimate collection of principal or interest due under a loan, the loan is placed on nonaccrual status, and the Company will not recognize interest income until the cash is received, or the loan returns to accrual status. If the Company determines that the collection of interest according to the contractual terms of the loan or through the receipts of assets in satisfaction of contractual amounts due is probable, the Company will resume the accrual of interest. In instances where borrowers are in default under the terms of their loans, the Company may continue recognizing interest income provided that all amounts owed under the contractual terms of the loan, including accrued and unpaid interest, do not exceed the estimated fair value of the collateral, less costs to sell.

Cash and Cash Equivalents

The Company considers all short-term (with an original maturity of three months or less), highly-liquid investments utilized as part of the Company’s cash-management activities to be cash equivalents. Cash equivalents may include cash and short-term investments. Short-term investments are stated at cost, which approximates fair value.

The Company’s cash and cash equivalents balance exceeded federally insurable limits as of December 31, 2019. To date, the Company has experienced no loss or lack of access to cash in its operating accounts. The Company has a corporate banking relationship with Bank of America, N.A. in which it deposits the majority of its cash.

Restricted Cash

Restricted cash primarily consists of amounts held by an exchange accommodation titleholder or by secured debt lenders to provide for future real estate tax expenditures, tenant improvements and capital expenditures. Pursuant to the terms of the Company’s leases with certain tenants, the Company has assigned its interests in certain of these restricted cash accounts with secured debt lenders to the tenants, and this amount is included in accounts payable and accrued liabilities on the Company’s consolidated balance sheets.

Stock-Based Compensation

Stock-based compensation expense for stock-based awards granted to Sabra’s employees and its non-employee directors is recognized in the statements of income based on the estimated grant date fair value, as adjusted. Compensation expense for awards with graded vesting schedules is generally recognized ratably over the period from the grant date to the date when the award is no longer contingent on the employee providing additional services. Compensation expense for awards with performance-based vesting conditions is recognized based on the Company’s estimate of the ultimate value of such award after considering the Company’s expectations of future performance. Forfeitures of stock-based awards are recognized as they occur.

Deferred Financing Costs

Deferred financing costs representing fees paid to third parties are amortized over the terms of the respective financing agreements using the interest method. Deferred financing costs related to secured debt, term loans and senior unsecured notes are recorded as a reduction of the related debt liability, and deferred financing costs related to the revolving credit facility are recorded in accounts receivable, prepaid expenses and other assets, net. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financings that do not close are expensed in the period in which it is determined that the financing will not close.

Income Taxes

The Company elected to be treated as a REIT with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. The Company believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. To qualify as a REIT, the Company must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of the Company’s annual REIT taxable income to stockholders (which is computed without regard to the dividends-paid deduction or net capital gains and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, the Company generally will not be subject to federal income tax on income that it distributes as dividends to its stockholders. If the Company fails to qualify as a REIT in any taxable year, it will be subject to U.S. federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost, unless the Internal Revenue Service grants the Company relief under certain statutory provisions. Such an event could materially and adversely affect the Company’s net income and net cash available for distribution to stockholders. However, the Company believes that it is organized and operates in such a manner as to qualify for treatment as a REIT.

 As a result of certain investments, the Company now records income tax expense or benefit with respect to certain of its entities that are taxed as taxable REIT subsidiaries under provisions similar to those applicable to regular corporations and not under the REIT provisions.

     The Company accounts for deferred income taxes using the asset and liability method and recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company’s financial statements or tax returns. Under this method, the Company determines deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in the deferred tax liability that results from a change in

circumstances, and that causes a change in the Company’s judgment about expected future tax consequences of events, is included in the tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss and tax credit carryforwards. A valuation allowance is provided if the Company believes it is more likely than not that all or some portion of the deferred tax asset will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, and that causes a change in the Company’s judgment about the realizability of the related deferred tax asset, is included in the tax provision when such changes occur. 

The Company evaluates its tax positions using a two step approach: step one (recognition) occurs when the Company concludes that a tax position, based solely on its technical merits, is more likely than not to be sustained upon examination, and step two (measurement) is only addressed if step one has been satisfied (i.e., the position is more likely than not to be sustained). Under step two, the tax benefit is measured as the largest amount of benefit (determined on a cumulative probability basis) that is more likely than not to be realized upon ultimate settlement. The Company will recognize tax penalties relating to unrecognized tax benefits as additional tax expense.

Foreign Currency

Certain of the Company’s subsidiaries’ functional currencies are the local currencies of their respective foreign jurisdictions. The Company translates the results of operations of its foreign subsidiaries into U.S. dollars using average rates of exchange in effect during the period presented, and it translates balance sheet accounts using exchange rates in effect at the end of the period presented. The Company records resulting currency translation adjustments in accumulated other comprehensive income (loss), a component of stockholders’ equity, on its consolidated balance sheets, and it records foreign currency transaction gains and losses as a component of interest and other income on its consolidated statements of income.

Derivative Instruments

The Company uses certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at inception, the Company must make an assessment that the transaction that the Company intends to hedge is probable of occurring, and this assessment must be updated each reporting period.

The Company recognizes all derivative instruments as assets or liabilities on the consolidated balance sheets at their fair value. For derivatives designated and qualified as a hedge, the change in fair value of the effective portion of the derivatives is recognized in accumulated other comprehensive income (loss). Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria for hedge accounting would be recognized in earnings.

The Company formally documents all relationships between hedging instruments and hedged items, as well as its risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific transactions, as well as recognizing obligations or assets on the consolidated balance sheets. The Company also assesses and documents, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying transaction will not occur, the Company would discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the then-current fair value of the derivative.

Fair Value Measurements

Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:

• Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;

• Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and

• Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.

When available, the Company utilizes quoted market prices from an independent third-party source to determine fair value and classifies such items as Level 1 or Level 2. In instances where the market for a financial instrument is not active, regardless of the availability of a nonbinding quoted market price, observable inputs might not be relevant and could require the Company to make a significant adjustment to derive a fair value measurement. Additionally, in an inactive market, a market price quoted from an independent third party may rely more on models with inputs based on information available only to that independent third party. When the Company determines the market for a financial instrument owned by the Company to be illiquid or when market transactions for similar instruments do not appear orderly, the Company may use several valuation sources (including internal valuations, discounted cash flow analysis and quoted market prices) to establish a fair value. If more than one valuation source is used, the Company will assign weights to the various valuation sources. Additionally, when determining the fair value of liabilities in circumstances in which a quoted price in an active market for an identical liability is not available, the Company measures fair value using (i) a valuation technique that uses the quoted price of the identical liability when traded as an asset or quoted prices for similar liabilities or similar liabilities when traded as assets or (ii) another valuation technique that is consistent with the principles of fair value measurement, such as the income approach or the market approach.

Changes in assumptions or estimation methodologies can have a material effect on these estimated fair values. In this regard, the derived fair value estimates cannot be substantiated by comparison to independent markets and, in many cases, may not be realized in an immediate settlement of the instrument.

The Company considers the following factors to be indicators of an inactive market: (i) there are few recent transactions, (ii) price quotations are not based on current information, (iii) price quotations vary substantially either over time or among market makers (for example, some brokered markets), (iv) indexes that previously were highly correlated with the fair values of the asset or liability are demonstrably uncorrelated with recent indications of fair value for that asset or liability, (v) there is a significant increase in implied liquidity risk premiums, yields, or performance indicators (such as delinquency rates or loss severities) for observed transactions or quoted prices when compared with the Company’s estimate of expected cash flows, considering all available market data about credit and other nonperformance risk for the asset or liability, (vi) there is a wide bid-ask spread or significant increase in the bid-ask spread, (vii) there is a significant decline or absence of a market for new issuances (that is, a primary market) for the asset or liability or similar assets or liabilities, and (viii) little information is released publicly (for example, a principal-to-principal market).

The Company considers the following factors to be indicators of non-orderly transactions: (i) there was not adequate exposure to the market for a period before the measurement date to allow for marketing activities that are usual and customary for transactions involving such assets or liabilities under current market conditions, (ii) there was a usual and customary marketing period, but the seller marketed the asset or liability to a single market participant, (iii) the seller is in or near bankruptcy or receivership (that is, distressed), or the seller was required to sell to meet regulatory or legal requirements (that is, forced), and (iv) the transaction price is an outlier when compared with other recent transactions for the same or similar assets or liabilities.

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. As such, the Company classifies these instruments as Level 3.

Per Share Data

Basic earnings per common share is computed by dividing net income applicable to common stockholders by the weighted average number of shares of common stock and common equivalents outstanding during the period. Diluted earnings per common share is calculated by including the effect of dilutive securities.

Industry Segments

The Company has one reportable segment consisting of investments in healthcare-related real estate properties.

Recently Issued Accounting Standards Update

Adopted

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”). Topic 842 supersedes guidance related to accounting for leases and provides for the recognition of lease assets and lease liabilities by lessees for those leases previously classified as operating leases under GAAP. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a

lease. Topic 842 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. Topic 842 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company elected to adopt Topic 842 on January 1, 2019 using the modified retrospective transition method, which permits application of the new standard on the adoption date as opposed to the earliest comparative period presented in the financial statements. In addition, the Company elected to use the available practical expedient package, and therefore did not reassess classification of its existing leases.

Additionally, the Company has elected a practical expedient not to separate lease and nonlease components (such as services rendered), which can only be applied to leasing arrangements for which (i) the timing and pattern of transfer are the same for the lease and nonlease components and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Under this practical expedient, contracts that are predominantly lease-based would be accounted for under Topic 842, and contracts that are predominantly service-based would be accounted for under Topic 606, Revenue from Contracts with Customers. As a result of electing this practical expedient, the Company, beginning January 1, 2019, recognizes revenue from its leased skilled nursing/transitional care facilities, senior housing communities, and specialty hospitals and other facilities under Topic 842 and recognizes revenue from its Senior Housing - Managed communities under the Revenue ASUs (codified under Topic 606). Upon adoption of Topic 842, the Company recognized its operating leases for which it is the lessee, mainly its corporate office lease and ground leases, on its consolidated balance sheets, as a lease liability of $10.0 million, included in accounts payable and accrued liabilities on the condensed consolidated balance sheets, and a corresponding right-of-use asset, included in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. As of December 31, 2019, the balances of the lease liability and the corresponding right-of-use asset were $9.8 million and $9.3 million, respectively.

The Company assesses the collectability of rental revenues on a lease-by-lease basis. Prior to the adoption of Topic 842, the Company recorded rental revenue and receivables to the extent those amounts were expected to be collected, irrespective of the Company’s determination of the collectability of substantially all rents over the life of a lease. Upon adoption of Topic 842, if at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Upon adoption of Topic 842 and as of the adoption date, the Company recorded a $32.5 million reduction in equity and accounts receivable due to the cumulative effect of this change. This reduction consisted of $17.5 million of straight-line rental income receivables and $15.0 million of cash rent receivables, although management believes the $15.0 million of cash rent receivables are collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Under Topic 842, future write-offs of receivables and any recoveries of previously written-off receivables will be recorded as adjustments to rental revenue.

Furthermore, Topic 842 requires lessors to exclude from variable payments lessor costs paid by lessees directly to third parties. In contrast, lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized $17.6 million of variable lease revenue and the associated expense during the year ended December 31, 2019.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold under current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which amends ASU 2016-13 to clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, and instead, impairment of such receivables should be accounted for in accordance with Topic 842, Leases. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2019-11”), which amends ASU 2016-13 to clarify or address stakeholders’ specific issues about certain aspects of ASU 2016-13. ASU 2016-13, ASU 2018-19 and ASU 2019-11 are effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in these updates through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company adopted ASU 2016-13, ASU 2018-19 and ASU 2019-11 on January 1, 2020. The adoption of these standards did not have a material impact on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 updates the fair value measurement disclosure requirements by (i) eliminating certain requirements, including disclosure of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements, (ii) modifying certain requirements, including clarifying that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date and (iii) adding certain requirements, including disclosure of the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted for any eliminated or modified disclosures. The Company adopted ASU 2018-13 on January 1, 2020. The Company does not expect the adoption of ASU 2018-13 to have a material impact on its consolidated financial statements.

XML

EQUITY (Tables)

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Summary of Accumulated Other Comprehensive Income

The following is a summary of the Company’s accumulated other comprehensive (loss) income (in thousands):

	Year Ended December 31,
	2019			2018
Foreign currency translation gain (loss)	$	(1,516	)	$	(2,193	)
Unrealized (loss) gain on cash flow hedges	(10,872		)	14,494
Total accumulated other comprehensive (loss) income	$	(12,388	)	$	12,301

XML

REAL ESTATE PROPERTIES HELD FOR INVESTMENT

12 Months Ended

Dec. 31, 2019

Real Estate Investments, Net [Abstract]

REAL ESTATE PROPERTIES HELD FOR INVESTMENT

REAL ESTATE PROPERTIES HELD FOR INVESTMENT

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of December 31, 2019  

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	296	33,290	$	3,701,666	$	(306,565	)	$	3,395,101
Senior Housing - Leased (1)	62	3,820	630,688		(72,278		)	558,410
Senior Housing - Managed (1)	46	4,809	907,771		(112,893		)	794,878
Specialty Hospitals and Other	25	1,193	639,721		(47,124		)	592,597
	429	43,112	5,879,846		(538,860		)	5,340,986
Corporate Level			737		(353		)	384
			$	5,880,583	$	(539,213	)	$	5,341,370

As of December 31, 2018

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	335	37,628	$	4,094,484	$	(224,942	)	$	3,869,542
Senior Housing - Leased (1)	90	7,332	1,237,790		(125,902		)	1,111,888
Senior Housing - Managed (1)	23	1,603	301,739		(19,537		)	282,202
Specialty Hospitals and Other	22	1,085	621,236		(31,640		)	589,596
	470	47,648	6,255,249		(402,021		)	5,853,228
Corporate Level			634		(317		)	317
			$	6,255,883	$	(402,338	)	$	5,853,545

⁽¹⁾ During the year ended December 31, 2019, the Company transitioned 21 senior housing communities to its Senior Housing - Managed portfolio.

	December 31, 2019			December 31, 2018
Building and improvements	$	5,042,435		$	5,388,102
Furniture and equipment	239,229			237,145
Land improvements	1,534			1,254
Land	597,385			629,382
	5,880,583			6,255,883
Accumulated depreciation	(539,213		)	(402,338		)
	$	5,341,370		$	5,853,545

Operating Leases

As of December 31, 2019, the substantial majority of the Company’s real estate properties (excluding 46 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 15 years. As of December 31, 2019, the leases had a weighted-average remaining term of eight years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee or other parties related to the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets and totaled $10.5 million and $12.4 million as of December 31, 2019 and 2018, respectively, and letters of credit deposited with the Company totaled approximately $83 million and $98 million as of December 31, 2019 and 2018, respectively. In addition, the Company’s tenants have deposited with the Company $14.3 million and $17.5 million as of December 31, 2019 and 2018, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations.

As of December 31, 2018, the Company had a $1.3 million reserve for unpaid cash rental income and a $35.8 million reserve associated with accumulated straight-line rental income. Upon adoption of Topic 842 on January 1, 2019, if at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received, and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. As such, the Company no longer records reserves for unpaid cash rental income or accumulated straight-line rental income.

On February 15, 2019, the Company entered into a settlement agreement with Senior Care Centers in connection with the notices of default and lease termination issued by the Company to Senior Care Centers during the third quarter of 2018. In accordance with the order entered by the bankruptcy court in March 2019, the settlement agreement provided for the discharge by the Company of its claims against Senior Care Centers in exchange for $9.5 million of settlement payments, a portion of which was applied to pay post-petition rent. The Company recorded $6.2 million of such post-petition rent during the year ended December 31, 2019. On April 1, 2019, the Company completed the sale of 28 facilities (26 skilled nursing/transitional care facilities and two senior housing communities) previously operated by Senior Care Centers and received gross sales proceeds of $282.5 million. In connection with the sale, the Company entered into an agreement to indemnify the buyer from certain costs, expenses and liabilities related to the historical operations of the facilities by Senior Care Centers. In May 2019, the Company transitioned eight facilities previously operated by Senior Care Centers to a current operator in the Sabra portfolio, and the Company subsequently sold the remaining two facilities previously operated by Senior Care Centers (one

during the fourth quarter of 2019 and one in January 2020). During the year ended December 31, 2019, the Company recorded an impairment charge of $95.2 million related to the Senior Care Centers facilities, which includes $10.2 million related to the Company’s estimated contractual indemnification obligations. As of December 31, 2019, the Company adjusted its contractual indemnification obligations estimate down to $8.8 million.

On December 19, 2018, the Company entered into a letter of intent to terminate its triple-net master lease with Holiday Retirement (“Holiday”) with respect to all 21 senior housing communities subject to the master lease (the “Holiday Communities”) and concurrently enter into management agreements pursuant to which Holiday would manage the Holiday Communities. On April 1, 2019, the Company completed the conversion of the Holiday Communities to its Senior Housing - Managed portfolio and recognized lease termination income of $66.9 million, which includes a $57.2 million lease termination payment received in exchange for terminating the Holiday master lease and a $9.7 million gain related to the assumption of fixed assets and liabilities.

The Company monitors the creditworthiness of its tenants by reviewing credit ratings (if available) and evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including the evaluation of any parent guarantees (or the guarantees of other related parties) of tenant lease obligations. As formal credit ratings may not be available for most of the Company’s tenants, the primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio or the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.

For the year ended December 31, 2019, no tenant relationship represented 10% or more of the Company’s total revenues.

The future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):

As of December 31, 2019

2020	$	428,101
2021	427,791
2022	404,568
2023	389,810
2024	380,944
Thereafter	1,672,008
	$	3,703,222

As of December 31, 2018

2019	$	465,766
2020	456,207
2021	452,346
2022	454,216
2023	437,277
Thereafter	2,407,064
	$	4,672,876

Senior Housing - Managed Communities

The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The

Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services includes ancillary service revenue of $0.8 million, $0.5 million and $0.3 million for the years ended December 31, 2019, 2018 and 2017, respectively.

XML

DEBT

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

DEBT

DEBT

Secured Indebtedness

The Company’s secured debt consists of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of December 31, 2019 (1)		Principal Balance as of December 31, 2018 (1)		Weighted Average Interest Rate at December 31, 2019 (2)		Maturity Date
Fixed Rate	$	114,777	$	117,464	3.67	%	December 2021 -  August 2051

⁽¹⁾  Principal balance does not include deferred financing costs, net of $1.7 million and $1.8 million as of December 31, 2019 and 2018, respectively.

⁽²⁾  Weighted average interest rate includes private mortgage insurance.

During the year ended December 31, 2018, the Company (i) prepaid a $98.5 million variable rate secured term loan and recognized a $2.0 million loss on extinguishment of debt related to prepayment penalty fees associated with the early repayment of the loan and (ii) repaid $37.6 million of fixed rate debt secured by facilities sold during the year ended December 31, 2018 and recognized a $0.9 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with this repayment.

Senior Unsecured Notes

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of December 31,
Title	Maturity Date	2019 (1)		2018 (1)
5.5% senior unsecured notes due 2021 (“2021 Notes”)	February 1, 2021	$	—	$	500,000
5.375% senior unsecured notes due 2023 (“2023 Notes”)	June 1, 2023	—		200,000
4.80% senior unsecured notes due 2024 (“2024 Notes”)	June 1, 2024	300,000		—
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	500,000		500,000
5.38% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
3.90% senior unsecured notes due 2029 (“2029 Notes”)	October 15, 2029	350,000		—
		$	1,250,000	$	1,300,000

⁽¹⁾  Principal balance does not include premium, net of $7.6 million and deferred financing costs, net of $8.8 million as of December 31, 2019 and does not include premium, net of $14.5 million and deferred financing costs, net of $7.1 million as of December 31, 2018.

 5.5% Notes Due 2021. On January 23, 2014, the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company (the “Issuers”), issued $350.0 million aggregate principal amount of 5.5% senior unsecured notes due 2021 (the “Original 2021 Notes”), and on October 10, 2014, they issued $150.0 million aggregate principal amount of 5.5% senior unsecured notes due 2021, which were treated as a single class with, and had the same terms as, the Original 2021 Notes (the additional notes and the Original 2021 Notes, together, the “2021 Notes”). The 2021 Notes accrued interest at a rate of 5.5% per annum payable semiannually on February 1 and August 1 of each year.

On June 29, 2019, the Issuers redeemed all $500.0 million aggregate principal amount outstanding of the 2021 Notes at a cash redemption price of 101.375% of the principal amount being redeemed, plus accrued and unpaid interest. The redemption resulted in $10.1 million of redemption related costs and write-offs for the year ended December 31, 2019, consisting of $6.9 million in payments made to noteholders and legal fees for early redemption and $3.2 million of write-offs associated with unamortized deferred financing and premium costs. These amounts are included in loss on extinguishment of debt on the accompanying consolidated statements of income.

5.375% Notes Due 2023. On May 23, 2013, the Issuers issued $200.0 million aggregate principal amount of 5.375% senior unsecured notes due 2023 (the “2023 Notes”). The 2023 Notes accrued interest at a rate of 5.375% per annum payable semiannually on June 1 and December 1 of each year.

On October 27, 2019, the Issuers redeemed all $200.0 million aggregate principal amount outstanding of the 2023 Notes at a cash redemption price of 101.792% of the principal amount being redeemed, plus accrued and unpaid interest. The redemption resulted in $5.6 million of redemption related costs and write-offs for the year ended December 31, 2019, consisting of $3.6 million in payments made to noteholders and legal fees for early redemption and $2.0 million of write-offs associated with unamortized deferred financing costs. These amounts are included in loss on extinguishment of debt on the accompanying consolidated statements of income.

4.80% Notes Due 2024. On May 29, 2019, the Issuers completed an underwritten public offering of $300.0 million aggregate principal amount of 4.80% senior unsecured notes due 2024 (the “2024 Notes”). The net proceeds were $295.3 million after deducting underwriting discounts and other offering expenses. The net proceeds, together with borrowings under the Revolving Credit Facility, were used to redeem the 2021 Notes as discussed above. The 2024 Notes accrue interest at a rate of 4.80% per annum payable semiannually on June 1 and December 1 of each year. Upon redemption of the 2023 Notes as discussed above, Sabra Capital Corporation’s obligations as a co-issuer under the 2024 Notes were automatically released and discharged.

The 2024 Notes are redeemable at the option of the Operating Partnership, in whole or in part at any time and from time to time, prior to May 1, 2024, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date, plus a make-whole premium. The Operating Partnership may also redeem the 2024 Notes on or after May 1, 2024, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date. Assuming the 2024 Notes are not redeemed, the 2024 Notes mature on June 1, 2024.

5.125% Notes Due 2026. In connection with the CCP Merger, on August 17, 2017, the Operating Partnership assumed $500.0 million aggregate principal amount of 5.125% senior unsecured notes due 2026 (the “2026 Notes”) issued by Care Capital Properties, LP in July 2016. The 2026 Notes accrue interest at a rate of 5.125% per annum payable semiannually on February 15 and August 15 of each year.

The Operating Partnership may, at its option, redeem the 2026 Notes at any time in whole or from time to time in part prior to their stated maturity. The redemption price for 2026 Notes that are redeemed will be equal to (i) 100% of their principal amount, together with accrued and unpaid interest thereon, if any, to (but excluding) the date of redemption, plus, (ii) if redeemed prior to May 15, 2026, a make-whole premium. Assuming the 2026 Notes are not redeemed, the 2026 Notes mature on August 15, 2026.

5.38% Notes Due 2027. In connection with the CCP Merger, on August 17, 2017, the Operating Partnership assumed $100.0 million aggregate principal amount of unregistered 5.38% senior unsecured notes due 2027 (the “2027 Notes”) issued by Care Capital Properties, LP in May 2016. The 2027 Notes accrue interest at a rate of 5.38% per annum payable semiannually on May 17 and November 17 of each year.

The Operating Partnership may prepay the 2027 Notes, in whole at any time or in part from time to time, at 100% of the principal amount to be prepaid plus a make-whole premium. Assuming the 2027 Notes are not redeemed, the 2027 Notes mature on May 17, 2027.

3.90% Notes Due 2029. On October 7, 2019, the Issuers completed an underwritten public offering of $350.0 million aggregate principal amount of 3.90% senior unsecured notes due 2029 (the “2029 Notes”). The net proceeds were $340.5 million after deducting underwriting discounts and other offering expenses. A portion of the net proceeds was used to redeem all of the 2023 Notes as discussed above, and the remaining net proceeds were used to repay borrowings outstanding on the Revolving Credit Facility. The 2029 Notes accrue interest at a rate of 3.90% per annum payable semiannually on April 15 and October 15 of each year. Upon redemption of the 2023 Notes as discussed above, Sabra Capital Corporation’s obligations as a co-issuer under the 2029 Notes were automatically released and discharged.

The 2029 Notes are redeemable at the option of the Operating Partnership, in whole or in part at any time and from time to time, prior to July 15, 2029, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date, plus a make-whole premium. The Operating Partnership may also redeem the 2029 Notes on or after July 15, 2029, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date. Assuming the 2029 Notes are not redeemed, the 2029 Notes mature on October 15, 2029.

The obligations under the 2024 Notes and 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes and 2029 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances.  See Note 15, “Summarized Consolidating Information,” for additional information concerning the circumstances pursuant to which the guarantors will be automatically and unconditionally released from their obligations under the guarantees.

The indenture governing the 2024 Notes contains restrictive covenants that, among other things, restrict the ability of Sabra, the Issuers and their restricted subsidiary to: (i) incur or guarantee additional indebtedness; (ii) incur or guarantee secured indebtedness; and (iii) merge or consolidate or sell all or substantially all of their assets. The indenture governing the 2024 Notes also provides for customary events of default, including, but not limited to, the failure to make payments of interest or premium, if any, on, or principal of, the 2024 Notes, the failure to comply with certain covenants and agreements specified in the indenture for a period of time after notice has been provided, the acceleration of other indebtedness resulting from the failure to pay principal on such other indebtedness prior to its maturity, and certain events of insolvency. If any event of default occurs, the principal of, premium, if any, and accrued interest on all the then-outstanding 2024 Notes may become due and payable immediately. The indenture governing the 2024 Notes requires Sabra, the Issuers and their restricted subsidiary to maintain Total Unencumbered Assets (as defined in the indentures) of at least 150% of the Company’s unsecured indebtedness.

The indenture governing the 2026 Notes contains certain covenants that, among other things, limits the ability of Sabra, the Issuers and their subsidiaries to: (i) consummate a merger, consolidate or sell all or substantially all of our consolidated assets and (ii) incur secured or unsecured indebtedness. In addition, Sabra, the Operating Partnership and their subsidiaries are required to maintain at all times consolidated unencumbered total asset value in an amount not less than 150% of the aggregate outstanding principal amount of the Company’s consolidated unsecured debt.

The agreement governing the 2027 Notes provides for customary events of default, including, but not limited to, the failure to make payments of interest or premium, if any, on, or principal of, the 2027 Notes, the failure to comply with certain covenants and agreements specified in the agreement governing the 2027 Notes for a period of time after notice has been provided, the acceleration of other indebtedness resulting from the failure to pay principal on such other indebtedness prior to its maturity, and certain events of insolvency. In addition, certain change of control events constitute an event of default under the agreement governing the 2027 Notes. If any event of default occurs, the principal of, premium, if any, and accrued interest on all the then-outstanding 2027 Notes may become due and payable immediately.

The indenture governing the 2029 Notes contains restrictive covenants that, among other things, restrict the ability of Sabra, the Issuers and their subsidiaries to: (i) incur or guarantee additional indebtedness; (ii) incur or guarantee secured indebtedness; and (iii) merge or consolidate or sell all or substantially all of their assets. The indenture governing the 2029 Notes also provides for customary events of default, including, but not limited to, the failure to make payments of interest or premium, if any, on, or principal of, the 2029 Notes, the failure to comply with certain covenants and agreements specified in the indenture for a period of time after notice has been provided, the acceleration of other indebtedness resulting from the failure to pay principal on such other indebtedness prior to its maturity, and certain events of insolvency. If any event of default occurs, the principal of, premium, if any, and accrued interest on all the then-outstanding 2029 Notes may become due and payable immediately. The indenture governing the 2029 Notes requires Sabra, the Issuers and their subsidiaries to maintain Total Unencumbered Assets (as defined in the indentures) of at least 150% of the Company’s unsecured indebtedness.

The Company was in compliance with all applicable financial covenants under the indentures and agreements (the “Senior Notes Indentures”) governing the 2024 Notes, 2026 Notes, 2027 Notes and 2029 Notes (collectively, the “Senior Notes”) outstanding as of December 31, 2019.

Credit Agreement

Effective on August 17, 2017, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fourth amended and restated unsecured credit agreement (the “Prior Credit Agreement”). The Prior Credit Agreement amended and restated the previous credit agreement entered into by the Borrowers in January 2016 (the “2016 Credit Agreement”). The Company recognized a $0.6 million loss on extinguishment of debt during the year ended December 31, 2017 related to write-offs of deferred financing costs in connection with amending and restating the 2016 Credit Agreement.

The Prior Credit Agreement included a $1.0 billion revolving credit facility (the “Prior Revolving Credit Facility”), $1.1 billion in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Prior Term Loans”). Further, up to $175.0 million of the Prior Revolving Credit Facility could be used for borrowings in certain foreign currencies. The Prior Credit Agreement also contained an accordion feature that allowed for an increase in the total available borrowings to $2.5 billion, subject to terms and conditions.

The Prior Revolving Credit Facility had a maturity date of August 17, 2021, and included two six-month extension options. $200.0 million of the U.S. dollar Prior Term Loans had a maturity date of August 17, 2020, and the other Prior Term Loans had a maturity date of August 17, 2022.

Borrowings under the Prior Revolving Credit Facility bore interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Base Rate”). On August 17, 2017, Sabra’s ratings met the Investment Grade Ratings Criteria (as defined in the Prior Credit Agreement), and Sabra elected to use the ratings-based applicable interest margin for borrowings which varied based on the Debt Ratings, as defined in the Prior Credit Agreement, and ranged from 0.875% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Base Rate. In addition, the Operating Partnership paid a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Prior Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Prior Term Loans bore interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings, as defined in the Prior Credit Agreement, and ranged from 0.90% to 1.90% per annum for LIBOR based borrowings and 0.00% to 0.90% per annum for borrowings at the Base Rate. The Canadian dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to the Canadian Dollar Offered Rate (“CDOR”) plus an interest margin that ranged from 0.90% to 1.90% depending on the Debt Ratings.

On September 9, 2019, the Borrowers, Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Credit Agreement”). The Credit Agreement amends and restates the Prior Credit Agreement. The Company recognized a $0.6 million loss on extinguishment of debt related to write-offs of unamortized deferred financing costs in connection with amending and restating the Prior Credit Agreement during the year ended December 31, 2019.

The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), $1.1 billion in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $175.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of September 9, 2023, and includes two six-month extension options. $250.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2022, $350.0 million of the U.S. dollar Term Loans has a maturity date of September 9, 2023, and the other Term Loans have a maturity date of September 9, 2024.

As of December 31, 2019, there were no amounts outstanding under the Revolving Credit Facility and $1.0 billion available for borrowing. As of December 31, 2019, $955.0 million in U.S. dollar term loans and the CAD $125.0 million Canadian dollar term loan were outstanding.

Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.45% per annum for LIBOR based borrowings and 0.00% to 0.45% per annum for borrowings at the Base Rate. As of December 31, 2019, the interest rate on the Revolving Credit Facility was 2.91%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Term Loans bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Base Rate. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal to CDOR plus an interest margin that ranges from 0.85% to 1.65% depending on the Debt Ratings.

On June 10, 2015, the Company entered into an interest rate swap agreement to fix the CDOR portion of the interest rate for CAD $90.0 million of its Canadian dollar Term Loan at 1.59%. In addition, CAD $90.0 million of the Canadian dollar Term Loan was designated as a net investment hedge. On August 10, 2016, the Company entered into two interest rate swap agreements to fix the LIBOR portion of the interest rate for $245.0 million of its U.S. dollar Term Loans at 0.90% and one interest rate swap agreement to fix the CDOR portion on CAD $35.0 million of its Canadian dollar Term Loan at 0.93%. See Note 9, “Derivative and Hedging Instruments,” for further information.

As a result of the CCP Merger, the Company assumed eight interest rate swap agreements that fix the LIBOR portion of the interest rate for $600 million of the Company’s U.S. dollar Term Loans at a weighted average rate of 1.31%. See Note 9, “Derivative and Hedging Instruments,” for further information.

The obligations of the Borrowers under the Credit Agreement are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances.

The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a minimum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of December 31, 2019, the Company was in compliance with all applicable financial covenants under the Credit Agreement.

Interest Expense

During the years ended December 31, 2019, 2018 and 2017, the Company incurred interest expense of $126.6 million, $147.1 million and $88.4 million, respectively. Interest expense includes non-cash interest expense of $10.1 million, $10.1 million and $7.8 million for the years ended December 31, 2019, 2018 and 2017, respectively. As of December 31, 2019 and 2018, the Company had $16.7 million and $24.0 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.

Maturities

The following is a schedule of maturities for the Company’s outstanding debt as of December 31, 2019 (in thousands):

	Secured Indebtedness			Term Loans			Senior Notes			Total
2020	$	3,568		$	—		$	—		$	3,568
2021	18,853			—			—			18,853
2022	3,198			105,000			—			108,198
2023	3,296			350,000			—			353,296
2024	3,396			596,025			300,000			899,421
Thereafter	82,466			—			950,000			1,032,466
Total Debt	114,777			1,051,025			1,250,000			2,415,802
Premium, net	—			—			7,612			7,612
Deferred financing costs, net	(1,707		)	(10,767		)	(8,839		)	(21,313		)
Total Debt, Net	$	113,070		$	1,040,258		$	1,248,773		$	2,402,101

XML

SUMMARIZED CONSOLIDATING INFORMATION - Consolidating Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Assets
Real estate investments, net of accumulated depreciation	$ 5,341,370	$ 5,853,545
Loans receivable and other investments, net	107,374	113,722
Investment in unconsolidated joint venture	319,460	340,120
Cash and cash equivalents	39,097	50,230
Restricted cash	10,046	9,428
Lease intangible assets, net	101,509	131,097
Accounts receivable, prepaid expenses and other assets, net	150,443	167,161
Intercompany	0	0
Investment in subsidiaries	0	0
Total assets	6,069,299	6,665,303
Liabilities
Secured debt, net	113,070	115,679
Revolving credit facility	0	624,000
Term loans, net	1,040,258	1,184,930
Senior unsecured notes, net	1,248,773	1,307,394
Accounts payable and accrued liabilities	108,792	94,827
Lease intangible liabilities, net	69,946	83,726
Intercompany	0	0
Total liabilities	2,580,839	3,410,556
Equity
Total Sabra Health Care REIT, Inc. stockholders’ equity	3,488,460	3,250,414
Noncontrolling interests	0	4,333
Total equity	3,488,460	3,254,747	$ 3,437,249	$ 1,015,609
Total liabilities and equity	6,069,299	6,665,303
Elimination
Assets
Real estate investments, net of accumulated depreciation	0	0
Loans receivable and other investments, net	0	0
Investment in unconsolidated joint venture	0	0
Cash and cash equivalents	0	0
Restricted cash	0	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	(10,212)	(11,019)
Intercompany	(3,854,294)	(4,618,728)
Investment in subsidiaries	(3,218,749)	(2,921,593)
Total assets	(7,083,255)	(7,551,340)
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	(10,212)	(11,019)
Lease intangible liabilities, net	0	0
Intercompany	(3,854,294)	(4,618,728)
Total liabilities	(3,864,506)	(4,629,747)
Equity
Total Sabra Health Care REIT, Inc. stockholders’ equity		(2,921,593)
Noncontrolling interests		0
Total equity	(3,218,749)	(2,921,593)
Total liabilities and equity	(7,083,255)	(7,551,340)
Parent Company | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	384	317
Loans receivable and other investments, net	(564)	(560)
Investment in unconsolidated joint venture	0	0
Cash and cash equivalents	29,369	40,835
Restricted cash	0	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	4,753	798
Intercompany	2,126,198	1,972,059
Investment in subsidiaries	1,359,702	1,258,715
Total assets	3,519,842	3,272,164
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	31,382	21,750
Lease intangible liabilities, net	0	0
Intercompany	0	0
Total liabilities	31,382	21,750
Equity
Total Sabra Health Care REIT, Inc. stockholders’ equity		3,250,414
Noncontrolling interests		0
Total equity	3,488,460	3,250,414
Total liabilities and equity	3,519,842	3,272,164
Operating Partnership | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	0	0
Loans receivable and other investments, net	0	0
Investment in unconsolidated joint venture	0	0
Cash and cash equivalents	0	0
Restricted cash	0	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	18,655	37,075
Intercompany	1,728,096	2,646,669
Investment in subsidiaries	1,823,897	1,629,795
Total assets	3,570,648	4,313,539
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	624,000
Term loans, net	945,393	1,094,177
Senior unsecured notes, net	1,248,773	1,307,394
Accounts payable and accrued liabilities	16,780	29,253
Lease intangible liabilities, net	0	0
Intercompany	0	0
Total liabilities	2,210,946	3,054,824
Equity
Total Sabra Health Care REIT, Inc. stockholders’ equity		1,258,715
Noncontrolling interests		0
Total equity	1,359,702	1,258,715
Total liabilities and equity	3,570,648	4,313,539
Sabra Health Care, L.L.C. | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	0	0
Loans receivable and other investments, net	0	0
Investment in unconsolidated joint venture	0	0
Cash and cash equivalents	0	0
Restricted cash	0	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	0	0
Intercompany	0	0
Investment in subsidiaries	0	0
Total assets	0	0
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	0	0
Lease intangible liabilities, net	0	0
Intercompany	0	0
Total liabilities	0	0
Equity
Total Sabra Health Care REIT, Inc. stockholders’ equity		0
Noncontrolling interests		0
Total equity	0	0
Total liabilities and equity	0	0
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	5,340,986	5,853,228
Loans receivable and other investments, net	107,938	114,282
Investment in unconsolidated joint venture	319,460	340,120
Cash and cash equivalents	9,728	9,395
Restricted cash	10,046	9,428
Lease intangible assets, net	101,509	131,097
Accounts receivable, prepaid expenses and other assets, net	137,247	140,307
Intercompany	0	0
Investment in subsidiaries	35,150	33,083
Total assets	6,062,064	6,630,940
Liabilities
Secured debt, net	113,070	115,679
Revolving credit facility	0	0
Term loans, net	94,865	90,753
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	70,842	54,843
Lease intangible liabilities, net	69,946	83,726
Intercompany	3,854,294	4,618,728
Total liabilities	4,203,017	4,963,729
Equity
Total Sabra Health Care REIT, Inc. stockholders’ equity		1,662,878
Noncontrolling interests		4,333
Total equity	1,859,047	1,667,211
Total liabilities and equity	$ 6,062,064	$ 6,630,940

XML

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Summary of Real Estate Properties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Real Estate and Accumulated Depreciation
Encumbrances	$ 114,777
Initial Cost to Company
Land	599,391
Buildings and Improvements	5,225,195
Total	5,824,586
Cost Capitalized Subsequent to Acquisition	84,862
Gross Amount at which Carried at Close of Period
Land	597,385
Building and Improvements	5,283,198
Total	5,880,583	$ 6,255,883	$ 6,334,855	$ 2,292,751
Accumulated Depreciation and Amortization	(539,213)	(402,338)	$ (340,423)	$ (282,812)
Deferred financing costs, net	21,313
Aggregate cost of real estate for federal income tax purposes	4,900,000
Secured Debt
Gross Amount at which Carried at Close of Period
Deferred financing costs, net	1,707	$ 1,800
Operating Segments
Real Estate and Accumulated Depreciation
Encumbrances	114,777
Initial Cost to Company
Land	599,391
Buildings and Improvements	5,225,059
Total	5,824,450
Cost Capitalized Subsequent to Acquisition	84,261
Gross Amount at which Carried at Close of Period
Land	597,385
Building and Improvements	5,282,461
Total	5,879,846
Accumulated Depreciation and Amortization	(538,860)
Corporate Assets
Real Estate and Accumulated Depreciation
Encumbrances	0
Initial Cost to Company
Land	0
Buildings and Improvements	136
Total	136
Cost Capitalized Subsequent to Acquisition	601
Gross Amount at which Carried at Close of Period
Land	0
Building and Improvements	737
Total	737
Accumulated Depreciation and Amortization	(353)
Multi-property Indebtedness
Real Estate and Accumulated Depreciation
Encumbrances	10,703
Initial Cost to Company
Land	0
Buildings and Improvements	0
Total	0
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	0
Building and Improvements	0
Total	0
Accumulated Depreciation and Amortization	0
Various Skilled Nursing/Transitional Care and Leased Senior Housing Facilities | Multi-property Indebtedness | Real Estate
Gross Amount at which Carried at Close of Period
Collateral amount	10,700
Skilled Nursing/Transitional Care Facilities
Real Estate and Accumulated Depreciation
Encumbrances	59,325
Initial Cost to Company
Land	386,812
Buildings and Improvements	3,298,282
Total	3,685,094
Cost Capitalized Subsequent to Acquisition	50,151
Gross Amount at which Carried at Close of Period
Land	384,785
Building and Improvements	3,316,881
Total	3,701,666
Accumulated Depreciation and Amortization	(306,565)
Skilled Nursing/Transitional Care Facilities | Forest Hills (SNF)
Initial Cost to Company
Land	1,653
Buildings and Improvements	11,259
Total	12,912
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,653
Building and Improvements	9,565
Total	11,218
Accumulated Depreciation and Amortization	$ (3,655)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Seminole Estates
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	655
Buildings and Improvements	3,527
Total	4,182
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	655
Building and Improvements	3,167
Total	3,822
Accumulated Depreciation and Amortization	$ (1,126)
Life on Which Depreciation in Latest Income Statement is Computed	32 years
Skilled Nursing/Transitional Care Facilities | Bedford Hills
Real Estate and Accumulated Depreciation
Encumbrances	$ 5,782
Initial Cost to Company
Land	1,911
Buildings and Improvements	12,245
Total	14,156
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,911
Building and Improvements	10,867
Total	12,778
Accumulated Depreciation and Amortization	$ (4,272)
Life on Which Depreciation in Latest Income Statement is Computed	36 years
Skilled Nursing/Transitional Care Facilities | The Elms Care
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	312
Buildings and Improvements	1,679
Total	1,991
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	312
Building and Improvements	1,334
Total	1,646
Accumulated Depreciation and Amortization	$ (895)
Life on Which Depreciation in Latest Income Statement is Computed	20 years
Skilled Nursing/Transitional Care Facilities | Missouri River
Real Estate and Accumulated Depreciation
Encumbrances	$ 10,366
Initial Cost to Company
Land	2,023
Buildings and Improvements	16,967
Total	18,990
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,023
Building and Improvements	15,531
Total	17,554
Accumulated Depreciation and Amortization	$ (7,673)
Life on Which Depreciation in Latest Income Statement is Computed	30 years
Skilled Nursing/Transitional Care Facilities | Deer Lodge
Real Estate and Accumulated Depreciation
Encumbrances	$ 3,940
Initial Cost to Company
Land	190
Buildings and Improvements	3,032
Total	3,222
Cost Capitalized Subsequent to Acquisition	2
Gross Amount at which Carried at Close of Period
Land	190
Building and Improvements	2,619
Total	2,809
Accumulated Depreciation and Amortization	$ (1,232)
Life on Which Depreciation in Latest Income Statement is Computed	30 years
Skilled Nursing/Transitional Care Facilities | Arden House
Real Estate and Accumulated Depreciation
Encumbrances	$ 17,879
Initial Cost to Company
Land	2,250
Buildings and Improvements	23,816
Total	26,066
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,250
Building and Improvements	22,119
Total	24,369
Accumulated Depreciation and Amortization	$ (9,913)
Life on Which Depreciation in Latest Income Statement is Computed	28 years
Skilled Nursing/Transitional Care Facilities | Lake Drive
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	160
Buildings and Improvements	549
Total	709
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	160
Building and Improvements	51
Total	211
Accumulated Depreciation and Amortization	$ (42)
Life on Which Depreciation in Latest Income Statement is Computed	10 years
Skilled Nursing/Transitional Care Facilities | Mineral Springs
Real Estate and Accumulated Depreciation
Encumbrances	$ 11,593
Initial Cost to Company
Land	417
Buildings and Improvements	5,352
Total	5,769
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	417
Building and Improvements	4,642
Total	5,059
Accumulated Depreciation and Amortization	$ (1,832)
Life on Which Depreciation in Latest Income Statement is Computed	43 years
Skilled Nursing/Transitional Care Facilities | Wolfeboro
Real Estate and Accumulated Depreciation
Encumbrances	$ 9,765
Initial Cost to Company
Land	454
Buildings and Improvements	4,531
Total	4,985
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	454
Building and Improvements	3,827
Total	4,281
Accumulated Depreciation and Amortization	$ (1,383)
Life on Which Depreciation in Latest Income Statement is Computed	41 years
Skilled Nursing/Transitional Care Facilities | Broadmeadow Healthcare
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,650
Buildings and Improvements	21,730
Total	23,380
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,650
Building and Improvements	21,730
Total	23,380
Accumulated Depreciation and Amortization	$ (5,275)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Capitol Healthcare
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	4,940
Buildings and Improvements	15,500
Total	20,440
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	4,940
Building and Improvements	15,500
Total	20,440
Accumulated Depreciation and Amortization	$ (3,935)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Pike Creek Healthcare
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,460
Buildings and Improvements	25,240
Total	27,700
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,460
Building and Improvements	25,240
Total	27,700
Accumulated Depreciation and Amortization	$ (6,195)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Renaissance Healthcare
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,640
Buildings and Improvements	22,620
Total	24,260
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,640
Building and Improvements	22,620
Total	24,260
Accumulated Depreciation and Amortization	$ (5,660)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Clara Burke
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,527
Buildings and Improvements	12,453
Total	14,980
Cost Capitalized Subsequent to Acquisition	179
Gross Amount at which Carried at Close of Period
Land	2,527
Building and Improvements	12,632
Total	15,159
Accumulated Depreciation and Amortization	$ (3,065)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Warrington
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,617
Buildings and Improvements	11,662
Total	14,279
Cost Capitalized Subsequent to Acquisition	106
Gross Amount at which Carried at Close of Period
Land	2,617
Building and Improvements	11,768
Total	14,385
Accumulated Depreciation and Amortization	$ (2,614)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Ridgecrest
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	509
Buildings and Improvements	5,018
Total	5,527
Cost Capitalized Subsequent to Acquisition	1,333
Gross Amount at which Carried at Close of Period
Land	509
Building and Improvements	6,351
Total	6,860
Accumulated Depreciation and Amortization	$ (1,687)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Arbrook Plaza
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	3,783
Buildings and Improvements	14,219
Total	18,002
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	3,783
Building and Improvements	14,219
Total	18,002
Accumulated Depreciation and Amortization	$ (2,895)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Northgate Plaza
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	4,901
Buildings and Improvements	10,299
Total	15,200
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	4,901
Building and Improvements	10,299
Total	15,200
Accumulated Depreciation and Amortization	$ (2,160)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Gulf Pointe Plaza
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,005
Buildings and Improvements	6,628
Total	7,633
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,005
Building and Improvements	6,628
Total	7,633
Accumulated Depreciation and Amortization	$ (1,461)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Gateway Senior Living
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	6,368
Buildings and Improvements	29,919
Total	36,287
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	6,368
Building and Improvements	29,919
Total	36,287
Accumulated Depreciation and Amortization	$ (4,982)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Legacy
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	615
Buildings and Improvements	16,176
Total	16,791
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	615
Building and Improvements	16,176
Total	16,791
Accumulated Depreciation and Amortization	$ (2,955)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Pointe
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	615
Buildings and Improvements	2,943
Total	3,558
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	615
Building and Improvements	2,943
Total	3,558
Accumulated Depreciation and Amortization	$ (638)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Regency
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	246
Buildings and Improvements	6,206
Total	6,452
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	246
Building and Improvements	6,206
Total	6,452
Accumulated Depreciation and Amortization	$ (1,380)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Parkmoor Village
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	430
Buildings and Improvements	13,703
Total	14,133
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	430
Building and Improvements	13,703
Total	14,133
Accumulated Depreciation and Amortization	$ (2,637)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Adams PARC
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,332
Buildings and Improvements	6,904
Total	8,236
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,332
Building and Improvements	6,904
Total	8,236
Accumulated Depreciation and Amortization	$ (1,121)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | PARCway
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,189
Buildings and Improvements	23,567
Total	25,756
Cost Capitalized Subsequent to Acquisition	890
Gross Amount at which Carried at Close of Period
Land	2,189
Building and Improvements	24,457
Total	26,646
Accumulated Depreciation and Amortization	$ (3,627)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Brookhaven Extensive Care
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	869
Buildings and Improvements	5,236
Total	6,105
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	869
Building and Improvements	5,237
Total	6,106
Accumulated Depreciation and Amortization	$ (950)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Cadia Healthcare of Hyattsville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	6,343
Buildings and Improvements	65,573
Total	71,916
Cost Capitalized Subsequent to Acquisition	14
Gross Amount at which Carried at Close of Period
Land	6,343
Building and Improvements	65,587
Total	71,930
Accumulated Depreciation and Amortization	$ (8,890)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Cadia Healthcare of Annapolis
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,548
Buildings and Improvements	40,773
Total	42,321
Cost Capitalized Subsequent to Acquisition	103
Gross Amount at which Carried at Close of Period
Land	1,548
Building and Improvements	40,876
Total	42,424
Accumulated Depreciation and Amortization	$ (5,155)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Cadia Healthcare of Wheaton
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	676
Buildings and Improvements	56,897
Total	57,573
Cost Capitalized Subsequent to Acquisition	22
Gross Amount at which Carried at Close of Period
Land	676
Building and Improvements	56,919
Total	57,595
Accumulated Depreciation and Amortization	$ (7,050)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Cadia Healthcare of Hagerstown
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,475
Buildings and Improvements	56,237
Total	57,712
Cost Capitalized Subsequent to Acquisition	1,236
Gross Amount at which Carried at Close of Period
Land	1,475
Building and Improvements	57,473
Total	58,948
Accumulated Depreciation and Amortization	$ (6,536)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Cadia Healthcare of Spring Brook
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	963
Buildings and Improvements	48,085
Total	49,048
Cost Capitalized Subsequent to Acquisition	7
Gross Amount at which Carried at Close of Period
Land	963
Building and Improvements	48,092
Total	49,055
Accumulated Depreciation and Amortization	$ (4,599)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Andrew Residence
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,931
Buildings and Improvements	6,943
Total	9,874
Cost Capitalized Subsequent to Acquisition	192
Gross Amount at which Carried at Close of Period
Land	2,931
Building and Improvements	7,135
Total	10,066
Accumulated Depreciation and Amortization	$ (596)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Riverpark of Eugene
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,205
Buildings and Improvements	28,700
Total	30,905
Cost Capitalized Subsequent to Acquisition	2,252
Gross Amount at which Carried at Close of Period
Land	2,205
Building and Improvements	30,952
Total	33,157
Accumulated Depreciation and Amortization	$ (2,167)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Rehab of Lebanon
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	958
Buildings and Improvements	14,176
Total	15,134
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	958
Building and Improvements	14,176
Total	15,134
Accumulated Depreciation and Amortization	$ (894)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Crestview of Portland
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,791
Buildings and Improvements	12,833
Total	14,624
Cost Capitalized Subsequent to Acquisition	2,761
Gross Amount at which Carried at Close of Period
Land	1,791
Building and Improvements	15,594
Total	17,385
Accumulated Depreciation and Amortization	$ (1,277)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Rehabilitation of King City
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,011
Buildings and Improvements	11,667
Total	13,678
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,011
Building and Improvements	11,667
Total	13,678
Accumulated Depreciation and Amortization	$ (761)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Rehabilitation of Hillsboro
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,387
Buildings and Improvements	14,028
Total	15,415
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,387
Building and Improvements	14,028
Total	15,415
Accumulated Depreciation and Amortization	$ (884)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Rehab of Junction City
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	584
Buildings and Improvements	7,901
Total	8,485
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	584
Building and Improvements	7,901
Total	8,485
Accumulated Depreciation and Amortization	$ (517)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Rehab of Eugene
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,380
Buildings and Improvements	14,921
Total	16,301
Cost Capitalized Subsequent to Acquisition	1,791
Gross Amount at which Carried at Close of Period
Land	1,380
Building and Improvements	16,712
Total	18,092
Accumulated Depreciation and Amortization	$ (1,260)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Rehab of Coos Bay
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	829
Buildings and Improvements	8,518
Total	9,347
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	829
Building and Improvements	8,518
Total	9,347
Accumulated Depreciation and Amortization	$ (578)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Rehab of Clackamas
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	792
Buildings and Improvements	5,000
Total	5,792
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	792
Building and Improvements	5,000
Total	5,792
Accumulated Depreciation and Amortization	$ (334)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Rehab of Newport
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	406
Buildings and Improvements	5,001
Total	5,407
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	406
Building and Improvements	5,001
Total	5,407
Accumulated Depreciation and Amortization	$ (319)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Rehab of Oregon City
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,496
Buildings and Improvements	12,142
Total	13,638
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,496
Building and Improvements	12,142
Total	13,638
Accumulated Depreciation and Amortization	$ (765)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Transitional Care of Puget Sound
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,771
Buildings and Improvements	11,595
Total	13,366
Cost Capitalized Subsequent to Acquisition	15
Gross Amount at which Carried at Close of Period
Land	1,771
Building and Improvements	11,610
Total	13,381
Accumulated Depreciation and Amortization	$ (852)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Richmond Beach Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	4,703
Buildings and Improvements	14,444
Total	19,147
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	4,703
Building and Improvements	14,444
Total	19,147
Accumulated Depreciation and Amortization	$ (943)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | St. Francis of Bellingham
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	0
Buildings and Improvements	15,330
Total	15,330
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	0
Building and Improvements	15,330
Total	15,330
Accumulated Depreciation and Amortization	$ (1,010)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Olympic Rehabilitation of Sequim
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	427
Buildings and Improvements	4,450
Total	4,877
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	427
Building and Improvements	4,450
Total	4,877
Accumulated Depreciation and Amortization	$ (352)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Heritage Rehabilitation of Tacoma
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,705
Buildings and Improvements	4,952
Total	6,657
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,705
Building and Improvements	4,952
Total	6,657
Accumulated Depreciation and Amortization	$ (341)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere at Pacific Ridge
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,195
Buildings and Improvements	1,956
Total	4,151
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,195
Building and Improvements	1,956
Total	4,151
Accumulated Depreciation and Amortization	$ (178)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Rehabilitation of Cascade Park
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,782
Buildings and Improvements	15,116
Total	16,898
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,782
Building and Improvements	15,116
Total	16,898
Accumulated Depreciation and Amortization	$ (1,031)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | The Pearl at Kruse Way
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	5,947
Buildings and Improvements	13,401
Total	19,348
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	5,947
Building and Improvements	13,401
Total	19,348
Accumulated Depreciation and Amortization	$ (882)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere at Medford
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,043
Buildings and Improvements	38,485
Total	40,528
Cost Capitalized Subsequent to Acquisition	2,960
Gross Amount at which Carried at Close of Period
Land	2,043
Building and Improvements	41,445
Total	43,488
Accumulated Depreciation and Amortization	$ (2,864)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Bellingham Healthcare and Rehab Services
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,908
Buildings and Improvements	2,058
Total	4,966
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,908
Building and Improvements	2,058
Total	4,966
Accumulated Depreciation and Amortization	$ (182)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Queen Anne Healthcare
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,508
Buildings and Improvements	6,401
Total	8,909
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,508
Building and Improvements	6,401
Total	8,909
Accumulated Depreciation and Amortization	$ (427)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Transitional Care and Rehab - Boise
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	681
Buildings and Improvements	9,348
Total	10,029
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	681
Building and Improvements	9,348
Total	10,029
Accumulated Depreciation and Amortization	$ (623)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Transitional Care at Sunnyside
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,114
Buildings and Improvements	15,651
Total	17,765
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,114
Building and Improvements	15,651
Total	17,765
Accumulated Depreciation and Amortization	$ (1,016)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Health Services of Rogue Valley
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,375
Buildings and Improvements	23,808
Total	25,183
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,375
Building and Improvements	23,808
Total	25,183
Accumulated Depreciation and Amortization	$ (1,559)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Transitional Care and Rehab - Malley
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,662
Buildings and Improvements	26,014
Total	27,676
Cost Capitalized Subsequent to Acquisition	3,258
Gross Amount at which Carried at Close of Period
Land	1,662
Building and Improvements	29,272
Total	30,934
Accumulated Depreciation and Amortization	$ (2,179)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avamere Transitional Care and Rehab - Brighton
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,933
Buildings and Improvements	11,624
Total	13,557
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,933
Building and Improvements	11,624
Total	13,557
Accumulated Depreciation and Amortization	$ (779)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Phoenix Rehabilitation Services
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,270
Buildings and Improvements	11,502
Total	12,772
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,270
Building and Improvements	11,502
Total	12,772
Accumulated Depreciation and Amortization	$ (726)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Tustin Subacute Care Facility
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,889
Buildings and Improvements	11,682
Total	13,571
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,889
Building and Improvements	11,682
Total	13,571
Accumulated Depreciation and Amortization	$ (717)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | La Mesa Inpatient Rehabilitation Facility
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,276
Buildings and Improvements	8,177
Total	9,453
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,276
Building and Improvements	8,177
Total	9,453
Accumulated Depreciation and Amortization	$ (522)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Westminster
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,128
Buildings and Improvements	6,614
Total	8,742
Cost Capitalized Subsequent to Acquisition	487
Gross Amount at which Carried at Close of Period
Land	2,128
Building and Improvements	7,101
Total	9,229
Accumulated Depreciation and Amortization	$ (630)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Maple Wood Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,142
Buildings and Improvements	3,226
Total	4,368
Cost Capitalized Subsequent to Acquisition	653
Gross Amount at which Carried at Close of Period
Land	1,142
Building and Improvements	3,879
Total	5,021
Accumulated Depreciation and Amortization	$ (539)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Garden Valley Nursing & Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,985
Buildings and Improvements	2,714
Total	4,699
Cost Capitalized Subsequent to Acquisition	303
Gross Amount at which Carried at Close of Period
Land	1,985
Building and Improvements	3,017
Total	5,002
Accumulated Depreciation and Amortization	$ (490)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Worthington Nursing & Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	697
Buildings and Improvements	10,688
Total	11,385
Cost Capitalized Subsequent to Acquisition	285
Gross Amount at which Carried at Close of Period
Land	697
Building and Improvements	10,973
Total	11,670
Accumulated Depreciation and Amortization	$ (892)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Burlington House Rehabilitative and Alzheimer’s Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,686
Buildings and Improvements	10,062
Total	12,748
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,686
Building and Improvements	10,062
Total	12,748
Accumulated Depreciation and Amortization	$ (758)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Charlottesville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,840
Buildings and Improvements	8,450
Total	11,290
Cost Capitalized Subsequent to Acquisition	1,157
Gross Amount at which Carried at Close of Period
Land	2,840
Building and Improvements	9,607
Total	12,447
Accumulated Depreciation and Amortization	$ (769)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Sleepy Hollow
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	7,241
Buildings and Improvements	17,727
Total	24,968
Cost Capitalized Subsequent to Acquisition	1,806
Gross Amount at which Carried at Close of Period
Land	7,241
Building and Improvements	19,533
Total	26,774
Accumulated Depreciation and Amortization	$ (1,405)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Petersburg
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	988
Buildings and Improvements	8,416
Total	9,404
Cost Capitalized Subsequent to Acquisition	146
Gross Amount at which Carried at Close of Period
Land	988
Building and Improvements	8,562
Total	9,550
Accumulated Depreciation and Amortization	$ (641)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Battlefield Park
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,174
Buildings and Improvements	8,858
Total	10,032
Cost Capitalized Subsequent to Acquisition	151
Gross Amount at which Carried at Close of Period
Land	1,174
Building and Improvements	9,009
Total	10,183
Accumulated Depreciation and Amortization	$ (664)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Hagerstown
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,393
Buildings and Improvements	13,438
Total	14,831
Cost Capitalized Subsequent to Acquisition	150
Gross Amount at which Carried at Close of Period
Land	1,393
Building and Improvements	13,588
Total	14,981
Accumulated Depreciation and Amortization	$ (959)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Cumberland
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	800
Buildings and Improvements	16,973
Total	17,773
Cost Capitalized Subsequent to Acquisition	457
Gross Amount at which Carried at Close of Period
Land	800
Building and Improvements	17,430
Total	18,230
Accumulated Depreciation and Amortization	$ (1,219)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Gilroy Healthcare and Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	662
Buildings and Improvements	23,775
Total	24,437
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	662
Building and Improvements	23,775
Total	24,437
Accumulated Depreciation and Amortization	$ (1,482)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | North Cascades Health and Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,437
Buildings and Improvements	14,196
Total	15,633
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,437
Building and Improvements	14,196
Total	15,633
Accumulated Depreciation and Amortization	$ (926)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Granite Rehabilitation & Wellness
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	387
Buildings and Improvements	13,613
Total	14,000
Cost Capitalized Subsequent to Acquisition	2,246
Gross Amount at which Carried at Close of Period
Land	387
Building and Improvements	15,859
Total	16,246
Accumulated Depreciation and Amortization	$ (1,170)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Rawlins Rehabilitation & Wellness
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	281
Buildings and Improvements	6,007
Total	6,288
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	281
Building and Improvements	6,007
Total	6,288
Accumulated Depreciation and Amortization	$ (389)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wind River Rehabilitation & Wellness
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	199
Buildings and Improvements	11,398
Total	11,597
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	199
Building and Improvements	11,398
Total	11,597
Accumulated Depreciation and Amortization	$ (720)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Sage View Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	420
Buildings and Improvements	8,665
Total	9,085
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	420
Building and Improvements	8,665
Total	9,085
Accumulated Depreciation and Amortization	$ (571)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Shelton Health and Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	415
Buildings and Improvements	8,965
Total	9,380
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	415
Building and Improvements	8,965
Total	9,380
Accumulated Depreciation and Amortization	$ (629)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Dundee Nursing Home
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,437
Buildings and Improvements	4,631
Total	6,068
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,437
Building and Improvements	4,631
Total	6,068
Accumulated Depreciation and Amortization	$ (334)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Mt. Pleasant Nursing Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,689
Buildings and Improvements	3,942
Total	6,631
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,689
Building and Improvements	3,942
Total	6,631
Accumulated Depreciation and Amortization	$ (302)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Tri-State Comp Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,811
Buildings and Improvements	4,963
Total	6,774
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,811
Building and Improvements	4,963
Total	6,774
Accumulated Depreciation and Amortization	$ (388)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Epic-Conway
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,408
Buildings and Improvements	10,784
Total	12,192
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,408
Building and Improvements	10,784
Total	12,192
Accumulated Depreciation and Amortization	$ (758)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Epic- Bayview
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,842
Buildings and Improvements	11,389
Total	13,231
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,842
Building and Improvements	11,389
Total	13,231
Accumulated Depreciation and Amortization	$ (777)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Baytown
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	479
Buildings and Improvements	6,351
Total	6,830
Cost Capitalized Subsequent to Acquisition	209
Gross Amount at which Carried at Close of Period
Land	479
Building and Improvements	6,456
Total	6,935
Accumulated Depreciation and Amortization	$ (451)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Allenbrook
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	426
Buildings and Improvements	3,236
Total	3,662
Cost Capitalized Subsequent to Acquisition	173
Gross Amount at which Carried at Close of Period
Land	426
Building and Improvements	3,371
Total	3,797
Accumulated Depreciation and Amortization	$ (297)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Huntsville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	302
Buildings and Improvements	3,153
Total	3,455
Cost Capitalized Subsequent to Acquisition	75
Gross Amount at which Carried at Close of Period
Land	302
Building and Improvements	3,200
Total	3,502
Accumulated Depreciation and Amortization	$ (250)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	231
Buildings and Improvements	1,335
Total	1,566
Cost Capitalized Subsequent to Acquisition	312
Gross Amount at which Carried at Close of Period
Land	231
Building and Improvements	1,555
Total	1,786
Accumulated Depreciation and Amortization	$ (174)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Humble
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,114
Buildings and Improvements	1,643
Total	3,757
Cost Capitalized Subsequent to Acquisition	596
Gross Amount at which Carried at Close of Period
Land	2,114
Building and Improvements	2,099
Total	4,213
Accumulated Depreciation and Amortization	$ (268)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Beechnut
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,019
Buildings and Improvements	5,734
Total	6,753
Cost Capitalized Subsequent to Acquisition	318
Gross Amount at which Carried at Close of Period
Land	1,019
Building and Improvements	5,876
Total	6,895
Accumulated Depreciation and Amortization	$ (436)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Linden
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	112
Buildings and Improvements	256
Total	368
Cost Capitalized Subsequent to Acquisition	133
Gross Amount at which Carried at Close of Period
Land	112
Building and Improvements	331
Total	443
Accumulated Depreciation and Amortization	$ (57)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Sherman
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	469
Buildings and Improvements	6,310
Total	6,779
Cost Capitalized Subsequent to Acquisition	255
Gross Amount at which Carried at Close of Period
Land	469
Building and Improvements	6,400
Total	6,869
Accumulated Depreciation and Amortization	$ (463)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Mount Pleasant
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	250
Buildings and Improvements	6,913
Total	7,163
Cost Capitalized Subsequent to Acquisition	345
Gross Amount at which Carried at Close of Period
Land	250
Building and Improvements	7,249
Total	7,499
Accumulated Depreciation and Amortization	$ (532)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Waxahachie
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	416
Buildings and Improvements	7,259
Total	7,675
Cost Capitalized Subsequent to Acquisition	205
Gross Amount at which Carried at Close of Period
Land	416
Building and Improvements	7,412
Total	7,828
Accumulated Depreciation and Amortization	$ (539)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Gilmer
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	707
Buildings and Improvements	4,552
Total	5,259
Cost Capitalized Subsequent to Acquisition	93
Gross Amount at which Carried at Close of Period
Land	707
Building and Improvements	4,605
Total	5,312
Accumulated Depreciation and Amortization	$ (352)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Hearthstone of Northern Nevada
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,986
Buildings and Improvements	9,004
Total	10,990
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,986
Building and Improvements	9,004
Total	10,990
Accumulated Depreciation and Amortization	$ (631)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Sunset Hills Healthcare and Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,595
Buildings and Improvements	5,822
Total	7,417
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	966
Building and Improvements	3,157
Total	4,123
Accumulated Depreciation and Amortization	$ 0
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Mountainview Specialty Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	549
Buildings and Improvements	9,926
Total	10,475
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	549
Building and Improvements	9,926
Total	10,475
Accumulated Depreciation and Amortization	$ (824)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Richmond
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	259
Buildings and Improvements	9,819
Total	10,078
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	259
Building and Improvements	9,819
Total	10,078
Accumulated Depreciation and Amortization	$ (655)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Petersburg
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	581
Buildings and Improvements	5,367
Total	5,948
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	581
Building and Improvements	5,367
Total	5,948
Accumulated Depreciation and Amortization	$ (383)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Beverly Health - Ft. Pierce
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	787
Buildings and Improvements	16,648
Total	17,435
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	787
Building and Improvements	16,648
Total	17,435
Accumulated Depreciation and Amortization	$ (1,067)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Maryville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	114
Buildings and Improvements	5,955
Total	6,069
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	150
Building and Improvements	5,955
Total	6,105
Accumulated Depreciation and Amortization	$ (437)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Ashland Healthcare
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	765
Buildings and Improvements	2,669
Total	3,434
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	765
Building and Improvements	2,669
Total	3,434
Accumulated Depreciation and Amortization	$ (210)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Bellefontaine Gardens
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,071
Buildings and Improvements	5,739
Total	7,810
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,071
Building and Improvements	5,739
Total	7,810
Accumulated Depreciation and Amortization	$ (451)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Current River Nursing Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	657
Buildings and Improvements	8,251
Total	8,908
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	657
Building and Improvements	8,251
Total	8,908
Accumulated Depreciation and Amortization	$ (571)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Dixon Nursing & Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	521
Buildings and Improvements	3,358
Total	3,879
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	521
Building and Improvements	3,358
Total	3,879
Accumulated Depreciation and Amortization	$ (252)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Forsyth Nursing & Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	594
Buildings and Improvements	8,549
Total	9,143
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	594
Building and Improvements	8,549
Total	9,143
Accumulated Depreciation and Amortization	$ (601)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Glenwood Healthcare
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	658
Buildings and Improvements	901
Total	1,559
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	658
Building and Improvements	901
Total	1,559
Accumulated Depreciation and Amortization	$ (88)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Silex Community Care
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	807
Buildings and Improvements	4,990
Total	5,797
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	807
Building and Improvements	4,990
Total	5,797
Accumulated Depreciation and Amortization	$ (356)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | South Hampton Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,322
Buildings and Improvements	6,547
Total	8,869
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,322
Building and Improvements	6,547
Total	8,869
Accumulated Depreciation and Amortization	$ (474)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Strafford Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,634
Buildings and Improvements	6,518
Total	8,152
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,634
Building and Improvements	6,518
Total	8,152
Accumulated Depreciation and Amortization	$ (462)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Windsor Healthcare & Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	471
Buildings and Improvements	6,819
Total	7,290
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	471
Building and Improvements	6,819
Total	7,290
Accumulated Depreciation and Amortization	$ (438)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Park Manor of Conroe
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,222
Buildings and Improvements	19,099
Total	20,321
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,222
Building and Improvements	19,099
Total	20,321
Accumulated Depreciation and Amortization	$ (1,198)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Park Manor of Cypress Station
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,334
Buildings and Improvements	11,615
Total	12,949
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,334
Building and Improvements	11,615
Total	12,949
Accumulated Depreciation and Amortization	$ (759)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Park Manor of Humble
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,541
Buildings and Improvements	12,332
Total	13,873
Cost Capitalized Subsequent to Acquisition	645
Gross Amount at which Carried at Close of Period
Land	1,541
Building and Improvements	12,977
Total	14,518
Accumulated Depreciation and Amortization	$ (870)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Park Manor of Quail Valley
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,825
Buildings and Improvements	9,681
Total	11,506
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,825
Building and Improvements	9,681
Total	11,506
Accumulated Depreciation and Amortization	$ (657)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Park Manor of Westchase
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,676
Buildings and Improvements	7,396
Total	10,072
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,676
Building and Improvements	7,396
Total	10,072
Accumulated Depreciation and Amortization	$ (514)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Park Manor of CyFair
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,732
Buildings and Improvements	12,921
Total	14,653
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,732
Building and Improvements	12,921
Total	14,653
Accumulated Depreciation and Amortization	$ (838)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Park Manor of McKinney
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,441
Buildings and Improvements	9,017
Total	10,458
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,441
Building and Improvements	9,017
Total	10,458
Accumulated Depreciation and Amortization	$ (638)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Tanglewood Health and Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	176
Buildings and Improvements	2,340
Total	2,516
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	176
Building and Improvements	2,340
Total	2,516
Accumulated Depreciation and Amortization	$ (175)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Smoky Hill Health and Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	301
Buildings and Improvements	4,201
Total	4,502
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	301
Building and Improvements	4,201
Total	4,502
Accumulated Depreciation and Amortization	$ (300)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Belleville Health Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	600
Buildings and Improvements	1,664
Total	2,264
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	600
Building and Improvements	1,664
Total	2,264
Accumulated Depreciation and Amortization	$ (149)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Westridge Healthcare Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,067
Buildings and Improvements	7,061
Total	8,128
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,067
Building and Improvements	7,061
Total	8,128
Accumulated Depreciation and Amortization	$ (474)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Willow Bend Living Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,168
Buildings and Improvements	9,562
Total	10,730
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,168
Building and Improvements	9,562
Total	10,730
Accumulated Depreciation and Amortization	$ (612)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Twin City Healthcare
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	345
Buildings and Improvements	8,852
Total	9,197
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	345
Building and Improvements	8,852
Total	9,197
Accumulated Depreciation and Amortization	$ (566)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Pine Knoll Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	711
Buildings and Improvements	5,554
Total	6,265
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	711
Building and Improvements	5,554
Total	6,265
Accumulated Depreciation and Amortization	$ (374)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Willow Crossing Health & Rehab Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,290
Buildings and Improvements	10,714
Total	12,004
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,290
Building and Improvements	10,714
Total	12,004
Accumulated Depreciation and Amortization	$ (688)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Persimmon Ridge Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	315
Buildings and Improvements	9,848
Total	10,163
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	315
Building and Improvements	9,848
Total	10,163
Accumulated Depreciation and Amortization	$ (642)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Vermillion Convalescent Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	884
Buildings and Improvements	9,839
Total	10,723
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	884
Building and Improvements	9,839
Total	10,723
Accumulated Depreciation and Amortization	$ (674)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Las Vegas Post Acute & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	509
Buildings and Improvements	18,216
Total	18,725
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	509
Building and Improvements	18,216
Total	18,725
Accumulated Depreciation and Amortization	$ (1,118)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Torey Pines Rehabilitation Hospital
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	3,169
Buildings and Improvements	7,863
Total	11,032
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	3,169
Building and Improvements	7,863
Total	11,032
Accumulated Depreciation and Amortization	$ (544)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Villa Campana Rehabilitation Hospital
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,800
Buildings and Improvements	4,387
Total	6,187
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,800
Building and Improvements	4,387
Total	6,187
Accumulated Depreciation and Amortization	$ (352)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Kachina Point Rehabilitation Hospital
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,035
Buildings and Improvements	10,981
Total	13,016
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,035
Building and Improvements	10,981
Total	13,016
Accumulated Depreciation and Amortization	$ (770)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Bay View Rehabilitation Hospital
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	3,078
Buildings and Improvements	22,328
Total	25,406
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	3,078
Building and Improvements	22,328
Total	25,406
Accumulated Depreciation and Amortization	$ (1,402)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Dover Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	522
Buildings and Improvements	5,839
Total	6,361
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	522
Building and Improvements	5,839
Total	6,361
Accumulated Depreciation and Amortization	$ (510)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Augusta Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	135
Buildings and Improvements	6,470
Total	6,605
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	135
Building and Improvements	6,470
Total	6,605
Accumulated Depreciation and Amortization	$ (444)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Eastside Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	302
Buildings and Improvements	1,811
Total	2,113
Cost Capitalized Subsequent to Acquisition	632
Gross Amount at which Carried at Close of Period
Land	302
Building and Improvements	2,443
Total	2,745
Accumulated Depreciation and Amortization	$ (147)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Winship Green Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	250
Buildings and Improvements	1,934
Total	2,184
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	250
Building and Improvements	1,934
Total	2,184
Accumulated Depreciation and Amortization	$ (148)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Brewer Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	177
Buildings and Improvements	14,497
Total	14,674
Cost Capitalized Subsequent to Acquisition	944
Gross Amount at which Carried at Close of Period
Land	177
Building and Improvements	15,441
Total	15,618
Accumulated Depreciation and Amortization	$ (967)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Kennebunk Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	198
Buildings and Improvements	6,822
Total	7,020
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	198
Building and Improvements	6,822
Total	7,020
Accumulated Depreciation and Amortization	$ (461)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Norway Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	791
Buildings and Improvements	3,680
Total	4,471
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	791
Building and Improvements	3,680
Total	4,471
Accumulated Depreciation and Amortization	$ (269)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Brentwood Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	134
Buildings and Improvements	2,072
Total	2,206
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	134
Building and Improvements	2,072
Total	2,206
Accumulated Depreciation and Amortization	$ (163)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Country Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	269
Buildings and Improvements	4,436
Total	4,705
Cost Capitalized Subsequent to Acquisition	12
Gross Amount at which Carried at Close of Period
Land	269
Building and Improvements	4,448
Total	4,717
Accumulated Depreciation and Amortization	$ (403)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Sachem Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	447
Buildings and Improvements	1,357
Total	1,804
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	447
Building and Improvements	1,357
Total	1,804
Accumulated Depreciation and Amortization	$ (151)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Eliot Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	475
Buildings and Improvements	1,491
Total	1,966
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	475
Building and Improvements	1,491
Total	1,966
Accumulated Depreciation and Amortization	$ (143)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | The Reservoir Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	942
Buildings and Improvements	1,541
Total	2,483
Cost Capitalized Subsequent to Acquisition	8,697
Gross Amount at which Carried at Close of Period
Land	942
Building and Improvements	10,238
Total	11,180
Accumulated Depreciation and Amortization	$ (547)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Newton Wellesley Center for Alzheimer’s Care
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,186
Buildings and Improvements	13,917
Total	15,103
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,186
Building and Improvements	13,917
Total	15,103
Accumulated Depreciation and Amortization	$ (894)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Colony Center for Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,727
Buildings and Improvements	2,103
Total	3,830
Cost Capitalized Subsequent to Acquisition	19
Gross Amount at which Carried at Close of Period
Land	1,727
Building and Improvements	2,122
Total	3,849
Accumulated Depreciation and Amortization	$ (188)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Westgate Center for Rehab & Alzheimer’s Care
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	229
Buildings and Improvements	7,171
Total	7,400
Cost Capitalized Subsequent to Acquisition	10
Gross Amount at which Carried at Close of Period
Land	229
Building and Improvements	7,181
Total	7,410
Accumulated Depreciation and Amortization	$ (501)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | New Orange Hills
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	4,163
Buildings and Improvements	14,755
Total	18,918
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	4,163
Building and Improvements	14,755
Total	18,918
Accumulated Depreciation and Amortization	$ (973)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Millbrook Healthcare & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	548
Buildings and Improvements	5,794
Total	6,342
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	548
Building and Improvements	5,794
Total	6,342
Accumulated Depreciation and Amortization	$ (420)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Pleasant Valley Health & Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,118
Buildings and Improvements	7,490
Total	8,608
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,118
Building and Improvements	7,490
Total	8,608
Accumulated Depreciation and Amortization	$ (517)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Clarksville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	279
Buildings and Improvements	4,269
Total	4,548
Cost Capitalized Subsequent to Acquisition	100
Gross Amount at which Carried at Close of Period
Land	279
Building and Improvements	4,369
Total	4,648
Accumulated Depreciation and Amortization	$ (338)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | McKinney Healthcare & Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,272
Buildings and Improvements	6,047
Total	7,319
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,272
Building and Improvements	6,047
Total	7,319
Accumulated Depreciation and Amortization	$ (448)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Hopkins
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	807
Buildings and Improvements	4,668
Total	5,475
Cost Capitalized Subsequent to Acquisition	530
Gross Amount at which Carried at Close of Period
Land	807
Building and Improvements	5,198
Total	6,005
Accumulated Depreciation and Amortization	$ (423)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Village Gardens
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,299
Buildings and Improvements	1,247
Total	2,546
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,299
Building and Improvements	1,247
Total	2,546
Accumulated Depreciation and Amortization	$ (142)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Florence
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	291
Buildings and Improvements	3,778
Total	4,069
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	291
Building and Improvements	3,778
Total	4,069
Accumulated Depreciation and Amortization	$ (293)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - South Shore
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	166
Buildings and Improvements	1,887
Total	2,053
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	166
Building and Improvements	1,887
Total	2,053
Accumulated Depreciation and Amortization	$ (152)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Rochester East
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	645
Buildings and Improvements	7,067
Total	7,712
Cost Capitalized Subsequent to Acquisition	178
Gross Amount at which Carried at Close of Period
Land	645
Building and Improvements	7,245
Total	7,890
Accumulated Depreciation and Amortization	$ (489)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Wisconsin Dells
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,640
Buildings and Improvements	1,599
Total	3,239
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,640
Building and Improvements	1,599
Total	3,239
Accumulated Depreciation and Amortization	$ (167)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Sheboygan
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,038
Buildings and Improvements	2,839
Total	3,877
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,038
Building and Improvements	2,839
Total	3,877
Accumulated Depreciation and Amortization	$ (251)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Golden Living Center - Hendersonville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,611
Buildings and Improvements	3,503
Total	5,114
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,611
Building and Improvements	3,503
Total	5,114
Accumulated Depreciation and Amortization	$ (285)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Corpus
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	366
Buildings and Improvements	6,961
Total	7,327
Cost Capitalized Subsequent to Acquisition	91
Gross Amount at which Carried at Close of Period
Land	51
Building and Improvements	1,025
Total	1,076
Accumulated Depreciation and Amortization	$ (152)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Burnet Bay
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	579
Buildings and Improvements	22,317
Total	22,896
Cost Capitalized Subsequent to Acquisition	28
Gross Amount at which Carried at Close of Period
Land	579
Building and Improvements	22,345
Total	22,924
Accumulated Depreciation and Amortization	$ (1,409)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Cedar Bayou
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	589
Buildings and Improvements	20,475
Total	21,064
Cost Capitalized Subsequent to Acquisition	35
Gross Amount at which Carried at Close of Period
Land	589
Building and Improvements	20,510
Total	21,099
Accumulated Depreciation and Amortization	$ (1,336)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Westwood
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,300
Buildings and Improvements	13,353
Total	14,653
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,300
Building and Improvements	13,353
Total	14,653
Accumulated Depreciation and Amortization	$ (906)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Pasadena
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,148
Buildings and Improvements	23,579
Total	24,727
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,148
Building and Improvements	23,579
Total	24,727
Accumulated Depreciation and Amortization	$ (1,515)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Webster
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	904
Buildings and Improvements	10,315
Total	11,219
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	904
Building and Improvements	10,315
Total	11,219
Accumulated Depreciation and Amortization	$ (716)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Summer Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	945
Buildings and Improvements	20,424
Total	21,369
Cost Capitalized Subsequent to Acquisition	18
Gross Amount at which Carried at Close of Period
Land	945
Building and Improvements	20,442
Total	21,387
Accumulated Depreciation and Amortization	$ (1,296)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Focused Care at Orange
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	711
Buildings and Improvements	10,737
Total	11,448
Cost Capitalized Subsequent to Acquisition	16
Gross Amount at which Carried at Close of Period
Land	711
Building and Improvements	10,753
Total	11,464
Accumulated Depreciation and Amortization	$ (711)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Cypress Glen
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,209
Buildings and Improvements	13,444
Total	14,653
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	90
Building and Improvements	814
Total	904
Accumulated Depreciation and Amortization	$ 0
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Whitesburg Gardens
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	634
Buildings and Improvements	28,071
Total	28,705
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	634
Building and Improvements	28,071
Total	28,705
Accumulated Depreciation and Amortization	$ (1,735)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Terre Haute
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	644
Buildings and Improvements	37,451
Total	38,095
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	644
Building and Improvements	37,451
Total	38,095
Accumulated Depreciation and Amortization	$ (2,601)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare at Larkin Springs
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	902
Buildings and Improvements	3,850
Total	4,752
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	902
Building and Improvements	3,850
Total	4,752
Accumulated Depreciation and Amortization	$ (325)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Savannah
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,235
Buildings and Improvements	3,765
Total	5,000
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,235
Building and Improvements	3,765
Total	5,000
Accumulated Depreciation and Amortization	$ (334)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Bluffton
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	254
Buildings and Improvements	5,105
Total	5,359
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	254
Building and Improvements	5,105
Total	5,359
Accumulated Depreciation and Amortization	$ (384)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Bowling Green
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	280
Buildings and Improvements	13,975
Total	14,255
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	280
Building and Improvements	13,975
Total	14,255
Accumulated Depreciation and Amortization	$ (955)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Oakview Nursing and Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,176
Buildings and Improvements	7,012
Total	8,188
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,176
Building and Improvements	7,012
Total	8,188
Accumulated Depreciation and Amortization	$ (509)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Fountain Circle Care and Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	554
Buildings and Improvements	13,207
Total	13,761
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	554
Building and Improvements	13,207
Total	13,761
Accumulated Depreciation and Amortization	$ (921)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Riverside Care & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	613
Buildings and Improvements	7,643
Total	8,256
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	613
Building and Improvements	7,643
Total	8,256
Accumulated Depreciation and Amortization	$ (570)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Bremen
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	173
Buildings and Improvements	7,393
Total	7,566
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	173
Building and Improvements	7,393
Total	7,566
Accumulated Depreciation and Amortization	$ (504)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Muncie
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	374
Buildings and Improvements	27,429
Total	27,803
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	374
Building and Improvements	27,429
Total	27,803
Accumulated Depreciation and Amortization	$ (1,733)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare at Parkwood
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	612
Buildings and Improvements	11,755
Total	12,367
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	612
Building and Improvements	11,755
Total	12,367
Accumulated Depreciation and Amortization	$ (787)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare at Tower Road
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	364
Buildings and Improvements	16,116
Total	16,480
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	364
Building and Improvements	16,116
Total	16,480
Accumulated Depreciation and Amortization	$ (1,106)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Danville Centre for Health and Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	790
Buildings and Improvements	9,356
Total	10,146
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	790
Building and Improvements	9,356
Total	10,146
Accumulated Depreciation and Amortization	$ (753)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare at Hillcrest
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,048
Buildings and Improvements	22,587
Total	23,635
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,048
Building and Improvements	22,587
Total	23,635
Accumulated Depreciation and Amortization	$ (1,483)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Elizabethtown
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	239
Buildings and Improvements	4,853
Total	5,092
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	239
Building and Improvements	4,853
Total	5,092
Accumulated Depreciation and Amortization	$ (357)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Primacy
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,633
Buildings and Improvements	9,371
Total	11,004
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,633
Building and Improvements	9,371
Total	11,004
Accumulated Depreciation and Amortization	$ (674)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Harbour Pointe
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	705
Buildings and Improvements	16,451
Total	17,156
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	705
Building and Improvements	16,451
Total	17,156
Accumulated Depreciation and Amortization	$ (1,222)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Harrodsburg Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,049
Buildings and Improvements	9,851
Total	10,900
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,049
Building and Improvements	9,851
Total	10,900
Accumulated Depreciation and Amortization	$ (754)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Putnam County
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,034
Buildings and Improvements	15,555
Total	16,589
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,034
Building and Improvements	15,555
Total	16,589
Accumulated Depreciation and Amortization	$ (1,045)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Fayette County
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	405
Buildings and Improvements	4,839
Total	5,244
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	405
Building and Improvements	4,839
Total	5,244
Accumulated Depreciation and Amortization	$ (385)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Warren
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	955
Buildings and Improvements	5,260
Total	6,215
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	955
Building and Improvements	5,260
Total	6,215
Accumulated Depreciation and Amortization	$ (489)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Galion
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	836
Buildings and Improvements	668
Total	1,504
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	836
Building and Improvements	668
Total	1,504
Accumulated Depreciation and Amortization	$ (86)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Roanoke Rapids
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	373
Buildings and Improvements	10,308
Total	10,681
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	373
Building and Improvements	10,308
Total	10,681
Accumulated Depreciation and Amortization	$ (761)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Kinston
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	954
Buildings and Improvements	7,987
Total	8,941
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	954
Building and Improvements	7,987
Total	8,941
Accumulated Depreciation and Amortization	$ (662)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Chapel Hill
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	809
Buildings and Improvements	2,703
Total	3,512
Cost Capitalized Subsequent to Acquisition	302
Gross Amount at which Carried at Close of Period
Land	809
Building and Improvements	3,005
Total	3,814
Accumulated Depreciation and Amortization	$ (321)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Chillicothe
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	260
Buildings and Improvements	8,924
Total	9,184
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	260
Building and Improvements	8,924
Total	9,184
Accumulated Depreciation and Amortization	$ (681)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Signature Healthcare of Coshocton
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	374
Buildings and Improvements	2,530
Total	2,904
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	374
Building and Improvements	2,530
Total	2,904
Accumulated Depreciation and Amortization	$ (261)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | McCreary Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	208
Buildings and Improvements	7,665
Total	7,873
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	208
Building and Improvements	7,665
Total	7,873
Accumulated Depreciation and Amortization	$ (532)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Colonial Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	634
Buildings and Improvements	4,094
Total	4,728
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	634
Building and Improvements	4,094
Total	4,728
Accumulated Depreciation and Amortization	$ (332)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Glasgow Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	83
Buildings and Improvements	2,057
Total	2,140
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	83
Building and Improvements	2,057
Total	2,140
Accumulated Depreciation and Amortization	$ (202)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Green Valley Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	124
Buildings and Improvements	1,693
Total	1,817
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	124
Building and Improvements	1,693
Total	1,817
Accumulated Depreciation and Amortization	$ (174)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Hart County Health & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	208
Buildings and Improvements	7,070
Total	7,278
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	208
Building and Improvements	7,070
Total	7,278
Accumulated Depreciation and Amortization	$ (536)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Heritage Hall Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	635
Buildings and Improvements	9,861
Total	10,496
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	635
Building and Improvements	9,861
Total	10,496
Accumulated Depreciation and Amortization	$ (694)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Jackson Manor
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	479
Buildings and Improvements	6,078
Total	6,557
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	479
Building and Improvements	6,078
Total	6,557
Accumulated Depreciation and Amortization	$ (419)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Jefferson Manor
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	3,528
Buildings and Improvements	4,653
Total	8,181
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	3,528
Building and Improvements	4,653
Total	8,181
Accumulated Depreciation and Amortization	$ (402)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Jefferson Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,207
Buildings and Improvements	20,733
Total	22,940
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,207
Building and Improvements	20,733
Total	22,940
Accumulated Depreciation and Amortization	$ (1,349)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Monroe Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	333
Buildings and Improvements	9,556
Total	9,889
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	333
Building and Improvements	9,556
Total	9,889
Accumulated Depreciation and Amortization	$ (665)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | North Hardin Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,815
Buildings and Improvements	7,470
Total	9,285
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,815
Building and Improvements	7,470
Total	9,285
Accumulated Depreciation and Amortization	$ (659)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Professional Care Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	312
Buildings and Improvements	8,189
Total	8,501
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	312
Building and Improvements	8,189
Total	8,501
Accumulated Depreciation and Amortization	$ (582)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Rockford Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	427
Buildings and Improvements	6,003
Total	6,430
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	427
Building and Improvements	6,003
Total	6,430
Accumulated Depreciation and Amortization	$ (455)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Summerfield Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,134
Buildings and Improvements	9,166
Total	10,300
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,134
Building and Improvements	9,166
Total	10,300
Accumulated Depreciation and Amortization	$ (712)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Tanbark Senior Living
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,558
Buildings and Improvements	4,311
Total	6,869
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,558
Building and Improvements	4,311
Total	6,869
Accumulated Depreciation and Amortization	$ (365)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Summit Manor Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	114
Buildings and Improvements	11,141
Total	11,255
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	114
Building and Improvements	11,141
Total	11,255
Accumulated Depreciation and Amortization	$ (759)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Belle View Estates Rehabilitation and Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	206
Buildings and Improvements	3,179
Total	3,385
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	206
Building and Improvements	3,179
Total	3,385
Accumulated Depreciation and Amortization	$ (259)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | River Chase Rehabilitation and Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	508
Buildings and Improvements	0
Total	508
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	508
Building and Improvements	0
Total	508
Accumulated Depreciation and Amortization	$ 0
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Heartland Rehabilitation and Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,336
Buildings and Improvements	7,386
Total	8,722
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,336
Building and Improvements	7,386
Total	8,722
Accumulated Depreciation and Amortization	$ (550)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | River Ridge Rehabilitation and Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	227
Buildings and Improvements	4,007
Total	4,234
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	227
Building and Improvements	4,007
Total	4,234
Accumulated Depreciation and Amortization	$ (301)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Brookridge Cove Rehabilitation and Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	412
Buildings and Improvements	2,642
Total	3,054
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	412
Building and Improvements	2,642
Total	3,054
Accumulated Depreciation and Amortization	$ (244)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Southern Trace Rehabilitation and Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	819
Buildings and Improvements	8,938
Total	9,757
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	819
Building and Improvements	8,938
Total	9,757
Accumulated Depreciation and Amortization	$ (593)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Lake Village Rehabilitation and Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	507
Buildings and Improvements	4,838
Total	5,345
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	507
Building and Improvements	4,838
Total	5,345
Accumulated Depreciation and Amortization	$ (369)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Savannah Specialty Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,194
Buildings and Improvements	11,711
Total	13,905
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,194
Building and Improvements	11,711
Total	13,905
Accumulated Depreciation and Amortization	$ (766)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Pettigrew Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	470
Buildings and Improvements	9,633
Total	10,103
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	470
Building and Improvements	9,633
Total	10,103
Accumulated Depreciation and Amortization	$ (624)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Sunnybrook Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,155
Buildings and Improvements	11,749
Total	12,904
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,155
Building and Improvements	11,749
Total	12,904
Accumulated Depreciation and Amortization	$ (780)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Raleigh Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	926
Buildings and Improvements	17,649
Total	18,575
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	926
Building and Improvements	17,649
Total	18,575
Accumulated Depreciation and Amortization	$ (1,151)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Cypress Pointe Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	611
Buildings and Improvements	5,051
Total	5,662
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	611
Building and Improvements	5,051
Total	5,662
Accumulated Depreciation and Amortization	$ (374)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Silas Creek Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	879
Buildings and Improvements	3,283
Total	4,162
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	879
Building and Improvements	3,283
Total	4,162
Accumulated Depreciation and Amortization	$ (277)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Lincolnton Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	0
Buildings and Improvements	9,967
Total	9,967
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	0
Building and Improvements	9,967
Total	9,967
Accumulated Depreciation and Amortization	$ (664)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Rehabilitation and Nursing Center of Monroe
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	166
Buildings and Improvements	5,906
Total	6,072
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	166
Building and Improvements	5,906
Total	6,072
Accumulated Depreciation and Amortization	$ (438)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Guardian Care of Zebulon
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	594
Buildings and Improvements	8,559
Total	9,153
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	594
Building and Improvements	8,559
Total	9,153
Accumulated Depreciation and Amortization	$ (548)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Guardian Care of Rocky Mount
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	0
Buildings and Improvements	18,314
Total	18,314
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	0
Building and Improvements	18,314
Total	18,314
Accumulated Depreciation and Amortization	$ (1,151)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | San Pedro Manor
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	671
Buildings and Improvements	2,504
Total	3,175
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	671
Building and Improvements	2,504
Total	3,175
Accumulated Depreciation and Amortization	$ (211)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Park Manor Health Care & Rehabilitation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	942
Buildings and Improvements	6,033
Total	6,975
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	942
Building and Improvements	6,033
Total	6,975
Accumulated Depreciation and Amortization	$ (440)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avalon Place - Trinity
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	363
Buildings and Improvements	3,852
Total	4,215
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	363
Building and Improvements	3,852
Total	4,215
Accumulated Depreciation and Amortization	$ (303)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Avalon Place - Kirbyville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	208
Buildings and Improvements	5,809
Total	6,017
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	208
Building and Improvements	5,809
Total	6,017
Accumulated Depreciation and Amortization	$ (437)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Heritage House of Marshall
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	732
Buildings and Improvements	4,288
Total	5,020
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	732
Building and Improvements	4,288
Total	5,020
Accumulated Depreciation and Amortization	$ (332)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Autumn Woods Residential Health Care Facility
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,052
Buildings and Improvements	25,539
Total	27,591
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,052
Building and Improvements	25,539
Total	27,591
Accumulated Depreciation and Amortization	$ (1,845)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Autumn View Health Care Facility
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,026
Buildings and Improvements	54,086
Total	55,112
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,026
Building and Improvements	54,086
Total	55,112
Accumulated Depreciation and Amortization	$ (3,416)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Brookhaven Health Care Facility
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,181
Buildings and Improvements	30,373
Total	32,554
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,181
Building and Improvements	30,373
Total	32,554
Accumulated Depreciation and Amortization	$ (2,018)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Harris Hill Nursing Facility
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,122
Buildings and Improvements	46,413
Total	47,535
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,122
Building and Improvements	46,413
Total	47,535
Accumulated Depreciation and Amortization	$ (2,879)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Garden Gate Health Care Facility
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,164
Buildings and Improvements	29,905
Total	31,069
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,164
Building and Improvements	29,905
Total	31,069
Accumulated Depreciation and Amortization	$ (1,966)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Northgate Health Care Facility
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	830
Buildings and Improvements	29,488
Total	30,318
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	830
Building and Improvements	29,488
Total	30,318
Accumulated Depreciation and Amortization	$ (1,937)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Seneca Health Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,325
Buildings and Improvements	26,839
Total	28,164
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,325
Building and Improvements	26,839
Total	28,164
Accumulated Depreciation and Amortization	$ (1,731)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Blueberry Hill Rehab and Healthcare Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,410
Buildings and Improvements	13,588
Total	15,998
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,410
Building and Improvements	13,588
Total	15,998
Accumulated Depreciation and Amortization	$ (1,179)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | River Terrace Rehabilitation and Healthcare Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	343
Buildings and Improvements	7,733
Total	8,076
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	343
Building and Improvements	7,733
Total	8,076
Accumulated Depreciation and Amortization	$ (518)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | The Crossings West Campus
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	356
Buildings and Improvements	152
Total	508
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	356
Building and Improvements	152
Total	508
Accumulated Depreciation and Amortization	$ (23)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | The Crossings East Campus
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	505
Buildings and Improvements	2,248
Total	2,753
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	505
Building and Improvements	2,248
Total	2,753
Accumulated Depreciation and Amortization	$ (257)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Parkway Pavilion Healthcare
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	437
Buildings and Improvements	16,461
Total	16,898
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	437
Building and Improvements	16,461
Total	16,898
Accumulated Depreciation and Amortization	$ (1,127)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Quincy Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	894
Buildings and Improvements	904
Total	1,798
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	894
Building and Improvements	904
Total	1,798
Accumulated Depreciation and Amortization	$ (111)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Den-Mar Health & Rehabilitation Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	0
Buildings and Improvements	1,765
Total	1,765
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	0
Building and Improvements	1,765
Total	1,765
Accumulated Depreciation and Amortization	$ (155)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Firesteel Healthcare Community
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	621
Buildings and Improvements	14,059
Total	14,680
Cost Capitalized Subsequent to Acquisition	8,716
Gross Amount at which Carried at Close of Period
Land	621
Building and Improvements	22,775
Total	23,396
Accumulated Depreciation and Amortization	$ (2,280)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Fountain Springs Healthcare Community
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,134
Buildings and Improvements	13,109
Total	14,243
Cost Capitalized Subsequent to Acquisition	169
Gross Amount at which Carried at Close of Period
Land	1,134
Building and Improvements	13,278
Total	14,412
Accumulated Depreciation and Amortization	$ (857)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Palisade Healthcare Community
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	362
Buildings and Improvements	2,548
Total	2,910
Cost Capitalized Subsequent to Acquisition	230
Gross Amount at which Carried at Close of Period
Land	362
Building and Improvements	2,778
Total	3,140
Accumulated Depreciation and Amortization	$ (216)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Shepherd of the Valley Healthcare Community
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	803
Buildings and Improvements	19,210
Total	20,013
Cost Capitalized Subsequent to Acquisition	573
Gross Amount at which Carried at Close of Period
Land	803
Building and Improvements	19,783
Total	20,586
Accumulated Depreciation and Amortization	$ (1,305)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wheatcrest Hills Healthcare Community
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	679
Buildings and Improvements	3,216
Total	3,895
Cost Capitalized Subsequent to Acquisition	269
Gross Amount at which Carried at Close of Period
Land	679
Building and Improvements	3,485
Total	4,164
Accumulated Depreciation and Amortization	$ (261)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Riverview Healthcare Community & Independent Living
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	240
Buildings and Improvements	6,327
Total	6,567
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	240
Building and Improvements	6,327
Total	6,567
Accumulated Depreciation and Amortization	$ (442)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Prairie View Healthcare Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	383
Buildings and Improvements	2,041
Total	2,424
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	383
Building and Improvements	2,041
Total	2,424
Accumulated Depreciation and Amortization	$ (167)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wingate at Dutchess (Fishkill)
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	964
Buildings and Improvements	30,107
Total	31,071
Cost Capitalized Subsequent to Acquisition	261
Gross Amount at which Carried at Close of Period
Land	964
Building and Improvements	30,368
Total	31,332
Accumulated Depreciation and Amortization	$ (2,001)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wingate at Ulster (Highland)
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	4,371
Buildings and Improvements	11,473
Total	15,844
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	4,371
Building and Improvements	11,473
Total	15,844
Accumulated Depreciation and Amortization	$ (813)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wingate at Beacon
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	0
Buildings and Improvements	25,400
Total	25,400
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	0
Building and Improvements	25,400
Total	25,400
Accumulated Depreciation and Amortization	$ (1,760)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wingate at Springfield
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	817
Buildings and Improvements	11,357
Total	12,174
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	817
Building and Improvements	11,357
Total	12,174
Accumulated Depreciation and Amortization	$ (763)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wingate at Andover
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,123
Buildings and Improvements	5,383
Total	7,506
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,123
Building and Improvements	5,383
Total	7,506
Accumulated Depreciation and Amortization	$ (414)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wingate at Reading
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,534
Buildings and Improvements	5,221
Total	6,755
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,534
Building and Improvements	5,221
Total	6,755
Accumulated Depreciation and Amortization	$ (412)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wingate at Sudbury
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,017
Buildings and Improvements	3,458
Total	5,475
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,017
Building and Improvements	3,458
Total	5,475
Accumulated Depreciation and Amortization	$ (315)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wingate at Belvidere (Lowell)
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,335
Buildings and Improvements	9,019
Total	10,354
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,335
Building and Improvements	9,019
Total	10,354
Accumulated Depreciation and Amortization	$ (654)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wingate at Worcester
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	945
Buildings and Improvements	8,770
Total	9,715
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	945
Building and Improvements	8,770
Total	9,715
Accumulated Depreciation and Amortization	$ (624)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wingate at West Springfield
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,022
Buildings and Improvements	7,345
Total	9,367
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,022
Building and Improvements	7,345
Total	9,367
Accumulated Depreciation and Amortization	$ (573)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Wingate at East Longmeadow
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,968
Buildings and Improvements	8,957
Total	11,925
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,968
Building and Improvements	8,957
Total	11,925
Accumulated Depreciation and Amortization	$ (704)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Broadway by the Sea
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,939
Buildings and Improvements	11,782
Total	14,721
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,939
Building and Improvements	11,690
Total	14,629
Accumulated Depreciation and Amortization	$ (809)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Coventry Court Health Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,044
Buildings and Improvements	14,167
Total	16,211
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,044
Building and Improvements	14,167
Total	16,211
Accumulated Depreciation and Amortization	$ (952)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Fairfield Post-Acute Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	586
Buildings and Improvements	23,582
Total	24,168
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	586
Building and Improvements	23,582
Total	24,168
Accumulated Depreciation and Amortization	$ (1,474)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Garden View Post-Acute Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,270
Buildings and Improvements	17,063
Total	19,333
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,270
Building and Improvements	17,063
Total	19,333
Accumulated Depreciation and Amortization	$ (1,125)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Grand Terrace Health Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	432
Buildings and Improvements	9,382
Total	9,814
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	432
Building and Improvements	9,382
Total	9,814
Accumulated Depreciation and Amortization	$ (624)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Pacifica Nursing & Rehab Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,510
Buildings and Improvements	27,397
Total	28,907
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,510
Building and Improvements	27,397
Total	28,907
Accumulated Depreciation and Amortization	$ (1,689)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Burien Nursing & Rehab Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	823
Buildings and Improvements	17,431
Total	18,254
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	823
Building and Improvements	17,431
Total	18,254
Accumulated Depreciation and Amortization	$ (1,132)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Park West Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	4,802
Buildings and Improvements	7,927
Total	12,729
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	4,802
Building and Improvements	7,927
Total	12,729
Accumulated Depreciation and Amortization	$ (577)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Beachside Nursing Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,312
Buildings and Improvements	9,885
Total	12,197
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,312
Building and Improvements	9,885
Total	12,197
Accumulated Depreciation and Amortization	$ (654)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Chatsworth Park Health Care
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	7,841
Buildings and Improvements	16,916
Total	24,757
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	7,841
Building and Improvements	16,916
Total	24,757
Accumulated Depreciation and Amortization	$ (1,166)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Cottonwood Post-Acute Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	504
Buildings and Improvements	7,369
Total	7,873
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	504
Building and Improvements	7,369
Total	7,873
Accumulated Depreciation and Amortization	$ (513)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Danville Post-Acute Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,491
Buildings and Improvements	17,157
Total	18,648
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,491
Building and Improvements	17,157
Total	18,648
Accumulated Depreciation and Amortization	$ (1,107)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Lake Balboa Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,456
Buildings and Improvements	16,462
Total	18,918
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,456
Building and Improvements	16,462
Total	18,918
Accumulated Depreciation and Amortization	$ (1,023)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Lomita Post-Acute Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,743
Buildings and Improvements	14,734
Total	17,477
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,743
Building and Improvements	14,734
Total	17,477
Accumulated Depreciation and Amortization	$ (995)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | University Post-Acute Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,846
Buildings and Improvements	17,962
Total	20,808
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,846
Building and Improvements	17,962
Total	20,808
Accumulated Depreciation and Amortization	$ (1,144)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Issaquah Nursing & Rehab Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	10,125
Buildings and Improvements	7,771
Total	17,896
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	10,125
Building and Improvements	7,771
Total	17,896
Accumulated Depreciation and Amortization	$ (595)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Alamitos-Belmont Rehab Hospital
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	3,157
Buildings and Improvements	22,067
Total	25,224
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	3,157
Building and Improvements	22,067
Total	25,224
Accumulated Depreciation and Amortization	$ (1,440)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Edgewater Skilled Nursing Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,857
Buildings and Improvements	5,878
Total	8,735
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,857
Building and Improvements	5,878
Total	8,735
Accumulated Depreciation and Amortization	$ (414)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Fairmont Rehabilitation Hospital
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	812
Buildings and Improvements	21,059
Total	21,871
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	812
Building and Improvements	21,059
Total	21,871
Accumulated Depreciation and Amortization	$ (1,279)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Palm Terrace Care Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,717
Buildings and Improvements	13,806
Total	15,523
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,717
Building and Improvements	13,806
Total	15,523
Accumulated Depreciation and Amortization	$ (981)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Woodland Nursing & Rehab
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	278
Buildings and Improvements	16,729
Total	17,007
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	278
Building and Improvements	16,729
Total	17,007
Accumulated Depreciation and Amortization	$ (1,076)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Park Manor at Bee Cave
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,107
Buildings and Improvements	10,413
Total	12,520
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,107
Building and Improvements	10,413
Total	12,520
Accumulated Depreciation and Amortization	$ (773)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Ramona
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,058
Buildings and Improvements	19,671
Total	21,729
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,058
Building and Improvements	19,671
Total	21,729
Accumulated Depreciation and Amortization	$ (1,138)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Skilled Nursing/Transitional Care Facilities | Park Ridge
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	8,861
Buildings and Improvements	11,478
Total	20,339
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	8,861
Building and Improvements	11,478
Total	20,339
Accumulated Depreciation and Amortization	$ (770)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased
Real Estate and Accumulated Depreciation
Encumbrances	$ 28,441
Initial Cost to Company
Land	56,002
Buildings and Improvements	569,489
Total	625,491
Cost Capitalized Subsequent to Acquisition	19,290
Gross Amount at which Carried at Close of Period
Land	56,171
Building and Improvements	574,517
Total	630,688
Accumulated Depreciation and Amortization	(72,278)
Senior Housing - Leased | Forest Hills (ALF)
Initial Cost to Company
Land	1,803
Buildings and Improvements	3,927
Total	5,730
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,803
Building and Improvements	3,323
Total	5,126
Accumulated Depreciation and Amortization	$ (1,571)
Life on Which Depreciation in Latest Income Statement is Computed	30 years
Senior Housing - Leased | Langdon Place of Exeter
Real Estate and Accumulated Depreciation
Encumbrances	$ 2,759
Initial Cost to Company
Land	571
Buildings and Improvements	7,183
Total	7,754
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	571
Building and Improvements	6,129
Total	6,700
Accumulated Depreciation and Amortization	$ (2,408)
Life on Which Depreciation in Latest Income Statement is Computed	43 years
Senior Housing - Leased | Langdon Place of Nashua
Real Estate and Accumulated Depreciation
Encumbrances	$ 4,999
Initial Cost to Company
Land	0
Buildings and Improvements	5,654
Total	5,654
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	0
Building and Improvements	4,635
Total	4,635
Accumulated Depreciation and Amortization	$ (1,549)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Langdon Place of Keene
Real Estate and Accumulated Depreciation
Encumbrances	$ 4,126
Initial Cost to Company
Land	304
Buildings and Improvements	3,992
Total	4,296
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	304
Building and Improvements	3,449
Total	3,753
Accumulated Depreciation and Amortization	$ (1,520)
Life on Which Depreciation in Latest Income Statement is Computed	46 years
Senior Housing - Leased | Langdon Place of Dover
Real Estate and Accumulated Depreciation
Encumbrances	$ 3,426
Initial Cost to Company
Land	801
Buildings and Improvements	10,036
Total	10,837
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	801
Building and Improvements	8,934
Total	9,735
Accumulated Depreciation and Amortization	$ (3,462)
Life on Which Depreciation in Latest Income Statement is Computed	42 years
Senior Housing - Leased | Age-Well Senior Living
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	256
Buildings and Improvements	2,262
Total	2,518
Cost Capitalized Subsequent to Acquisition	1,032
Gross Amount at which Carried at Close of Period
Land	256
Building and Improvements	3,294
Total	3,550
Accumulated Depreciation and Amortization	$ (1,569)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | New Dawn Aurora
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,874
Buildings and Improvements	12,829
Total	15,703
Cost Capitalized Subsequent to Acquisition	6
Gross Amount at which Carried at Close of Period
Land	2,874
Building and Improvements	12,835
Total	15,709
Accumulated Depreciation and Amortization	$ (2,521)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Gulf Pointe Village
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	789
Buildings and Improvements	607
Total	1,396
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	789
Building and Improvements	607
Total	1,396
Accumulated Depreciation and Amortization	$ (210)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Aspen Ridge Retirement Village
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,024
Buildings and Improvements	5,467
Total	7,491
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,024
Building and Improvements	5,467
Total	7,491
Accumulated Depreciation and Amortization	$ (1,375)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Green Acres of Cadillac
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	217
Buildings and Improvements	3,000
Total	3,217
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	217
Building and Improvements	3,000
Total	3,217
Accumulated Depreciation and Amortization	$ (638)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Green Acres of Greenville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	684
Buildings and Improvements	5,832
Total	6,516
Cost Capitalized Subsequent to Acquisition	249
Gross Amount at which Carried at Close of Period
Land	684
Building and Improvements	6,081
Total	6,765
Accumulated Depreciation and Amortization	$ (1,281)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Green Acres of Manistee
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	952
Buildings and Improvements	2,578
Total	3,530
Cost Capitalized Subsequent to Acquisition	2,547
Gross Amount at which Carried at Close of Period
Land	952
Building and Improvements	5,125
Total	6,077
Accumulated Depreciation and Amortization	$ (963)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Green Acres of Mason
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	198
Buildings and Improvements	4,131
Total	4,329
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	198
Building and Improvements	4,131
Total	4,329
Accumulated Depreciation and Amortization	$ (916)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Nottingham Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	744
Buildings and Improvements	1,745
Total	2,489
Cost Capitalized Subsequent to Acquisition	400
Gross Amount at which Carried at Close of Period
Land	744
Building and Improvements	2,145
Total	2,889
Accumulated Depreciation and Amortization	$ (491)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Royal View
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	307
Buildings and Improvements	2,477
Total	2,784
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	307
Building and Improvements	2,477
Total	2,784
Accumulated Depreciation and Amortization	$ (601)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Tawas Village
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	258
Buildings and Improvements	3,713
Total	3,971
Cost Capitalized Subsequent to Acquisition	45
Gross Amount at which Carried at Close of Period
Land	258
Building and Improvements	3,758
Total	4,016
Accumulated Depreciation and Amortization	$ (1,074)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Turning Brook
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	546
Buildings and Improvements	13,139
Total	13,685
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	546
Building and Improvements	13,139
Total	13,685
Accumulated Depreciation and Amortization	$ (2,503)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Greenfield of Woodstock
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	597
Buildings and Improvements	5,465
Total	6,062
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	597
Building and Improvements	5,465
Total	6,062
Accumulated Depreciation and Amortization	$ (1,034)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Nye Square
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	504
Buildings and Improvements	17,670
Total	18,174
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	504
Building and Improvements	17,670
Total	18,174
Accumulated Depreciation and Amortization	$ (2,995)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | The Meadows
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	217
Buildings and Improvements	9,906
Total	10,123
Cost Capitalized Subsequent to Acquisition	1,000
Gross Amount at which Carried at Close of Period
Land	217
Building and Improvements	10,906
Total	11,123
Accumulated Depreciation and Amortization	$ (1,812)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Park Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 13,131
Initial Cost to Company
Land	2,300
Buildings and Improvements	21,115
Total	23,415
Cost Capitalized Subsequent to Acquisition	2,747
Gross Amount at which Carried at Close of Period
Land	2,300
Building and Improvements	23,861
Total	26,161
Accumulated Depreciation and Amortization	$ (4,441)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Avalon MC - Boat Club
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	359
Buildings and Improvements	8,126
Total	8,485
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	359
Building and Improvements	8,126
Total	8,485
Accumulated Depreciation and Amortization	$ (1,224)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Avalon MC - 7200
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	123
Buildings and Improvements	4,914
Total	5,037
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	123
Building and Improvements	4,914
Total	5,037
Accumulated Depreciation and Amortization	$ (742)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Avalon MC - 7204
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	215
Buildings and Improvements	4,821
Total	5,036
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	215
Building and Improvements	4,822
Total	5,037
Accumulated Depreciation and Amortization	$ (732)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Avalon MC - 7140
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	143
Buildings and Improvements	6,653
Total	6,796
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	143
Building and Improvements	6,653
Total	6,796
Accumulated Depreciation and Amortization	$ (980)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Delaney Creek Lodge
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,283
Buildings and Improvements	8,424
Total	9,707
Cost Capitalized Subsequent to Acquisition	483
Gross Amount at which Carried at Close of Period
Land	1,283
Building and Improvements	8,907
Total	10,190
Accumulated Depreciation and Amortization	$ (1,459)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Nature Coast Lodge
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,031
Buildings and Improvements	5,577
Total	6,608
Cost Capitalized Subsequent to Acquisition	452
Gross Amount at which Carried at Close of Period
Land	1,031
Building and Improvements	6,030
Total	7,061
Accumulated Depreciation and Amortization	$ (1,134)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | West Winds
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,688
Buildings and Improvements	9,098
Total	10,786
Cost Capitalized Subsequent to Acquisition	360
Gross Amount at which Carried at Close of Period
Land	1,688
Building and Improvements	9,459
Total	11,147
Accumulated Depreciation and Amortization	$ (1,683)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Tudor Heights
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	561
Buildings and Improvements	4,865
Total	5,426
Cost Capitalized Subsequent to Acquisition	1,255
Gross Amount at which Carried at Close of Period
Land	561
Building and Improvements	6,121
Total	6,682
Accumulated Depreciation and Amortization	$ (1,178)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Life’s Journey of Mattoon
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	812
Buildings and Improvements	6,796
Total	7,608
Cost Capitalized Subsequent to Acquisition	63
Gross Amount at which Carried at Close of Period
Land	264
Building and Improvements	1,921
Total	2,185
Accumulated Depreciation and Amortization	$ (59)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Life’s Journey of Pana
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	154
Buildings and Improvements	2,098
Total	2,252
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	46
Building and Improvements	524
Total	570
Accumulated Depreciation and Amortization	$ (20)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Life’s Journey of Taylorville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	267
Buildings and Improvements	5,201
Total	5,468
Cost Capitalized Subsequent to Acquisition	50
Gross Amount at which Carried at Close of Period
Land	106
Building and Improvements	1,794
Total	1,900
Accumulated Depreciation and Amortization	$ (45)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Life’s Journey of Paris
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	132
Buildings and Improvements	3,090
Total	3,222
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	49
Building and Improvements	996
Total	1,045
Accumulated Depreciation and Amortization	$ (23)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Ashley Pointe
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,559
Buildings and Improvements	9,059
Total	10,618
Cost Capitalized Subsequent to Acquisition	68
Gross Amount at which Carried at Close of Period
Land	1,559
Building and Improvements	9,127
Total	10,686
Accumulated Depreciation and Amortization	$ (1,186)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Farmington Square Eugene
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,428
Buildings and Improvements	16,138
Total	17,566
Cost Capitalized Subsequent to Acquisition	101
Gross Amount at which Carried at Close of Period
Land	1,428
Building and Improvements	16,239
Total	17,667
Accumulated Depreciation and Amortization	$ (1,870)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Farmington Square Tualatin
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	527
Buildings and Improvements	14,659
Total	15,186
Cost Capitalized Subsequent to Acquisition	101
Gross Amount at which Carried at Close of Period
Land	527
Building and Improvements	14,760
Total	15,287
Accumulated Depreciation and Amortization	$ (1,709)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Farmington Square of Salem
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,074
Buildings and Improvements	19,421
Total	20,495
Cost Capitalized Subsequent to Acquisition	408
Gross Amount at which Carried at Close of Period
Land	1,074
Building and Improvements	19,829
Total	20,903
Accumulated Depreciation and Amortization	$ (2,345)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Colorado Springs
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,210
Buildings and Improvements	9,490
Total	10,700
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,210
Building and Improvements	9,490
Total	10,700
Accumulated Depreciation and Amortization	$ (1,175)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Sun City West
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	930
Buildings and Improvements	9,170
Total	10,100
Cost Capitalized Subsequent to Acquisition	248
Gross Amount at which Carried at Close of Period
Land	930
Building and Improvements	9,418
Total	10,348
Accumulated Depreciation and Amortization	$ (1,005)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Poet’s Walk at Fredericksburg
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,379
Buildings and Improvements	21,209
Total	22,588
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,379
Building and Improvements	21,209
Total	22,588
Accumulated Depreciation and Amortization	$ (2,167)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Poet’s Walk at Chandler Oaks
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	679
Buildings and Improvements	13,642
Total	14,321
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	679
Building and Improvements	13,642
Total	14,321
Accumulated Depreciation and Amortization	$ (1,398)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | The Montecito Santa Fe
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,536
Buildings and Improvements	19,441
Total	21,977
Cost Capitalized Subsequent to Acquisition	1,892
Gross Amount at which Carried at Close of Period
Land	2,807
Building and Improvements	23,468
Total	26,275
Accumulated Depreciation and Amortization	$ (1,996)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | The Golden Crest
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	292
Buildings and Improvements	6,889
Total	7,181
Cost Capitalized Subsequent to Acquisition	97
Gross Amount at which Carried at Close of Period
Land	292
Building and Improvements	6,996
Total	7,288
Accumulated Depreciation and Amortization	$ (736)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Poet’s Walk at Henderson
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,430
Buildings and Improvements	21,850
Total	23,280
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,430
Building and Improvements	21,862
Total	23,292
Accumulated Depreciation and Amortization	$ (1,920)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Kruse Village
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	476
Buildings and Improvements	11,912
Total	12,388
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	476
Building and Improvements	11,922
Total	12,398
Accumulated Depreciation and Amortization	$ (1,198)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Poet’s Walk of Cedar Parks
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,035
Buildings and Improvements	13,127
Total	14,162
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,035
Building and Improvements	13,127
Total	14,162
Accumulated Depreciation and Amortization	$ (999)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Avamere Court at Keizer
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,220
Buildings and Improvements	31,783
Total	33,003
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,220
Building and Improvements	31,783
Total	33,003
Accumulated Depreciation and Amortization	$ (2,002)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Arbor Court Retirement Community at Alvamar
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	584
Buildings and Improvements	4,431
Total	5,015
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	584
Building and Improvements	4,431
Total	5,015
Accumulated Depreciation and Amortization	$ (313)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Arbor Court Retirement Community at Salina
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	584
Buildings and Improvements	3,020
Total	3,604
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	584
Building and Improvements	3,020
Total	3,604
Accumulated Depreciation and Amortization	$ (212)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Arbor Court Retirement Community at Topeka
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	313
Buildings and Improvements	5,492
Total	5,805
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	313
Building and Improvements	5,492
Total	5,805
Accumulated Depreciation and Amortization	$ (356)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Aspen Grove Assisted Living
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	555
Buildings and Improvements	6,487
Total	7,042
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	555
Building and Improvements	6,487
Total	7,042
Accumulated Depreciation and Amortization	$ (464)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Maurice Griffith Manor Living Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	294
Buildings and Improvements	72
Total	366
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	294
Building and Improvements	72
Total	366
Accumulated Depreciation and Amortization	$ (9)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | The Peaks at Old Laramie Trail (Lafayette)
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,085
Buildings and Improvements	19,243
Total	20,328
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,883
Building and Improvements	19,196
Total	21,079
Accumulated Depreciation and Amortization	$ (1,217)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Prairie View
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	263
Buildings and Improvements	3,743
Total	4,006
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	263
Building and Improvements	3,743
Total	4,006
Accumulated Depreciation and Amortization	$ (229)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Arbor View Assisted Living
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,019
Buildings and Improvements	3,606
Total	4,625
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,019
Building and Improvements	3,606
Total	4,625
Accumulated Depreciation and Amortization	$ (187)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Legacy Assisted Living
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	661
Buildings and Improvements	5,680
Total	6,341
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	661
Building and Improvements	5,680
Total	6,341
Accumulated Depreciation and Amortization	$ (272)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Greenfield of Strasburg
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	666
Buildings and Improvements	5,551
Total	6,217
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	666
Building and Improvements	5,551
Total	6,217
Accumulated Depreciation and Amortization	$ (273)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Poets Walk of Sarasota
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,440
Buildings and Improvements	22,541
Total	23,981
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,440
Building and Improvements	22,541
Total	23,981
Accumulated Depreciation and Amortization	$ (991)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | The Pointe at Lifespring
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,603
Buildings and Improvements	9,219
Total	10,822
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,603
Building and Improvements	9,219
Total	10,822
Accumulated Depreciation and Amortization	$ (413)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Shavano Park Senior Living
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,131
Buildings and Improvements	11,541
Total	13,672
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,131
Building and Improvements	11,541
Total	13,672
Accumulated Depreciation and Amortization	$ (472)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Traditions of Beavercreek
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,622
Buildings and Improvements	24,215
Total	25,837
Cost Capitalized Subsequent to Acquisition	5,686
Gross Amount at which Carried at Close of Period
Land	1,622
Building and Improvements	29,901
Total	31,523
Accumulated Depreciation and Amortization	$ (916)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Leased | Cadence at Poway Gardens
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	3,693
Buildings and Improvements	14,467
Total	18,160
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	3,693
Building and Improvements	14,467
Total	18,160
Accumulated Depreciation and Amortization	$ (35)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed
Real Estate and Accumulated Depreciation
Encumbrances	$ 16,308
Initial Cost to Company
Land	76,883
Buildings and Improvements	804,427
Total	881,310
Cost Capitalized Subsequent to Acquisition	7,652
Gross Amount at which Carried at Close of Period
Land	76,735
Building and Improvements	831,036
Total	907,771
Accumulated Depreciation and Amortization	(112,893)
Senior Housing - Managed | Winter Village
Real Estate and Accumulated Depreciation
Encumbrances	0
Initial Cost to Company
Land	5,027
Buildings and Improvements	20,929
Total	25,956
Cost Capitalized Subsequent to Acquisition	871
Gross Amount at which Carried at Close of Period
Land	5,027
Building and Improvements	21,800
Total	26,827
Accumulated Depreciation and Amortization	$ (4,475)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Stoney River Marshfield
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	574
Buildings and Improvements	8,733
Total	9,307
Cost Capitalized Subsequent to Acquisition	163
Gross Amount at which Carried at Close of Period
Land	574
Building and Improvements	8,896
Total	9,470
Accumulated Depreciation and Amortization	$ (1,806)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Kensington Court
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,360
Buildings and Improvements	16,855
Total	18,215
Cost Capitalized Subsequent to Acquisition	590
Gross Amount at which Carried at Close of Period
Land	1,405
Building and Improvements	17,993
Total	19,398
Accumulated Depreciation and Amortization	$ (2,458)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Masonville Manor
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	960
Buildings and Improvements	19,056
Total	20,016
Cost Capitalized Subsequent to Acquisition	376
Gross Amount at which Carried at Close of Period
Land	991
Building and Improvements	20,051
Total	21,042
Accumulated Depreciation and Amortization	$ (2,662)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Okanagan Chateau
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,321
Buildings and Improvements	8,308
Total	10,629
Cost Capitalized Subsequent to Acquisition	1,065
Gross Amount at which Carried at Close of Period
Land	2,396
Building and Improvements	9,643
Total	12,039
Accumulated Depreciation and Amortization	$ (1,381)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Court at Laurelwood
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,823
Buildings and Improvements	22,135
Total	23,958
Cost Capitalized Subsequent to Acquisition	283
Gross Amount at which Carried at Close of Period
Land	1,881
Building and Improvements	23,138
Total	25,019
Accumulated Depreciation and Amortization	$ (3,035)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Fairwinds Lodge
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,187
Buildings and Improvements	20,346
Total	21,533
Cost Capitalized Subsequent to Acquisition	485
Gross Amount at which Carried at Close of Period
Land	1,224
Building and Improvements	21,493
Total	22,717
Accumulated Depreciation and Amortization	$ (2,811)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | The Shores
Real Estate and Accumulated Depreciation
Encumbrances	$ 4,957
Initial Cost to Company
Land	679
Buildings and Improvements	8,024
Total	8,703
Cost Capitalized Subsequent to Acquisition	222
Gross Amount at which Carried at Close of Period
Land	700
Building and Improvements	8,507
Total	9,207
Accumulated Depreciation and Amortization	$ (1,163)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Orchard Valley
Real Estate and Accumulated Depreciation
Encumbrances	$ 6,599
Initial Cost to Company
Land	843
Buildings and Improvements	10,724
Total	11,567
Cost Capitalized Subsequent to Acquisition	178
Gross Amount at which Carried at Close of Period
Land	278
Building and Improvements	11,251
Total	11,529
Accumulated Depreciation and Amortization	$ (1,456)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Cherry Park
Real Estate and Accumulated Depreciation
Encumbrances	$ 4,752
Initial Cost to Company
Land	763
Buildings and Improvements	6,771
Total	7,534
Cost Capitalized Subsequent to Acquisition	592
Gross Amount at which Carried at Close of Period
Land	787
Building and Improvements	7,584
Total	8,371
Accumulated Depreciation and Amortization	$ (1,013)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Maison Senior Living
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	3,908
Buildings and Improvements	20,996
Total	24,904
Cost Capitalized Subsequent to Acquisition	508
Gross Amount at which Carried at Close of Period
Land	4,034
Building and Improvements	22,187
Total	26,221
Accumulated Depreciation and Amortization	$ (2,631)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Ramsey
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,182
Buildings and Improvements	13,280
Total	14,462
Cost Capitalized Subsequent to Acquisition	31
Gross Amount at which Carried at Close of Period
Land	1,182
Building and Improvements	13,316
Total	14,498
Accumulated Depreciation and Amortization	$ (909)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Marshfield II
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	500
Buildings and Improvements	4,134
Total	4,634
Cost Capitalized Subsequent to Acquisition	9
Gross Amount at which Carried at Close of Period
Land	500
Building and Improvements	4,148
Total	4,648
Accumulated Depreciation and Amortization	$ (317)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Dover Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,797
Buildings and Improvements	23,054
Total	25,851
Cost Capitalized Subsequent to Acquisition	99
Gross Amount at which Carried at Close of Period
Land	2,797
Building and Improvements	23,153
Total	25,950
Accumulated Depreciation and Amortization	$ (1,381)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Kanawha Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	419
Buildings and Improvements	4,239
Total	4,658
Cost Capitalized Subsequent to Acquisition	305
Gross Amount at which Carried at Close of Period
Land	419
Building and Improvements	4,544
Total	4,963
Accumulated Depreciation and Amortization	$ (368)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Leighton Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	296
Buildings and Improvements	9,191
Total	9,487
Cost Capitalized Subsequent to Acquisition	174
Gross Amount at which Carried at Close of Period
Land	296
Building and Improvements	9,365
Total	9,661
Accumulated Depreciation and Amortization	$ (591)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Maidencreek Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	684
Buildings and Improvements	12,950
Total	13,634
Cost Capitalized Subsequent to Acquisition	34
Gross Amount at which Carried at Close of Period
Land	684
Building and Improvements	12,984
Total	13,668
Accumulated Depreciation and Amortization	$ (796)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Rolling Meadows Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	230
Buildings and Improvements	6,271
Total	6,501
Cost Capitalized Subsequent to Acquisition	238
Gross Amount at which Carried at Close of Period
Land	230
Building and Improvements	6,510
Total	6,740
Accumulated Depreciation and Amortization	$ (483)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Willowbrook Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	406
Buildings and Improvements	9,471
Total	9,877
Cost Capitalized Subsequent to Acquisition	352
Gross Amount at which Carried at Close of Period
Land	406
Building and Improvements	9,823
Total	10,229
Accumulated Depreciation and Amortization	$ (667)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Wyncote Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,781
Buildings and Improvements	4,911
Total	6,692
Cost Capitalized Subsequent to Acquisition	289
Gross Amount at which Carried at Close of Period
Land	1,781
Building and Improvements	5,199
Total	6,980
Accumulated Depreciation and Amortization	$ (419)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Amity Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	611
Buildings and Improvements	19,083
Total	19,694
Cost Capitalized Subsequent to Acquisition	74
Gross Amount at which Carried at Close of Period
Land	611
Building and Improvements	19,157
Total	19,768
Accumulated Depreciation and Amortization	$ (1,111)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Milford Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,199
Buildings and Improvements	18,786
Total	19,985
Cost Capitalized Subsequent to Acquisition	153
Gross Amount at which Carried at Close of Period
Land	1,199
Building and Improvements	18,939
Total	20,138
Accumulated Depreciation and Amortization	$ (1,131)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Oak Hill Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	609
Buildings and Improvements	2,636
Total	3,245
Cost Capitalized Subsequent to Acquisition	128
Gross Amount at which Carried at Close of Period
Land	609
Building and Improvements	2,765
Total	3,374
Accumulated Depreciation and Amortization	$ (258)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Seasons Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	355
Buildings and Improvements	5,055
Total	5,410
Cost Capitalized Subsequent to Acquisition	339
Gross Amount at which Carried at Close of Period
Land	355
Building and Improvements	5,394
Total	5,749
Accumulated Depreciation and Amortization	$ (443)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Parkview in Allen
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,190
Buildings and Improvements	45,767
Total	47,957
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,190
Building and Improvements	46,425
Total	48,615
Accumulated Depreciation and Amortization	$ (6,898)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | The Atrium At Gainesville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,139
Buildings and Improvements	44,789
Total	46,928
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,139
Building and Improvements	46,439
Total	48,578
Accumulated Depreciation and Amortization	$ (7,164)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | The Chateau
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,760
Buildings and Improvements	44,397
Total	47,157
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,760
Building and Improvements	45,243
Total	48,003
Accumulated Depreciation and Amortization	$ (6,787)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Gardens At Wakefield Plantation
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,344
Buildings and Improvements	37,506
Total	39,850
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,344
Building and Improvements	38,200
Total	40,544
Accumulated Depreciation and Amortization	$ (5,572)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Las Brisas
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	4,992
Buildings and Improvements	30,909
Total	35,901
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	4,992
Building and Improvements	31,349
Total	36,341
Accumulated Depreciation and Amortization	$ (4,749)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Creekside Terrace
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,995
Buildings and Improvements	24,428
Total	27,423
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,995
Building and Improvements	24,713
Total	27,708
Accumulated Depreciation and Amortization	$ (3,822)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Colonial Village
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	805
Buildings and Improvements	26,498
Total	27,303
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	805
Building and Improvements	27,458
Total	28,263
Accumulated Depreciation and Amortization	$ (4,157)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Garden Village
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,325
Buildings and Improvements	20,510
Total	21,835
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,325
Building and Improvements	21,381
Total	22,706
Accumulated Depreciation and Amortization	$ (3,413)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Desert Rose
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	530
Buildings and Improvements	21,775
Total	22,305
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	530
Building and Improvements	22,066
Total	22,596
Accumulated Depreciation and Amortization	$ (3,395)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Windland South
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,996
Buildings and Improvements	19,368
Total	21,364
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,996
Building and Improvements	20,281
Total	22,277
Accumulated Depreciation and Amortization	$ (3,330)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Cedar Woods
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,403
Buildings and Improvements	18,821
Total	21,224
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,403
Building and Improvements	19,263
Total	21,666
Accumulated Depreciation and Amortization	$ (2,962)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Virginian
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,080
Buildings and Improvements	19,545
Total	20,625
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,080
Building and Improvements	20,131
Total	21,211
Accumulated Depreciation and Amortization	$ (3,141)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Monarch Estates
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	3,209
Buildings and Improvements	17,326
Total	20,535
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	3,209
Building and Improvements	17,640
Total	20,849
Accumulated Depreciation and Amortization	$ (2,821)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Village At The Falls
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,477
Buildings and Improvements	18,778
Total	20,255
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,477
Building and Improvements	19,044
Total	20,521
Accumulated Depreciation and Amortization	$ (3,030)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Holiday At The Atrium
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	978
Buildings and Improvements	18,257
Total	19,235
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	978
Building and Improvements	18,967
Total	19,945
Accumulated Depreciation and Amortization	$ (2,919)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Lake Ridge Village
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,152
Buildings and Improvements	17,523
Total	18,675
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,152
Building and Improvements	18,330
Total	19,482
Accumulated Depreciation and Amortization	$ (2,885)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Heritage Village
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	4,092
Buildings and Improvements	13,823
Total	17,915
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	4,092
Building and Improvements	14,321
Total	18,413
Accumulated Depreciation and Amortization	$ (2,339)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Madison Meadows
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,567
Buildings and Improvements	12,029
Total	14,596
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,567
Building and Improvements	12,807
Total	15,374
Accumulated Depreciation and Amortization	$ (2,136)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | South Wind Heights
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,782
Buildings and Improvements	11,244
Total	13,026
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,782
Building and Improvements	11,721
Total	13,503
Accumulated Depreciation and Amortization	$ (1,939)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Harrison Regent
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	794
Buildings and Improvements	10,873
Total	11,667
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	794
Building and Improvements	11,607
Total	12,401
Accumulated Depreciation and Amortization	$ (1,843)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | Capital Place
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,477
Buildings and Improvements	23,767
Total	26,244
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,477
Building and Improvements	25,160
Total	27,637
Accumulated Depreciation and Amortization	$ (3,769)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Senior Housing - Managed | The Monarch at Richardson
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,282
Buildings and Improvements	10,556
Total	12,838
Cost Capitalized Subsequent to Acquisition	94
Gross Amount at which Carried at Close of Period
Land	2,282
Building and Improvements	10,650
Total	12,932
Accumulated Depreciation and Amortization	$ (57)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	79,694
Buildings and Improvements	552,861
Total	632,555
Cost Capitalized Subsequent to Acquisition	7,168
Gross Amount at which Carried at Close of Period
Land	79,694
Building and Improvements	560,027
Total	639,721
Accumulated Depreciation and Amortization	(47,124)
Specialty Hospitals and Other | Texas Regional Medical Center
Real Estate and Accumulated Depreciation
Encumbrances	0
Initial Cost to Company
Land	4,020
Buildings and Improvements	57,620
Total	61,640
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	4,020
Building and Improvements	57,620
Total	61,640
Accumulated Depreciation and Amortization	$ (15,928)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Baylor Orthopedic Spine Hospital at Arlington
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	0
Buildings and Improvements	44,217
Total	44,217
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	0
Building and Improvements	44,217
Total	44,217
Accumulated Depreciation and Amortization	$ (2,651)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Touchstone Neurorecovery Center
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,935
Buildings and Improvements	25,003
Total	27,938
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,935
Building and Improvements	25,003
Total	27,938
Accumulated Depreciation and Amortization	$ (1,695)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | HealthBridge Children’s Hospital (Houston)
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	3,001
Buildings and Improvements	14,581
Total	17,582
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	3,001
Building and Improvements	14,581
Total	17,582
Accumulated Depreciation and Amortization	$ (890)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Nexus Specialty Hospital - Woodlands Campus
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,319
Buildings and Improvements	15,153
Total	16,472
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,319
Building and Improvements	15,153
Total	16,472
Accumulated Depreciation and Amortization	$ (927)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | HealthBridge Children’s Hospital (Orange)
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,060
Buildings and Improvements	5,538
Total	7,598
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,060
Building and Improvements	5,538
Total	7,598
Accumulated Depreciation and Amortization	$ (353)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | ResCare Tangram - Texas Hill Country School
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	902
Buildings and Improvements	2,384
Total	3,286
Cost Capitalized Subsequent to Acquisition	1
Gross Amount at which Carried at Close of Period
Land	902
Building and Improvements	2,385
Total	3,287
Accumulated Depreciation and Amortization	$ (170)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | ResCare Tangram - Chaparral
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	901
Buildings and Improvements	1,198
Total	2,099
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	901
Building and Improvements	1,198
Total	2,099
Accumulated Depreciation and Amortization	$ (103)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | ResCare Tangram - Sierra Verde & Roca Vista
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	456
Buildings and Improvements	2,632
Total	3,088
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	456
Building and Improvements	2,632
Total	3,088
Accumulated Depreciation and Amortization	$ (176)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | ResCare Tangram - 618 W. Hutchinson
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	51
Buildings and Improvements	359
Total	410
Cost Capitalized Subsequent to Acquisition	62
Gross Amount at which Carried at Close of Period
Land	51
Building and Improvements	421
Total	472
Accumulated Depreciation and Amortization	$ (70)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | ResCare Tangram - Ranch
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	539
Buildings and Improvements	2,627
Total	3,166
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	539
Building and Improvements	2,627
Total	3,166
Accumulated Depreciation and Amortization	$ (223)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | ResCare Tangram - Mesquite
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	228
Buildings and Improvements	3,407
Total	3,635
Cost Capitalized Subsequent to Acquisition	79
Gross Amount at which Carried at Close of Period
Land	228
Building and Improvements	3,486
Total	3,714
Accumulated Depreciation and Amortization	$ (247)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | ResCare Tangram - Hacienda
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	104
Buildings and Improvements	2,788
Total	2,892
Cost Capitalized Subsequent to Acquisition	27
Gross Amount at which Carried at Close of Period
Land	104
Building and Improvements	2,814
Total	2,918
Accumulated Depreciation and Amortization	$ (182)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | ResCare Tangram - Loma Linda
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	52
Buildings and Improvements	805
Total	857
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	52
Building and Improvements	805
Total	857
Accumulated Depreciation and Amortization	$ (57)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Aurora Chicago Lakeshore Hospital
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	8,574
Buildings and Improvements	39,732
Total	48,306
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	8,574
Building and Improvements	39,732
Total	48,306
Accumulated Depreciation and Amortization	$ (2,576)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Aurora Arizona West
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,501
Buildings and Improvements	67,046
Total	68,547
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,501
Building and Improvements	67,046
Total	68,547
Accumulated Depreciation and Amortization	$ (4,104)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Aurora Arizona East
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	3,137
Buildings and Improvements	50,073
Total	53,210
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	3,137
Building and Improvements	50,073
Total	53,210
Accumulated Depreciation and Amortization	$ (3,133)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Aurora Charter Oak Hospital
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	23,472
Buildings and Improvements	71,542
Total	95,014
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	23,472
Building and Improvements	71,542
Total	95,014
Accumulated Depreciation and Amortization	$ (4,549)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Aurora Vista del Mar Hospital
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	8,089
Buildings and Improvements	43,645
Total	51,734
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	8,089
Building and Improvements	43,645
Total	51,734
Accumulated Depreciation and Amortization	$ (3,017)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Aurora San Diego Hospital
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	8,403
Buildings and Improvements	55,015
Total	63,418
Cost Capitalized Subsequent to Acquisition	6,999
Gross Amount at which Carried at Close of Period
Land	8,403
Building and Improvements	62,013
Total	70,416
Accumulated Depreciation and Amortization	$ (3,855)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Gateway Rehabilitation Hospital at Florence
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	3,866
Buildings and Improvements	26,447
Total	30,313
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	3,866
Building and Improvements	26,447
Total	30,313
Accumulated Depreciation and Amortization	$ (1,615)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Highlands Regional Rehabilitation Hospital
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,009
Buildings and Improvements	6,639
Total	8,648
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,009
Building and Improvements	6,639
Total	8,648
Accumulated Depreciation and Amortization	$ (450)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Landmark Carmel
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	963
Buildings and Improvements	4,347
Total	5,310
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	963
Building and Improvements	4,347
Total	5,310
Accumulated Depreciation and Amortization	$ (64)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Landmark Louisville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	1,078
Buildings and Improvements	8,305
Total	9,383
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	1,078
Building and Improvements	8,305
Total	9,383
Accumulated Depreciation and Amortization	$ (89)
Life on Which Depreciation in Latest Income Statement is Computed	40 years
Specialty Hospitals and Other | Recovery Centers of America at Monroeville
Real Estate and Accumulated Depreciation
Encumbrances	$ 0
Initial Cost to Company
Land	2,034
Buildings and Improvements	1,758
Total	3,792
Cost Capitalized Subsequent to Acquisition	0
Gross Amount at which Carried at Close of Period
Land	2,034
Building and Improvements	1,758
Total	3,792
Accumulated Depreciation and Amortization	$ 0
Life on Which Depreciation in Latest Income Statement is Computed	40 years

XML

STOCK-BASED COMPENSATION - Summary of Assumptions Used in Total Stockholder Return-Based Stock Units Valuation (Details) - TSR Units	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Assumptions used in fair value valuation
Expected dividend yield (assuming full reinvestment)	0.00%	0.00%	0.00%
Minimum
Assumptions used in fair value valuation
Risk free interest rate	1.57%	2.36%	1.42%
Expected stock price volatility	23.80%	28.57%	28.86%
Expected service period	2 years 4 months 24 days	2 years 6 months	2 years 2 months 12 days
Maximum
Assumptions used in fair value valuation
Risk free interest rate	2.54%	2.59%	1.99%
Expected stock price volatility	28.57%	30.02%	30.97%
Expected service period	3 years	3 years	3 years

XML

DEBT - Schedule of Maturities of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
2020	$ 3,568
2021	18,853
2022	108,198
2023	353,296
2024	899,421
Thereafter	1,032,466
Total debt	2,415,802
Premium, net	7,612
Deferred financing costs, net	(21,313)
Total Debt, Net	2,402,101
Secured Indebtedness
Debt Instrument [Line Items]
2020	3,568
2021	18,853
2022	3,198
2023	3,296
2024	3,396
Thereafter	82,466
Total debt	114,777
Premium, net	0
Deferred financing costs, net	(1,707)	$ (1,800)
Total Debt, Net	113,070
Term Loans
Debt Instrument [Line Items]
2020	0
2021	0
2022	105,000
2023	350,000
2024	596,025
Thereafter	0
Total debt	1,051,025
Premium, net	0
Deferred financing costs, net	(10,767)
Total Debt, Net	1,040,258
Senior Notes
Debt Instrument [Line Items]
2020	0
2021	0
2022	0
2023	0
2024	300,000
Thereafter	950,000
Total debt	1,250,000
Premium, net	7,612
Deferred financing costs, net	(8,839)	$ (7,100)
Total Debt, Net	$ 1,248,773

XML

INTANGIBLE ASSETS AND LIABILITIES - Summary of Real Estate Intangible Amortization (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Increase (decrease) to rental income related to above/below market leases, net
Finite-Lived Intangible Assets
Increase (decrease) to rental income related to above/below market leases, net	$ 508	$ (7,701)	$ 912
Depreciation and amortization related to tenant origination and absorption costs and tenant relationship
Finite-Lived Intangible Assets
Depreciation and amortization related to tenant origination and absorption costs and tenant relationship	$ (17,674)	$ (16,118)	$ (11,822)

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Changes in Accretable Yield (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Certain Loans Acquired in Transfer Not Accounted for as Debt Securities, Accretable Yield Movement Schedule [Roll Forward]
Accretable yield, beginning of period	$ 449	$ 2,483
Accretion recognized in earnings	(377)	(2,761)
Reduction due to payoff	(33)	0
Net reclassification from nonaccretable difference	0	727
Accretable yield, end of period	$ 39	$ 449

XML

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Summary of Additional Information Concerning Restricted Stock Units

The following table summarizes additional information concerning restricted stock units at December 31, 2019:

	Restricted Stock Units		Weighted Average Grant Date Fair Value Per Unit
Unvested as of December 31, 2018	1,477,318		$	17.88
Granted	603,131		20.59
Vested	(433,181	)	18.34
Dividends reinvested	152,329		18.60
Cancelled/forfeited	(61,735	)	18.29
Unvested as of December 31, 2019	1,737,862		$	18.90

Summary of Assumptions Used in Total Stockholder Return-Based Stock Units Valuation

The following are the key assumptions used in this valuation:

	2019		2018		2017
Risk free interest rate	1.57% - 2.54%		2.36% - 2.59%		1.42% - 1.99%
Expected stock price volatility	23.80% - 28.57%		28.57% - 30.02%		28.86% - 30.97%
Expected service period	2.4 - 3.0 years		2.5 - 3.0 years		2.2 - 3.0 years
Expected dividend yield (assuming full reinvestment)	—	%	—	%	—	%

XML

DEBT (Tables)

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Debt

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of December 31,
Title	Maturity Date	2019 (1)		2018 (1)
5.5% senior unsecured notes due 2021 (“2021 Notes”)	February 1, 2021	$	—	$	500,000
5.375% senior unsecured notes due 2023 (“2023 Notes”)	June 1, 2023	—		200,000
4.80% senior unsecured notes due 2024 (“2024 Notes”)	June 1, 2024	300,000		—
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	500,000		500,000
5.38% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
3.90% senior unsecured notes due 2029 (“2029 Notes”)	October 15, 2029	350,000		—
		$	1,250,000	$	1,300,000

⁽¹⁾ 

Principal balance does not include premium, net of $7.6 million and deferred financing costs, net of $8.8 million as of December 31, 2019 and does not include premium, net of $14.5 million and deferred financing costs, net of $7.1 million as of December 31, 2018.

The Company’s secured debt consists of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of December 31, 2019 (1)		Principal Balance as of December 31, 2018 (1)		Weighted Average Interest Rate at December 31, 2019 (2)		Maturity Date
Fixed Rate	$	114,777	$	117,464	3.67	%	December 2021 -  August 2051

⁽¹⁾  Principal balance does not include deferred financing costs, net of $1.7 million and $1.8 million as of December 31, 2019 and 2018, respectively.

⁽²⁾ 

Weighted average interest rate includes private mortgage insurance.

Schedule of Maturities for Outstanding Debt

The following is a schedule of maturities for the Company’s outstanding debt as of December 31, 2019 (in thousands):

	Secured Indebtedness			Term Loans			Senior Notes			Total
2020	$	3,568		$	—		$	—		$	3,568
2021	18,853			—			—			18,853
2022	3,198			105,000			—			108,198
2023	3,296			350,000			—			353,296
2024	3,396			596,025			300,000			899,421
Thereafter	82,466			—			950,000			1,032,466
Total Debt	114,777			1,051,025			1,250,000			2,415,802
Premium, net	—			—			7,612			7,612
Deferred financing costs, net	(1,707		)	(10,767		)	(8,839		)	(21,313		)
Total Debt, Net	$	113,070		$	1,040,258		$	1,248,773		$	2,402,101

XML

RECENT REAL ESTATE ACQUISITIONS (Tables)

12 Months Ended

Dec. 31, 2019

Business Combinations [Abstract]

Purchase Price Allocation

The consideration was allocated as follows (in thousands):

	Year Ended December 31,
	2019		2018
Land	$	10,049	$	29,712
Building and improvements	39,434		232,893
Tenant origination and absorption costs intangible assets	1,438		2,046
Tenant relationship intangible assets	215		677
Total consideration	$	51,136	$	265,328

XML

RECENT REAL ESTATE ACQUISITIONS

12 Months Ended

Dec. 31, 2019

Business Combinations [Abstract]

RECENT REAL ESTATE ACQUISITIONS

RECENT REAL ESTATE ACQUISITIONS

During the year ended December 31, 2019, the Company acquired two senior housing communities, two specialty hospitals/other facilities and one Senior Housing - Managed community. During the year ended December 31, 2018, the Company acquired 11 Senior Housing - Managed communities, eight senior housing communities and two skilled nursing/transitional care facilities. The consideration was allocated as follows (in thousands):

	Year Ended December 31,
	2019		2018
Land	$	10,049	$	29,712
Building and improvements	39,434		232,893
Tenant origination and absorption costs intangible assets	1,438		2,046
Tenant relationship intangible assets	215		677
Total consideration	$	51,136	$	265,328

The tenant origination and absorption costs intangible assets and tenant relationship intangible assets acquired in connection with these acquisitions had weighted-average amortization periods as of the respective dates of acquisition of 6 years and 21 years, respectively, for acquisitions completed during the year ended December 31, 2019, and 13 years and 22 years, respectively, for acquisitions completed during the year ended December 31, 2018.

For the year ended December 31, 2019, the Company recognized $0.8 million and $0.4 million of total revenues and net income attributable to common stockholders, respectively, from the properties acquired during the year ended December 31, 2019. For the year ended December 31, 2018, the Company recognized $44.0 million and $14.0 million of total revenues and net income attributable to common stockholders, respectively, from the properties acquired during the year ended December 31, 2018.

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS

12 Months Ended

Dec. 31, 2019

REAL ESTATE LOANS RECEIVABLE [Abstract]

LOANS RECEIVABLE AND OTHER INVESTMENTS

LOANS RECEIVABLE AND OTHER INVESTMENTS

As of December 31, 2019 and 2018, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

											December 31, 2019
Investment	Quantity as of December 31, 2019	Property Type	Principal Balance as of December 31, 2019 (1)		Book Value as of December 31, 2019			Book Value as of December 31, 2018			Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of December 31, 2019
Loans Receivable:
Mortgage	1	Specialty Hospital	$	19,000	$	19,000		$	18,577		10.0	%	10.0	%	01/31/27
Construction	1	Senior Housing	2,468		2,487			4,629			8.0	%	7.8	%	09/30/22
Mezzanine	—	Skilled Nursing	—		—			2,188			N/A		N/A		N/A
Other	16	Multiple	46,059		42,147			45,324			6.8	%	7.0	%	09/23/19- 08/31/28
	18		67,527		63,634			70,718			7.8	%	7.9	%
Loan loss reserve			—		(564		)	(1,258		)
			$	67,527	$	63,070		$	69,460
Other Investments:
Preferred Equity	9	Skilled Nursing / Senior Housing	43,893		44,304			44,262			12.0	%	12.0	%	N/A
Total	27		$	111,420	$	107,374		$	113,722		9.4	%	9.6	%

⁽¹⁾  Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

As of December 31, 2019 and 2018, the Company had four and seven loans receivable investments, respectively, with an aggregate principal balance of $2.3 million and $27.7 million, respectively, that were considered to have deteriorated credit quality. As of December 31, 2019 and 2018, the book value of the outstanding loans with deteriorated credit quality was $0.8 million and $4.2 million, respectively. During the year ended December 31, 2019, three loans with deteriorated credit quality were repaid.

The following table presents changes in the accretable yield for the years ended December 31, 2019 and 2018 (in thousands):

	Year Ended December 31,
	2019			2018
Accretable yield, beginning of period	$	449		$	2,483
Accretion recognized in earnings	(377		)	(2,761		)
Reduction due to payoff	(33		)	—
Net reclassification from nonaccretable difference	—			727
Accretable yield, end of period	$	39		$	449

During the year ended December 31, 2019, the Company recorded a $1.2 million provision for specific loan losses and increased its portfolio-based loan loss reserve by $4,000.

As of December 31, 2019, the Company had no asset-specific loan loss reserve and a $0.6 million portfolio-based loan loss reserve. As of December 31, 2019, the Company did not consider any loans receivable investments to be impaired. As of December 31, 2019, two loans receivable investments with no book value were on nonaccrual status. As of December 31, 2019, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

During the year ended December 31, 2018, the Company recorded a $0.7 million provision for asset-specific loan losses and increased its portfolio-based loan loss reserve by $0.5 million.

As of December 31, 2018, the Company had a $0.7 million asset-specific loan loss reserve, and the portfolio-based loan loss reserve was $0.6 million. As of December 31, 2018, the Company considered one loan receivable investment to be impaired, which had a principal balance of $1.3 million and $1.4 million as of December 31, 2018 and 2017, respectively. As of December 31, 2018, two loans receivable investments with an aggregate book value of $1.3 million were on nonaccrual status. Additionally, as of December 31, 2018, the Company recognized interest income related to one loan receivable investment, with a book value of $4.3 million, that was more than 90 days past due. As of December 31, 2018, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

XML

SUMMARIZED CONSOLIDATING INFORMATION - Consolidating Statement of Income (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Rental and related revenues	$ 452,138	$ 536,605	$ 364,191
Interest and other income	81,540	16,667	17,660
Resident fees and services	128,058	70,137	26,430
Total revenues	661,736	623,409	408,281
Expenses:
Depreciation and amortization	181,549	191,379	113,882
Interest	126,610	147,106	88,440
Operating expenses		49,546	17,860
General and administrative	30,462	36,458	32,401
Merger and acquisition costs	424	636	30,255
Provision for doubtful accounts, straight-line rental income and loan losses	1,238	39,075	17,113
Impairment of real estate	121,819	1,413	1,326
Total expenses	570,574	465,613	301,277
Other income (expense):
Loss on extinguishment of debt	(16,340)	(2,917)	(553)
Other income	2,094	4,480	536
Net gain on sales of real estate	2,300	128,198	52,029
Total other (expense) income	(11,946)	129,761	52,012
Income in subsidiary	0	0	0
Income before loss from unconsolidated joint venture and income tax expense	79,216	287,557	159,016
Loss from unconsolidated joint venture	(6,796)	(5,431)	0
Income tax expense	(3,402)	(3,011)	(651)
Net income	69,018	279,115	158,365
Net income attributable to noncontrolling interests	(22)	(33)	18
Net income attributable to Sabra Health Care REIT, Inc.	68,996	279,082	158,383
Preferred stock dividends	0	(9,768)	(10,242)
Net income attributable to common stockholders	$ 68,996	$ 269,314	$ 148,141
Net income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ 0.37	$ 1.51	$ 1.40
Diluted common share (in dollars per share)	$ 0.37	$ 1.51	$ 1.40
Weighted-average number of common shares outstanding, basic (in shares)	187,172,210	178,305,738	105,621,242
Weighted-average number of common shares outstanding, diluted (in shares)	188,127,092	178,721,744	105,842,434
Elimination
Revenues:
Rental and related revenues	$ (33,000)	$ (17,425)	$ (7,513)
Interest and other income	(5,655)	(399)	(161)
Resident fees and services	0	0	0
Total revenues	(38,655)	(17,824)	(7,674)
Expenses:
Depreciation and amortization	0	0	0
Interest	(5,655)	(399)	(143)
Operating expenses		(17,425)	(7,531)
General and administrative	0	0	0
Merger and acquisition costs	0	0	0
Provision for doubtful accounts, straight-line rental income and loan losses	0	0	0
Impairment of real estate	0	0	0
Total expenses	(38,655)	(17,824)	(7,674)
Other income (expense):
Loss on extinguishment of debt	0	0	0
Other income	0	0	0
Net gain on sales of real estate	0	0	0
Total other (expense) income	0	0	0
Income in subsidiary	(333,970)	(773,612)	(509,045)
Income before loss from unconsolidated joint venture and income tax expense	(333,970)	(773,612)	(509,045)
Loss from unconsolidated joint venture	0	0
Income tax expense	0	0	0
Net income	(333,970)	(773,612)	(509,045)
Net income attributable to noncontrolling interests	0	0	0
Net income attributable to Sabra Health Care REIT, Inc.		(773,612)	(509,045)
Preferred stock dividends		0	0
Net income attributable to common stockholders	(333,970)	(773,612)	(509,045)
Parent Company | Reportable Legal Entities
Revenues:
Rental and related revenues	0	0	0
Interest and other income	255	110	2,673
Resident fees and services	0	0	0
Total revenues	255	110	2,673
Expenses:
Depreciation and amortization	50	887	867
Interest	0	0	0
Operating expenses		0	0
General and administrative	28,486	26,801	24,810
Merger and acquisition costs	423	642	30,208
Provision for doubtful accounts, straight-line rental income and loan losses	4	822	227
Impairment of real estate	0	0	0
Total expenses	28,963	29,152	56,112
Other income (expense):
Loss on extinguishment of debt	0	0	0
Other income	0	1,977	0
Net gain on sales of real estate	0	0	0
Total other (expense) income	0	1,977	0
Income in subsidiary	98,665	307,736	212,432
Income before loss from unconsolidated joint venture and income tax expense	69,957	280,671	158,993
Loss from unconsolidated joint venture	0	0
Income tax expense	(961)	(1,589)	(610)
Net income	68,996	279,082	158,383
Net income attributable to noncontrolling interests	0	0	0
Net income attributable to Sabra Health Care REIT, Inc.		279,082	158,383
Preferred stock dividends		(9,768)	(10,242)
Net income attributable to common stockholders	68,996	269,314	148,141
Operating Partnership | Reportable Legal Entities
Revenues:
Rental and related revenues	0	0	0
Interest and other income	5,655	399	143
Resident fees and services	0	0	0
Total revenues	5,655	399	143
Expenses:
Depreciation and amortization	0	0	0
Interest	118,656	134,096	77,767
Operating expenses		0	0
General and administrative	175	71	65
Merger and acquisition costs	0	0	0
Provision for doubtful accounts, straight-line rental income and loan losses	0	0	0
Impairment of real estate	0	0	0
Total expenses	118,831	134,167	77,832
Other income (expense):
Loss on extinguishment of debt	(16,296)	0	(422)
Other income	(321)	(55)	1,130
Net gain on sales of real estate	0	0	0
Total other (expense) income	(16,617)	(55)	708
Income in subsidiary	228,459	441,560	289,414
Income before loss from unconsolidated joint venture and income tax expense	98,666	307,737	212,433
Loss from unconsolidated joint venture	0	0
Income tax expense	(1)	(1)	(1)
Net income	98,665	307,736	212,432
Net income attributable to noncontrolling interests	0	0	0
Net income attributable to Sabra Health Care REIT, Inc.		307,736	212,432
Preferred stock dividends		0	0
Net income attributable to common stockholders	98,665	307,736	212,432
Sabra Health Care, L.L.C. | Reportable Legal Entities
Revenues:
Rental and related revenues	0	0	0
Interest and other income	0	0	0
Resident fees and services	0	0	0
Total revenues	0	0	0
Expenses:
Depreciation and amortization	0	0	0
Interest	0	0	0
Operating expenses		0	0
General and administrative	0	0	0
Merger and acquisition costs	0	0	0
Provision for doubtful accounts, straight-line rental income and loan losses	0	0	0
Impairment of real estate	0	0	0
Total expenses	0	0	0
Other income (expense):
Loss on extinguishment of debt	0	0	0
Other income	0	0	0
Net gain on sales of real estate	0	0	0
Total other (expense) income	0	0	0
Income in subsidiary	0	0	0
Income before loss from unconsolidated joint venture and income tax expense	0	0	0
Loss from unconsolidated joint venture	0	0
Income tax expense	0	0	0
Net income	0	0	0
Net income attributable to noncontrolling interests	0	0	0
Net income attributable to Sabra Health Care REIT, Inc.		0	0
Preferred stock dividends		0	0
Net income attributable to common stockholders	0	0	0
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Revenues:
Rental and related revenues	485,138	554,030	371,704
Interest and other income	81,285	16,557	15,005
Resident fees and services	128,058	70,137	26,430
Total revenues	694,481	640,724	413,139
Expenses:
Depreciation and amortization	181,499	190,492	113,015
Interest	13,609	13,409	10,816
Operating expenses		66,971	25,391
General and administrative	1,801	9,586	7,526
Merger and acquisition costs	1	(6)	47
Provision for doubtful accounts, straight-line rental income and loan losses	1,234	38,253	16,886
Impairment of real estate	121,819	1,413	1,326
Total expenses	461,435	320,118	175,007
Other income (expense):
Loss on extinguishment of debt	(44)	(2,917)	(131)
Other income	2,415	2,558	(594)
Net gain on sales of real estate	2,300	128,198	52,029
Total other (expense) income	4,671	127,839	51,304
Income in subsidiary	6,846	24,316	7,199
Income before loss from unconsolidated joint venture and income tax expense	244,563	472,761	296,635
Loss from unconsolidated joint venture	(6,796)	(5,431)
Income tax expense	(2,440)	(1,421)	(40)
Net income	235,327	465,909	296,595
Net income attributable to noncontrolling interests	(22)	(33)	18
Net income attributable to Sabra Health Care REIT, Inc.		465,876	296,613
Preferred stock dividends		0	0
Net income attributable to common stockholders	235,305	465,876	296,613
Triple-Net Portfolio
Expenses:
Operating expenses	22,215	0	0
Triple-Net Portfolio | Elimination
Expenses:
Operating expenses	0
Triple-Net Portfolio | Parent Company | Reportable Legal Entities
Expenses:
Operating expenses	0
Triple-Net Portfolio | Operating Partnership | Reportable Legal Entities
Expenses:
Operating expenses	0
Triple-Net Portfolio | Sabra Health Care, L.L.C. | Reportable Legal Entities
Expenses:
Operating expenses	0
Triple-Net Portfolio | Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Expenses:
Operating expenses	22,215
Senior Housing - Managed
Expenses:
Operating expenses	86,257	$ 49,546	$ 17,860
Senior Housing - Managed | Elimination
Expenses:
Operating expenses	(33,000)
Senior Housing - Managed | Parent Company | Reportable Legal Entities
Expenses:
Operating expenses	0
Senior Housing - Managed | Operating Partnership | Reportable Legal Entities
Expenses:
Operating expenses	0
Senior Housing - Managed | Sabra Health Care, L.L.C. | Reportable Legal Entities
Expenses:
Operating expenses	0
Senior Housing - Managed | Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Expenses:
Operating expenses	$ 119,257

XML

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Rollforward of Real Estate and Accumulated Depreciation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Real estate:
Balance at the beginning of the year	$ 6,255,883	$ 6,334,855	$ 2,292,751
Acquisitions	49,483	262,605	4,145,977
Real estate assumed	12,962	0	0
Real estate acquired through loan receivable foreclosure	0	0	19,096
Improvements	25,451	27,697	6,954
Impairment	(143,655)	(1,576)	(2,211)
Sale of real estate	(322,910)	(351,922)	(133,897)
Foreign currency translation	6,918	(12,639)	10,556
Write-off of fully depreciated assets	(3,549)	(3,137)	(4,371)
Balance at the end of the year	5,880,583	6,255,883	6,334,855
Accumulated depreciation:
Balance at the beginning of the year	(402,338)	(340,423)	(282,812)
Depreciation expense	(163,863)	(174,398)	(101,198)
Impairment	22,070	163	885
Sale of real estate	2,092	108,122	38,914
Foreign currency translation	(723)	1,061	(583)
Write-off of fully depreciated assets	3,549	3,137	4,371
Balance at the end of the year	$ (539,213)	$ (402,338)	$ (340,423)

XML

INCOME TAXES - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Income tax benefit	$ (3,402)	$ (3,011)	$ (651)
Acquisitions in Canada | Foreign Tax Authority | Canada Revenue Agency
Business Acquisition [Line Items]
Income tax benefit	500	600	1,300
Valuation allowance	$ 500	$ 700	$ 1,200

XML

INTANGIBLE ASSETS AND LIABILITIES - Summary of Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Lease Intangible Assets:
Gross lease intangible assets	$ 139,424	$ 161,831
Accumulated amortization	(37,915)	(30,734)
Lease intangible assets, net	101,509	131,097
Lease Intangible Liabilities:
Below market leases	99,133	102,098
Accumulated amortization	(29,187)	(18,372)
Lease intangible liabilities, net	69,946	83,726
Above market leases
Lease Intangible Assets:
Gross lease intangible assets	51,040	61,572
Tenant origination and absorption costs
Lease Intangible Assets:
Gross lease intangible assets	65,234	73,323
Tenant relationship
Lease Intangible Assets:
Gross lease intangible assets	$ 23,150	$ 26,936

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($) loan	Dec. 31, 2018 USD ($) loan	Dec. 31, 2017 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Book value of loans	$ 67,527	$ 96,492
Loan loss reserve	$ 564	$ 1,258
Loan receivable investment with recognized interest income | loan		1
Book value of loan receivable investment with recognized interest income		$ 4,300
Nonperforming Financial Instruments
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of impaired loans | loan	0	1
Number of loans on nonaccrual status | loan	2	2
Value of loans on nonaccrual status	$ 0	$ 1,300
Principal balance of impaired loan		1,300	$ 1,400
Portfolio-Based Loan Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Increase (decrease) in provision	4	500
Loan loss reserve	600	600
Specific Loans | Nonperforming Financial Instruments
Accounts, Notes, Loans and Financing Receivable [Line Items]
Provision for loan losses	1,200	700
Loan loss reserve	$ 0	$ 700
Receivables Acquired with Deteriorated Credit Quality
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of impaired loans | loan	4	7
Book value of loans	$ 2,300	$ 27,700
Outstanding principal balance	$ 800	$ 4,200
Number of loans with deteriorated credit quality repaid | loan	3

XML

DEBT - Senior Unsecured Notes (Details) - USD ($)	Dec. 31, 2019	Oct. 07, 2019	May 29, 2019	Dec. 31, 2018	Aug. 17, 2017	Jan. 23, 2014	May 23, 2013
Debt Instrument [Line Items]
Deferred financing costs, net	$ 21,313,000
5.5% senior unsecured notes due 2021 (“2021 Notes”)
Debt Instrument [Line Items]
Principal balance	$ 0			$ 500,000,000
Interest rate	5.50%					5.50%
5.375% senior unsecured notes due 2023 (“2023 Notes”)
Debt Instrument [Line Items]
Principal balance	$ 0			200,000,000
Interest rate	5.375%						5.375%
5.125% senior unsecured notes due 2026 (“2026 Notes”)
Debt Instrument [Line Items]
Principal balance	$ 500,000,000			500,000,000
Interest rate	5.125%				5.125%
5.38% senior unsecured notes due 2027 (“2027 Notes”)
Debt Instrument [Line Items]
Principal balance	$ 100,000,000			100,000,000
Interest rate	5.38%				5.38%
Senior Notes
Debt Instrument [Line Items]
Principal balance	$ 1,250,000,000			1,300,000,000
Premium, net	7,600,000			14,500,000
Deferred financing costs, net	8,839,000			7,100,000
Senior Notes | 4.80% senior unsecured notes due 2024 (“2024 Notes”)
Debt Instrument [Line Items]
Principal balance	$ 300,000,000			0
Interest rate	4.80%		4.80%
Senior Notes | 3.90% senior unsecured notes due 2029 (“2029 Notes”)
Debt Instrument [Line Items]
Principal balance	$ 350,000,000			$ 0
Interest rate	3.90%	3.90%

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Summary of Derivative and Financial Instruments Designated as Hedging Instruments (Details) $ in Thousands	Dec. 31, 2019 USD ($) instrument	Dec. 31, 2018 USD ($)
Asset:
Fair value	$ 7,477	$ 29,344
Liability:
Fair value	626	4,529
Designated as Hedging Instrument
Asset:
Fair value	7,477	29,344
Liability:
Fair value	$ 96,651	96,229
Designated as Hedging Instrument | Interest rate swaps | Cash flow | Accounts receivable, prepaid expenses and other assets, net
Asset:
Count | instrument	10
Fair value	$ 4,239	25,184
Designated as Hedging Instrument | Interest rate swaps | Cash flow | Accounts payable and accrued liabilities
Liability:
Count | instrument	6
Fair value	$ 494	4,529
Designated as Hedging Instrument | Forward Starting Interest Rate Collar | Cash flow | Accounts payable and accrued liabilities
Liability:
Count | instrument	2
Fair value	$ 132	0
Designated as Hedging Instrument | Cross currency interest rate swaps | Net investment | Accounts receivable, prepaid expenses and other assets, net
Asset:
Count | instrument	2
Fair value	$ 3,238	4,160
Designated as Hedging Instrument | CAD term loan | Net investment | Term loans, net
Liability:
Count | instrument	1
Fair value	$ 96,025	$ 91,700

XML

FAIR VALUE DISCLOSURES - Inputs Used for Valuation of Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	$ 59,832	$ 65,797
Preferred equity investments	44,493	43,825
Total | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,328,714	1,270,877
Total | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	105,510	$ 101,820
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Recurring | Significant Other Observable Inputs (Level 2) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,328,714
Recurring | Significant Other Observable Inputs (Level 2) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	59,832
Preferred equity investments	44,493
Recurring | Significant Unobservable Inputs (Level 3) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Recurring | Significant Unobservable Inputs (Level 3) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	105,510
Recurring | Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	59,832
Preferred equity investments	44,493
Recurring | Total | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,328,714
Recurring | Total | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ 105,510

XML

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Details)		9 Months Ended	10 Months Ended	12 Months Ended
	Apr. 01, 2019 facility	Dec. 31, 2019 USD ($) facility	Jan. 31, 2020 facility	Dec. 31, 2019 USD ($) facility	Dec. 31, 2018 USD ($) facility	Dec. 31, 2017 USD ($) facility
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment losses on real estate investments				$ 121,819,000	$ 1,413,000	$ 1,326,000
Skilled Nursing Transitional Care Facilities and Senior Housing Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment losses on real estate investments				$ 26,600,000
Skilled Nursing/Transitional Care
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of real estate properties impaired | facility				6
Senior Housing Communities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of real estate properties impaired | facility				4
Disposed by Sale | Skilled Nursing/Transitional Care
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of real estate properties impaired | facility						1
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Skilled Nursing/Transitional Care
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment losses on real estate investments					$ 900,000
Number of properties with impairment | facility					1
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Senior Housing Communities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties with impairment | facility						1
2019 Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment losses on real estate investments				$ 95,200,000
2019 Dispositions | Senior Care Centers Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of real estate properties impaired | facility				3
2019 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Skilled Nursing Transitional Care Facilities and Senior Housing Facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate consideration received		$ 323,600,000		$ 323,600,000
Carrying value of assets and liabilities received		$ 321,300,000		321,300,000
Gain (loss) on sale				2,300,000
Net income (loss) on discontinued operations				$ 2,200,000	$ 19,100,000	$ 13,000,000.0
2019 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Skilled Nursing/Transitional Care
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | facility		5		39
2019 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Senior Housing Communities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | facility				7
2018 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate consideration received					382,600,000
Carrying value of assets and liabilities received					254,400,000
Gain (loss) on sale					128,200,000
Net income (loss) on discontinued operations					$ 23,600,000	47,100,000
2018 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Skilled Nursing/Transitional Care
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | facility					51
2018 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Senior Housing Communities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment losses on real estate investments					$ 500,000
Number of properties sold | facility					6
Number of properties with impairment | facility					1
2018 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Senior Housing - Managed
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | facility					1
2017 Dispositions | Disposed by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate consideration received						150,200,000
Carrying value of assets and liabilities received						98,200,000
Gain (loss) on sale						$ 52,000,000.0
2017 Dispositions | Disposed by Sale | Skilled Nursing/Transitional Care
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | facility						31
2017 Dispositions | Disposed by Sale | Senior Nursing Facilities and Land
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income (loss) on discontinued operations						$ 12,600,000
Senior Care Centers | 2019 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | facility	28
Senior Care Centers | 2019 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | facility			2

XML

RECENT REAL ESTATE ACQUISITIONS - Recent Real Estate Acquisitions Purchase Price Allocation (Details) - Recent Real Estate Acquisitions - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Land	$ 10,049	$ 29,712
Building and improvements	39,434	232,893
Total consideration	51,136	265,328
Tenant origination and absorption costs intangible assets
Business Acquisition [Line Items]
Lease intangible assets, net	1,438	2,046
Tenant relationship intangible assets
Business Acquisition [Line Items]
Lease intangible assets, net	$ 215	$ 677

XML

SUMMARIZED CONSOLIDATING INFORMATION (Tables)

12 Months Ended

Dec. 31, 2019

Summarized Condensed Consolidating Information [Abstract]

Consolidating Balance Sheet

CONSOLIDATING BALANCE SHEET

December 31, 2019

(in thousands, except share and per share amounts)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)		Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	384		$	—	$	—	$	5,340,986	$	—		$	5,341,370
Loans receivable and other investments, net	(564		)	—		—		107,938		—			107,374
Investment in unconsolidated joint venture	—			—		—		319,460		—			319,460
Cash and cash equivalents	29,369			—		—		9,728		—			39,097
Restricted cash	—			—		—		10,046		—			10,046
Lease intangible assets, net	—			—		—		101,509		—			101,509
Accounts receivable, prepaid expenses and other assets, net	4,753			18,655		—		137,247		(10,212		)	150,443
Intercompany	2,126,198			1,728,096		—		—		(3,854,294		)	—
Investment in subsidiaries	1,359,702			1,823,897		—		35,150		(3,218,749		)	—
Total assets	$	3,519,842		$	3,570,648	$	—	$	6,062,064	$	(7,083,255	)	$	6,069,299
Liabilities
Secured debt, net	$	—		$	—	$	—	$	113,070	$	—		$	113,070
Revolving credit facility	—			—		—		—		—			—
Term loans, net	—			945,393		—		94,865		—			1,040,258
Senior unsecured notes, net	—			1,248,773		—		—		—			1,248,773
Accounts payable and accrued liabilities	31,382			16,780		—		70,842		(10,212		)	108,792
Lease intangible liabilities, net	—			—		—		69,946		—			69,946
Intercompany	—			—		—		3,854,294		(3,854,294		)	—
Total liabilities	31,382			2,210,946		—		4,203,017		(3,864,506		)	2,580,839
Total equity	3,488,460			1,359,702		—		1,859,047		(3,218,749		)	3,488,460
Total liabilities and equity	$	3,519,842		$	3,570,648	$	—	$	6,062,064	$	(7,083,255	)	$	6,069,299

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING BALANCE SHEET

December 31, 2018

(in thousands, except share and per share amounts)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)		Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	317		$	—	$	—	$	5,853,228	$	—		$	5,853,545
Loans receivable and other investments, net	(560		)	—		—		114,282		—			113,722
Investment in unconsolidated joint venture	—			—		—		340,120		—			340,120
Cash and cash equivalents	40,835			—		—		9,395		—			50,230
Restricted cash	—			—		—		9,428		—			9,428
Lease intangible assets, net	—			—		—		131,097		—			131,097
Accounts receivable, prepaid expenses and other assets, net	798			37,075		—		140,307		(11,019		)	167,161
Intercompany	1,972,059			2,646,669		—		—		(4,618,728		)	—
Investment in subsidiaries	1,258,715			1,629,795		—		33,083		(2,921,593		)	—
Total assets	$	3,272,164		$	4,313,539	$	—	$	6,630,940	$	(7,551,340	)	$	6,665,303
Liabilities
Secured debt, net	$	—		$	—	$	—	$	115,679	$	—		$	115,679
Revolving credit facility	—			624,000		—		—		—			624,000
Term loans, net	—			1,094,177		—		90,753		—			1,184,930
Senior unsecured notes, net	—			1,307,394		—		—		—			1,307,394
Accounts payable and accrued liabilities	21,750			29,253		—		54,843		(11,019		)	94,827
Lease intangible liabilities, net	—			—		—		83,726		—			83,726
Intercompany	—			—		—		4,618,728		(4,618,728		)	—
Total liabilities	21,750			3,054,824		—		4,963,729		(4,629,747		)	3,410,556
Total Sabra Health Care REIT, Inc. stockholders’ equity	3,250,414			1,258,715		—		1,662,878		(2,921,593		)	3,250,414
Noncontrolling interests	—			—		—		4,333		—			4,333
Total equity	3,250,414			1,258,715		—		1,667,211		(2,921,593		)	3,254,747
Total liabilities and equity	$	3,272,164		$	4,313,539	$	—	$	6,630,940	$	(7,551,340	)	$	6,665,303

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾ 

None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

Consolidating Statement of Income

CONSOLIDATING STATEMENT OF INCOME

For the Year Ended December 31, 2019

(in thousands, except share and per share amounts)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Revenues:
Rental and related revenues	$	—		$	—		$	—	$	485,138		$	(33,000	)	$	452,138
Interest and other income	255			5,655			—		81,285			(5,655		)	81,540
Resident fees and services	—			—			—		128,058			—			128,058
Total revenues	255			5,655			—		694,481			(38,655		)	661,736
Expenses:
Depreciation and amortization	50			—			—		181,499			—			181,549
Interest	—			118,656			—		13,609			(5,655		)	126,610
Triple-net portfolio operating expenses	—			—			—		22,215			—			22,215
Senior housing - managed portfolio operating expenses	—			—			—		119,257			(33,000		)	86,257
General and administrative	28,486			175			—		1,801			—			30,462
Merger and acquisition costs	423			—			—		1			—			424
Provision for doubtful accounts, straight-line rental income and loan losses	4			—			—		1,234			—			1,238
Impairment of real estate	—			—			—		121,819			—			121,819
Total expenses	28,963			118,831			—		461,435			(38,655		)	570,574
Other income (expense):
Loss on extinguishment of debt	—			(16,296		)	—		(44		)	—			(16,340		)
Other (expense) income	—			(321		)	—		2,415			—			2,094
Net gain on sales of real estate	—			—			—		2,300			—			2,300
Total other (expense) income	—			(16,617		)	—		4,671			—			(11,946		)
Income in subsidiary	98,665			228,459			—		6,846			(333,970		)	—
Income before loss from unconsolidated joint venture and income tax expense	69,957			98,666			—		244,563			(333,970		)	79,216
Loss from unconsolidated joint venture	—			—			—		(6,796		)	—			(6,796		)
Income tax expense	(961		)	(1		)	—		(2,440		)	—			(3,402		)
Net income	68,996			98,665			—		235,327			(333,970		)	69,018
Net income attributable to noncontrolling interests	—			—			—		(22		)	—			(22		)
Net income attributable to common stockholders	$	68,996		$	98,665		$	—	$	235,305		$	(333,970	)	$	68,996
Net income attributable to common stockholders, per:
Basic common share															$	0.37
Diluted common share															$	0.37
Weighted-average number of common shares outstanding, basic															187,172,210
Weighted-average number of common shares outstanding, diluted															188,127,092

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF INCOME

For the Year Ended December 31, 2018

(in thousands, except share and per share amounts)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Revenues:
Rental and related revenues	$	—		$	—		$	—	$	554,030		$	(17,425	)	$	536,605
Interest and other income	110			399			—		16,557			(399		)	16,667
Resident fees and services	—			—			—		70,137			—			70,137
Total revenues	110			399			—		640,724			(17,824		)	623,409
Expenses:
Depreciation and amortization	887			—			—		190,492			—			191,379
Interest	—			134,096			—		13,409			(399		)	147,106
Senior housing - managed portfolio operating expenses	—			—			—		66,971			(17,425		)	49,546
General and administrative	26,801			71			—		9,586			—			36,458
Merger and acquisition costs	642			—			—		(6		)	—			636
Provision for doubtful accounts, straight-line rental income and loan losses	822			—			—		38,253			—			39,075
Impairment of real estate	—			—			—		1,413			—			1,413
Total expenses	29,152			134,167			—		320,118			(17,824		)	465,613
Other income (expense):
Loss on extinguishment of debt	—			—			—		(2,917		)	—			(2,917		)
Other income (expense)	1,977			(55		)	—		2,558			—			4,480
Net gain on sales of real estate	—			—			—		128,198			—			128,198
Total other income (expense)	1,977			(55		)	—		127,839			—			129,761
Income in subsidiary	307,736			441,560			—		24,316			(773,612		)	—
Income before loss from unconsolidated joint venture and income tax expense	280,671			307,737			—		472,761			(773,612		)	287,557
Loss from unconsolidated joint venture	—			—			—		(5,431		)	—			(5,431		)
Income tax expense	(1,589		)	(1		)	—		(1,421		)	—			(3,011		)
Net income	279,082			307,736			—		465,909			(773,612		)	279,115
Net loss attributable to noncontrolling interests	—			—			—		(33		)	—			(33		)
Net income attributable to Sabra Health Care REIT, Inc.	279,082			307,736			—		465,876			(773,612		)	279,082
Preferred stock dividends	(9,768		)	—			—		—			—			(9,768		)
Net income attributable to common stockholders	$	269,314		$	307,736		$	—	$	465,876		$	(773,612	)	$	269,314
Net income attributable to common stockholders, per:
Basic common share															$	1.51
Diluted common share															$	1.51
Weighted-average number of common shares outstanding, basic															178,305,738
Weighted-average number of common shares outstanding, diluted															178,721,744

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF INCOME

For the Year Ended December 31, 2017

(in thousands, except share and per share amounts)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Revenues:
Rental and related revenues	$	—		$	—		$	—	$	371,704		$	(7,513	)	$	364,191
Interest and other income	2,673			143			—		15,005			(161		)	17,660
Resident fee and services	—			—			—		26,430			—			26,430
Total revenues	2,673			143			—		413,139			(7,674		)	408,281
Expenses:
Depreciation and amortization	867			—			—		113,015			—			113,882
Interest	—			77,767			—		10,816			(143		)	88,440
Senior housing - managed portfolio operating expenses	—			—			—		25,391			(7,531		)	17,860
General and administrative	24,810			65			—		7,526			—			32,401
Merger and acquisition costs	30,208			—			—		47			—			30,255
Provision for doubtful accounts, straight-line rental income and loan losses	227			—			—		16,886			—			17,113
Impairment of real estate	—			—			—		1,326			—			1,326
Total expenses	56,112			77,832			—		175,007			(7,674		)	301,277
Other income (expense):
Loss on extinguishment of debt	—			(422		)	—		(131		)	—			(553		)
Other income (expense)	—			1,130			—		(594		)	—			536
Net gain on sales of real estate	—			—			—		52,029			—			52,029
Total other income	—			708			—		51,304			—			52,012
Income in subsidiary	212,432			289,414			—		7,199			(509,045		)	—
Income before income tax expense	158,993			212,433			—		296,635			(509,045		)	159,016
Income tax expense	(610		)	(1		)	—		(40		)	—			(651		)
Net income	158,383			212,432			—		296,595			(509,045		)	158,365
Net loss attributable to noncontrolling interests	—			—			—		18			—			18
Net income attributable to Sabra Health Care REIT, Inc.	158,383			212,432			—		296,613			(509,045		)	158,383
Preferred stock dividends	(10,242		)	—			—		—			—			(10,242		)
Net income attributable to common stockholders	$	148,141		$	212,432		$	—	$	296,613		$	(509,045	)	$	148,141
Net income attributable to common stockholders, per:
Basic common share															$	1.40
Diluted common share															$	1.40
Weighted-average number of common shares outstanding, basic															105,621,242
Weighted-average number of common shares outstanding, diluted															105,842,434

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾ 

None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

Consolidating Statement of Comprehensive Income

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Year Ended December 31, 2019

(in thousands)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)		Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net income	$	68,996	$	98,665		$	—	$	235,327		$	(333,970	)	$	69,018
Other comprehensive (loss) income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(1,276		)	—		1,955			—			679
Unrealized (loss) gain on cash flow hedge	—		(25,416		)	—		48			—			(25,368		)
Total other comprehensive (loss) income	—		(26,692		)	—		2,003			—			(24,689		)
Comprehensive income	68,996		71,973			—		237,330			(333,970		)	44,329
Comprehensive income attributable to noncontrolling interests	—		—			—		(22		)	—			(22		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	68,996	$	71,973		$	—	$	237,308		$	(333,970	)	$	44,307

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Year Ended December 31, 2018

(in thousands)

					Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)		Operating Partnership(2)		Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net income	$	279,082	$	307,736	$	—	$	465,909		$	(773,612	)	$	279,115
Other comprehensive income (loss):
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	—		4,329		—		(3,609		)	—			720
Unrealized gain on cash flow hedge	—		244		—		48			—			292
Total other comprehensive income (loss)	—		4,573		—		(3,561		)	—			1,012
Comprehensive income	279,082		312,309		—		462,348			(773,612		)	280,127
Comprehensive income attributable to noncontrolling interests	—		—		—		(33		)	—			(33		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	279,082	$	312,309	$	—	$	462,315		$	(773,612	)	$	280,094

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Year Ended December 31, 2017

(in thousands)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)		Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net income	$	158,383	$	212,432		$	—	$	296,595		$	(509,045	)	$	158,365
Other comprehensive income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(2,821		)	—		2,975			—			154
Unrealized gain (loss) on cash flow hedges	—		13,078			—		(145		)	—			12,933
Total other comprehensive income	—		10,257			—		2,830			—			13,087
Comprehensive income	158,383		222,689			—		299,425			(509,045		)	171,452
Comprehensive loss attributable to noncontrolling interests	—		—			—		18			—			18
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	158,383	$	222,689		$	—	$	299,443		$	(509,045	)	$	171,470

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾ 

None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

Consolidating Statement of Cash Flows

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Year Ended December 31, 2019

(in thousands)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net cash provided by operating activities	$	359,681		$	—		$	—	$	12,794		$	—		$	372,475
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(51,136		)	—			(51,136		)
Origination and fundings of loans receivable	—			—			—		(13,065		)	—			(13,065		)
Additions to real estate	(115		)	—			—		(25,336		)	—			(25,451		)
Repayment of loans receivable	—			—			—		18,367			—			18,367
Repayment of preferred equity investments	—			—			—		5,079			—			5,079
Net proceeds from sales of real estate	—			—			—		329,050			—			329,050
Distribution from subsidiaries	5,248			5,248			—		—			(10,496		)	—
Intercompany financing	(590,173		)	266,148			—		—			324,025			—
Net cash (used in) provided by investing activities	(585,040		)	271,396			—		262,959			313,529			262,844
Cash flows from financing activities:
Net repayments of revolving credit facility	—			(624,000		)	—		—			—			(624,000		)
Proceeds from issuance of senior unsecured notes	—			638,779			—		—			—			638,779
Principal payments on senior unsecured notes	—			(700,000		)	—		—			—			(700,000		)
Principal payments on term loans	—			(145,000		)	—		—			—			(145,000		)
Principal payments on secured debt	—			—			—		(3,436		)	—			(3,436		)
Payments of deferred financing costs	—			(15,598		)	—		—			—			(15,598		)
Payments related to extinguishment of debt	—			(10,502		)	—		—			—			(10,502		)
Distributions to noncontrolling interests	—			—			—		(316		)	—			(316		)
Issuance of common stock, net	549,328			—			—		—			—			549,328
Dividends paid on common stock	(335,435		)	—			—		—			—			(335,435		)
Distribution to parent	—			(5,248		)	—		(5,248		)	10,496			—
Intercompany financing	—			590,173			—		(266,148		)	(324,025		)	—
Net cash provided by (used in) financing activities	213,893			(271,396		)	—		(275,148		)	(313,529		)	(646,180		)
Net (decrease) increase in cash, cash equivalents and restricted cash	(11,466		)	—			—		605			—			(10,861		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		346			—			346
Cash, cash equivalents and restricted cash, beginning of period	40,835			—			—		18,823			—			59,658
Cash, cash equivalents and restricted cash, end of period	$	29,369		$	—		$	—	$	19,774		$	—		$	49,143

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Year Ended December 31, 2018

(in thousands)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net cash provided by operating activities	$	312,485		$	—		$	—	$	48,101		$	—		$	360,586
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(261,511		)	—			(261,511		)
Origination and fundings of loans receivable	—			—			—		(50,731		)	—			(50,731		)
Origination and fundings of preferred equity investments	—			—			—		(5,313		)	—			(5,313		)
Additions to real estate	(40		)	—			—		(27,657		)	—			(27,697		)
Repayment of loans receivable	—			—			—		51,789			—			51,789
Repayment of preferred equity investments	—			—			—		6,870			—			6,870
Investment in unconsolidated JV	—			—			—		(354,461		)	—			(354,461		)
Net proceeds from sales of real estate	—			—			—		382,560			—			382,560
Distribution from subsidiaries	5,457			5,457			—		—			(10,914		)	—
Intercompany financing	(319,268		)	(299,873		)	—		—			619,141			—
Net cash used in investing activities	(313,851		)	(294,416		)	—		(258,454		)	608,227			(258,494		)
Cash flows from financing activities:
Net repayments of revolving credit facility	—			(17,000		)	—		—			—			(17,000		)
Principal payments on secured debt	—			—			—		(140,338		)	—			(140,338		)
Payments of deferred financing costs	—			(352		)	—		—			—			(352		)
Payments related to extinguishment of debt	—			(2,043		)	—		—			—			(2,043		)
Distributions to noncontrolling interests	—			—			—		(142		)	—			(142		)
Preferred stock redemption	(143,750		)	—			—		—			—			(143,750		)
Issuance of common stock, net	(499		)	—			—		—			—			(499		)
Dividends paid on common and preferred stock	(325,220		)	—			—		—			—			(325,220		)
Distribution to parent	—			(5,457		)	—		(5,457		)	10,914			—
Intercompany financing	—			319,268			—		299,873			(619,141		)	—
Net cash (used in) provided by financing activities	(469,469		)	294,416			—		153,936			(608,227		)	(629,344		)
Net decrease in cash, cash equivalents and restricted cash	(470,835		)	—			—		(56,417		)	—			(527,252		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		(539		)	—			(539		)
Cash, cash equivalents and restricted cash, beginning of period	511,670			—			—		75,779			—			587,449
Cash, cash equivalents and restricted cash, end of period	$	40,835		$	—		$	—	$	18,823		$	—		$	59,658

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Year Ended December 31, 2017

(in thousands)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net cash provided by operating activities	$	59,640		$	—		$	—	$	76,149		$	—		$	135,789
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(419,905		)	—			(419,905		)
Cash received in CCP Merger	77,859			—			—		—			—			77,859
Origination and fundings of loans receivable	—			—			—		(17,239		)	—			(17,239		)
Origination and fundings of preferred equity investments	—			—			—		(2,749		)	—			(2,749		)
Additions to real estate	(181		)	—			—		(6,773		)	—			(6,954		)
Repayment of loans receivable	—			—			—		32,430			—			32,430
Repayment of preferred equity investments	—			—			—		3,755			—			3,755
Net proceeds from the sales of real estate	—			—			—		150,243			—			150,243
Distribution from subsidiaries	2,474			2,474			—		—			(4,948		)	—
Intercompany financing	168,999			(249,664		)	—		—			80,665			—
Net cash provided by (used in) investing activities	249,151			(247,190		)	—		(260,238		)	75,717			(182,560		)
Cash flows from financing activities:
Net borrowings from revolving credit facility	—			253,000			—		—			—			253,000
Proceeds from term loans	—			181,000			—		—			—			181,000
Principal payments on secured debt	—			—			—		(4,145		)	—			(4,145		)
Payments of deferred financing costs	—			(15,337		)	—		—			—			(15,337		)
Payment of contingent consideration	—			—			—		(382		)	—			(382		)
Distributions to noncontrolling interests	—			—			—		(30		)	—			(30		)
Issuance of common stock, net	366,800			—			—		—			—			366,800
Dividends paid on common and preferred stock	(182,089		)	—			—		—			—			(182,089		)
Distribution to parent	—			(2,474		)	—		(2,474		)	4,948			—
Intercompany financing	—			(168,999		)	—		249,664			(80,665		)	—
Net cash provided by financing activities	184,711			247,190			—		242,633			(75,717		)	598,817
Net increase in cash, cash equivalents and restricted cash	493,502			—			—		58,544			—			552,046
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		738			—			738
Cash, cash equivalents and restricted cash, beginning of period	18,168			—			—		16,497			—			34,665
Cash, cash equivalents and restricted cash, end of period	$	511,670		$	—		$	—	$	75,779		$	—		$	587,449

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾ 

None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

XML

EQUITY

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

EQUITY

EQUITY

Preferred Stock

The Company redeemed all 5,750,000 shares of its 7.125% Series A Cumulative Redeemable Preferred Stock (the “Series A Preferred Stock”) on June 1, 2018 (the “Redemption Date”) for $25.00 per share, plus accrued and unpaid dividends to, but

not including, the Redemption Date, without interest, in the amount of $0.4453125 per share of Series A Preferred Stock, for a total redemption price per share of Series A Preferred Stock equal to $25.4453125. As a result of the redemption, the Company incurred a charge of $5.5 million related to the original issuance costs of the Series A Preferred Stock. The charge is presented as an additional preferred stock dividend in the Company’s consolidated statements of income for the year ended December 31, 2018.

Common Stock

On February 25, 2019, the Company established an at-the-market equity offering program (the “Prior ATM Program”) to sell shares of its common stock having an aggregate gross sales price of up to $500.0 million from time to time through a consortium of banks acting as sales agents. On December 5, 2019, the Prior ATM Program automatically terminated in accordance with its terms upon the issuance and sale of the maximum aggregate amount of the shares subject to the Prior ATM Program.

During the year ended December 31, 2019, the Company sold 23.9 million shares under the Prior ATM Program at an average price of $20.92 per share, generating gross proceeds of $500.0 million, before $7.5 million of commissions.

On December 11, 2019, the Company established a new ATM program (the “New ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $400.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement.

During December 2019, the Company sold 2.9 million shares under the New ATM Program at an average price of $20.86 per share, generating gross proceeds of $60.0 million, before $0.2 million of commissions. As of December 31, 2019, the Company had $340.0 million available under the New ATM Program.

Other Common Stock Issuances

During each of the years ended December 31, 2019 and 2018, the Company issued 0.1 million shares of common stock as a result of restricted stock unit vestings.

Upon any payment of shares to employees as a result of restricted stock unit vestings, the employees’ related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the years ended December 31, 2019, 2018 and 2017, the Company incurred $1.5 million, $0.4 million and $3.1 million, respectively, in tax withholding obligations on behalf of its employees that were satisfied through a reduction in the number of shares delivered to those participants.

Accumulated Other Comprehensive (Loss) Income

The following is a summary of the Company’s accumulated other comprehensive (loss) income (in thousands):

	Year Ended December 31,
	2019			2018
Foreign currency translation gain (loss)	$	(1,516	)	$	(2,193	)
Unrealized (loss) gain on cash flow hedges	(10,872		)	14,494
Total accumulated other comprehensive (loss) income	$	(12,388	)	$	12,301

XML

SUMMARIZED CONSOLIDATING INFORMATION

12 Months Ended

Dec. 31, 2019

Summarized Condensed Consolidating Information [Abstract]

SUMMARIZED CONSOLIDATING INFORMATION

SUMMARIZED CONSOLIDATING INFORMATION

The 2024 Notes are issued by the Operating Partnership and fully and unconditionally guaranteed, jointly and severally, by the Company and one of the Company’s non-operating subsidiaries, subject to release under certain customary circumstances as described below. In connection with the Operating Partnership’s assumption of the 2026 Notes as a result of the CCP Merger, the Company has fully and unconditionally guaranteed the 2026 Notes, subject to release under certain circumstances as described below. The 2029 Notes are issued by the Operating Partnership and guaranteed, fully and unconditionally, by the Company.

These guarantees are subordinated to all existing and future senior debt and senior guarantees of the applicable guarantors and are unsecured. The Company conducts all of its business through and derives virtually all of its income from its subsidiaries. Therefore, the Company’s ability to make required payments with respect to its indebtedness (including the Senior Notes) and other obligations depends on the financial results and condition of its subsidiaries and its ability to receive funds from its subsidiaries.

A guarantor will be automatically and unconditionally released from its obligations under the guarantee with respect to the 2024 Notes in the event of:

• Any sale of the subsidiary guarantor or of all or substantially all of its assets;

• A merger or consolidation of the subsidiary guarantor with the Operating Partnership or the Company, provided that the surviving entity remains a guarantor;

• The requirements for legal defeasance or covenant defeasance or to discharge the indenture governing the 2024 Notes have been satisfied;

• A liquidation or dissolution, to the extent permitted under the indenture governing the 2024 Notes, of the subsidiary guarantor;

• The release or discharge of the guaranty that resulted in the creation of the subsidiary guaranty, except a discharge or release by or as a result of payment under such guaranty; or

• If the subsidiary guarantor is not a guarantor or is not otherwise liable in respect of any obligations under any credit facility (as defined in the indenture governing the 2024 Notes) of the Company or any of its subsidiaries.

The Company will be automatically and unconditionally released from its obligations under the guarantee with respect to the 2026 Notes in the event of:

• A liquidation or dissolution, to the extent permitted under the indenture governing the 2026 Notes;

• A merger or consolidation, provided that the surviving entity remains a guarantor; or

• The requirements for legal defeasance or covenant defeasance or to discharge the indenture governing the 2026 Notes have been satisfied.

Pursuant to Rule 3-10 of Regulation S-X, the following summarized consolidating information is provided for the Company (the “Parent Company”), the Operating Partnership, Sabra Health Care, L.L.C. (the guarantor subsidiary of the 2024 Notes) and the Company’s non-guarantor subsidiaries with respect to the 2024 Notes. This summarized financial information has been prepared from the books and records maintained by the Company, the Operating Partnership, Sabra Health Care, L.L.C. and the non-guarantor subsidiaries. The summarized financial information may not necessarily be indicative of the results of operations or financial position had the Operating Partnership, Sabra Health Care, L.L.C. or non-guarantor subsidiaries operated as independent entities. Sabra’s investments in its consolidated subsidiaries are presented based upon Sabra’s proportionate share of each subsidiary’s net assets. Intercompany activities between subsidiaries and the Parent Company are presented within operating activities on the consolidating statement of cash flows.

Consolidating financial statements for the Company and its subsidiaries, including the Parent Company only, the Operating Partnership only, Sabra Health Care, L.L.C. only and the combined non-guarantor subsidiaries, are as follows:

CONSOLIDATING BALANCE SHEET

December 31, 2019

(in thousands, except share and per share amounts)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)		Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	384		$	—	$	—	$	5,340,986	$	—		$	5,341,370
Loans receivable and other investments, net	(564		)	—		—		107,938		—			107,374
Investment in unconsolidated joint venture	—			—		—		319,460		—			319,460
Cash and cash equivalents	29,369			—		—		9,728		—			39,097
Restricted cash	—			—		—		10,046		—			10,046
Lease intangible assets, net	—			—		—		101,509		—			101,509
Accounts receivable, prepaid expenses and other assets, net	4,753			18,655		—		137,247		(10,212		)	150,443
Intercompany	2,126,198			1,728,096		—		—		(3,854,294		)	—
Investment in subsidiaries	1,359,702			1,823,897		—		35,150		(3,218,749		)	—
Total assets	$	3,519,842		$	3,570,648	$	—	$	6,062,064	$	(7,083,255	)	$	6,069,299
Liabilities
Secured debt, net	$	—		$	—	$	—	$	113,070	$	—		$	113,070
Revolving credit facility	—			—		—		—		—			—
Term loans, net	—			945,393		—		94,865		—			1,040,258
Senior unsecured notes, net	—			1,248,773		—		—		—			1,248,773
Accounts payable and accrued liabilities	31,382			16,780		—		70,842		(10,212		)	108,792
Lease intangible liabilities, net	—			—		—		69,946		—			69,946
Intercompany	—			—		—		3,854,294		(3,854,294		)	—
Total liabilities	31,382			2,210,946		—		4,203,017		(3,864,506		)	2,580,839
Total equity	3,488,460			1,359,702		—		1,859,047		(3,218,749		)	3,488,460
Total liabilities and equity	$	3,519,842		$	3,570,648	$	—	$	6,062,064	$	(7,083,255	)	$	6,069,299

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING BALANCE SHEET

December 31, 2018

(in thousands, except share and per share amounts)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)		Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	317		$	—	$	—	$	5,853,228	$	—		$	5,853,545
Loans receivable and other investments, net	(560		)	—		—		114,282		—			113,722
Investment in unconsolidated joint venture	—			—		—		340,120		—			340,120
Cash and cash equivalents	40,835			—		—		9,395		—			50,230
Restricted cash	—			—		—		9,428		—			9,428
Lease intangible assets, net	—			—		—		131,097		—			131,097
Accounts receivable, prepaid expenses and other assets, net	798			37,075		—		140,307		(11,019		)	167,161
Intercompany	1,972,059			2,646,669		—		—		(4,618,728		)	—
Investment in subsidiaries	1,258,715			1,629,795		—		33,083		(2,921,593		)	—
Total assets	$	3,272,164		$	4,313,539	$	—	$	6,630,940	$	(7,551,340	)	$	6,665,303
Liabilities
Secured debt, net	$	—		$	—	$	—	$	115,679	$	—		$	115,679
Revolving credit facility	—			624,000		—		—		—			624,000
Term loans, net	—			1,094,177		—		90,753		—			1,184,930
Senior unsecured notes, net	—			1,307,394		—		—		—			1,307,394
Accounts payable and accrued liabilities	21,750			29,253		—		54,843		(11,019		)	94,827
Lease intangible liabilities, net	—			—		—		83,726		—			83,726
Intercompany	—			—		—		4,618,728		(4,618,728		)	—
Total liabilities	21,750			3,054,824		—		4,963,729		(4,629,747		)	3,410,556
Total Sabra Health Care REIT, Inc. stockholders’ equity	3,250,414			1,258,715		—		1,662,878		(2,921,593		)	3,250,414
Noncontrolling interests	—			—		—		4,333		—			4,333
Total equity	3,250,414			1,258,715		—		1,667,211		(2,921,593		)	3,254,747
Total liabilities and equity	$	3,272,164		$	4,313,539	$	—	$	6,630,940	$	(7,551,340	)	$	6,665,303

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF INCOME

For the Year Ended December 31, 2019

(in thousands, except share and per share amounts)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Revenues:
Rental and related revenues	$	—		$	—		$	—	$	485,138		$	(33,000	)	$	452,138
Interest and other income	255			5,655			—		81,285			(5,655		)	81,540
Resident fees and services	—			—			—		128,058			—			128,058
Total revenues	255			5,655			—		694,481			(38,655		)	661,736
Expenses:
Depreciation and amortization	50			—			—		181,499			—			181,549
Interest	—			118,656			—		13,609			(5,655		)	126,610
Triple-net portfolio operating expenses	—			—			—		22,215			—			22,215
Senior housing - managed portfolio operating expenses	—			—			—		119,257			(33,000		)	86,257
General and administrative	28,486			175			—		1,801			—			30,462
Merger and acquisition costs	423			—			—		1			—			424
Provision for doubtful accounts, straight-line rental income and loan losses	4			—			—		1,234			—			1,238
Impairment of real estate	—			—			—		121,819			—			121,819
Total expenses	28,963			118,831			—		461,435			(38,655		)	570,574
Other income (expense):
Loss on extinguishment of debt	—			(16,296		)	—		(44		)	—			(16,340		)
Other (expense) income	—			(321		)	—		2,415			—			2,094
Net gain on sales of real estate	—			—			—		2,300			—			2,300
Total other (expense) income	—			(16,617		)	—		4,671			—			(11,946		)
Income in subsidiary	98,665			228,459			—		6,846			(333,970		)	—
Income before loss from unconsolidated joint venture and income tax expense	69,957			98,666			—		244,563			(333,970		)	79,216
Loss from unconsolidated joint venture	—			—			—		(6,796		)	—			(6,796		)
Income tax expense	(961		)	(1		)	—		(2,440		)	—			(3,402		)
Net income	68,996			98,665			—		235,327			(333,970		)	69,018
Net income attributable to noncontrolling interests	—			—			—		(22		)	—			(22		)
Net income attributable to common stockholders	$	68,996		$	98,665		$	—	$	235,305		$	(333,970	)	$	68,996
Net income attributable to common stockholders, per:
Basic common share															$	0.37
Diluted common share															$	0.37
Weighted-average number of common shares outstanding, basic															187,172,210
Weighted-average number of common shares outstanding, diluted															188,127,092

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF INCOME

For the Year Ended December 31, 2018

(in thousands, except share and per share amounts)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Revenues:
Rental and related revenues	$	—		$	—		$	—	$	554,030		$	(17,425	)	$	536,605
Interest and other income	110			399			—		16,557			(399		)	16,667
Resident fees and services	—			—			—		70,137			—			70,137
Total revenues	110			399			—		640,724			(17,824		)	623,409
Expenses:
Depreciation and amortization	887			—			—		190,492			—			191,379
Interest	—			134,096			—		13,409			(399		)	147,106
Senior housing - managed portfolio operating expenses	—			—			—		66,971			(17,425		)	49,546
General and administrative	26,801			71			—		9,586			—			36,458
Merger and acquisition costs	642			—			—		(6		)	—			636
Provision for doubtful accounts, straight-line rental income and loan losses	822			—			—		38,253			—			39,075
Impairment of real estate	—			—			—		1,413			—			1,413
Total expenses	29,152			134,167			—		320,118			(17,824		)	465,613
Other income (expense):
Loss on extinguishment of debt	—			—			—		(2,917		)	—			(2,917		)
Other income (expense)	1,977			(55		)	—		2,558			—			4,480
Net gain on sales of real estate	—			—			—		128,198			—			128,198
Total other income (expense)	1,977			(55		)	—		127,839			—			129,761
Income in subsidiary	307,736			441,560			—		24,316			(773,612		)	—
Income before loss from unconsolidated joint venture and income tax expense	280,671			307,737			—		472,761			(773,612		)	287,557
Loss from unconsolidated joint venture	—			—			—		(5,431		)	—			(5,431		)
Income tax expense	(1,589		)	(1		)	—		(1,421		)	—			(3,011		)
Net income	279,082			307,736			—		465,909			(773,612		)	279,115
Net loss attributable to noncontrolling interests	—			—			—		(33		)	—			(33		)
Net income attributable to Sabra Health Care REIT, Inc.	279,082			307,736			—		465,876			(773,612		)	279,082
Preferred stock dividends	(9,768		)	—			—		—			—			(9,768		)
Net income attributable to common stockholders	$	269,314		$	307,736		$	—	$	465,876		$	(773,612	)	$	269,314
Net income attributable to common stockholders, per:
Basic common share															$	1.51
Diluted common share															$	1.51
Weighted-average number of common shares outstanding, basic															178,305,738
Weighted-average number of common shares outstanding, diluted															178,721,744

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF INCOME

For the Year Ended December 31, 2017

(in thousands, except share and per share amounts)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Revenues:
Rental and related revenues	$	—		$	—		$	—	$	371,704		$	(7,513	)	$	364,191
Interest and other income	2,673			143			—		15,005			(161		)	17,660
Resident fee and services	—			—			—		26,430			—			26,430
Total revenues	2,673			143			—		413,139			(7,674		)	408,281
Expenses:
Depreciation and amortization	867			—			—		113,015			—			113,882
Interest	—			77,767			—		10,816			(143		)	88,440
Senior housing - managed portfolio operating expenses	—			—			—		25,391			(7,531		)	17,860
General and administrative	24,810			65			—		7,526			—			32,401
Merger and acquisition costs	30,208			—			—		47			—			30,255
Provision for doubtful accounts, straight-line rental income and loan losses	227			—			—		16,886			—			17,113
Impairment of real estate	—			—			—		1,326			—			1,326
Total expenses	56,112			77,832			—		175,007			(7,674		)	301,277
Other income (expense):
Loss on extinguishment of debt	—			(422		)	—		(131		)	—			(553		)
Other income (expense)	—			1,130			—		(594		)	—			536
Net gain on sales of real estate	—			—			—		52,029			—			52,029
Total other income	—			708			—		51,304			—			52,012
Income in subsidiary	212,432			289,414			—		7,199			(509,045		)	—
Income before income tax expense	158,993			212,433			—		296,635			(509,045		)	159,016
Income tax expense	(610		)	(1		)	—		(40		)	—			(651		)
Net income	158,383			212,432			—		296,595			(509,045		)	158,365
Net loss attributable to noncontrolling interests	—			—			—		18			—			18
Net income attributable to Sabra Health Care REIT, Inc.	158,383			212,432			—		296,613			(509,045		)	158,383
Preferred stock dividends	(10,242		)	—			—		—			—			(10,242		)
Net income attributable to common stockholders	$	148,141		$	212,432		$	—	$	296,613		$	(509,045	)	$	148,141
Net income attributable to common stockholders, per:
Basic common share															$	1.40
Diluted common share															$	1.40
Weighted-average number of common shares outstanding, basic															105,621,242
Weighted-average number of common shares outstanding, diluted															105,842,434

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Year Ended December 31, 2019

(in thousands)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)		Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net income	$	68,996	$	98,665		$	—	$	235,327		$	(333,970	)	$	69,018
Other comprehensive (loss) income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(1,276		)	—		1,955			—			679
Unrealized (loss) gain on cash flow hedge	—		(25,416		)	—		48			—			(25,368		)
Total other comprehensive (loss) income	—		(26,692		)	—		2,003			—			(24,689		)
Comprehensive income	68,996		71,973			—		237,330			(333,970		)	44,329
Comprehensive income attributable to noncontrolling interests	—		—			—		(22		)	—			(22		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	68,996	$	71,973		$	—	$	237,308		$	(333,970	)	$	44,307

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Year Ended December 31, 2018

(in thousands)

					Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)		Operating Partnership(2)		Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net income	$	279,082	$	307,736	$	—	$	465,909		$	(773,612	)	$	279,115
Other comprehensive income (loss):
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	—		4,329		—		(3,609		)	—			720
Unrealized gain on cash flow hedge	—		244		—		48			—			292
Total other comprehensive income (loss)	—		4,573		—		(3,561		)	—			1,012
Comprehensive income	279,082		312,309		—		462,348			(773,612		)	280,127
Comprehensive income attributable to noncontrolling interests	—		—		—		(33		)	—			(33		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	279,082	$	312,309	$	—	$	462,315		$	(773,612	)	$	280,094

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Year Ended December 31, 2017

(in thousands)

						Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)		Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net income	$	158,383	$	212,432		$	—	$	296,595		$	(509,045	)	$	158,365
Other comprehensive income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(2,821		)	—		2,975			—			154
Unrealized gain (loss) on cash flow hedges	—		13,078			—		(145		)	—			12,933
Total other comprehensive income	—		10,257			—		2,830			—			13,087
Comprehensive income	158,383		222,689			—		299,425			(509,045		)	171,452
Comprehensive loss attributable to noncontrolling interests	—		—			—		18			—			18
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	158,383	$	222,689		$	—	$	299,443		$	(509,045	)	$	171,470

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Year Ended December 31, 2019

(in thousands)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net cash provided by operating activities	$	359,681		$	—		$	—	$	12,794		$	—		$	372,475
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(51,136		)	—			(51,136		)
Origination and fundings of loans receivable	—			—			—		(13,065		)	—			(13,065		)
Additions to real estate	(115		)	—			—		(25,336		)	—			(25,451		)
Repayment of loans receivable	—			—			—		18,367			—			18,367
Repayment of preferred equity investments	—			—			—		5,079			—			5,079
Net proceeds from sales of real estate	—			—			—		329,050			—			329,050
Distribution from subsidiaries	5,248			5,248			—		—			(10,496		)	—
Intercompany financing	(590,173		)	266,148			—		—			324,025			—
Net cash (used in) provided by investing activities	(585,040		)	271,396			—		262,959			313,529			262,844
Cash flows from financing activities:
Net repayments of revolving credit facility	—			(624,000		)	—		—			—			(624,000		)
Proceeds from issuance of senior unsecured notes	—			638,779			—		—			—			638,779
Principal payments on senior unsecured notes	—			(700,000		)	—		—			—			(700,000		)
Principal payments on term loans	—			(145,000		)	—		—			—			(145,000		)
Principal payments on secured debt	—			—			—		(3,436		)	—			(3,436		)
Payments of deferred financing costs	—			(15,598		)	—		—			—			(15,598		)
Payments related to extinguishment of debt	—			(10,502		)	—		—			—			(10,502		)
Distributions to noncontrolling interests	—			—			—		(316		)	—			(316		)
Issuance of common stock, net	549,328			—			—		—			—			549,328
Dividends paid on common stock	(335,435		)	—			—		—			—			(335,435		)
Distribution to parent	—			(5,248		)	—		(5,248		)	10,496			—
Intercompany financing	—			590,173			—		(266,148		)	(324,025		)	—
Net cash provided by (used in) financing activities	213,893			(271,396		)	—		(275,148		)	(313,529		)	(646,180		)
Net (decrease) increase in cash, cash equivalents and restricted cash	(11,466		)	—			—		605			—			(10,861		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		346			—			346
Cash, cash equivalents and restricted cash, beginning of period	40,835			—			—		18,823			—			59,658
Cash, cash equivalents and restricted cash, end of period	$	29,369		$	—		$	—	$	19,774		$	—		$	49,143

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Year Ended December 31, 2018

(in thousands)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net cash provided by operating activities	$	312,485		$	—		$	—	$	48,101		$	—		$	360,586
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(261,511		)	—			(261,511		)
Origination and fundings of loans receivable	—			—			—		(50,731		)	—			(50,731		)
Origination and fundings of preferred equity investments	—			—			—		(5,313		)	—			(5,313		)
Additions to real estate	(40		)	—			—		(27,657		)	—			(27,697		)
Repayment of loans receivable	—			—			—		51,789			—			51,789
Repayment of preferred equity investments	—			—			—		6,870			—			6,870
Investment in unconsolidated JV	—			—			—		(354,461		)	—			(354,461		)
Net proceeds from sales of real estate	—			—			—		382,560			—			382,560
Distribution from subsidiaries	5,457			5,457			—		—			(10,914		)	—
Intercompany financing	(319,268		)	(299,873		)	—		—			619,141			—
Net cash used in investing activities	(313,851		)	(294,416		)	—		(258,454		)	608,227			(258,494		)
Cash flows from financing activities:
Net repayments of revolving credit facility	—			(17,000		)	—		—			—			(17,000		)
Principal payments on secured debt	—			—			—		(140,338		)	—			(140,338		)
Payments of deferred financing costs	—			(352		)	—		—			—			(352		)
Payments related to extinguishment of debt	—			(2,043		)	—		—			—			(2,043		)
Distributions to noncontrolling interests	—			—			—		(142		)	—			(142		)
Preferred stock redemption	(143,750		)	—			—		—			—			(143,750		)
Issuance of common stock, net	(499		)	—			—		—			—			(499		)
Dividends paid on common and preferred stock	(325,220		)	—			—		—			—			(325,220		)
Distribution to parent	—			(5,457		)	—		(5,457		)	10,914			—
Intercompany financing	—			319,268			—		299,873			(619,141		)	—
Net cash (used in) provided by financing activities	(469,469		)	294,416			—		153,936			(608,227		)	(629,344		)
Net decrease in cash, cash equivalents and restricted cash	(470,835		)	—			—		(56,417		)	—			(527,252		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		(539		)	—			(539		)
Cash, cash equivalents and restricted cash, beginning of period	511,670			—			—		75,779			—			587,449
Cash, cash equivalents and restricted cash, end of period	$	40,835		$	—		$	—	$	18,823		$	—		$	59,658

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾  None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Year Ended December 31, 2017

(in thousands)

							Combined Non-Guarantor Subsidiaries of 2026 Notes and 2029 Notes(5)
	Parent Company(1)			Operating Partnership(2)			Sabra Health Care, L.L.C.(3)		Combined Non-Guarantor Subsidiaries of 2024 Notes(4)			Elimination			Consolidated
Net cash provided by operating activities	$	59,640		$	—		$	—	$	76,149		$	—		$	135,789
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(419,905		)	—			(419,905		)
Cash received in CCP Merger	77,859			—			—		—			—			77,859
Origination and fundings of loans receivable	—			—			—		(17,239		)	—			(17,239		)
Origination and fundings of preferred equity investments	—			—			—		(2,749		)	—			(2,749		)
Additions to real estate	(181		)	—			—		(6,773		)	—			(6,954		)
Repayment of loans receivable	—			—			—		32,430			—			32,430
Repayment of preferred equity investments	—			—			—		3,755			—			3,755
Net proceeds from the sales of real estate	—			—			—		150,243			—			150,243
Distribution from subsidiaries	2,474			2,474			—		—			(4,948		)	—
Intercompany financing	168,999			(249,664		)	—		—			80,665			—
Net cash provided by (used in) investing activities	249,151			(247,190		)	—		(260,238		)	75,717			(182,560		)
Cash flows from financing activities:
Net borrowings from revolving credit facility	—			253,000			—		—			—			253,000
Proceeds from term loans	—			181,000			—		—			—			181,000
Principal payments on secured debt	—			—			—		(4,145		)	—			(4,145		)
Payments of deferred financing costs	—			(15,337		)	—		—			—			(15,337		)
Payment of contingent consideration	—			—			—		(382		)	—			(382		)
Distributions to noncontrolling interests	—			—			—		(30		)	—			(30		)
Issuance of common stock, net	366,800			—			—		—			—			366,800
Dividends paid on common and preferred stock	(182,089		)	—			—		—			—			(182,089		)
Distribution to parent	—			(2,474		)	—		(2,474		)	4,948			—
Intercompany financing	—			(168,999		)	—		249,664			(80,665		)	—
Net cash provided by financing activities	184,711			247,190			—		242,633			(75,717		)	598,817
Net increase in cash, cash equivalents and restricted cash	493,502			—			—		58,544			—			552,046
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		738			—			738
Cash, cash equivalents and restricted cash, beginning of period	18,168			—			—		16,497			—			34,665
Cash, cash equivalents and restricted cash, end of period	$	511,670		$	—		$	—	$	75,779		$	—		$	587,449

⁽¹⁾  The Parent Company guarantees the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽²⁾  The Operating Partnership is the issuer of the 2024 Notes, the 2026 Notes and the 2029 Notes.

⁽³⁾  Sabra Health Care, L.L.C. guarantees the 2024 Notes.

⁽⁴⁾  The Combined Non-Guarantor Subsidiaries of the 2024 Notes consist of the subsidiaries that do not guarantee the 2024 Notes.

⁽⁵⁾ 

None of Sabra Health Care, L.L.C. nor the Combined Non-Guarantor Subsidiaries of the 2024 Notes guarantee the 2026 Notes or the 2029 Notes.

XML

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION

12 Months Ended

Dec. 31, 2019

SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION

SCHEDULE III

REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION

As of December 31, 2019

(dollars in thousands)

				Initial Cost to Company						Cost Capitalized Subsequent to Acquisition		Gross Amount at which Carried at Close of Period											Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land		Building and Improve- ments(2)(3)		Total				Land		Building and Improve- ments(2)(3)		Total		Accumulated Depreciation and Amortization			Original Date of Construction/ Renovation	Date Acquired
Skilled Nursing/Transitional Care Facilities
Forest Hills (SNF)	Broken Arrow, OK	100%	(4)	$	1,653	$	11,259	$	12,912	$	—	$	1,653	$	9,565	$	11,218	$	(3,655	)	1994/2008, 2009/2010, 2015	11/15/10	40
Seminole Estates	Seminole, OK	100%	—	655		3,527		4,182		—		655		3,167		3,822		(1,126		)	1987	11/15/10	32
Bedford Hills	Bedford, NH	100%	5,782	1,911		12,245		14,156		—		1,911		10,867		12,778		(4,272		)	1992/2010, 2019	11/15/10	36
The Elms Care	Milford, NH	100%	—	312		1,679		1,991		—		312		1,334		1,646		(895		)	1890/2005	11/15/10	20
Missouri River	Great Falls, MT	100%	10,366	2,023		16,967		18,990		—		2,023		15,531		17,554		(7,673		)	1960/1990, 2010	11/15/10	30
Deer Lodge	Deer Lodge, MT	100%	3,940	190		3,032		3,222		2		190		2,619		2,809		(1,232		)	1973	11/15/10	30
Arden House	Hamden, CT	100%	17,879	2,250		23,816		26,066		—		2,250		22,119		24,369		(9,913		)	1973/2008, 2010	11/15/10	28
Lake Drive	Henryetta, OK	100%	—	160		549		709		—		160		51		211		(42		)	1968	11/15/10	10
Mineral Springs	North Conway, NH	100%	11,593	417		5,352		5,769		—		417		4,642		5,059		(1,832		)	1988/2009	11/15/10	43
Wolfeboro	Wolfeboro, NH	100%	9,765	454		4,531		4,985		—		454		3,827		4,281		(1,383		)	1984/1986, 1987, 2009	11/15/10	41
Broadmeadow Healthcare	Middletown, DE	100%	—	1,650		21,730		23,380		—		1,650		21,730		23,380		(5,275		)	2005	08/01/11	40
Capitol Healthcare	Dover, DE	100%	—	4,940		15,500		20,440		—		4,940		15,500		20,440		(3,935		)	1996/2016	08/01/11	40
Pike Creek Healthcare	Wilmington, DE	100%	—	2,460		25,240		27,700		—		2,460		25,240		27,700		(6,195		)	2009	08/01/11	40
Renaissance Healthcare	Millsboro, DE	100%	—	1,640		22,620		24,260		—		1,640		22,620		24,260		(5,660		)	2008	08/01/11	40
Clara Burke	Plymouth Meeting, PA	100%	—	2,527		12,453		14,980		179		2,527		12,632		15,159		(3,065		)	1927/1990, 2007/2016	03/30/12	40
Warrington	Warrington, PA	100%	—	2,617		11,662		14,279		106		2,617		11,768		14,385		(2,614		)	1958/2009/2016	03/30/12	40
Ridgecrest	Duffield, VA	100%	—	509		5,018		5,527		1,333		509		6,351		6,860		(1,687		)	1981/2013	05/10/12	40
Arbrook Plaza	Arlington, TX	100%	—	3,783		14,219		18,002		—		3,783		14,219		18,002		(2,895		)	2002/2012	11/30/12	40
Northgate Plaza	Irving, TX	100%	—	4,901		10,299		15,200		—		4,901		10,299		15,200		(2,160		)	2003/2012, 2015	11/30/12	40
Gulf Pointe Plaza	Rockport, TX	100%	—	1,005		6,628		7,633		—		1,005		6,628		7,633		(1,461		)	2002/2012, 2018	11/30/12	40
Gateway Senior Living	Lincoln, NE	100%	—	6,368		29,919		36,287		—		6,368		29,919		36,287		(4,982		)	1962/1996/2013	02/14/14	40
Legacy	Fremont, NE	100%	—	615		16,176		16,791		—		615		16,176		16,791		(2,955		)	2008	02/14/14	40
Pointe	Fremont, NE	100%	—	615		2,943		3,558		—		615		2,943		3,558		(638		)	1970/1979/1983/1994	02/14/14	40
Regency	South Sioux City, NE	100%	—	246		6,206		6,452		—		246		6,206		6,452		(1,380		)	1962/1968/1975/2000/2004	02/14/14	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Parkmoor Village	Colorado Springs, CO	100%	—	430	13,703	14,133	—	430	13,703	14,133	(2,637	)	1985/2017, 2018	03/05/14	40
Adams PARC	Barlesville, OK	100%	—	1,332	6,904	8,236	—	1,332	6,904	8,236	(1,121	)	1989/2019	10/29/14	40
PARCway	Oklahoma City, OK	100%	—	2,189	23,567	25,756	890	2,189	24,457	26,646	(3,627	)	1963/1984, 2018, 2019	10/29/14	40
Brookhaven Extensive Care	Norman, OK	100%	—	869	5,236	6,105	—	869	5,237	6,106	(950	)	2001/2013, 2019	10/29/14	40
Cadia Healthcare of Hyattsville	Hyattsville, MD	100%	—	6,343	65,573	71,916	14	6,343	65,587	71,930	(8,890	)	1950/1976, 2008	06/30/15	40
Cadia Healthcare of Annapolis	Annapolis, MD	100%	—	1,548	40,773	42,321	103	1,548	40,876	42,424	(5,155	)	1964/1993, 2012	06/30/15	40
Cadia Healthcare of Wheaton	Wheaton, MD	100%	—	676	56,897	57,573	22	676	56,919	57,595	(7,050	)	1966/1991, 2012	06/30/15	40
Cadia Healthcare of Hagerstown	Hagerstown, MD	100%	—	1,475	56,237	57,712	1,236	1,475	57,473	58,948	(6,536	)	1953/1975, 2014, 2019	11/25/15	40
Cadia Healthcare of Spring Brook	Silver Spring, MD	100%	—	963	48,085	49,048	7	963	48,092	49,055	(4,599	)	1965/2015	07/26/16	40
Andrew Residence	Minneapolis, MN	100%	—	2,931	6,943	9,874	192	2,931	7,135	10,066	(596	)	1941/2014, 2019	08/17/17	40
Avamere Riverpark of Eugene	Eugene, OR	100%	—	2,205	28,700	30,905	2,252	2,205	30,952	33,157	(2,167	)	1988/2016	08/17/17	40
Avamere Rehab of Lebanon	Lebanon, OR	100%	—	958	14,176	15,134	—	958	14,176	15,134	(894	)	1974	08/17/17	40
Avamere Crestview of Portland	Portland, OR	100%	—	1,791	12,833	14,624	2,761	1,791	15,594	17,385	(1,277	)	1964/2016	08/17/17	40
Avamere Rehabilitation of King City	Tigard, OR	100%	—	2,011	11,667	13,678	—	2,011	11,667	13,678	(761	)	1975	08/17/17	40
Avamere Rehabilitation of Hillsboro	Hillsboro, OR	100%	—	1,387	14,028	15,415	—	1,387	14,028	15,415	(884	)	1973	08/17/17	40
Avamere Rehab of Junction City	Junction City, OR	100%	—	584	7,901	8,485	—	584	7,901	8,485	(517	)	1966/2015	08/17/17	40
Avamere Rehab of Eugene	Eugene, OR	100%	—	1,380	14,921	16,301	1,791	1,380	16,712	18,092	(1,260	)	1966/2016	08/17/17	40
Avamere Rehab of Coos Bay	Coos Bay, OR	100%	—	829	8,518	9,347	—	829	8,518	9,347	(578	)	1968	08/17/17	40
Avamere Rehab of Clackamas	Gladstone, OR	100%	—	792	5,000	5,792	—	792	5,000	5,792	(334	)	1961	08/17/17	40
Avamere Rehab of Newport	Newport, OR	100%	—	406	5,001	5,407	—	406	5,001	5,407	(319	)	1973/2014	08/17/17	40
Avamere Rehab of Oregon City	Oregon City, OR	100%	—	1,496	12,142	13,638	—	1,496	12,142	13,638	(765	)	1974	08/17/17	40
Avamere Transitional Care of Puget Sound	Tacoma, WA	100%	—	1,771	11,595	13,366	15	1,771	11,610	13,381	(852	)	2017	08/17/17	40
Richmond Beach Rehab	Shoreline, WA	100%	—	4,703	14,444	19,147	—	4,703	14,444	19,147	(943	)	1993/2014	08/17/17	40
St. Francis of Bellingham	Bellingham, WA	100%	—	—	15,330	15,330	—	—	15,330	15,330	(1,010	)	1984/2015	08/17/17	40
Avamere Olympic Rehabilitation of Sequim	Sequim, WA	100%	—	427	4,450	4,877	—	427	4,450	4,877	(352	)	1974	08/17/17	40
Avamere Heritage Rehabilitation of Tacoma	Tacoma, WA	100%	—	1,705	4,952	6,657	—	1,705	4,952	6,657	(341	)	1968	08/17/17	40
Avamere at Pacific Ridge	Tacoma, WA	100%	—	2,195	1,956	4,151	—	2,195	1,956	4,151	(178	)	1972/2014	08/17/17	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Avamere Rehabilitation of Cascade Park	Vancouver, WA	100%	—	1,782	15,116	16,898	—	1,782	15,116	16,898	(1,031	)	1991	08/17/17	40
The Pearl at Kruse Way	Lake Oswego, OR	100%	—	5,947	13,401	19,348	—	5,947	13,401	19,348	(882	)	2005/2016	08/17/17	40
Avamere at Medford	Medford, OR	100%	—	2,043	38,485	40,528	2,960	2,043	41,445	43,488	(2,864	)	1974/2016	08/17/17	40
Avamere Bellingham Healthcare and Rehab Services	Bellingham, WA	100%	—	2,908	2,058	4,966	—	2,908	2,058	4,966	(182	)	1972/2015	08/17/17	40
Queen Anne Healthcare	Seattle, WA	100%	—	2,508	6,401	8,909	—	2,508	6,401	8,909	(427	)	1970	08/17/17	40
Avamere Transitional Care and Rehab - Boise	Boise, ID	100%	—	681	9,348	10,029	—	681	9,348	10,029	(623	)	1979	08/17/17	40
Avamere Transitional Care at Sunnyside	Salem, OR	100%	—	2,114	15,651	17,765	—	2,114	15,651	17,765	(1,016	)	1981	08/17/17	40
Avamere Health Services of Rogue Valley	Medford, OR	100%	—	1,375	23,808	25,183	—	1,375	23,808	25,183	(1,559	)	1961/2016	08/17/17	40
Avamere Transitional Care and Rehab - Malley	Northglenn, CO	100%	—	1,662	26,014	27,676	3,258	1,662	29,272	30,934	(2,179	)	1972/2016	08/17/17	40
Avamere Transitional Care and Rehab - Brighton	Brighton, CO	100%	—	1,933	11,624	13,557	—	1,933	11,624	13,557	(779	)	1971	08/17/17	40
Phoenix Rehabilitation Services	Phoenix, AZ	100%	—	1,270	11,502	12,772	—	1,270	11,502	12,772	(726	)	2008	08/17/17	40
Tustin Subacute Care Facility	Santa Ana, CA	100%	—	1,889	11,682	13,571	—	1,889	11,682	13,571	(717	)	2008	08/17/17	40
La Mesa Inpatient Rehabilitation Facility	La Mesa, CA	100%	—	1,276	8,177	9,453	—	1,276	8,177	9,453	(522	)	2012	08/17/17	40
Golden Living Center - Westminster	Westminster, MD	100%	—	2,128	6,614	8,742	487	2,128	7,101	9,229	(630	)	1973/2010, 2019	08/17/17	40
Maple Wood Care Center	Kansas City, MO	100%	—	1,142	3,226	4,368	653	1,142	3,879	5,021	(539	)	1983	08/17/17	40
Garden Valley Nursing & Rehab	Kansas City, MO	100%	—	1,985	2,714	4,699	303	1,985	3,017	5,002	(490	)	1983	08/17/17	40
Worthington Nursing & Rehab	Parkersburg, WV	100%	—	697	10,688	11,385	285	697	10,973	11,670	(892	)	1974/1999, 2019	08/17/17	40
Burlington House Rehabilitative and Alzheimer’s Care Center	Cincinnati, OH	100%	—	2,686	10,062	12,748	—	2,686	10,062	12,748	(758	)	1989/2015	08/17/17	40
Golden Living Center - Charlottesville	Charlottesville, VA	100%	—	2,840	8,450	11,290	1,157	2,840	9,607	12,447	(769	)	1964/2009, 2019	08/17/17	40
Golden Living Center - Sleepy Hollow	Annandale, VA	100%	—	7,241	17,727	24,968	1,806	7,241	19,533	26,774	(1,405	)	1963/2013, 2019	08/17/17	40
Golden Living Center - Petersburg	Petersburg, VA	100%	—	988	8,416	9,404	146	988	8,562	9,550	(641	)	1970/2009	08/17/17	40
Golden Living Center - Battlefield Park	Petersburg, VA	100%	—	1,174	8,858	10,032	151	1,174	9,009	10,183	(664	)	1976/2010	08/17/17	40
Golden Living Center - Hagerstown	Hagerstown, MD	100%	—	1,393	13,438	14,831	150	1,393	13,588	14,981	(959	)	1971/2010	08/17/17	40
Golden Living Center - Cumberland	Cumberland, MD	100%	—	800	16,973	17,773	457	800	17,430	18,230	(1,219	)	1968	08/17/17	40
Gilroy Healthcare and Rehabilitation Center	Gilroy, CA	100%	—	662	23,775	24,437	—	662	23,775	24,437	(1,482	)	1968	08/17/17	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
North Cascades Health and Rehabilitation Center	Bellingham, WA	100%	—	1,437	14,196	15,633	—	1,437	14,196	15,633	(926	)	1999	08/17/17	40
Granite Rehabilitation & Wellness	Cheyenne, WY	100%	—	387	13,613	14,000	2,246	387	15,859	16,246	(1,170	)	1967/2017	08/17/17	40
Rawlins Rehabilitation & Wellness	Rawlins, WY	100%	—	281	6,007	6,288	—	281	6,007	6,288	(389	)	1967	08/17/17	40
Wind River Rehabilitation & Wellness	Riverton, WY	100%	—	199	11,398	11,597	—	199	11,398	11,597	(720	)	1967	08/17/17	40
Sage View Care Center	Rock Springs, WY	100%	—	420	8,665	9,085	—	420	8,665	9,085	(571	)	1964/2017	08/17/17	40
Shelton Health and Rehabilitation Center	Shelton, WA	100%	—	415	8,965	9,380	—	415	8,965	9,380	(629	)	1998	08/17/17	40
Dundee Nursing Home	Bennettsville, SC	100%	—	1,437	4,631	6,068	—	1,437	4,631	6,068	(334	)	1958	08/17/17	40
Mt. Pleasant Nursing Center	Mount Pleasant, SC	100%	—	2,689	3,942	6,631	—	2,689	3,942	6,631	(302	)	1977/2015	08/17/17	40
Tri-State Comp Care Center	Harrogate, TN	100%	—	1,811	4,963	6,774	—	1,811	4,963	6,774	(388	)	1990/2005	08/17/17	40
Epic-Conway	Conway, SC	100%	—	1,408	10,784	12,192	—	1,408	10,784	12,192	(758	)	1975	08/17/17	40
Epic- Bayview	Beaufort, SC	100%	—	1,842	11,389	13,231	—	1,842	11,389	13,231	(777	)	1970	08/17/17	40
Focused Care at Baytown	Baytown, TX	100%	—	479	6,351	6,830	209	479	6,456	6,935	(451	)	1970/2019	08/17/17	40
Focused Care at Allenbrook	Baytown, TX	100%	—	426	3,236	3,662	173	426	3,371	3,797	(297	)	1975/2019	08/17/17	40
Focused Care at Huntsville	Huntsville, TX	100%	—	302	3,153	3,455	75	302	3,200	3,502	(250	)	1968/2019	08/17/17	40
Focused Care at Center	Center, TX	100%	—	231	1,335	1,566	312	231	1,555	1,786	(174	)	1972/2019	08/17/17	40
Focused Care at Humble	Humble, TX	100%	—	2,114	1,643	3,757	596	2,114	2,099	4,213	(268	)	1972/2019	08/17/17	40
Focused Care at Beechnut	Houston, TX	100%	—	1,019	5,734	6,753	318	1,019	5,876	6,895	(436	)	1982/2019	08/17/17	40
Focused Care at Linden	Linden, TX	100%	—	112	256	368	133	112	331	443	(57	)	1968/2019	08/17/17	40
Focused Care at Sherman	Sherman, TX	100%	—	469	6,310	6,779	255	469	6,400	6,869	(463	)	1971/2019	08/17/17	40
Focused Care at Mount Pleasant	Mount Pleasant, TX	100%	—	250	6,913	7,163	345	250	7,249	7,499	(532	)	1970/2019	08/17/17	40
Focused Care at Waxahachie	Waxahachie, TX	100%	—	416	7,259	7,675	205	416	7,412	7,828	(539	)	1976/2019	08/17/17	40
Focused Care at Gilmer	Gilmer, TX	100%	—	707	4,552	5,259	93	707	4,605	5,312	(352	)	1990/2019	08/17/17	40
Hearthstone of Northern Nevada	Sparks, NV	100%	—	1,986	9,004	10,990	—	1,986	9,004	10,990	(631	)	1988	08/17/17	40
Sunset Hills Healthcare and Rehabilitation Center	St. Louis, MO	100%	—	1,595	5,822	7,417	—	966	3,157	4,123	—		1954/2016	08/17/17	40
Mountainview Specialty Care Center	Greensburg, PA	100%	—	549	9,926	10,475	—	549	9,926	10,475	(824	)	1971/2016	08/17/17	40
Golden Living Center - Richmond	Richmond, IN	100%	—	259	9,819	10,078	—	259	9,819	10,078	(655	)	1975	08/17/17	40
Golden Living Center - Petersburg	Petersburg, IN	100%	—	581	5,367	5,948	—	581	5,367	5,948	(383	)	1970/2009	08/17/17	40
Beverly Health - Ft. Pierce	Fort Pierce, FL	100%	—	787	16,648	17,435	—	787	16,648	17,435	(1,067	)	1960/2011	08/17/17	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Maryville	Maryville, MO	100%	—	114	5,955	6,069	—	150	5,955	6,105	(437	)	1972	08/17/17	40
Ashland Healthcare	Ashland, MO	100%	—	765	2,669	3,434	—	765	2,669	3,434	(210	)	1993	08/17/17	40
Bellefontaine Gardens	St. Louis, MO	100%	—	2,071	5,739	7,810	—	2,071	5,739	7,810	(451	)	1988/1991	08/17/17	40
Current River Nursing Center	Doniphan, MO	100%	—	657	8,251	8,908	—	657	8,251	8,908	(571	)	1991	08/17/17	40
Dixon Nursing & Rehab	Dixon, MO	100%	—	521	3,358	3,879	—	521	3,358	3,879	(252	)	1989/2011	08/17/17	40
Forsyth Nursing & Rehab	Forsyth, MO	100%	—	594	8,549	9,143	—	594	8,549	9,143	(601	)	1993/2007	08/17/17	40
Glenwood Healthcare	Seymour, MO	100%	—	658	901	1,559	—	658	901	1,559	(88	)	1990	08/17/17	40
Silex Community Care	Silex, MO	100%	—	807	4,990	5,797	—	807	4,990	5,797	(356	)	1991	08/17/17	40
South Hampton Place	Columbia, MO	100%	—	2,322	6,547	8,869	—	2,322	6,547	8,869	(474	)	1994	08/17/17	40
Strafford Care Center	Strafford, MO	100%	—	1,634	6,518	8,152	—	1,634	6,518	8,152	(462	)	1995	08/17/17	40
Windsor Healthcare & Rehab	Windsor, MO	100%	—	471	6,819	7,290	—	471	6,819	7,290	(438	)	1996	08/17/17	40
Park Manor of Conroe	Conroe, TX	100%	—	1,222	19,099	20,321	—	1,222	19,099	20,321	(1,198	)	2001	08/17/17	40
Park Manor of Cypress Station	Houston, TX	100%	—	1,334	11,615	12,949	—	1,334	11,615	12,949	(759	)	2003/2013	08/17/17	40
Park Manor of Humble	Humble, TX	100%	—	1,541	12,332	13,873	645	1,541	12,977	14,518	(870	)	2003/2019	08/17/17	40
Park Manor of Quail Valley	Missouri City, TX	100%	—	1,825	9,681	11,506	—	1,825	9,681	11,506	(657	)	2005	08/17/17	40
Park Manor of Westchase	Houston, TX	100%	—	2,676	7,396	10,072	—	2,676	7,396	10,072	(514	)	2005	08/17/17	40
Park Manor of CyFair	Houston, TX	100%	—	1,732	12,921	14,653	—	1,732	12,921	14,653	(838	)	1999	08/17/17	40
Park Manor of McKinney	McKinney, TX	100%	—	1,441	9,017	10,458	—	1,441	9,017	10,458	(638	)	1993/2012	08/17/17	40
Tanglewood Health and Rehabilitation	Topeka, KS	100%	—	176	2,340	2,516	—	176	2,340	2,516	(175	)	1973/2013	08/17/17	40
Smoky Hill Health and Rehabilitation	Salina, KS	100%	—	301	4,201	4,502	—	301	4,201	4,502	(300	)	1981	08/17/17	40
Belleville Health Center	Belleville, KS	100%	—	600	1,664	2,264	—	600	1,664	2,264	(149	)	1977	08/17/17	40
Westridge Healthcare Center	Terre Haute, IN	100%	—	1,067	7,061	8,128	—	1,067	7,061	8,128	(474	)	1965/1984	08/17/17	40
Willow Bend Living Center	Muncie, IN	100%	—	1,168	9,562	10,730	—	1,168	9,562	10,730	(612	)	1976/1986	08/17/17	40
Twin City Healthcare	Gas City, IN	100%	—	345	8,852	9,197	—	345	8,852	9,197	(566	)	1974	08/17/17	40
Pine Knoll Rehabilitation Center	Winchester, IN	100%	—	711	5,554	6,265	—	711	5,554	6,265	(374	)	1986/1998	08/17/17	40
Willow Crossing Health & Rehab Center	Columbus, IN	100%	—	1,290	10,714	12,004	—	1,290	10,714	12,004	(688	)	1988/2004	08/17/17	40
Persimmon Ridge Center	Portland, IN	100%	—	315	9,848	10,163	—	315	9,848	10,163	(642	)	1964	08/17/17	40
Vermillion Convalescent Center	Clinton, IN	100%	—	884	9,839	10,723	—	884	9,839	10,723	(674	)	1971	08/17/17	40
Las Vegas Post Acute & Rehabilitation	Las Vegas, NV	100%	—	509	18,216	18,725	—	509	18,216	18,725	(1,118	)	1964	08/17/17	40
Torey Pines Rehabilitation Hospital	Las Vegas, NV	100%	—	3,169	7,863	11,032	—	3,169	7,863	11,032	(544	)	1972/1997	08/17/17	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Villa Campana Rehabilitation Hospital	Tucson, AZ	100%	—	1,800	4,387	6,187	—	1,800	4,387	6,187	(352	)	1983/2011	08/17/17	40
Kachina Point Rehabilitation Hospital	Sedona, AZ	100%	—	2,035	10,981	13,016	—	2,035	10,981	13,016	(770	)	1984/2011	08/17/17	40
Bay View Rehabilitation Hospital	Alameda, CA	100%	—	3,078	22,328	25,406	—	3,078	22,328	25,406	(1,402	)	1967	08/17/17	40
Dover Center for Health & Rehabilitation	Dover, NH	100%	—	522	5,839	6,361	—	522	5,839	6,361	(510	)	1969/1992, 2017	08/17/17	40
Augusta Center for Health & Rehabilitation	Augusta, ME	100%	—	135	6,470	6,605	—	135	6,470	6,605	(444	)	1967	08/17/17	40
Eastside Center for Health & Rehabilitation	Bangor, ME	100%	—	302	1,811	2,113	632	302	2,443	2,745	(147	)	1967/1993, 2019	08/17/17	40
Winship Green Center for Health & Rehabilitation	Bath, ME	100%	—	250	1,934	2,184	—	250	1,934	2,184	(148	)	1974	08/17/17	40
Brewer Center for Health & Rehabilitation	Brewer, ME	100%	—	177	14,497	14,674	944	177	15,441	15,618	(967	)	1974/1990, 2019	08/17/17	40
Kennebunk Center for Health & Rehabilitation	Kennebunk, ME	100%	—	198	6,822	7,020	—	198	6,822	7,020	(461	)	1977	08/17/17	40
Norway Center for Health & Rehabilitation	Norway, ME	100%	—	791	3,680	4,471	—	791	3,680	4,471	(269	)	1976	08/17/17	40
Brentwood Center for Health & Rehabilitation	Yarmouth, ME	100%	—	134	2,072	2,206	—	134	2,072	2,206	(163	)	1952	08/17/17	40
Country Center for Health & Rehabilitation	Newburyport, MA	100%	—	269	4,436	4,705	12	269	4,448	4,717	(403	)	1968/2009	08/17/17	40
Sachem Center for Health & Rehabilitation	E. Bridgewater, MA	100%	—	447	1,357	1,804	—	447	1,357	1,804	(151	)	1968	08/17/17	40
Eliot Center for Health & Rehabilitation	Natick, MA	100%	—	475	1,491	1,966	—	475	1,491	1,966	(143	)	1964	08/17/17	40
The Reservoir Center for Health & Rehabilitation	Marlborough, MA	100%	—	942	1,541	2,483	8,697	942	10,238	11,180	(547	)	1973/2018	08/17/17	40
Newton Wellesley Center for Alzheimer’s Care	Wellesley, MA	100%	—	1,186	13,917	15,103	—	1,186	13,917	15,103	(894	)	1971	08/17/17	40
Colony Center for Health & Rehabilitation	Abington, MA	100%	—	1,727	2,103	3,830	19	1,727	2,122	3,849	(188	)	1965	08/17/17	40
Westgate Center for Rehab & Alzheimer’s Care	Bangor, ME	100%	—	229	7,171	7,400	10	229	7,181	7,410	(501	)	1969/1993	08/17/17	40
New Orange Hills	Orange, CA	100%	—	4,163	14,755	18,918	—	4,163	14,755	18,918	(973	)	1987	08/17/17	40
Millbrook Healthcare & Rehabilitation Center	Lancaster, TX	100%	—	548	5,794	6,342	—	548	5,794	6,342	(420	)	2008	08/17/17	40
Pleasant Valley Health & Rehab	Garland, TX	100%	—	1,118	7,490	8,608	—	1,118	7,490	8,608	(517	)	2008	08/17/17	40
Focused Care at Clarksville	Clarksville, TX	100%	—	279	4,269	4,548	100	279	4,369	4,648	(338	)	1989/2019	08/17/17	40
McKinney Healthcare & Rehab	McKinney, TX	100%	—	1,272	6,047	7,319	—	1,272	6,047	7,319	(448	)	2006	08/17/17	40
Golden Living Center - Hopkins	Hopkins, MN	100%	—	807	4,668	5,475	530	807	5,198	6,005	(423	)	1961/2008, 2019	08/17/17	40
Golden Living Center - Village Gardens	Green Bay, WI	100%	—	1,299	1,247	2,546	—	1,299	1,247	2,546	(142	)	1965/2012	08/17/17	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Golden Living Center - Florence	Florence, WI	100%	—	291	3,778	4,069	—	291	3,778	4,069	(293	)	1970	08/17/17	40
Golden Living Center - South Shore	St. Francis, WI	100%	—	166	1,887	2,053	—	166	1,887	2,053	(152	)	1960/1997	08/17/17	40
Golden Living Center - Rochester East	Rochester, MN	100%	—	645	7,067	7,712	178	645	7,245	7,890	(489	)	1967/2011, 2019	08/17/17	40
Golden Living Center - Wisconsin Dells	Wisconsin Dells, WI	100%	—	1,640	1,599	3,239	—	1,640	1,599	3,239	(167	)	1972/2006	08/17/17	40
Golden Living Center - Sheboygan	Sheboygan, WI	100%	—	1,038	2,839	3,877	—	1,038	2,839	3,877	(251	)	1967/2012	08/17/17	40
Golden Living Center - Hendersonville	Hendersonville, NC	100%	—	1,611	3,503	5,114	—	1,611	3,503	5,114	(285	)	1979	08/17/17	40
Focused Care at Corpus	Corpus Christi, TX	100%	—	366	6,961	7,327	91	51	1,025	1,076	(152	)	1973/2010	08/17/17	40
Focused Care at Burnet Bay	Baytown, TX	100%	—	579	22,317	22,896	28	579	22,345	22,924	(1,409	)	2000/2013	08/17/17	40
Focused Care at Cedar Bayou	Baytown, TX	100%	—	589	20,475	21,064	35	589	20,510	21,099	(1,336	)	2008	08/17/17	40
Focused Care at Westwood	Houston, TX	100%	—	1,300	13,353	14,653	—	1,300	13,353	14,653	(906	)	2006	08/17/17	40
Focused Care at Pasadena	Pasadena, TX	100%	—	1,148	23,579	24,727	—	1,148	23,579	24,727	(1,515	)	2004	08/17/17	40
Focused Care at Webster	Webster, TX	100%	—	904	10,315	11,219	—	904	10,315	11,219	(716	)	2000/2009	08/17/17	40
Focused Care at Summer Place	Beaumont, TX	100%	—	945	20,424	21,369	18	945	20,442	21,387	(1,296	)	2009	08/17/17	40
Focused Care at Orange	Orange, TX	100%	—	711	10,737	11,448	16	711	10,753	11,464	(711	)	2006	08/17/17	40
Cypress Glen	Port Arthur, TX	100%	—	1,209	13,444	14,653	—	90	814	904	—		2000/2008	08/17/17	40
Signature Healthcare of Whitesburg Gardens	Huntsville, AL	100%	—	634	28,071	28,705	—	634	28,071	28,705	(1,735	)	1968/2012	08/17/17	40
Signature Healthcare of Terre Haute	Terre Haute, IN	100%	—	644	37,451	38,095	—	644	37,451	38,095	(2,601	)	1996/2013	08/17/17	40
Signature Healthcare at Larkin Springs	Madison, TN	100%	—	902	3,850	4,752	—	902	3,850	4,752	(325	)	1969/2016	08/17/17	40
Signature Healthcare of Savannah	Savannah, GA	100%	—	1,235	3,765	5,000	—	1,235	3,765	5,000	(334	)	1970/2015	08/17/17	40
Signature Healthcare of Bluffton	Bluffton, IN	100%	—	254	5,105	5,359	—	254	5,105	5,359	(384	)	1970	08/17/17	40
Signature Healthcare of Bowling Green	Bowling Green, KY	100%	—	280	13,975	14,255	—	280	13,975	14,255	(955	)	1970/2015	08/17/17	40
Oakview Nursing and Rehabilitation Center	Calvert City, KY	100%	—	1,176	7,012	8,188	—	1,176	7,012	8,188	(509	)	1962/2015	08/17/17	40
Fountain Circle Care and Rehabilitation Center	Winchester, KY	100%	—	554	13,207	13,761	—	554	13,207	13,761	(921	)	1967/2015	08/17/17	40
Riverside Care & Rehabilitation Center	Calhoun, KY	100%	—	613	7,643	8,256	—	613	7,643	8,256	(570	)	1963/2015	08/17/17	40
Signature Healthcare of Bremen	Bremen, IN	100%	—	173	7,393	7,566	—	173	7,393	7,566	(504	)	1982/2015	08/17/17	40
Signature Healthcare of Muncie	Muncie, IN	100%	—	374	27,429	27,803	—	374	27,429	27,803	(1,733	)	1980/2013	08/17/17	40
Signature Healthcare at Parkwood	Lebanon, IN	100%	—	612	11,755	12,367	—	612	11,755	12,367	(787	)	1977/2012	08/17/17	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Signature Healthcare at Tower Road	Marietta, GA	100%	—	364	16,116	16,480	—	364	16,116	16,480	(1,106	)	1969/2015	08/17/17	40
Danville Centre for Health and Rehabilitation	Danville, KY	100%	—	790	9,356	10,146	—	790	9,356	10,146	(753	)	1962/2015	08/17/17	40
Signature Healthcare at Hillcrest	Owensboro, KY	100%	—	1,048	22,587	23,635	—	1,048	22,587	23,635	(1,483	)	1963/2011	08/17/17	40
Signature Healthcare of Elizabethtown	Elizabethtown, KY	100%	—	239	4,853	5,092	—	239	4,853	5,092	(357	)	1969	08/17/17	40
Signature Healthcare of Primacy	Memphis, TN	100%	—	1,633	9,371	11,004	—	1,633	9,371	11,004	(674	)	1981/2015	08/17/17	40
Signature Healthcare of Harbour Pointe	Norfolk, VA	100%	—	705	16,451	17,156	—	705	16,451	17,156	(1,222	)	1969/2015	08/17/17	40
Harrodsburg Health & Rehabilitation Center	Harrodsburg, KY	100%	—	1,049	9,851	10,900	—	1,049	9,851	10,900	(754	)	1975/2016	08/17/17	40
Signature Healthcare of Putnam County	Cookeville, TN	100%	—	1,034	15,555	16,589	—	1,034	15,555	16,589	(1,045	)	1979/2016	08/17/17	40
Signature Healthcare of Fayette County	Washington Court House, OH	100%	—	405	4,839	5,244	—	405	4,839	5,244	(385	)	1984/2015	08/17/17	40
Signature Healthcare of Warren	Warren, OH	100%	—	955	5,260	6,215	—	955	5,260	6,215	(489	)	1967/2015	08/17/17	40
Signature Healthcare of Galion	Galion, OH	100%	—	836	668	1,504	—	836	668	1,504	(86	)	1967/1985	08/17/17	40
Signature Healthcare of Roanoke Rapids	Roanoke Rapids, NC	100%	—	373	10,308	10,681	—	373	10,308	10,681	(761	)	1967/2015	08/17/17	40
Signature Healthcare of Kinston	Kinston, NC	100%	—	954	7,987	8,941	—	954	7,987	8,941	(662	)	1960/2015	08/17/17	40
Signature Healthcare of Chapel Hill	Chapel Hill, NC	100%	—	809	2,703	3,512	302	809	3,005	3,814	(321	)	1984/2015	08/17/17	40
Signature Healthcare of Chillicothe	Chillicothe, OH	100%	—	260	8,924	9,184	—	260	8,924	9,184	(681	)	1974/2015	08/17/17	40
Signature Healthcare of Coshocton	Coshocton, OH	100%	—	374	2,530	2,904	—	374	2,530	2,904	(261	)	1974/2015	08/17/17	40
McCreary Health & Rehabilitation Center	Pine Knot, KY	100%	—	208	7,665	7,873	—	208	7,665	7,873	(532	)	1990	08/17/17	40
Colonial Health & Rehabilitation Center	Bardstown, KY	100%	—	634	4,094	4,728	—	634	4,094	4,728	(332	)	1968/2010	08/17/17	40
Glasgow Health & Rehabilitation Center	Glasgow, KY	100%	—	83	2,057	2,140	—	83	2,057	2,140	(202	)	1968	08/17/17	40
Green Valley Health & Rehabilitation Center	Carrollton, KY	100%	—	124	1,693	1,817	—	124	1,693	1,817	(174	)	1978/2016	08/17/17	40
Hart County Health & Rehabilitation	Horse Cave, KY	100%	—	208	7,070	7,278	—	208	7,070	7,278	(536	)	1993	08/17/17	40
Heritage Hall Health & Rehabilitation Center	Lawrenceburg, KY	100%	—	635	9,861	10,496	—	635	9,861	10,496	(694	)	1973	08/17/17	40
Jackson Manor	Annville, KY	100%	—	479	6,078	6,557	—	479	6,078	6,557	(419	)	1989	08/17/17	40
Jefferson Manor	Louisville, KY	100%	—	3,528	4,653	8,181	—	3,528	4,653	8,181	(402	)	1982/2012	08/17/17	40
Jefferson Place	Louisville, KY	100%	—	2,207	20,733	22,940	—	2,207	20,733	22,940	(1,349	)	1991/2010	08/17/17	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Monroe Health & Rehabilitation Center	Tompkinsville, KY	100%	—	333	9,556	9,889	—	333	9,556	9,889	(665	)	1969	08/17/17	40
North Hardin Health & Rehabilitation Center	Radcliff, KY	100%	—	1,815	7,470	9,285	—	1,815	7,470	9,285	(659	)	1986	08/17/17	40
Professional Care Health & Rehabilitation Center	Hartford, KY	100%	—	312	8,189	8,501	—	312	8,189	8,501	(582	)	1967	08/17/17	40
Rockford Health & Rehabilitation Center	Louisville, KY	100%	—	427	6,003	6,430	—	427	6,003	6,430	(455	)	1975/2005	08/17/17	40
Summerfield Health & Rehabilitation Center	Louisville, KY	100%	—	1,134	9,166	10,300	—	1,134	9,166	10,300	(712	)	1979/2013	08/17/17	40
Tanbark Senior Living	Lexington, KY	100%	—	2,558	4,311	6,869	—	2,558	4,311	6,869	(365	)	1989	08/17/17	40
Summit Manor Health & Rehabilitation Center	Columbia, KY	100%	—	114	11,141	11,255	—	114	11,141	11,255	(759	)	1965	08/17/17	40
Belle View Estates Rehabilitation and Care Center	Monticello, AR	100%	—	206	3,179	3,385	—	206	3,179	3,385	(259	)	1995	08/17/17	40
River Chase Rehabilitation and Care Center	Morrilton, AR	100%	—	508	—	508	—	508	—	508	—		1988/2019	08/17/17	40
Heartland Rehabilitation and Care Center	Benton, AR	100%	—	1,336	7,386	8,722	—	1,336	7,386	8,722	(550	)	1992	08/17/17	40
River Ridge Rehabilitation and Care Center	Wynne, AR	100%	—	227	4,007	4,234	—	227	4,007	4,234	(301	)	1990	08/17/17	40
Brookridge Cove Rehabilitation and Care Center	Morrilton, AR	100%	—	412	2,642	3,054	—	412	2,642	3,054	(244	)	1996	08/17/17	40
Southern Trace Rehabilitation and Care Center	Bryant, AR	100%	—	819	8,938	9,757	—	819	8,938	9,757	(593	)	1989/2015	08/17/17	40
Lake Village Rehabilitation and Care Center	Lake Village, AR	100%	—	507	4,838	5,345	—	507	4,838	5,345	(369	)	1998	08/17/17	40
Savannah Specialty Care Center	Savannah, GA	100%	—	2,194	11,711	13,905	—	2,194	11,711	13,905	(766	)	1972	08/17/17	40
Pettigrew Rehabilitation Center	Durham, NC	100%	—	470	9,633	10,103	—	470	9,633	10,103	(624	)	1968/2006	08/17/17	40
Sunnybrook Rehabilitation Center	Raleigh, NC	100%	—	1,155	11,749	12,904	—	1,155	11,749	12,904	(780	)	1971	08/17/17	40
Raleigh Rehabilitation Center	Raleigh, NC	100%	—	926	17,649	18,575	—	926	17,649	18,575	(1,151	)	1967/2007	08/17/17	40
Cypress Pointe Rehabilitation Center	Wilmington, NC	100%	—	611	5,051	5,662	—	611	5,051	5,662	(374	)	1966/2013	08/17/17	40
Silas Creek Rehabilitation Center	Winston-Salem, NC	100%	—	879	3,283	4,162	—	879	3,283	4,162	(277	)	1965	08/17/17	40
Lincolnton Rehabilitation Center	Lincolnton, NC	100%	—	—	9,967	9,967	—	—	9,967	9,967	(664	)	1976	08/17/17	40
Rehabilitation and Nursing Center of Monroe	Monroe, NC	100%	—	166	5,906	6,072	—	166	5,906	6,072	(438	)	1963/2005	08/17/17	40
Guardian Care of Zebulon	Zebulon, NC	100%	—	594	8,559	9,153	—	594	8,559	9,153	(548	)	1973/2010	08/17/17	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Guardian Care of Rocky Mount	Rocky Mount, NC	100%	—	—	18,314	18,314	—	—	18,314	18,314	(1,151	)	1975	08/17/17	40
San Pedro Manor	San Antonio, TX	100%	—	671	2,504	3,175	—	671	2,504	3,175	(211	)	1986	08/17/17	40
Park Manor Health Care & Rehabilitation	DeSoto, TX	100%	—	942	6,033	6,975	—	942	6,033	6,975	(440	)	1987	08/17/17	40
Avalon Place - Trinity	Trinity, TX	100%	—	363	3,852	4,215	—	363	3,852	4,215	(303	)	1985/2019	08/17/17	40
Avalon Place - Kirbyville	Kirbyville, TX	100%	—	208	5,809	6,017	—	208	5,809	6,017	(437	)	1987	08/17/17	40
Heritage House of Marshall	Marshall, TX	100%	—	732	4,288	5,020	—	732	4,288	5,020	(332	)	2008	08/17/17	40
Autumn Woods Residential Health Care Facility	Warren, MI	100%	—	2,052	25,539	27,591	—	2,052	25,539	27,591	(1,845	)	1961/2001	08/17/17	40
Autumn View Health Care Facility	Hamburg, NY	100%	—	1,026	54,086	55,112	—	1,026	54,086	55,112	(3,416	)	1983/2014	08/17/17	40
Brookhaven Health Care Facility	East Patchogue, NY	100%	—	2,181	30,373	32,554	—	2,181	30,373	32,554	(2,018	)	1988/2011	08/17/17	40
Harris Hill Nursing Facility	Williamsville, NY	100%	—	1,122	46,413	47,535	—	1,122	46,413	47,535	(2,879	)	1992/2007	08/17/17	40
Garden Gate Health Care Facility	Cheektowaga, NY	100%	—	1,164	29,905	31,069	—	1,164	29,905	31,069	(1,966	)	1979/2006	08/17/17	40
Northgate Health Care Facility	North Tonawanda, NY	100%	—	830	29,488	30,318	—	830	29,488	30,318	(1,937	)	1982/2007	08/17/17	40
Seneca Health Care Center	West Seneca, NY	100%	—	1,325	26,839	28,164	—	1,325	26,839	28,164	(1,731	)	1974/2008	08/17/17	40
Blueberry Hill Rehab and Healthcare Center	Beverly, MA	100%	—	2,410	13,588	15,998	—	2,410	13,588	15,998	(1,179	)	1965/2015	08/17/17	40
River Terrace Rehabilitation and Healthcare Center	Lancaster, MA	100%	—	343	7,733	8,076	—	343	7,733	8,076	(518	)	1970/2005	08/17/17	40
The Crossings West Campus	New London, CT	100%	—	356	152	508	—	356	152	508	(23	)	1967/2016	08/17/17	40
The Crossings East Campus	New London, CT	100%	—	505	2,248	2,753	—	505	2,248	2,753	(257	)	1967/2016	08/17/17	40
Parkway Pavilion Healthcare	Enfield, CT	100%	—	437	16,461	16,898	—	437	16,461	16,898	(1,127	)	1968/2015	08/17/17	40
Quincy Health & Rehabilitation Center	Quincy, MA	100%	—	894	904	1,798	—	894	904	1,798	(111	)	1965/2003	08/17/17	40
Den-Mar Health & Rehabilitation Center	Rockport, MA	100%	—	—	1,765	1,765	—	—	1,765	1,765	(155	)	1963/1993	08/17/17	40
Firesteel Healthcare Community	Mitchell, SD	100%	—	621	14,059	14,680	8,716	621	22,775	23,396	(2,280	)	1966/2017	08/17/17	40
Fountain Springs Healthcare Community	Rapid City, SD	100%	—	1,134	13,109	14,243	169	1,134	13,278	14,412	(857	)	1989/2016, 2019	08/17/17	40
Palisade Healthcare Community	Garretson, SD	100%	—	362	2,548	2,910	230	362	2,778	3,140	(216	)	1971/1982, 2019	08/17/17	40
Shepherd of the Valley Healthcare Community	Casper, WY	100%	—	803	19,210	20,013	573	803	19,783	20,586	(1,305	)	1961/1990, 2019	08/17/17	40
Wheatcrest Hills Healthcare Community	Britton, SD	100%	—	679	3,216	3,895	269	679	3,485	4,164	(261	)	1969/2019	08/17/17	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Riverview Healthcare Community & Independent Living	Flandreau, SD	100%	—	240	6,327	6,567	—	240	6,327	6,567	(442	)	1965/1989	08/17/17	40
Prairie View Healthcare Center	Woonsocket, SD	100%	—	383	2,041	2,424	—	383	2,041	2,424	(167	)	1968/2012	08/17/17	40
Wingate at Dutchess (Fishkill)	Fishkill, NY	100%	—	964	30,107	31,071	261	964	30,368	31,332	(2,001	)	1995	08/17/17	40
Wingate at Ulster (Highland)	Highland, NY	100%	—	4,371	11,473	15,844	—	4,371	11,473	15,844	(813	)	1998	08/17/17	40
Wingate at Beacon	Beacon, NY	100%	—	—	25,400	25,400	—	—	25,400	25,400	(1,760	)	2002	08/17/17	40
Wingate at Springfield	Springfield, MA	100%	—	817	11,357	12,174	—	817	11,357	12,174	(763	)	1987	08/17/17	40
Wingate at Andover	Andover, MA	100%	—	2,123	5,383	7,506	—	2,123	5,383	7,506	(414	)	1992	08/17/17	40
Wingate at Reading	Reading, MA	100%	—	1,534	5,221	6,755	—	1,534	5,221	6,755	(412	)	1988	08/17/17	40
Wingate at Sudbury	Sudbury, MA	100%	—	2,017	3,458	5,475	—	2,017	3,458	5,475	(315	)	1997	08/17/17	40
Wingate at Belvidere (Lowell)	Lowell, MA	100%	—	1,335	9,019	10,354	—	1,335	9,019	10,354	(654	)	1966/2007	08/17/17	40
Wingate at Worcester	Worcester, MA	100%	—	945	8,770	9,715	—	945	8,770	9,715	(624	)	1970/1988	08/17/17	40
Wingate at West Springfield	W. Springfield, MA	100%	—	2,022	7,345	9,367	—	2,022	7,345	9,367	(573	)	1960/1985	08/17/17	40
Wingate at East Longmeadow	East Longmeadow, MA	100%	—	2,968	8,957	11,925	—	2,968	8,957	11,925	(704	)	1985/2005	08/17/17	40
Broadway by the Sea	Long Beach, CA	100%	—	2,939	11,782	14,721	—	2,939	11,690	14,629	(809	)	1968/2011	09/19/17	40
Coventry Court Health Center	Anaheim, CA	100%	—	2,044	14,167	16,211	—	2,044	14,167	16,211	(952	)	1968/2011	09/19/17	40
Fairfield Post-Acute Rehab	Fairfield, CA	100%	—	586	23,582	24,168	—	586	23,582	24,168	(1,474	)	1966/2006	09/19/17	40
Garden View Post-Acute Rehab	Baldwin Park, CA	100%	—	2,270	17,063	19,333	—	2,270	17,063	19,333	(1,125	)	1970/2015	09/19/17	40
Grand Terrace Health Care Center	Grand Terrace, CA	100%	—	432	9,382	9,814	—	432	9,382	9,814	(624	)	1945/2017	09/19/17	40
Pacifica Nursing & Rehab Center	Pacifica, CA	100%	—	1,510	27,397	28,907	—	1,510	27,397	28,907	(1,689	)	1975	09/19/17	40
Burien Nursing & Rehab Center	Burien, WA	100%	—	823	17,431	18,254	—	823	17,431	18,254	(1,132	)	1965/2014	09/19/17	40
Park West Care Center	Seattle, WA	100%	—	4,802	7,927	12,729	—	4,802	7,927	12,729	(577	)	1963/2016	09/19/17	40
Beachside Nursing Center	Huntington Beach, CA	100%	—	2,312	9,885	12,197	—	2,312	9,885	12,197	(654	)	1965/2010	09/19/17	40
Chatsworth Park Health Care	Chatsworth, CA	100%	—	7,841	16,916	24,757	—	7,841	16,916	24,757	(1,166	)	1976	09/19/17	40
Cottonwood Post-Acute Rehab	Woodland, CA	100%	—	504	7,369	7,873	—	504	7,369	7,873	(513	)	1975/2010	09/19/17	40
Danville Post-Acute Rehab	Danville, CA	100%	—	1,491	17,157	18,648	—	1,491	17,157	18,648	(1,107	)	1965	09/19/17	40
Lake Balboa Care Center	Van Nuys, CA	100%	—	2,456	16,462	18,918	—	2,456	16,462	18,918	(1,023	)	1958/2015	09/19/17	40
Lomita Post-Acute Care Center	Lomita, CA	100%	—	2,743	14,734	17,477	—	2,743	14,734	17,477	(995	)	1969	09/19/17	40
University Post-Acute Rehab	Sacramento, CA	100%	—	2,846	17,962	20,808	—	2,846	17,962	20,808	(1,144	)	1972	09/19/17	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Issaquah Nursing & Rehab Center	Issaquah, WA	100%	—	10,125	7,771	17,896	—	10,125	7,771	17,896	(595	)	1975/2012	09/19/17	40
Alamitos-Belmont Rehab Hospital	Long Beach, CA	100%	—	3,157	22,067	25,224	—	3,157	22,067	25,224	(1,440	)	1966/2014	09/19/17	40
Edgewater Skilled Nursing Center	Long Beach, CA	100%	—	2,857	5,878	8,735	—	2,857	5,878	8,735	(414	)	1952/2013	09/19/17	40
Fairmont Rehabilitation Hospital	Lodi, CA	100%	—	812	21,059	21,871	—	812	21,059	21,871	(1,279	)	1965	09/19/17	40
Palm Terrace Care Center	Riverside, CA	100%	—	1,717	13,806	15,523	—	1,717	13,806	15,523	(981	)	1966	09/19/17	40
Woodland Nursing & Rehab	Woodland, CA	100%	—	278	16,729	17,007	—	278	16,729	17,007	(1,076	)	1930/2007	09/19/17	40
Park Manor at Bee Cave	Bee Cave, TX	100%	—	2,107	10,413	12,520	—	2,107	10,413	12,520	(773	)	2014	12/15/17	40
Ramona	El Monte, CA	100%	—	2,058	19,671	21,729	—	2,058	19,671	21,729	(1,138	)	1965	01/10/18	40
Park Ridge	Shoreline, WA	100%	—	8,861	11,478	20,339	—	8,861	11,478	20,339	(770	)	1964/2012	01/19/18	40
			59,325	386,812	3,298,282	3,685,094	50,151	384,785	3,316,881	3,701,666	(306,565	)
Senior Housing - Leased
Forest Hills (ALF)	Broken Arrow, OK	100%	(4)	1,803	3,927	5,730	—	1,803	3,323	5,126	(1,571	)	2000/2018	11/15/10	30
Langdon Place of Exeter	Exeter, NH	100%	2,759	571	7,183	7,754	—	571	6,129	6,700	(2,408	)	1987	11/15/10	43
Langdon Place of Nashua	Nashua, NH	100%	4,999	—	5,654	5,654	—	—	4,635	4,635	(1,549	)	1989	11/15/10	40
Langdon Place of Keene	Keene, NH	100%	4,126	304	3,992	4,296	—	304	3,449	3,753	(1,520	)	1995	11/15/10	46
Langdon Place of Dover	Dover, NH	100%	3,426	801	10,036	10,837	—	801	8,934	9,735	(3,462	)	1987/2009, 2019	11/15/10	42
Age-Well Senior Living	Green Bay, WI	100%	—	256	2,262	2,518	1,032	256	3,294	3,550	(1,569	)	2004/2011	11/22/11	40
New Dawn Aurora	Aurora, CO	100%	—	2,874	12,829	15,703	6	2,874	12,835	15,709	(2,521	)	2009/2018	09/20/12	40
Gulf Pointe Village	Rockport, TX	100%	—	789	607	1,396	—	789	607	1,396	(210	)	1996/2018	11/30/12	40
Aspen Ridge Retirement Village	Gaylord, MI	100%	—	2,024	5,467	7,491	—	2,024	5,467	7,491	(1,375	)	2002	12/14/12	40
Green Acres of Cadillac	Cadillac, MI	100%	—	217	3,000	3,217	—	217	3,000	3,217	(638	)	2001/2006	12/14/12	40
Green Acres of Greenville	Greenville, MI	100%	—	684	5,832	6,516	249	684	6,081	6,765	(1,281	)	1999/2001, 2012, 2013, 2018	12/14/12	40
Green Acres of Manistee	Manistee, MI	100%	—	952	2,578	3,530	2,547	952	5,125	6,077	(963	)	2002/2017	12/14/12	40
Green Acres of Mason	Mason, MI	100%	—	198	4,131	4,329	—	198	4,131	4,329	(916	)	2009/2012	12/14/12	40
Nottingham Place	Midland, MI	100%	—	744	1,745	2,489	400	744	2,145	2,889	(491	)	1995/2015	12/14/12	40
Royal View	Mecosta, MI	100%	—	307	2,477	2,784	—	307	2,477	2,784	(601	)	2001	12/14/12	40
Tawas Village	East Tawas, MI	100%	—	258	3,713	3,971	45	258	3,758	4,016	(1,074	)	2005	12/14/12	40
Turning Brook	Alpena, MI	100%	—	546	13,139	13,685	—	546	13,139	13,685	(2,503	)	2006/2008, 2010	12/14/12	40
Greenfield of Woodstock	Woodstock, VA	100%	—	597	5,465	6,062	—	597	5,465	6,062	(1,034	)	1996/2015	06/28/13	40
Nye Square	Fremont, NE	100%	—	504	17,670	18,174	—	504	17,670	18,174	(2,995	)	1989/2002	02/14/14	40
The Meadows	Norfolk, NE	100%	—	217	9,906	10,123	1,000	217	10,906	11,123	(1,812	)	1989/1991, 1994, 2018, 2019	02/14/14	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Park Place	Fort Wayne, IN	100%	13,131	2,300	21,115	23,415	2,747	2,300	23,861	26,161	(4,441	)	2011/2016, 2018	04/30/14	40
Avalon MC - Boat Club	Fort Worth, TX	100%	—	359	8,126	8,485	—	359	8,126	8,485	(1,224	)	1996/2015	09/29/14	40
Avalon MC - 7200	Arlington, TX	100%	—	123	4,914	5,037	—	123	4,914	5,037	(742	)	1988/2014	09/29/14	40
Avalon MC - 7204	Arlington, TX	100%	—	215	4,821	5,036	—	215	4,822	5,037	(732	)	1988/2014	09/29/14	40
Avalon MC - 7140	Arlington, TX	100%	—	143	6,653	6,796	—	143	6,653	6,796	(980	)	2011	09/29/14	40
Delaney Creek Lodge	Brandon, FL	100%	—	1,283	8,424	9,707	483	1,283	8,907	10,190	(1,459	)	1999/2016	10/01/14	40
Nature Coast Lodge	Lecanto, FL	100%	—	1,031	5,577	6,608	452	1,031	6,030	7,061	(1,134	)	1997/2016	10/01/14	40
West Winds	Zephyrhills, FL	100%	—	1,688	9,098	10,786	360	1,688	9,459	11,147	(1,683	)	2008/2016	10/01/14	40
Tudor Heights	Baltimore, MD	100%	—	561	4,865	5,426	1,255	561	6,121	6,682	(1,178	)	1920/1997, 2015	10/14/14	40
Life’s Journey of Mattoon	Mattoon, IL	100%	—	812	6,796	7,608	63	264	1,921	2,185	(59	)	2006/2008	09/01/15	40
Life’s Journey of Pana	Pana, IL	100%	—	154	2,098	2,252	—	46	524	570	(20	)	1998/2012	09/01/15	40
Life’s Journey of Taylorville	Taylorville, IL	100%	—	267	5,201	5,468	50	106	1,794	1,900	(45	)	2012/2014	09/01/15	40
Life’s Journey of Paris	Paris, IL	100%	—	132	3,090	3,222	—	49	996	1,045	(23	)	1998/2013	09/01/15	40
Ashley Pointe	Lake Stevens, WA	100%	—	1,559	9,059	10,618	68	1,559	9,127	10,686	(1,186	)	1998/2012	09/17/15	40
Farmington Square Eugene	Eugene, OR	100%	—	1,428	16,138	17,566	101	1,428	16,239	17,667	(1,870	)	1996/1997, 2011, 2019	09/17/15	40
Farmington Square Tualatin	Tualatin, OR	100%	—	527	14,659	15,186	101	527	14,760	15,287	(1,709	)	1995/1997, 2019	09/17/15	40
Farmington Square of Salem	Salem, OR	100%	—	1,074	19,421	20,495	408	1,074	19,829	20,903	(2,345	)	1989/1995, 2018	09/17/15	40
Colorado Springs	Colorado Springs, CO	100%	—	1,210	9,490	10,700	—	1,210	9,490	10,700	(1,175	)	2013/2019	11/16/15	40
Sun City West	Sun City West, AZ	100%	—	930	9,170	10,100	248	930	9,418	10,348	(1,005	)	2012	07/01/16	40
Poet’s Walk at Fredericksburg	Fredericksburg, VA	100%	—	1,379	21,209	22,588	—	1,379	21,209	22,588	(2,167	)	2016	07/14/16	40
Poet’s Walk at Chandler Oaks	Round Rock, TX	100%	—	679	13,642	14,321	—	679	13,642	14,321	(1,398	)	2016	08/01/16	40
The Montecito Santa Fe	Santa Fe, NM	100%	—	2,536	19,441	21,977	1,892	2,807	23,468	26,275	(1,996	)	2006	09/23/16	40
The Golden Crest	Franklin, NH	100%	—	292	6,889	7,181	97	292	6,996	7,288	(736	)	1988	11/30/16	40
Poet’s Walk at Henderson	Henderson, NV	100%	—	1,430	21,850	23,280	—	1,430	21,862	23,292	(1,920	)	2016	12/01/16	40
Kruse Village	Brenham, TX	100%	—	476	11,912	12,388	—	476	11,922	12,398	(1,198	)	1991	12/02/16	40
Poet’s Walk of Cedar Parks	Cedar Park, TX	100%	—	1,035	13,127	14,162	—	1,035	13,127	14,162	(999	)	2017	06/01/17	40
Avamere Court at Keizer	Keizer, OR	100%	—	1,220	31,783	33,003	—	1,220	31,783	33,003	(2,002	)	1970	08/17/17	40
Arbor Court Retirement Community at Alvamar	Lawrence, KS	100%	—	584	4,431	5,015	—	584	4,431	5,015	(313	)	1995/2014	08/17/17	40
Arbor Court Retirement Community at Salina	Salina, KS	100%	—	584	3,020	3,604	—	584	3,020	3,604	(212	)	1989/2014	08/17/17	40
Arbor Court Retirement Community at Topeka	Topeka, KS	100%	—	313	5,492	5,805	—	313	5,492	5,805	(356	)	1986/2014	08/17/17	40
Aspen Grove Assisted Living	Sturgis, SD	100%	—	555	6,487	7,042	—	555	6,487	7,042	(464	)	2013	08/17/17	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Maurice Griffith Manor Living Center	Casper, WY	100%	—	294	72	366	—	294	72	366	(9	)	1984/1985	08/17/17	40
The Peaks at Old Laramie Trail (Lafayette)	Lafayette, CO	100%	—	1,085	19,243	20,328	—	1,883	19,196	21,079	(1,217	)	2016	12/15/17	40
Prairie View	Winnebago, IL	100%	—	263	3,743	4,006	—	263	3,743	4,006	(229	)	2007	01/31/18	40
Arbor View Assisted Living	Pewaukee, WI	100%	—	1,019	3,606	4,625	—	1,019	3,606	4,625	(187	)	2010	04/16/18	40
Legacy Assisted Living	Pewaukee, WI	100%	—	661	5,680	6,341	—	661	5,680	6,341	(272	)	2015	04/16/18	40
Greenfield of Strasburg	Strasburg, VA	100%	—	666	5,551	6,217	—	666	5,551	6,217	(273	)	2001	04/30/18	40
Poets Walk of Sarasota	Sarasota, FL	100%	—	1,440	22,541	23,981	—	1,440	22,541	23,981	(991	)	2018	05/18/18	40
The Pointe at Lifespring	Knoxville, TN	100%	—	1,603	9,219	10,822	—	1,603	9,219	10,822	(413	)	2017	08/31/18	40
Shavano Park Senior Living	Shavano Park, TX	100%	—	2,131	11,541	13,672	—	2,131	11,541	13,672	(472	)	2015	08/31/18	40
Traditions of Beavercreek	Beavercreek, OH	100%	—	1,622	24,215	25,837	5,686	1,622	29,901	31,523	(916	)	2016	11/01/18	40
Cadence at Poway Gardens	Poway, CA	100%	—	3,693	14,467	18,160	—	3,693	14,467	18,160	(35	)	1987/2011	11/22/19	40
			28,441	56,002	569,489	625,491	19,290	56,171	574,517	630,688	(72,278	)
Senior Housing - Managed
Winter Village	Frankenmuth, MI	100%	—	5,027	20,929	25,956	871	5,027	21,800	26,827	(4,475	)	1982/2008	09/21/12	40
Stoney River Marshfield	Marshfield, WI	100%	—	574	8,733	9,307	163	574	8,896	9,470	(1,806	)	2010	12/18/12	40
Kensington Court	Windsor, ON	100%	—	1,360	16,855	18,215	590	1,405	17,993	19,398	(2,458	)	1998	06/11/15	40
Masonville Manor	London, ON	100%	—	960	19,056	20,016	376	991	20,051	21,042	(2,662	)	1998/2015, 2019	06/11/15	40
Okanagan Chateau	Kelowna, BC	100%	—	2,321	8,308	10,629	1,065	2,396	9,643	12,039	(1,381	)	1990/2019	06/11/15	40
Court at Laurelwood	Waterloo, ON	100%	—	1,823	22,135	23,958	283	1,881	23,138	25,019	(3,035	)	2005/2015	06/11/15	40
Fairwinds Lodge	Sarnia, ON	100%	—	1,187	20,346	21,533	485	1,224	21,493	22,717	(2,811	)	2000/2019	06/11/15	40
The Shores	Kamloops, BC	100%	4,957	679	8,024	8,703	222	700	8,507	9,207	(1,163	)	1992/2014	06/11/15	40
Orchard Valley	Vernon, BC	100%	6,599	843	10,724	11,567	178	278	11,251	11,529	(1,456	)	1990/2008	06/11/15	40
Cherry Park	Penticton, BC	100%	4,752	763	6,771	7,534	592	787	7,584	8,371	(1,013	)	1990/1991, 2014, 2019	06/11/15	40
Maison Senior Living	Calgary, AB	100%	—	3,908	20,996	24,904	508	4,034	22,187	26,221	(2,631	)	2013	09/17/15	40
Ramsey	Ramsey, MN	100%	—	1,182	13,280	14,462	31	1,182	13,316	14,498	(909	)	2015	10/06/17	40
Marshfield II	Marshfield, WI	100%	—	500	4,134	4,634	9	500	4,148	4,648	(317	)	2014	10/06/17	40
Dover Place	Dover, DE	100%	—	2,797	23,054	25,851	99	2,797	23,153	25,950	(1,381	)	1999	01/02/18	40
Kanawha Place	Charleston, WV	100%	—	419	4,239	4,658	305	419	4,544	4,963	(368	)	1969	01/02/18	40
Leighton Place	Williamsport, PA	100%	—	296	9,191	9,487	174	296	9,365	9,661	(591	)	1990/2009	01/02/18	40
Maidencreek Place	Reading, PA	100%	—	684	12,950	13,634	34	684	12,984	13,668	(796	)	2004	01/02/18	40
Rolling Meadows Place	Scott Depot, WV	100%	—	230	6,271	6,501	238	230	6,510	6,740	(483	)	1996	01/02/18	40
Willowbrook Place	Clarks Summit, PA	100%	—	406	9,471	9,877	352	406	9,823	10,229	(667	)	1997	01/02/18	40
Wyncote Place	Wyncote, PA	100%	—	1,781	4,911	6,692	289	1,781	5,199	6,980	(419	)	1909	01/02/18	40
Amity Place	Douglassville, PA	100%	—	611	19,083	19,694	74	611	19,157	19,768	(1,111	)	2008	01/02/18	40
Milford Place	Milford, DE	100%	—	1,199	18,786	19,985	153	1,199	18,939	20,138	(1,131	)	1999	01/02/18	40

				Initial Cost to Company			Cost Capitalized Subsequent to Acquisition	Gross Amount at which Carried at Close of Period							Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)	Land	Building and Improve- ments(2)(3)	Total		Land	Building and Improve- ments(2)(3)	Total	Accumulated Depreciation and Amortization		Original Date of Construction/ Renovation	Date Acquired
Oak Hill Place	Oak Hill, WV	100%	—	609	2,636	3,245	128	609	2,765	3,374	(258	)	2001/2014	01/02/18	40
Seasons Place	Lewisburg, WV	100%	—	355	5,055	5,410	339	355	5,394	5,749	(443	)	1995	01/02/18	40
Parkview in Allen	Allen, TX	100%	—	2,190	45,767	47,957	—	2,190	46,425	48,615	(6,898	)	2004/2010	09/25/14	40
The Atrium At Gainesville	Gainesville, FL	100%	—	2,139	44,789	46,928	—	2,139	46,439	48,578	(7,164	)	1986/2013, 2015, 2019	09/25/14	40
The Chateau	McKinney, TX	100%	—	2,760	44,397	47,157	—	2,760	45,243	48,003	(6,787	)	2006/2010, 2019	09/25/14	40
Gardens At Wakefield Plantation	Raleigh, NC	100%	—	2,344	37,506	39,850	—	2,344	38,200	40,544	(5,572	)	2002/2014	09/25/14	40
Las Brisas	San Luis Obispo, CA	100%	—	4,992	30,909	35,901	—	4,992	31,349	36,341	(4,749	)	1987/2006, 2015	09/25/14	40
Creekside Terrace	Winston-Salem, NC	100%	—	2,995	24,428	27,423	—	2,995	24,713	27,708	(3,822	)	2001	09/25/14	40
Colonial Village	Longview, TX	100%	—	805	26,498	27,303	—	805	27,458	28,263	(4,157	)	1985/2010	09/25/14	40
Garden Village	Kansas City, MO	100%	—	1,325	20,510	21,835	—	1,325	21,381	22,706	(3,413	)	1983	09/25/14	40
Desert Rose	Yuma, AZ	100%	—	530	21,775	22,305	—	530	22,066	22,596	(3,395	)	1996/2014	09/25/14	40
Windland South	Nashville, TN	100%	—	1,996	19,368	21,364	—	1,996	20,281	22,277	(3,330	)	1986/2000	09/25/14	40
Cedar Woods	Branford, CT	100%	—	2,403	18,821	21,224	—	2,403	19,263	21,666	(2,962	)	1987	09/25/14	40
Virginian	Richmond, VA	100%	—	1,080	19,545	20,625	—	1,080	20,131	21,211	(3,141	)	1989/2007	09/25/14	40
Monarch Estates	Auburn, AL	100%	—	3,209	17,326	20,535	—	3,209	17,640	20,849	(2,821	)	2001	09/25/14	40
Village At The Falls	Menomonee Falls, WI	100%	—	1,477	18,778	20,255	—	1,477	19,044	20,521	(3,030	)	2005/2006, 2007/2011, 2019	09/25/14	40
Holiday At The Atrium	Glenville, NY	100%	—	978	18,257	19,235	—	978	18,967	19,945	(2,919	)	2001/2014	09/25/14	40
Lake Ridge Village	Eustis, FL	100%	—	1,152	17,523	18,675	—	1,152	18,330	19,482	(2,885	)	1984/1988, 2013	09/25/14	40
Heritage Village	McAllen, TX	100%	—	4,092	13,823	17,915	—	4,092	14,321	18,413	(2,339	)	1988	09/25/14	40
Madison Meadows	Phoenix, AZ	100%	—	2,567	12,029	14,596	—	2,567	12,807	15,374	(2,136	)	1986	09/25/14	40
South Wind Heights	Jonesboro, AR	100%	—	1,782	11,244	13,026	—	1,782	11,721	13,503	(1,939	)	1999	09/25/14	40
Harrison Regent	Ogden, UT	100%	—	794	10,873	11,667	—	794	11,607	12,401	(1,843	)	1985/2016	09/25/14	40
Capital Place	Olympia, WA	100%	—	2,477	23,767	26,244	—	2,477	25,160	27,637	(3,769	)	1986/2016	10/07/14	40
The Monarch at Richardson	Richardson, TX	100%	—	2,282	10,556	12,838	94	2,282	10,650	12,932	(57	)	1999	11/01/19	40
			16,308	76,883	804,427	881,310	7,652	76,735	831,036	907,771	(112,893	)
Specialty Hospitals and Other
Texas Regional Medical Center	Sunnyvale, TX	100%	—	4,020	57,620	61,640	—	4,020	57,620	61,640	(15,928	)	2009	05/03/11	40
Baylor Orthopedic Spine Hospital at Arlington	Arlington, TX	100%	—	—	44,217	44,217	—	—	44,217	44,217	(2,651	)	2009/2016	08/17/17	40
Touchstone Neurorecovery Center	Conroe, TX	100%	—	2,935	25,003	27,938	—	2,935	25,003	27,938	(1,695	)	1992	08/17/17	40
HealthBridge Children’s Hospital (Houston)	Houston, TX	100%	—	3,001	14,581	17,582	—	3,001	14,581	17,582	(890	)	1999/2009	08/17/17	40
Nexus Specialty Hospital - Woodlands Campus	Spring, TX	100%	—	1,319	15,153	16,472	—	1,319	15,153	16,472	(927	)	1995/1998	08/17/17	40
HealthBridge Children’s Hospital (Orange)	Orange, CA	100%	—	2,060	5,538	7,598	—	2,060	5,538	7,598	(353	)	2000	08/17/17	40

					Initial Cost to Company						Cost Capitalized Subsequent to Acquisition		Gross Amount at which Carried at Close of Period											Life on Which Depreciation in Latest Income Statement is Computed
Description	Location	Ownership Percentage	Encum- brances(1)		Land		Building and Improve- ments(2)(3)		Total				Land		Building and Improve- ments(2)(3)		Total		Accumulated Depreciation and Amortization			Original Date of Construction/ Renovation	Date Acquired
ResCare Tangram - Texas Hill Country School	Maxwell, TX	100%	—		902		2,384		3,286		1		902		2,385		3,287		(170		)	1993	08/17/17	40
ResCare Tangram - Chaparral	Maxwell, TX	100%	—		901		1,198		2,099		—		901		1,198		2,099		(103		)	1994/2009	08/17/17	40
ResCare Tangram - Sierra Verde & Roca Vista	Maxwell, TX	100%	—		456		2,632		3,088		—		456		2,632		3,088		(176		)	1992	08/17/17	40
ResCare Tangram - 618 W. Hutchinson	San Marcos, TX	100%	—		51		359		410		62		51		421		472		(70		)	1869	08/17/17	40
ResCare Tangram - Ranch	Seguin, TX	100%	—		539		2,627		3,166		—		539		2,627		3,166		(223		)	1989	08/17/17	40
ResCare Tangram - Mesquite	Seguin, TX	100%	—		228		3,407		3,635		79		228		3,486		3,714		(247		)	1985/1991	08/17/17	40
ResCare Tangram - Hacienda	Kingsbury, TX	100%	—		104		2,788		2,892		27		104		2,814		2,918		(182		)	1990/2012	08/17/17	40
ResCare Tangram - Loma Linda	Seguin, TX	100%	—		52		805		857		—		52		805		857		(57		)	1970	08/17/17	40
Aurora Chicago Lakeshore Hospital	Chicago, IL	100%	—		8,574		39,732		48,306		—		8,574		39,732		48,306		(2,576		)	1992/2011	08/17/17	40
Aurora Arizona West	Glendale, AZ	100%	—		1,501		67,046		68,547		—		1,501		67,046		68,547		(4,104		)	1996/2013	08/17/17	40
Aurora Arizona East	Tempe, AZ	100%	—		3,137		50,073		53,210		—		3,137		50,073		53,210		(3,133		)	2001/2016	08/17/17	40
Aurora Charter Oak Hospital	Covina, CA	100%	—		23,472		71,542		95,014		—		23,472		71,542		95,014		(4,549		)	1974/2011	08/17/17	40
Aurora Vista del Mar Hospital	Ventura, CA	100%	—		8,089		43,645		51,734		—		8,089		43,645		51,734		(3,017		)	1984/2018	08/17/17	40
Aurora San Diego Hospital	San Diego, CA	100%	—		8,403		55,015		63,418		6,999		8,403		62,013		70,416		(3,855		)	1988/2017	08/17/17	40
Gateway Rehabilitation Hospital at Florence	Florence, KY	100%	—		3,866		26,447		30,313		—		3,866		26,447		30,313		(1,615		)	2000	08/17/17	40
Highlands Regional Rehabilitation Hospital	El Paso, TX	100%	—		2,009		6,639		8,648		—		2,009		6,639		8,648		(450		)	1999/2009	08/17/17	40
Landmark Carmel	Carmel, IN	100%	—		963		4,347		5,310		—		963		4,347		5,310		(64		)	1996/2019	07/24/19	40
Landmark Louisville	Louisville, KY	100%	—		1,078		8,305		9,383		—		1,078		8,305		9,383		(89		)	2002/2018	08/21/19	40
Recovery Centers of America at Monroeville	Monroeville, PA	100%	—		2,034		1,758		3,792		—		2,034		1,758		3,792		—			1987/2020	12/18/19	40
			—		79,694		552,861		632,555		7,168		79,694		560,027		639,721		(47,124		)
Multi-property Indebtedness			10,703		—		—		—		—		—		—		—		—
			114,777		599,391		5,225,059		5,824,450		84,261		597,385		5,282,461		5,879,846		(538,860		)
Corporate Assets			—		—		136		136		601		—		737		737		(353		)
			$	114,777	$	599,391	$	5,225,195	$	5,824,586	$	84,862	$	597,385	$	5,283,198	$	5,880,583	$	(539,213	)

⁽¹⁾  Encumbrances do not include deferred financing costs, net of $1.7 million as of December 31, 2019.

⁽²⁾  Building and building improvements include land improvements and furniture and equipment.

⁽³⁾  The aggregate cost of real estate for federal income tax purposes was $4.9 billion.

⁽⁴⁾ 

Property serves as collateral for secured debt totaling $10.7 million as of December 31, 2019.

SCHEDULE III

REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION

(dollars in thousands)

	Year Ended December 31,
	2019			2018			2017
Real estate:
Balance at the beginning of the year	$	6,255,883		$	6,334,855		$	2,292,751
Acquisitions	49,483			262,605			4,145,977
Real estate assumed	12,962			—			—
Real estate acquired through loans receivable foreclosure	—			—			19,096
Improvements	25,451			27,697			6,954
Impairment	(143,655		)	(1,576		)	(2,211		)
Sale of real estate	(322,910		)	(351,922		)	(133,897		)
Foreign currency translation	6,918			(12,639		)	10,556
Write-off of fully depreciated assets	(3,549		)	(3,137		)	(4,371		)
Balance at the end of the year	$	5,880,583		$	6,255,883		$	6,334,855
Accumulated depreciation:
Balance at the beginning of the year	$	(402,338	)	$	(340,423	)	$	(282,812	)
Depreciation expense	(163,863		)	(174,398		)	(101,198		)
Impairment	22,070			163			885
Sale of real estate	2,092			108,122			38,914
Foreign currency translation	(723		)	1,061			(583		)
Write-off of fully depreciated assets	3,549			3,137			4,371
Balance at the end of the year	$	(539,213	)	$	(402,338	)	$	(340,423	)

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net income	$ 69,018	$ 279,115	$ 158,365
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	181,549	191,379	113,882
Non-cash rental and related revenues	(19,449)	(36,443)	(30,352)
Non-cash interest income	(2,212)	(2,300)	(769)
Non-cash interest expense	10,080	10,137	7,776
Stock-based compensation expense	9,819	7,648	8,359
Non-cash lease termination income	(10,579)	0	0
Loss on extinguishment of debt	16,340	2,917	553
Provision for doubtful accounts, straight-line rental income and loan losses	1,238	39,075	17,113
Change in fair value of contingent consideration	0	0	(426)
Net gain on sales of real estate	(2,300)	(128,198)	(52,029)
Impairment of real estate	121,819	1,413	1,326
Loss from unconsolidated joint venture	6,796	5,431	0
Distributions of earnings from unconsolidated joint venture	13,865	8,910	0
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net	(9,639)	(6,753)	(16,811)
Accounts payable and accrued liabilities	(13,870)	(11,745)	(71,198)
Net cash provided by operating activities	372,475	360,586	135,789
Cash flows from investing activities:
Acquisition of real estate	(51,136)	(261,511)	(419,905)
Cash received in CCP Merger	0	0	77,859
Origination and fundings of loans receivable	(13,065)	(50,731)	(17,239)
Origination and fundings of preferred equity investments	0	(5,313)	(2,749)
Additions to real estate	(25,451)	(27,697)	(6,954)
Repayments of loans receivable	18,367	51,789	32,430
Repayments of preferred equity investments	5,079	6,870	3,755
Investment in unconsolidated joint venture	0	(354,461)	0
Net proceeds from sales of real estate	329,050	382,560	150,243
Net cash provided by (used in) investing activities	262,844	(258,494)	(182,560)
Cash flows from financing activities:
Net (repayments of) proceeds from revolving credit facility	(624,000)	(17,000)	253,000
Proceeds from issuance of senior unsecured notes	638,779	0	0
Principal payments on senior unsecured notes	(700,000)	0	0
Proceeds from term loans	0	0	181,000
Principal payments on term loans	(145,000)	0	0
Principal payments on secured debt	(3,436)	(140,338)	(4,145)
Payments of deferred financing costs	(15,598)	(352)	(15,337)
Payments related to extinguishment of debt	(10,502)	(2,043)	0
Payment of contingent consideration	0	0	(382)
Distributions to noncontrolling interests	(316)	(142)	(30)
Preferred stock redemption	0	(143,750)	0
Issuance of common stock, net	549,328	(499)	366,800
Dividends paid on common and preferred stock	(335,435)	(325,220)	(182,089)
Net cash (used in) provided by financing activities	(646,180)	(629,344)	598,817
Net (decrease) increase in cash, cash equivalents and restricted cash	(10,861)	(527,252)	552,046
Effect of foreign currency translation on cash, cash equivalents and restricted cash	346	(539)	738
Cash, cash equivalents and restricted cash, beginning of period	59,658	587,449	34,665
Cash, cash equivalents and restricted cash, end of period	49,143	59,658	587,449
Supplemental disclosure of cash flow information:
Interest paid	123,854	137,668	69,686
Income taxes paid	3,911	1,800	714
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of business in CCP Merger	0	0	3,726,092
Assumption of indebtedness in CCP Merger	0	0	(1,751,373)
Stock exchanged in CCP Merger	0	0	(2,052,578)
Real estate acquired through loan receivable foreclosure	0	0	19,096
Decrease in loans receivable and other investments due to acquisition of real estate	$ 0	$ 0	$ (6,913)

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net income	$ 69,018	$ 279,115	$ 158,365
Unrealized gain (loss), net of tax:
Foreign currency translation gain	679	720	154
Unrealized (loss) gain on cash flow hedges	(25,368)	292	12,933
Total other comprehensive (loss) income	(24,689)	1,012	13,087
Comprehensive income	44,329	280,127	171,452
Comprehensive (income) loss attributable to noncontrolling interest	(22)	(33)	18
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$ 44,307	$ 280,094	$ 171,470

XML

Document and Entity Information - USD ($)
$ in Billions

12 Months Ended

Dec. 31, 2019

Feb. 17, 2020

Jun. 30, 2019

Document and Entity Information [Abstract]

Document Type

10-K

Document Annual Report

true

Document Transition Report

false

Entity File Number

001-34950

Entity Registrant Name

SABRA HEALTH CARE REIT, INC.

Entity Incorporation, State or Country Code

MD

Entity Tax Identification Number

27-2560479

Entity Address, Address Line One

18500 Von Karman Avenue

Entity Address, Address Line Two

Suite 550

Entity Address, City or Town

Irvine

Entity Address, State or Province

CA

Entity Address, Postal Zip Code

92612

City Area Code

888

Local Phone Number

393-8248

Title of 12(b) Security

Common Stock, $0.01 par value

Trading Symbol

SBRA

Security Exchange Name

NASDAQ

Entity Well-known Seasoned Issuer

Yes

Entity Voluntary Filers

No

Entity Current Reporting Status

Yes

Entity Interactive Data Current

Yes

Entity Filer Category

Large Accelerated Filer

Entity Small Business

false

Entity Emerging Growth Company

false

Entity Shell Company

false

Entity Public Float

$ 3.7

Entity Common Stock, Shares Outstanding

205,274,476

Entity Central Index Key

0001492298

Current Fiscal Year End Date

--12-31

Document Period End Date

Dec. 31, 2019

Document Fiscal Year Focus

2019

Document Fiscal Period Focus

FY

Amendment Flag

false

Documents Incorporated by Reference

Portions of the Proxy Statement for the registrant’s 2020 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2019, are incorporated by reference in Part III herein.

XML

DERIVATIVE AND HEDGING INSTRUMENTS

12 Months Ended

Dec. 31, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE AND HEDGING INSTRUMENTS

DERIVATIVE AND HEDGING INSTRUMENTS

The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.

Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.

Cash Flow Hedges

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and collars as part of its interest rate risk management strategy. In May 2019, the Company terminated three forward starting interest rate swaps, resulting in a payment to counterparties totaling $12.6 million. The balance of the loss in other comprehensive income will be reclassified to earnings through 2029. As of December 31, 2019, approximately $1.2 million of gains, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months.

Net Investment Hedges

The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.

The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):  

	December 31, 2019		December 31, 2018
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)	$	1,490,000	$	1,045,000
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	54,489	$	55,401
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars	$	1,811	$	899

⁽¹⁾ Balance includes four forward starting interest rate swaps and one forward starting interest rate collar with an effective date of August 2020 and two forward starting interest rate swaps and one forward starting interest rate collar with an effective date of January 2021 that had been entered into as of December 31, 2019. The forward starting interest rate swaps and forward starting interest rate collars have an aggregate initial notional amount of $645.0 million accreting to $845.0 million in January 2023.

Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at December 31, 2019 and 2018 (dollars in thousands):    

		Count as of December 31, 2019	Fair Value				Maturity Dates
			December 31,
Type	Designation		2019		2018			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	10	$	4,239	$	25,184	2020 - 2023	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	3,238		4,160		2025	Accounts receivable, prepaid expenses and other assets, net
			$	7,477	$	29,344
Liabilities:
Forward starting interest rate swaps	Cash flow	6	$	494	$	4,529	2024	Accounts payable and accrued liabilities
Forward starting interest rate collars	Cash flow	2	132		—		2024	Accounts payable and accrued liabilities
CAD term loan	Net investment	1	96,025		91,700		2024	Term loans, net
			$	96,651	$	96,229

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of income and the consolidated statements of equity for the years ended December 31, 2019, 2018 and 2017:

	Gain (Loss) Recognized in Other Comprehensive Income								Gain (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income							Income Statement Location
	For the year ended December 31,
	2019			2018		2017			2019		2018		2017
Cash Flow Hedges:
Interest rate products	$	(19,932	)	$	2,707	$	10,807		$	5,545	$	3,099	$	(2,174	)	Interest expense
Net Investment Hedges:
Foreign currency products	(772		)	3,554		(2,378		)	—		—		—			N/A
CAD term loan	(4,325		)	7,888		(6,588		)	—		—		—			N/A
	$	(25,029	)	$	14,149	$	1,841		$	5,545	$	3,099	$	(2,174	)

The gain (loss) in the table above related to interest rate products was reclassified from accumulated other comprehensive income into interest expense. Interest expense totaled $126.6 million, $147.1 million and $88.4 million for the years ended December 31, 2019, 2018 and 2017, respectively.

During the years ended December 31, 2019 and 2018, no cash flow hedges were determined to be ineffective. During the year ended December 31, 2017, the Company determined that a portion of a cash flow hedge was ineffective and recognized $22,000 of unrealized gains related to its interest rate swaps to other income on the consolidated statements of income.

Derivatives Not Designated as Hedging Instruments

As of December 31, 2019, the Company had one outstanding cross currency interest rate swap, of which a portion was not designated as a hedging instrument, in an asset position with a fair value of $105,000 and included this amount in accounts receivable, prepaid expenses and other assets, net on the consolidated balance sheets. During the years ended December 31, 2019, 2018 and 2017, the Company recorded $5,000 and $34,000 of other income and $8,000 of other expense, respectively, related to the portion of derivatives not designated as hedging instruments.

Offsetting Derivatives

The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2019 and 2018 (in thousands):

	As of December 31, 2019
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Financial Instruments			Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	7,477	$	—	$	7,477	$	(544	)	$	—	$	6,933
Offsetting Liabilities:
Derivatives	$	626	$	—	$	626	$	(544	)	$	—	$	82

	As of December 31, 2018
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Financial Instruments			Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	29,344	$	—	$	29,344	$	(2,069	)	$	—	$	27,275
Offsetting Liabilities:
Derivatives	$	4,529	$	—	$	4,529	$	(2,069	)	$	—	$	2,460

Credit-risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of December 31, 2019, the fair value of derivatives in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, related to these agreements was $0.1 million. As of December 31, 2019, the Company has not posted any collateral related to these agreements. If the Company had breached any of these provisions at December 31, 2019, it could have been required to settle its obligations under the agreements at their termination value of $0.1 million.

XML

BUSINESS

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BUSINESS

BUSINESS

Overview

Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun (the “Separation Date”). Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants and operators throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in loans receivable; preferred equity investments; and an investment in an unconsolidated joint venture.

On August 17, 2017, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) entered into by the Company, the Operating Partnership, PR Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Merger Sub”), Care Capital Properties, Inc., a Delaware corporation (“CCP”), and Care Capital Properties, L.P. (“CCPLP”), a Delaware limited partnership and wholly owned subsidiary of CCP, CCP merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation (the “CCP Merger”), following which Merger Sub merged with and into the Company, with the Company continuing as the surviving entity (the “Subsequent Merger”), and, simultaneous with the Subsequent Merger, CCPLP merged with and into the Operating Partnership, with the Operating Partnership continuing as the surviving entity.

Pursuant to the Merger Agreement, as of the effective time of the CCP Merger, each share of CCP common stock, par value $0.01 per share, issued and outstanding immediately prior to the effective time of the CCP Merger (other than shares of CCP common stock owned directly by CCP, the Company or their respective subsidiaries, in each case not held on behalf of third parties) was converted into the right to receive 1.123 newly issued shares of Company common stock, par value $0.01 per share, plus cash in lieu of any fractional shares.

The acquisition of CCP has been reflected in the Company’s consolidated financial statements since the effective date of the CCP Merger.

XML

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

12 Months Ended

Dec. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

2019

Impairment of Real Estate

During the year ended December 31, 2019, the Company recognized a $121.8 million real estate impairment, of which amount $95.2 million related to the 28 Senior Care Centers facilities sold on April 1, 2019 and three additional Senior Care Centers facilities, two of which were subsequently sold, and the remaining $26.6 million related to six skilled nursing/transitional care facilities, five of which were subsequently sold, and four senior housing communities.

Dispositions

During the year ended December 31, 2019, the Company completed the sale of 39 skilled nursing/transitional care facilities and seven senior housing communities for aggregate consideration, net of closing costs, of $323.6 million. The net carrying value of the assets and liabilities of these facilities was $321.3 million, which resulted in an aggregate $2.3 million net gain on sale.

Excluding the net gain on sale and real estate impairment, the Company recognized $2.2 million, $19.1 million and $13.0 million of net income during the years ended December 31, 2019, 2018 and 2017, respectively, from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

2018

Impairment of Real Estate

During the year ended December 31, 2018, the Company recognized a $1.4 million real estate impairment, of which $0.9 million related to one skilled nursing/transitional care facility and $0.5 million related to one senior housing community sold during the year.

Dispositions

During the year ended December 31, 2018, the Company completed the sale of 51 skilled nursing/transitional care facilities, six senior housing communities and one Senior Housing - Managed community for aggregate consideration, net of closing costs, of $382.6 million. The net carrying value of the assets and liabilities of these facilities was $254.4 million, resulting in an aggregate $128.2 million net gain on sale.

Excluding the net gain on sale and real estate impairment to one senior housing community sold during the year, the Company recognized $23.6 million and $47.1 million of net income during the years ended December 31, 2018 and 2017, respectively, from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

2017

Impairment of Real Estate

During the year ended December 31, 2017, the Company recognized a $1.3 million real estate impairment related to one skilled nursing/transitional care facility.

Dispositions

During the year ended December 31, 2017, the Company completed the sale of 31 skilled nursing/transitional care facilities and one senior housing community for aggregate consideration, net of closing costs, of $150.2 million. The net carrying value of the assets and liabilities of these facilities was $98.2 million, resulting in an aggregate $52.0 million net gain on sale.

Excluding the net gain on sale, the Company recognized $12.6 million of net income during the year ended December 31, 2017 from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

XML

FAIR VALUE DISCLOSURES (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Face Values, Carrying Amounts and Fair Values of Financial Instruments

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of December 31, 2019 and 2018 whose carrying amounts do not approximate their fair value (in thousands):

	December 31, 2019						December 31, 2018
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	67,527	$	63,070	$	59,832	$	96,492	$	69,460	$	65,797
Preferred equity investments	43,893		44,304		44,493		43,851		44,262		43,825
Financial liabilities:
Senior Notes	1,250,000		1,248,773		1,328,714		1,300,000		1,307,394		1,270,877
Secured indebtedness	114,777		113,070		105,510		117,464		115,679		101,820

⁽¹⁾  Face value represents amounts contractually due under the terms of the respective agreements.

⁽²⁾ 

Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

Inputs Used for Valuation of Financial Instruments

The Company determined the fair value of financial instruments as of December 31, 2019 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets:
Loans receivable	$	59,832	$	—	$	—	$	59,832
Preferred equity investments	44,493		—		—		44,493
Financial liabilities:
Senior Notes	1,328,714		—		1,328,714		—
Secured indebtedness	105,510		—		—		105,510

Amounts Measured at Fair Value

During the year ended December 31, 2019, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps	$	4,239	$	—	$	4,239	$	—
Cross currency swaps	3,238		—		3,238		—
Financial liabilities:
Forward starting interest rate swaps	494		—		494		—
Forward starting interest rate collars	132		—		132		—

XML

INTANGIBLE ASSETS AND LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets and Liabilities

The following table summarizes the Company’s intangible assets and liabilities as of December 31, 2019 and 2018 (in thousands):

	December 31,
	2019			2018
Lease Intangible Assets:
Above market leases	$	51,040		$	61,572
Tenant origination and absorption costs	65,234			73,323
Tenant relationship	23,150			26,936
Gross lease intangible assets	139,424			161,831
Accumulated amortization	(37,915		)	(30,734		)
Lease intangible assets, net	$	101,509		$	131,097
Lease Intangible Liabilities:
Below market leases	$	99,133		$	102,098
Accumulated amortization	(29,187		)	(18,372		)
Lease intangible liabilities, net	$	69,946		$	83,726

Summary of Real Estate Intangible Amortization

The following is a summary of real estate intangible amortization income (expense) for the years ended December 31, 2019, 2018 and 2017 (in thousands): 

	Year Ended December 31,
	2019			2018			2017
Increase (decrease) to rental income related to above/below market leases, net	$	508		$	(7,701	)	$	912
Depreciation and amortization related to tenant origination and absorption costs and tenant relationship	(17,674		)	(16,118		)	(11,822		)

Remaining Unamortized Balance for Outstanding Intangible Assets and Liabilities

The remaining unamortized balance for these outstanding intangible assets and liabilities as of December 31, 2019 will be amortized for the years ending December 31 as follows (dollars in thousands):

	Lease Intangible Assets		Lease Intangible Liabilities
2020	$	14,140	$	12,221
2021	11,782		8,012
2022	11,441		7,269
2023	9,702		7,269
2024	9,061		7,168
Thereafter	45,383		28,007
	$	101,509	$	69,946
Weighted-average remaining amortization period	10.5 years		8.9 years

XML

INTANGIBLE ASSETS AND LIABILITIES - Remaining Unamortized Balance for Outstanding Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets
Lease intangible assets, net	$ 101,509	$ 131,097
Lease Intangible Assets
Finite-Lived Intangible Assets
2020	14,140
2021	11,782
2022	11,441
2023	9,702
2024	9,061
Thereafter	45,383
Lease intangible assets, net	$ 101,509
Lease Intangible Assets | Weighted Average
Finite-Lived Intangible Assets
Weighted-average remaining amortization period	10 years 6 months
Lease Intangible Liabilities
Finite-Lived Intangible Assets
2020	$ 12,221
2021	8,012
2022	7,269
2023	7,269
2024	7,168
Thereafter	28,007
Lease intangible assets, net	$ 69,946
Lease Intangible Liabilities | Weighted Average
Finite-Lived Intangible Assets
Weighted-average remaining amortization period	8 years 10 months 24 days

XML

DEBT - Secured Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Deferred financing costs, net	$ 21,313
Secured Debt
Debt Instrument [Line Items]
Deferred financing costs, net	1,707	$ 1,800
Secured Debt | Fixed Rate
Debt Instrument [Line Items]
Principal, fixed rate	$ 114,777	$ 117,464
Weighted average effective interest rate	3.67%

XML

EARNINGS PER COMMON SHARE - Narrative (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share
Stock options outstanding (in shares)	0
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share
Anti-dilutive shares excluded from the computation of earnings per share (in shares)	1,000	121,000	132,000
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share
Anti-dilutive shares excluded from the computation of earnings per share (in shares)		0	0

XML

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 40,742	$ 17,972	$ 10,111
Charged to Earnings	1,238	41,793	17,498
Recoveries	0	(2,718)	(385)
Uncollectible Accounts Written-off	(41,416)	(16,305)	(9,252)
Balance at End of Year	564	40,742	17,972
Allowance for doubtful accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	3,706	5,520	3,693
Charged to Earnings	0	986	2,485
Recoveries	0	(2,718)	(385)
Uncollectible Accounts Written-off	(3,706)	(82)	(273)
Balance at End of Year	0	3,706	5,520
Straight-line rent receivable allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	35,778	12,355	3,668
Charged to Earnings	0	39,646	10,487
Recoveries	0	0	0
Uncollectible Accounts Written-off	(35,778)	(16,223)	(1,800)
Balance at End of Year	0	35,778	12,355
Loan loss reserves
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	1,258	97	2,750
Charged to Earnings	1,238	1,161	4,526
Recoveries	0	0	0
Uncollectible Accounts Written-off	(1,932)	0	(7,179)
Balance at End of Year	$ 564	$ 1,258	$ 97

XML

STOCK-BASED COMPENSATION - Summary of Additional Information Concerning Restricted Stock Units (Details) - Restricted Stock Units - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restricted Stock Units Activity
Unvested beginning balance (in shares)	1,477,318
Granted (in shares)	603,131
Vested (in shares)	(433,181)
Dividends reinvested (in shares)	152,329
Cancelled (in shares)	(61,735)
Unvested ending balance (in shares)	1,737,862	1,477,318
Weighted Average Grant Date Fair Value Per Unit
Unvested beginning balance (in dollars per share)	$ 17.88
Granted (in dollars per share)	20.59	$ 16.02	$ 19.38
Vested (in dollars per share)	18.34
Dividends reinvested (in dollars per share)	18.60
Cancelled (in dollars per share)	18.29
Unvested ending balance (in dollars per share)	$ 18.90	$ 17.88

XML

SUMMARIZED CONSOLIDATING INFORMATION - Consolidating Statement of Cash Flows (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	$ 372,475	$ 360,586	$ 135,789
Cash flows from investing activities:
Acquisition of real estate	(51,136)	(261,511)	(419,905)
Cash received in CCP Merger	0	0	77,859
Origination and fundings of loans receivable	(13,065)	(50,731)	(17,239)
Origination and fundings of preferred equity investments	0	(5,313)	(2,749)
Additions to real estate	(25,451)	(27,697)	(6,954)
Repayments of loans receivable	18,367	51,789	32,430
Repayments of preferred equity investments	5,079	6,870	3,755
Investment in unconsolidated joint venture	0	(354,461)	0
Net proceeds from sales of real estate	329,050	382,560	150,243
Distribution from subsidiaries	0	0	0
Intercompany financing	0	0	0
Net cash provided by (used in) investing activities	262,844	(258,494)	(182,560)
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	(624,000)	(17,000)	253,000
Proceeds from term loans	0	0	181,000
Proceeds from issuance of senior unsecured notes	638,779	0	0
Principal payments on senior unsecured notes	(700,000)	0	0
Principal payments on term loans	(145,000)	0	0
Principal payments on secured debt	(3,436)	(140,338)	(4,145)
Payments of deferred financing costs	(15,598)	(352)	(15,337)
Payments related to extinguishment of debt	(10,502)	(2,043)	0
Payment for Contingent Consideration Liability, Financing Activities	0	0	382
Distributions to noncontrolling interests	(316)	(142)	(30)
Issuance of common stock, net	549,328	(499)	366,800
Preferred stock redemption	0	(143,750)	0
Dividends paid on common and preferred stock	(335,435)	(325,220)	(182,089)
Distribution to parent	0	0	0
Intercompany financing	0	0	0
Net cash (used in) provided by financing activities	(646,180)	(629,344)	598,817
Net (decrease) increase in cash, cash equivalents and restricted cash	(10,861)	(527,252)	552,046
Effect of foreign currency translation on cash, cash equivalents and restricted cash	346	(539)	738
Cash, cash equivalents and restricted cash, beginning of period	59,658	587,449	34,665
Cash, cash equivalents and restricted cash, end of period	49,143	59,658	587,449
Elimination
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	0	0	0
Cash flows from investing activities:
Acquisition of real estate	0	0	0
Cash received in CCP Merger			0
Origination and fundings of loans receivable	0	0	0
Origination and fundings of preferred equity investments		0	0
Additions to real estate	0	0	0
Repayments of loans receivable	0	0	0
Repayments of preferred equity investments	0	0	0
Investment in unconsolidated joint venture		0
Net proceeds from sales of real estate	0	0	0
Distribution from subsidiaries	(10,496)	(10,914)	(4,948)
Intercompany financing	324,025	619,141	80,665
Net cash provided by (used in) investing activities	313,529	608,227	75,717
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	0	0	0
Proceeds from term loans			0
Proceeds from issuance of senior unsecured notes	0
Principal payments on senior unsecured notes	0
Principal payments on term loans	0
Principal payments on secured debt	0	0	0
Payments of deferred financing costs	0	0	0
Payments related to extinguishment of debt	0	0
Payment for Contingent Consideration Liability, Financing Activities			0
Distributions to noncontrolling interests	0	0	0
Issuance of common stock, net	0	0	0
Preferred stock redemption		0
Dividends paid on common and preferred stock	0	0	0
Distribution to parent	10,496	10,914	4,948
Intercompany financing	(324,025)	(619,141)	(80,665)
Net cash (used in) provided by financing activities	(313,529)	(608,227)	(75,717)
Net (decrease) increase in cash, cash equivalents and restricted cash	0	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0	0
Cash, cash equivalents and restricted cash, end of period	0	0	0
Parent Company | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	359,681	312,485	59,640
Cash flows from investing activities:
Acquisition of real estate	0	0	0
Cash received in CCP Merger			77,859
Origination and fundings of loans receivable	0	0	0
Origination and fundings of preferred equity investments		0	0
Additions to real estate	(115)	(40)	(181)
Repayments of loans receivable	0	0	0
Repayments of preferred equity investments	0	0	0
Investment in unconsolidated joint venture		0
Net proceeds from sales of real estate	0	0	0
Distribution from subsidiaries	5,248	5,457	2,474
Intercompany financing	(590,173)	(319,268)	168,999
Net cash provided by (used in) investing activities	(585,040)	(313,851)	249,151
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	0	0	0
Proceeds from term loans			0
Proceeds from issuance of senior unsecured notes	0
Principal payments on senior unsecured notes	0
Principal payments on term loans	0
Principal payments on secured debt	0	0	0
Payments of deferred financing costs	0	0	0
Payments related to extinguishment of debt	0	0
Payment for Contingent Consideration Liability, Financing Activities			0
Distributions to noncontrolling interests	0	0	0
Issuance of common stock, net	549,328	(499)	366,800
Preferred stock redemption		(143,750)
Dividends paid on common and preferred stock	(335,435)	(325,220)	(182,089)
Distribution to parent	0	0	0
Intercompany financing	0	0	0
Net cash (used in) provided by financing activities	213,893	(469,469)	184,711
Net (decrease) increase in cash, cash equivalents and restricted cash	(11,466)	(470,835)	493,502
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0	0
Cash, cash equivalents and restricted cash, beginning of period	40,835	511,670	18,168
Cash, cash equivalents and restricted cash, end of period	29,369	40,835	511,670
Operating Partnership | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	0	0	0
Cash flows from investing activities:
Acquisition of real estate	0	0	0
Cash received in CCP Merger			0
Origination and fundings of loans receivable	0	0	0
Origination and fundings of preferred equity investments		0	0
Additions to real estate	0	0	0
Repayments of loans receivable	0	0	0
Repayments of preferred equity investments	0	0	0
Investment in unconsolidated joint venture		0
Net proceeds from sales of real estate	0	0	0
Distribution from subsidiaries	5,248	5,457	2,474
Intercompany financing	266,148	(299,873)	(249,664)
Net cash provided by (used in) investing activities	271,396	(294,416)	(247,190)
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	(624,000)	(17,000)	253,000
Proceeds from term loans			181,000
Proceeds from issuance of senior unsecured notes	638,779
Principal payments on senior unsecured notes	(700,000)
Principal payments on term loans	(145,000)
Principal payments on secured debt	0	0	0
Payments of deferred financing costs	(15,598)	(352)	(15,337)
Payments related to extinguishment of debt	(10,502)	(2,043)
Payment for Contingent Consideration Liability, Financing Activities			0
Distributions to noncontrolling interests	0	0	0
Issuance of common stock, net	0	0	0
Preferred stock redemption		0
Dividends paid on common and preferred stock	0	0	0
Distribution to parent	(5,248)	(5,457)	(2,474)
Intercompany financing	590,173	319,268	(168,999)
Net cash (used in) provided by financing activities	(271,396)	294,416	247,190
Net (decrease) increase in cash, cash equivalents and restricted cash	0	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0	0
Cash, cash equivalents and restricted cash, end of period	0	0	0
Sabra Health Care, L.L.C. | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	0	0	0
Cash flows from investing activities:
Acquisition of real estate	0	0	0
Cash received in CCP Merger			0
Origination and fundings of loans receivable	0	0	0
Origination and fundings of preferred equity investments		0	0
Additions to real estate	0	0	0
Repayments of loans receivable	0	0	0
Repayments of preferred equity investments	0	0	0
Investment in unconsolidated joint venture		0
Net proceeds from sales of real estate	0	0	0
Distribution from subsidiaries	0	0	0
Intercompany financing	0	0	0
Net cash provided by (used in) investing activities	0	0	0
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	0	0	0
Proceeds from term loans			0
Proceeds from issuance of senior unsecured notes	0
Principal payments on senior unsecured notes	0
Principal payments on term loans	0
Principal payments on secured debt	0	0	0
Payments of deferred financing costs	0	0	0
Payments related to extinguishment of debt	0	0
Payment for Contingent Consideration Liability, Financing Activities			0
Distributions to noncontrolling interests	0	0	0
Issuance of common stock, net	0	0	0
Preferred stock redemption		0
Dividends paid on common and preferred stock	0	0	0
Distribution to parent	0	0	0
Intercompany financing	0	0	0
Net cash (used in) provided by financing activities	0	0	0
Net (decrease) increase in cash, cash equivalents and restricted cash	0	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0	0
Cash, cash equivalents and restricted cash, end of period	0	0	0
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	12,794	48,101	76,149
Cash flows from investing activities:
Acquisition of real estate	(51,136)	(261,511)	(419,905)
Cash received in CCP Merger			0
Origination and fundings of loans receivable	(13,065)	(50,731)	(17,239)
Origination and fundings of preferred equity investments		(5,313)	(2,749)
Additions to real estate	(25,336)	(27,657)	(6,773)
Repayments of loans receivable	18,367	51,789	32,430
Repayments of preferred equity investments	5,079	6,870	3,755
Investment in unconsolidated joint venture		(354,461)
Net proceeds from sales of real estate	329,050	382,560	150,243
Distribution from subsidiaries	0	0	0
Intercompany financing	0	0	0
Net cash provided by (used in) investing activities	262,959	(258,454)	(260,238)
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	0	0	0
Proceeds from term loans			0
Proceeds from issuance of senior unsecured notes	0
Principal payments on senior unsecured notes	0
Principal payments on term loans	0
Principal payments on secured debt	(3,436)	(140,338)	(4,145)
Payments of deferred financing costs	0	0	0
Payments related to extinguishment of debt	0	0
Payment for Contingent Consideration Liability, Financing Activities			382
Distributions to noncontrolling interests	(316)	(142)	(30)
Issuance of common stock, net	0	0	0
Preferred stock redemption		0
Dividends paid on common and preferred stock	0	0	0
Distribution to parent	(5,248)	(5,457)	(2,474)
Intercompany financing	(266,148)	299,873	249,664
Net cash (used in) provided by financing activities	(275,148)	153,936	242,633
Net (decrease) increase in cash, cash equivalents and restricted cash	605	(56,417)	58,544
Effect of foreign currency translation on cash, cash equivalents and restricted cash	346	(539)	738
Cash, cash equivalents and restricted cash, beginning of period	18,823	75,779	16,497
Cash, cash equivalents and restricted cash, end of period	$ 19,774	$ 18,823	$ 75,779

XML

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Narrative (Details)			1 Months Ended			3 Months Ended	4 Months Ended	9 Months Ended	10 Months Ended	12 Months Ended
	Apr. 01, 2019 USD ($) facility	Dec. 19, 2018 facility	Jan. 31, 2020 facility	May 31, 2019 facility	Mar. 31, 2019 USD ($)	Dec. 31, 2019 USD ($) facility	Jan. 31, 2020 facility	Dec. 31, 2019 USD ($) facility	Jan. 31, 2020 facility	Dec. 31, 2019 USD ($) facility	Dec. 31, 2018 USD ($) facility	Dec. 31, 2017 USD ($)
Real Estate Properties [Line Items]
Weighted average expiration period						8 years		8 years		8 years
Security deposit liability						$ 10,500,000		$ 10,500,000		$ 10,500,000	$ 12,400,000
Letters of credit deposited						83,000,000		83,000,000		83,000,000	98,000,000
Deposits held for future real estate taxes, insurance expenditures and tenant improvement						$ 14,300,000		$ 14,300,000		14,300,000	17,500,000
Reserve for unpaid cash rents											1,300,000
Reserve associated with straight-line rental income											35,800,000
Portion of settlement applied to post-petition rent										6,200,000
Impairment of real estate										121,819,000	1,413,000	$ 1,326,000
Gain (loss) on termination of lease										10,579,000	0	0
Resident fees and services										128,058,000	70,137,000	26,430,000
Ancillary Services
Real Estate Properties [Line Items]
Resident fees and services										$ 800,000	500,000	$ 300,000
Minimum
Real Estate Properties [Line Items]
Operating lease expiration period						1 year		1 year		1 year
Maximum
Real Estate Properties [Line Items]
Operating lease expiration period						15 years		15 years		15 years
Holiday Retirement
Real Estate Properties [Line Items]
Lease termination, income	$ 66,900,000
Total consideration received upon termination	57,200,000
Gain (loss) on termination of lease	$ 9,700,000
2019 Dispositions
Real Estate Properties [Line Items]
Impairment of real estate										$ 95,200,000
Senior Care Centers Sale Facilities
Real Estate Properties [Line Items]
Impairment of real state, related to indemnity										10,200,000
Contractual indemnification obligation						$ 8,800,000		$ 8,800,000		$ 8,800,000
Senior Care Centers
Real Estate Properties [Line Items]
Litigation settlement, amount awarded from other party					$ 9,500,000
Senior Care Centers | 2019 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Real Estate Properties [Line Items]
Number of properties sold | facility	28
Senior Care Centers | 2019 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Subsequent Event
Real Estate Properties [Line Items]
Number of properties sold | facility									2
Senior Care Centers | Senior Care Centers Sale Facilities
Real Estate Properties [Line Items]
Aggregate sales price	$ 282,500,000
Senior Housing - Managed
Real Estate Properties [Line Items]
Senior housing communities subject to the master lease | facility		21
Skilled Nursing/Transitional Care | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Real Estate Properties [Line Items]
Impairment of real estate											$ 900,000
Skilled Nursing/Transitional Care | 2019 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Real Estate Properties [Line Items]
Number of properties sold | facility								5		39
Skilled Nursing/Transitional Care | Senior Care Centers Sale Facilities
Real Estate Properties [Line Items]
Number of properties sold | facility	26					1
Number of real estate properties transitioned | facility				8
Skilled Nursing/Transitional Care | Senior Care Centers Sale Facilities | Subsequent Event
Real Estate Properties [Line Items]
Number of properties sold | facility			1				2
Senior Housing Communities | 2019 Dispositions | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Real Estate Properties [Line Items]
Number of properties sold | facility										7
Senior Housing Communities | Senior Care Centers Sale Facilities
Real Estate Properties [Line Items]
Number of properties sold | facility	2
Operating Segments
Real Estate Properties [Line Items]
Number of properties | facility						429		429		429	470
Operating Segments | Senior Housing - Managed
Real Estate Properties [Line Items]
Number of properties | facility						46		46		46	23

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)		12 Months Ended
	Jan. 02, 2018 USD ($) Property director	Dec. 31, 2019 USD ($) Property variable_interest_entity Segment Investment	Dec. 31, 2018 USD ($) Investment	Dec. 31, 2017 USD ($)	Jan. 01, 2019 USD ($)
Property, Plant and Equipment [Line Items]
Number of investments in loans accounted for as real estate joint ventures | Investment		0	0
Acquisition costs capitalized		$ 600,000	$ 700,000
Merger and acquisition costs		$ 424,000	636,000	$ 30,255,000
Extension period for tenant relationship intangible assets		10 years
Assets held for sale		$ 0	0
Book value of investment in the joint venture		319,460,000	340,120,000
Restricted cash		$ 10,046,000	9,428,000
Number of reportable segments | Segment		1
Operating lease liability		$ 9,800,000
Operating lease right-of-use asset		9,300,000
ASU 2016-02
Property, Plant and Equipment [Line Items]
Operating lease liability					$ 10,000,000.0
Operating lease right-of-use asset					10,000,000
Cumulative effect of Topic 842 adoption					32,502,000
Straight-line rent receivable					17,500,000
Cash rent receivable					$ 15,000,000.0
Variable lease, income		17,600,000
Restricted Cash Obligations
Property, Plant and Equipment [Line Items]
Restricted cash		5,600,000	5,500,000
Skilled Nursing/Transitional Care
Property, Plant and Equipment [Line Items]
Net investment in direct financing lease		$ 23,900,000
Properties in direct financing lease | Property		1
Undiscounted rental payments		$ 4,000,000.0
Estimated unguaranteed residual value		24,700,000
Unearned lease income		4,800,000
Income from direct financing lease		2,700,000
Income from direct financing lease			$ 2,600,000	$ 1,000,000.0
Future minimum lease payments contractually due under direct financing lease, 2020		2,300,000
Future minimum lease payments contractually due under direct financing lease, 2021		$ 2,100,000
Land Improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets		5 years
Land Improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets		20 years
Buildings and Building Improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets		5 years
Buildings and Building Improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets		40 years
Furniture and Equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets		3 years
Furniture and Equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets		20 years
Enlivant Joint Venture
Property, Plant and Equipment [Line Items]
Number of real estate properties acquired | Property	172
Enlivant Joint Venture | Senior Housing Facilities
Property, Plant and Equipment [Line Items]
Number of properties sold | Property		2
Proceeds from sale of real estate		$ 6,300,000
Enlivant Joint Venture
Property, Plant and Equipment [Line Items]
Payments to acquire equity interest, before closing costs	$ 352,700,000
Equity interest acquired	49.00%
Outstanding indebtedness	$ 791,300,000
Net working capital	$ 22,900,000
Number of directors appointed by minority interest | director	3
Total number of directors | director	7
Gain (loss) on sale of properties		(1,700,000)
Book value of investment in the joint venture		$ 319,500,000
Primary Beneficiary
Property, Plant and Equipment [Line Items]
Number of variable interest entities | variable_interest_entity		0

XML

EQUITY - Narrative (Details) - USD ($)					12 Months Ended
	Dec. 11, 2019	Feb. 25, 2019	Jun. 01, 2018	Mar. 21, 2013	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Preferred stock dividend rate				7.125%
Redemption price per share (in dollars per share)			$ 25.00
Accrued and unpaid dividends (in dollars per share)			0.4453125
Redemption price per share (in dollars per share)			$ 25.4453125
Vesting of common stock units (in shares)					100,000	100,000
Tax withholding obligations					$ 1,500,000	$ 400,000	$ 3,100,000
Prior ATM Program
Class of Stock [Line Items]
Sale of stock, maximum proceeds from common stock issuances		$ 500,000,000.0
Shares of common stock issued (in shares)					23,900,000
Sale of stock, average price per share (in dollars per share)					$ 20.92
Proceeds from issuance of common stock					$ 500,000,000.0
Payments of stock issuance costs					$ 7,500,000
New ATM Program
Class of Stock [Line Items]
Sale of stock, maximum proceeds from common stock issuances	$ 400,000,000.0
Shares of common stock issued (in shares)					2,900,000
Sale of stock, average price per share (in dollars per share)					$ 20.86
Proceeds from issuance of common stock					$ 60,000,000.0
Payments of stock issuance costs					200,000
Sale of stock, remaining amount available for issuance					$ 340,000,000.0
Preferred Stock Dividends
Class of Stock [Line Items]
Charge related to original issuance costs						$ 5,500,000
Preferred Stock
Class of Stock [Line Items]
Shares redeemed (in shares)			5,750,000			5,750,000

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details)	1 Months Ended	12 Months Ended
	May 31, 2019 USD ($) derivative	Dec. 31, 2019 USD ($) derivative	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2019 CAD ($) derivative	Dec. 31, 2018 CAD ($)
Derivative [Line Items]
Interest		$ 126,610,000	$ 147,106,000	$ 88,440,000
Fair value of derivatives in a net liability position		626,000	4,529,000
Forward Starting Interest Rate Swaps
Derivative [Line Items]
Number of derivative contracts terminated | derivative	3
Payments for termination of derivative instruments	$ 12,600,000
Credit-Risk-Related Contingent Features
Derivative [Line Items]
Fair value of derivatives in a net liability position		100,000
Termination value		100,000
Cash Flow Hedges | Interest Rate Swap
Derivative [Line Items]
Hedge ineffectiveness recorded in earnings		0	0	22,000
Designated as Hedging Instrument
Derivative [Line Items]
Fair value of derivatives in a net liability position		96,651,000	96,229,000
Designated as Hedging Instrument | Cash Flow Hedges
Derivative [Line Items]
Losses included in accumulated other comprehensive loss		1,200,000
Notional amount		$ 1,490,000,000	1,045,000,000
Designated as Hedging Instrument | Cash Flow Hedges | Cross Currency Interest Rate Swaps
Derivative [Line Items]
Notional amount					$ 125,000,000	$ 125,000,000
Not Designated as Hedging Instrument | Cross Currency Interest Rate Swaps
Derivative [Line Items]
Derivative instruments | derivative		1			1
Fair value of derivative asset		$ 105,000
Other income (expense)		$ 5,000	$ 34,000	$ (8,000)

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Offsetting Assets:
Gross amounts of recognized assets	$ 7,477	$ 29,344
Gross amounts offset in the balance sheet, assets	0	0
Net amounts of assets presented in the balance sheet	7,477	29,344
Financial instruments, assets	(544)	(2,069)
Cash collateral received, assets	0	0
Net amount, assets	6,933	27,275
Offsetting Liabilities:
Gross amounts of recognized liabilities	626	4,529
Gross amounts offset in the balance sheet, liabilities	0	0
Liabilities presented in the balance sheet	626	4,529
Financial Instruments, liabilities	(544)	(2,069)
Cash collateral received, liabilities	0	0
Net amount, liabilities	$ 82	$ 2,460

XML

CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Total Stockholders’ Equity	Preferred Stock	Common Stock	Additional Paid-in Capital	Cumulative Distributions in Excess of Net Income	Accumulated Other Comprehensive (Loss) Income	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2016			5,750,000	65,285,614
Beginning balance at Dec. 31, 2016	$ 1,015,609	$ 1,015,574	$ 58	$ 653	$ 1,208,862	$ (192,201)	$ (1,798)	$ 35
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	158,365	158,383				158,383		(18)
Other comprehensive income (loss)	13,087	13,087					13,087
Change in noncontrolling interests	4,455							4,455
Distributions to noncontrolling interests	(30)							(30)
Amortization of stock-based compensation	9,244	9,244			9,244
Common stock issuance, net (in shares)				112,970,229
Common stock issuance, net	2,419,937	2,419,937		$ 1,130	2,418,807
Preferred dividends	(10,242)	(10,242)				(10,242)
Common dividends	(173,176)	(173,176)				(173,176)
Ending balance (in shares) at Dec. 31, 2017			5,750,000	178,255,843
Ending balance at Dec. 31, 2017	3,437,249	3,432,807	$ 58	$ 1,783	3,636,913	(217,236)	11,289	4,442
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	279,115	279,082				279,082		33
Other comprehensive income (loss)	217	217					217
Distributions to noncontrolling interests	(142)							(142)
Amortization of stock-based compensation	9,574	9,574			9,574
Preferred stock redemption (in shares)			(5,750,000)
Preferred stock redemption	(143,750)	(143,750)	$ (58)		(138,191)	(5,501)
Common stock issuance, net (in shares)				50,685
Common stock issuance, net	(371)	(371)		$ 0	(371)
Preferred dividends	(4,267)	(4,267)				(4,267)
Common dividends	(322,878)	(322,878)				(322,878)
Ending balance (in shares) at Dec. 31, 2018			0	178,306,528
Ending balance at Dec. 31, 2018	3,254,747	3,250,414	$ 0	$ 1,783	3,507,925	(271,595)	12,301	4,333
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	69,018	68,996				68,996		22
Other comprehensive income (loss)	(24,689)	(24,689)					(24,689)
Buyout of noncontrolling interests	0	4,039			4,039			(4,039)
Distributions to noncontrolling interests	(316)							(316)
Amortization of stock-based compensation	12,567	12,567			12,567
Common stock issuance, net (in shares)				26,901,490
Common stock issuance, net	547,817	547,817		$ 269	547,548
Common dividends	(338,182)	(338,182)				(338,182)
Ending balance (in shares) at Dec. 31, 2019			0	205,208,018
Ending balance at Dec. 31, 2019	$ 3,488,460	$ 3,488,460	$ 0	$ 2,052	$ 4,072,079	$ (573,283)	$ (12,388)	$ 0

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Assets
Accumulated depreciation	$ 539,213	$ 402,338
Equity
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	205,208,018	178,306,528
Common stock, shares outstanding (in shares)	205,208,018	178,306,528

XML

INCOME TAXES

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

The Company elected to be treated as a REIT with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. To qualify as a REIT, the Company must meet a number of organizational and operational requirements, including a requirement to distribute at least 90% of its taxable ordinary income. In addition, the Company is required to meet certain asset and income tests. As a REIT, the Company generally will not be subject to corporate level federal income tax on taxable income that it distributes to its stockholders. The Company also elected to treat certain of its consolidated subsidiaries as taxable REIT subsidiaries, which are subject to federal, state and foreign income taxes.

As a result of acquisitions in Canada during 2015, the Company is subject to income taxes under the laws of Canada. The Company recorded a $0.5 million, $0.6 million and $1.3 million income tax benefit during the years ended December 31, 2019, 2018 and 2017, respectively, with respect to its Canadian operations. Due to uncertainty over the Company’s ability to utilize this income tax benefit in future periods, the Company recorded a valuation allowance of $0.5 million, $0.7 million and $1.2 million against the deferred tax benefit during the years ended December 31, 2019, 2018 and 2017, respectively.

The Company classifies interest and penalties from significant uncertain tax positions as interest expense and operating expenses, respectively, in its consolidated financial statements. During the years ended December 31, 2019, 2018 and 2017, the Company did not incur any such interest or penalties. With certain exceptions, the tax years 2016 and thereafter remain open to examination by the major taxing jurisdictions with which the Company files tax returns.

XML

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2019

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

The Company evaluates subsequent events up until the date the consolidated financial statements are issued.

Dividend Declaration

On February 4, 2020, the Company announced that its board of directors declared a quarterly cash dividend of $0.45 per share of common stock. The dividend will be paid on February 28, 2020 to stockholders of record as of the close of business on February 14, 2020.

XML

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Real Estate Properties Held for Investment (Details) $ in Thousands	Dec. 31, 2019 USD ($) Bed facility	Dec. 31, 2018 USD ($) Bed facility
Real Estate Properties [Line Items]
Building and improvements	$ 5,042,435	$ 5,388,102
Furniture and equipment	239,229	237,145
Land improvements	1,534	1,254
Land	597,385	629,382
Total Real Estate at Cost	5,880,583	6,255,883
Accumulated Depreciation	(539,213)	(402,338)
Total Real Estate Investments, Net	$ 5,341,370	$ 5,853,545
Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	429	470
Number of Beds/Units | Bed	43,112	47,648
Total Real Estate at Cost	$ 5,879,846	$ 6,255,249
Accumulated Depreciation	(538,860)	(402,021)
Total Real Estate Investments, Net	$ 5,340,986	$ 5,853,228
Operating Segments | Skilled Nursing/Transitional Care
Real Estate Properties [Line Items]
Number of Properties | facility	296	335
Number of Beds/Units | Bed	33,290	37,628
Total Real Estate at Cost	$ 3,701,666	$ 4,094,484
Accumulated Depreciation	(306,565)	(224,942)
Total Real Estate Investments, Net	$ 3,395,101	$ 3,869,542
Operating Segments | Senior Housing - Leased
Real Estate Properties [Line Items]
Number of Properties | facility	62	90
Number of Beds/Units | Bed	3,820	7,332
Total Real Estate at Cost	$ 630,688	$ 1,237,790
Accumulated Depreciation	(72,278)	(125,902)
Total Real Estate Investments, Net	$ 558,410	$ 1,111,888
Operating Segments | Senior Housing Facilities - Managed Portfolio
Real Estate Properties [Line Items]
Number of Properties | facility	46	23
Number of Beds/Units | Bed	4,809	1,603
Total Real Estate at Cost	$ 907,771	$ 301,739
Accumulated Depreciation	(112,893)	(19,537)
Total Real Estate Investments, Net	$ 794,878	$ 282,202
Operating Segments | Specialty Hospitals and Other
Real Estate Properties [Line Items]
Number of Properties | facility	25	22
Number of Beds/Units | Bed	1,193	1,085
Total Real Estate at Cost	$ 639,721	$ 621,236
Accumulated Depreciation	(47,124)	(31,640)
Total Real Estate Investments, Net	592,597	589,596
Corporate Level
Real Estate Properties [Line Items]
Total Real Estate at Cost	737	634
Accumulated Depreciation	(353)	(317)
Total Real Estate Investments, Net	$ 384	$ 317

XML

BUSINESS (Details) - $ / shares	Aug. 17, 2017	Dec. 31, 2019	Dec. 31, 2018
Business [Line Items]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Care Capital Properties
Business [Line Items]
Common stock, par value (in dollars per share)	$ 0.01
Shares of Sabra common stock issued per share of CCP common stock (in shares)	1.123

XML

Label	Element	Value
Accounting Standards Update 2017-12 [Member] | AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 795,000
Accounting Standards Update 2017-12 [Member] | Accumulated Distributions in Excess of Net Income [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(795,000)
Accounting Standards Update 2016-02 [Member] | Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(32,502,000)
Accounting Standards Update 2016-02 [Member] | Accumulated Distributions in Excess of Net Income [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (32,502,000)

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amounts of Derivative Instruments (Details)	Jan. 31, 2023 USD ($)	Dec. 31, 2019 USD ($) derivative	Dec. 31, 2019 CAD ($) derivative	Dec. 31, 2018 USD ($)	Dec. 31, 2018 CAD ($)
Not Designated as Hedging Instrument | Cross Currency Interest Rate Swaps
Derivative [Line Items]
Derivative instruments | derivative		1	1
Cash Flow Hedges | Designated as Hedging Instrument
Derivative [Line Items]
Notional amount		$ 1,490,000,000		$ 1,045,000,000
Cash Flow Hedges | Designated as Hedging Instrument | Forward Starting Interest Rate Swaps - Effective August 2020
Derivative [Line Items]
Derivative instruments | derivative		4	4
Cash Flow Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swaps
Derivative [Line Items]
Notional amount			$ 125,000,000		$ 125,000,000
Cash Flow Hedges | Designated as Hedging Instrument | Forward Starting Interest Rate Collar - Effective August 2020
Derivative [Line Items]
Derivative instruments | derivative		1	1
Cash Flow Hedges | Designated as Hedging Instrument | Forward Starting Interest Rate Swaps - Effective January 2021
Derivative [Line Items]
Derivative instruments | derivative		2	2
Cash Flow Hedges | Designated as Hedging Instrument | Forward Starting Interest Rate Collar - Effective January 2021
Derivative [Line Items]
Derivative instruments | derivative		1	1
Cash Flow Hedges | Designated as Hedging Instrument | Forward Starting Interest Rate Swaps And Forward Starting Interest Rate Collars
Derivative [Line Items]
Notional amount		$ 645,000,000.0
Cash Flow Hedges | Designated as Hedging Instrument | Forward Starting Interest Rate Swaps And Forward Starting Interest Rate Collars | Forecast
Derivative [Line Items]
Notional amount	$ 845,000,000.0
Net Investment Hedges | Designated as Hedging Instrument
Derivative [Line Items]
Notional amount			$ 125,000,000		125,000,000
Net Investment Hedges | Designated as Hedging Instrument | Cross Currency Interest Rate Swaps
Derivative [Line Items]
Notional amount			54,489,000		55,401,000
Net Investment Hedges | Not Designated as Hedging Instrument | Cross Currency Interest Rate Swaps
Derivative [Line Items]
Notional amount			$ 1,811,000		$ 899,000

XML

FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable, face value	$ 67,527,000	$ 96,492,000
Preferred equity investments, face value	43,893,000	43,851,000
Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities, face value	1,250,000,000	1,300,000,000
Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities, face value	114,777,000	117,464,000
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	63,070,000	69,460,000
Preferred equity investments	44,304,000	44,262,000
Carrying Amount | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,248,773,000	1,307,394,000
Carrying Amount | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	113,070,000	115,679,000
Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	59,832,000	65,797,000
Preferred equity investments	44,493,000	43,825,000
Fair Value | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,328,714,000	1,270,877,000
Fair Value | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ 105,510,000	$ 101,820,000

XML

EQUITY - Summary of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity	$ 3,488,460	$ 3,254,747	$ 3,437,249	$ 1,015,609
Total accumulated other comprehensive loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity	(12,388)	12,301	$ 11,289	$ (1,798)
Foreign currency translation gain (loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity	(1,516)	(2,193)
Unrealized (loss) gain on cash flow hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity	$ (10,872)	$ 14,494

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Income tax expense (benefit) on unrealized gains on cash flow hedges	$ (49,000)	$ (48,000)	$ 100,000

XML

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Assets
Real estate investments, net of accumulated depreciation of $539,213 and $402,338 as of December 31, 2019 and 2018, respectively	$ 5,341,370	$ 5,853,545
Loans receivable and other investments, net	107,374	113,722
Investment in unconsolidated joint venture	319,460	340,120
Cash and cash equivalents	39,097	50,230
Restricted cash	10,046	9,428
Lease intangible assets, net	101,509	131,097
Accounts receivable, prepaid expenses and other assets, net	150,443	167,161
Total assets	6,069,299	6,665,303
Liabilities
Secured debt, net	113,070	115,679
Revolving credit facility	0	624,000
Term loans, net	1,040,258	1,184,930
Senior unsecured notes, net	1,248,773	1,307,394
Accounts payable and accrued liabilities	108,792	94,827
Lease intangible liabilities, net	69,946	83,726
Total liabilities	2,580,839	3,410,556
Commitments and contingencies (Note 16)
Equity
Preferred stock, $.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of December 31, 2019 and 2018	0	0
Common stock, $.01 par value; 250,000,000 shares authorized, 205,208,018 and 178,306,528 shares issued and outstanding as of December 31, 2019 and 2018, respectively	2,052	1,783
Additional paid-in capital	4,072,079	3,507,925
Cumulative distributions in excess of net income	(573,283)	(271,595)
Accumulated other comprehensive (loss) income	(12,388)	12,301
Total Sabra Health Care REIT, Inc. stockholders’ equity	3,488,460	3,250,414
Noncontrolling interests	0	4,333
Total equity	3,488,460	3,254,747
Total liabilities and equity	$ 6,069,299	$ 6,665,303

XML

EARNINGS PER COMMON SHARE

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

EARNINGS PER COMMON SHARE

EARNINGS PER COMMON SHARE

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except share and per share amounts):

	Year Ended December 31,
	2019		2018		2017
Numerator
Net income attributable to common stockholders	$	68,996	$	269,314	$	148,141
Denominator
Basic weighted average common shares and common equivalents	187,172,210		178,305,738		105,621,242
Dilutive stock options and restricted stock units	954,882		416,006		221,192
Diluted weighted average common shares	188,127,092		178,721,744		105,842,434
Net income attributable to common stockholders, per:
Basic common share	$	0.37	$	1.51	$	1.40
Diluted common share	$	0.37	$	1.51	$	1.40

During the years ended December 31, 2019, 2018 and 2017, approximately 1,000, 121,000 and 132,000 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. No stock options were outstanding as of December 31, 2019, and no stock options were considered anti-dilutive during the years ended December 31, 2018 and 2017.

XML

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

12 Months Ended

Dec. 31, 2019

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

SCHEDULE II

VALUATION AND QUALIFYING ACCOUNTS

For the Years Ended December 31, 2019, 2018 and 2017

(dollars in thousands)

	Balance at Beginning of Year		Charged to Earnings		Recoveries			Uncollectible Accounts Written-off			Balance at End of Year
Year ended December 31, 2019
Allowance for doubtful accounts (1)	$	3,706	$	—	$	—		$	(3,706	)	$	—
Straight-line rent receivable allowance (1)	35,778		—		—			(35,778		)	—
Loan loss reserves	1,258		1,238		—			(1,932		)	564
	$	40,742	$	1,238	$	—		$	(41,416	)	$	564
Year ended December 31, 2018
Allowance for doubtful accounts	$	5,520	$	986	$	(2,718	)	$	(82	)	$	3,706
Straight-line rent receivable allowance	12,355		39,646		—			(16,223		)	35,778
Loan loss reserves	97		1,161		—			—			1,258
	$	17,972	$	41,793	$	(2,718	)	$	(16,305	)	$	40,742
Year ended December 31, 2017
Allowance for doubtful accounts	$	3,693	$	2,485	$	(385	)	$	(273	)	$	5,520
Straight-line rent receivable allowance	3,668		10,487		—			(1,800		)	12,355
Loan loss reserves	2,750		4,526		—			(7,179		)	97
	$	10,111	$	17,498	$	(385	)	$	(9,252	)	$	17,972

⁽¹⁾ Balances written-off in connection with the adoption of Topic 842 on January 1, 2019.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of December 31, 2019 and 2018 and for the years ended December 31, 2019, 2018 and 2017. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements

that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of December 31, 2019, the Company determined that it was not the primary beneficiary of any VIEs.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At December 31, 2019 and 2018, none of the Company’s investments in loans were accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of December 31, 2019, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications

Certain amounts in the Company’s consolidated statements of income and consolidated statements of cash flows for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations.

Real Estate Investments and Rental Revenue Recognition

Real Estate Acquisition Valuation

All assets acquired and liabilities assumed in an acquisition of real estate accounted for as a business combination are measured at their acquisition date fair values. For acquisitions of real estate accounted for as an asset acquisition, the fair value of consideration transferred by the Company (including transaction costs) is allocated to all assets acquired and liabilities assumed on a relative fair value basis. The acquisition value of land, building and improvements are included in real estate investments on the accompanying consolidated balance sheets. The acquisition value of above market lease, tenant origination and absorption costs and tenant relationship intangible assets is included in lease intangible assets, net on the accompanying consolidated balance sheets. The acquisition value of below market lease intangible liabilities is included in lease intangible liabilities, net on the accompanying consolidated balance sheets. Acquisition costs associated with real estate acquisitions deemed asset acquisitions are capitalized, and costs associated with real estate acquisitions deemed business combinations are expensed as incurred. The Company capitalized $0.6 million and $0.7 million of acquisition costs during the years ended December 31, 2019 and 2018, respectively. Restructuring costs that do not meet the definition of a liability at the acquisition date are expensed in periods subsequent to the acquisition date. During the years ended December 31, 2019, 2018 and 2017, the Company expensed $0.4 million, $0.6 million and $30.3 million, respectively, of merger and acquisition costs.

Estimates of the fair values of the tangible assets, identifiable intangibles and assumed liabilities require the Company to make significant assumptions to estimate market lease rates, property operating expenses, carrying costs during lease-up periods, discount rates, market absorption periods, and the number of years the property will be held for investment. The Company makes its best estimate based on the Company’s evaluation of the specific characteristics of each tenant’s lease. The use of inappropriate assumptions would result in an incorrect valuation of the Company’s acquired tangible assets, identifiable intangibles and assumed liabilities, which would impact the amount of the Company’s net income.

Depreciation and Amortization

Real estate costs related to the acquisition and improvement of properties are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term of any property subject to a ground lease. Tenant improvements are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term. Depreciation is discontinued when a property is identified as held for sale. Repair and maintenance costs are charged to expense as incurred and significant replacements and betterments are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate asset. The Company considers the period of future benefit of an asset to determine its appropriate useful life. Depreciation of real estate assets and amortization of tenant origination and absorption costs and tenant relationship lease intangibles are included in depreciation and amortization on the accompanying consolidated statements of income. Amortization of above and below market lease intangibles is included in rental income on the accompanying consolidated statements of income. The Company anticipates the estimated useful lives of its assets by class to be generally as follows: land improvements, five to 20 years; buildings and building improvements, five to 40 years; and furniture and equipment, three to 20 years. Intangibles are generally amortized over the remaining noncancellable lease terms, with tenant relationship intangible amortization periods including extension periods of up to 10 years.

Impairment of Real Estate Investments

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its real estate investments may not be recoverable or realized. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, the Company assesses the recoverability by estimating whether the Company will recover the carrying value of its real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. In some instances, there may be various potential outcomes for an investment and its potential future cash flows. In these instances, the undiscounted future cash flows used to assess recoverability are based on several assumptions and are probability-weighted based on the Company’s best estimates as of the date of evaluation. These assumptions include, among others, cash flow projections, discount rates, market capitalization rates and recent sales data for comparable properties. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its real estate investments, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its real estate investments.

Revenue Recognition

The Company recognizes rental revenue from tenants, including rental abatements, lease incentives and contractual fixed increases attributable to operating leases, on a straight-line basis over the term of the related leases when it is probable that substantially all rents over the life of a lease are collectible. Certain of the Company’s leases provide for contingent rents equal to a percentage of the facility’s revenue in excess of specified base amounts or other thresholds. Such revenue is recognized when actual results reported by the tenant, or estimates of tenant results, exceed the applicable base amount or other threshold.

The Company assesses the collectability of rents on a lease-by-lease basis, and in doing so, considers such things as historical bad debts, tenant creditworthiness, current economic trends, facility operating performance, lease structure, credit enhancements (including guarantees), current developments relevant to a tenant’s business specifically and to its business category generally, and changes in tenants’ payment patterns. The Company’s assessment includes an estimation of a tenant’s ability to fulfill all of its rental obligations over the remaining lease term. In addition, with respect to tenants in bankruptcy, management makes estimates of the expected recovery of pre-petition and post-petition claims in assessing the estimated collectability of the related receivable. If at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received, and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Write-offs of receivables and any recoveries of previously written-off receivables are recorded as adjustments to rental revenue.

Revenue from resident fees and services is recorded monthly as services are provided and includes resident room and care charges, ancillary services charges and other resident charges.

Assets Held for Sale, Dispositions and Discontinued Operations

The Company generally considers real estate to be “held for sale” when the following criteria are met: (i) management commits to a plan to sell the property, (ii) the property is available for sale immediately, (iii) the property is actively being marketed for sale at a price that is reasonable in relation to its current fair value, (iv) the sale of the property within one year is considered probable and (v) significant changes to the plan to sell are not expected. Real estate that is held for sale and its related assets are classified as assets held for sale and are included in accounts receivable, prepaid expenses and other assets,

net on the accompanying consolidated balance sheets. Secured indebtedness and other liabilities related to real estate held for sale are classified as liabilities related to assets held for sale and are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets. Real estate classified as held for sale is no longer depreciated and is reported at the lower of its carrying value or its estimated fair value less estimated costs to sell. As of December 31, 2019 and 2018, the Company did not have any assets held for sale.

For sales of real estate where the Company has collected the consideration to which it is entitled in exchange for transferring the real estate, the related assets and liabilities are removed from the balance sheet and the resultant gain or loss is recorded in the period in which the transaction closes. Any post-sale involvement is accounted for as separate performance obligations, and when the separate performance obligations are satisfied, the portion of the sales price allocated to each such obligation is recognized.

Additionally, the Company records the operating results related to real estate that has been disposed of or classified as held for sale as discontinued operations for all periods presented if it represents a strategic shift that has or will have a major effect on the Company’s operations and financial results.

Investment in Unconsolidated Joint Venture

The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in the Company’s consolidated statements of income. The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company’s cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings of the joint venture.

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its equity method investments may not be recoverable or realized. When indicators of potential impairment are identified, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period and any estimated debt premiums or discounts. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its equity method investment.

On January 2, 2018, the Company completed its transaction with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, and contributed $352.7 million, before closing costs, to acquire a 49% equity interest in an entity that owned 172 senior housing communities managed by Enlivant (the “Enlivant Joint Venture”). At closing, the Enlivant Joint Venture had outstanding indebtedness of $791.3 million and net working capital of $22.9 million. The joint venture agreement includes an option for the Company to acquire the remainder of the outstanding equity interests in the Enlivant Joint Venture by January 2, 2021 and grants the Company the right of first offer if the Company’s partner in the Enlivant Joint Venture desires to transfer its equity interest (which it may do commencing on January 2, 2020). Sabra also has the right to designate three directors on the seven member board of directors of the Enlivant Joint Venture and has other customary minority rights. During 2019, the Enlivant Joint Venture sold two senior housing communities for gross proceeds of $6.3 million, and the Company recorded an aggregate net loss on sale of real estate related to unconsolidated joint venture of $1.7 million. As of December 31, 2019, the book value of the Company’s investment in the Enlivant Joint Venture was $319.5 million.

Net Investment in Direct Financing Lease

As of December 31, 2019, the Company had a $23.9 million net investment in one skilled nursing/transitional care facility leased to an operator under a direct financing lease, as the tenant is obligated to purchase the property at the end of the lease term. The net investment in direct financing lease is recorded in accounts receivable, prepaid expenses and other assets, net on the accompanying consolidated balance sheets and represents the present value of total rental payments of $4.0 million, plus the estimated unguaranteed residual value of $24.7 million, less the unearned lease income of $4.8 million as of December 31, 2019. Unearned lease income represents the excess of the minimum lease payments and residual value over the cost of the investment. Unearned lease income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured. Income from the Company’s net investment in direct financing lease was $2.7 million, $2.6 million and $1.0 million for the years ended December 31, 2019, 2018 and 2017, respectively, and is reflected in interest and other income on the accompanying consolidated statements of income. Future minimum lease payments contractually due under the direct financing lease at December 31, 2019, were as follows: $2.3 million for 2020 and $2.1 million for 2021.

Loans Receivable and Interest Income

Loans Receivable

The Company’s loans receivable are reflected at amortized cost on the accompanying consolidated balance sheets. The amortized cost of a loan receivable is the outstanding unpaid principal balance, net of unamortized discounts, costs and fees directly associated with the origination of the loan.

Loans acquired in connection with a business combination are recorded at their acquisition date fair value. The Company determines the fair value of loans receivable based on estimates of expected discounted cash flows, collateral, credit risk and other factors. The Company does not establish a valuation allowance at the acquisition date, as the amount of estimated future cash flows reflects its judgment regarding their uncertainty. The Company recognizes the difference between the acquisition date fair value and the total expected cash flows as interest income using the effective interest method over the life of the applicable loan. The Company immediately recognizes in income any unamortized balances if the loan is repaid before its contractual maturity.

On a quarterly basis, the Company evaluates the collectability of its loan portfolio, including related interest income receivable, and establishes a reserve for loan losses. The Company’s evaluation includes reviewing credit quality indicators such as payment status, changes affecting the underlying real estate collateral (for collateral dependent loans), changes affecting the operations of the facilities securing the loans, and national and regional economic factors. The reserve for loan losses is a valuation allowance that reflects management’s estimate of loan losses inherent in the loan portfolio as of the balance sheet date. The reserve is adjusted through provision for doubtful accounts, straight-line rental income and loan losses on the Company’s consolidated statements of income and is decreased by charge-offs to specific loans when losses are confirmed. The reserve for loan losses includes an asset-specific component and a portfolio-based component.

An asset-specific reserve relates to reserves for losses on loans considered impaired and interest income receivable that is deemed uncollectible. The Company considers a loan to be impaired when, based upon current information and events, management believes that it is probable that the Company will be unable to collect all amounts due under the contractual terms of the loan agreement resulting from the borrower’s failure to repay contractual amounts due, the granting of a concession by the Company or the expectation that the Company will receive assets with fair values less than the carrying value of the loan in satisfaction of the loan. If a loan is considered to be impaired, a reserve is established when the carrying value of that loan is greater than the present value of payments expected to be received, the observable market prices for similar instruments, the estimated fair value of the collateral (for loans that are dependent on the collateral for repayment) or other amounts expected to be received in satisfaction of the loan.

A portfolio-based reserve covers the pool of loans that do not have asset-specific reserves. A provision for loan losses is recorded when available information as of each balance sheet date indicates that it is probable that a loss occurred in the pool of loans and the amount of the loss can be reasonably estimated, but the Company does not know which specific loans within the pool will ultimately result in losses. The required reserve balances for this pool of loans is derived based on estimated probabilities of default and estimated loss severities assuming a default occurs.

Interest Income

Interest income on the Company’s loans receivable is recognized on an accrual basis over the life of the investment using the interest method. Direct loan origination costs are amortized over the term of the loan as an adjustment to interest income. When concerns exist as to the ultimate collection of principal or interest due under a loan, the loan is placed on nonaccrual status, and the Company will not recognize interest income until the cash is received, or the loan returns to accrual status. If the Company determines that the collection of interest according to the contractual terms of the loan or through the receipts of assets in satisfaction of contractual amounts due is probable, the Company will resume the accrual of interest. In instances where borrowers are in default under the terms of their loans, the Company may continue recognizing interest income provided that all amounts owed under the contractual terms of the loan, including accrued and unpaid interest, do not exceed the estimated fair value of the collateral, less costs to sell.

Preferred Equity Investments and Preferred Return

Preferred equity investments are accounted for at unreturned capital contributions, plus accrued and unpaid preferred returns. The Company recognizes preferred return income on a monthly basis based on the outstanding investment including any previously accrued and unpaid return. As a preferred member of the preferred equity joint ventures in which the Company participates, the Company is not entitled to share in the joint venture’s earnings or losses. Rather, the Company is entitled to receive a preferred return, which is deferred if the cash flow of the joint venture is insufficient to currently pay the accrued preferred return.

Cash and Cash Equivalents

The Company considers all short-term (with an original maturity of three months or less), highly-liquid investments utilized as part of the Company’s cash-management activities to be cash equivalents. Cash equivalents may include cash and short-term investments. Short-term investments are stated at cost, which approximates fair value.

The Company’s cash and cash equivalents balance exceeded federally insurable limits as of December 31, 2019. To date, the Company has experienced no loss or lack of access to cash in its operating accounts. The Company has a corporate banking relationship with Bank of America, N.A. in which it deposits the majority of its cash.

Restricted Cash

Restricted cash primarily consists of amounts held by an exchange accommodation titleholder or by secured debt lenders to provide for future real estate tax expenditures, tenant improvements and capital expenditures. Pursuant to the terms of the Company’s leases with certain tenants, the Company has assigned its interests in certain of these restricted cash accounts with secured debt lenders to the tenants, and this amount is included in accounts payable and accrued liabilities on the Company’s consolidated balance sheets. As of December 31, 2019 and 2018, restricted cash totaled $10.0 million and $9.4 million, respectively, and restricted cash obligations totaled $5.6 million and $5.5 million, respectively.

Stock-Based Compensation

Stock-based compensation expense for stock-based awards granted to Sabra’s employees and its non-employee directors is recognized in the statements of income based on the estimated grant date fair value, as adjusted. Compensation expense for awards with graded vesting schedules is generally recognized ratably over the period from the grant date to the date when the award is no longer contingent on the employee providing additional services. Compensation expense for awards with performance-based vesting conditions is recognized based on the Company’s estimate of the ultimate value of such award after considering the Company’s expectations of future performance. Forfeitures of stock-based awards are recognized as they occur.

Deferred Financing Costs

Deferred financing costs representing fees paid to third parties are amortized over the terms of the respective financing agreements using the interest method. Deferred financing costs related to secured debt, term loans and senior unsecured notes are recorded as a reduction of the related debt liability, and deferred financing costs related to the revolving credit facility are recorded in accounts receivable, prepaid expenses and other assets, net. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financings that do not close are expensed in the period in which it is determined that the financing will not close.

Income Taxes

The Company elected to be treated as a REIT with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. The Company believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. To qualify as a REIT, the Company must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of the Company’s annual REIT taxable income to stockholders (which is computed without regard to the dividends-paid deduction or net capital gains and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, the Company generally will not be subject to federal income tax on income that it distributes as dividends to its stockholders. If the Company fails to qualify as a REIT in any taxable year, it will be subject to U.S. federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost, unless the Internal Revenue Service grants the Company relief under certain statutory provisions. Such an event could materially and adversely affect the Company’s net income and net cash available for distribution to stockholders. However, the Company believes that it is organized and operates in such a manner as to qualify for treatment as a REIT.

 As a result of certain investments, the Company now records income tax expense or benefit with respect to certain of its entities that are taxed as taxable REIT subsidiaries under provisions similar to those applicable to regular corporations and not under the REIT provisions.

     The Company accounts for deferred income taxes using the asset and liability method and recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company’s financial statements or tax returns. Under this method, the Company determines deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in the deferred tax liability that results from a change in

circumstances, and that causes a change in the Company’s judgment about expected future tax consequences of events, is included in the tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss and tax credit carryforwards. A valuation allowance is provided if the Company believes it is more likely than not that all or some portion of the deferred tax asset will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, and that causes a change in the Company’s judgment about the realizability of the related deferred tax asset, is included in the tax provision when such changes occur. 

The Company evaluates its tax positions using a two step approach: step one (recognition) occurs when the Company concludes that a tax position, based solely on its technical merits, is more likely than not to be sustained upon examination, and step two (measurement) is only addressed if step one has been satisfied (i.e., the position is more likely than not to be sustained). Under step two, the tax benefit is measured as the largest amount of benefit (determined on a cumulative probability basis) that is more likely than not to be realized upon ultimate settlement. The Company will recognize tax penalties relating to unrecognized tax benefits as additional tax expense.

Foreign Currency

Certain of the Company’s subsidiaries’ functional currencies are the local currencies of their respective foreign jurisdictions. The Company translates the results of operations of its foreign subsidiaries into U.S. dollars using average rates of exchange in effect during the period presented, and it translates balance sheet accounts using exchange rates in effect at the end of the period presented. The Company records resulting currency translation adjustments in accumulated other comprehensive income (loss), a component of stockholders’ equity, on its consolidated balance sheets, and it records foreign currency transaction gains and losses as a component of interest and other income on its consolidated statements of income.

Derivative Instruments

The Company uses certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at inception, the Company must make an assessment that the transaction that the Company intends to hedge is probable of occurring, and this assessment must be updated each reporting period.

The Company recognizes all derivative instruments as assets or liabilities on the consolidated balance sheets at their fair value. For derivatives designated and qualified as a hedge, the change in fair value of the effective portion of the derivatives is recognized in accumulated other comprehensive income (loss). Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria for hedge accounting would be recognized in earnings.

The Company formally documents all relationships between hedging instruments and hedged items, as well as its risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific transactions, as well as recognizing obligations or assets on the consolidated balance sheets. The Company also assesses and documents, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying transaction will not occur, the Company would discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the then-current fair value of the derivative.

Fair Value Measurements

Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:

• Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;

• Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and

• Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.

When available, the Company utilizes quoted market prices from an independent third-party source to determine fair value and classifies such items as Level 1 or Level 2. In instances where the market for a financial instrument is not active, regardless of the availability of a nonbinding quoted market price, observable inputs might not be relevant and could require the Company to make a significant adjustment to derive a fair value measurement. Additionally, in an inactive market, a market price quoted from an independent third party may rely more on models with inputs based on information available only to that independent third party. When the Company determines the market for a financial instrument owned by the Company to be illiquid or when market transactions for similar instruments do not appear orderly, the Company may use several valuation sources (including internal valuations, discounted cash flow analysis and quoted market prices) to establish a fair value. If more than one valuation source is used, the Company will assign weights to the various valuation sources. Additionally, when determining the fair value of liabilities in circumstances in which a quoted price in an active market for an identical liability is not available, the Company measures fair value using (i) a valuation technique that uses the quoted price of the identical liability when traded as an asset or quoted prices for similar liabilities or similar liabilities when traded as assets or (ii) another valuation technique that is consistent with the principles of fair value measurement, such as the income approach or the market approach.

Changes in assumptions or estimation methodologies can have a material effect on these estimated fair values. In this regard, the derived fair value estimates cannot be substantiated by comparison to independent markets and, in many cases, may not be realized in an immediate settlement of the instrument.

The Company considers the following factors to be indicators of an inactive market: (i) there are few recent transactions, (ii) price quotations are not based on current information, (iii) price quotations vary substantially either over time or among market makers (for example, some brokered markets), (iv) indexes that previously were highly correlated with the fair values of the asset or liability are demonstrably uncorrelated with recent indications of fair value for that asset or liability, (v) there is a significant increase in implied liquidity risk premiums, yields, or performance indicators (such as delinquency rates or loss severities) for observed transactions or quoted prices when compared with the Company’s estimate of expected cash flows, considering all available market data about credit and other nonperformance risk for the asset or liability, (vi) there is a wide bid-ask spread or significant increase in the bid-ask spread, (vii) there is a significant decline or absence of a market for new issuances (that is, a primary market) for the asset or liability or similar assets or liabilities, and (viii) little information is released publicly (for example, a principal-to-principal market).

The Company considers the following factors to be indicators of non-orderly transactions: (i) there was not adequate exposure to the market for a period before the measurement date to allow for marketing activities that are usual and customary for transactions involving such assets or liabilities under current market conditions, (ii) there was a usual and customary marketing period, but the seller marketed the asset or liability to a single market participant, (iii) the seller is in or near bankruptcy or receivership (that is, distressed), or the seller was required to sell to meet regulatory or legal requirements (that is, forced), and (iv) the transaction price is an outlier when compared with other recent transactions for the same or similar assets or liabilities.

Per Share Data

Basic earnings per common share is computed by dividing net income applicable to common stockholders by the weighted average number of shares of common stock and common equivalents outstanding during the period. Diluted earnings per common share is calculated by including the effect of dilutive securities. See Note 14, “Earnings Per Common Share.”

Industry Segments

The Company has one reportable segment consisting of investments in healthcare-related real estate properties.

Beds, Units and Other Measures

The number of beds, units and other measures used to describe the Company’s real estate investments included in the Notes to Consolidated Financial Statements are presented on an unaudited basis.

Recently Issued Accounting Standards Update

Adopted

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”). Topic 842 supersedes guidance related to accounting for leases and provides for the recognition of lease assets and lease liabilities by lessees for those leases previously classified as operating leases under GAAP. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a

lease. Topic 842 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. Topic 842 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company elected to adopt Topic 842 on January 1, 2019 using the modified retrospective transition method, which permits application of the new standard on the adoption date as opposed to the earliest comparative period presented in the financial statements. In addition, the Company elected to use the available practical expedient package, and therefore did not reassess classification of its existing leases.

Additionally, the Company has elected a practical expedient not to separate lease and nonlease components (such as services rendered), which can only be applied to leasing arrangements for which (i) the timing and pattern of transfer are the same for the lease and nonlease components and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Under this practical expedient, contracts that are predominantly lease-based would be accounted for under Topic 842, and contracts that are predominantly service-based would be accounted for under Topic 606, Revenue from Contracts with Customers. As a result of electing this practical expedient, the Company, beginning January 1, 2019, recognizes revenue from its leased skilled nursing/transitional care facilities, senior housing communities, and specialty hospitals and other facilities under Topic 842 and recognizes revenue from its Senior Housing - Managed communities under the Revenue ASUs (codified under Topic 606). Upon adoption of Topic 842, the Company recognized its operating leases for which it is the lessee, mainly its corporate office lease and ground leases, on its consolidated balance sheets, as a lease liability of $10.0 million, included in accounts payable and accrued liabilities on the condensed consolidated balance sheets, and a corresponding right-of-use asset, included in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. As of December 31, 2019, the balances of the lease liability and the corresponding right-of-use asset were $9.8 million and $9.3 million, respectively.

The Company assesses the collectability of rental revenues on a lease-by-lease basis. Prior to the adoption of Topic 842, the Company recorded rental revenue and receivables to the extent those amounts were expected to be collected, irrespective of the Company’s determination of the collectability of substantially all rents over the life of a lease. Upon adoption of Topic 842, if at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Upon adoption of Topic 842 and as of the adoption date, the Company recorded a $32.5 million reduction in equity and accounts receivable due to the cumulative effect of this change. This reduction consisted of $17.5 million of straight-line rental income receivables and $15.0 million of cash rent receivables, although management believes the $15.0 million of cash rent receivables are collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Under Topic 842, future write-offs of receivables and any recoveries of previously written-off receivables will be recorded as adjustments to rental revenue.

Furthermore, Topic 842 requires lessors to exclude from variable payments lessor costs paid by lessees directly to third parties. In contrast, lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized $17.6 million of variable lease revenue and the associated expense during the year ended December 31, 2019.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold under current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2018-19”), which amends ASU 2016-13 to clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, and instead, impairment of such receivables should be accounted for in accordance with Topic 842, Leases. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses (“ASU 2019-11”), which amends ASU 2016-13 to clarify or address stakeholders’ specific issues about certain aspects of ASU 2016-13. ASU 2016-13, ASU 2018-19 and ASU 2019-11 are effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in these updates through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company adopted ASU 2016-13, ASU 2018-19 and ASU 2019-11 on January 1, 2020. The adoption of these standards did not have a material impact on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 updates the fair value measurement disclosure requirements by (i) eliminating certain requirements, including disclosure of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements, (ii) modifying certain requirements, including clarifying that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date and (iii) adding certain requirements, including disclosure of the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted for any eliminated or modified disclosures. The Company adopted ASU 2018-13 on January 1, 2020. The Company does not expect the adoption of ASU 2018-13 to have a material impact on its consolidated financial statements.

XML

INTANGIBLE ASSETS AND LIABILITIES

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS AND LIABILITIES

INTANGIBLE ASSETS AND LIABILITIES

The following table summarizes the Company’s intangible assets and liabilities as of December 31, 2019 and 2018 (in thousands):

	December 31,
	2019			2018
Lease Intangible Assets:
Above market leases	$	51,040		$	61,572
Tenant origination and absorption costs	65,234			73,323
Tenant relationship	23,150			26,936
Gross lease intangible assets	139,424			161,831
Accumulated amortization	(37,915		)	(30,734		)
Lease intangible assets, net	$	101,509		$	131,097
Lease Intangible Liabilities:
Below market leases	$	99,133		$	102,098
Accumulated amortization	(29,187		)	(18,372		)
Lease intangible liabilities, net	$	69,946		$	83,726

The following is a summary of real estate intangible amortization income (expense) for the years ended December 31, 2019, 2018 and 2017 (in thousands): 

	Year Ended December 31,
	2019			2018			2017
Increase (decrease) to rental income related to above/below market leases, net	$	508		$	(7,701	)	$	912
Depreciation and amortization related to tenant origination and absorption costs and tenant relationship	(17,674		)	(16,118		)	(11,822		)

The remaining unamortized balance for these outstanding intangible assets and liabilities as of December 31, 2019 will be amortized for the years ending December 31 as follows (dollars in thousands):

	Lease Intangible Assets		Lease Intangible Liabilities
2020	$	14,140	$	12,221
2021	11,782		8,012
2022	11,441		7,269
2023	9,702		7,269
2024	9,061		7,168
Thereafter	45,383		28,007
	$	101,509	$	69,946
Weighted-average remaining amortization period	10.5 years		8.9 years

XML

FAIR VALUE DISCLOSURES

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

FAIR VALUE DISCLOSURES

FAIR VALUE DISCLOSURES

Financial Instruments

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. As such, the Company classifies these instruments as Level 3.

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of December 31, 2019 and 2018 whose carrying amounts do not approximate their fair value (in thousands):

	December 31, 2019						December 31, 2018
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	67,527	$	63,070	$	59,832	$	96,492	$	69,460	$	65,797
Preferred equity investments	43,893		44,304		44,493		43,851		44,262		43,825
Financial liabilities:
Senior Notes	1,250,000		1,248,773		1,328,714		1,300,000		1,307,394		1,270,877
Secured indebtedness	114,777		113,070		105,510		117,464		115,679		101,820

⁽¹⁾  Face value represents amounts contractually due under the terms of the respective agreements.

⁽²⁾  Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

The Company determined the fair value of financial instruments as of December 31, 2019 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets:
Loans receivable	$	59,832	$	—	$	—	$	59,832
Preferred equity investments	44,493		—		—		44,493
Financial liabilities:
Senior Notes	1,328,714		—		1,328,714		—
Secured indebtedness	105,510		—		—		105,510

Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Despite increased capital market and credit market activity, transaction volume for certain financial instruments remains relatively low. This has made the estimation of fair values difficult and, therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.

Items Measured at Fair Value on a Recurring Basis

During the year ended December 31, 2019, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps	$	4,239	$	—	$	4,239	$	—
Cross currency swaps	3,238		—		3,238		—
Financial liabilities:
Forward starting interest rate swaps	494		—		494		—
Forward starting interest rate collars	132		—		132		—

XML

DERIVATIVE AND HEDGING INSTRUMENTS (Tables)

12 Months Ended

Dec. 31, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Notional Amounts of Derivative Instruments

The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):  

	December 31, 2019		December 31, 2018
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)	$	1,490,000	$	1,045,000
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	54,489	$	55,401
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars	$	1,811	$	899

⁽¹⁾ Balance includes four forward starting interest rate swaps and one forward starting interest rate collar with an effective date of August 2020 and two forward starting interest rate swaps and one forward starting interest rate collar with an effective date of January 2021 that had been entered into as of December 31, 2019. The forward starting interest rate swaps and forward starting interest rate collars have an aggregate initial notional amount of $645.0 million accreting to $845.0 million in January 2023.

Summary of Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at December 31, 2019 and 2018 (dollars in thousands):    

		Count as of December 31, 2019	Fair Value				Maturity Dates
			December 31,
Type	Designation		2019		2018			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	10	$	4,239	$	25,184	2020 - 2023	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	3,238		4,160		2025	Accounts receivable, prepaid expenses and other assets, net
			$	7,477	$	29,344
Liabilities:
Forward starting interest rate swaps	Cash flow	6	$	494	$	4,529	2024	Accounts payable and accrued liabilities
Forward starting interest rate collars	Cash flow	2	132		—		2024	Accounts payable and accrued liabilities
CAD term loan	Net investment	1	96,025		91,700		2024	Term loans, net
			$	96,651	$	96,229

Effect of Derivatives and Financial Instruments Designated as Hedging Instruments on Income and Equity

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of income and the consolidated statements of equity for the years ended December 31, 2019, 2018 and 2017:

	Gain (Loss) Recognized in Other Comprehensive Income								Gain (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income							Income Statement Location
	For the year ended December 31,
	2019			2018		2017			2019		2018		2017
Cash Flow Hedges:
Interest rate products	$	(19,932	)	$	2,707	$	10,807		$	5,545	$	3,099	$	(2,174	)	Interest expense
Net Investment Hedges:
Foreign currency products	(772		)	3,554		(2,378		)	—		—		—			N/A
CAD term loan	(4,325		)	7,888		(6,588		)	—		—		—			N/A
	$	(25,029	)	$	14,149	$	1,841		$	5,545	$	3,099	$	(2,174	)

Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives, Assets

The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2019 and 2018 (in thousands):

	As of December 31, 2019
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Financial Instruments			Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	7,477	$	—	$	7,477	$	(544	)	$	—	$	6,933
Offsetting Liabilities:
Derivatives	$	626	$	—	$	626	$	(544	)	$	—	$	82

	As of December 31, 2018
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Financial Instruments			Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	29,344	$	—	$	29,344	$	(2,069	)	$	—	$	27,275
Offsetting Liabilities:
Derivatives	$	4,529	$	—	$	4,529	$	(2,069	)	$	—	$	2,460

Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives, Liabilities

The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2019 and 2018 (in thousands):

	As of December 31, 2019
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Financial Instruments			Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	7,477	$	—	$	7,477	$	(544	)	$	—	$	6,933
Offsetting Liabilities:
Derivatives	$	626	$	—	$	626	$	(544	)	$	—	$	82

	As of December 31, 2018
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Financial Instruments			Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	29,344	$	—	$	29,344	$	(2,069	)	$	—	$	27,275
Offsetting Liabilities:
Derivatives	$	4,529	$	—	$	4,529	$	(2,069	)	$	—	$	2,460

XML

REAL ESTATE PROPERTIES HELD FOR INVESTMENT (Tables)

12 Months Ended

Dec. 31, 2019

Real Estate Investments, Net [Abstract]

Real Estate Properties Held for Investment

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of December 31, 2019  

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	296	33,290	$	3,701,666	$	(306,565	)	$	3,395,101
Senior Housing - Leased (1)	62	3,820	630,688		(72,278		)	558,410
Senior Housing - Managed (1)	46	4,809	907,771		(112,893		)	794,878
Specialty Hospitals and Other	25	1,193	639,721		(47,124		)	592,597
	429	43,112	5,879,846		(538,860		)	5,340,986
Corporate Level			737		(353		)	384
			$	5,880,583	$	(539,213	)	$	5,341,370

As of December 31, 2018

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	335	37,628	$	4,094,484	$	(224,942	)	$	3,869,542
Senior Housing - Leased (1)	90	7,332	1,237,790		(125,902		)	1,111,888
Senior Housing - Managed (1)	23	1,603	301,739		(19,537		)	282,202
Specialty Hospitals and Other	22	1,085	621,236		(31,640		)	589,596
	470	47,648	6,255,249		(402,021		)	5,853,228
Corporate Level			634		(317		)	317
			$	6,255,883	$	(402,338	)	$	5,853,545

⁽¹⁾ During the year ended December 31, 2019, the Company transitioned 21 senior housing communities to its Senior Housing - Managed portfolio.

	December 31, 2019			December 31, 2018
Building and improvements	$	5,042,435		$	5,388,102
Furniture and equipment	239,229			237,145
Land improvements	1,534			1,254
Land	597,385			629,382
	5,880,583			6,255,883
Accumulated depreciation	(539,213		)	(402,338		)
	$	5,341,370		$	5,853,545

Lessor, Operating Lease, Payments to be Received, Maturity

The future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):

As of December 31, 2019

2020	$	428,101
2021	427,791
2022	404,568
2023	389,810
2024	380,944
Thereafter	1,672,008
	$	3,703,222

Future Minimum Rental Payments from Non-Cancelable Operating Leases

As of December 31, 2018

2019	$	465,766
2020	456,207
2021	452,346
2022	454,216
2023	437,277
Thereafter	2,407,064
	$	4,672,876

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Loans Receivable and Other Investments (Details) $ in Thousands	Dec. 31, 2019 USD ($) Investment	Dec. 31, 2018 USD ($)
Loans Receivable:
Quantity | Investment	18
Principal Balance	$ 67,527	$ 96,492
Book Value	$ 63,634	70,718
Weighted Average Contractual Interest Rate / Rate of Return	7.80%
Weighted Average Annualized Effective Interest Rate / Rate of Return	7.90%
Loan loss reserve	$ (564)	(1,258)
Loans Receivable, Net Amount	$ 63,070	69,460
Preferred Equity
Quantity | Investment	9
Principal Balance	$ 43,893	43,851
Book Value	$ 44,304	44,262
Weighted Average Contractual Interest Rate / Rate of Return	12.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	12.00%
Total Quantity | Investment	27
Total Principal Balance	$ 111,420
Total Book Value	$ 107,374	113,722
Total Weighted Average Contractual Interest Rate / Rate of Return	9.40%
Total Weighted Average Annualized Effective Interest Rate / Rate of Return	9.60%
Mortgage
Loans Receivable:
Quantity | Investment	1
Principal Balance	$ 19,000
Book Value	$ 19,000	18,577
Weighted Average Contractual Interest Rate / Rate of Return	10.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	10.00%
Construction
Loans Receivable:
Quantity | Investment	1
Principal Balance	$ 2,468
Book Value	$ 2,487	4,629
Weighted Average Contractual Interest Rate / Rate of Return	8.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	7.80%
Mezzanine
Loans Receivable:
Quantity | Investment	0
Principal Balance	$ 0
Book Value	$ 0	2,188
Other
Loans Receivable:
Quantity | Investment	16
Principal Balance	$ 46,059
Book Value	$ 42,147	$ 45,324
Weighted Average Contractual Interest Rate / Rate of Return	6.80%
Weighted Average Annualized Effective Interest Rate / Rate of Return	7.00%

XML

DEBT - Narrative (Details)							12 Months Ended
	Oct. 27, 2019 USD ($)	Oct. 07, 2019 USD ($)	Sep. 09, 2019 USD ($) extension_option	Jun. 29, 2019 USD ($)	May 29, 2019 USD ($)	Aug. 17, 2017 USD ($) extension_option	Dec. 31, 2019 USD ($) instrument	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2019 CAD ($) instrument	Sep. 09, 2019 CAD ($) extension_option	Aug. 17, 2017 CAD ($) extension_option	Aug. 10, 2016 USD ($) agreement	Aug. 10, 2016 CAD ($) agreement	Jun. 10, 2015 CAD ($)	Oct. 10, 2014 USD ($)	Jan. 23, 2014 USD ($)	May 23, 2013 USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of senior unsecured notes							$ 638,779,000	$ 0	$ 0
Loss on extinguishment of debt							16,340,000	2,917,000	553,000
Repayments of fixed rate secured debt							3,436,000	140,338,000	4,145,000
Payment for debt extinguishment or debt prepayment cost							10,502,000	2,043,000	0
Revolving credit facility							0	624,000,000
Term loans, net							1,040,258,000	1,184,930,000
Interest expense							126,610,000	147,106,000	88,440,000
Non-cash interest expense							10,080,000	10,137,000	$ 7,776,000
Interest payable							16,700,000	24,000,000.0
Secured Indebtedness
Debt Instrument [Line Items]
Debt amount							114,777,000	117,464,000
Loss on extinguishment of debt								900,000
Repayments of fixed rate secured debt								37,600,000
Senior Notes
Debt Instrument [Line Items]
Debt amount							1,250,000,000	1,300,000,000
Care Capital Properties | U.S. Dollar Term Loan
Debt Instrument [Line Items]
Debt amount							$ 600,000,000
Care Capital Properties | Interest Rate Swap | U.S. Dollar Term Loan
Debt Instrument [Line Items]
Interest rate swap, fixed							1.31%			1.31%
Derivative instruments | instrument							8			8
Variable Rate Secured Term Loan | Care Capital Properties | Secured Indebtedness
Debt Instrument [Line Items]
Debt amount								98,500,000
Loss on extinguishment of debt								$ 2,000,000.0
5.5% Senior Unsecured Notes due 2021
Debt Instrument [Line Items]
Interest rate							5.50%			5.50%							5.50%
5.5% Senior Unsecured Notes due 2021 | Senior Notes
Debt Instrument [Line Items]
Loss on extinguishment of debt							$ 10,100,000
Debt instrument, repurchase amount				$ 500,000,000.0
Debt instrument, redemption price, percentage of principal amount redeemed				101.375%
Payment for debt extinguishment or debt prepayment cost							6,900,000
Write off of deferred debt issuance cost							$ 3,200,000
5.5% Senior Unsecured Notes due 2021 (Issued January 2014)
Debt Instrument [Line Items]
Interest rate																	5.50%
Debt amount																	$ 350,000,000.0
5.5% Senior Unsecured Notes due 2021 (Issued October 2014)
Debt Instrument [Line Items]
Interest rate																5.50%
Debt amount																$ 150,000,000.0
5.375% Senior Unsecured Notes due 2023
Debt Instrument [Line Items]
Interest rate							5.375%			5.375%								5.375%
Debt amount																		$ 200,000,000.0
5.375% Senior Unsecured Notes due 2023 | Senior Notes
Debt Instrument [Line Items]
Debt amount	$ 200,000,000.0
Loss on extinguishment of debt							$ 5,600,000
Debt instrument, redemption price, percentage of principal amount redeemed	101.792%
Payment for debt extinguishment or debt prepayment cost							3,600,000
Write off of deferred debt issuance cost							$ 2,000,000.0
4.80% Senior Unsecured Notes due 2024
Debt Instrument [Line Items]
Required ratio of total unencumbered assets to unsecured debt							150.00%
4.80% Senior Unsecured Notes due 2024 | Senior Notes
Debt Instrument [Line Items]
Interest rate					4.80%		4.80%			4.80%
Proceeds from issuance of senior unsecured notes					$ 295,300,000
Debt amount					$ 300,000,000.0
4.80% Senior Unsecured Notes due 2024 | Senior Notes | Redemption Period One
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage					100.00%
4.80% Senior Unsecured Notes due 2024 | Senior Notes | Redemption Period Two
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage					100.00%
5.125% Senior Unsecured Notes due 2026
Debt Instrument [Line Items]
Interest rate						5.125%	5.125%			5.125%		5.125%
Debt instrument, redemption price, percentage						100.00%
Required ratio of total unencumbered assets to unsecured debt							150.00%
Debt amount						$ 500,000,000.0
5.38% Senior Unsecured Notes due 2027
Debt Instrument [Line Items]
Interest rate						5.38%	5.38%			5.38%		5.38%
Debt instrument, redemption price, percentage						100.00%
Debt amount						$ 100,000,000.0
3.90% Senior Unsecured Notes due 2029
Debt Instrument [Line Items]
Required ratio of total unencumbered assets to unsecured debt							150.00%
3.90% Senior Unsecured Notes due 2029 | Senior Notes
Debt Instrument [Line Items]
Interest rate		3.90%					3.90%			3.90%
Proceeds from issuance of senior unsecured notes		$ 340,500,000
Debt amount		$ 350,000,000.0
3.90% Senior Unsecured Notes due 2029 | Senior Notes | Redemption Period One
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage		100.00%
3.90% Senior Unsecured Notes due 2029 | Senior Notes | Redemption Period Two
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage		100.00%
2016 Credit Agreement
Debt Instrument [Line Items]
Loss on extinguishment of debt						600,000
Fourth Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 600,000
Fourth Amended and Restated Credit Agreement | U.S. Dollar Term Loan
Debt Instrument [Line Items]
Debt amount						1,100,000,000
Fourth Amended and Restated Credit Agreement | U.S. Dollar Term Loan | Redemption Period Two
Debt Instrument [Line Items]
Debt amount						$ 200,000,000.0
Fourth Amended and Restated Credit Agreement | U.S. Dollar Term Loan | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate						0.00%
Fourth Amended and Restated Credit Agreement | U.S. Dollar Term Loan | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate						0.90%
Fourth Amended and Restated Credit Agreement | U.S. Dollar Term Loan | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate						0.90%
Fourth Amended and Restated Credit Agreement | U.S. Dollar Term Loan | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate						1.90%
Fourth Amended and Restated Credit Agreement | Canadian Dollar Term Loan
Debt Instrument [Line Items]
Debt amount												$ 125,000,000.0
Fourth Amended and Restated Credit Agreement | Canadian Dollar Term Loan | CDOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate						0.90%
Fourth Amended and Restated Credit Agreement | Canadian Dollar Term Loan | CDOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate						1.90%
Fourth Amended and Restated Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing capacity in certain foreign currencies (up to)						$ 175,000,000.0
Borrowing capacity (up to)						$ 1,000,000,000.0
Number of optional extensions | extension_option						2						2
Optional extension period						6 months
Fourth Amended and Restated Credit Agreement | Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Annum percent unused borrowing fee						0.125%
Fourth Amended and Restated Credit Agreement | Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Annum percent unused borrowing fee						0.30%
Fourth Amended and Restated Credit Agreement | Revolving Credit Facility | Federal Funds Rate
Debt Instrument [Line Items]
Basis spread on variable rate						0.50%
Fourth Amended and Restated Credit Agreement | Revolving Credit Facility | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate						1.00%
Fourth Amended and Restated Credit Agreement | Revolving Credit Facility | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate						0.00%
Fourth Amended and Restated Credit Agreement | Revolving Credit Facility | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate						0.65%
Fourth Amended and Restated Credit Agreement | Revolving Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate						0.875%
Fourth Amended and Restated Credit Agreement | Revolving Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate						1.65%
Fourth Amended and Restated Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Borrowing capacity (up to)						$ 2,500,000,000
Fifth Amended and Restated Credit Agreement | U.S. Dollar Term Loan
Debt Instrument [Line Items]
Debt amount			1,100,000,000										$ 245,000,000.0
Term loans, net							$ 955,000,000.0
Fifth Amended and Restated Credit Agreement | U.S. Dollar Term Loan | Redemption Period One
Debt Instrument [Line Items]
Debt amount			250,000,000.0
Fifth Amended and Restated Credit Agreement | U.S. Dollar Term Loan | Redemption Period Two
Debt Instrument [Line Items]
Debt amount			$ 350,000,000.0
Fifth Amended and Restated Credit Agreement | U.S. Dollar Term Loan | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			0.00%
Fifth Amended and Restated Credit Agreement | U.S. Dollar Term Loan | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			0.65%
Fifth Amended and Restated Credit Agreement | U.S. Dollar Term Loan | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			0.85%
Fifth Amended and Restated Credit Agreement | U.S. Dollar Term Loan | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			1.65%
Fifth Amended and Restated Credit Agreement | Canadian Dollar Term Loan
Debt Instrument [Line Items]
Debt amount											$ 125,000,000.0			$ 35,000,000.0	$ 90,000,000.0
Interest rate swap, fixed															1.59%
Term loans, net										$ 125,000,000.0
Fifth Amended and Restated Credit Agreement | Canadian Dollar Term Loan | CDOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			0.85%
Fifth Amended and Restated Credit Agreement | Canadian Dollar Term Loan | CDOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			1.65%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing capacity in certain foreign currencies (up to)			$ 175,000,000.0
Borrowing capacity (up to)			$ 1,000,000,000.0
Number of optional extensions | extension_option			2								2
Optional extension period			6 months
Interest rate							2.91%			2.91%
Revolving credit facility							$ 0
Available borrowing capacity							$ 1,000,000,000.0
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Annum percent unused borrowing fee			0.125%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Annum percent unused borrowing fee			0.30%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			0.00%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			0.45%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate			0.775%
Fifth Amended and Restated Credit Agreement | Revolving Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate			1.45%
Fifth Amended and Restated Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Borrowing capacity (up to)			$ 2,750,000,000
Fifth Amended and Restated Credit Agreement | Interest Rate Swap | U.S. Dollar Term Loan
Debt Instrument [Line Items]
Interest rate swap, fixed													0.90%	0.90%
Derivative instruments | agreement													2	2
Fifth Amended and Restated Credit Agreement | Interest Rate Swap | Canadian Dollar Term Loan
Debt Instrument [Line Items]
Interest rate swap, fixed													0.93%	0.93%
Derivative instruments | agreement													1	1

XML

SUMMARIZED CONSOLIDATING INFORMATION - Consolidating Statement of Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Financial Statements, Captions [Line Items]
Net income	$ 69,018	$ 279,115	$ 158,365
Other comprehensive (loss) income:
Foreign currency translation gain	679	720	154
Unrealized (loss) gain on cash flow hedge	(25,368)	292	12,933
Total other comprehensive (loss) income	(24,689)	1,012	13,087
Comprehensive income	44,329	280,127	171,452
Comprehensive (income) loss attributable to noncontrolling interest	(22)	(33)	18
Comprehensive income attributable to Sabra Health Care REIT, Inc.	44,307	280,094	171,470
Elimination
Condensed Financial Statements, Captions [Line Items]
Net income	(333,970)	(773,612)	(509,045)
Other comprehensive (loss) income:
Foreign currency translation gain	0	0	0
Unrealized (loss) gain on cash flow hedge	0	0	0
Total other comprehensive (loss) income	0	0	0
Comprehensive income	(333,970)	(773,612)	(509,045)
Comprehensive (income) loss attributable to noncontrolling interest	0	0	0
Comprehensive income attributable to Sabra Health Care REIT, Inc.	(333,970)	(773,612)	(509,045)
Parent Company | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net income	68,996	279,082	158,383
Other comprehensive (loss) income:
Foreign currency translation gain	0	0	0
Unrealized (loss) gain on cash flow hedge	0	0	0
Total other comprehensive (loss) income	0	0	0
Comprehensive income	68,996	279,082	158,383
Comprehensive (income) loss attributable to noncontrolling interest	0	0	0
Comprehensive income attributable to Sabra Health Care REIT, Inc.	68,996	279,082	158,383
Operating Partnership | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net income	98,665	307,736	212,432
Other comprehensive (loss) income:
Foreign currency translation gain	(1,276)	4,329	(2,821)
Unrealized (loss) gain on cash flow hedge	(25,416)	244	13,078
Total other comprehensive (loss) income	(26,692)	4,573	10,257
Comprehensive income	71,973	312,309	222,689
Comprehensive (income) loss attributable to noncontrolling interest	0	0	0
Comprehensive income attributable to Sabra Health Care REIT, Inc.	71,973	312,309	222,689
Sabra Health Care, L.L.C. | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net income	0	0	0
Other comprehensive (loss) income:
Foreign currency translation gain	0	0	0
Unrealized (loss) gain on cash flow hedge	0	0	0
Total other comprehensive (loss) income	0	0	0
Comprehensive income	0	0	0
Comprehensive (income) loss attributable to noncontrolling interest	0	0	0
Comprehensive income attributable to Sabra Health Care REIT, Inc.	0	0	0
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net income	235,327	465,909	296,595
Other comprehensive (loss) income:
Foreign currency translation gain	1,955	(3,609)	2,975
Unrealized (loss) gain on cash flow hedge	48	48	(145)
Total other comprehensive (loss) income	2,003	(3,561)	2,830
Comprehensive income	237,330	462,348	299,425
Comprehensive (income) loss attributable to noncontrolling interest	(22)	(33)	18
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$ 237,308	$ 462,315	$ 299,443

XML

EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Numerator
Net income attributable to common stockholders	$ 68,996	$ 269,314	$ 148,141
Denominator
Basic weighted average common shares and common equivalents (in shares)	187,172,210	178,305,738	105,621,242
Dilutive stock options and restricted stock units (in shares)	954,882	416,006	221,192
Dilutive weighted average common shares (in shares)	188,127,092	178,721,744	105,842,434
Net income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ 0.37	$ 1.51	$ 1.40
Diluted common share (in dollars per share)	$ 0.37	$ 1.51	$ 1.40

XML

SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Prior Liens				$ 0
Principal Balance	$ 23,146	$ 16,033	$ 16,033	21,468
Book Value				21,487
Aggregate cost for federal income tax purposes				21,600
SEC Schedule, 12-29, Real Estate Companies, Investment in Movement in Mortgage Loans on Real Estate [Roll Forward]
Balance at the beginning of the year	23,146	16,033	39,026
Additions during period:
Draws	1,689	10,943	1,738
New mortgage loans	0	0	12,987
Interest income added to principal	194	1,528	539
Deductions during period:
Paydowns/repayments	(3,561)	(5,358)	(14,570)
Conversion to real property	0	0	(19,085)
Write-offs	0	0	(4,602)
Balance at the end of the year	$ 21,468	$ 23,146	$ 16,033
Mortgages | River Vista
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Contractual Interest Rate	10.00%
Prior Liens				0
Principal Balance	$ 19,000			19,000
Book Value				19,000
Deductions during period:
Balance at the end of the year	$ 19,000
Construction Mortgages | Arlington
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Contractual Interest Rate	8.00%
Prior Liens				0
Principal Balance	$ 2,468			2,468
Book Value				$ 2,487
Deductions during period:
Balance at the end of the year	$ 2,468

XML

SUBSEQUENT EVENTS (Details) - $ / shares		12 Months Ended
	Feb. 04, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Subsequent Event
Common stock dividends declared (in dollars per share)		$ 1.80	$ 1.80	$ 1.73
Dividend Declared | Subsequent Event
Subsequent Event
Common stock dividends declared (in dollars per share)	$ 0.45

XML

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding (in shares)	0
Total fair value of units vested	$ 7,900	$ 3,600	$ 8,400
Stock-based compensation expense	9,819	7,648	8,359
Total unrecognized stock-based compensation expense	$ 20,100
Weighted average period to recognized stock-based compensation expense	2 years 6 months
Discretionary matching contribution percent	3.00%
Matching contributions	$ 211	171	143
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 9,800	$ 7,600	$ 7,000
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock convertible upon each performance-based restricted stock unit vesting (in shares)	1
Weighted average remaining vesting period	2 years 6 months
Weighted average fair value per share (in dollars per share)	$ 20.59	$ 16.02	$ 19.38
Restricted Stock Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
FFO Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	0.00%
FFO Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	200.00%
TSR Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Historical volatility rate period	3 years
TSR Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	0.00%
TSR Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	200.00%
Care Capital Properties
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercised (in shares)	0
Stock options expired (in shares)	1,200,000
Stock options outstanding (in shares)	0	1,200,000
Weighted average exercise price (in dollars per share)		$ 28.04
Care Capital Properties | General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 1,400